GWAS_SteroidHormones

List Annotations

Export Data

Plot Data

Clear Selection

New Annotation

Cell Range:

Content:

Export Selection

The data in the text box below can be copied and pasted into Microsoft Excel.
Make sure when pasting the data, "tabs" are selected as the column delimiter.

Data plot

Listing Annotations

Content SupTab1 SupTab2 SupTab3 SupTab4 SupTab5 SupTab6 SupTab7 SupTab8 SupTab9

Supplement data
Genetic association study of eight steroid hormones and implications for sexual dimorphism of coronary artery disease
Pott J, Bae YJ, Horn K et al.

Supplement Tables
SupTab 1	Correlation Results	Correlation ECLIA - LC-MSMS; Sample sizes; Correlation hormones
SupTab 2	GWAS Toplist
SupTab 3	GWAS eQTL-lookup of Table 2&3 SNPs
SupTab 4	GWAS catalog-lookup of Table 2&3 SNPs
SupTab 5	Sex-Interaction Test
SupTab 6	GWAS candidates: candidate steroid loci
SupTab 7	GWAS candidates: replication of steroid loci
SupTab 8	GWAS candidates: CAD lookup
SupTab 9	MR Results

Supplemental Table 1a) Correaltion analysis for methods ECLIA amd LC-MSMS in LIFE-Adult. Spearman's rank test applied. Only women were analyzed.

hormone	n	spearman rho	p-value
TESTO	419	0.71	<0.001
E2	129	0.89	<0.001
DHEAS	445	0.95	<0.001

Supplemental Table 1b): Sample sizes of LIFE-Heart, LIFE-Adult and the combined analyses for analysis modus ALL, MEN and WOMEN.

b)	LIFE-Heart			LIFE-Adult			combined
steroid hormone	ALL	MEN	WOMEN	ALL	MEN	WOMEN	ALL	MEN	WOMEN
CORT	2070	1358	712	5597	2943	2654	7667	4301	3366
DHEAS	2070	1358	712	5589	2943	2646	7659	4301	3358
TESTO	2070	1358	712	5573	2933	2640	7643	4291	3352
E2	1860	1239	621	4938	2952	1986	6798	4191	2607
PROG	2070	1358	712			549	2070	1358	1261
17-OHP	2070	1358	712				2070	1358	712
ANDRO	2070	1358	712				2070	1358	712
ALDO	1993	1307	686				1993	1307	686

Supplemental Table 1c): Within-study correlation of the used steroid hormons. Spearman's rank correlation was applied. Correlation analyses were performed in ALL, MEN and WOMEN. Significant correlations are colored red (p<0.05).

c)		LIFE-HEART						LIFE-Adult
hormon i	hormon j	r ALL	pval ALL	r MEN	pval MEN	r WOMEN	pval WOMEN	r ALL	pval ALL	r MEN	pval MEN	r WOMEN	pval WOMEN
PROG	CORT	0.22074161	<0.001	0.2450436	<0.001	0.189032254	<0.001					0.155247017	0.001256554
E2	CORT	-0.03713844	0.1093	-0.039746575	0.1621	-0.058457529	0.1457	0.03111601	0.02890692	-0.06489648	<0.001	-0.059735526	0.007811673
DHEAS	CORT	0.07139557	0.0012	0.076044	0.0051	0.07239222	0.0051	0.09897996	<0.001	0.09591042	<0.001	0.03286918	0.09070256
E2	PROG	0.18365596	<0.001	0.085638636	0.0026	0.158854332	<0.001					0.004598856	0.9320749
TESTO	CORT	0.03446559	0.117	0.005028213	0.8531	0.16571676	<0.001	0.1476409	<0.001	0.02527848	0.1703813	0.1613698	<0.001
E2	DHEAS	0.1384493	<0.001	-0.048539447	0.0877	0.157264774	<0.001	0.32471561	<0.001	-0.01501395	0.4150563	0.182868126	<0.001
DHEAS	PROG	0.19561174	<0.001	0.132429064	<0.001	0.20989092	<0.001					0.33814397	<0.001
TESTO	PROG	0.22003467	<0.001	0.169039191	<0.001	0.20730762	<0.001					0.1773084	<0.001
TESTO	DHEAS	0.28016023	<0.001	-0.003013129	0.9117	0.34662266	<0.001	0.4136335		0.06069065	<0.001	0.5831732	<0.001
E2	TESTO	0.50266793	<0.001	0.302722162	<0.001	0.111597434	0.0054	0.69504175	<0.001	0.29189251	<0.001	0.23323751	<0.001
TESTO	ALDO	-0.01963063	0.3811	-0.050499746	0.068	0.01434253	0.7077
DHEAS	ALDO	0.01195215	0.5939	0.00551266	0.8422	0.0271477	0.8422
PROG	ALDO	0.01249697	0.5771	0.01659016	0.549	-0.002017921	0.9579
E2	ALDO	0.01401824	0.5465	0.006662448	0.8152	-0.008999006	0.823
17-OHP	ALDO	0.04244963	0.0581	0.01628787	0.5563	0.08160071	0.0326
CORT	ALDO	0.07064875	0.0016	0.080941377	0.0034	0.0510758	0.1815
ANDRO	ALDO	0.09344553	<0.001	0.1147304	<0.001	0.06224259	0.1033
17-OHP	CORT	0.20494148	<0.001	0.17283659	<0.001	0.45073089	<0.001
E2	ANDRO	0.21868986	<0.001	0.107833072	<0.001	0.164245137	<0.001
17-OHP	DHEAS	0.25060668	<0.001	0.0464823	0.0868	0.17285562	<0.001
TESTO	ANDRO	0.32515188	<0.001	0.171341157	<0.001	0.56698618	<0.001
ANDRO	PROG	0.35763623	<0.001	0.3088505	<0.001	0.36533597	<0.001
E2	17-OHP	0.37189008	<0.001	0.121158568	<0.001	0.103496759	0.0099
ANDRO	CORT	0.40179684	<0.001	0.4092078	<0.001	0.41598091	<0.001
17-OHP	PROG	0.4608033	<0.001	0.45783111	<0.001	0.43083307	<0.001
ANDRO	17-OHP	0.49006453	<0.001	0.3752697	<0.001	0.65456122	<0.001
ANDRO	DHEAS	0.51609266	<0.001	0.4582237	<0.001	0.54452933	<0.001
TESTO	17-OHP	0.70727209	<0.001	0.465784634	<0.001	0.43037347	<0.001

Supplemental Table 2: Toplist of all SNPs with genome-wide significance after pruning (r²>0.5), with MAF>1%, info>0.8 (and p(Q)>0.1 for meta-analyzed SNPs). Column "#SNPs in LD" counts all SNPs in LD (r²>0.5) and with p<10^-6. Lead SNPs are marked yellow. Columns with -logp values are color-coded: red genome-wide significant, yellow suggestive significant, green nominal significant

SNP INFO									top phenotype					Annotation with nearby genes, eQTLs in LD, known traits of other GWAS, and pathway enrichment								PROG ALL			PROG MEN			PROG WOMEN			17-OHP ALL			17-OHP MEN			17-OHP WOMEN			ANDRO ALL			ANDRO MEN			ANDRO WOMEN			DHEAS ALL			DHEAS MEN			DHEAS WOMEN			TESTO ALL			TESTO MEN			TESTO WOMEN			E2 ALL			E2 MEN			E2 WOMEN			CORT ALL			CORT MEN			CORT WOMEN			ALDO ALL			ALDO MEN			ALDO WOMEN
SNP	status	chr	position	Cytoband	EA	OA	info-score	#SNPs in LD	phenotype	N	log-p	EAF	Cochran's Q	nearest genes (functional relevance)	correlating GWAS	cis-eQTL genes	trans-eQTL genes	KEGG pathway	Reactome pathway	DOSE pathway	GO pathway	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p
7:99025328:C:T	known [9, 10]	7	99025328	7q22.1	T	C	0.983	8	DHEAS ALL	7659	27.8599919032424	0.0351457109283196	0.042833	PTCD1 (0 kb, intron/Intron/MODIFIER \| near gene/Downstream gene/MODIFIER); ATP5J2-PTCD1 (0 kb, intron/Intron/MODIFIER); BUD31 (8.1 kb); CPSF4 (11 kb); PDAP1 (19 kb); ATP5J2 (21 kb); ARPC1B (33 kb); ARPC1A (40 kb); ZNF789 (45 kb)	0.888 Blood protein levels // 0.855 Sex hormone levels // 0.855 Total body bone mineral density (age over 60) // 0.855 Total body bone mineral density // 0.855 Femoral neck bone mineral density // 0.855 Lumbar spine bone mineral density // 0.472 Blood metabolite levels // 0.401 Dehydroepiandrosterone sulphate levels // 0.385 Diffuse cutaneous systemic sclerosis // 0.385 Blood metabolite ratios // 0.302 Metabolic traits // 0.302 Estrone levels	- \| AP4M1 \| ARPC1A \| ARPC1B \| ATP5J2 \| BUD31 \| CNPY4 \| COPS6 \| CPSF4 \| CYP3A5 \| CYP3A7 \| GAL3ST4 \| GS1-259H13.2 \| LAMTOR4 \| MEPCE \| NYAP1 \| OR2AE1 \| PDAP1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| STAG3 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| TAF6 \| TRIM4 \| ZCWPW1 \| ZKSCAN1 \| ZKSCAN5 \| ZNF3 \| ZNF394 \| ZNF498 \| ZNF655 \| ZNF789 \| ZSCAN21	RRAGA	Influenza A:CPSF4 \| Endocytosis:ARPC1A,ARPC1B \| Pathogenic Escherichia coli infection:ARPC1A,ARPC1B \| Spliceosome:BUD31 \| Shigellosis:ARPC1A,ARPC1B \| Bacterial invasion of epithelial cells:ARPC1A,ARPC1B \| Salmonella infection:ARPC1A,ARPC1B \| Regulation of actin cytoskeleton:ARPC1A,ARPC1B \| Fc gamma R-mediated phagocytosis:ARPC1A,ARPC1B \| Lysosome:AP4M1	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:PILRB \| EPHB-mediated forward signaling:ARPC1A,ARPC1B \| EPH-Ephrin signaling:ARPC1A,ARPC1B \| RHO GTPases Activate WASPs and WAVEs:ARPC1A,ARPC1B \| Infectious disease:CPSF4 \| NS1 Mediated Effects on Host Pathways:CPSF4 \| Host Interactions with Influenza Factors:CPSF4 \| Influenza Infection:CPSF4 \| Regulation of actin dynamics for phagocytic cup formation:ARPC1A,ARPC1B \| Fcgamma receptor (FCGR) dependent phagocytosis:ARPC1A,ARPC1B	influenza:CPSF4 \| specific developmental disorder:AP4M1 \| cerebral palsy:AP4M1	modulation by virus of host morphology or physiology:CPSF4 \| modification by symbiont of host morphology or physiology:CPSF4 \| modulation by virus of host process:CPSF4 \| immune response-activating signal transduction:ARPC1A,ARPC1B \| modulation by symbiont of host cellular process:CPSF4 \| immune response-activating cell surface receptor signaling pathway:ARPC1A,ARPC1B \| immune response-regulating cell surface receptor signaling pathway:ARPC1A,ARPC1B \| modification of morphology or physiology of other organism involved in symbiotic interaction:CPSF4 \| modification of morphology or physiology of other organism:CPSF4 \| protein localization to vacuole:AP4M1 \| ephrin receptor signaling pathway:ARPC1A,ARPC1B \| interaction with host:CPSF4 \| nucleocytoplasmic transport:CPSF4 \| protein localization to lysosome:AP4M1 \| nuclear transport:CPSF4 \| Arp2/3 complex-mediated actin nucleation:ARPC1A,ARPC1B \| protein targeting to vacuole:AP4M1 \| mRNA cleavage:CPSF4 \| actin nucleation:ARPC1A,ARPC1B \| post-translational protein modification:COPS6 \| protein export from nucleus:CPSF4 \| phagocytosis:ARPC1A,ARPC1B \| mRNA cleavage involved in mRNA processing:CPSF4 \| positive regulation of protein complex assembly:ARPC1A,ARPC1B \| nuclear export:CPSF4 \| immune response-regulating cell surface receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| Fc-gamma receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| mitochondrial membrane organization:ATP5J2 \| Fc-gamma receptor signaling pathway:ARPC1A,ARPC1B \| Fc receptor mediated stimulatory signaling pathway:ARPC1A,ARPC1B \| nucleic acid phosphodiester bond hydrolysis:CPSF4 \| RNA phosphodiester bond hydrolysis:CPSF4 \| positive regulation of actin filament polymerization:ARPC1A,ARPC1B \| RNA splicing, via endonucleolytic cleavage and ligation:CPSF4 \| regulation of protein complex assembly:ARPC1A,ARPC1B \| DNA-templated transcription, termination:CPSF4	0.0665944	0.0432676	0.906837567942443	0.0533068	0.0389159	0.767059767346268	0.0363958	0.0851492	0.174533635580083	0.0112235	0.0476292	0.0895186050438858	-0.0367422	0.0513199	0.324085161048934	0.111712	0.0972221	0.600447413394065	0.00130646	0.0355356	0.0129257081902594	-0.0152203	0.0404334	0.150790720076652	0.0407439	0.0682398	0.259122779054721	-0.303133	0.0273303	27.8599919032424	-0.325069	0.0342714	20.6161110614346	-0.274535	0.0435938	9.51951157354003				0.0281353	0.028764	0.484122184100859							-0.0538194	0.0329102	0.99149350970019				-0.0017787	0.0157073	0.0410349738619594	-0.0154834	0.0203962	0.348941127336596	0.0149582	0.0244355	0.267252514690005	0.0825005	0.0715957	0.603221979291795	0.0985096	0.0891034	0.570055639642916	0.0510241	0.120591	0.172408466416079
rs77356530:99019565:G:A		7	99019565	7q22.1	A	G	0.812	2	DHEAS ALL	7659	18.9836269559386	0.017496996996997	0.0997051	PTCD1 (0 kb, intron/Intron/MODIFIER); ATP5J2-PTCD1 (0 kb, intron/Intron/MODIFIER); BUD31 (2.3 kb, near gene/Downstream gene/MODIFIER); PDAP1 (13 kb); CPSF4 (17 kb); ATP5J2 (27 kb); ARPC1B (27 kb); ARPC1A (34 kb)	0.49 Blood metabolite levels // 0.49 Blood metabolite ratios // 0.442 Blood protein levels // 0.405 Sex hormone levels // 0.405 Total body bone mineral density (age over 60) // 0.405 Total body bone mineral density // 0.405 Femoral neck bone mineral density // 0.405 Lumbar spine bone mineral density // 0.3 Metabolic traits // 0.3 Dehydroepiandrosterone sulphate levels // 0.3 Estrone levels	- \| AP4M1 \| ARPC1B \| ATP5J2 \| C7orf59 \| CNPY4 \| COPS6 \| CPSF4 \| CYP3A7 \| GS1-259H13.2 \| LAMTOR4 \| MEPCE \| NYAP1 \| OR2AE1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| RP11-307C18.1 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| TAF6 \| TRIM4 \| ZCWPW1 \| ZKSCAN5 \| ZNHIT1 \| ZSCAN21		Influenza A:CPSF4 \| Endocytosis:ARPC1A,ARPC1B \| Pathogenic Escherichia coli infection:ARPC1A,ARPC1B \| Spliceosome:BUD31 \| Shigellosis:ARPC1A,ARPC1B \| Bacterial invasion of epithelial cells:ARPC1A,ARPC1B \| Salmonella infection:ARPC1A,ARPC1B \| Regulation of actin cytoskeleton:ARPC1A,ARPC1B \| Fc gamma R-mediated phagocytosis:ARPC1A,ARPC1B	EPHB-mediated forward signaling:ARPC1A,ARPC1B \| EPH-Ephrin signaling:ARPC1A,ARPC1B \| RHO GTPases Activate WASPs and WAVEs:ARPC1A,ARPC1B \| Infectious disease:CPSF4 \| NS1 Mediated Effects on Host Pathways:CPSF4 \| Host Interactions with Influenza Factors:CPSF4 \| Influenza Infection:CPSF4 \| Regulation of actin dynamics for phagocytic cup formation:ARPC1A,ARPC1B \| Fcgamma receptor (FCGR) dependent phagocytosis:ARPC1A,ARPC1B	influenza:CPSF4	modulation by virus of host morphology or physiology:CPSF4 \| modification by symbiont of host morphology or physiology:CPSF4 \| modulation by virus of host process:CPSF4 \| immune response-activating signal transduction:ARPC1A,ARPC1B \| modulation by symbiont of host cellular process:CPSF4 \| immune response-activating cell surface receptor signaling pathway:ARPC1A,ARPC1B \| immune response-regulating cell surface receptor signaling pathway:ARPC1A,ARPC1B \| modification of morphology or physiology of other organism involved in symbiotic interaction:CPSF4 \| modification of morphology or physiology of other organism:CPSF4 \| ephrin receptor signaling pathway:ARPC1A,ARPC1B \| interaction with host:CPSF4 \| nucleocytoplasmic transport:CPSF4 \| nuclear transport:CPSF4 \| Arp2/3 complex-mediated actin nucleation:ARPC1A,ARPC1B \| mRNA cleavage:CPSF4 \| actin nucleation:ARPC1A,ARPC1B \| protein export from nucleus:CPSF4 \| phagocytosis:ARPC1A,ARPC1B \| mRNA cleavage involved in mRNA processing:CPSF4 \| positive regulation of protein complex assembly:ARPC1A,ARPC1B \| nuclear export:CPSF4 \| immune response-regulating cell surface receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| Fc-gamma receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| mitochondrial membrane organization:ATP5J2 \| Fc-gamma receptor signaling pathway:ARPC1A,ARPC1B \| Fc receptor mediated stimulatory signaling pathway:ARPC1A,ARPC1B \| nucleic acid phosphodiester bond hydrolysis:CPSF4 \| RNA phosphodiester bond hydrolysis:CPSF4 \| positive regulation of actin filament polymerization:ARPC1A,ARPC1B \| RNA splicing, via endonucleolytic cleavage and ligation:CPSF4 \| regulation of protein complex assembly:ARPC1A,ARPC1B \| DNA-templated transcription, termination:CPSF4	0.0774081	0.0663361	0.613711544387558	0.0728149	0.0575797	0.68563762897987	-0.0105833	0.142001	0.0266001045472381	0.0461216	0.0729992	0.277710853276807	0.0016677	0.0759391	0.00767539756554741	0.174072	0.160468	0.555349489054664	0.0289086	0.0544647	0.225022707194905	0.0484298	0.0598075	0.378595202312351	0.00202106	0.112649	0.00625920881855314	-0.385515	0.042435	18.9836269559386	-0.395127	0.054245	12.489772784409	-0.368652	0.0661692	7.59725385435719				0.04711	0.0452137	0.526602087682491				-0.0728813	0.0417611	1.09177939144646	-0.0539264	0.052341	0.518739440677241	-0.117372	0.0653288	1.14030042607991	-0.0172564	0.0242938	0.321021167011083	-0.0433332	0.0318313	0.760933375141165	0.0147751	0.037272	0.160019442321657	0.0803994	0.109925	0.332902099523538	0.163476	0.133165	0.657948602214958	-0.11058	0.195584	0.242603971206976
rs111390579:99173193:TAC:TACACAC		7	99173193	7q22.1	TACACAC	TAC	0.873	0	DHEAS ALL	7659	18.7201027402333	0.0278484123253688	0.104506	ZNF655 (0 kb, 3'utr/3 prime UTR/MODIFIER \| nc-exon/Non coding transcript exon/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Downstream gene/MODIFIER); GS1-259H13.10 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); FAM200A (17 kb); ZKSCAN5 (41 kb); ZSCAN25 (41 kb)	0.511 Blood metabolite levels // 0.468 Platelet count	- \| AP4M1 \| ARPC1A \| ARPC1B \| ATP5J2 \| AZGP1 \| BUD31 \| C7orf43 \| CNPY4 \| COPS6 \| CPSF4 \| CYP3A5 \| CYP3A7 \| EPHB4 \| GAL3ST4 \| GATS \| GJC3 \| GS1-259H13.2 \| LRCH4 \| MCM7 \| MEPCE \| MOSPD3 \| OR2AE1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| RP11-44M6.1 \| RP4-604G5.1 \| STAG3 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| TAF6 \| TRIM4 \| TRIP6 \| TSC22D4 \| ZCWPW1 \| ZKSCAN1 \| ZKSCAN5 \| ZNF3 \| ZNF394 \| ZNF498 \| ZNF655 \| ZNF789 \| ZSCAN21 \| ZSCAN25	FRMD3 \| NINJ2 \| PMS2 \| RRAGA \| USP3	Herpes simplex infection:PILRA \| Chemical carcinogenesis:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Influenza A:CPSF4 \| Metabolism of xenobiotics by cytochrome P450:CYP3A5 \| Steroid hormone biosynthesis:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Drug metabolism - cytochrome P450:CYP3A5 \| Retinol metabolism:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Endocytosis:ARPC1A,ARPC1B \| Pathogenic Escherichia coli infection:ARPC1A,ARPC1B \| Spliceosome:BUD31 \| Shigellosis:ARPC1A,ARPC1B \| Bacterial invasion of epithelial cells:ARPC1A,ARPC1B \| Salmonella infection:ARPC1A,ARPC1B \| Regulation of actin cytoskeleton:ARPC1A,ARPC1B \| Fc gamma R-mediated phagocytosis:ARPC1A,ARPC1B \| Lysosome:AP4M1	Xenobiotics:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Biological oxidations:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Cytochrome P450 - arranged by substrate type:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Phase I - Functionalization of compounds:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:PILRA,PILRB \| TP53 Regulates Transcription of DNA Repair Genes:PMS2 \| EPHB-mediated forward signaling:ARPC1A,ARPC1B,EPHB4 \| Aflatoxin activation and detoxification:CYP3A5 \| EPH-Ephrin signaling:ARPC1A,ARPC1B,EPHB4 \| RHO GTPases Activate WASPs and WAVEs:ARPC1A,ARPC1B \| Infectious disease:CPSF4 \| NS1 Mediated Effects on Host Pathways:CPSF4 \| Host Interactions with Influenza Factors:CPSF4 \| Influenza Infection:CPSF4 \| Transcriptional Regulation by TP53:PMS2 \| Regulation of actin dynamics for phagocytic cup formation:ARPC1A,ARPC1B \| Fcgamma receptor (FCGR) dependent phagocytosis:ARPC1A,ARPC1B	endocrine system disease:PMS2 \| hyperaldosteronism:PMS2 \| urinary system disease:CYP3A5 \| multiple myeloma:CYP3A5,EPHB4 \| myeloma:CYP3A5,EPHB4 \| bone marrow cancer:CYP3A5,EPHB4 \| kidney disease:CYP3A5 \| ataxia telangiectasia:PMS2 \| polycystic ovary syndrome:CYP3A7 \| adrenal cortex disease:PMS2 \| adrenal gland disease:PMS2 \| prostate cancer:PMS2 \| male reproductive organ cancer:PMS2 \| influenza:CPSF4 \| adrenal gland hyperfunction:PMS2 \| toxic encephalopathy:CYP3A5 \| specific developmental disorder:AP4M1 \| autosomal recessive disease:PMS2 \| cerebral palsy:AP4M1	modulation by virus of host morphology or physiology:CPSF4 \| modification by symbiont of host morphology or physiology:CPSF4 \| modulation by virus of host process:CPSF4 \| immune response-activating signal transduction:ARPC1A,ARPC1B,PVRIG \| modulation by symbiont of host cellular process:CPSF4 \| immune response-activating cell surface receptor signaling pathway:ARPC1A,ARPC1B,PVRIG \| T cell receptor signaling pathway:PVRIG \| immune response-regulating cell surface receptor signaling pathway:ARPC1A,ARPC1B,PVRIG \| modification of morphology or physiology of other organism involved in symbiotic interaction:CPSF4 \| cellular response to xenobiotic stimulus:CYP3A5,CYP3A7 \| response to xenobiotic stimulus:CYP3A5,CYP3A7 \| antigen receptor-mediated signaling pathway:PVRIG \| oxidative demethylation:CYP3A5 \| drug catabolic process:CYP3A5 \| modification of morphology or physiology of other organism:CPSF4 \| protein localization to vacuole:AP4M1 \| xenobiotic metabolic process:CYP3A5,CYP3A7 \| ephrin receptor signaling pathway:ARPC1A,ARPC1B,EPHB4 \| steroid metabolic process:CYP3A5,CYP3A7 \| sulfur compound metabolic process:GAL3ST4 \| interaction with host:CPSF4 \| nucleocytoplasmic transport:CPSF4 \| protein localization to lysosome:AP4M1 \| nuclear transport:CPSF4 \| drug metabolic process:CYP3A5 \| Arp2/3 complex-mediated actin nucleation:ARPC1A,ARPC1B \| leukocyte homeostasis:TSC22D4 \| protein targeting to vacuole:AP4M1 \| mRNA cleavage:CPSF4 \| actin nucleation:ARPC1A,ARPC1B \| response to drug:PMS2 \| lipid modification:CYP3A5,CYP3A7 \| protein export from nucleus:CPSF4 \| phagocytosis:ARPC1A,ARPC1B \| mRNA cleavage involved in mRNA processing:CPSF4 \| demethylation:CYP3A5 \| positive regulation of protein complex assembly:ARPC1A,ARPC1B \| nuclear export:CPSF4 \| immune response-regulating cell surface receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| Fc-gamma receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| mitochondrial membrane organization:ATP5J2 \| Fc-gamma receptor signaling pathway:ARPC1A,ARPC1B \| immunoglobulin production:PMS2 \| Fc receptor mediated stimulatory signaling pathway:ARPC1A,ARPC1B \| nucleic acid phosphodiester bond hydrolysis:CPSF4,PMS2 \| RNA phosphodiester bond hydrolysis:CPSF4 \| negative regulation of immune system process:PVRIG,TSC22D4 \| snRNA metabolic process:MEPCE \| positive regulation of actin filament polymerization:ARPC1A,ARPC1B \| RNA splicing, via endonucleolytic cleavage and ligation:CPSF4 \| negative regulation of mitotic cell cycle phase transition:ZNF655 \| blood vessel endothelial cell migration:EPHB4 \| sprouting angiogenesis:EPHB4 \| regulation of protein complex assembly:ARPC1A,ARPC1B \| DNA-templated transcription, termination:CPSF4 \| negative regulation of cell cycle phase transition:ZNF655	0.077732	0.050941	0.895574349802678	0.0702248	0.0449809	0.925523670500023	0.0508081	0.104313	0.203283469035072	0.0788288	0.0560495	0.796556414589765	0.0249894	0.0593376	0.171520560023435	0.210575	0.118493	1.11929785283807	0.0102243	0.0418368	0.0931501449286865	-0.0138012	0.0467455	0.114720783412906	0.0752991	0.0832505	0.436466707478076	-0.291854	0.0323613	18.7201027402333	-0.284515	0.0406101	11.6104441119048	-0.297282	0.0515701	8.0870189903457				0.0391475	0.033883	0.60565865799709				-0.0547612	0.0314879	1.08611200610688	-0.0566636	0.038949	0.836477857104897	-0.0566712	0.0499826	0.590284923568968	-0.00692527	0.0185409	0.149496511284011	-0.0265398	0.0239763	0.571332387859685	0.017659	0.0289535	0.266064019300565	0.0819346	0.08447	0.478636978621514	0.136484	0.103095	0.731001041457326	-0.041041	0.147886	0.107089356762517
rs10278040:99141373:G:A		7	99141373	7q22.1	A	G	0.994	54	DHEAS ALL	7659	17.2104756933791	0.0544743047395221	0.0439519	FAM200A (2.6 kb, near gene/Downstream gene/MODIFIER); ZKSCAN5 (9 kb); ZNF655 (15 kb); ZNF789 (40 kb); ZNF394 (43 kb)	1 Blood metabolite levels // 0.64 Diffuse cutaneous systemic sclerosis // 0.64 Blood metabolite ratios // 0.612 Dehydroepiandrosterone sulphate levels // 0.608 Sex hormone levels // 0.597 Total body bone mineral density (age over 60) // 0.597 Total body bone mineral density // 0.597 Femoral neck bone mineral density // 0.597 Lumbar spine bone mineral density // 0.48 Blood protein levels // 0.397 Hand grip strength	- \| AP4M1 \| ARPC1A \| ARPC1B \| ATP5J2 \| BUD31 \| CNPY4 \| COPS6 \| CPSF4 \| CYP3A5 \| CYP3A7 \| GAL3ST4 \| GS1-259H13.2 \| LAMTOR4 \| MCM7 \| MEPCE \| MOSPD3 \| NYAP1 \| OR2AE1 \| PDAP1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| SMURF1 \| STAG3 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| TAF6 \| TRIM4 \| ZCWPW1 \| ZKSCAN1 \| ZKSCAN5 \| ZNF3 \| ZNF394 \| ZNF498 \| ZNF655 \| ZNF789	RRAGA	Chemical carcinogenesis:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Influenza A:CPSF4 \| Metabolism of xenobiotics by cytochrome P450:CYP3A5 \| Steroid hormone biosynthesis:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Drug metabolism - cytochrome P450:CYP3A5 \| Retinol metabolism:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Endocytosis:ARPC1A,ARPC1B \| Pathogenic Escherichia coli infection:ARPC1A,ARPC1B \| Spliceosome:BUD31 \| Shigellosis:ARPC1A,ARPC1B \| Bacterial invasion of epithelial cells:ARPC1A,ARPC1B \| Salmonella infection:ARPC1A,ARPC1B \| Regulation of actin cytoskeleton:ARPC1A,ARPC1B \| Fc gamma R-mediated phagocytosis:ARPC1A,ARPC1B	Xenobiotics:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Biological oxidations:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Cytochrome P450 - arranged by substrate type:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Phase I - Functionalization of compounds:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:PILRB \| EPHB-mediated forward signaling:ARPC1A,ARPC1B \| Aflatoxin activation and detoxification:CYP3A5 \| mTORC1-mediated signalling:RRAGA \| EPH-Ephrin signaling:ARPC1A,ARPC1B \| Energy dependent regulation of mTOR by LKB1-AMPK:RRAGA \| RHO GTPases Activate WASPs and WAVEs:ARPC1A,ARPC1B \| Infectious disease:CPSF4 \| NS1 Mediated Effects on Host Pathways:CPSF4 \| Host Interactions with Influenza Factors:CPSF4 \| mTOR signalling:RRAGA \| Influenza Infection:CPSF4 \| Transcriptional Regulation by TP53:RRAGA \| Regulation of actin dynamics for phagocytic cup formation:ARPC1A,ARPC1B \| Regulation of PTEN gene transcription:RRAGA \| Macroautophagy:RRAGA \| TP53 Regulates Metabolic Genes:RRAGA \| Fcgamma receptor (FCGR) dependent phagocytosis:ARPC1A,ARPC1B	urinary system disease:CYP3A5 \| multiple myeloma:CYP3A5 \| myeloma:CYP3A5 \| bone marrow cancer:CYP3A5 \| kidney disease:CYP3A5 \| polycystic ovary syndrome:CYP3A7 \| influenza:CPSF4 \| toxic encephalopathy:CYP3A5	modulation by virus of host morphology or physiology:CPSF4,RRAGA \| modification by symbiont of host morphology or physiology:CPSF4,RRAGA \| modulation by virus of host process:CPSF4 \| immune response-activating signal transduction:ARPC1A,ARPC1B \| modulation by symbiont of host cellular process:CPSF4 \| immune response-activating cell surface receptor signaling pathway:ARPC1A,ARPC1B \| immune response-regulating cell surface receptor signaling pathway:ARPC1A,ARPC1B \| modification of morphology or physiology of other organism involved in symbiotic interaction:CPSF4,RRAGA \| cellular response to xenobiotic stimulus:CYP3A5,CYP3A7 \| response to xenobiotic stimulus:CYP3A5,CYP3A7 \| oxidative demethylation:CYP3A5 \| drug catabolic process:CYP3A5 \| modification of morphology or physiology of other organism:CPSF4,RRAGA \| xenobiotic metabolic process:CYP3A5,CYP3A7 \| ephrin receptor signaling pathway:ARPC1A,ARPC1B \| steroid metabolic process:CYP3A5,CYP3A7 \| interaction with host:CPSF4,RRAGA \| nucleocytoplasmic transport:CPSF4 \| nuclear transport:CPSF4 \| drug metabolic process:CYP3A5 \| Arp2/3 complex-mediated actin nucleation:ARPC1A,ARPC1B \| positive regulation of TOR signaling:RRAGA \| cellular response to amino acid starvation:RRAGA \| mRNA cleavage:CPSF4 \| actin nucleation:ARPC1A,ARPC1B \| post-translational protein modification:COPS6 \| lipid modification:CYP3A5,CYP3A7 \| protein export from nucleus:CPSF4 \| phagocytosis:ARPC1A,ARPC1B \| mRNA cleavage involved in mRNA processing:CPSF4 \| demethylation:CYP3A5 \| cellular response to amino acid stimulus:RRAGA \| regulation of autophagy:RRAGA \| positive regulation of protein complex assembly:ARPC1A,ARPC1B \| negative regulation of autophagy:RRAGA \| nuclear export:CPSF4 \| immune response-regulating cell surface receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| Fc-gamma receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| regulation of macroautophagy:RRAGA \| mitochondrial membrane organization:ATP5J2 \| Fc-gamma receptor signaling pathway:ARPC1A,ARPC1B \| Fc receptor mediated stimulatory signaling pathway:ARPC1A,ARPC1B \| nucleic acid phosphodiester bond hydrolysis:CPSF4 \| RNA phosphodiester bond hydrolysis:CPSF4 \| negative regulation of cellular catabolic process:RRAGA \| snRNA metabolic process:MEPCE \| positive regulation of actin filament polymerization:ARPC1A,ARPC1B \| regulation of TOR signaling:RRAGA \| RNA splicing, via endonucleolytic cleavage and ligation:CPSF4 \| autophagy:RRAGA \| process utilizing autophagic mechanism:RRAGA \| cytolysis:RRAGA \| negative regulation of mitotic cell cycle phase transition:ZNF655 \| negative regulation of catabolic process:RRAGA \| regulation of protein complex assembly:ARPC1A,ARPC1B \| DNA-templated transcription, termination:CPSF4 \| negative regulation of cell cycle phase transition:ZNF655	0.0185085	0.0355734	0.21974319080788	0.00841224	0.0318349	0.101477207308833	-0.00761317	0.0706005	0.0389934633825315	-5.86034E-4	0.03914	0.00521887977301887	-0.0408051	0.0419472	0.480380675146125	0.0801613	0.0807389	0.493327235143373	-0.0329378	0.0291925	0.586153938724438	-0.0538585	0.0330236	0.986564451555031	0.0100658	0.05667	0.0659709413678645	-0.189853	0.0220003	17.2104756933791	-0.190167	0.0272721	11.5081622442041	-0.189366	0.0355939	6.98435527994763	-0.0432698	0.0215849	1.34676239437946	0.0178116	0.0228089	0.361652535882764				-0.0438867	0.0211287	1.42261276512508	-0.0431868	0.0259836	1.01548618824893				-0.00426086	0.0126219	0.13330986975104	-0.0085497	0.016219	0.223229102091716	4.55559E-4	0.0198982	0.00800616799829703	0.0557562	0.0585423	0.467239253099908	0.0741286	0.072594	0.51232721953151	0.0234154	0.0992907	0.0895687764017753
rs145827824:32103749:C:G	novel1	6	32103749	6p21.32	G	C	0.991	122	OHP17 ALL	2070	15.6246729803774	0.0114659420289855		FKBPL (5.7 kb); ATF6B (7.7 kb); PRRT1 (12 kb); PPT2 (17 kb); PPT2-EGFL8 (18 kb); TNXB (21 kb); EGFL8 (29 kb); AGPAT1 (32 kb); RNF5 (42 kb); AGER (45 kb); PBX2 (49 kb)	0.489 Blood protein levels // 0.329 Blood metabolite levels // 0.31 Marginal zone lymphoma // 0.302 Economic and political preferences (environmentalism) // 0.302 Hepatitis B vaccine response	- \| ABCF1 \| ABHD16A \| AGER \| AIF1 \| APOM \| ATF6B \| ATP6V1G2 \| BAG6 \| BRD2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf25 \| C6orf48 \| CCHCR1 \| CFB \| CLIC1 \| CSNK2B \| CUTA \| CYP21A2 \| DDAH2 \| DDR1 \| DDX39B \| DOM3Z \| DXO \| EHMT2 \| FLOT1 \| GPANK1 \| GPSM3 \| GTF2H4 \| HCG22 \| HCG23 \| HCG27 \| HCP5 \| HLA-B \| HLA-C \| HLA-DOA \| HLA-DOB \| HLA-DPA1 \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DQB1-AS1 \| HLA-DQB2 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB2 \| HLA-DRB3 \| HLA-DRB4 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB7 \| HLA-DRB8 \| HLA-DRB9 \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LY6G5B \| LY6G5C \| LY6G6E \| MCCD1 \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| NOTCH4 \| PBX2 \| PHF1 \| PPP1R10 \| PPT2 \| PRRC2A \| PRRT1 \| PSMB8 \| PSMB9 \| RDBP \| RNF5 \| RPP21 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP1 \| TAP2 \| TNF \| unnamed \| VARS \| VARS2 \| VPS52 \| XXbac-BPG154L12.4 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.12 \| XXbac-BPG254F23.6 \| XXbac-BPG299F13.17 \| ZBTB12	ABP1 \| CCDC69 \| FLOT1 \| HLA-E \| HLA-F \| HLA-H \| HLA-V \| IER3 \| LIMS1 \| LINC00243 \| MDC1 \| NHP2 \| PPP1R11 \| TRAV12-1 \| VARS2 \| ZNRD1	Type I diabetes mellitus:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Allograft rejection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Graft-versus-host disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L,TAP2 \| Autoimmune thyroid disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Viral myocarditis:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Staphylococcus aureus infection:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Asthma:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Phagosome:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,TAP2 \| Herpes simplex infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,TAP2 \| Intestinal immune network for IgA production:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Rheumatoid arthritis:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Inflammatory bowel disease (IBD):HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Toxoplasmosis:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L \| Systemic lupus erythematosus:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Cell adhesion molecules (CAMs):HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Leishmaniasis:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Influenza A:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L \| Hematopoietic cell lineage:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Epstein-Barr virus infection:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Th1 and Th2 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Th17 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Tuberculosis:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Natural killer cell mediated cytotoxicity:HLA-C,NCR3 \| Endocytosis:HLA-C,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L \| Human cytomegalovirus infection:ATF6B,HLA-C,TAP2 \| Kaposi sarcoma-associated herpesvirus infection:HLA-C \| Viral carcinogenesis:ATF6B,GTF2H4,HLA-C \| Spliceosome:HSPA1A,HSPA1B,HSPA1L,LSM2 \| Human immunodeficiency virus 1 infection:HLA-C,TAP2 \| Protein processing in endoplasmic reticulum:ATF6B,HSPA1A,HSPA1B,HSPA1L,RNF5 \| Cellular senescence:HLA-C \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:ATF6B,HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:HLA-C,TNXB \| Proteasome:PSMB8,PSMB9 \| TNF signaling pathway:ATF6B \| Aminoacyl-tRNA biosynthesis:VARS2 \| Lysosome:NEU1,PPT2 \| Cortisol synthesis and secretion:ATF6B	Translocation of ZAP-70 to Immunological synapse:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Interferon gamma signaling:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| PD-1 signaling:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Generation of second messenger molecules:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Downstream TCR signaling:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB8,PSMB9 \| Interferon Signaling:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB8 \| TCR signaling:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB8,PSMB9 \| MHC class II antigen presentation:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Costimulation by the CD28 family:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Endosomal/Vacuolar pathway:HLA-C \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,TAP2 \| ER-Phagosome pathway:HLA-C,PSMB8,PSMB9,TAP2 \| Antigen processing-Cross presentation:HLA-C,PSMB8,PSMB9,TAP2 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,NCR3 \| Interferon alpha/beta signaling:HLA-C,PSMB8 \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:GTF2H4,HSPA1A,HSPA1B,PSMB8,PSMB9 \| TNFR2 non-canonical NF-kB pathway:PSMB8,PSMB9 \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| TP53 Regulates Transcription of DNA Repair Genes:GTF2H4 \| HIV Infection:GTF2H4,PSMB8,PSMB9 \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B,PSMB8,PSMB9 \| Class I MHC mediated antigen processing & presentation:HLA-C,PSMB8,PSMB9,TAP2 \| Transcriptional regulation by RUNX3:PSMB8,PSMB9 \| HIV Transcription Elongation:GTF2H4 \| Formation of HIV-1 elongation complex containing HIV-1 Tat:GTF2H4 \| Tat-mediated elongation of the HIV-1 transcript:GTF2H4 \| Formation of HIV elongation complex in the absence of HIV Tat:GTF2H4 \| Vpu mediated degradation of CD4:PSMB8,PSMB9 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B,PSMB8,PSMB9 \| SCF-beta-TrCP mediated degradation of Emi1:PSMB8,PSMB9 \| NIK-->noncanonical NF-kB signaling:PSMB8,PSMB9 \| Dectin-1 mediated noncanonical NF-kB signaling:PSMB8,PSMB9 \| Degradation of GLI1 by the proteasome:PSMB8,PSMB9 \| Degradation of GLI2 by the proteasome:PSMB8,PSMB9 \| GLI3 is processed to GLI3R by the proteasome:PSMB8,PSMB9 \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Regulation of PTEN stability and activity:PSMB8,PSMB9 \| Influenza Infection:HSPA1A,HSPA1B \| Defective CFTR causes cystic fibrosis:PSMB8,PSMB9,RNF5 \| Formation of RNA Pol II elongation complex :GTF2H4 \| RNA Polymerase II Transcription Elongation:GTF2H4 \| Formation of the Early Elongation Complex:GTF2H4 \| Formation of the HIV-1 Early Elongation Complex:GTF2H4 \| ABC-family proteins mediated transport:PSMB8,PSMB9,RNF5 \| Activation of NF-kappaB in B cells:PSMB8,PSMB9 \| G2/M Transition:FKBPL,PSMB8,PSMB9 \| HIV Life Cycle:GTF2H4 \| Mitotic G2-G2/M phases:FKBPL,PSMB8,PSMB9 \| RNA Polymerase I Promoter Escape:GTF2H4,ZNRD1 \| Transcription of the HIV genome:GTF2H4 \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Transcriptional Regulation by TP53:GTF2H4 \| RNA Polymerase I Transcription Termination:GTF2H4,ZNRD1 \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| RNA Polymerase I Transcription Initiation:GTF2H4,ZNRD1 \| Diseases associated with glycosylation precursor biosynthesis:NEU1 \| The role of GTSE1 in G2/M progression after G2 checkpoint:FKBPL,PSMB8,PSMB9 \| Neutrophil degranulation:HLA-C,HSPA1A,HSPA1B,NEU1 \| Regulation of APC/C activators between G1/S and early anaphase:PSMB8,PSMB9 \| ABC transporter disorders:PSMB8,PSMB9,RNF5 \| Cyclin A:Cdk2-associated events at S phase entry:PSMB8,PSMB9 \| Interleukin-1 family signaling:AGER,PSMB8,PSMB9 \| Degradation of beta-catenin by the destruction complex:PSMB8,PSMB9 \| FCERI mediated NF-kB activation:PSMB8,PSMB9 \| Cyclin E associated events during G1/S transition :PSMB8,PSMB9 \| Downstream signaling events of B Cell Receptor (BCR):PSMB8,PSMB9 \| Influenza Life Cycle:HSPA1A,HSPA1B \| RNA Polymerase II Pre-transcription Events:GTF2H4 \| APC/C-mediated degradation of cell cycle proteins:PSMB8,PSMB9 \| Regulation of mitotic cell cycle:PSMB8,PSMB9 \| Dual Incision in GG-NER:GTF2H4 \| tRNA Aminoacylation:VARS2 \| Cross-presentation of soluble exogenous antigens (endosomes):PSMB8,PSMB9 \| Regulation of activated PAK-2p34 by proteasome mediated degradation:PSMB8,PSMB9 \| Formation of Incision Complex in GG-NER:GTF2H4 \| Regulation of ornithine decarboxylase (ODC):PSMB8,PSMB9 \| CDK-mediated phosphorylation and removal of Cdc6:PSMB8,PSMB9 \| Ubiquitin-dependent degradation of Cyclin D1:PSMB8,PSMB9 \| Ubiquitin-dependent degradation of Cyclin D:PSMB8,PSMB9 \| Autodegradation of the E3 ubiquitin ligase COP1:PSMB8,PSMB9 \| Regulation of Apoptosis:PSMB8,PSMB9 \| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A:PSMB8,PSMB9 \| p53-Independent DNA Damage Response:PSMB8,PSMB9 \| p53-Independent G1/S DNA damage checkpoint:PSMB8,PSMB9 \| Late Phase of HIV Life Cycle:GTF2H4 \| Vif-mediated degradation of APOBEC3G:PSMB8,PSMB9 \| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis:PSMB8,PSMB9 \| C-type lectin receptors (CLRs):PSMB8,PSMB9 \| Degradation of AXIN:PSMB8,PSMB9 \| Regulation of RUNX3 expression and activity:PSMB8,PSMB9 \| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD:PSMB8,PSMB9 \| Degradation of DVL:PSMB8,PSMB9 \| Stabilization of p53:PSMB8,PSMB9 \| CLEC7A (Dectin-1) signaling:PSMB8,PSMB9 \| Hh mutants abrogate ligand secretion:PSMB8,PSMB9 \| CDT1 association with the CDC6:ORC:origin complex:PSMB8,PSMB9 \| SCF(Skp2)-mediated degradation of p27/p21:PSMB8,PSMB9 \| Regulation of expression of SLITs and ROBOs:PSMB8,PSMB9 \| Deadenylation-dependent mRNA decay:LSM2,SKIV2L \| Cytosolic sensors of pathogen-associated DNA :AGER \| Chaperonin-mediated protein folding:SKIV2L \| Association of TriC/CCT with target proteins during biosynthesis:SKIV2L \| Autodegradation of Cdh1 by Cdh1:APC/C:PSMB8,PSMB9 \| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection:GTF2H4 \| RNA Pol II CTD phosphorylation and interaction with CE:GTF2H4 \| RNA Polymerase I Promoter Clearance:GTF2H4,ZNRD1 \| Asymmetric localization of PCP proteins:PSMB8,PSMB9 \| Hedgehog ligand biogenesis:PSMB8,PSMB9 \| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha:PSMB8,PSMB9 \| p53-Dependent G1 DNA Damage Response:PSMB8,PSMB9 \| p53-Dependent G1/S DNA damage checkpoint:PSMB8,PSMB9 \| RNA Polymerase I Transcription:GTF2H4,ZNRD1 \| mRNA Capping:GTF2H4 \| APC/C:Cdc20 mediated degradation of Securin:PSMB8,PSMB9 \| Hedgehog 'off' state:PSMB8,PSMB9	Kawasaki disease:BAG6,HLA-C,HLA-DRB1,PRRC2A \| lymphadenitis:BAG6,HLA-C,HLA-DRB1,PRRC2A \| lymph node disease:BAG6,HLA-C,HLA-DRB1,PRRC2A \| lymphatic system disease:BAG6,HLA-C,HLA-DRB1,PRRC2A \| leprosy:HLA-DRB1 \| sarcoidosis:AGER,DDR1,HLA-DQA1,HLA-DRB1,HSPA1L \| hypersensitivity reaction type IV disease:AGER,DDR1,HLA-DQA1,HLA-DRB1,HSPA1L \| autoimmune disease of endocrine system:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| multiple sclerosis:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| endocrine system disease:AGER,HLA-C,HLA-DQA1,HLA-DRB1,HSPA1B,TAP2 \| autoimmune thyroiditis:HLA-DRB1 \| demyelinating disease:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Graves' disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| thyroid gland disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| intrahepatic cholestasis:HLA-DQA1,HLA-DRB1 \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HLA-C,HLA-DQA1,HLA-DRB1,AGER \| primary bacterial infectious disease:FLOT1,HLA-DRB1,PSMB8,PSMB9,TAP2 \| hepatitis:HLA-C,HLA-DQA1,HLA-DRB1,NCR3,PSMB9 \| hyperthyroidism:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| vitiligo:DDR1,HLA-C,PSMB8 \| spondylitis:HLA-C \| ankylosing spondylitis:HLA-C \| rheumatic fever:HLA-DQA1,HLA-DRB1 \| bacterial infectious disease:FLOT1,HLA-DRB1,PSMB8,PSMB9,TAP2 \| aplastic anemia:HLA-DQA1,HLA-DRB1 \| urticaria:HLA-DRB1 \| spondyloarthropathy:HLA-C \| vasculitis:DDR1,HLA-DRB1 \| hypothyroidism:HLA-DRB1 \| Behcet's disease:HLA-DRB1 \| hepatitis C:HLA-C,HLA-DQA1,HLA-DRB1,NCR3 \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1 \| arthropathy:HLA-C \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,NCR3,PRRC2A,TAP2 \| malaria:HLA-DRB1,NCR3,PRRC2A \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:DDR1,HLA-DRB1 \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-DRB1 \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DQA1,HLA-DRA \| neuromuscular junction disease:HLA-DQA1,HLA-DRA \| brucellosis:PSMB8,TAP2,PSMB9 \| duodenal ulcer:HSPA1A \| cholestasis:HLA-DQA1,HLA-DRB1 \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-C,HLA-DQA1,HLA-DRB1,PSMB9 \| upper respiratory tract disease:HLA-C,HSPA1A,TAP2 \| uveitis:HLA-DQA1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,NCR3,PRRC2A \| urinary system disease:AGER,DDR1,HLA-DQA1,HLA-DRB1,HSPA1A,LIMS1,PSMB8 \| multiple myeloma:BAG6,IER3,NCR3 \| myeloma:BAG6,IER3,NCR3 \| reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| bone marrow cancer:BAG6,IER3,NCR3 \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L \| bile duct disease:HLA-C,HLA-DQA1,HLA-DRB1 \| biliary tract disease:HLA-C,HLA-DQA1,HLA-DRB1 \| azoospermia:HLA-DRB1,MSH5 \| proteinuria:DDR1,HLA-DRB1,PSMB8 \| kidney disease:AGER,DDR1,HLA-DQA1,HLA-DRB1,HSPA1A,LIMS1,PSMB8 \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DRB1 \| type 1 diabetes mellitus:HLA-DQA1 \| blood coagulation disease:HLA-DRA,HLA-DRB1 \| allergic rhinitis:HLA-C,TAP2 \| hemorrhagic disease:HLA-DRA,HLA-DRB1 \| neuromuscular disease:HLA-DQA1,HLA-DRA \| thyroiditis:HLA-DRB1 \| nasal cavity disease:HLA-C,TAP2 \| nose disease:HLA-C,TAP2 \| rhinitis:HLA-C,TAP2 \| collagen disease:AGER,HLA-DRB1,TAP2,TNXB \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:AGER,HLA-DRB1,HSPA1B \| nephritis:HLA-DQA1,HLA-DRB1 \| periodontitis:AGER \| celiac disease:HLA-DQA1,HLA-DRB1 \| peptic ulcer disease:HSPA1A \| hematopoietic system disease:HLA-DQA1,HLA-DRA,HLA-DRB1 \| gestational diabetes:AGER \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DQA1,HLA-DRB1 \| rheumatic disease:AGER,HLA-DRB1,TAP2 \| systemic scleroderma:AGER,HLA-DRB1,TAP2 \| scleroderma:AGER,HLA-DRB1,TAP2 \| male reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| male infertility:HLA-DRB1,MSH5 \| silicosis:HLA-DRB1 \| integumentary system disease:HLA-DQA1,HLA-DRB1 \| sickle cell anemia:HLA-DRB1 \| periodontal disease:AGER \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2 \| Human immunodeficiency virus infectious disease:HLA-C,HLA-DRB1 \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B \| interstitial lung disease:AGER,DDR1,HLA-DRB1 \| bronchial disease:HSPA1A,HSPA1B,TAP2 \| acute pancreatitis:HSPA1B \| tuberculosis:HLA-DRB1 \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| prostate disease:HLA-DRB1,HSPA1A \| aortic valve disease:AGER \| pneumoconiosis:HLA-DRB1 \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1 \| tooth disease:AGER \| germ cell and embryonal cancer:PBX2 \| autoimmune disease of peripheral nervous system:HLA-DRB1 \| Guillain-Barre syndrome:HLA-DRB1 \| pancreas disease:HLA-DRB1,HSPA1B,AGER \| open-angle glaucoma:HLA-DRB1,TAP2 \| influenza:HLA-DRB1 \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-DQA1,HLA-DRB1 \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:AGER,DDR1,HLA-DRB1,HSPA1A,HSPA1B,TAP2 \| ovarian disease:MSH5 \| gastritis:HLA-DRB1 \| dermatomyositis:AGER,HLA-DRB1 \| essential hypertension:HSPA1A,HSPA1B,HSPA1L,PSMB9 \| female reproductive system disease:MSH5 \| osteomyelitis:HLA-DRB1 \| neuropathy:AGER,HLA-DQA1,HLA-DRA \| mouth disease:AGER \| Sjogren's syndrome:AGER,PSMB9 \| migraine:HLA-DRB1 \| infertility:MSH5 \| peripheral nervous system disease:HLA-DRB1 \| autoimmune disease of urogenital tract:HLA-DRB1 \| primary biliary cirrhosis:HLA-DRB1 \| cell type benign neoplasm:DDR1,TNXB \| stomach disease:HLA-DRB1 \| cholangitis:HLA-C,HLA-DRB1 \| Crohn's disease:HSPA1B \| osteosarcoma:BAG6 \| lung disease:AGER,DDR1,HLA-DRB1,HSPA1A,HSPA1B \| spinal cord disease:HLA-C,HLA-DRB1 \| heart valve disease:AGER \| pulmonary edema:HSPA1A \| aortic valve stenosis:AGER \| myositis:AGER,HLA-DRB1 \| neurofibroma:TNXB \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B \| myopathy:AGER,HLA-DRB1 \| muscle tissue disease:AGER,HLA-DRB1 \| bone cancer:BAG6 \| nasopharynx carcinoma:DDR1,HSPA1B \| pharynx cancer:DDR1,HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| muscular disease:AGER,HLA-DRB1 \| endocrine organ benign neoplasm:DDR1 \| bronchiectasis:TAP2 \| premature ovarian failure:MSH5 \| liver cirrhosis:DDR1,HLA-DRB1 \| renal cell carcinoma:HLA-DRB1,TAP2 \| glaucoma:HLA-DRB1,TAP2 \| esophageal carcinoma:HLA-DRB1 \| retinal disease:AGER,HLA-DRB1,TAP2 \| skin disease:HLA-DRB1 \| female reproductive organ cancer:DDR1,HLA-DQA1,HLA-DRB1 \| connective tissue cancer:BAG6 \| adenoma:DDR1,TNXB \| pulmonary fibrosis:AGER \| primary open angle glaucoma:TAP2 \| severe combined immunodeficiency:HLA-DRB1 \| coronary artery disease:AGER,PSMB8 \| retinal degeneration:HLA-DRB1,TAP2 \| malignant ovarian surface epithelial-stromal neoplasm:DDR1,HLA-DQA1,HLA-DRB1 \| ovary epithelial cancer:DDR1,HLA-DQA1,HLA-DRB1 \| ovarian carcinoma:DDR1,HLA-DQA1,HLA-DRB1 \| combined T cell and B cell immunodeficiency:HLA-DRB1	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB8,PSMB9,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB8,PSMB9,TAP2 \| antigen processing and presentation of peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB8,PSMB9,TAP2 \| antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB8,PSMB9,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| cellular response to interferon-gamma:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| response to interferon-gamma:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| T cell receptor signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB8,PSMB9 \| immune response-activating signal transduction:BAG6,FLOT1,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,NCR3,PSMB8,PSMB9 \| T cell costimulation:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| immune response-activating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,NCR3,PSMB8,PSMB9 \| lymphocyte costimulation:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen receptor-mediated signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB8,PSMB9 \| immune response-regulating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,NCR3,PSMB8,PSMB9 \| positive regulation of cell-cell adhesion:AGER,FLOT1,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of leukocyte cell-cell adhesion:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of T cell activation:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| T cell activation:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of cell-cell adhesion:AGER,FLOT1,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,PSMB8,PSMB9,TAP2 \| regulation of leukocyte cell-cell adhesion:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,PSMB8,PSMB9,TAP2 \| positive regulation of cell adhesion:AGER,FLOT1,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,LIMS1 \| positive regulation of lymphocyte activation:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of cell activation:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of lymphocyte activation:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,LST1 \| regulation of T cell activation:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of leukocyte activation:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5,LST1 \| leukocyte cell-cell adhesion:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,PSMB8,PSMB9,TAP2 \| positive regulation of leukocyte activation:AGER,HLA-DQA1,HLA-DQA2,HLA-DRA,HLA-DRB1,HLA-DRB5 \| lymphocyte mediated immunity:AGER,NCR3 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:AGER,NCR3 \| adaptive immune response:AGER,NCR3,TAP2 \| natural killer cell mediated cytotoxicity:NCR3 \| natural killer cell mediated immunity:NCR3 \| T cell mediated cytotoxicity:NCR3,AGER \| response to type I interferon:HLA-C,PSMB8 \| type I interferon signaling pathway:HLA-C,PSMB8 \| cellular response to type I interferon:HLA-C,PSMB8 \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,LIMS1,PSMB8,PSMB9 \| leukocyte mediated cytotoxicity:NCR3,AGER \| positive regulation of defense response:FLOT1,GPSM3,HSPA1A,HSPA1B,NCR3,PSMB8,PSMB9 \| positive regulation of cytokine production:AGER,AGPAT1,FLOT1,GPSM3,HSPA1A,HSPA1B \| T cell mediated immunity:AGER,NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:AGER,NCR3 \| positive regulation of innate immune response:FLOT1,HSPA1A,HSPA1B,NCR3,PSMB8,PSMB9 \| positive regulation of T cell proliferation:AGER \| regulation of lymphocyte mediated immunity:NCR3,AGER \| NIK/NF-kappaB signaling:AGER,LIMS1,PSMB8,PSMB9 \| regulation of innate immune response:FLOT1,HSPA1A,HSPA1B,NCR3,PSMB8,PSMB9 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B,LIMS1,PSMB8,PSMB9 \| regulation of T cell proliferation:AGER \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B,PSMB8,PSMB9 \| cell killing:NCR3,AGER \| positive regulation of lymphocyte mediated immunity:NCR3 \| regulation of lymphocyte proliferation:AGER,LST1 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| regulation of mononuclear cell proliferation:AGER,LST1 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of natural killer cell mediated cytotoxicity:NCR3 \| positive regulation of adaptive immune response:NCR3 \| regulation of natural killer cell mediated immunity:NCR3 \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B,PSMB8,PSMB9 \| regulation of leukocyte proliferation:AGER,LST1 \| mRNA catabolic process:HSPA1A,HSPA1B,LSM2,PSMB8,PSMB9,SKIV2L \| response to tumor necrosis factor:HSPA1A,HSPA1B,LIMS1,PSMB8,PSMB9 \| response to heat:HSPA1A,HSPA1B,HSPA1L \| antigen processing and presentation via MHC class Ib:TAP2 \| positive regulation of nitric oxide biosynthetic process:DDAH2 \| positive regulation of nitric oxide metabolic process:DDAH2 \| regulation of leukocyte mediated immunity:NCR3,AGER \| activation of innate immune response:FLOT1,HSPA1A,HSPA1B,PSMB8,PSMB9 \| regulation of T cell mediated cytotoxicity:AGER,NCR3 \| positive regulation of leukocyte mediated immunity:NCR3 \| T cell proliferation:AGER \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| antigen processing and presentation of endogenous antigen:TAP2 \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B \| microtubule nucleation:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of lymphocyte proliferation:AGER \| positive regulation of mononuclear cell proliferation:AGER \| positive regulation of heterotypic cell-cell adhesion:FLOT1 \| regulation of leukocyte mediated cytotoxicity:AGER,NCR3 \| regulation of DNA-templated transcription in response to stress:ATF6B,HSPA1A,PSMB8,PSMB9 \| ER-associated misfolded protein catabolic process:BAG6,RNF5 \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B,PSMB8,PSMB9 \| positive regulation of ubiquitin protein ligase activity:PSMB8,PSMB9 \| RNA catabolic process:HSPA1A,HSPA1B,LSM2,PSMB8,PSMB9,SKIV2L \| positive regulation of leukocyte proliferation:AGER \| positive regulation of reactive oxygen species biosynthetic process:DDAH2 \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,HSPA1L,RNF5 \| positive regulation of T cell mediated cytotoxicity:NCR3 \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| DNA-templated transcription, elongation:GTF2H4,ZNRD1 \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| innate immune response-activating signal transduction:FLOT1,HSPA1A,HSPA1B,PSMB8,PSMB9 \| regulation of ubiquitin protein ligase activity:PSMB8,PSMB9 \| regulation of nitric oxide biosynthetic process:DDAH2 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3,AGER \| lymphocyte proliferation:AGER,LST1 \| mononuclear cell proliferation:AGER,LST1 \| regulation of translational fidelity:VARS2 \| positive regulation of interleukin-12 production:AGER \| regulation of cell killing:AGER,NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B,PSMB8,PSMB9 \| regulation of interleukin-8 production:HSPA1A,HSPA1B \| regulation of antigen processing and presentation:HLA-DOB \| RNA phosphodiester bond hydrolysis:HSPA1A,ZNRD1 \| regulation of dendritic cell differentiation:AGER \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| regulation of adaptive immune response:NCR3,AGER \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| leukocyte proliferation:AGER,LST1 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B,AGER \| regulation of protein stability:BAG6,FKBPL,FLOT1,HSPA1A,HSPA1B,RNF5 \| nitric oxide biosynthetic process:DDAH2 \| interleukin-8 production:HSPA1A,HSPA1B \| regulation of heterotypic cell-cell adhesion:FLOT1 \| extracellular matrix assembly:TNXB \| positive regulation of protein complex assembly:GTF2H4,HSPA1A,HSPA1B \| interaction with host:HSPA1A,HSPA1B \| positive regulation of ubiquitin-protein transferase activity:PSMB8,PSMB9 \| signal transduction in absence of ligand:HSPA1A,HSPA1B \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| nucleocytoplasmic transport:AGER \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of natural killer cell mediated immunity:NCR3 \| regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB8,PSMB9 \| nitric oxide metabolic process:DDAH2 \| nuclear transport:AGER \| cellular response to misfolded protein:BAG6,RNF5 \| natural killer cell activation:BAG6,NCR3 \| reactive nitrogen species metabolic process:DDAH2 \| nuclear-transcribed mRNA catabolic process, exonucleolytic:LSM2,SKIV2L \| cellular response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,RNF5 \| protein stabilization:BAG6,FLOT1,HSPA1A,HSPA1B,FKBPL \| positive regulation of cytokine-mediated signaling pathway:AGPAT1,HSPA1A,HSPA1B \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| response to misfolded protein:BAG6,RNF5 \| mRNA cleavage:HSPA1A,ZNRD1 \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of organelle assembly:HSPA1A,HSPA1B,RNF5 \| regulation of transcription from RNA polymerase II promoter in response to stress:ATF6B,HSPA1A,PSMB8,PSMB9 \| regulation of reactive oxygen species biosynthetic process:DDAH2 \| SCF-dependent proteasomal ubiquitin-dependent protein catabolic process:PSMB8,PSMB9 \| protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB8,PSMB9,RNF5 \| regulation of endocytosis:FLOT1 \| protein K63-linked ubiquitination:RNF5 \| protein quality control for misfolded or incompletely synthesized proteins:BAG6,RNF5 \| positive regulation of response to cytokine stimulus:AGPAT1,HSPA1A,HSPA1B \| positive regulation of endocytosis:FLOT1 \| positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition:PSMB8,PSMB9 \| response to endoplasmic reticulum stress:ATF6B,BAG6,FLOT1,HSPA1A,RNF5 \| positive regulation of immune effector process:NCR3 \| stimulatory C-type lectin receptor signaling pathway:PSMB8,PSMB9 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| regulation of ubiquitin-protein transferase activity:PSMB8,PSMB9 \| transcription elongation from RNA polymerase I promoter:GTF2H4,ZNRD1 \| termination of RNA polymerase I transcription:GTF2H4,ZNRD1 \| pattern recognition receptor signaling pathway:FLOT1,HSPA1A,HSPA1B \| innate immune response activating cell surface receptor signaling pathway:PSMB8,PSMB9 \| positive regulation of T cell mediated immunity:NCR3 \| positive regulation of NIK/NF-kappaB signaling:AGER,LIMS1 \| spindle assembly:HSPA1A,HSPA1B \| ganglioside metabolic process:NEU1 \| regulation of interleukin-12 production:AGER \| nucleic acid phosphodiester bond hydrolysis:GTF2H4,HSPA1A,ZNRD1 \| transcription initiation from RNA polymerase I promoter:GTF2H4,ZNRD1 \| exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay:LSM2,SKIV2L \| nuclear-transcribed mRNA catabolic process:LSM2,SKIV2L \| interleukin-12 production:AGER \| collagen fibril organization:TNXB \| positive regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| positive regulation of leukocyte mediated cytotoxicity:NCR3 \| reactive oxygen species biosynthetic process:DDAH2 \| negative regulation of immune system process:HLA-DOB,LST1 \| positive regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A,PSMB8,PSMB9 \| positive regulation of NF-kappaB import into nucleus:AGER \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| post-translational protein modification:PSMB8,PSMB9 \| macroautophagy:RNF5 \| regulation of T cell mediated immunity:AGER,NCR3 \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| receptor-mediated endocytosis:AGER,FLOT1 \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| DNA-templated transcription, termination:GTF2H4,ZNRD1 \| positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB8,PSMB9 \| regulation of macroautophagy:RNF5 \| membrane assembly:FLOT1 \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:FLOT1,LY6G5C \| viral life cycle:HSPA1A,HSPA1B \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress:ATF6B \| protein localization to nucleus:AGER \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A,PSMB8,PSMB9 \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| positive regulation of catabolic process:BAG6,HSPA1A,PSMB8,PSMB9 \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:BAG6,HSPA1A,PSMB8,PSMB9 \| microglial cell activation:AGER \| negative regulation of proteolysis involved in cellular protein catabolic process:BAG6 \| positive regulation of cell killing:NCR3 \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| mRNA cleavage involved in mRNA processing:HSPA1A \| regulation of autophagy:RNF5 \| microtubule polymerization:HSPA1A,HSPA1B \| regulation of inflammatory response:AGER,GPSM3 \| synapsis:BAG6,MSH5 \| macrophage activation:AGER \| protein folding:HSPA1A,HSPA1B,HSPA1L \| positive regulation of protein catabolic process:BAG6,HSPA1A,PSMB8,PSMB9 \| positive regulation of cellular catabolic process:BAG6,HSPA1A,PSMB8,PSMB9 \| tRNA aminoacylation for protein translation:VARS2 \| regulation of transcription factor import into nucleus:AGER \| nuclear-transcribed mRNA catabolic process, nonsense-mediated decay:SKIV2L \| extracellular matrix organization:DDR1,FLOT1,TNXB \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| membrane biogenesis:FLOT1 \| extracellular structure organization:DDR1,FLOT1,TNXB \| heterotypic cell-cell adhesion:FLOT1 \| branching involved in mammary gland duct morphogenesis:DDR1 \| negative regulation of growth:HSPA1A,HSPA1B \| transcription factor import into nucleus:AGER \| tRNA aminoacylation:VARS2 \| regulation of binding:AGER,FLOT1 \| transcription elongation from RNA polymerase II promoter:GTF2H4 \| regulation of mRNA metabolic process:HSPA1A,PSMB8,PSMB9 \| regulation of NIK/NF-kappaB signaling:AGER,LIMS1 \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| syncytium formation by plasma membrane fusion:FLOT1 \| amino acid activation:VARS2 \| regulation of RNA stability:HSPA1A,PSMB8,PSMB9 \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| regulation of cellular amino acid metabolic process:PSMB8,PSMB9 \| syncytium formation:FLOT1 \| regulation of monooxygenase activity:DDAH2 \| positive regulation of cellular component biogenesis:FLOT1,GTF2H4,HSPA1A,HSPA1B \| regulation of cellular protein catabolic process:BAG6,HSPA1A,PSMB8,PSMB9 \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,AGER \| glial cell activation:AGER \| protein polymerization:HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| regulation of mitotic cell cycle phase transition:PSMB8,PSMB9 \| mitochondrial membrane organization:HSPA1A \| receptor metabolic process:FLOT1 \| reactive oxygen species metabolic process:DDAH2 \| regulation of receptor internalization:FLOT1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| protein polyubiquitination:PSMB8,PSMB9,RNF5 \| homologous chromosome segregation:BAG6,MSH5 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:BAG6,HSPA1A \| positive regulation of cell junction assembly:FLOT1,LIMS1 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| negative regulation of cellular protein catabolic process:BAG6 \| negative regulation of catabolic process:BAG6,RNF5 \| regulation of macrophage activation:AGER \| regulation of mRNA catabolic process:HSPA1A,PSMB8,PSMB9 \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| negative regulation of cellular catabolic process:BAG6,RNF5 \| negative regulation of autophagy:RNF5 \| cellular amino acid metabolic process:DDAH2,PSMB8,PSMB9,VARS2 \| transcription from RNA polymerase I promoter:GTF2H4,ZNRD1 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,AGER \| gland morphogenesis:DDR1 \| regulation of protein complex assembly:GTF2H4,HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| spindle organization:HSPA1A,HSPA1B \| negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle:PSMB8,PSMB9 \| regulation of protein catabolic process:BAG6,HSPA1A,PSMB8 \| negative regulation of mitotic cell cycle:PSMB8,PSMB9 \| DNA-templated transcription, initiation:GTF2H4,ZNRD1 \| Fc-epsilon receptor signaling pathway:PSMB8,PSMB9 \| regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle:PSMB8,PSMB9 \| chromosome organization involved in meiotic cell cycle:BAG6,MSH5 \| regulation of cell cycle phase transition:PSMB8,PSMB9 \| positive regulation of protein ubiquitination:PSMB8,PSMB9 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| transcription initiation from RNA polymerase II promoter:GTF2H4 \| mammary gland duct morphogenesis:DDR1 \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| autophagy:RNF5 \| process utilizing autophagic mechanism:RNF5 \| cellular response to oxidative stress:HSPA1A,HSPA1B \| regulation of striated muscle tissue development:FLOT1 \| positive regulation of striated muscle cell differentiation:FLOT1 \| regulation of autophagosome assembly:RNF5 \| G2/M transition of mitotic cell cycle:PSMB8,PSMB9 \| protein complex localization:AGER \| receptor internalization:FLOT1 \| regulation of reactive oxygen species metabolic process:DDAH2 \| negative regulation of proteolysis:BAG6 \| ubiquitin-dependent ERAD pathway:BAG6,RNF5 \| regulation of muscle tissue development:FLOT1 \| negative regulation of ubiquitin protein ligase activity:PSMB8,PSMB9 \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| 7-methylguanosine mRNA capping:GTF2H4 \| regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| regulation of leukocyte chemotaxis:GPSM3 \| mammary gland development:DDR1 \| response to unfolded protein:ATF6B,HSPA1A,HSPA1L \| regulation of transcription from RNA polymerase II promoter in response to hypoxia:PSMB8,PSMB9 \| response to oxidative stress:HSPA1A,HSPA1B \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| 7-methylguanosine RNA capping:GTF2H4 \| RNA capping:GTF2H4 \| regulation of cellular amine metabolic process:PSMB8,PSMB9 \| smooth muscle cell migration:DDR1 \| negative regulation of leukocyte activation:LST1 \| cell cycle G2/M phase transition:PSMB8,PSMB9 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:LSM2,SKIV2L \| anaphase-promoting complex-dependent catabolic process:PSMB8,PSMB9 \| regulation of G2/M transition of mitotic cell cycle:PSMB8,PSMB9	0.115141	0.0781383	0.851542339854514				-0.022121	0.129894	0.0630973762081611	0.699809	0.0846222	15.6246729803774	0.57225	0.107828	6.885936	0.797658	0.139096	7.83924043604593	0.156049	0.0640799	1.82487394646913				0.147423	0.099651	0.855488061296061	-0.0170733	0.0430819	0.159966712454831				-0.00501429	0.0739626	0.0241322775682269	0.0211014	0.0431127	0.204450171950002				0.11945	0.0718557	1.01574144731841							-0.0416208	0.0694779	0.26031771148398	-0.00102413	0.0249061	0.0144832631250995				-0.00357361	0.0406791	0.0315184523982661	0.372766	0.127692	2.45000537249092				0.231618	0.175142	0.729418978452739
rs615567:22319209:A:T	novel2	13	22319209	13q12.11	T	A	0.987	30	DHEAS ALL	7659	13.529742435831	0.392975780127954	0.6987	FGF9 (41 kb); RN7SL766P (45 kb); RPS7P10 (120 kb); LINC00424 (130 kb)	NA	EFHA1 \| FGF9		Regulation of actin cytoskeleton:FGF9		endocrine system disease:FGF9 \| gonadal dysgenesis:FGF9 \| gonadal disease:FGF9	organ growth:FGF9 \| nucleocytoplasmic transport:FGF9 \| nuclear transport:FGF9 \| regulation of activin receptor signaling pathway:FGF9 \| cellular response to fibroblast growth factor stimulus:FGF9 \| lipid modification:FGF9 \| response to fibroblast growth factor:FGF9 \| protein localization to nucleus:FGF9 \| regulation of cardiac muscle tissue growth:FGF9 \| smoothened signaling pathway:FGF9 \| regulation of heart growth:FGF9 \| activin receptor signaling pathway:FGF9 \| regulation of protein kinase B signaling:FGF9 \| regulation of cardiac muscle tissue development:FGF9 \| cardiac muscle tissue growth:FGF9 \| regulation of striated muscle tissue development:FGF9 \| regulation of muscle tissue development:FGF9 \| heart growth:FGF9 \| positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway:FGF9 \| regulation of organ growth:FGF9	0.0036083	0.0171961	0.0789276921007416	0.0208011	0.0153647	0.75444785266381	-0.00761486	0.0341674	0.0842641519339287	0.00535116	0.0189188	0.109399599294482	0.0194903	0.0202585	0.473426835299672	-0.0186107	0.0389864	0.198424115719587	-0.0239302	0.0141054	1.04606836362669	-0.00490317	0.0159638	0.119882980094123	-0.0583439	0.0272622	1.48561962241625	-0.0778523	0.0102432	13.529742435831	-0.0716892	0.0128678	7.59688634519438	-0.0851216	0.016306	6.74796780868763	0.00261437	0.0101286	0.0989140127336415	0.0275065	0.0107532	1.97764587353337	-0.034564	0.0171348	1.35975316527966	-0.00160901	0.0098721	0.0602162577345234	2.28004E-4	0.0122095	0.0065192400668815	-0.01028	0.0156561	0.291214649436612	-0.00805549	0.00589449	0.765113368959283	0.00397338	0.00766053	0.218975285071077	-0.02152	0.00914843	1.72915818846681	-0.0371514	0.0283557	0.720602292482328	-0.0439925	0.0352545	0.673031595247614	-0.026691	0.0477159	0.239509663364885
rs79040733:32473007:T:TG		6	32473007	6p21.32	TG	T	0.89	1	OHP17 ALL	2070	13.4109433502101	0.0107493719806763		HLA-DRB5 (12 kb); HLA-DRB9 (32 kb); RNU1-61P (45 kb); HLA-DRB6 (47 kb)	0.328 Marginal zone lymphoma	- \| AGER \| AIF1 \| APOM \| ATP6V1G2 \| B3GALT4 \| BAG6 \| BRD2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| CFB \| CLIC1 \| CSNK2B \| CUTA \| CYP21A2 \| DDAH2 \| DOM3Z \| DXO \| GPSM3 \| HCG23 \| HCP5 \| HLA-DMA \| HLA-DMB \| HLA-DOA \| HLA-DOB \| HLA-DPB1 \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DQB1-AS1 \| HLA-DQB2 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB4 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB9 \| HSPA1A \| HSPA1B \| HSPA1L \| LSM2 \| LST1 \| LTB \| LY6G5B \| LY6G5C \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| NOTCH4 \| PRRC2A \| PRRT1 \| PSMB8 \| PSMB9 \| RNF5 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP2 \| unnamed \| XXbac-BPG154L12.4 \| XXbac-BPG254F23.6	ARHGAP24 \| BTN3A2 \| CLK3 \| DEF8 \| EEF1G \| EXOC1 \| FLOT1 \| GOLGA2 \| HCP5 \| HLA-C \| HLA-G \| HLA-H \| KPNA2 \| LIMS1 \| LINC00243 \| ME2 \| NCR3 \| RPL34 \| SSRP1 \| TINF2 \| TMEM154 \| TOMM22 \| TRIM56 \| unnamed \| VARS2 \| XRCC6 \| ZNF672	Type I diabetes mellitus:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Allograft rejection:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Graft-versus-host disease:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Antigen processing and presentation:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1L,TAP2 \| Autoimmune thyroid disease:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Viral myocarditis:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Staphylococcus aureus infection:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Asthma:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Phagosome:ATP6V1G2,HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,TAP2 \| Herpes simplex infection:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,TAP2 \| Intestinal immune network for IgA production:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Rheumatoid arthritis:ATP6V1G2,HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,LTB \| Inflammatory bowel disease (IBD):HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Toxoplasmosis:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1L \| Systemic lupus erythematosus:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Cell adhesion molecules (CAMs):HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Leishmaniasis:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Influenza A:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1L,KPNA2 \| Hematopoietic cell lineage:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Epstein-Barr virus infection:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Th1 and Th2 cell differentiation:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Th17 cell differentiation:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Tuberculosis:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Endocytosis:HSPA1L \| Legionellosis:HSPA1L \| Human cytomegalovirus infection:TAP2 \| Spliceosome:HSPA1L,LSM2 \| Human immunodeficiency virus 1 infection:TAP2 \| NF-kappa B signaling pathway:LTB \| Protein processing in endoplasmic reticulum:HSPA1L,RNF5 \| Longevity regulating pathway - multiple species:HSPA1L \| Measles:HSPA1L \| Estrogen signaling pathway:HSPA1L \| Human papillomavirus infection:ATP6V1G2 \| Proteasome:PSMB9 \| Aminoacyl-tRNA biosynthesis:VARS2 \| Lysosome:NEU1	Translocation of ZAP-70 to Immunological synapse:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Interferon gamma signaling:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| PD-1 signaling:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Generation of second messenger molecules:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Downstream TCR signaling:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| Interferon Signaling:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,KPNA2 \| TCR signaling:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| MHC class II antigen presentation:HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Costimulation by the CD28 family:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:TAP2 \| ER-Phagosome pathway:PSMB9,TAP2 \| Antigen processing-Cross presentation:PSMB9,TAP2 \| Attenuation phase:HSPA1L \| Infectious disease:KPNA2,PSMB9,RPL34,SSRP1,XRCC6 \| TNFR2 non-canonical NF-kB pathway:LTB,PSMB9 \| Butyrophilin (BTN) family interactions:BTN3A2 \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1L \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:LTB \| HSF1-dependent transactivation:HSPA1L \| TP53 Regulates Transcription of DNA Repair Genes:SSRP1 \| HIV Infection:PSMB9,SSRP1,XRCC6 \| AUF1 (hnRNP D0) binds and destabilizes mRNA:PSMB9 \| Class I MHC mediated antigen processing & presentation:PSMB9,TAP2 \| Transcriptional regulation by RUNX3:PSMB9 \| HIV Transcription Elongation:SSRP1 \| Formation of HIV-1 elongation complex containing HIV-1 Tat:SSRP1 \| Tat-mediated elongation of the HIV-1 transcript:SSRP1 \| Formation of HIV elongation complex in the absence of HIV Tat:SSRP1 \| Vpu mediated degradation of CD4:PSMB9 \| Regulation of mRNA stability by proteins that bind AU-rich elements:PSMB9 \| SCF-beta-TrCP mediated degradation of Emi1:PSMB9 \| NIK-->noncanonical NF-kB signaling:PSMB9 \| Dectin-1 mediated noncanonical NF-kB signaling:PSMB9 \| Degradation of GLI1 by the proteasome:PSMB9 \| Degradation of GLI2 by the proteasome:PSMB9 \| GLI3 is processed to GLI3R by the proteasome:PSMB9 \| Regulation of HSF1-mediated heat shock response:HSPA1L \| Regulation of PTEN stability and activity:PSMB9 \| Influenza Infection:KPNA2,RPL34 \| Defective CFTR causes cystic fibrosis:PSMB9,RNF5 \| Formation of RNA Pol II elongation complex :SSRP1 \| RNA Polymerase II Transcription Elongation:SSRP1 \| Pausing and recovery of Tat-mediated HIV elongation:SSRP1 \| Tat-mediated HIV elongation arrest and recovery:SSRP1 \| ABC-family proteins mediated transport:PSMB9,RNF5 \| Activation of NF-kappaB in B cells:PSMB9 \| G2/M Transition:PSMB9 \| HIV elongation arrest and recovery:SSRP1 \| Pausing and recovery of HIV elongation:SSRP1 \| HIV Life Cycle:SSRP1,XRCC6 \| Mitotic G2-G2/M phases:PSMB9 \| Transcription of the HIV genome:SSRP1 \| Cellular response to heat stress:HSPA1L \| Transcriptional Regulation by TP53:SSRP1 \| Diseases associated with glycosylation precursor biosynthesis:NEU1 \| The role of GTSE1 in G2/M progression after G2 checkpoint:PSMB9 \| Neutrophil degranulation:NEU1,XRCC6 \| Regulation of APC/C activators between G1/S and early anaphase:PSMB9 \| ABC transporter disorders:PSMB9,RNF5 \| Cyclin A:Cdk2-associated events at S phase entry:PSMB9 \| Interleukin-1 family signaling:PSMB9 \| Degradation of beta-catenin by the destruction complex:PSMB9 \| FCERI mediated NF-kB activation:PSMB9 \| Cyclin E associated events during G1/S transition :PSMB9 \| Eukaryotic Translation Elongation:RPL34 \| Downstream signaling events of B Cell Receptor (BCR):PSMB9 \| Influenza Life Cycle:RPL34 \| RNA Polymerase II Pre-transcription Events:SSRP1 \| APC/C-mediated degradation of cell cycle proteins:PSMB9 \| Regulation of mitotic cell cycle:PSMB9 \| tRNA Aminoacylation:VARS2 \| Cross-presentation of soluble exogenous antigens (endosomes):PSMB9 \| Regulation of activated PAK-2p34 by proteasome mediated degradation:PSMB9 \| Regulation of ornithine decarboxylase (ODC):PSMB9 \| CDK-mediated phosphorylation and removal of Cdc6:PSMB9 \| Ubiquitin-dependent degradation of Cyclin D1:PSMB9 \| Ubiquitin-dependent degradation of Cyclin D:PSMB9 \| Autodegradation of the E3 ubiquitin ligase COP1:PSMB9 \| Regulation of Apoptosis:PSMB9 \| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A:PSMB9 \| p53-Independent DNA Damage Response:PSMB9 \| p53-Independent G1/S DNA damage checkpoint:PSMB9 \| Late Phase of HIV Life Cycle:SSRP1 \| Vif-mediated degradation of APOBEC3G:PSMB9 \| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis:PSMB9 \| C-type lectin receptors (CLRs):PSMB9 \| Degradation of AXIN:PSMB9 \| Regulation of RUNX3 expression and activity:PSMB9 \| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD:PSMB9 \| Degradation of DVL:PSMB9 \| Stabilization of p53:PSMB9 \| CLEC7A (Dectin-1) signaling:PSMB9 \| Hh mutants abrogate ligand secretion:PSMB9 \| CDT1 association with the CDC6:ORC:origin complex:PSMB9 \| SCF(Skp2)-mediated degradation of p27/p21:PSMB9 \| Regulation of expression of SLITs and ROBOs:PSMB9,RPL34 \| Deadenylation-dependent mRNA decay:LSM2,SKIV2L \| Cytosolic sensors of pathogen-associated DNA :XRCC6 \| Chaperonin-mediated protein folding:SKIV2L \| NS1 Mediated Effects on Host Pathways:KPNA2 \| Association of TriC/CCT with target proteins during biosynthesis:SKIV2L \| Autodegradation of Cdh1 by Cdh1:APC/C:PSMB9 \| Asymmetric localization of PCP proteins:PSMB9 \| Hedgehog ligand biogenesis:PSMB9 \| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha:PSMB9 \| p53-Dependent G1 DNA Damage Response:PSMB9 \| p53-Dependent G1/S DNA damage checkpoint:PSMB9 \| APC/C:Cdc20 mediated degradation of Securin:PSMB9 \| Hedgehog 'off' state:PSMB9	Kawasaki disease:HLA-DRB1 \| lymphadenitis:HLA-DRB1 \| lymph node disease:HLA-DRB1 \| lymphatic system disease:HLA-DRB1 \| leprosy:HLA-DRB1 \| sarcoidosis:HLA-DQA1,HLA-DRB1,HSPA1L \| hypersensitivity reaction type IV disease:HLA-DQA1,HLA-DRB1,HSPA1L \| autoimmune disease of endocrine system:HLA-DPB1,HLA-DQA1,HLA-DRB1,TAP2 \| multiple sclerosis:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| endocrine system disease:HLA-DPB1,HLA-DQA1,HLA-DRB1,TAP2 \| autoimmune thyroiditis:HLA-DRB1 \| demyelinating disease:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Graves' disease:HLA-DPB1,HLA-DQA1,HLA-DRB1,TAP2 \| thyroid gland disease:HLA-DPB1,HLA-DQA1,HLA-DRB1,TAP2 \| intrahepatic cholestasis:HLA-DQA1,HLA-DRB1 \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HLA-DQA1,HLA-DRB1 \| primary bacterial infectious disease:HLA-DPB1,HLA-DRB1,PSMB9,TAP2 \| hepatitis:APOM,HLA-DPB1,HLA-DQA1,HLA-DRB1,PSMB9 \| hyperthyroidism:HLA-DPB1,HLA-DQA1,HLA-DRB1,TAP2 \| rheumatic fever:HLA-DQA1,HLA-DRB1 \| bacterial infectious disease:HLA-DPB1,HLA-DRB1,PSMB9,TAP2 \| aplastic anemia:HLA-DQA1,HLA-DRB1 \| urticaria:HLA-DRB1 \| vasculitis:HLA-DRB1 \| hypothyroidism:HLA-DRB1 \| Behcet's disease:HLA-DRB1 \| hepatitis C:HLA-DQA1,HLA-DRB1 \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1 \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,TAP2 \| malaria:HLA-DRB1 \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:HLA-DRB1 \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-DRB1 \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DQA1,HLA-DRA \| neuromuscular junction disease:HLA-DQA1,HLA-DRA \| brucellosis:TAP2,PSMB9 \| cholestasis:HLA-DQA1,HLA-DRB1 \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-DPB1,HLA-DQA1,HLA-DRB1,PSMB9 \| upper respiratory tract disease:TAP2 \| uveitis:HLA-DQA1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1 \| urinary system disease:HLA-DQA1,HLA-DRB1 \| reproductive system disease:HLA-DRB1 \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L \| bile duct disease:HLA-DQA1,HLA-DRB1 \| biliary tract disease:HLA-DQA1,HLA-DRB1 \| azoospermia:HLA-DRB1 \| proteinuria:HLA-DRB1 \| borna disease:KPNA2 \| kidney disease:HLA-DQA1,HLA-DRB1 \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DRB1 \| type 1 diabetes mellitus:HLA-DQA1 \| blood coagulation disease:HLA-DRA,HLA-DRB1 \| allergic rhinitis:TAP2 \| hemorrhagic disease:HLA-DRA,HLA-DRB1 \| neuromuscular disease:HLA-DQA1,HLA-DRA \| thyroiditis:HLA-DRB1 \| nasal cavity disease:TAP2 \| nose disease:TAP2 \| rhinitis:TAP2 \| collagen disease:HLA-DPB1,HLA-DRB1,TAP2 \| prostatitis:HLA-DRB1 \| pancreatitis:HLA-DRB1 \| nephritis:HLA-DQA1,HLA-DRB1 \| celiac disease:HLA-DQA1,HLA-DRB1 \| hematopoietic system disease:HLA-DQA1,HLA-DRA,HLA-DRB1 \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DQA1,HLA-DRB1 \| rheumatic disease:HLA-DPB1,HLA-DRB1,TAP2 \| systemic scleroderma:HLA-DPB1,HLA-DRB1,TAP2 \| scleroderma:HLA-DPB1,HLA-DRB1,TAP2 \| male reproductive system disease:HLA-DRB1 \| male infertility:HLA-DRB1 \| silicosis:HLA-DRB1 \| integumentary system disease:HLA-DQA1,HLA-DRB1 \| sickle cell anemia:HLA-DRB1 \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2 \| Human immunodeficiency virus infectious disease:HLA-DRB1 \| reactive arthritis:HLA-DRB1 \| interstitial lung disease:HLA-DRB1 \| bronchial disease:TAP2 \| tuberculosis:HLA-DPB1,HLA-DRB1 \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| prostate disease:HLA-DRB1 \| pneumoconiosis:HLA-DRB1 \| schistosomiasis:HLA-DRB1 \| sclerosing cholangitis:HLA-DRB1 \| autoimmune disease of peripheral nervous system:HLA-DRB1 \| Guillain-Barre syndrome:HLA-DRB1 \| pancreas disease:HLA-DRB1 \| open-angle glaucoma:HLA-DRB1,TAP2 \| influenza:HLA-DRB1 \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-DPB1,HLA-DQA1,HLA-DRB1 \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:HLA-DRB1,TAP2 \| gastritis:HLA-DRB1 \| dermatomyositis:HLA-DRB1 \| essential hypertension:HSPA1L,PSMB9 \| osteomyelitis:HLA-DRB1 \| neuropathy:HLA-DQA1,HLA-DRA \| Sjogren's syndrome:PSMB9 \| migraine:HLA-DRB1 \| peripheral nervous system disease:HLA-DRB1 \| autoimmune disease of urogenital tract:HLA-DRB1 \| primary biliary cirrhosis:HLA-DRB1 \| cell type benign neoplasm:XRCC6 \| stomach disease:HLA-DRB1 \| cholangitis:HLA-DRB1 \| lung disease:HLA-DRB1 \| spinal cord disease:HLA-DRB1 \| myositis:HLA-DRB1 \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| myopathy:HLA-DPB1,HLA-DRB1 \| muscle tissue disease:HLA-DPB1,HLA-DRB1 \| lymphoblastic leukemia:HLA-DRB1,HSPA1L \| cardiomyopathy:HLA-DPB1 \| muscular disease:HLA-DPB1,HLA-DRB1 \| bronchiectasis:TAP2 \| liver cirrhosis:APOM,HLA-DRB1 \| renal cell carcinoma:HLA-DRB1,TAP2 \| pleural cancer:XRCC6 \| malignant pleural mesothelioma:XRCC6 \| glaucoma:HLA-DRB1,TAP2 \| esophageal carcinoma:HLA-DRB1 \| skin disease:HLA-DRB1 \| retinal disease:HLA-DRB1,TAP2 \| female reproductive organ cancer:HLA-DQA1,HLA-DRB1,KPNA2 \| primary open angle glaucoma:TAP2 \| severe combined immunodeficiency:HLA-DRB1 \| retinal degeneration:HLA-DRB1,TAP2 \| malignant ovarian surface epithelial-stromal neoplasm:HLA-DQA1,HLA-DRB1 \| ovary epithelial cancer:HLA-DQA1,HLA-DRB1 \| ovarian carcinoma:HLA-DQA1,HLA-DRB1 \| combined T cell and B cell immunodeficiency:HLA-DRB1	antigen processing and presentation of exogenous peptide antigen:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| antigen processing and presentation of peptide antigen:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| antigen processing and presentation:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| cellular response to interferon-gamma:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| response to interferon-gamma:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DMA,HLA-DOB,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| T cell receptor signaling pathway:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| immune response-activating signal transduction:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| T cell costimulation:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| immune response-activating cell surface receptor signaling pathway:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| lymphocyte costimulation:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen receptor-mediated signaling pathway:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| immune response-regulating cell surface receptor signaling pathway:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| positive regulation of cell-cell adhesion:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of leukocyte cell-cell adhesion:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of T cell activation:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| T cell activation:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of cell-cell adhesion:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:PSMB9,TAP2 \| regulation of leukocyte cell-cell adhesion:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class I:PSMB9,TAP2 \| positive regulation of cell adhesion:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of lymphocyte activation:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of cell activation:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of lymphocyte activation:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,LST1 \| regulation of T cell activation:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of leukocyte activation:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,LST1 \| leukocyte cell-cell adhesion:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide antigen via MHC class I:PSMB9,TAP2 \| positive regulation of leukocyte activation:HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| lymphocyte mediated immunity:BTN3A2 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:BTN3A2 \| adaptive immune response:BTN3A2,TAP2 \| tumor necrosis factor-mediated signaling pathway:LTB,PSMB9 \| positive regulation of defense response:PSMB9,XRCC6 \| positive regulation of cytokine production:HLA-DPB1,LTB,XRCC6 \| T cell mediated immunity:BTN3A2 \| protein refolding:HSPA1L \| positive regulation of innate immune response:PSMB9,XRCC6 \| positive regulation of T cell proliferation:HLA-DPB1 \| NIK/NF-kappaB signaling:PSMB9 \| regulation of innate immune response:PSMB9,XRCC6 \| cellular response to tumor necrosis factor:LTB,PSMB9 \| regulation of T cell proliferation:HLA-DPB1 \| regulation of lymphocyte proliferation:HLA-DPB1,LST1 \| regulation of mononuclear cell proliferation:HLA-DPB1,LST1 \| modulation by virus of host morphology or physiology:KPNA2 \| negative regulation of protein ubiquitination:PSMB9 \| interferon-gamma production:BTN3A2,HLA-DPB1 \| lymph node development:LTB \| regulation of leukocyte proliferation:HLA-DPB1,LST1 \| mRNA catabolic process:LSM2,PSMB9,RPL34,SKIV2L \| response to tumor necrosis factor:LTB,PSMB9 \| response to heat:HSPA1L \| negative regulation of protein modification by small protein conjugation or removal:PSMB9 \| antigen processing and presentation via MHC class Ib:TAP2 \| positive regulation of nitric oxide biosynthetic process:DDAH2 \| positive regulation of nitric oxide metabolic process:DDAH2 \| activation of innate immune response:PSMB9,XRCC6 \| modulation by virus of host process:KPNA2 \| T cell proliferation:HLA-DPB1 \| antigen processing and presentation of endogenous antigen:TAP2 \| microtubule nucleation:GOLGA2 \| positive regulation of lymphocyte proliferation:HLA-DPB1 \| modification by symbiont of host morphology or physiology:KPNA2 \| positive regulation of mononuclear cell proliferation:HLA-DPB1 \| regulation of DNA-templated transcription in response to stress:PSMB9 \| ER-associated misfolded protein catabolic process:RNF5 \| regulation of protein ubiquitination:GOLGA2,PSMB9 \| positive regulation of ubiquitin protein ligase activity:GOLGA2,PSMB9 \| RNA catabolic process:LSM2,PSMB9,RPL34,SKIV2L \| positive regulation of leukocyte proliferation:HLA-DPB1 \| positive regulation of reactive oxygen species biosynthetic process:DDAH2 \| modulation by symbiont of host cellular process:KPNA2 \| response to topologically incorrect protein:HSPA1L,RNF5 \| DNA-templated transcription, elongation:SSRP1 \| innate immune response-activating signal transduction:PSMB9 \| regulation of ubiquitin protein ligase activity:GOLGA2,PSMB9 \| regulation of nitric oxide biosynthetic process:DDAH2 \| lymphocyte proliferation:HLA-DPB1,LST1 \| mononuclear cell proliferation:HLA-DPB1,LST1 \| regulation of translational fidelity:VARS2 \| positive regulation of interleukin-12 production:LTB \| regulation of protein modification by small protein conjugation or removal:GOLGA2,PSMB9 \| regulation of antigen processing and presentation:HLA-DOB \| response to temperature stimulus:HSPA1L \| leukocyte proliferation:HLA-DPB1,LST1 \| regulation of protein stability:RNF5 \| positive regulation of interferon-gamma production:HLA-DPB1 \| nitric oxide biosynthetic process:DDAH2 \| interaction with host:KPNA2 \| positive regulation of ubiquitin-protein transferase activity:GOLGA2,PSMB9 \| nucleocytoplasmic transport:KPNA2 \| regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB9 \| nitric oxide metabolic process:DDAH2 \| nuclear transport:KPNA2 \| cellular response to misfolded protein:RNF5 \| viral latency:XRCC6 \| reactive nitrogen species metabolic process:DDAH2 \| nuclear-transcribed mRNA catabolic process, exonucleolytic:LSM2,SKIV2L \| cellular response to topologically incorrect protein:RNF5 \| regulation of cellular response to heat:HSPA1L \| response to misfolded protein:RNF5 \| positive regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of organelle assembly:RNF5 \| regulation of transcription from RNA polymerase II promoter in response to stress:PSMB9 \| regulation of reactive oxygen species biosynthetic process:DDAH2 \| SCF-dependent proteasomal ubiquitin-dependent protein catabolic process:PSMB9 \| protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB9,RNF5 \| protein K63-linked ubiquitination:RNF5 \| protein quality control for misfolded or incompletely synthesized proteins:RNF5 \| cellular response to X-ray:XRCC6 \| positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition:PSMB9 \| response to endoplasmic reticulum stress:RNF5 \| stimulatory C-type lectin receptor signaling pathway:PSMB9 \| regulation of ubiquitin-protein transferase activity:GOLGA2,PSMB9 \| innate immune response activating cell surface receptor signaling pathway:PSMB9 \| ganglioside metabolic process:NEU1 \| regulation of interleukin-12 production:LTB \| spindle assembly:GOLGA2 \| exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay:LSM2,SKIV2L \| nuclear-transcribed mRNA catabolic process:LSM2,RPL34,SKIV2L \| interferon-gamma secretion:BTN3A2 \| interleukin-12 production:LTB \| reactive oxygen species biosynthetic process:DDAH2 \| negative regulation of immune system process:HLA-DOB,LST1 \| positive regulation of proteolysis involved in cellular protein catabolic process:PSMB9 \| post-translational protein modification:PSMB9 \| macroautophagy:ATP6V1G2,EXOC1,RNF5 \| positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB9 \| regulation of macroautophagy:ATP6V1G2,EXOC1,RNF5 \| mitotic spindle assembly:GOLGA2 \| regulation of interferon-gamma production:HLA-DPB1 \| viral life cycle:KPNA2 \| protein localization to nucleus:KPNA2 \| asymmetric cell division:GOLGA2 \| regulation of proteolysis involved in cellular protein catabolic process:PSMB9 \| cellular response to heat:HSPA1L \| positive regulation of cellular protein catabolic process:PSMB9 \| regulation of protein glycosylation:GOLGA2 \| response to salt stress:XRCC6 \| regulation of autophagy:ATP6V1G2,EXOC1,GOLGA2,RNF5 \| DNA ligation:XRCC6 \| microtubule polymerization:GOLGA2 \| protein folding:HSPA1L \| positive regulation of protein catabolic process:PSMB9 \| viral transcription:RPL34 \| positive regulation of cellular catabolic process:PSMB9 \| tRNA aminoacylation for protein translation:VARS2 \| nuclear-transcribed mRNA catabolic process, nonsense-mediated decay:RPL34,SKIV2L \| lipoprotein metabolic process:APOM \| tRNA aminoacylation:VARS2 \| regulation of binding:GOLGA2 \| transcription elongation from RNA polymerase II promoter:SSRP1 \| regulation of mRNA metabolic process:PSMB9 \| amino acid activation:VARS2 \| regulation of RNA stability:PSMB9 \| regulation of cellular amino acid metabolic process:PSMB9 \| regulation of monooxygenase activity:DDAH2 \| regulation of cellular protein catabolic process:PSMB9 \| viral gene expression:RPL34 \| regulation of mitotic cell cycle phase transition:PSMB9 \| protein glycosylation:GOLGA2 \| macromolecule glycosylation:GOLGA2 \| reactive oxygen species metabolic process:DDAH2 \| protein polyubiquitination:PSMB9,RNF5 \| positive regulation of cytokine biosynthetic process:LTB \| negative regulation of catabolic process:RNF5,GOLGA2 \| regulation of mRNA catabolic process:PSMB9 \| glycosylation:GOLGA2 \| negative regulation of cellular catabolic process:GOLGA2,RNF5 \| negative regulation of autophagy:GOLGA2,RNF5 \| cellular amino acid metabolic process:DDAH2,PSMB9,VARS2 \| ruffle assembly:DEF8 \| negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle:PSMB9 \| negative regulation of mitotic cell cycle:PSMB9 \| Fc-epsilon receptor signaling pathway:PSMB9 \| regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle:PSMB9 \| modification of morphology or physiology of other organism involved in symbiotic interaction:KPNA2 \| regulation of cell cycle phase transition:PSMB9 \| positive regulation of protein ubiquitination:GOLGA2,PSMB9 \| positive regulation of catabolic process:PSMB9 \| multi-organism transport:KPNA2 \| multi-organism localization:KPNA2 \| autophagy:ATP6V1G2,EXOC1,GOLGA2,RNF5 \| process utilizing autophagic mechanism:ATP6V1G2,EXOC1,GOLGA2,RNF5 \| regulation of autophagosome assembly:RNF5 \| G2/M transition of mitotic cell cycle:PSMB9 \| protein complex localization:EXOC1 \| regulation of reactive oxygen species metabolic process:DDAH2 \| ubiquitin-dependent ERAD pathway:RNF5 \| negative regulation of ubiquitin protein ligase activity:PSMB9 \| regulation of smooth muscle cell proliferation:XRCC6 \| response to unfolded protein:HSPA1L \| regulation of transcription from RNA polymerase II promoter in response to hypoxia:PSMB9 \| microtubule polymerization or depolymerization:GOLGA2 \| SRP-dependent cotranslational protein targeting to membrane:RPL34 \| translational initiation:RPL34 \| regulation of cellular amine metabolic process:PSMB9 \| smooth muscle cell proliferation:XRCC6 \| spindle organization:GOLGA2 \| negative regulation of leukocyte activation:LST1 \| cell cycle G2/M phase transition:PSMB9 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:LSM2,SKIV2L \| anaphase-promoting complex-dependent catabolic process:PSMB9 \| regulation of G2/M transition of mitotic cell cycle:PSMB9 \| response to X-ray:XRCC6	0.203377	0.0848679	1.77869271871296				0.088668	0.14836	0.259581250654605	0.702532	0.0922135	13.4109433502101				0.915222	0.159774	7.82370322352484	0.222614	0.0695865	2.85403951022214				0.224415	0.114325	1.30065839860833	-0.0466049	0.0491017	0.46528236733087				-0.0774115	0.0829994	0.454707731462583	-0.00376147	0.0486776	0.0276092240824664				0.00669294	0.0814077	0.0294318480587302	0.093462	0.046509	1.35184107975439				-0.00206821	0.0769072	0.00941875398492458	0.0261762	0.0282655	0.450502610492856				0.014175	0.0457636	0.121044127019475	0.334994	0.139233	1.78998128160806				0.301226	0.197251	0.895529960347109
rs143524414:98965615:G:A		7	98965615	7q22.1	A	G	0.959	0	DHEAS ALL	7659	13.2961766146305	0.0689792662227445	0.264591	ARPC1A (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| near gene/Downstream gene/MODIFIER); ARPC1B (6.3 kb); PDAP1 (24 kb); BUD31 (41 kb); PTCD1 (49 kb)	0.321 Blood metabolite levels // 0.321 Hand grip strength	- \| AP4M1 \| ARPC1A \| ARPC1B \| ATP5J2 \| AZGP1 \| BUD31 \| CNPY4 \| COPS6 \| CPSF4 \| CYP3A5 \| CYP3A7 \| EPHB4 \| GAL3ST4 \| GS1-259H13.2 \| LAMTOR4 \| LRCH4 \| MCM7 \| MEPCE \| MOSPD3 \| OR2AE1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| RP11-44M6.1 \| STAG3 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| TRIM4 \| TSC22D4 \| ZCWPW1 \| ZKSCAN1 \| ZKSCAN5 \| ZNF3 \| ZNF394 \| ZNF498 \| ZNF655 \| ZNF789 \| ZSCAN21	FRMD3 \| PILRB \| PMS2 \| RRAGA	Influenza A:CPSF4 \| Endocytosis:ARPC1A,ARPC1B \| Pathogenic Escherichia coli infection:ARPC1A,ARPC1B \| Spliceosome:BUD31 \| Shigellosis:ARPC1A,ARPC1B \| Bacterial invasion of epithelial cells:ARPC1A,ARPC1B \| Salmonella infection:ARPC1A,ARPC1B \| Regulation of actin cytoskeleton:ARPC1A,ARPC1B \| Fc gamma R-mediated phagocytosis:ARPC1A,ARPC1B \| Lysosome:AP4M1	EPHB-mediated forward signaling:ARPC1A,ARPC1B \| EPH-Ephrin signaling:ARPC1A,ARPC1B \| RHO GTPases Activate WASPs and WAVEs:ARPC1A,ARPC1B \| Infectious disease:CPSF4 \| NS1 Mediated Effects on Host Pathways:CPSF4 \| Host Interactions with Influenza Factors:CPSF4 \| Influenza Infection:CPSF4 \| Regulation of actin dynamics for phagocytic cup formation:ARPC1A,ARPC1B \| Fcgamma receptor (FCGR) dependent phagocytosis:ARPC1A,ARPC1B	influenza:CPSF4 \| specific developmental disorder:AP4M1 \| cerebral palsy:AP4M1	modulation by virus of host morphology or physiology:CPSF4 \| modification by symbiont of host morphology or physiology:CPSF4 \| modulation by virus of host process:CPSF4 \| immune response-activating signal transduction:ARPC1A,ARPC1B,PVRIG \| modulation by symbiont of host cellular process:CPSF4 \| immune response-activating cell surface receptor signaling pathway:ARPC1A,ARPC1B,PVRIG \| T cell receptor signaling pathway:PVRIG \| immune response-regulating cell surface receptor signaling pathway:ARPC1A,ARPC1B,PVRIG \| modification of morphology or physiology of other organism involved in symbiotic interaction:CPSF4 \| antigen receptor-mediated signaling pathway:PVRIG \| modification of morphology or physiology of other organism:CPSF4 \| protein localization to vacuole:AP4M1 \| ephrin receptor signaling pathway:ARPC1A,ARPC1B \| interaction with host:CPSF4 \| nucleocytoplasmic transport:CPSF4 \| protein localization to lysosome:AP4M1 \| nuclear transport:CPSF4 \| Arp2/3 complex-mediated actin nucleation:ARPC1A,ARPC1B \| protein targeting to vacuole:AP4M1 \| mRNA cleavage:CPSF4 \| actin nucleation:ARPC1A,ARPC1B \| protein export from nucleus:CPSF4 \| phagocytosis:ARPC1A,ARPC1B \| mRNA cleavage involved in mRNA processing:CPSF4 \| positive regulation of protein complex assembly:ARPC1A,ARPC1B \| nuclear export:CPSF4 \| immune response-regulating cell surface receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| Fc-gamma receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| mitochondrial membrane organization:ATP5J2 \| Fc-gamma receptor signaling pathway:ARPC1A,ARPC1B \| Fc receptor mediated stimulatory signaling pathway:ARPC1A,ARPC1B \| nucleic acid phosphodiester bond hydrolysis:CPSF4 \| RNA phosphodiester bond hydrolysis:CPSF4 \| negative regulation of immune system process:PVRIG \| positive regulation of actin filament polymerization:ARPC1A,ARPC1B \| RNA splicing, via endonucleolytic cleavage and ligation:CPSF4 \| regulation of protein complex assembly:ARPC1A,ARPC1B \| DNA-templated transcription, termination:CPSF4	0.0621654	0.0324561	1.25505645391819	0.0241457	0.0299129	0.377069309056245				0.0321756	0.0357325	0.434173424510897	-0.00783146	0.0394363	0.0743697831254838	0.0974706	0.0697512	0.788532375560858	0.00884104	0.0266638	0.13062510407031	0.00236464	0.0310669	0.0271776460088078	0.0192401	0.0489869	0.158255842466533	-0.15273	0.0202816	13.2961766146305	-0.155228	0.0254982	8.94128555402359	-0.151289	0.0322826	5.55583180699517				0.00528595	0.0213238	0.0946251307088186				-0.03762	0.0194549	1.27449591403048	-0.0282872	0.0243081	0.611635884641986	-0.056281	0.030171	1.20673359825861	0.0103753	0.0116132	0.429875211423522	-0.00656157	0.0151619	0.177058858521272	0.030923	0.0179572	1.0702562413369	0.0515366	0.0531362	0.478579455134541	0.0954361	0.0680025	0.793905757314418	-0.018884	0.0849097	0.0840369499457458
rs10257273:99188589:A:T		7	99188589	7q22.1	T	A	0.996	52	DHEAS ALL	7659	13.0505494891252	0.147950058754407	1.154	GS1-259H13.10 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); AC005020.1 (4 kb, near gene/Downstream gene/MODIFIER); ZNF655 (15 kb); ZSCAN25 (26 kb); FAM200A (32 kb)	0.993 Hand grip strength // 0.815 Blood metabolite levels // 0.63 Diffuse cutaneous systemic sclerosis // 0.63 Blood metabolite ratios // 0.618 Dehydroepiandrosterone sulphate levels // 0.331 Sex hormone levels // 0.331 Total body bone mineral density (age over 60) // 0.331 Total body bone mineral density // 0.331 Femoral neck bone mineral density // 0.331 Lumbar spine bone mineral density	- \| AP4M1 \| ARPC1A \| ARPC1B \| ATP5J2 \| BUD31 \| CNPY4 \| COPS6 \| CPSF4 \| CYP3A5 \| CYP3A7 \| GAL3ST4 \| GS1-259H13.2 \| LAMTOR4 \| MCM7 \| MEPCE \| MOSPD3 \| NYAP1 \| OR2AE1 \| PDAP1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| SMURF1 \| STAG3 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| TAF6 \| TRIM4 \| ZCWPW1 \| ZKSCAN1 \| ZKSCAN5 \| ZNF3 \| ZNF394 \| ZNF498 \| ZNF655 \| ZNF789 \| ZSCAN21	RRAGA	Herpes simplex infection:PILRA,TAF6 \| Chemical carcinogenesis:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Influenza A:CPSF4 \| Metabolism of xenobiotics by cytochrome P450:CYP3A5 \| Steroid hormone biosynthesis:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Drug metabolism - cytochrome P450:CYP3A5 \| Retinol metabolism:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Endocytosis:ARPC1A,ARPC1B \| Pathogenic Escherichia coli infection:ARPC1A,ARPC1B \| Spliceosome:BUD31 \| DNA replication:MCM7 \| Shigellosis:ARPC1A,ARPC1B \| Bacterial invasion of epithelial cells:ARPC1A,ARPC1B \| Salmonella infection:ARPC1A,ARPC1B \| Regulation of actin cytoskeleton:ARPC1A,ARPC1B \| Fc gamma R-mediated phagocytosis:ARPC1A,ARPC1B \| Lysosome:AP4M1	Xenobiotics:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Biological oxidations:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Cytochrome P450 - arranged by substrate type:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Phase I - Functionalization of compounds:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:PILRA,PILRB \| EPHB-mediated forward signaling:ARPC1A,ARPC1B \| Unwinding of DNA:MCM7 \| Aflatoxin activation and detoxification:CYP3A5 \| mTORC1-mediated signalling:RRAGA \| EPH-Ephrin signaling:ARPC1A,ARPC1B \| Energy dependent regulation of mTOR by LKB1-AMPK:RRAGA \| RHO GTPases Activate WASPs and WAVEs:ARPC1A,ARPC1B \| Infectious disease:CPSF4,TAF6 \| NS1 Mediated Effects on Host Pathways:CPSF4 \| Host Interactions with Influenza Factors:CPSF4 \| mTOR signalling:RRAGA \| Influenza Infection:CPSF4 \| Activation of the pre-replicative complex:MCM7 \| DNA strand elongation:MCM7 \| Transcriptional Regulation by TP53:RRAGA,TAF6 \| Transcription of the HIV genome:TAF6 \| Activation of ATR in response to replication stress:MCM7 \| Regulation of actin dynamics for phagocytic cup formation:ARPC1A,ARPC1B \| Regulation of PTEN gene transcription:RRAGA \| RNA Polymerase II Pre-transcription Events:TAF6 \| Macroautophagy:RRAGA \| TP53 Regulates Metabolic Genes:RRAGA \| Fcgamma receptor (FCGR) dependent phagocytosis:ARPC1A,ARPC1B	urinary system disease:CYP3A5 \| multiple myeloma:CYP3A5 \| myeloma:CYP3A5 \| bone marrow cancer:CYP3A5 \| kidney disease:CYP3A5 \| ataxia telangiectasia:MCM7 \| polycystic ovary syndrome:CYP3A7 \| prostate cancer:MCM7 \| male reproductive organ cancer:MCM7 \| influenza:CPSF4 \| astrocytoma:MCM7 \| toxic encephalopathy:CYP3A5 \| specific developmental disorder:AP4M1 \| autosomal recessive disease:MCM7 \| female reproductive organ cancer:STAG3 \| cerebral palsy:AP4M1	modulation by virus of host morphology or physiology:CPSF4,RRAGA \| modification by symbiont of host morphology or physiology:CPSF4,RRAGA \| modulation by virus of host process:CPSF4 \| immune response-activating signal transduction:ARPC1A,ARPC1B,PVRIG \| modulation by symbiont of host cellular process:CPSF4 \| immune response-activating cell surface receptor signaling pathway:ARPC1A,ARPC1B,PVRIG \| T cell receptor signaling pathway:PVRIG \| immune response-regulating cell surface receptor signaling pathway:ARPC1A,ARPC1B,PVRIG \| modification of morphology or physiology of other organism involved in symbiotic interaction:CPSF4,RRAGA \| cellular response to xenobiotic stimulus:CYP3A5,CYP3A7,MCM7 \| response to xenobiotic stimulus:CYP3A5,CYP3A7,MCM7 \| antigen receptor-mediated signaling pathway:PVRIG \| oxidative demethylation:CYP3A5 \| drug catabolic process:CYP3A5 \| modification of morphology or physiology of other organism:CPSF4,RRAGA \| DNA replication initiation:MCM7 \| protein localization to vacuole:AP4M1 \| xenobiotic metabolic process:CYP3A5,CYP3A7 \| ephrin receptor signaling pathway:ARPC1A,ARPC1B \| steroid metabolic process:CYP3A5,CYP3A7 \| sulfur compound metabolic process:GAL3ST4 \| interaction with host:CPSF4,RRAGA \| nucleocytoplasmic transport:CPSF4 \| protein localization to lysosome:AP4M1 \| nuclear transport:CPSF4 \| drug metabolic process:CYP3A5 \| Arp2/3 complex-mediated actin nucleation:ARPC1A,ARPC1B \| positive regulation of TOR signaling:RRAGA \| cellular response to epidermal growth factor stimulus:MCM7 \| response to epidermal growth factor:MCM7 \| protein targeting to vacuole:AP4M1 \| DNA-templated transcription, elongation:TAF6 \| cellular response to amino acid starvation:RRAGA \| mRNA cleavage:CPSF4 \| actin nucleation:ARPC1A,ARPC1B \| post-translational protein modification:COPS6 \| response to drug:MCM7 \| lipid modification:CYP3A5,CYP3A7 \| protein export from nucleus:CPSF4 \| phagocytosis:ARPC1A,ARPC1B \| mRNA cleavage involved in mRNA processing:CPSF4 \| demethylation:CYP3A5 \| cellular response to amino acid stimulus:RRAGA \| regulation of autophagy:RRAGA \| positive regulation of protein complex assembly:ARPC1A,ARPC1B \| negative regulation of autophagy:RRAGA \| nuclear export:CPSF4 \| immune response-regulating cell surface receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| Fc-gamma receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| regulation of macroautophagy:RRAGA \| mitochondrial membrane organization:ATP5J2 \| Fc-gamma receptor signaling pathway:ARPC1A,ARPC1B \| Fc receptor mediated stimulatory signaling pathway:ARPC1A,ARPC1B \| nucleic acid phosphodiester bond hydrolysis:CPSF4 \| RNA phosphodiester bond hydrolysis:CPSF4 \| negative regulation of immune system process:PVRIG \| negative regulation of cellular catabolic process:RRAGA \| snRNA metabolic process:MEPCE,TAF6 \| positive regulation of actin filament polymerization:ARPC1A,ARPC1B \| regulation of TOR signaling:RRAGA \| RNA splicing, via endonucleolytic cleavage and ligation:CPSF4 \| autophagy:RRAGA \| process utilizing autophagic mechanism:RRAGA \| transcription elongation from RNA polymerase II promoter:TAF6 \| cytolysis:RRAGA \| negative regulation of mitotic cell cycle phase transition:ZNF655 \| negative regulation of catabolic process:RRAGA \| regulation of protein complex assembly:ARPC1A,ARPC1B \| DNA-templated transcription, termination:CPSF4 \| negative regulation of cell cycle phase transition:ZNF655 \| ncRNA transcription:TAF6	0.0155791	0.023157	0.300009734400011	-0.00564042	0.0210918	0.102821177954993	0.0237904	0.0450752	0.223558889560641	-0.0102452	0.0254789	0.162634447367375	-0.0404791	0.0277795	0.837719441207495	0.044105	0.0507235	0.414699481380078	-0.0125702	0.019008	0.293721853976858	-0.0359382	0.021879	0.996966216712265	0.0295445	0.0355801	0.390819808538904	-0.10549	0.0141479	13.0505494891252	-0.0892611	0.0178588	6.23745647109209	-0.123667	0.0224046	7.46911673015212				-0.00112236	0.0149101	0.0268739944658585				-0.0329809	0.0136608	1.80225644131677	-0.0229002	0.0169356	0.753718128106649				-0.001781	0.00812302	0.0827818395166649	-0.0115466	0.0106126	0.558160385347822	0.0102185	0.0125387	0.381850405354687	0.011949	0.0380205	0.123007242802717	0.0616918	0.0480295	0.700688864527717	-0.0750121	0.0620118	0.644289934196573
rs34022779:99039313:A:AT		7	99039313	7q22.1	AT	A	0.982	0	DHEAS ALL	7659	12.7300249881969	0.0924461156808983	0.272062	ATP5J2-PTCD1 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); CPSF4 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); PTCD1 (0 kb, intron/Intron/MODIFIER \| near gene/Upstream gene/MODIFIER); AC073063.10 (1.2 kb, near gene/Downstream gene/MODIFIER); AC073063.1 (1.2 kb, near gene/Upstream gene/MODIFIER); ATP5J2 (6.8 kb); BUD31 (22 kb); ZNF789 (31 kb); PDAP1 (33 kb); ZNF394 (45 kb); ARPC1B (47 kb)	0.858 Blood metabolite levels // 0.803 Diffuse cutaneous systemic sclerosis // 0.803 Blood metabolite ratios // 0.782 Dehydroepiandrosterone sulphate levels // 0.54 Hand grip strength // 0.381 Sex hormone levels // 0.381 Total body bone mineral density (age over 60) // 0.381 Total body bone mineral density // 0.381 Femoral neck bone mineral density // 0.381 Lumbar spine bone mineral density // 0.333 Blood protein levels	- \| AP4M1 \| ARPC1A \| ARPC1B \| ATP5J2 \| BUD31 \| CNPY4 \| COPS6 \| CPSF4 \| CYP3A5 \| CYP3A7 \| GAL3ST4 \| GS1-259H13.2 \| LAMTOR4 \| MCM7 \| MEPCE \| MOSPD3 \| NYAP1 \| OR2AE1 \| PDAP1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| SMURF1 \| SPDYE3 \| STAG3 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| TAF6 \| TRIM4 \| ZCWPW1 \| ZKSCAN1 \| ZKSCAN5 \| ZNF3 \| ZNF394 \| ZNF498 \| ZNF655 \| ZNF789	RRAGA	Herpes simplex infection:PILRA \| Chemical carcinogenesis:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Influenza A:CPSF4 \| Metabolism of xenobiotics by cytochrome P450:CYP3A5 \| Steroid hormone biosynthesis:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Drug metabolism - cytochrome P450:CYP3A5 \| Retinol metabolism:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Endocytosis:ARPC1A,ARPC1B \| Pathogenic Escherichia coli infection:ARPC1A,ARPC1B \| Spliceosome:BUD31 \| DNA replication:MCM7 \| Shigellosis:ARPC1A,ARPC1B \| Bacterial invasion of epithelial cells:ARPC1A,ARPC1B \| Salmonella infection:ARPC1A,ARPC1B \| Regulation of actin cytoskeleton:ARPC1A,ARPC1B \| Fc gamma R-mediated phagocytosis:ARPC1A,ARPC1B \| Lysosome:AP4M1	Xenobiotics:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Biological oxidations:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Cytochrome P450 - arranged by substrate type:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Phase I - Functionalization of compounds:CYP3A5,CYP3A7,CYP3A7-CYP3A51P \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:PILRA,PILRB \| EPHB-mediated forward signaling:ARPC1A,ARPC1B \| Unwinding of DNA:MCM7 \| Aflatoxin activation and detoxification:CYP3A5 \| mTORC1-mediated signalling:RRAGA \| EPH-Ephrin signaling:ARPC1A,ARPC1B \| Energy dependent regulation of mTOR by LKB1-AMPK:RRAGA \| RHO GTPases Activate WASPs and WAVEs:ARPC1A,ARPC1B \| Infectious disease:CPSF4 \| NS1 Mediated Effects on Host Pathways:CPSF4 \| Host Interactions with Influenza Factors:CPSF4 \| mTOR signalling:RRAGA \| Influenza Infection:CPSF4 \| Activation of the pre-replicative complex:MCM7 \| DNA strand elongation:MCM7 \| Transcriptional Regulation by TP53:RRAGA \| Activation of ATR in response to replication stress:MCM7 \| Regulation of actin dynamics for phagocytic cup formation:ARPC1A,ARPC1B \| Regulation of PTEN gene transcription:RRAGA \| Macroautophagy:RRAGA \| TP53 Regulates Metabolic Genes:RRAGA \| Fcgamma receptor (FCGR) dependent phagocytosis:ARPC1A,ARPC1B	urinary system disease:CYP3A5 \| multiple myeloma:CYP3A5 \| myeloma:CYP3A5 \| bone marrow cancer:CYP3A5 \| kidney disease:CYP3A5 \| ataxia telangiectasia:MCM7 \| polycystic ovary syndrome:CYP3A7 \| prostate cancer:MCM7 \| male reproductive organ cancer:MCM7 \| influenza:CPSF4 \| astrocytoma:MCM7 \| toxic encephalopathy:CYP3A5 \| specific developmental disorder:AP4M1 \| autosomal recessive disease:MCM7 \| female reproductive organ cancer:STAG3 \| cerebral palsy:AP4M1	modulation by virus of host morphology or physiology:CPSF4,RRAGA \| modification by symbiont of host morphology or physiology:CPSF4,RRAGA \| modulation by virus of host process:CPSF4 \| immune response-activating signal transduction:ARPC1A,ARPC1B,PVRIG \| modulation by symbiont of host cellular process:CPSF4 \| immune response-activating cell surface receptor signaling pathway:ARPC1A,ARPC1B,PVRIG \| T cell receptor signaling pathway:PVRIG \| immune response-regulating cell surface receptor signaling pathway:ARPC1A,ARPC1B,PVRIG \| modification of morphology or physiology of other organism involved in symbiotic interaction:CPSF4,RRAGA \| cellular response to xenobiotic stimulus:CYP3A5,CYP3A7,MCM7 \| response to xenobiotic stimulus:CYP3A5,CYP3A7,MCM7 \| antigen receptor-mediated signaling pathway:PVRIG \| oxidative demethylation:CYP3A5 \| drug catabolic process:CYP3A5 \| modification of morphology or physiology of other organism:CPSF4,RRAGA \| DNA replication initiation:MCM7 \| protein localization to vacuole:AP4M1 \| xenobiotic metabolic process:CYP3A5,CYP3A7 \| ephrin receptor signaling pathway:ARPC1A,ARPC1B \| steroid metabolic process:CYP3A5,CYP3A7 \| sulfur compound metabolic process:GAL3ST4 \| interaction with host:CPSF4,RRAGA \| nucleocytoplasmic transport:CPSF4 \| protein localization to lysosome:AP4M1 \| nuclear transport:CPSF4 \| drug metabolic process:CYP3A5 \| Arp2/3 complex-mediated actin nucleation:ARPC1A,ARPC1B \| positive regulation of TOR signaling:RRAGA \| cellular response to epidermal growth factor stimulus:MCM7 \| response to epidermal growth factor:MCM7 \| protein targeting to vacuole:AP4M1 \| cellular response to amino acid starvation:RRAGA \| mRNA cleavage:CPSF4 \| actin nucleation:ARPC1A,ARPC1B \| post-translational protein modification:COPS6 \| response to drug:MCM7 \| lipid modification:CYP3A5,CYP3A7 \| protein export from nucleus:CPSF4 \| phagocytosis:ARPC1A,ARPC1B \| mRNA cleavage involved in mRNA processing:CPSF4 \| demethylation:CYP3A5 \| cellular response to amino acid stimulus:RRAGA \| regulation of autophagy:RRAGA \| positive regulation of protein complex assembly:ARPC1A,ARPC1B \| negative regulation of autophagy:RRAGA \| nuclear export:CPSF4 \| immune response-regulating cell surface receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| Fc-gamma receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| regulation of macroautophagy:RRAGA \| mitochondrial membrane organization:ATP5J2 \| Fc-gamma receptor signaling pathway:ARPC1A,ARPC1B \| Fc receptor mediated stimulatory signaling pathway:ARPC1A,ARPC1B \| nucleic acid phosphodiester bond hydrolysis:CPSF4 \| RNA phosphodiester bond hydrolysis:CPSF4 \| negative regulation of immune system process:PVRIG \| negative regulation of cellular catabolic process:RRAGA \| snRNA metabolic process:MEPCE \| positive regulation of actin filament polymerization:ARPC1A,ARPC1B \| regulation of TOR signaling:RRAGA \| RNA splicing, via endonucleolytic cleavage and ligation:CPSF4 \| autophagy:RRAGA \| process utilizing autophagic mechanism:RRAGA \| cytolysis:RRAGA \| negative regulation of mitotic cell cycle phase transition:ZNF655 \| negative regulation of catabolic process:RRAGA \| regulation of protein complex assembly:ARPC1A,ARPC1B \| DNA-templated transcription, termination:CPSF4 \| negative regulation of cell cycle phase transition:ZNF655	0.0119182	0.0281879	0.172323210587351	-0.00709707	0.0250531	0.109576745454612	0.00742526	0.0565208	0.0479436244243246	0.00486692	0.0310131	0.057836125257949	-0.0315546	0.0330116	0.469400780963114	0.0779349	0.0646707	0.640988371974764	-0.00388626	0.0231382	0.0621652788755655	-0.0364383	0.0259953	0.792564920682231	0.061783	0.0453484	0.760695514625513	-0.128029	0.0173991	12.7300249881969	-0.118528	0.0217692	7.28501928662517	-0.137454	0.0278273	6.10620440533476				0.0187177	0.0181453	0.519583402868016				-0.0323111	0.0167963	1.26446257648196	-0.0279201	0.0207303	0.749492171733047				-0.00679848	0.00997489	0.304940564874592	-0.0174802	0.0128949	0.756386582218142	0.00657176	0.0155847	0.171818477373989	0.0679441	0.0462989	0.846502210153703	0.107996	0.0570261	1.23305279386395	-0.0106692	0.0793318	0.0491213073729879
rs17601876:51553909:A:G	known [3, 4]	15	51553909	15q21.2	G	A	0.999	77	E2 ALL	6798	12.3343871181176	0.489910856134157	2.30876	RP11-108K3.1 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); CYP19A1 (0 kb, intron/Intron/MODIFIER); MIR4713 (19 kb); GLDN (80 kb)	1 Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer // 0.682 Menarche (age at onset) // 0.525 Endometrial cancer // 0.525 Endometrial endometrioid carcinoma // 0.525 Total body bone mineral density // 0.458 Hormone measurements // 0.458 Follicule stimulating hormone // 0.454 Estradiol levels // 0.454 Estrone levels // 0.342 Cerebrospinal fluid AB1-42 levels	AP4E1 \| CYP19A1 \| DCAF13P3 \| DMXL2 \| GABPB1-AS1 \| GLDN \| GNB5 \| LYSMD2 \| MAPK6 \| MYO5C \| RP11-108K3.1 \| RP11-707P17.2 \| SPPL2A \| TMOD2 \| TRPM7 \| USP8		Steroid hormone biosynthesis:CYP19A1 \| Endocytosis:USP8 \| Kaposi sarcoma-associated herpesvirus infection:GNB5 \| Human cytomegalovirus infection:GNB5 \| Lysosome:AP4E1	Cytochrome P450 - arranged by substrate type:CYP19A1 \| Metabolism of steroid hormones:CYP19A1 \| Phase I - Functionalization of compounds:CYP19A1 \| Endogenous sterols:CYP19A1 \| Metabolic disorders of biological oxidation enzymes:CYP19A1 \| Biological oxidations:CYP19A1 \| Chaperonin-mediated protein folding:GNB5	endocrine system disease:CYP19A1 \| hepatitis:GNB5 \| hepatitis B:GNB5 \| male reproductive system disease:CYP19A1 \| male infertility:CYP19A1 \| hyperandrogenism:CYP19A1 \| gonadal disease:CYP19A1 \| polycystic ovary syndrome:CYP19A1 \| reproductive system disease:CYP19A1 \| prostate disease:CYP19A1 \| sex differentiation disease:CYP19A1 \| essential hypertension:CYP19A1 \| osteoporosis:CYP19A1 \| bone resorption disease:CYP19A1 \| cell type benign neoplasm:CYP19A1 \| infertility:CYP19A1 \| sporadic breast cancer:CYP19A1 \| ovarian disease:CYP19A1 \| female reproductive organ cancer:CYP19A1 \| cerebral palsy:AP4E1	tumor necrosis factor-mediated signaling pathway:SPPL2A \| cellular response to tumor necrosis factor:SPPL2A \| chronic inflammatory response:CYP19A1 \| response to tumor necrosis factor:SPPL2A \| regulation of chronic inflammatory response:CYP19A1 \| cellular hormone metabolic process:CYP19A1 \| steroid catabolic process:CYP19A1 \| hormone biosynthetic process:CYP19A1 \| steroid metabolic process:CYP19A1 \| hormone metabolic process:CYP19A1 \| mammary gland development:CYP19A1 \| androgen metabolic process:CYP19A1 \| steroid biosynthetic process:CYP19A1 \| regulation of tumor necrosis factor-mediated signaling pathway:SPPL2A \| protein folding:GNB5 \| estrogen biosynthetic process:CYP19A1 \| ketone biosynthetic process:CYP19A1 \| negative regulation of immune system process:CYP19A1 \| protein deubiquitination:USP8 \| negative regulation of chemotaxis:CYP19A1 \| calcium ion transmembrane transport:GNB5 \| protein modification by small protein removal:USP8 \| lipid transport:CYP19A1,TNFAIP8L3 \| regulation of leukocyte chemotaxis:CYP19A1 \| lipid localization:CYP19A1,TNFAIP8L3	0.0272259	0.0166617	0.989691561128922	-0.00243341	0.0149764	0.0600067765048384	0.0828909	0.0329852	1.92183691943204	0.0144801	0.01834	0.366641646977089	0.00296994	0.0197401	0.055305167603832	0.0383274	0.0374233	0.514122482640886	0.0037359	0.0136849	0.105193970673964	-0.00431526	0.0155502	0.107107696654686	0.0205378	0.0262575	0.362132178632265	-0.00263696	0.0100011	0.101254529874527	-0.0185079	0.0124609	0.861792067331837				-0.0116514	0.00984153	0.626255171497654	-0.0226742	0.0103759	1.53957728575651	0.00463487	0.0167361	0.106889335504521	0.0694361	0.00959628	12.3343871181176	0.07022449	0.01173398	8.663996	0.063851	0.0154557	4.44267208683599	0.00171458	0.00573495	0.116359570446954	0.00199223	0.0074026	0.103565831831343	5.24171E-4	0.00898758	0.0206829464254538	0.0258039	0.0274827	0.458560551487147	0.0168536	0.0342593	0.20562071485436	0.0418843	0.0459939	0.440330327492401
rs80193476:99433590:A:T		7	99433590	7q22.1	T	A	0.899	5	DHEAS ALL	7659	12.19307557796	0.0406460373416895	0.403526	CYP3A43 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); CYP3A52P (36 kb); OR2AE1 (40 kb); TRIM4 (41 kb)	0.792 Metabolic traits // 0.792 Dehydroepiandrosterone sulphate levels // 0.792 Estrone levels // 0.391 Blood protein levels // 0.355 Sex hormone levels // 0.355 Total body bone mineral density (age over 60) // 0.355 Total body bone mineral density // 0.355 Femoral neck bone mineral density // 0.355 Lumbar spine bone mineral density	- \| AP4M1 \| ARPC1B \| C7orf43 \| C7orf59 \| CNPY4 \| COPS6 \| CYP3A7 \| EPHB4 \| GAL3ST4 \| GS1-259H13.2 \| LAMTOR4 \| MCM7 \| MEPCE \| NYAP1 \| OR2AE1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| SAP25 \| STAG3 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| STAG3OS \| TAF6 \| TRIM4 \| TRIP6 \| TSC22D4 \| ZCWPW1 \| ZKSCAN1 \| ZKSCAN5 \| ZNF3 \| ZNF394 \| ZNHIT1 \| ZSCAN21	TIMP1	Herpes simplex infection:PILRA \| Chemical carcinogenesis:CYP3A4,CYP3A43 \| Metabolism of xenobiotics by cytochrome P450:CYP3A4 \| Steroid hormone biosynthesis:CYP3A4 \| Drug metabolism - cytochrome P450:CYP3A4 \| Drug metabolism - other enzymes:CYP3A4 \| Retinol metabolism:CYP3A4 \| Bile secretion:CYP3A4 \| Lysosome:AP4M1	Xenobiotics:CYP3A4,CYP3A43 \| Biological oxidations:CYP3A4,CYP3A43 \| Cytochrome P450 - arranged by substrate type:CYP3A4,CYP3A43 \| Phase I - Functionalization of compounds:CYP3A4,CYP3A43 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:PILRA,PILRB \| Aflatoxin activation and detoxification:CYP3A4	aplastic anemia:CYP3A4 \| multiple myeloma:CYP3A4 \| myeloma:CYP3A4 \| bone marrow cancer:CYP3A4 \| Human immunodeficiency virus infectious disease:CYP3A4 \| hematopoietic system disease:CYP3A4 \| prostate cancer:CYP3A43 \| male reproductive organ cancer:CYP3A43 \| osteoporosis:CYP3A4 \| bone resorption disease:CYP3A4 \| specific developmental disorder:AP4M1 \| anemia:CYP3A4 \| autosomal recessive disease:CYP3A4 \| liver cirrhosis:CYP3A4 \| cerebral palsy:AP4M1 \| coronary artery disease:CYP3A4	steroid catabolic process:CYP3A4 \| cellular response to xenobiotic stimulus:CYP3A4 \| response to xenobiotic stimulus:CYP3A4 \| oxidative demethylation:CYP3A4 \| drug catabolic process:CYP3A4 \| cellular hormone metabolic process:CYP3A4 \| protein localization to vacuole:AP4M1 \| xenobiotic metabolic process:CYP3A4 \| steroid metabolic process:CYP3A4 \| protein localization to lysosome:AP4M1 \| drug metabolic process:CYP3A4 \| hormone metabolic process:CYP3A4 \| protein targeting to vacuole:AP4M1 \| androgen metabolic process:CYP3A4 \| response to drug:CYP3A4 \| lipid modification:CYP3A4 \| vitamin D biosynthetic process:CYP3A4 \| steroid biosynthetic process:CYP3A4 \| demethylation:CYP3A4 \| fat-soluble vitamin biosynthetic process:CYP3A4 \| snRNA metabolic process:MEPCE	0.0284362	0.041549	0.306450673397045	0.0164859	0.0371801	0.182075841238061	0.0137785	0.0829782	0.0614212388029801	0.0300648	0.0457121	0.291744010093846	-0.00590067	0.0490094	0.0437427019812908	0.0981351	0.0941322	0.526476536134149	0.00133906	0.0341084	0.0138160802219482	-0.0153371	0.0386057	0.160379306232296	0.0328541	0.0660653	0.2082153458709	-0.194554	0.0270536	12.19307557796	-0.221598	0.034685	9.77698456671428	-0.165746	0.0420886	4.08539454687549	-0.0179881	0.0262056	0.307639622030041	0.0225776	0.028827	0.363005889053084	-0.0594041	0.0433251	0.768693555507339	-0.041145	0.0263863	0.924752403505679	-0.0217482	0.0333754	0.28849224222742	-0.0549241	0.0406304	0.753405412329317	-0.0089073	0.0154209	0.249086041647976	-0.0423054	0.0203524	1.42424078702458	0.0279808	0.0234923	0.63147139102061	0.0291433	0.0685369	0.17345744836055	0.0501714	0.0848194	0.256269224650555	-0.00775715	0.116541	0.0236729516169649
rs11575837:31560670:C:T		6	31560670	6p21.33	T	C	0.988	165	OHP17 ALL	2070	12.1100336353341	0.0129900966183575		NCR3 (0 kb, 5'utr/5 prime UTR/MODIFIER \| nc-exon/Non coding transcript exon/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); LST1 (4 kb, near gene/Downstream gene/MODIFIER); LTB (10 kb); TNF (15 kb); UQCRHP1 (18 kb); LTA (19 kb); AIF1 (22 kb); PRRC2A (28 kb); SNORA38 (30 kb); NFKBIL1 (34 kb); ATP6V1G2 (44 kb); BAG6 (46 kb); ATP6V1G2-DDX39B (46 kb); DDX39B-AS1 (50 kb)	0.943 Blood protein levels // 0.721 Plantar warts // 0.721 Response to angiotensin II receptor blocker therapy // 0.314 Mumps	- \| ABCF1 \| ABHD16A \| AGER \| AIF1 \| APOM \| ATF6B \| ATP6V1G2 \| ATP6V1G2-DDX39B \| BAG6 \| C2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf48 \| CCHCR1 \| CLIC1 \| CSNK2B \| DDAH2 \| DDR1 \| DDX39B \| DHX16 \| DOM3Z \| DXO \| EHMT2 \| FLOT1 \| GPANK1 \| GPSM3 \| GTF2H4 \| HCG22 \| HCG23 \| HCG27 \| HCG4B \| HCG4P3 \| HCP5 \| HLA-A \| HLA-B \| HLA-C \| HLA-DOB \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DQB2 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB2 \| HLA-DRB3 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB7 \| HLA-DRB8 \| HLA-E \| HLA-H \| HLA-J \| HLA-T \| HLA-W \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LTB \| LY6G5B \| LY6G5C \| LY6G6E \| MCCD1 \| MDC1 \| MICA \| MICB \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| NRM \| PBX2 \| POU5F1 \| PPP1R10 \| PPP1R11 \| PRRC2A \| PSMB8 \| PSMB9 \| PSORS1C1 \| RDBP \| RNF5 \| RPP21 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP2 \| TCF19 \| TNF \| TRIM10 \| TRIM39 \| TUBB \| unnamed \| VARS \| VARS2 \| XXbac-BPG154L12.4 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.12 \| XXbac-BPG299F13.17 \| Y RNA \| ZBTB12 \| ZNRD1	BTN3A2 \| CDC42EP4 \| HLA-A \| HLA-DQA1 \| HLA-DQA2 \| HLA-DRB1 \| HLA-DRB4 \| HLA-DRB5 \| HLA-F \| HLA-H \| HLA-V \| IER3 \| NHP2 \| PARP2 \| PDIA6 \| PSMB9 \| TAP2 \| TMEM154 \| XRCC6 \| ZNRD1	Type I diabetes mellitus:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA,TNF \| Allograft rejection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| Graft-versus-host disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| Antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,HSPA1A,HSPA1B,HSPA1L,TAP2,TNF \| Autoimmune thyroid disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Viral myocarditis:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Staphylococcus aureus infection:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Asthma:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Phagosome:ATP6V1G2,HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TAP2 \| Herpes simplex infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA,TAP2,TNF \| Intestinal immune network for IgA production:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Rheumatoid arthritis:ATP6V1G2,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,LTB,TNF \| Inflammatory bowel disease (IBD):HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Toxoplasmosis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TNF \| Systemic lupus erythematosus:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Cell adhesion molecules (CAMs):HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Leishmaniasis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Influenza A:DDX39B,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TNF \| Hematopoietic cell lineage:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Epstein-Barr virus infection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA,TNF \| Th1 and Th2 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Th17 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Tuberculosis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Natural killer cell mediated cytotoxicity:HLA-C,HLA-E,NCR3,TNF \| Endocytosis:HLA-C,HLA-E,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L,TNF \| Human cytomegalovirus infection:ATF6B,HLA-C,HLA-E,TAP2,TNF \| Kaposi sarcoma-associated herpesvirus infection:HLA-C,HLA-E \| Viral carcinogenesis:ATF6B,GTF2H4,HLA-C,HLA-E \| Spliceosome:DDX39B,HSPA1A,HSPA1B,HSPA1L,LSM2 \| Human immunodeficiency virus 1 infection:HLA-C,HLA-E,TAP2,TNF \| NF-kappa B signaling pathway:LTA,LTB,TNF \| Protein processing in endoplasmic reticulum:ATF6B,HSPA1A,HSPA1B,HSPA1L,RNF5 \| Cellular senescence:HLA-C,HLA-E \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:ATF6B,HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:ATP6V1G2,HLA-C,HLA-E,TNF \| Pertussis:TNF \| TNF signaling pathway:ATF6B,LTA,TNF \| Aminoacyl-tRNA biosynthesis:VARS2 \| Type II diabetes mellitus:TNF \| Lysosome:NEU1 \| Cortisol synthesis and secretion:ATF6B	Translocation of ZAP-70 to Immunological synapse:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon gamma signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| PD-1 signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Generation of second messenger molecules:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Downstream TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon Signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| MHC class II antigen presentation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Costimulation by the CD28 family:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Endosomal/Vacuolar pathway:HLA-C,HLA-E \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,HLA-E,TAP2 \| ER-Phagosome pathway:HLA-C,HLA-E,TAP2 \| Antigen processing-Cross presentation:HLA-C,HLA-E,TAP2 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,HLA-E,NCR3 \| Interferon alpha/beta signaling:HLA-C,HLA-E \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:GTF2H4,HSPA1A,HSPA1B \| TNFR2 non-canonical NF-kB pathway:LTA,LTB,TNF \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:LTA,LTB \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| TP53 Regulates Transcription of DNA Repair Genes:GTF2H4 \| HIV Infection:GTF2H4 \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B \| Class I MHC mediated antigen processing & presentation:HLA-C,HLA-E,TAP2 \| HIV Transcription Elongation:GTF2H4 \| Formation of HIV-1 elongation complex containing HIV-1 Tat:GTF2H4 \| Tat-mediated elongation of the HIV-1 transcript:GTF2H4 \| Formation of HIV elongation complex in the absence of HIV Tat:GTF2H4 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Influenza Infection:HSPA1A,HSPA1B \| Defective CFTR causes cystic fibrosis:RNF5 \| Formation of RNA Pol II elongation complex :GTF2H4 \| RNA Polymerase II Transcription Elongation:GTF2H4 \| Formation of the Early Elongation Complex:GTF2H4 \| Formation of the HIV-1 Early Elongation Complex:GTF2H4 \| ABC-family proteins mediated transport:ABCF1,RNF5 \| HIV Life Cycle:GTF2H4 \| RNA Polymerase I Promoter Escape:GTF2H4,ZNRD1 \| Transcription of the HIV genome:GTF2H4 \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Transcriptional Regulation by TP53:GTF2H4 \| RNA Polymerase I Transcription Termination:GTF2H4,ZNRD1 \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| RNA Polymerase I Transcription Initiation:GTF2H4,ZNRD1 \| Diseases associated with glycosylation precursor biosynthesis:NEU1 \| Neutrophil degranulation:HLA-C,HSPA1A,HSPA1B,NEU1 \| ABC transporter disorders:RNF5 \| Influenza Life Cycle:HSPA1A,HSPA1B \| RNA Polymerase II Pre-transcription Events:GTF2H4 \| Transcriptional regulation of white adipocyte differentiation:TNF \| Dual Incision in GG-NER:GTF2H4 \| tRNA Aminoacylation:VARS2 \| Formation of Incision Complex in GG-NER:GTF2H4 \| Late Phase of HIV Life Cycle:GTF2H4 \| Deadenylation-dependent mRNA decay:LSM2,SKIV2L \| Chaperonin-mediated protein folding:SKIV2L \| Association of TriC/CCT with target proteins during biosynthesis:SKIV2L \| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection:GTF2H4 \| RNA Pol II CTD phosphorylation and interaction with CE:GTF2H4 \| RNA Polymerase I Promoter Clearance:GTF2H4,ZNRD1 \| RNA Polymerase I Transcription:GTF2H4,ZNRD1 \| mRNA Capping:GTF2H4	Kawasaki disease:BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A,TNF \| lymphadenitis:BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A,TNF \| lymph node disease:BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A,TNF \| lymphatic system disease:BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A,TNF \| leprosy:HLA-DRB1,LTA,TNF \| sarcoidosis:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L,LTA,TNF \| hypersensitivity reaction type IV disease:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L,LTA,TNF \| autoimmune disease of endocrine system:HLA-C,HLA-DQA1,HLA-DRB1,TAP2,TNF \| multiple sclerosis:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| endocrine system disease:ABCF1,HLA-C,HLA-DQA1,HLA-DRB1,HSPA1B,LTA,TAP2,TNF \| autoimmune thyroiditis:HLA-DRB1 \| demyelinating disease:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Graves' disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2,TNF \| thyroid gland disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2,TNF \| intrahepatic cholestasis:HLA-DQA1,HLA-DRB1,HLA-E \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HLA-C,HLA-DQA1,HLA-DRB1,TNF \| primary bacterial infectious disease:FLOT1,HLA-DRB1,LTA,TAP2,TNF \| hepatitis:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E,LTA,NCR3,TNF \| hyperthyroidism:HLA-C,HLA-DQA1,HLA-DRB1,TAP2,TNF \| vitiligo:DDR1,HLA-C,TNF \| spondylitis:HLA-C,HLA-E,TNF \| ankylosing spondylitis:HLA-C,HLA-E,TNF \| rheumatic fever:HLA-DQA1,HLA-DRB1,TNF \| bacterial infectious disease:FLOT1,HLA-DRB1,LTA,TAP2,TNF \| aplastic anemia:HLA-DQA1,HLA-DRB1,TNF \| urticaria:HLA-DRB1,TNF \| spondyloarthropathy:HLA-C,HLA-E,TNF \| vasculitis:DDR1,HLA-DRB1,HLA-E,TNF \| hypothyroidism:HLA-DRB1,TNF \| Behcet's disease:HLA-DRB1,HLA-E,TNF \| hepatitis C:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E,LTA,NCR3,TNF \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| arthropathy:HLA-C,HLA-E,TNF \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,LTA,NCR3,PRRC2A,TAP2,TNF \| malaria:HLA-DRB1,LTA,NCR3,PRRC2A,TNF \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:DDR1,HLA-DRB1,TNF \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-DRB1,LTA \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DQA1,HLA-DRA,HLA-E,TNF \| neuromuscular junction disease:HLA-DQA1,HLA-DRA,HLA-E,TNF \| brucellosis:TAP2,TNF \| duodenal ulcer:HSPA1A,LTA,TNF \| cholestasis:HLA-DQA1,HLA-DRB1,HLA-E \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-C,HLA-DQA1,HLA-DRB1,TNF \| upper respiratory tract disease:HLA-C,HSPA1A,TAP2,TNF \| uveitis:HLA-DQA1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,LTA,NCR3,PRRC2A,TNF \| urinary system disease:AIF1,DDR1,HLA-DQA1,HLA-DRB1,HSPA1A,TNF \| multiple myeloma:BAG6,IER3,LTA,NCR3,TNF \| myeloma:BAG6,IER3,LTA,NCR3,TNF \| reproductive system disease:HLA-DRB1,HLA-E,HSPA1A,LTA,MSH5,TNF \| bone marrow cancer:BAG6,IER3,LTA,NCR3,TNF \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L,TNF \| bile duct disease:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E \| complex regional pain syndrome:TNF \| biliary tract disease:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E \| azoospermia:HLA-DRB1,MSH5 \| proteinuria:DDR1,HLA-DRB1 \| kidney disease:AIF1,DDR1,HLA-DQA1,HLA-DRB1,HSPA1A,TNF \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DRB1,TNF \| type 1 diabetes mellitus:HLA-DQA1,LTA,TNF \| blood coagulation disease:HLA-DRA,HLA-DRB1,LTA \| allergic rhinitis:HLA-C,TAP2,TNF \| hemorrhagic disease:HLA-DRA,HLA-DRB1,LTA \| neuromuscular disease:HLA-DQA1,HLA-DRA,HLA-E,TNF \| thyroiditis:HLA-DRB1 \| nasal cavity disease:HLA-C,TAP2,TNF \| nose disease:HLA-C,TAP2,TNF \| rhinitis:HLA-C,TAP2,TNF \| collagen disease:AIF1,HLA-DRB1,TAP2,TNF \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:ABCF1,HLA-DRB1,HSPA1B,LTA,TNF \| nephritis:AIF1,HLA-DQA1,HLA-DRB1,TNF \| periodontitis:TNF \| celiac disease:HLA-DQA1,HLA-DRB1,TNF \| peptic ulcer disease:HSPA1A,LTA,TNF \| hematopoietic system disease:HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA,TNF \| gestational diabetes:TNF \| esophageal varix:TNF \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DQA1,HLA-DRB1,HLA-E,TNF \| rheumatic disease:AIF1,HLA-DRB1,TAP2,TNF \| systemic scleroderma:AIF1,HLA-DRB1,TAP2,TNF \| scleroderma:AIF1,HLA-DRB1,TAP2,TNF \| male reproductive system disease:HLA-DRB1,HSPA1A,MSH5,TNF \| male infertility:HLA-DRB1,MSH5,TNF \| silicosis:HLA-DRB1,TNF \| integumentary system disease:HLA-DQA1,HLA-DRB1,TNF \| polycystic ovary syndrome:TNF \| sickle cell anemia:HLA-DRB1,HLA-E,TNF \| periodontal disease:TNF \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2,TNF \| alpha 1-antitrypsin deficiency:TNF \| Human immunodeficiency virus infectious disease:HLA-C,HLA-DRB1,TNF \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B,TNF \| interstitial lung disease:DDR1,HLA-DRB1,TNF \| bronchial disease:HSPA1A,HSPA1B,LTA,TAP2,TNF \| acute pancreatitis:HSPA1B,LTA \| acne:TNF \| sebaceous gland disease:TNF \| tuberculosis:HLA-DRB1,TNF \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| dengue hemorrhagic fever:LTA,TNF \| autonomic nervous system disease:TNF \| prostate disease:HLA-DRB1,HSPA1A \| pneumoconiosis:HLA-DRB1,TNF \| aortic valve disease:TNF \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1,TNF \| tooth disease:TNF \| dengue disease:LTA,TNF \| autoimmune disease of peripheral nervous system:HLA-DRB1,TNF \| Guillain-Barre syndrome:HLA-DRB1,TNF \| pancreas disease:ABCF1,HLA-DRB1,HSPA1B,LTA,TNF \| open-angle glaucoma:HLA-DRB1,TAP2,TNF \| varicose veins:TNF \| influenza:HLA-DRB1,TNF \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-DQA1,HLA-DRB1,TNF \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B,LTA,TAP2,TNF \| ovarian disease:MSH5 \| neutropenia:TNF \| agranulocytosis:TNF \| gastritis:HLA-DRB1,TNF \| dermatomyositis:HLA-DRB1,TNF \| essential hypertension:HSPA1A,HSPA1B,HSPA1L,LTA \| female reproductive system disease:LTA,MSH5,TNF \| osteomyelitis:HLA-DRB1 \| neuropathy:HLA-DQA1,HLA-DRA,HLA-E,TNF \| plasma protein metabolism disease:TNF \| mouth disease:TNF \| osteoporosis:TNF \| Sjogren's syndrome:NFKBIL1,TNF \| bone resorption disease:TNF \| migraine:HLA-DRB1,LTA,TNF \| infertility:HLA-E,MSH5,TNF \| peripheral nervous system disease:HLA-DRB1,TNF \| age related macular degeneration:TNF \| degeneration of macula and posterior pole:TNF \| autoimmune disease of urogenital tract:HLA-DRB1,TNF \| primary biliary cirrhosis:HLA-DRB1,TNF \| cell type benign neoplasm:DDR1,TNF \| macular degeneration:TNF \| stomach disease:HLA-DRB1,TNF \| cholangitis:HLA-C,HLA-DRB1 \| pulmonary hypertension:TNF \| Crohn's disease:HSPA1B,LTA \| osteosarcoma:BAG6,TNF \| lung disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B,LTA,TNF \| spinal cord disease:HLA-C,HLA-DRB1 \| gallbladder carcinoma:CLIC1,TNF \| heart valve disease:TNF \| pulmonary edema:HSPA1A \| aortic valve stenosis:TNF \| gallbladder cancer:CLIC1,TNF \| myositis:HLA-DRB1,TNF \| lipodystrophy:TNF \| leukopenia:TNF \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B,LTA \| myopathy:HLA-DRB1,TNF \| muscle tissue disease:HLA-DRB1,TNF \| bone cancer:BAG6,TNF \| nasopharynx carcinoma:DDR1,HSPA1B \| axonal neuropathy:TNF \| pharynx cancer:DDR1,HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TNF \| cardiomyopathy:TNF \| muscular disease:HLA-DRB1,TNF \| endocrine organ benign neoplasm:DDR1 \| bronchiectasis:TAP2 \| premature ovarian failure:MSH5 \| liver cirrhosis:DDR1,HLA-DRB1,TNF \| renal cell carcinoma:HLA-DRB1,TAP2 \| muscular dystrophy:TNF \| glaucoma:HLA-DRB1,TAP2,TNF \| esophageal carcinoma:HLA-DRB1 \| skin disease:HLA-DRB1,TNF \| retinal disease:HLA-DRB1,LTA,TAP2,TNF \| female reproductive organ cancer:DDR1,HLA-DQA1,HLA-DRB1,TNF \| vein disease:TNF \| connective tissue cancer:BAG6,TNF \| adenoma:DDR1 \| primary open angle glaucoma:TAP2,TNF \| severe combined immunodeficiency:HLA-DRB1,TNF \| coronary artery disease:DDX39B,LTA,NFKBIL1,TNF \| retinal degeneration:HLA-DRB1,TAP2,TNF \| integumentary system cancer:LTA \| skin cancer:LTA \| malignant ovarian surface epithelial-stromal neoplasm:DDR1,HLA-DQA1,HLA-DRB1,TNF \| ovary epithelial cancer:DDR1,HLA-DQA1,HLA-DRB1,TNF \| ovarian carcinoma:DDR1,HLA-DQA1,HLA-DRB1,TNF \| combined T cell and B cell immunodeficiency:HLA-DRB1,TNF	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TAP2 \| antigen processing and presentation of peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TAP2 \| antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| cellular response to interferon-gamma:AIF1,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| response to interferon-gamma:AIF1,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell receptor signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating signal transduction:BAG6,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,NCR3,NFKBIL1 \| T cell costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| lymphocyte costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen receptor-mediated signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-regulating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| positive regulation of cell-cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| positive regulation of leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| positive regulation of T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| regulation of cell-cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,HLA-E,TAP2 \| regulation of leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,HLA-E,TAP2 \| positive regulation of cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| positive regulation of lymphocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| positive regulation of cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| regulation of lymphocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LST1 \| regulation of T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| regulation of leukocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LST1 \| leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,HLA-E,TAP2 \| positive regulation of leukocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| lymphocyte mediated immunity:HLA-E,LTA,NCR3,TNF \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,LTA,NCR3,TNF \| adaptive immune response:HLA-E,LTA,NCR3,TAP2,TNF \| humoral immune response mediated by circulating immunoglobulin:LTA,TNF \| natural killer cell mediated cytotoxicity:HLA-E,NCR3 \| natural killer cell mediated immunity:HLA-E,NCR3 \| T cell mediated cytotoxicity:HLA-E,NCR3 \| response to type I interferon:HLA-C,HLA-E \| type I interferon signaling pathway:HLA-C,HLA-E \| cellular response to type I interferon:HLA-C,HLA-E \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,LTA,LTB,TNF \| leukocyte mediated cytotoxicity:HLA-E,NCR3 \| regulation of humoral immune response:LTA,TNF \| positive regulation of defense response:FLOT1,HLA-E,HSPA1A,HSPA1B,LTA,NCR3,NFKBIL1,TNF \| positive regulation of cytokine production:FLOT1,HLA-E,HSPA1A,HSPA1B,LTA,LTB,TNF \| T cell mediated immunity:HLA-E,NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:HLA-E,LTA,NCR3,TNF \| positive regulation of innate immune response:FLOT1,HLA-E,HSPA1A,HSPA1B,NCR3,NFKBIL1 \| positive regulation of T cell proliferation:AIF1,HLA-E \| regulation of lymphocyte mediated immunity:HLA-E,LTA,NCR3,TNF \| NIK/NF-kappaB signaling:TNF \| regulation of innate immune response:FLOT1,HLA-E,HSPA1A,HSPA1B,NCR3,NFKBIL1 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B,LTA,LTB,TNF \| regulation of T cell proliferation:AIF1,HLA-E \| cell killing:HLA-E,NCR3 \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B \| positive regulation of lymphocyte mediated immunity:HLA-E,LTA,NCR3,TNF \| regulation of lymphocyte proliferation:AIF1,HLA-E,LST1 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,LTA,NCR3,TNF \| regulation of mononuclear cell proliferation:AIF1,HLA-E,LST1 \| regulation of natural killer cell mediated cytotoxicity:HLA-E,NCR3 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B,TNF \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B,TNF \| chronic inflammatory response:LTA,TNF \| positive regulation of adaptive immune response:HLA-E,LTA,NCR3,TNF \| regulation of natural killer cell mediated immunity:HLA-E,NCR3 \| interferon-gamma production:LTA,TNF \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| lymph node development:LTA,LTB \| immunoglobulin mediated immune response:LTA,TNF \| regulation of leukocyte proliferation:AIF1,HLA-E,LST1 \| B cell mediated immunity:LTA,TNF \| mRNA catabolic process:HSPA1A,HSPA1B,LSM2,SKIV2L \| response to tumor necrosis factor:HSPA1A,HSPA1B,LTA,LTB,TNF \| regulation of chronic inflammatory response:LTA,TNF \| response to heat:HSPA1A,HSPA1B,HSPA1L \| antigen processing and presentation via MHC class Ib:HLA-E,TAP2 \| regulation of humoral immune response mediated by circulating immunoglobulin:LTA,TNF \| positive regulation of nitric oxide biosynthetic process:AIF1,DDAH2,TNF \| positive regulation of nitric oxide metabolic process:AIF1,DDAH2,TNF \| regulation of leukocyte mediated immunity:HLA-E,LTA,NCR3,TNF \| activation of innate immune response:FLOT1,HSPA1A,HSPA1B,NFKBIL1 \| regulation of T cell mediated cytotoxicity:HLA-E,NCR3 \| positive regulation of leukocyte mediated immunity:HLA-E,LTA,NCR3,TNF \| T cell proliferation:AIF1,HLA-E \| antigen processing and presentation of endogenous antigen:HLA-E,TAP2 \| negative regulation of natural killer cell mediated cytotoxicity:HLA-E \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of inflammatory response to antigenic stimulus:LTA,TNF \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B,TNF \| microtubule nucleation:HSPA1A,HSPA1B \| positive regulation of phagocytosis:TNF \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B,TNF \| positive regulation of lymphocyte proliferation:AIF1,HLA-E \| positive regulation of mononuclear cell proliferation:AIF1,HLA-E \| positive regulation of heterotypic cell-cell adhesion:FLOT1,TNF \| negative regulation of natural killer cell mediated immunity:HLA-E \| regulation of leukocyte mediated cytotoxicity:HLA-E,NCR3 \| regulation of DNA-templated transcription in response to stress:ATF6B,HSPA1A \| negative regulation of immune effector process:HLA-E,TNF \| ER-associated misfolded protein catabolic process:BAG6,RNF5 \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B \| RNA catabolic process:HSPA1A,HSPA1B,LSM2,SKIV2L \| positive regulation of leukocyte proliferation:AIF1,HLA-E \| positive regulation of reactive oxygen species biosynthetic process:AIF1,DDAH2,TNF \| negative regulation of growth of symbiont in host:LTA,TNF \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,HSPA1L,RNF5 \| negative regulation of leukocyte mediated cytotoxicity:HLA-E \| positive regulation of T cell mediated cytotoxicity:HLA-E,NCR3 \| positive regulation of humoral immune response:LTA,TNF \| regulation of growth of symbiont in host:LTA,TNF \| negative regulation of growth of symbiont involved in interaction with host:LTA,TNF \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,TNF \| DNA-templated transcription, elongation:DDX39B,GTF2H4,ZNRD1 \| humoral immune response:HLA-E,LTA,TNF \| regulation of acute inflammatory response:TNF \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| modulation of growth of symbiont involved in interaction with host:LTA,TNF \| innate immune response-activating signal transduction:FLOT1,HSPA1A,HSPA1B,NFKBIL1 \| regulation of nitric oxide biosynthetic process:AIF1,DDAH2,TNF \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,LTA,NCR3,TNF \| lymphocyte proliferation:AIF1,HLA-E,LST1 \| negative regulation of phosphoprotein phosphatase activity:TNF \| mononuclear cell proliferation:AIF1,HLA-E,LST1 \| regulation of immunoglobulin secretion:HLA-E,TNF \| regulation of translational fidelity:VARS2 \| positive regulation of interleukin-12 production:LTB \| positive regulation of translational initiation:TNF \| regulation of cell killing:HLA-E,NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| negative regulation of cell killing:HLA-E \| growth of symbiont in host:LTA,TNF \| regulation of interleukin-8 production:HSPA1A,HSPA1B,TNF \| regulation of antigen processing and presentation:HLA-DOB \| RNA phosphodiester bond hydrolysis:HSPA1A,NHP2,RPP21,ZNRD1 \| steroid metabolic process:TNF \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| growth involved in symbiotic interaction:LTA,TNF \| growth of symbiont involved in interaction with host:LTA,TNF \| regulation of adaptive immune response:HLA-E,LTA,NCR3,TNF \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| leukocyte proliferation:AIF1,HLA-E,LST1 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B,TNF \| regulation of protein stability:BAG6,FLOT1,HSPA1A,HSPA1B,RNF5 \| positive regulation of interferon-gamma production:LTA,TNF \| positive regulation of translation:DDX39B,TNF \| nitric oxide biosynthetic process:AIF1,DDAH2,TNF \| interleukin-8 production:HSPA1A,HSPA1B,TNF \| regulation of heterotypic cell-cell adhesion:FLOT1,TNF \| immunoglobulin secretion:HLA-E,TNF \| positive regulation of protein complex assembly:GTF2H4,HSPA1A,HSPA1B,TNF \| interaction with host:DDX39B,HSPA1A,HSPA1B \| signal transduction in absence of ligand:HSPA1A,HSPA1B,TNF \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B,TNF \| nucleocytoplasmic transport:DDX39B,NFKBIL1,TNF \| positive regulation of natural killer cell mediated immunity:HLA-E,NCR3 \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| podosome assembly:TNF \| nitric oxide metabolic process:AIF1,DDAH2,TNF \| nuclear transport:DDX39B,NFKBIL1,TNF \| cellular response to misfolded protein:BAG6,RNF5 \| positive regulation of vascular smooth muscle cell proliferation:DDX39B,TNF \| regulation of inflammatory response to antigenic stimulus:LTA,TNF \| regulation of phagocytosis:TNF \| natural killer cell activation:BAG6,NCR3 \| reactive nitrogen species metabolic process:AIF1,DDAH2,TNF \| nuclear-transcribed mRNA catabolic process, exonucleolytic:LSM2,SKIV2L \| positive regulation of mononuclear cell migration:AIF1,TNF \| cellular response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,RNF5 \| protein stabilization:BAG6,FLOT1,HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| positive regulation of smooth muscle cell proliferation:AIF1,DDX39B,TNF \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| response to misfolded protein:BAG6,RNF5 \| mRNA cleavage:HSPA1A,ZNRD1 \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:AIF1,DDAH2,TNF \| regulation of organelle assembly:HSPA1A,HSPA1B,RNF5,TNF \| regulation of transcription from RNA polymerase II promoter in response to stress:ATF6B,HSPA1A \| regulation of reactive oxygen species biosynthetic process:AIF1,DDAH2,TNF \| protein ubiquitination involved in ubiquitin-dependent protein catabolic process:RNF5 \| regulation of endocytosis:FLOT1,TNF \| cytoplasmic sequestering of transcription factor:NFKBIL1 \| protein K63-linked ubiquitination:RNF5 \| protein quality control for misfolded or incompletely synthesized proteins:BAG6,RNF5 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| positive regulation of endocytosis:FLOT1,TNF \| negative regulation of multi-organism process:LTA,TNF,NFKBIL1 \| negative regulation of protein dephosphorylation:TNF \| defense response to Gram-positive bacterium:HLA-E,LTA,TNF \| response to endoplasmic reticulum stress:ATF6B,BAG6,FLOT1,HSPA1A,RNF5 \| positive regulation of immune effector process:HLA-E,LTA,NCR3,TNF \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| transcription elongation from RNA polymerase I promoter:GTF2H4,ZNRD1 \| termination of RNA polymerase I transcription:GTF2H4,ZNRD1 \| pattern recognition receptor signaling pathway:FLOT1,HSPA1A,HSPA1B \| response to isoquinoline alkaloid:AIF1 \| response to morphine:AIF1 \| positive regulation of T cell mediated immunity:HLA-E,NCR3 \| positive regulation of NIK/NF-kappaB signaling:TNF \| spindle assembly:HSPA1A,HSPA1B \| ganglioside metabolic process:NEU1 \| positive regulation of cellular amide metabolic process:DDX39B,TNF \| regulation of interleukin-12 production:LTB \| nucleic acid phosphodiester bond hydrolysis:GTF2H4,HSPA1A,NHP2,RPP21,ZNRD1 \| transcription initiation from RNA polymerase I promoter:GTF2H4,ZNRD1 \| exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay:LSM2,SKIV2L \| nuclear-transcribed mRNA catabolic process:LSM2,SKIV2L \| positive regulation of B cell mediated immunity:LTA,TNF \| positive regulation of immunoglobulin mediated immune response:LTA,TNF \| interleukin-12 production:LTB \| positive regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| positive regulation of leukocyte mediated cytotoxicity:HLA-E,NCR3 \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| reactive oxygen species biosynthetic process:AIF1,DDAH2,TNF \| CD8-positive, alpha-beta T cell activation:HLA-E \| negative regulation of immune system process:HLA-DOB,HLA-E,LST1,TNF,NFKBIL1 \| positive regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| positive regulation of NF-kappaB import into nucleus:TNF \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B,TNF \| macroautophagy:ATP6V1G2,RNF5 \| regulation of T cell mediated immunity:HLA-E,NCR3 \| negative regulation of lymphocyte mediated immunity:HLA-E \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| cytoplasmic sequestering of protein:NFKBIL1 \| receptor-mediated endocytosis:FLOT1 \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| DNA-templated transcription, termination:DDX39B,GTF2H4,ZNRD1 \| regulation of vascular smooth muscle cell proliferation:DDX39B,TNF \| vascular smooth muscle cell proliferation:DDX39B,TNF \| regulation of macroautophagy:ATP6V1G2,RNF5 \| membrane assembly:FLOT1 \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:FLOT1,LY6G5C \| regulation of interferon-gamma production:LTA,TNF \| protein export from nucleus:DDX39B \| viral life cycle:HSPA1A,HSPA1B,TNF \| regulation of osteoblast differentiation:CLIC1,TNF \| negative regulation of osteoblast differentiation:TNF \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress:ATF6B \| vitamin D biosynthetic process:TNF \| protein localization to nucleus:NFKBIL1,TNF \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| steroid biosynthetic process:TNF \| regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| regulation of mononuclear cell migration:AIF1,TNF \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| inflammatory response to antigenic stimulus:LTA,TNF \| positive regulation of catabolic process:BAG6,HSPA1A,TNF \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:BAG6,HSPA1A \| microglial cell activation:AIF1 \| negative regulation of proteolysis involved in cellular protein catabolic process:BAG6 \| response to salt stress:TNF \| positive regulation of cell killing:HLA-E,NCR3 \| endothelial cell development:TNF \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B,TNF \| negative regulation of innate immune response:HLA-E \| phagocytosis:AIF1,TNF \| mRNA cleavage involved in mRNA processing:HSPA1A \| regulation of heat generation:TNF \| regulation of autophagy:ATP6V1G2,RNF5 \| response to ammonium ion:AIF1 \| microtubule polymerization:HSPA1A,HSPA1B \| regulation of inflammatory response:LTA,TNF \| synapsis:BAG6,MSH5 \| macrophage activation:AIF1 \| protein folding:HSPA1A,HSPA1B,HSPA1L \| negative regulation of leukocyte mediated immunity:HLA-E \| positive regulation of protein catabolic process:BAG6,HSPA1A,TNF \| positive regulation of cellular catabolic process:BAG6,HSPA1A,TNF \| acute inflammatory response:TNF \| regulation of B cell mediated immunity:LTA,TNF \| regulation of immunoglobulin mediated immune response:LTA,TNF \| tRNA aminoacylation for protein translation:VARS2 \| regulation of transcription factor import into nucleus:NFKBIL1,TNF \| nuclear-transcribed mRNA catabolic process, nonsense-mediated decay:SKIV2L \| extracellular matrix organization:DDR1,FLOT1,TNF \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| regulation of smooth muscle cell proliferation:AIF1,DDX39B,TNF \| membrane biogenesis:FLOT1 \| extracellular structure organization:DDR1,FLOT1,TNF \| heterotypic cell-cell adhesion:FLOT1,TNF \| branching involved in mammary gland duct morphogenesis:DDR1 \| negative regulation of growth:HSPA1A,HSPA1B,LTA,TNF \| negative regulation of immune response:HLA-E,TNF \| transcription factor import into nucleus:NFKBIL1,TNF \| regulation of lipid catabolic process:TNF \| tRNA aminoacylation:VARS2 \| regulation of binding:FLOT1 \| transcription elongation from RNA polymerase II promoter:GTF2H4 \| regulation of mRNA metabolic process:HSPA1A \| regulation of NIK/NF-kappaB signaling:TNF \| smooth muscle cell proliferation:AIF1,DDX39B,TNF \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| syncytium formation by plasma membrane fusion:FLOT1 \| amino acid activation:VARS2 \| regulation of RNA stability:HSPA1A \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| cellular response to amino acid stimulus:TNF \| nuclear export:DDX39B \| cleavage involved in rRNA processing:NHP2 \| syncytium formation:FLOT1 \| lipopolysaccharide-mediated signaling pathway:TNF \| fat-soluble vitamin biosynthetic process:TNF \| regulation of symbiosis, encompassing mutualism through parasitism:LTA,TNF \| regulation of monooxygenase activity:DDAH2,TNF \| positive regulation of cellular component biogenesis:FLOT1,GTF2H4,HSPA1A,HSPA1B,TNF \| regulation of cellular protein catabolic process:BAG6,HSPA1A \| defense response to bacterium:HLA-E,LTA,TNF \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,TNF \| glial cell activation:AIF1 \| protein polymerization:AIF1,HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| regulation of mitotic cell cycle phase transition:AIF1 \| mitochondrial membrane organization:HSPA1A \| receptor metabolic process:FLOT1,TNF \| immunoglobulin production:HLA-E,TNF \| reactive oxygen species metabolic process:AIF1,DDAH2,TNF \| regulation of immunoglobulin production:HLA-E,TNF \| viral genome replication:TNF \| regulation of receptor internalization:FLOT1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| protein polyubiquitination:RNF5 \| cellular response to ammonium ion:AIF1 \| homologous chromosome segregation:BAG6,MSH5 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:BAG6,HSPA1A \| positive regulation of cell junction assembly:FLOT1 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| positive regulation of cytokine biosynthetic process:LTB,TNF \| negative regulation of cellular protein catabolic process:BAG6 \| negative regulation of catabolic process:BAG6,RNF5,TNF \| regulation of mRNA catabolic process:HSPA1A \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| negative regulation of cellular catabolic process:BAG6,RNF5 \| negative regulation of autophagy:RNF5 \| cellular amino acid metabolic process:DDAH2,VARS2 \| transcription from RNA polymerase I promoter:GTF2H4,ZNRD1 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,TNF,NFKBIL1 \| gland morphogenesis:DDR1,TNF \| endothelium development:TNF \| regulation of phosphoprotein phosphatase activity:TNF \| regulation of protein complex assembly:GTF2H4,HSPA1A,HSPA1B,TNF \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B,TNF \| spindle organization:HSPA1A,HSPA1B \| superoxide metabolic process:TNF \| negative regulation of phosphatase activity:TNF \| negative regulation of ossification:TNF \| ruffle assembly:AIF1 \| regulation of protein catabolic process:BAG6,HSPA1A,TNF \| platelet activation:CLIC1 \| negative regulation of mitotic cell cycle:TNF \| DNA-templated transcription, initiation:GTF2H4,ZNRD1 \| negative regulation of hydrolase activity:TNF \| chromosome organization involved in meiotic cell cycle:BAG6,MSH5 \| negative regulation of chemotaxis:AIF1 \| negative regulation of transcription factor import into nucleus:NFKBIL1 \| regulation of cell cycle phase transition:AIF1 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B,TNF \| transcription initiation from RNA polymerase II promoter:GTF2H4 \| mammary gland duct morphogenesis:DDR1 \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| multi-organism transport:DDX39B \| multi-organism localization:DDX39B \| autophagy:ATP6V1G2,RNF5 \| process utilizing autophagic mechanism:ATP6V1G2,RNF5 \| cellular response to oxidative stress:AIF1,HSPA1A,HSPA1B,TNF \| regulation of striated muscle tissue development:DDX39B,FLOT1 \| positive regulation of striated muscle cell differentiation:DDX39B,FLOT1 \| regulation of autophagosome assembly:RNF5 \| protein complex localization:TNF \| receptor internalization:FLOT1 \| regulation of translational initiation:TNF \| regulation of reactive oxygen species metabolic process:AIF1,DDAH2,TNF \| negative regulation of proteolysis:BAG6 \| ubiquitin-dependent ERAD pathway:BAG6,RNF5 \| regulation of muscle tissue development:DDX39B,FLOT1 \| regulation of multi-organism process:LTA,NFKBIL1,TNF \| RNA localization to Cajal body:NHP2 \| telomerase RNA localization to Cajal body:NHP2 \| telomerase RNA localization:NHP2 \| RNA localization to nucleus:NHP2 \| heat generation:TNF \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B,TNF \| 7-methylguanosine mRNA capping:GTF2H4 \| negative regulation of fibroblast proliferation:LTA \| regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| regulation of leukocyte chemotaxis:AIF1 \| mammary gland development:DDR1 \| response to unfolded protein:ATF6B,HSPA1A,HSPA1L \| response to oxidative stress:AIF1,HSPA1A,HSPA1B,TNF \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| negative regulation of defense response:HLA-E \| translational initiation:TNF \| 7-methylguanosine RNA capping:GTF2H4 \| RNA capping:GTF2H4 \| regulation of viral process:TNF \| smooth muscle cell migration:AIF1,DDR1 \| negative regulation of viral life cycle:TNF \| negative regulation of leukocyte activation:LST1 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:LSM2,SKIV2L	0.0952747	0.0741737	0.700889478559598				-0.0302276	0.119039	0.0971549155606244	0.58141	0.0806288	12.1100336353341				0.570743	0.129792	4.89825636194129	0.0824868	0.0608811	0.755468068883695				0.0870553	0.0922153	0.46159091712615	0.0240386	0.0402877	0.259065208400485				0.112006	0.0666056	1.03319864083765	0.0587986	0.0404269	0.836173971317767				0.163728	0.0653613	1.91199865212002	0.0403241	0.0382237	0.535438920587954				-0.0489441	0.0621333	0.365666846813388	0.0170901	0.0233206	0.333800369121636				0.00647908	0.0367463	0.0654798345751871	0.209706	0.121231	1.07664560789673				0.133521	0.161474	0.388713329587092
rs7759215:31403625:C:G		6	31403625	6p21.33	G	C	0.999	0	OHP17 ALL	2070	12.0699173666076	0.0135265700483092		HCP5 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); LINC01149 (5.8 kb); MICA (21 kb); HLA-S (54 kb)	NA	HLA-C \| MICA \| MICB \| NOTCH4 \| XXbac-BPG181B23.7 \| XXbac-BPG299F13.17 \| Y RNA \| ZBTB12		Type I diabetes mellitus:HLA-C \| Allograft rejection:HLA-C \| Graft-versus-host disease:HLA-C \| Antigen processing and presentation:HLA-C \| Autoimmune thyroid disease:HLA-C \| Viral myocarditis:HLA-C \| Phagosome:HLA-C \| Herpes simplex infection:HLA-C \| Cell adhesion molecules (CAMs):HLA-C \| Epstein-Barr virus infection:HLA-C \| Human T-cell leukemia virus 1 infection:HLA-C \| Natural killer cell mediated cytotoxicity:HLA-C,MICA \| Endocytosis:HLA-C \| Human cytomegalovirus infection:HLA-C \| Kaposi sarcoma-associated herpesvirus infection:HLA-C,MICA \| Viral carcinogenesis:HLA-C \| Human immunodeficiency virus 1 infection:HLA-C \| Cellular senescence:HLA-C \| Human papillomavirus infection:HLA-C	Interferon gamma signaling:HLA-C \| Interferon Signaling:HLA-C \| Endosomal/Vacuolar pathway:HLA-C \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C \| ER-Phagosome pathway:HLA-C \| Antigen processing-Cross presentation:HLA-C \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,MICA \| Interferon alpha/beta signaling:HLA-C \| Class I MHC mediated antigen processing & presentation:HLA-C \| Neutrophil degranulation:HLA-C	Kawasaki disease:HLA-C \| lymphadenitis:HLA-C \| lymph node disease:HLA-C \| lymphatic system disease:HLA-C \| leprosy:MICA \| autoimmune disease of endocrine system:HLA-C \| multiple sclerosis:HLA-C \| endocrine system disease:HLA-C,MICA \| demyelinating disease:HLA-C \| Graves' disease:HLA-C \| thyroid gland disease:HLA-C \| hypersensitivity reaction type I disease:HCP5,HLA-C,MICA \| primary bacterial infectious disease:MICA \| hepatitis:HLA-C,MICA \| hyperthyroidism:HLA-C \| vitiligo:HLA-C \| spondylitis:HLA-C,MICA \| ankylosing spondylitis:HLA-C,MICA \| bacterial infectious disease:MICA \| urticaria:HCP5 \| spondyloarthropathy:HLA-C,MICA \| vasculitis:MICA \| Behcet's disease:MICA \| hepatitis C:HLA-C \| arthropathy:HLA-C,MICA \| hypotrichosis:MICA \| tropical spastic paraparesis:HLA-C \| hair disease:MICA \| purpura:MICA \| brucellosis:MICA \| hepatitis B:HLA-C,MICA \| upper respiratory tract disease:HLA-C \| multiple myeloma:MICA \| myeloma:MICA \| reproductive system disease:MICA \| bone marrow cancer:MICA \| bile duct disease:HLA-C \| biliary tract disease:HLA-C \| alopecia:MICA \| autoimmune disease of gastrointestinal tract:MICA \| blood coagulation disease:MICA \| allergic rhinitis:HLA-C \| hemorrhagic disease:MICA \| nasal cavity disease:HLA-C \| nose disease:HLA-C \| rhinitis:HLA-C \| celiac disease:MICA \| hematopoietic system disease:MICA \| gestational diabetes:MICA \| integumentary system disease:HCP5,MICA \| adrenal cortex disease:MICA \| Human immunodeficiency virus infectious disease:HLA-C \| adrenal gland disease:MICA \| interstitial lung disease:MICA \| sclerosing cholangitis:HLA-C \| lower respiratory tract disease:MICA \| Addison's disease:MICA \| adrenal cortical hypofunction:MICA \| alopecia areata:MICA \| infertility:MICA \| cell type benign neoplasm:MICA \| cholangitis:HLA-C \| osteosarcoma:MICA \| lung disease:MICA \| spinal cord disease:HLA-C \| bone cancer:MICA \| endocrine organ benign neoplasm:MICA \| gallbladder disease:MICA \| cholelithiasis:MICA \| skin disease:HCP5 \| connective tissue cancer:MICA \| adenoma:MICA \| pulmonary fibrosis:MICA	antigen processing and presentation of exogenous peptide antigen:HLA-C \| antigen processing and presentation of exogenous antigen:HLA-C \| antigen processing and presentation of peptide antigen:HLA-C \| antigen processing and presentation:HLA-C \| interferon-gamma-mediated signaling pathway:HLA-C \| cellular response to interferon-gamma:HLA-C \| response to interferon-gamma:HLA-C \| T cell activation:MICA \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C \| regulation of lymphocyte activation:MICA \| regulation of leukocyte activation:MICA \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C \| lymphocyte mediated immunity:MICA \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:MICA \| adaptive immune response:MICA \| natural killer cell mediated cytotoxicity:MICA \| natural killer cell mediated immunity:MICA \| T cell mediated cytotoxicity:MICA \| response to type I interferon:HLA-C \| type I interferon signaling pathway:HLA-C \| cellular response to type I interferon:HLA-C \| leukocyte mediated cytotoxicity:MICA \| T cell mediated immunity:MICA \| regulation of immune effector process:MICA \| regulation of lymphocyte mediated immunity:MICA \| regulation of innate immune response:MICA \| cell killing:MICA \| regulation of natural killer cell mediated cytotoxicity:MICA \| regulation of natural killer cell mediated immunity:MICA \| response to heat:MICA \| regulation of leukocyte mediated immunity:MICA \| negative regulation of natural killer cell mediated cytotoxicity:MICA \| negative regulation of natural killer cell mediated immunity:MICA \| regulation of leukocyte mediated cytotoxicity:MICA \| negative regulation of immune effector process:MICA \| gamma-delta T cell activation:MICA \| immune response to tumor cell:MICA \| negative regulation of leukocyte mediated cytotoxicity:MICA \| regulation of cell killing:MICA \| negative regulation of cell killing:MICA \| response to temperature stimulus:MICA \| response to tumor cell:MICA \| natural killer cell activation:MICA \| negative regulation of immune system process:MICA \| negative regulation of lymphocyte mediated immunity:MICA \| cytolysis:MICA \| negative regulation of innate immune response:MICA \| negative regulation of leukocyte mediated immunity:MICA \| negative regulation of immune response:MICA \| defense response to bacterium:MICA \| negative regulation of defense response:MICA \| negative regulation of leukocyte activation:MICA	0.15951100000000001	0.0720506	1.56950730627816							0.564225	0.0783859	12.0699173666076				0.575344	0.125102	5.29853390910084	0.0624278	0.0591953	0.535021885372935				0.0676137	0.0890139	0.348959555763051																																					0.166228	0.117831	0.800025537469509				0.112269	0.155723	0.32680854360491
rs145214406:31040655:C:CAA		6	31040655	6p21.33	CAA	C	0.992	0	OHP17 ALL	2070	11.9262523311848	0.0120420289855072		RNU6-1133P (10 kb); HCG22 (13 kb); MUC22 (37 kb); C6orf15 (38 kb); PSORS1C1 (42 kb); CDSN (42 kb)	NA	DDR1 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.12				hypotrichosis:CDSN \| hair disease:CDSN \| integumentary system disease:CDSN	regulation of cell-cell adhesion:CDSN \| extracellular matrix organization:C6orf15 \| extracellular structure organization:C6orf15	0.101945	0.0762957	0.740795679718688				-0.00304116	0.119882	0.00887985189937931	0.593265	0.0829549	11.9262523311848				0.565882	0.129698	4.83167638692441	0.0769567	0.0626298	0.65895542726213				0.062927	0.0921575	0.305443936150865	0.0275915	0.0437553	0.277109524700917				0.0592538	0.0733302	0.37771653692844	0.048064	0.0434451	0.570908543848325				0.147334	0.0691666	1.4793723813807	0.0499238	0.0415275	0.639612991615662				-0.0230702	0.0673967	0.135417135759166	0.0115228	0.0252071	0.188705231273384				0.0158953	0.0400241	0.160357316463307	0.165049	0.124806	0.730080970212662				0.122821	0.161341	0.349917941019979
rs77533229:43479638:G:A	novel4	2	43479638	2p21	A	G	0.834	1	DHEAS WOMEN	3358	11.7056396046769	0.0218878796902918	0.100822	THADA (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); ZFP36L2 (26 kb); RNU6-958P (160 kb); RNU6-242P (160 kb)	NA	THADA		Cellular senescence:ZFP36L2		cell type benign neoplasm:THADA \| thyroid cancer:THADA,ZFP36L2 \| endocrine organ benign neoplasm:THADA \| adenoma:THADA	regulation of leukocyte activation:ZFP36L2 \| regulation of lymphocyte activation:ZFP36L2 \| cellular response to tumor necrosis factor:ZFP36L2 \| T cell activation:ZFP36L2 \| response to tumor necrosis factor:ZFP36L2 \| cellular response to epidermal growth factor stimulus:ZFP36L2 \| response to epidermal growth factor:ZFP36L2 \| cellular response to fibroblast growth factor stimulus:ZFP36L2 \| response to fibroblast growth factor:ZFP36L2 \| mRNA catabolic process:ZFP36L2 \| RNA catabolic process:ZFP36L2 \| negative regulation of hydrolase activity:THADA \| negative regulation of ion transmembrane transport:THADA \| somatic stem cell population maintenance:ZFP36L2 \| negative regulation of mitotic cell cycle phase transition:ZFP36L2 \| negative regulation of transmembrane transport:THADA \| negative regulation of cell cycle phase transition:ZFP36L2	-0.0437251	0.0584349	0.342578881204411	-0.0467416	0.0516626	0.436804978661987	-0.0995086	0.123353	0.376915152213136	-0.0368352	0.064293	0.24660310720921	-0.0987407	0.0680628	0.832425709854082	0.0828756	0.135491	0.266841269200211	-0.00351205	0.0479714	0.026112795295564	-0.020864	0.053656	0.156486921391193	0.0262092	0.0950559	0.106326436964639	-0.149331	0.0371098	4.24254930820895	0.0646403	0.0455445	0.807379587150932	-0.425435	0.0604601	11.7056396046769				0.0130621	0.0377788	0.136957439494114				-0.00976764	0.0354164	0.106401336990256	0.0423844	0.0433436	0.483943473257049	-0.09594	0.0572581	1.02769346188742	-0.0287865	0.0211038	0.763074968810671							-0.0225615	0.0962893	0.0889655032175971	-0.0388966	0.118077	0.129658141221815	0.0213734	0.166621	0.0467386559399626
6:32009354:T:C		6	32009354	6p21.33	C	T	0.837	1	OHP17 ALL	2070	11.5913293467582	0.010216370531401		CYP21A2 (0 kb, 3'utr/3 prime UTR/MODIFIER \| nc-exon/Non coding transcript exon/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Downstream gene/MODIFIER); TNXB (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Downstream gene/MODIFIER); C4B-AS1 (5.3 kb); C4B (6.2 kb); STK19P (28 kb); TNXA (29 kb); CYP21A1P (33 kb); RNA5SP206 (37 kb); C4A-AS1 (38 kb); C4A (39 kb)	NA	- \| ABCF1 \| ABHD16A \| AIF1 \| ATF6B \| ATP6V1G2 \| ATP6V1G2-DDX39B \| BAG6 \| C2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf48 \| CLIC1 \| CSNK2B \| DDAH2 \| DDR1 \| DDX39B \| DXO \| FLOT1 \| GPANK1 \| GPSM3 \| GTF2H4 \| HCG22 \| HCG23 \| HCG27 \| HCP5 \| HLA-B \| HLA-C \| HLA-DOB \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB2 \| HLA-DRB3 \| HLA-DRB4 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB7 \| HLA-DRB8 \| HLA-E \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LY6G5B \| LY6G5C \| MICA \| MICB \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| PPP1R11 \| PRRC2A \| PSMB8 \| PSMB9 \| RDBP \| RNF5 \| RPP21 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP2 \| TCF19 \| TNF \| TRIM10 \| unnamed \| VARS \| VARS2 \| XXbac-BPG154L12.4 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.12 \| ZBTB12	BTN3A2 \| FLOT1 \| HLA-DQA1 \| HLA-DRB1 \| HLA-DRB4 \| HLA-DRB5 \| HLA-F \| HLA-H \| IER3 \| LINC00243 \| VARS2 \| ZNRD1	Staphylococcus aureus infection:C4A,C4B \| Systemic lupus erythematosus:C4A,C4B \| Steroid hormone biosynthesis:CYP21A2 \| Complement and coagulation cascades:C4A,C4B \| Pertussis:C4A,C4B \| Human papillomavirus infection:TNXB \| Cortisol synthesis and secretion:CYP21A2	Cytochrome P450 - arranged by substrate type:CYP21A2 \| Initial triggering of complement:C4A,C4B,C4B 2 \| Metabolism of steroid hormones:CYP21A2 \| Phase I - Functionalization of compounds:CYP21A2 \| Regulation of Complement cascade:C4A,C4B,C4B 2 \| Endogenous sterols:CYP21A2 \| Complement cascade:C4A,C4B,C4B 2 \| Metabolic disorders of biological oxidation enzymes:CYP21A2 \| Biological oxidations:CYP21A2	multiple sclerosis:C4A \| endocrine system disease:CYP21A2 \| demyelinating disease:C4A \| urinary system disease:C4A,C4B \| purpura:C4B \| proteinuria:C4A,C4B \| kidney disease:C4A,C4B \| blood coagulation disease:C4B \| collagen disease:TNXB \| hemorrhagic disease:C4B \| nephritis:C4A,C4B \| periodontitis:C4A,C4B \| hematopoietic system disease:C4B \| hyperandrogenism:CYP21A2 \| integumentary system disease:C4A,CYP21A2 \| polycystic ovary syndrome:CYP21A2 \| periodontal disease:C4A,C4B \| adrenal cortex disease:CYP21A2 \| adrenal gland disease:CYP21A2 \| acne:CYP21A2 \| sebaceous gland disease:CYP21A2 \| reproductive system disease:CYP21A2 \| sex differentiation disease:CYP21A2 \| tooth disease:C4A,C4B \| lower respiratory tract disease:C4A \| Addison's disease:CYP21A2 \| gonadal disease:CYP21A2 \| mouth disease:C4A,C4B \| adrenal cortical hypofunction:CYP21A2 \| cell type benign neoplasm:TNXB \| lung disease:C4A \| infertility:CYP21A2 \| neurofibroma:TNXB \| Henoch-Schoenlein purpura:C4B \| hypersensitivity reaction type III disease:C4B \| hypersensitivity vasculitis:C4B \| renal cell carcinoma:C4A,C4B \| skin disease:C4A,CYP21A2 \| adenoma:TNXB \| coronary artery disease:C4B	lymphocyte mediated immunity:C4A,C4B \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:C4A,C4B \| adaptive immune response:C4A,C4B \| humoral immune response mediated by circulating immunoglobulin:C4A,C4B \| glucocorticoid metabolic process:CYP21A2 \| regulation of humoral immune response:C4A,C4B \| regulation of apoptotic cell clearance:C4A,C4B \| glucocorticoid biosynthetic process:CYP21A2 \| regulation of immune effector process:C4A,C4B \| immunoglobulin mediated immune response:C4A,C4B \| B cell mediated immunity:C4A,C4B \| regulation of complement activation:C4A,C4B \| regulation of protein activation cascade:C4A,C4B \| cellular hormone metabolic process:CYP21A2 \| mineralocorticoid biosynthetic process:CYP21A2 \| mineralocorticoid metabolic process:CYP21A2 \| hormone biosynthetic process:CYP21A2 \| positive regulation of phagocytosis:C4A,C4B \| complement activation:C4A,C4B \| humoral immune response:C4A,C4B \| regulation of acute inflammatory response:C4A,C4B \| complement activation, classical pathway:C4A,C4B \| apoptotic cell clearance:C4A,C4B \| steroid metabolic process:CYP21A2 \| extracellular matrix assembly:TNXB \| regulation of phagocytosis:C4A,C4B \| regulation of endocytosis:C4A,C4B \| protein activation cascade:C4A,C4B \| hormone metabolic process:CYP21A2 \| positive regulation of endocytosis:C4A,C4B \| collagen fibril organization:TNXA,TNXB \| post-translational protein modification:C4A \| regulation of protein processing:C4A,C4B \| regulation of protein maturation:C4A,C4B \| steroid biosynthetic process:CYP21A2 \| phagocytosis:C4A,C4B \| regulation of inflammatory response:C4A,C4B \| acute inflammatory response:C4A,C4B \| extracellular matrix organization:TNXA,TNXB \| extracellular structure organization:TNXA,TNXB \| negative regulation of hydrolase activity:C4A,C4B \| negative regulation of proteolysis:C4A,C4B	0.0959522	0.090228	0.54105108096779				0.00866304	0.154547	0.0198611314868144	0.691029	0.0981236	11.5913293467582				0.808789	0.165115	5.92133297339584	0.104204	0.0740464	0.797250204141037				0.144172	0.117636	0.656063876733499	0.0161869	0.0509319	0.124576975253019				0.118893	0.0832017	0.815274508205802	0.0383074	0.0507305	0.346613803166191				0.187129	0.0823089	1.63834392291184	0.0345017	0.0485196	0.321454307700426				-0.0744194	0.0779427	0.468928744639915	-0.0164607	0.0293819	0.240091283094439				-0.0284315	0.0459856	0.270513659767286	0.406604	0.147439	2.23115626794226				0.453868	0.206239	1.55141424832256
rs296360:48388658:T:C	known [10]	19	48388658	19q13.33	C	T	0.988	101	DHEAS ALL	7659	11.4516523547738	0.173465008486747	0.0784955	SULT2A1 (0 kb, intron/Intron/MODIFIER); TPRX2P (24 kb); CRX (42 kb); TPRX1 (66 kb)	0.984 Blood metabolite levels // 0.984 Blood metabolite ratios // 0.984 Gallstone disease // 0.719 Dehydroepiandrosterone sulphate levels // 0.719 Sex hormone levels	CABP5 \| CTD-3098H1.2 \| EMP3 \| GLTSCR1 \| GLTSCR2 \| LIG1 \| PRR24 \| SEPW1 \| SULT2A1 \| TMEM160	VRK3	Herpes simplex infection:NOP53 \| Chemical carcinogenesis:SULT2A1 \| Metabolism of xenobiotics by cytochrome P450:SULT2A1 \| Bile secretion:SULT2A1	Biological oxidations:SULT2A1 \| Phase II - Conjugation of compounds:SULT2A1	multiple myeloma:SELENOW \| myeloma:SELENOW \| bone marrow cancer:SELENOW \| polycystic ovary syndrome:SULT2A1 \| integumentary system disease:NOP53	immune response-activating signal transduction:NOP53 \| steroid catabolic process:SULT2A1 \| regulation of immune effector process:NOP53 \| steroid metabolic process:SULT2A1 \| sulfur compound metabolic process:SULT2A1 \| sperm capacitation:BSPH1 \| nucleocytoplasmic transport:NOP53 \| nuclear transport:NOP53 \| protein stabilization:NOP53 \| positive regulation of cytokine production:NOP53 \| protein localization to nucleoplasm:NOP53 \| regulation of protein stability:NOP53 \| protein export from nucleus:NOP53 \| protein localization to nucleus:NOP53 \| negative regulation of proteolysis involved in cellular protein catabolic process:NOP53 \| regulation of defense response to virus:NOP53 \| nuclear export:NOP53 \| positive regulation of defense response:NOP53 \| negative regulation of cellular protein catabolic process:NOP53 \| negative regulation of cellular catabolic process:NOP53 \| regulation of protein modification by small protein conjugation or removal:NOP53 \| regulation of protein kinase B signaling:NOP53 \| negative regulation of mitotic cell cycle phase transition:NOP53 \| negative regulation of catabolic process:NOP53 \| negative regulation of proteolysis:NOP53 \| positive regulation of innate immune response:NOP53 \| regulation of protein complex assembly:NOP53 \| negative regulation of cell cycle phase transition:NOP53 \| ncRNA transcription:NOP53	-0.0204121	0.0224773	0.438992882800751	-0.0177179	0.020436	0.413302448029443	-0.0332925	0.0447364	0.340311935716469	-0.0780676	0.0246745	2.80151886543607	-0.0332243	0.0269285	0.662554716227941	-0.161036	0.0490999	2.9626412413437	-5.31247E-4	0.0184537	0.0100894339134606	0.0374142	0.0212008	1.10885296955123	-0.0699805	0.0346005	1.36153869853243	-0.0922151	0.0132595	11.4516523547738	-0.0489511	0.0166344	2.48771193156156	-0.142747	0.0211364	10.8409684861503	-0.00474807	0.0131364	0.144015907570358	0.0175793	0.0138913	0.686772042252513	-0.0320818	0.02214	0.831723550232813	0.0440163	0.0127762	3.24359517140411	0.0359022	0.0156914	1.65489104429046	0.0443888	0.0204591	1.52237814760041	-0.00709862	0.00763634	0.452733704323552	0.00795425	0.00991402	0.374311049296907	-0.0237809	0.0118826	1.3433451458435	-0.00775464	0.037235	0.0782895999704003	0.026746	0.0467824	0.245944605998863	-0.0656949	0.0615359	0.543504912512834
rs151302046:30775131:G:A		6	30775131	6p21.33	A	G	0.989	0	OHP17 ALL	2070	11.2452527248307	0.0113304347826087		LINC00243 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); HCG20 (15 kb); RN7SL353P (56 kb); RN7SKP186 (57 kb)	1 Plantar warts // 1 Response to angiotensin II receptor blocker therapy // 0.717 Blood protein levels	- \| ABCF1 \| ABHD16A \| AIF1 \| APOM \| ATF6B \| ATP6V1G2 \| BAG6 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf48 \| CCHCR1 \| CLIC1 \| CSNK2B \| DDAH2 \| DDR1 \| DDX39B \| DHX16 \| DXO \| FLOT1 \| GPANK1 \| GPSM3 \| GTF2H4 \| HCG22 \| HCG27 \| HCG4B \| HCG4P3 \| HCP5 \| HLA-A \| HLA-B \| HLA-C \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB6 \| HLA-E \| HLA-H \| HLA-T \| HLA-W \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LTB \| LY6G5B \| LY6G5C \| LY6G6E \| MCCD1 \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| NRM \| PBX2 \| POU5F1 \| PPP1R10 \| PPP1R11 \| PRRC2A \| RDBP \| RNF5 \| RPP21 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TNF \| TRIM10 \| TRIM39 \| TUBB \| unnamed \| VARS2 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.12 \| XXbac-BPG299F13.17 \| Y RNA \| ZNRD1	C4A \| C4B \| C4B 2 \| C6orf10 \| DXO \| HLA-DQA1 \| HLA-DRB1 \| HLA-F \| HLA-G \| HLA-H \| HLA-V \| NHP2 \| PARP2 \| STK19 \| TAP2 \| TMEM154	Type I diabetes mellitus:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Allograft rejection:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Graft-versus-host disease:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Antigen processing and presentation:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TNF \| Autoimmune thyroid disease:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Viral myocarditis:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Staphylococcus aureus infection:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Asthma:HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Phagosome:ATP6V1G2,HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TUBB \| Herpes simplex infection:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Intestinal immune network for IgA production:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Rheumatoid arthritis:ATP6V1G2,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Inflammatory bowel disease (IBD):HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Toxoplasmosis:HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TNF \| Systemic lupus erythematosus:HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Cell adhesion molecules (CAMs):HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Leishmaniasis:HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Influenza A:HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TNF \| Hematopoietic cell lineage:HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Epstein-Barr virus infection:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Th1 and Th2 cell differentiation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Th17 cell differentiation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Tuberculosis:HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Natural killer cell mediated cytotoxicity:HLA-A,HLA-C,NCR3,TNF \| Endocytosis:HLA-A,HLA-C,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L,TNF \| Human cytomegalovirus infection:ATF6B,HLA-A,HLA-C,TNF \| Kaposi sarcoma-associated herpesvirus infection:HLA-A,HLA-C \| Viral carcinogenesis:ATF6B,HLA-A,HLA-C \| Spliceosome:HSPA1A,HSPA1B,HSPA1L \| Human immunodeficiency virus 1 infection:HLA-A,HLA-C,TNF \| NF-kappa B signaling pathway:TNF \| Protein processing in endoplasmic reticulum:ATF6B,HSPA1A,HSPA1B,HSPA1L \| Cellular senescence:HLA-A,HLA-C \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:ATF6B,HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:ATP6V1G2,HLA-A,HLA-C,TNF \| Pertussis:TNF \| TNF signaling pathway:ATF6B,TNF \| Aminoacyl-tRNA biosynthesis:VARS2 \| Type II diabetes mellitus:TNF \| Lysosome:NEU1 \| Cortisol synthesis and secretion:ATF6B	Translocation of ZAP-70 to Immunological synapse:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon gamma signaling:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| PD-1 signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Generation of second messenger molecules:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Downstream TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon Signaling:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| MHC class II antigen presentation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Costimulation by the CD28 family:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Endosomal/Vacuolar pathway:HLA-A,HLA-C \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-A,HLA-C \| ER-Phagosome pathway:HLA-A,HLA-C \| Antigen processing-Cross presentation:HLA-A,HLA-C \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-A,HLA-C,NCR3 \| Interferon alpha/beta signaling:HLA-A,HLA-C \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:HSPA1A,HSPA1B \| TNFR2 non-canonical NF-kB pathway:TNF \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B \| Class I MHC mediated antigen processing & presentation:HLA-A,HLA-C,TRIM39 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Influenza Infection:HSPA1A,HSPA1B \| ABC-family proteins mediated transport:ABCF1 \| G2/M Transition:TUBB \| Mitotic G2-G2/M phases:TUBB \| RNA Polymerase I Promoter Escape:ZNRD1 \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| RNA Polymerase I Transcription Termination:ZNRD1 \| RNA Polymerase I Transcription Initiation:ZNRD1 \| Diseases associated with glycosylation precursor biosynthesis:NEU1 \| Neutrophil degranulation:HLA-C,HSPA1A,HSPA1B,NEU1,TUBB \| Influenza Life Cycle:HSPA1A,HSPA1B \| Transcriptional regulation of white adipocyte differentiation:TNF \| tRNA Aminoacylation:VARS2 \| RNA Polymerase I Promoter Clearance:ZNRD1 \| RNA Polymerase I Transcription:ZNRD1	Kawasaki disease:BAG6,HLA-A,HLA-C,HLA-DRB1,PRRC2A,TNF \| lymphadenitis:BAG6,HLA-A,HLA-C,HLA-DRB1,PRRC2A,TNF \| lymph node disease:BAG6,HLA-A,HLA-C,HLA-DRB1,PRRC2A,TNF \| lymphatic system disease:BAG6,HLA-A,HLA-C,HLA-DRB1,PRRC2A,TNF \| leprosy:HLA-A,HLA-DRB1,TNF \| sarcoidosis:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L,TNF \| hypersensitivity reaction type IV disease:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L,TNF \| autoimmune disease of endocrine system:HLA-A,HLA-C,HLA-DQA1,HLA-DRB1,TNF \| multiple sclerosis:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| endocrine system disease:ABCF1,HLA-A,HLA-C,HLA-DQA1,HLA-DRB1,HSPA1B,TNF \| autoimmune thyroiditis:HLA-A,HLA-DRB1 \| demyelinating disease:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Graves' disease:HLA-A,HLA-C,HLA-DQA1,HLA-DRB1,TNF \| thyroid gland disease:HLA-A,HLA-C,HLA-DQA1,HLA-DRB1,TNF \| intrahepatic cholestasis:HLA-DQA1,HLA-DRB1 \| cavernous hemangioma:HLA-A,HLA-DRA \| vascular hemostatic disease:HLA-A,HLA-DRA \| hypersensitivity reaction type I disease:HLA-A,HLA-C,HLA-DQA1,HLA-DRB1,TNF \| primary bacterial infectious disease:FLOT1,HLA-A,HLA-DRB1,TNF \| hepatitis:HLA-A,HLA-C,HLA-DQA1,HLA-DRB1,NCR3,TNF \| hyperthyroidism:HLA-A,HLA-C,HLA-DQA1,HLA-DRB1,TNF \| vitiligo:DDR1,HLA-A,HLA-C,TNF \| spondylitis:HLA-A,HLA-C,TNF \| ankylosing spondylitis:HLA-A,HLA-C,TNF \| rheumatic fever:HLA-DQA1,HLA-DRB1,TNF \| bacterial infectious disease:FLOT1,HLA-A,HLA-DRB1,TNF \| aplastic anemia:HLA-A,HLA-DQA1,HLA-DRB1,TNF \| urticaria:HLA-A,HLA-DRB1,TNF \| spondyloarthropathy:HLA-A,HLA-C,TNF \| vasculitis:DDR1,HLA-A,HLA-DRB1,TNF,TRIM39 \| hypothyroidism:HLA-DRB1,TNF \| Behcet's disease:HLA-A,HLA-DRB1,TNF,TRIM39 \| hepatitis C:HLA-C,HLA-DQA1,HLA-DRB1,NCR3,TNF \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| arthropathy:HLA-A,HLA-C,TNF \| hypotrichosis:HLA-A,HLA-DQA1 \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,NCR3,PRRC2A,TNF \| malaria:HLA-DRB1,NCR3,PRRC2A,TNF \| hair disease:HLA-A,HLA-DQA1 \| pulmonary sarcoidosis:DDR1,HLA-DRB1,TNF \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-A,HLA-DRB1 \| cystic echinococcosis:HLA-DRB1 \| myasthenia gravis:HLA-DQA1,HLA-DRA,TNF \| neuromuscular junction disease:HLA-DQA1,HLA-DRA,TNF \| brucellosis:TNF \| duodenal ulcer:HSPA1A,TNF \| cholestasis:HLA-DQA1,HLA-DRB1 \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-A,HLA-C,HLA-DQA1,HLA-DRB1,TNF \| upper respiratory tract disease:HLA-A,HLA-C,HSPA1A,TNF \| uveitis:HLA-DQA1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,NCR3,PRRC2A,TNF \| urinary system disease:AIF1,DDR1,HLA-DQA1,HLA-DRB1,HSPA1A,TNF \| multiple myeloma:BAG6,HLA-A,IER3,NCR3,TNF \| myeloma:BAG6,HLA-A,IER3,NCR3,TNF \| reproductive system disease:HLA-DRB1,HSPA1A,MSH5,TNF \| bone marrow cancer:BAG6,HLA-A,IER3,NCR3,TNF \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L,TNF \| bile duct disease:HLA-C,HLA-DQA1,HLA-DRB1 \| complex regional pain syndrome:TNF \| biliary tract disease:HLA-C,HLA-DQA1,HLA-DRB1 \| azoospermia:HLA-DRB1,MSH5 \| proteinuria:DDR1,HLA-DRB1 \| kidney disease:AIF1,DDR1,HLA-DQA1,HLA-DRB1,HSPA1A,TNF \| alopecia:HLA-A,HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DRB1,TNF \| type 1 diabetes mellitus:HLA-DQA1,TNF \| blood coagulation disease:HLA-A,HLA-DRA,HLA-DRB1 \| allergic rhinitis:HLA-A,HLA-C,TNF \| hemorrhagic disease:HLA-A,HLA-DRA,HLA-DRB1 \| neuromuscular disease:HLA-DQA1,HLA-DRA,TNF \| thyroiditis:HLA-A,HLA-DRB1 \| nasal cavity disease:HLA-A,HLA-C,TNF \| nose disease:HLA-A,HLA-C,TNF \| rhinitis:HLA-A,HLA-C,TNF \| collagen disease:AIF1,HLA-DRB1,TNF \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:ABCF1,HLA-DRB1,HSPA1B,TNF \| nephritis:AIF1,HLA-DQA1,HLA-DRB1,TNF \| periodontitis:HLA-A,TNF \| celiac disease:HLA-DQA1,HLA-DRB1,TNF \| peptic ulcer disease:HSPA1A,TNF \| hematopoietic system disease:HLA-A,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| gestational diabetes:TNF \| esophageal varix:TNF \| echinococcosis:HLA-DRB1 \| anemia:HLA-A,HLA-DQA1,HLA-DRB1,TNF \| rheumatic disease:AIF1,HLA-DRB1,TNF \| systemic scleroderma:AIF1,HLA-DRB1,TNF \| scleroderma:AIF1,HLA-DRB1,TNF \| male reproductive system disease:HLA-DRB1,HSPA1A,MSH5,TNF \| male infertility:HLA-DRB1,MSH5,TNF \| silicosis:HLA-DRB1,TNF \| integumentary system disease:HLA-A,HLA-DQA1,HLA-DRB1,TNF \| polycystic ovary syndrome:TNF \| sickle cell anemia:HLA-DRB1,TNF \| periodontal disease:HLA-A,TNF \| parasitic helminthiasis infectious disease:HLA-DRB1,TNF \| alpha 1-antitrypsin deficiency:TNF \| Human immunodeficiency virus infectious disease:HLA-A,HLA-C,HLA-DRB1,TNF \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B,TNF \| interstitial lung disease:DDR1,HLA-DRB1,TNF \| bronchial disease:HSPA1A,HSPA1B,TNF \| acute pancreatitis:HSPA1B \| acne:TNF \| sebaceous gland disease:TNF \| tuberculosis:HLA-A,HLA-DRB1,TNF \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| autonomic nervous system disease:TNF \| dengue hemorrhagic fever:TNF \| prostate disease:HLA-DRB1,HSPA1A \| pneumoconiosis:HLA-DRB1,TNF \| aortic valve disease:TNF \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1,TNF \| tooth disease:HLA-A,TNF \| dengue disease:TNF \| autoimmune disease of peripheral nervous system:HLA-DRB1,TNF \| Guillain-Barre syndrome:HLA-DRB1,TNF \| pancreas disease:ABCF1,HLA-DRB1,HSPA1B,TNF \| open-angle glaucoma:HLA-DRB1,TNF \| varicose veins:TNF \| influenza:HLA-A,HLA-DRB1,TNF \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-A,HLA-DQA1,HLA-DRB1,TNF \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B,TNF \| ovarian disease:MSH5 \| neutropenia:TNF \| agranulocytosis:TNF \| gastritis:HLA-DRB1,TNF \| dermatomyositis:HLA-DRB1,TNF \| essential hypertension:HSPA1A,HSPA1B,HSPA1L \| female reproductive system disease:MSH5,TNF \| osteomyelitis:HLA-DRB1 \| neuropathy:HLA-DQA1,HLA-DRA,TNF \| plasma protein metabolism disease:TNF \| Duchenne muscular dystrophy:HLA-A \| mouth disease:HLA-A,TNF \| osteoporosis:TNF \| Sjogren's syndrome:TNF \| bone resorption disease:TNF \| migraine:HLA-DRB1,TNF \| infertility:MSH5,TNF \| peripheral nervous system disease:HLA-DRB1,TNF \| age related macular degeneration:TNF \| degeneration of macula and posterior pole:TNF \| hemochromatosis:HLA-A \| autoimmune disease of urogenital tract:HLA-DRB1,TNF \| primary biliary cirrhosis:HLA-DRB1,TNF \| cell type benign neoplasm:DDR1,TNF \| macular degeneration:TNF \| stomach disease:HLA-DRB1,TNF \| cholangitis:HLA-C,HLA-DRB1 \| pulmonary hypertension:HLA-A,TNF \| Crohn's disease:HSPA1B \| osteosarcoma:BAG6,HLA-A,TNF \| lung disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B,TNF \| spinal cord disease:HLA-C,HLA-DRB1 \| heart valve disease:TNF \| gallbladder carcinoma:TNF \| pulmonary edema:HSPA1A \| aortic valve stenosis:TNF \| gallbladder cancer:TNF \| myositis:HLA-DRB1,TNF \| lipodystrophy:TNF \| leukopenia:TNF \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B \| myopathy:HLA-A,HLA-DRB1,TNF \| muscle tissue disease:HLA-A,HLA-DRB1,TNF \| bone cancer:BAG6,HLA-A,TNF \| nasopharynx carcinoma:DDR1,HSPA1B \| axonal neuropathy:TNF \| pharynx cancer:DDR1,HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TNF \| cardiomyopathy:TNF \| muscular disease:HLA-A,HLA-DRB1,TNF \| endocrine organ benign neoplasm:DDR1 \| metal metabolism disorder:HLA-A \| premature ovarian failure:MSH5 \| liver cirrhosis:DDR1,HLA-DRB1,TNF \| renal cell carcinoma:HLA-A,HLA-DRB1 \| muscular dystrophy:HLA-A,TNF \| glaucoma:HLA-DRB1,TNF \| esophageal carcinoma:HLA-A,HLA-DRB1 \| skin disease:HLA-A,HLA-DRB1,TNF \| retinal disease:HLA-DRB1,TNF \| female reproductive organ cancer:DDR1,HLA-DQA1,HLA-DRB1,TNF \| vein disease:TNF \| connective tissue cancer:BAG6,HLA-A,TNF \| adenoma:DDR1 \| primary open angle glaucoma:TNF \| severe combined immunodeficiency:HLA-DRB1,TNF \| coronary artery disease:TNF \| retinal degeneration:HLA-DRB1,TNF \| integumentary system cancer:CCHCR1 \| skin cancer:CCHCR1 \| malignant ovarian surface epithelial-stromal neoplasm:DDR1,HLA-DQA1,HLA-DRB1,TNF \| ovary epithelial cancer:DDR1,HLA-DQA1,HLA-DRB1,TNF \| ovarian carcinoma:DDR1,HLA-DQA1,HLA-DRB1,TNF \| combined T cell and B cell immunodeficiency:HLA-DRB1,TNF	antigen processing and presentation of exogenous peptide antigen:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous antigen:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide antigen:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| interferon-gamma-mediated signaling pathway:HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| cellular response to interferon-gamma:AIF1,HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DQA1,HLA-DRA,HLA-DRB1 \| response to interferon-gamma:AIF1,HLA-A,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell receptor signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating signal transduction:BAG6,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,NCR3 \| T cell costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| lymphocyte costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen receptor-mediated signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-regulating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| positive regulation of cell-cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| positive regulation of leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| positive regulation of T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of cell-cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-A,HLA-C \| regulation of leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-A,HLA-C \| positive regulation of cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| positive regulation of lymphocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of lymphocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,LST1 \| regulation of T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of leukocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,LST1 \| leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| antigen processing and presentation of peptide antigen via MHC class I:HLA-A,HLA-C \| positive regulation of leukocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| lymphocyte mediated immunity:NCR3,TNF,TUBB \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3,TNF \| adaptive immune response:NCR3,TNF \| humoral immune response mediated by circulating immunoglobulin:TNF \| natural killer cell mediated cytotoxicity:NCR3,TUBB \| natural killer cell mediated immunity:NCR3,TUBB \| T cell mediated cytotoxicity:NCR3 \| response to type I interferon:HLA-A,HLA-C \| type I interferon signaling pathway:HLA-A,HLA-C \| cellular response to type I interferon:HLA-A,HLA-C \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,TNF \| leukocyte mediated cytotoxicity:NCR3,TUBB \| regulation of humoral immune response:TNF \| positive regulation of defense response:FLOT1,HSPA1A,HSPA1B,NCR3,TNF \| positive regulation of cytokine production:FLOT1,HSPA1A,HSPA1B,TNF \| T cell mediated immunity:NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:NCR3,TNF \| positive regulation of innate immune response:FLOT1,HSPA1A,HSPA1B,NCR3 \| positive regulation of T cell proliferation:AIF1 \| regulation of lymphocyte mediated immunity:NCR3,TNF \| NIK/NF-kappaB signaling:TNF \| regulation of innate immune response:FLOT1,HSPA1A,HSPA1B,NCR3 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B,TNF \| regulation of T cell proliferation:AIF1 \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B,TRIM39 \| cell killing:NCR3,TUBB \| positive regulation of lymphocyte mediated immunity:NCR3,TNF \| regulation of lymphocyte proliferation:AIF1,LST1 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3,TNF \| regulation of mononuclear cell proliferation:AIF1,LST1 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B,TNF \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B,TNF \| regulation of natural killer cell mediated cytotoxicity:NCR3 \| chronic inflammatory response:TNF \| positive regulation of adaptive immune response:NCR3,TNF \| regulation of natural killer cell mediated immunity:NCR3 \| interferon-gamma production:TNF \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B,TRIM39 \| immunoglobulin mediated immune response:TNF \| regulation of leukocyte proliferation:AIF1,LST1 \| B cell mediated immunity:TNF \| mRNA catabolic process:HSPA1A,HSPA1B \| response to tumor necrosis factor:HSPA1A,HSPA1B,TNF \| regulation of chronic inflammatory response:TNF \| response to heat:HSPA1A,HSPA1B,HSPA1L \| regulation of humoral immune response mediated by circulating immunoglobulin:TNF \| positive regulation of nitric oxide biosynthetic process:AIF1,DDAH2,TNF \| positive regulation of nitric oxide metabolic process:AIF1,DDAH2,TNF \| regulation of leukocyte mediated immunity:NCR3,TNF \| activation of innate immune response:FLOT1,HSPA1A,HSPA1B \| regulation of T cell mediated cytotoxicity:NCR3 \| positive regulation of leukocyte mediated immunity:NCR3,TNF \| T cell proliferation:AIF1 \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of inflammatory response to antigenic stimulus:TNF \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B,TNF \| microtubule nucleation:HSPA1A,HSPA1B \| positive regulation of phagocytosis:TNF \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B,TNF \| positive regulation of lymphocyte proliferation:AIF1 \| positive regulation of mononuclear cell proliferation:AIF1 \| positive regulation of heterotypic cell-cell adhesion:FLOT1,TNF \| regulation of leukocyte mediated cytotoxicity:NCR3 \| regulation of DNA-templated transcription in response to stress:ATF6B,HSPA1A \| negative regulation of immune effector process:TNF \| ER-associated misfolded protein catabolic process:BAG6 \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B,TRIM39 \| RNA catabolic process:HSPA1A,HSPA1B \| positive regulation of leukocyte proliferation:AIF1 \| positive regulation of reactive oxygen species biosynthetic process:AIF1,DDAH2,TNF \| immune response to tumor cell:NCR3 \| negative regulation of growth of symbiont in host:TNF \| response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,HSPA1L \| positive regulation of T cell mediated cytotoxicity:NCR3 \| positive regulation of humoral immune response:TNF \| regulation of growth of symbiont in host:TNF \| negative regulation of growth of symbiont involved in interaction with host:TNF \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,TNF \| DNA-templated transcription, elongation:ZNRD1 \| humoral immune response:TNF \| regulation of acute inflammatory response:TNF \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| modulation of growth of symbiont involved in interaction with host:TNF \| innate immune response-activating signal transduction:FLOT1,HSPA1A,HSPA1B \| regulation of nitric oxide biosynthetic process:AIF1,DDAH2,TNF \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3,TNF \| lymphocyte proliferation:AIF1,LST1 \| negative regulation of phosphoprotein phosphatase activity:TNF \| mononuclear cell proliferation:AIF1,LST1 \| regulation of immunoglobulin secretion:TNF \| regulation of translational fidelity:VARS2 \| positive regulation of translational initiation:TNF \| regulation of cell killing:NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B,TRIM39 \| growth of symbiont in host:TNF \| regulation of interleukin-8 production:HSPA1A,HSPA1B,TNF \| RNA phosphodiester bond hydrolysis:HSPA1A,NHP2,RPP21,ZNRD1 \| steroid metabolic process:TNF \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| growth involved in symbiotic interaction:TNF \| growth of symbiont involved in interaction with host:TNF \| regulation of adaptive immune response:NCR3,TNF \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| leukocyte proliferation:AIF1,LST1 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B,TNF \| regulation of protein stability:BAG6,FLOT1,HSPA1A,HSPA1B \| positive regulation of interferon-gamma production:TNF \| positive regulation of translation:TNF \| nitric oxide biosynthetic process:AIF1,DDAH2,TNF \| interleukin-8 production:HSPA1A,HSPA1B,TNF \| regulation of heterotypic cell-cell adhesion:FLOT1,TNF \| immunoglobulin secretion:TNF \| positive regulation of protein complex assembly:HSPA1A,HSPA1B,TNF \| interaction with host:HSPA1A,HSPA1B \| signal transduction in absence of ligand:HSPA1A,HSPA1B,TNF \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B,TNF \| nucleocytoplasmic transport:CCHCR1,TNF \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of natural killer cell mediated immunity:NCR3 \| podosome assembly:TNF \| regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:TRIM39 \| nitric oxide metabolic process:AIF1,DDAH2,TNF \| nuclear transport:CCHCR1,TNF \| cellular response to misfolded protein:BAG6 \| regulation of inflammatory response to antigenic stimulus:TNF \| positive regulation of vascular smooth muscle cell proliferation:TNF \| regulation of phagocytosis:TNF \| natural killer cell activation:BAG6,NCR3 \| reactive nitrogen species metabolic process:AIF1,DDAH2,TNF \| positive regulation of mononuclear cell migration:AIF1,TNF \| cellular response to topologically incorrect protein:ATF6B,BAG6,HSPA1A \| protein stabilization:BAG6,FLOT1,HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| positive regulation of smooth muscle cell proliferation:AIF1,TNF \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| response to misfolded protein:BAG6 \| mRNA cleavage:HSPA1A,ZNRD1 \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:AIF1,DDAH2,TNF \| regulation of organelle assembly:HSPA1A,HSPA1B,TNF \| regulation of transcription from RNA polymerase II promoter in response to stress:ATF6B,HSPA1A \| regulation of reactive oxygen species biosynthetic process:AIF1,DDAH2,TNF \| protein ubiquitination involved in ubiquitin-dependent protein catabolic process:TRIM39 \| regulation of endocytosis:FLOT1,TNF \| protein quality control for misfolded or incompletely synthesized proteins:BAG6 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| positive regulation of endocytosis:FLOT1,TNF \| negative regulation of multi-organism process:TNF \| negative regulation of protein dephosphorylation:TNF \| defense response to Gram-positive bacterium:TNF \| response to endoplasmic reticulum stress:ATF6B,BAG6,FLOT1,HSPA1A \| positive regulation of immune effector process:NCR3,TNF \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| transcription elongation from RNA polymerase I promoter:ZNRD1 \| termination of RNA polymerase I transcription:ZNRD1 \| pattern recognition receptor signaling pathway:FLOT1,HSPA1A,HSPA1B \| response to isoquinoline alkaloid:AIF1 \| response to morphine:AIF1 \| positive regulation of T cell mediated immunity:NCR3 \| positive regulation of NIK/NF-kappaB signaling:TNF \| spindle assembly:HSPA1A,HSPA1B,TUBB \| ganglioside metabolic process:NEU1 \| positive regulation of cellular amide metabolic process:TNF \| nucleic acid phosphodiester bond hydrolysis:HSPA1A,NHP2,RPP21,ZNRD1 \| transcription initiation from RNA polymerase I promoter:ZNRD1 \| positive regulation of B cell mediated immunity:TNF \| positive regulation of immunoglobulin mediated immune response:TNF \| positive regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| positive regulation of leukocyte mediated cytotoxicity:NCR3 \| reactive oxygen species biosynthetic process:AIF1,DDAH2,TNF \| negative regulation of immune system process:LST1,TNF \| positive regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| positive regulation of NF-kappaB import into nucleus:TNF \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B,TNF \| macroautophagy:ATP6V1G2 \| regulation of T cell mediated immunity:NCR3 \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| receptor-mediated endocytosis:FLOT1 \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| DNA-templated transcription, termination:ZNRD1 \| regulation of vascular smooth muscle cell proliferation:TNF \| vascular smooth muscle cell proliferation:TNF \| regulation of macroautophagy:ATP6V1G2 \| membrane assembly:FLOT1 \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:FLOT1,LY6G5C \| regulation of interferon-gamma production:TNF \| protein export from nucleus:CCHCR1 \| viral life cycle:HSPA1A,HSPA1B,TNF \| regulation of osteoblast differentiation:TNF \| negative regulation of osteoblast differentiation:TNF \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress:ATF6B \| vitamin D biosynthetic process:TNF \| protein localization to nucleus:TNF \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| steroid biosynthetic process:TNF \| regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A,TRIM39 \| regulation of mononuclear cell migration:AIF1,TNF \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| inflammatory response to antigenic stimulus:TNF \| positive regulation of catabolic process:BAG6,HSPA1A,TNF \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:BAG6,HSPA1A \| microglial cell activation:AIF1 \| negative regulation of proteolysis involved in cellular protein catabolic process:BAG6,TRIM39 \| response to salt stress:TNF \| positive regulation of cell killing:NCR3 \| endothelial cell development:TNF \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B,TNF \| phagocytosis:AIF1,TNF \| mRNA cleavage involved in mRNA processing:HSPA1A \| regulation of heat generation:TNF \| regulation of autophagy:ATP6V1G2 \| response to ammonium ion:AIF1 \| microtubule polymerization:HSPA1A,HSPA1B \| regulation of inflammatory response:TNF \| synapsis:BAG6,MSH5 \| macrophage activation:AIF1 \| protein folding:HSPA1A,HSPA1B,HSPA1L \| positive regulation of protein catabolic process:BAG6,HSPA1A,TNF \| positive regulation of cellular catabolic process:BAG6,HSPA1A,TNF \| acute inflammatory response:TNF \| regulation of B cell mediated immunity:TNF \| regulation of immunoglobulin mediated immune response:TNF \| tRNA aminoacylation for protein translation:VARS2 \| regulation of transcription factor import into nucleus:TNF \| negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:TRIM39 \| extracellular matrix organization:DDR1,FLOT1,TNF \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| regulation of smooth muscle cell proliferation:AIF1,TNF \| membrane biogenesis:FLOT1 \| extracellular structure organization:DDR1,FLOT1,TNF \| heterotypic cell-cell adhesion:FLOT1,TNF \| branching involved in mammary gland duct morphogenesis:DDR1 \| negative regulation of growth:HSPA1A,HSPA1B,TNF \| negative regulation of immune response:TNF \| transcription factor import into nucleus:TNF \| regulation of lipid catabolic process:TNF \| tRNA aminoacylation:VARS2 \| regulation of binding:FLOT1 \| regulation of mRNA metabolic process:HSPA1A \| regulation of NIK/NF-kappaB signaling:TNF \| smooth muscle cell proliferation:AIF1,TNF \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| syncytium formation by plasma membrane fusion:FLOT1 \| amino acid activation:VARS2 \| regulation of RNA stability:HSPA1A \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| cellular response to amino acid stimulus:TNF \| nuclear export:CCHCR1 \| cleavage involved in rRNA processing:NHP2 \| syncytium formation:FLOT1 \| lipopolysaccharide-mediated signaling pathway:TNF \| fat-soluble vitamin biosynthetic process:TNF \| regulation of symbiosis, encompassing mutualism through parasitism:TNF \| regulation of monooxygenase activity:DDAH2,TNF \| positive regulation of cellular component biogenesis:FLOT1,HSPA1A,HSPA1B,TNF \| regulation of cellular protein catabolic process:BAG6,HSPA1A,TRIM39 \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,TNF \| defense response to bacterium:TNF \| glial cell activation:AIF1 \| protein polymerization:AIF1,HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| regulation of mitotic cell cycle phase transition:AIF1,TUBB \| mitochondrial membrane organization:HSPA1A \| receptor metabolic process:FLOT1,TNF \| immunoglobulin production:TNF \| reactive oxygen species metabolic process:AIF1,DDAH2,TNF \| regulation of immunoglobulin production:TNF \| viral genome replication:TNF \| regulation of receptor internalization:FLOT1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| cellular response to ammonium ion:AIF1 \| homologous chromosome segregation:BAG6,MSH5 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:BAG6,HSPA1A \| positive regulation of cell junction assembly:FLOT1 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| positive regulation of cytokine biosynthetic process:TNF \| negative regulation of cellular protein catabolic process:BAG6,TRIM39 \| negative regulation of catabolic process:BAG6,TNF,TRIM39 \| regulation of mRNA catabolic process:HSPA1A \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| negative regulation of cellular catabolic process:BAG6,TRIM39 \| cellular amino acid metabolic process:DDAH2,VARS2 \| transcription from RNA polymerase I promoter:ZNRD1 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,TNF \| gland morphogenesis:DDR1,TNF \| endothelium development:TNF \| regulation of phosphoprotein phosphatase activity:TNF \| regulation of protein complex assembly:HSPA1A,HSPA1B,TNF \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B,TNF \| spindle organization:HSPA1A,HSPA1B,TUBB \| superoxide metabolic process:TNF \| negative regulation of phosphatase activity:TNF \| negative regulation of ossification:TNF \| ruffle assembly:AIF1 \| regulation of protein catabolic process:BAG6,HSPA1A,TNF \| negative regulation of mitotic cell cycle:TNF \| DNA-templated transcription, initiation:ZNRD1 \| negative regulation of hydrolase activity:TNF \| chromosome organization involved in meiotic cell cycle:BAG6,MSH5 \| negative regulation of chemotaxis:AIF1 \| regulation of cell cycle phase transition:AIF1,TUBB \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B,TNF \| mammary gland duct morphogenesis:DDR1 \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| autophagy:ATP6V1G2 \| process utilizing autophagic mechanism:ATP6V1G2 \| cellular response to oxidative stress:AIF1,HSPA1A,HSPA1B,TNF \| regulation of striated muscle tissue development:FLOT1 \| positive regulation of striated muscle cell differentiation:FLOT1 \| G2/M transition of mitotic cell cycle:TUBB \| protein complex localization:TNF \| receptor internalization:FLOT1 \| regulation of translational initiation:TNF \| regulation of reactive oxygen species metabolic process:AIF1,DDAH2,TNF \| negative regulation of proteolysis:BAG6,TRIM39 \| ubiquitin-dependent ERAD pathway:BAG6 \| regulation of muscle tissue development:FLOT1 \| regulation of multi-organism process:TNF \| RNA localization to Cajal body:NHP2 \| telomerase RNA localization to Cajal body:NHP2 \| telomerase RNA localization:NHP2 \| RNA localization to nucleus:NHP2 \| heat generation:TNF \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B,TNF \| regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| regulation of leukocyte chemotaxis:AIF1 \| mammary gland development:DDR1 \| response to unfolded protein:ATF6B,HSPA1A,HSPA1L \| response to oxidative stress:AIF1,HSPA1A,HSPA1B,TNF \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| translational initiation:TNF \| regulation of viral process:TNF \| smooth muscle cell migration:AIF1,DDR1 \| negative regulation of viral life cycle:TNF \| negative regulation of leukocyte activation:LST1 \| cell cycle G2/M phase transition:TUBB \| regulation of G2/M transition of mitotic cell cycle:TUBB	0.134646	0.0783961	1.06531575086694							0.591132	0.0853262	11.2452527248307				0.578224	0.136149	4.60982115275367	0.0380274	0.0643902	0.255810320823165				0.00470828	0.0967061	0.0171939189662252																																					0.262571	0.127039	1.41030837251555				0.26629	0.166393	0.95868628465414
rs36139342:119204625:A:AC	novel3	6	119204625	6q22.31	AC	A	0.99	144	DHEAS ALL	7659	11.1240421208632	0.192311398354877	0.0122193	MCM9 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); ASF1A (11 kb); FAM184A (76 kb); CEP85L (170 kb)	NA	- \| ASF1A \| BRD7P3 \| CEP85L \| FAM184A \| MCM9 \| MCMDC1 \| PLN \| RP11-210H10 A.1 \| RP11-351A11.1	BORA \| HIST1H2BJ		Formation of Senescence-Associated Heterochromatin Foci (SAHF):ASF1A		DNA replication initiation:MCM9	-0.0136144	0.0219172	0.27201004122303	0.0137521	0.0199672	0.30882299128571	-0.0203303	0.0422	0.200675306031217	-0.0139282	0.0241133	0.24903826252731	0.0236426	0.026315	0.432845365254941	-0.0703964	0.0480011	0.844846222234852	-0.0128406	0.0179897	0.322897888590765	0.00863642	0.0207348	0.169348469011978	-0.0434887	0.0336804	0.705425764785102	-0.0871928	0.0127335	11.1240421208632	-0.0882746	0.0160836	7.39215053776423	-0.0861025	0.0201414	4.71844170391325	-0.0148015	0.0126471	0.616432360189955	0.0344536	0.0134652	1.97856673732835	-0.0737033	0.0210931	3.32284856538477	0.0165791	0.012273	0.752662692098834	0.0289053	0.0151596	1.24752208209511	-0.00663392	0.0194488	0.134877658586354	-0.004363	0.00733817	0.257953148789202	-0.00757347	0.00962503	0.365151068349575	-3.59975E-4	0.0112772	0.0112025587691333	-0.0241021	0.036145	0.296737862494172	-0.0605412	0.0456336	0.733187593476151	0.0350676	0.0591096	0.257116258448133
rs35695070:7343539:GC:G	known [3, 5, 7]	17	7343539	17p13.1	G	GC	0.894	17	TESTO MEN	4291	10.8095394335565	0.507888021440224	0.233061	FGF11 (0 kb); TMEM102 (2.5 kb); CHRNB1 (4.8 kb); C17orf74 (13 kb); SPEM1 (19 kb); ZBTB4 (19 kb); NLGN2 (20 kb); TMEM256 (36 kb); TMEM256-PLSCR3 (36 kb); SLC35G6 (41 kb); POLR2A (44 kb)	NA	- \| ACAP1 \| ARHGEF15 \| C17orf61 \| C17orf61-PLSCR3 \| C17orf74 \| C17orf81 \| CD68 \| CHRNB1 \| CTC1 \| EIF4A1 \| EIF5A \| FGF11 \| LSMD1 \| MPDU1 \| NLGN2 \| PFAS \| PLSCR3 \| POLR2A \| RP11-186B7.4 \| SAT2 \| SENP3 \| SNORA48 \| SNORA67 \| SOX15 \| TMEM102 \| TMEM256-PLSCR3 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| TP53 \| ZBTB4		Herpes simplex infection:POLR2A \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Cell adhesion molecules (CAMs):NLGN2 \| Epstein-Barr virus infection:POLR2A \| Endocytosis:ACAP1 \| Huntington disease:POLR2A \| Ferroptosis:SAT2 \| Lysosome:CD68 \| RNA transport:EIF4A1	Interferon Signaling:EIF4A1 \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13 \| TP53 Regulates Transcription of DNA Repair Genes:POLR2A \| TNFR2 non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13,TNFSF13 \| MicroRNA (miRNA) biogenesis:POLR2A \| Transcriptional regulation of pluripotent stem cells:POLR2A \| Infectious disease:POLR2A \| Influenza Infection:POLR2A \| Transcriptional Regulation by TP53:POLR2A \| HIV Transcription Elongation:POLR2A \| Formation of HIV-1 elongation complex containing HIV-1 Tat:POLR2A \| Tat-mediated elongation of the HIV-1 transcript:POLR2A \| Neurexins and neuroligins:NLGN2 \| Transcription of the HIV genome:POLR2A \| Formation of HIV elongation complex in the absence of HIV Tat:POLR2A \| ISG15 antiviral mechanism:EIF4A1 \| Antiviral mechanism by IFN-stimulated genes:EIF4A1 \| RNA Polymerase II Pre-transcription Events:POLR2A \| Formation of the Early Elongation Complex:POLR2A \| Formation of the HIV-1 Early Elongation Complex:POLR2A \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Pausing and recovery of Tat-mediated HIV elongation:POLR2A \| Tat-mediated HIV elongation arrest and recovery:POLR2A \| Protein-protein interactions at synapses:NLGN2 \| Formation of RNA Pol II elongation complex :POLR2A \| RNA Polymerase II Transcription Elongation:POLR2A \| HIV elongation arrest and recovery:POLR2A \| Pausing and recovery of HIV elongation:POLR2A \| Transcriptional regulation by small RNAs:POLR2A	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| lymphatic system disease:TNFSF13 \| hepatitis:EIF4A1 \| hepatitis C:EIF4A1 \| hypotrichosis:TNFSF13 \| urinary system disease:TNFSF12,TNFSF13 \| multiple myeloma:TNFSF13 \| myeloma:TNFSF13 \| bone marrow cancer:TNFSF13 \| hair disease:TNFSF13 \| proteinuria:TNFSF12 \| kidney disease:TNFSF12,TNFSF13 \| purpura:TNFSF13 \| alopecia:TNFSF13 \| collagen disease:TNFSF12,TNFSF13 \| nephritis:TNFSF12,TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| rheumatic disease:TNFSF12,TNFSF13 \| systemic scleroderma:TNFSF12,TNFSF13 \| scleroderma:TNFSF12,TNFSF13 \| integumentary system disease:TNFSF12,TNFSF13 \| hematopoietic system disease:TNFSF13 \| colon carcinoma:TNFSF13 \| intestinal cancer:SAT2,TNFSF13 \| interstitial lung disease:TNFSF12 \| myopathy:TNFSF12,TNFSF13 \| muscle tissue disease:TNFSF12,TNFSF13 \| Sjogren's syndrome:TNFSF13 \| muscular disease:TNFSF12,TNFSF13 \| alopecia areata:TNFSF13 \| non-small cell lung carcinoma:EIF5A,TNFSF13 \| colon cancer:TNFSF13 \| colorectal cancer:TNFSF13 \| large intestine cancer:TNFSF13 \| myositis:TNFSF13 \| lower respiratory tract disease:TNFSF12 \| lung adenocarcinoma:EIF5A \| cardiomyopathy:TNFSF12 \| liver cirrhosis:TNFSF13 \| lung disease:TNFSF12 \| chronic lymphocytic leukemia:TNFSF13 \| dilated cardiomyopathy:TNFSF12 \| acute myocardial infarction:TNFSF12 \| coronary artery disease:TNFSF12	positive regulation of cell activation:SOX15,TNFSF13 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF12,TNFSF13 \| positive regulation of cell adhesion:TMEM102 \| positive regulation of lymphocyte activation:TNFSF13 \| positive regulation of leukocyte activation:TNFSF13 \| regulation of leukocyte activation:TNFSF13 \| regulation of lymphocyte activation:TNFSF13 \| postsynaptic membrane organization:CHRNB1,NLGN2 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| regulation of DNA biosynthetic process:CTC1 \| RNA secondary structure unwinding:EIF4A1 \| cellular response to tumor necrosis factor:TNFSF12,TNFSF13 \| DNA biosynthetic process:CTC1 \| replicative senescence:CTC1 \| locomotory exploration behavior:NLGN2 \| response to tumor necrosis factor:TNFSF12,TNFSF13 \| ammonium ion metabolic process:SAT2 \| regulation of immune effector process:TNFSF13 \| telomere maintenance via telomerase:CTC1 \| RNA-dependent DNA biosynthetic process:CTC1 \| positive regulation of cell cycle process:SOX15 \| telomere maintenance via telomere lengthening:CTC1 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| hematopoietic stem cell proliferation:CTC1 \| positive regulation of excitatory postsynaptic potential:NLGN2 \| B cell mediated immunity:TNFSF13 \| exploration behavior:NLGN2 \| translational initiation:EIF4A1 \| positive regulation of adaptive immune response:TNFSF13 \| regulation of neurotransmitter receptor activity:NLGN2 \| regulation of cell cycle G2/M phase transition:CTC1 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:CHRNB1,NLGN2 \| nucleocytoplasmic transport:EIF5A \| protein localization to synapse:NLGN2 \| nuclear transport:EIF5A \| positive regulation of DNA metabolic process:CTC1,TNFSF13 \| chemical synaptic transmission, postsynaptic:CHRNB1,NLGN2 \| spleen development:CTC1 \| negative regulation of DNA biosynthetic process:CTC1 \| modulation of excitatory postsynaptic potential:NLGN2 \| regulation of glutamate receptor signaling pathway:NLGN2 \| positive regulation of reactive oxygen species metabolic process:EIF5A \| stem cell proliferation:CTC1 \| positive regulation of cell cycle:SOX15 \| peptidyl-tyrosine phosphorylation:TMEM102 \| regulation of lymphocyte mediated immunity:TNFSF13 \| peptidyl-tyrosine modification:TMEM102 \| nuclear-transcribed mRNA poly(A) tail shortening:EIF4A1 \| regulation of DNA metabolic process:CTC1,TNFSF13 \| negative regulation of translation:POLR2A \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:TMEM102 \| cell cycle G2/M phase transition:CTC1 \| thymus development:CTC1 \| DNA-templated transcription, elongation:POLR2A \| regulation of postsynaptic membrane potential:CHRNB1,NLGN2 \| synapse organization:CHRNB1,NLGN2 \| positive regulation of cellular amide metabolic process:EIF5A \| negative regulation of cellular amide metabolic process:POLR2A \| neuromuscular process controlling balance:NLGN2 \| regulation of mitotic cell cycle phase transition:CTC1 \| regulation of adaptive immune response:TNFSF13 \| regulation of telomere maintenance via telomerase:CTC1 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| receptor-mediated endocytosis:NLGN2 \| mitochondrial outer membrane permeabilization:TMEM102 \| postsynaptic membrane assembly:NLGN2 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| telomere maintenance:CTC1 \| regulation of cell cycle phase transition:CTC1 \| telomere capping:CTC1 \| aging:CTC1,EIF5A \| membrane assembly:NLGN2 \| protein export from nucleus:EIF5A \| presynaptic membrane organization:NLGN2 \| regulation of telomere maintenance via telomere lengthening:CTC1 \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:TMEM102 \| telomere organization:CTC1 \| mitochondrial outer membrane permeabilization involved in programmed cell death:TMEM102 \| flagellated sperm motility:SPEM1 \| sperm motility:SPEM1 \| positive regulation of mitochondrial membrane permeability:TMEM102 \| regulation of mitochondrial membrane permeability involved in apoptotic process:TMEM102 \| positive regulation of membrane permeability:TMEM102 \| mRNA catabolic process:EIF4A1,TNFSF13 \| membrane biogenesis:NLGN2 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| somatic stem cell population maintenance:POLR2A \| locomotory behavior:NLGN2 \| regulation of viral process:POLR2A \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| regulation of G2/M transition of mitotic cell cycle:CTC1 \| nuclear export:EIF5A \| postsynapse assembly:NLGN2 \| regulation of telomere maintenance:CTC1 \| glutamate receptor signaling pathway:NLGN2 \| regulation of mitochondrial membrane permeability:TMEM102 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:EIF4A1 \| mitochondrial membrane organization:TMEM102 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| neuron cell-cell adhesion:NLGN2 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| regulation of membrane permeability:TMEM102 \| regulation of synapse assembly:NLGN2 \| regulation of symbiosis, encompassing mutualism through parasitism:POLR2A \| regulation of fibroblast proliferation:CTC1 \| regulation of ion transmembrane transporter activity:NLGN2 \| fibroblast proliferation:CTC1 \| regulation of apoptotic signaling pathway:TMEM102,TNFSF12 \| regulation of transmembrane transporter activity:NLGN2 \| RNA catabolic process:EIF4A1,TNFSF13 \| neuromuscular process:NLGN2 \| regulation of G0 to G1 transition:SOX15 \| regulation of membrane potential:CHRNB1,NLGN2 \| presynapse assembly:NLGN2 \| cell aging:CTC1 \| transcription elongation from RNA polymerase II promoter:POLR2A \| synaptic vesicle recycling:NLGN2 \| regulation of striated muscle tissue development:SOX15 \| regulation of transporter activity:NLGN2 \| G0 to G1 transition:SOX15 \| positive regulation of viral process:POLR2A \| regulation of muscle tissue development:SOX15 \| G2/M transition of mitotic cell cycle:CTC1 \| DNA-templated transcription, termination:POLR2A \| regulation of leukocyte chemotaxis:TMEM102 \| regulation of gene silencing by miRNA:POLR2A \| regulation of posttranscriptional gene silencing:POLR2A \| regulation of gene silencing by RNA:POLR2A	6.65759E-4	0.01765	0.013266324134237	-0.0159478	0.0157748	0.505547626621375				0.038949	0.0193994	1.34871810838986	0.0361014	0.0207771	1.08346078017817	0.0385849	0.040036	0.474311358920536	8.03698E-4	0.0144876	0.0196488773360241	0.00511865	0.0163851	0.122175588471182	-0.0120564	0.0280968	0.175236540547911	-0.0111995	0.0104162	0.549313737186538	-0.00147011	0.0131442	0.0405068900710457	-0.0199096	0.0164999	0.642890715725955	0.0408821	0.0102775	4.15770536341877	0.0734806	0.0108972	10.8095394335565	-0.00266917	0.0173836	0.0565213128828303	0.0237466	0.0100144	1.75132800829537	0.0383878	0.0123827	2.71344922628234	0.00764896	0.0158951	0.200409286266302	0.003398	0.00598208	0.24411371567573	0.00409667	0.00780552	0.222071020495414	0.0032477	0.00924791	0.139391317650456	-0.0386952	0.0290385	0.737947789963467	-0.0623227	0.0360024	1.07739960776694	0.0108996	0.0491201	0.0838298832400691
rs115310850:31823256:C:A		6	31823256	6p21.33	A	C	0.984	0	OHP17 ALL	2070	10.7875274001115	0.0104466183574879		NEU1 (2.2 kb, near gene/Downstream gene/MODIFIER); SLC44A4 (7.7 kb); C6orf48 (16 kb); SNORD52 (18 kb); SNORD48 (20 kb); EHMT2 (24 kb); HSPA1B (25 kb); EHMT2-AS1 (28 kb); HSPA1A (38 kb); HSPA1L (40 kb); C2 (42 kb); ZBTB12 (44 kb); LSM2 (48 kb)	0.569 Blood protein levels // 0.402 Economic and political preferences (environmentalism) // 0.402 Hepatitis B vaccine response // 0.368 Blood metabolite levels	- \| ABCF1 \| ABHD16A \| AGER \| AIF1 \| APOM \| ATF6B \| ATP6V1G2 \| BAG6 \| BAT4 \| BRD2 \| BTNL2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf25 \| C6orf48 \| CCHCR1 \| CFB \| CLIC1 \| CSNK2B \| CUTA \| DDAH2 \| DDR1 \| DDX39B \| DOM3Z \| DXO \| EHMT2 \| FLOT1 \| GPANK1 \| GPSM3 \| GTF2H4 \| HCG22 \| HCG23 \| HCG27 \| HCP5 \| HLA-A \| HLA-B \| HLA-C \| HLA-DOA \| HLA-DOB \| HLA-DPA1 \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DQB2 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB2 \| HLA-DRB3 \| HLA-DRB4 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB7 \| HLA-DRB8 \| HLA-E \| HLA-H \| HLA-T \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LTB \| LY6G5B \| LY6G5C \| LY6G6E \| MCCD1 \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| PBX2 \| PHF1 \| PPP1R10 \| PPP1R11 \| PPT2 \| PRRC2A \| PSMB8 \| PSMB9 \| PSORS1C2 \| RDBP \| RNF5 \| RPP21 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP1 \| TAP2 \| TNF \| TRIM10 \| TRIM39 \| TUBB \| unnamed \| VARS \| VARS2 \| VPS52 \| XXbac-BPG154L12.4 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.12 \| XXbac-BPG299F13.17 \| ZBTB12 \| ZNRD1	ABP1 \| CCDC69 \| EXOC1 \| HLA-E \| HLA-F \| HLA-V \| IER3 \| LIMS1 \| MDC1 \| NHP2 \| PARP2 \| PPP1R11 \| TMEM154 \| TRAV12-1 \| TUBB \| ZNRD1	Type I diabetes mellitus:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Allograft rejection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Graft-versus-host disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TAP2 \| Autoimmune thyroid disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Viral myocarditis:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Staphylococcus aureus infection:C2,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Asthma:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phagosome:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| Herpes simplex infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| Intestinal immune network for IgA production:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Rheumatoid arthritis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Inflammatory bowel disease (IBD):HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Toxoplasmosis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Systemic lupus erythematosus:C2,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Cell adhesion molecules (CAMs):HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Leishmaniasis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Influenza A:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Hematopoietic cell lineage:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Epstein-Barr virus infection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Th1 and Th2 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Th17 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Tuberculosis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Natural killer cell mediated cytotoxicity:HLA-C,NCR3 \| Endocytosis:HLA-C,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L \| Human cytomegalovirus infection:ATF6B,HLA-C,TAP2 \| Kaposi sarcoma-associated herpesvirus infection:HLA-C \| Viral carcinogenesis:ATF6B,GTF2H4,HLA-C \| Spliceosome:HSPA1A,HSPA1B,HSPA1L,LSM2 \| Human immunodeficiency virus 1 infection:HLA-C,TAP2 \| Protein processing in endoplasmic reticulum:ATF6B,HSPA1A,HSPA1B,HSPA1L,RNF5 \| Cellular senescence:HLA-C \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:ATF6B,HSPA1A,HSPA1B,HSPA1L \| Complement and coagulation cascades:C2 \| Human papillomavirus infection:HLA-C \| Pertussis:C2 \| TNF signaling pathway:ATF6B \| Aminoacyl-tRNA biosynthesis:VARS2 \| Lysosome:NEU1 \| Cortisol synthesis and secretion:ATF6B	Translocation of ZAP-70 to Immunological synapse:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon gamma signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| PD-1 signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Generation of second messenger molecules:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Downstream TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon Signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| MHC class II antigen presentation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Costimulation by the CD28 family:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Endosomal/Vacuolar pathway:HLA-C \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,TAP2 \| ER-Phagosome pathway:HLA-C,TAP2 \| Antigen processing-Cross presentation:HLA-C,TAP2 \| Initial triggering of complement:C2 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,NCR3 \| Interferon alpha/beta signaling:HLA-C \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:GTF2H4,HSPA1A,HSPA1B \| Regulation of Complement cascade:C2 \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| TP53 Regulates Transcription of DNA Repair Genes:GTF2H4 \| Complement cascade:C2 \| HIV Infection:GTF2H4 \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B \| Class I MHC mediated antigen processing & presentation:HLA-C,TAP2 \| HIV Transcription Elongation:GTF2H4 \| Formation of HIV-1 elongation complex containing HIV-1 Tat:GTF2H4 \| Tat-mediated elongation of the HIV-1 transcript:GTF2H4 \| Formation of HIV elongation complex in the absence of HIV Tat:GTF2H4 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Influenza Infection:HSPA1A,HSPA1B \| Defective CFTR causes cystic fibrosis:RNF5 \| Formation of RNA Pol II elongation complex :GTF2H4 \| RNA Polymerase II Transcription Elongation:GTF2H4 \| Formation of the Early Elongation Complex:GTF2H4 \| Formation of the HIV-1 Early Elongation Complex:GTF2H4 \| ABC-family proteins mediated transport:ABCF1,RNF5 \| HIV Life Cycle:GTF2H4 \| RNA Polymerase I Promoter Escape:GTF2H4,ZNRD1 \| Transcription of the HIV genome:GTF2H4 \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Transcriptional Regulation by TP53:EHMT2,GTF2H4 \| RNA Polymerase I Transcription Termination:GTF2H4,ZNRD1 \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| RNA Polymerase I Transcription Initiation:EHMT2,GTF2H4,ZNRD1 \| Diseases associated with glycosylation precursor biosynthesis:NEU1 \| Neutrophil degranulation:HLA-C,HSPA1A,HSPA1B,NEU1 \| ABC transporter disorders:RNF5 \| Influenza Life Cycle:HSPA1A,HSPA1B \| RNA Polymerase II Pre-transcription Events:GTF2H4 \| Dual Incision in GG-NER:GTF2H4 \| tRNA Aminoacylation:VARS2 \| Formation of Incision Complex in GG-NER:GTF2H4 \| Late Phase of HIV Life Cycle:GTF2H4 \| Synthesis of PC:SLC44A4 \| Deadenylation-dependent mRNA decay:LSM2 \| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection:GTF2H4 \| RNA Pol II CTD phosphorylation and interaction with CE:GTF2H4 \| RNA Polymerase I Promoter Clearance:EHMT2,GTF2H4,ZNRD1 \| RNA Polymerase I Transcription:EHMT2,GTF2H4,ZNRD1 \| mRNA Capping:GTF2H4	Kawasaki disease:BAG6,HLA-C,HLA-DRB1,PRRC2A \| lymphadenitis:BAG6,HLA-C,HLA-DRB1,PRRC2A \| lymph node disease:BAG6,HLA-C,HLA-DRB1,PRRC2A \| lymphatic system disease:BAG6,HLA-C,HLA-DRB1,PRRC2A \| leprosy:HLA-DRB1 \| sarcoidosis:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L \| hypersensitivity reaction type IV disease:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L \| autoimmune disease of endocrine system:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| multiple sclerosis:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| endocrine system disease:ABCF1,HLA-C,HLA-DQA1,HLA-DRB1,HSPA1B,TAP2 \| autoimmune thyroiditis:HLA-DRB1 \| demyelinating disease:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Graves' disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| thyroid gland disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| intrahepatic cholestasis:HLA-DQA1,HLA-DRB1 \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HLA-C,HLA-DQA1,HLA-DRB1 \| primary bacterial infectious disease:FLOT1,HLA-DRB1,TAP2 \| hepatitis:HLA-C,HLA-DQA1,HLA-DRB1,NCR3 \| hyperthyroidism:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| vitiligo:DDR1,HLA-C \| spondylitis:HLA-C \| ankylosing spondylitis:HLA-C \| rheumatic fever:HLA-DQA1,HLA-DRB1 \| bacterial infectious disease:FLOT1,HLA-DRB1,TAP2 \| aplastic anemia:HLA-DQA1,HLA-DRB1 \| urticaria:HLA-DRB1 \| spondyloarthropathy:HLA-C \| vasculitis:DDR1,HLA-DRB1 \| hypothyroidism:HLA-DRB1 \| Behcet's disease:HLA-DRB1 \| hepatitis C:HLA-C,HLA-DQA1,HLA-DRB1,NCR3 \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1 \| arthropathy:HLA-C \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,NCR3,PRRC2A,TAP2 \| malaria:HLA-DRB1,NCR3,PRRC2A \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:DDR1,HLA-DRB1 \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-DRB1 \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DQA1,HLA-DRA \| neuromuscular junction disease:HLA-DQA1,HLA-DRA \| brucellosis:TAP2 \| duodenal ulcer:HSPA1A \| cholestasis:HLA-DQA1,HLA-DRB1 \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-C,HLA-DQA1,HLA-DRB1 \| upper respiratory tract disease:HLA-C,HSPA1A,TAP2 \| uveitis:HLA-DQA1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,NCR3,PRRC2A \| urinary system disease:DDR1,HLA-DQA1,HLA-DRB1,HSPA1A \| multiple myeloma:BAG6,IER3,NCR3 \| myeloma:BAG6,IER3,NCR3 \| reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| bone marrow cancer:BAG6,IER3,NCR3 \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L \| bile duct disease:HLA-C,HLA-DQA1,HLA-DRB1 \| biliary tract disease:HLA-C,HLA-DQA1,HLA-DRB1 \| azoospermia:HLA-DRB1,MSH5 \| proteinuria:DDR1,HLA-DRB1 \| kidney disease:DDR1,HLA-DQA1,HLA-DRB1,HSPA1A \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DRB1 \| type 1 diabetes mellitus:HLA-DQA1 \| blood coagulation disease:HLA-DRA,HLA-DRB1 \| allergic rhinitis:HLA-C,TAP2 \| hemorrhagic disease:HLA-DRA,HLA-DRB1 \| neuromuscular disease:HLA-DQA1,HLA-DRA \| thyroiditis:HLA-DRB1 \| nasal cavity disease:HLA-C,TAP2 \| nose disease:HLA-C,TAP2 \| rhinitis:HLA-C,TAP2 \| collagen disease:HLA-DRB1,TAP2 \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:ABCF1,HLA-DRB1,HSPA1B \| nephritis:HLA-DQA1,HLA-DRB1 \| celiac disease:HLA-DQA1,HLA-DRB1 \| peptic ulcer disease:HSPA1A \| hematopoietic system disease:HLA-DQA1,HLA-DRA,HLA-DRB1 \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DQA1,HLA-DRB1 \| rheumatic disease:HLA-DRB1,TAP2 \| systemic scleroderma:HLA-DRB1,TAP2 \| scleroderma:HLA-DRB1,TAP2 \| male reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| male infertility:HLA-DRB1,MSH5 \| silicosis:HLA-DRB1 \| integumentary system disease:HLA-DQA1,HLA-DRB1 \| sickle cell anemia:HLA-DRB1 \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2 \| Human immunodeficiency virus infectious disease:HLA-C,HLA-DRB1 \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B \| interstitial lung disease:DDR1,HLA-DRB1 \| bronchial disease:HSPA1A,HSPA1B,TAP2 \| acute pancreatitis:HSPA1B \| tuberculosis:HLA-DRB1 \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| prostate disease:HLA-DRB1,HSPA1A \| pneumoconiosis:HLA-DRB1 \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1 \| autoimmune disease of peripheral nervous system:HLA-DRB1 \| Guillain-Barre syndrome:HLA-DRB1 \| pancreas disease:ABCF1,HLA-DRB1,HSPA1B \| open-angle glaucoma:HLA-DRB1,TAP2 \| influenza:HLA-DRB1 \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-DQA1,HLA-DRB1 \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B,TAP2 \| ovarian disease:MSH5 \| gastritis:HLA-DRB1 \| dermatomyositis:HLA-DRB1 \| essential hypertension:HSPA1A,HSPA1B,HSPA1L \| female reproductive system disease:MSH5 \| osteomyelitis:HLA-DRB1 \| neuropathy:HLA-DQA1,HLA-DRA \| migraine:HLA-DRB1 \| infertility:MSH5 \| peripheral nervous system disease:HLA-DRB1 \| age related macular degeneration:C2 \| degeneration of macula and posterior pole:C2 \| autoimmune disease of urogenital tract:HLA-DRB1 \| primary biliary cirrhosis:HLA-DRB1 \| cell type benign neoplasm:DDR1 \| macular degeneration:C2 \| stomach disease:HLA-DRB1 \| cholangitis:HLA-C,HLA-DRB1 \| Crohn's disease:HSPA1B \| osteosarcoma:BAG6 \| lung disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B \| spinal cord disease:HLA-C,HLA-DRB1 \| pulmonary edema:HSPA1A \| myositis:HLA-DRB1 \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B \| myopathy:HLA-DRB1 \| muscle tissue disease:HLA-DRB1 \| bone cancer:BAG6 \| nasopharynx carcinoma:DDR1,HSPA1B \| pharynx cancer:DDR1,HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| muscular disease:HLA-DRB1 \| endocrine organ benign neoplasm:DDR1 \| bronchiectasis:TAP2 \| premature ovarian failure:MSH5 \| liver cirrhosis:DDR1,HLA-DRB1 \| renal cell carcinoma:HLA-DRB1,TAP2 \| glaucoma:HLA-DRB1,TAP2 \| esophageal carcinoma:HLA-DRB1 \| retinal disease:C2,HLA-DRB1,TAP2 \| skin disease:HLA-DRB1 \| female reproductive organ cancer:DDR1,HLA-DQA1,HLA-DRB1 \| connective tissue cancer:BAG6 \| adenoma:DDR1 \| primary open angle glaucoma:TAP2 \| severe combined immunodeficiency:HLA-DRB1 \| retinal degeneration:C2,HLA-DRB1,TAP2 \| malignant ovarian surface epithelial-stromal neoplasm:DDR1,HLA-DQA1,HLA-DRB1 \| ovary epithelial cancer:DDR1,HLA-DQA1,HLA-DRB1 \| ovarian carcinoma:DDR1,HLA-DQA1,HLA-DRB1 \| combined T cell and B cell immunodeficiency:HLA-DRB1	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation of peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| cellular response to interferon-gamma:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| response to interferon-gamma:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell receptor signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating signal transduction:BAG6,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,NCR3 \| T cell costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| lymphocyte costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen receptor-mediated signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-regulating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| positive regulation of cell-cell adhesion:FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of leukocyte cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of T cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of cell-cell adhesion:FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,TAP2 \| regulation of leukocyte cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,TAP2 \| positive regulation of cell adhesion:FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of lymphocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of lymphocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1,LST1 \| regulation of T cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of leukocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1,LST1 \| leukocyte cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,TAP2 \| positive regulation of leukocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| lymphocyte mediated immunity:C2,NCR3 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:C2,NCR3 \| adaptive immune response:C2,NCR3,TAP2 \| humoral immune response mediated by circulating immunoglobulin:C2 \| natural killer cell mediated cytotoxicity:NCR3 \| natural killer cell mediated immunity:NCR3 \| T cell mediated cytotoxicity:NCR3 \| response to type I interferon:HLA-C \| type I interferon signaling pathway:HLA-C \| cellular response to type I interferon:HLA-C \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| leukocyte mediated cytotoxicity:NCR3 \| regulation of humoral immune response:C2 \| positive regulation of defense response:FLOT1,HSPA1A,HSPA1B,NCR3 \| positive regulation of cytokine production:FLOT1,HSPA1A,HSPA1B \| T cell mediated immunity:NCR3 \| regulation of apoptotic cell clearance:C2 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:C2,NCR3 \| positive regulation of innate immune response:FLOT1,HSPA1A,HSPA1B,NCR3 \| regulation of lymphocyte mediated immunity:NCR3 \| regulation of innate immune response:FLOT1,HSPA1A,HSPA1B,NCR3 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B \| cell killing:NCR3 \| positive regulation of lymphocyte mediated immunity:NCR3 \| regulation of lymphocyte proliferation:LST1 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| regulation of mononuclear cell proliferation:LST1 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of natural killer cell mediated cytotoxicity:NCR3 \| positive regulation of adaptive immune response:NCR3 \| regulation of natural killer cell mediated immunity:NCR3 \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| immunoglobulin mediated immune response:C2 \| regulation of leukocyte proliferation:LST1 \| B cell mediated immunity:C2 \| mRNA catabolic process:HSPA1A,HSPA1B,LSM2 \| response to tumor necrosis factor:HSPA1A,HSPA1B \| regulation of complement activation:C2 \| response to heat:HSPA1A,HSPA1B,HSPA1L \| regulation of protein activation cascade:C2 \| antigen processing and presentation via MHC class Ib:TAP2 \| positive regulation of nitric oxide biosynthetic process:DDAH2 \| positive regulation of nitric oxide metabolic process:DDAH2 \| regulation of leukocyte mediated immunity:NCR3 \| activation of innate immune response:FLOT1,HSPA1A,HSPA1B \| regulation of T cell mediated cytotoxicity:NCR3 \| positive regulation of leukocyte mediated immunity:NCR3 \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| antigen processing and presentation of endogenous antigen:TAP2 \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B \| microtubule nucleation:HSPA1A,HSPA1B \| positive regulation of phagocytosis:C2 \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of heterotypic cell-cell adhesion:FLOT1 \| regulation of leukocyte mediated cytotoxicity:NCR3 \| regulation of DNA-templated transcription in response to stress:ATF6B,HSPA1A \| ER-associated misfolded protein catabolic process:BAG6,RNF5 \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B \| RNA catabolic process:HSPA1A,HSPA1B,LSM2 \| positive regulation of reactive oxygen species biosynthetic process:DDAH2 \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,HSPA1L,RNF5 \| positive regulation of T cell mediated cytotoxicity:NCR3 \| complement activation:C2 \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| DNA-templated transcription, elongation:GTF2H4,ZNRD1 \| humoral immune response:C2 \| regulation of acute inflammatory response:C2 \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| innate immune response-activating signal transduction:FLOT1,HSPA1A,HSPA1B \| regulation of nitric oxide biosynthetic process:DDAH2 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| lymphocyte proliferation:LST1 \| mononuclear cell proliferation:LST1 \| regulation of translational fidelity:VARS2 \| complement activation, classical pathway:C2 \| regulation of cell killing:NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| regulation of interleukin-8 production:HSPA1A,HSPA1B \| regulation of antigen processing and presentation:HLA-DOB \| RNA phosphodiester bond hydrolysis:HSPA1A,RPP21,ZNRD1 \| apoptotic cell clearance:C2 \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| regulation of adaptive immune response:NCR3 \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| leukocyte proliferation:LST1 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B \| regulation of protein stability:BAG6,FLOT1,HSPA1A,HSPA1B,RNF5 \| nitric oxide biosynthetic process:DDAH2 \| interleukin-8 production:HSPA1A,HSPA1B \| regulation of heterotypic cell-cell adhesion:FLOT1 \| positive regulation of protein complex assembly:GTF2H4,HSPA1A,HSPA1B \| interaction with host:HSPA1A,HSPA1B \| signal transduction in absence of ligand:HSPA1A,HSPA1B \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of natural killer cell mediated immunity:NCR3 \| nitric oxide metabolic process:DDAH2 \| cellular response to misfolded protein:BAG6,RNF5 \| regulation of phagocytosis:C2 \| natural killer cell activation:BAG6,NCR3 \| reactive nitrogen species metabolic process:DDAH2 \| nuclear-transcribed mRNA catabolic process, exonucleolytic:LSM2 \| cellular response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,RNF5 \| protein stabilization:BAG6,FLOT1,HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| response to misfolded protein:BAG6,RNF5 \| mRNA cleavage:HSPA1A,ZNRD1 \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of organelle assembly:HSPA1A,HSPA1B,RNF5 \| regulation of transcription from RNA polymerase II promoter in response to stress:ATF6B,HSPA1A \| regulation of reactive oxygen species biosynthetic process:DDAH2 \| protein ubiquitination involved in ubiquitin-dependent protein catabolic process:RNF5 \| regulation of endocytosis:C2,FLOT1 \| protein K63-linked ubiquitination:RNF5 \| protein quality control for misfolded or incompletely synthesized proteins:BAG6,RNF5 \| protein activation cascade:C2 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| positive regulation of endocytosis:C2,FLOT1 \| response to endoplasmic reticulum stress:ATF6B,BAG6,FLOT1,HSPA1A,RNF5 \| positive regulation of immune effector process:NCR3 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| transcription elongation from RNA polymerase I promoter:GTF2H4,ZNRD1 \| termination of RNA polymerase I transcription:GTF2H4,ZNRD1 \| pattern recognition receptor signaling pathway:FLOT1,HSPA1A,HSPA1B \| positive regulation of T cell mediated immunity:NCR3 \| spindle assembly:HSPA1A,HSPA1B \| ganglioside metabolic process:NEU1 \| nucleic acid phosphodiester bond hydrolysis:GTF2H4,HSPA1A,RPP21,ZNRD1 \| transcription initiation from RNA polymerase I promoter:GTF2H4,ZNRD1 \| exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay:LSM2 \| nuclear-transcribed mRNA catabolic process:LSM2 \| positive regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| positive regulation of leukocyte mediated cytotoxicity:NCR3 \| reactive oxygen species biosynthetic process:DDAH2 \| negative regulation of immune system process:HLA-DOB,LST1 \| positive regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| macroautophagy:RNF5 \| regulation of T cell mediated immunity:NCR3 \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| receptor-mediated endocytosis:FLOT1 \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| DNA-templated transcription, termination:GTF2H4,ZNRD1 \| regulation of macroautophagy:RNF5 \| membrane assembly:FLOT1 \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:FLOT1,LY6G5C \| regulation of protein processing:C2 \| viral life cycle:HSPA1A,HSPA1B \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress:ATF6B \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| regulation of protein maturation:C2 \| regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| positive regulation of catabolic process:BAG6,HSPA1A \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:BAG6,HSPA1A \| negative regulation of proteolysis involved in cellular protein catabolic process:BAG6 \| positive regulation of cell killing:NCR3 \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| phagocytosis:C2 \| mRNA cleavage involved in mRNA processing:HSPA1A \| regulation of autophagy:RNF5 \| microtubule polymerization:HSPA1A,HSPA1B \| regulation of inflammatory response:C2 \| synapsis:BAG6,MSH5 \| protein folding:HSPA1A,HSPA1B,HSPA1L \| positive regulation of protein catabolic process:BAG6,HSPA1A \| positive regulation of cellular catabolic process:BAG6,HSPA1A \| acute inflammatory response:C2 \| tRNA aminoacylation for protein translation:VARS2 \| extracellular matrix organization:DDR1,FLOT1 \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| membrane biogenesis:FLOT1 \| extracellular structure organization:DDR1,FLOT1 \| heterotypic cell-cell adhesion:FLOT1 \| branching involved in mammary gland duct morphogenesis:DDR1 \| negative regulation of growth:HSPA1A,HSPA1B \| tRNA aminoacylation:VARS2 \| regulation of binding:FLOT1 \| transcription elongation from RNA polymerase II promoter:GTF2H4 \| regulation of mRNA metabolic process:HSPA1A \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| syncytium formation by plasma membrane fusion:FLOT1 \| amino acid activation:VARS2 \| regulation of RNA stability:HSPA1A \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| syncytium formation:FLOT1 \| regulation of monooxygenase activity:DDAH2 \| positive regulation of cellular component biogenesis:FLOT1,GTF2H4,HSPA1A,HSPA1B \| regulation of cellular protein catabolic process:BAG6,HSPA1A \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| protein polymerization:HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| mitochondrial membrane organization:HSPA1A \| receptor metabolic process:FLOT1 \| reactive oxygen species metabolic process:DDAH2 \| regulation of receptor internalization:FLOT1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| protein polyubiquitination:RNF5 \| homologous chromosome segregation:BAG6,MSH5 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:BAG6,HSPA1A \| positive regulation of cell junction assembly:FLOT1 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| negative regulation of cellular protein catabolic process:BAG6 \| negative regulation of catabolic process:BAG6,RNF5 \| regulation of mRNA catabolic process:HSPA1A \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| negative regulation of cellular catabolic process:BAG6,RNF5 \| negative regulation of autophagy:RNF5 \| cellular amino acid metabolic process:DDAH2,VARS2 \| transcription from RNA polymerase I promoter:GTF2H4,ZNRD1 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| gland morphogenesis:DDR1 \| regulation of protein complex assembly:GTF2H4,HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| spindle organization:HSPA1A,HSPA1B \| regulation of protein catabolic process:BAG6,HSPA1A \| DNA-templated transcription, initiation:GTF2H4,ZNRD1 \| chromosome organization involved in meiotic cell cycle:BAG6,MSH5 \| regulation of G0 to G1 transition:EHMT2 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| transcription initiation from RNA polymerase II promoter:GTF2H4 \| mammary gland duct morphogenesis:DDR1 \| phosphatidylcholine biosynthetic process:SLC44A4 \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| autophagy:RNF5 \| process utilizing autophagic mechanism:RNF5 \| cellular response to oxidative stress:HSPA1A,HSPA1B \| regulation of striated muscle tissue development:FLOT1 \| positive regulation of striated muscle cell differentiation:FLOT1 \| regulation of autophagosome assembly:RNF5 \| receptor internalization:FLOT1 \| regulation of reactive oxygen species metabolic process:DDAH2 \| G0 to G1 transition:EHMT2 \| negative regulation of proteolysis:BAG6 \| ubiquitin-dependent ERAD pathway:BAG6,RNF5 \| regulation of muscle tissue development:FLOT1 \| negative regulation of G0 to G1 transition:EHMT2 \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| 7-methylguanosine mRNA capping:GTF2H4 \| regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| mammary gland development:DDR1 \| response to unfolded protein:ATF6B,HSPA1A,HSPA1L \| response to oxidative stress:HSPA1A,HSPA1B \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| 7-methylguanosine RNA capping:GTF2H4 \| RNA capping:GTF2H4 \| smooth muscle cell migration:DDR1 \| negative regulation of leukocyte activation:LST1 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:LSM2	0.092686	0.0836609	0.571793909744608							0.616842	0.0910639	10.7875274001115				0.643126	0.156804	4.33892406344598	0.0812383	0.0686683	0.625390943753266				0.0719273	0.111251	0.285547850176964																																					0.231453	0.137069	1.03878684749192				0.0836754	0.196212	0.173982242708816
rs114811870:31324938:C:T		6	31324938	6p21.33	T	C	0.991	3	OHP17 ALL	2070	10.6697323690065	0.0176869565217391		HLA-B (0 kb, 5'utr/5 prime UTR/MODIFIER \| nc-exon/Non coding transcript exon/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); XXbac-BPG248L24.12 (0 kb, nc-exon/Non coding transcript exon/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); DHFRP2 (9.2 kb); RNU6-283P (13 kb); FGFR3P1 (20 kb); ZDHHC20P2 (23 kb); HLA-S (25 kb); HCP5 (44 kb); MICA (46 kb)	0.943 Blood protein levels // 0.414 Plantar warts // 0.414 Response to angiotensin II receptor blocker therapy // 0.357 Tuberculosis	- \| ABCF1 \| ABHD16A \| AGER \| AGPAT1 \| AIF1 \| AL645933.8 \| APOM \| ATF6B \| ATP6V1G2 \| ATP6V1G2-DDX39B \| BAG6 \| C2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf15 \| C6orf25 \| C6orf48 \| CCHCR1 \| CFB \| CLIC1 \| CSNK2B \| CYP21A1P \| DDAH2 \| DDR1 \| DDX39B \| DHX16 \| DOM3Z \| DPCR1 \| DXO \| EHMT2 \| FLOT1 \| GPANK1 \| GPSM3 \| GTF2H4 \| HCG22 \| HCG27 \| HCP5 \| HLA-B \| HLA-C \| HLA-DOB \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB5 \| HLA-E \| HLA-J \| HLA-L \| HLA-S \| HLA-T \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LTB \| LY6G5B \| LY6G5C \| LY6G6C \| LY6G6E \| MDC1 \| MICA \| MICB \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| MUC22 \| NCR3 \| NEU1 \| NRM \| POU5F1 \| PPP1R10 \| PPP1R11 \| PPP1R18 \| PRRC2A \| PSMB9 \| PSORS1C1 \| PSORS1C2 \| PSORS1C3 \| RANP1 \| RDBP \| RNF5 \| RPP21 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP2 \| TCF19 \| TNF \| TNXA \| TRIM10 \| TRIM26 \| TRIM39 \| TUBB \| unnamed \| VARS \| VARS2 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.10 \| XXbac-BPG248L24.12 \| XXbac-BPG299F13.17 \| ZNRD1	BTN3A2 \| C6orf10 \| CARM1 \| CD248 \| DPM3 \| EHBP1L1 \| GABBR1 \| HCG18 \| HLA-A \| HLA-DOB \| HLA-DQA1 \| HLA-DQA2 \| HLA-DRB1 \| HLA-DRB2 \| HLA-DRB3 \| HLA-DRB4 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB7 \| HLA-DRB8 \| HLA-F \| HLA-G \| HLA-H \| HLA-V \| IER3 \| LAT \| NHP2 \| NMT1 \| OTUB1 \| PARP2 \| POLR2G \| PPP1R11 \| TMEM154 \| TMEM50B \| VKORC1 \| XRCC6 \| ZNRD1	Type I diabetes mellitus:HLA-B,HLA-C,HLA-DRA,LTA \| Allograft rejection:HLA-B,HLA-C,HLA-DRA \| Graft-versus-host disease:HLA-B,HLA-C,HLA-DRA \| Antigen processing and presentation:HLA-B,HLA-C,HLA-DRA,HSPA1A,HSPA1B,HSPA1L \| Autoimmune thyroid disease:HLA-B,HLA-C,HLA-DRA \| Viral myocarditis:HLA-B,HLA-C,HLA-DRA \| Staphylococcus aureus infection:HLA-DRA \| Asthma:HLA-DRA \| Phagosome:HLA-B,HLA-C,HLA-DRA \| Herpes simplex infection:HLA-B,HLA-C,HLA-DRA,LTA \| Intestinal immune network for IgA production:HLA-DRA \| Rheumatoid arthritis:HLA-DRA \| Inflammatory bowel disease (IBD):HLA-DRA \| Toxoplasmosis:HLA-DRA,HSPA1A,HSPA1B,HSPA1L \| Systemic lupus erythematosus:HLA-DRA \| Cell adhesion molecules (CAMs):HLA-B,HLA-C,HLA-DRA \| Leishmaniasis:HLA-DRA \| Influenza A:HLA-DRA,HSPA1A,HSPA1B,HSPA1L \| Hematopoietic cell lineage:HLA-DRA \| Epstein-Barr virus infection:HLA-B,HLA-C,HLA-DRA,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-B,HLA-C,HLA-DRA,LTA \| Th1 and Th2 cell differentiation:HLA-DRA \| Th17 cell differentiation:HLA-DRA \| Tuberculosis:HLA-DRA \| Natural killer cell mediated cytotoxicity:HLA-B,HLA-C,MICA,NCR3 \| Endocytosis:HLA-B,HLA-C,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L \| Human cytomegalovirus infection:HLA-B,HLA-C \| Kaposi sarcoma-associated herpesvirus infection:HLA-B,HLA-C,MICA \| Viral carcinogenesis:HLA-B,HLA-C \| Spliceosome:HSPA1A,HSPA1B,HSPA1L \| Human immunodeficiency virus 1 infection:HLA-B,HLA-C \| NF-kappa B signaling pathway:LTA \| Protein processing in endoplasmic reticulum:HSPA1A,HSPA1B,HSPA1L \| Cellular senescence:HLA-B,HLA-C \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:HLA-B,HLA-C \| TNF signaling pathway:LTA \| Aminoacyl-tRNA biosynthesis:VARS2	Translocation of ZAP-70 to Immunological synapse:HLA-DRA \| Phosphorylation of CD3 and TCR zeta chains:HLA-DRA \| Interferon gamma signaling:HLA-B,HLA-C,HLA-DRA \| PD-1 signaling:HLA-DRA \| Generation of second messenger molecules:HLA-DRA \| Downstream TCR signaling:HLA-DRA \| Interferon Signaling:HLA-B,HLA-C,HLA-DRA \| TCR signaling:HLA-DRA \| MHC class II antigen presentation:HLA-DRA \| Costimulation by the CD28 family:HLA-DRA \| Endosomal/Vacuolar pathway:HLA-C,HLA-B \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,HLA-B \| ER-Phagosome pathway:HLA-B,HLA-C \| Antigen processing-Cross presentation:HLA-B,HLA-C \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-B,HLA-C,MICA,NCR3 \| Interferon alpha/beta signaling:HLA-B,HLA-C \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:HSPA1A,HSPA1B \| TNFR2 non-canonical NF-kB pathway:LTA \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:LTA \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B \| Class I MHC mediated antigen processing & presentation:HLA-B,HLA-C \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Influenza Infection:HSPA1A,HSPA1B \| RNA Polymerase I Promoter Escape:ZNRD1 \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| RNA Polymerase I Transcription Termination:ZNRD1 \| RNA Polymerase I Transcription Initiation:ZNRD1 \| Neutrophil degranulation:HLA-B,HLA-C,HSPA1A,HSPA1B \| Influenza Life Cycle:HSPA1A,HSPA1B \| tRNA Aminoacylation:VARS2 \| RNA Polymerase I Promoter Clearance:ZNRD1 \| RNA Polymerase I Transcription:ZNRD1	Kawasaki disease:BAG6,HLA-B,HLA-C,PRRC2A \| lymphadenitis:BAG6,HLA-B,HLA-C,PRRC2A \| lymph node disease:BAG6,HLA-B,HLA-C,PRRC2A \| lymphatic system disease:BAG6,HLA-B,HLA-C,PRRC2A \| leprosy:LTA,MICA \| sarcoidosis:DDR1,HLA-B,HSPA1L,LTA \| hypersensitivity reaction type IV disease:DDR1,HLA-B,HSPA1L,LTA \| autoimmune disease of endocrine system:HLA-B,HLA-C \| multiple sclerosis:HLA-C,HLA-DRA,HLA-B \| endocrine system disease:HLA-B,HLA-C,HSPA1B,LTA,MICA \| autoimmune thyroiditis:HLA-B \| demyelinating disease:HLA-C,HLA-DRA,HLA-B \| Graves' disease:HLA-B,HLA-C \| thyroid gland disease:HLA-B,HLA-C \| cavernous hemangioma:HLA-B,HLA-DRA \| vascular hemostatic disease:HLA-B,HLA-DRA \| hypersensitivity reaction type I disease:HCP5,HLA-B,HLA-C,MICA \| primary bacterial infectious disease:FLOT1,HLA-B,LTA,MICA \| hepatitis:HLA-B,HLA-C,LTA,MICA,NCR3 \| hyperthyroidism:HLA-B,HLA-C \| vitiligo:DDR1,HLA-B,HLA-C \| spondylitis:HLA-B,HLA-C,MICA \| ankylosing spondylitis:HLA-B,HLA-C,MICA \| bacterial infectious disease:FLOT1,HLA-B,LTA,MICA \| aplastic anemia:HLA-B \| urticaria:HCP5,HLA-B \| spondyloarthropathy:HLA-B,HLA-C,MICA \| vasculitis:DDR1,HLA-B,MICA \| Behcet's disease:HLA-B,MICA \| hepatitis C:HLA-B,HLA-C,LTA,NCR3 \| autoimmune disease of the nervous system:HLA-DRA \| arthropathy:HLA-B,HLA-C,MICA \| hypotrichosis:HLA-B,MICA \| tropical spastic paraparesis:HLA-C \| parasitic infectious disease:HLA-B,LTA,NCR3,PRRC2A \| malaria:HLA-B,LTA,NCR3,PRRC2A \| hair disease:HLA-B,MICA \| pulmonary sarcoidosis:DDR1 \| purpura:HLA-B,LTA,MICA \| myasthenia gravis:HLA-DRA \| neuromuscular junction disease:HLA-DRA \| brucellosis:MICA \| duodenal ulcer:HSPA1A,LTA \| autoimmune hepatitis:HLA-B \| hepatitis B:HLA-C,MICA \| upper respiratory tract disease:HLA-B,HLA-C,HSPA1A \| uveitis:HSPA1L \| parasitic protozoa infectious disease:HLA-B,LTA,NCR3,PRRC2A \| urinary system disease:DDR1,HLA-B,HSPA1A \| multiple myeloma:BAG6,HLA-B,IER3,LTA,MICA,NCR3 \| myeloma:BAG6,HLA-B,IER3,LTA,MICA,NCR3 \| reproductive system disease:HSPA1A,LTA,MICA,MSH5 \| bone marrow cancer:BAG6,HLA-B,IER3,LTA,MICA,NCR3 \| uveal disease:HSPA1L \| bile duct disease:HLA-C \| complex regional pain syndrome:HLA-B \| biliary tract disease:HLA-C \| azoospermia:MSH5 \| proteinuria:DDR1 \| kidney disease:DDR1,HLA-B,HSPA1A \| alopecia:HLA-B,MICA \| autoimmune disease of gastrointestinal tract:HLA-B,MICA \| type 1 diabetes mellitus:LTA \| blood coagulation disease:HLA-B,HLA-DRA,LTA,MICA \| allergic rhinitis:HLA-B,HLA-C \| hemorrhagic disease:HLA-B,HLA-DRA,LTA,MICA \| neuromuscular disease:HLA-DRA \| thyroiditis:HLA-B \| nasal cavity disease:HLA-B,HLA-C \| nose disease:HLA-B,HLA-C \| rhinitis:HLA-B,HLA-C \| prostatitis:HSPA1A \| pancreatitis:HSPA1B,LTA \| periodontitis:HLA-B \| celiac disease:MICA \| peptic ulcer disease:HSPA1A,LTA \| hematopoietic system disease:HLA-B,HLA-DRA,LTA,MICA \| gestational diabetes:MICA \| anemia:HLA-B \| male reproductive system disease:HSPA1A,MSH5 \| male infertility:MSH5 \| integumentary system disease:HCP5,HLA-B,MICA \| periodontal disease:HLA-B \| adrenal cortex disease:MICA \| Human immunodeficiency virus infectious disease:HLA-B,HLA-C \| adrenal gland disease:MICA \| reactive arthritis:HLA-B \| alcoholic pancreatitis:HSPA1B \| interstitial lung disease:DDR1,MICA \| bronchial disease:HSPA1A,HSPA1B,LTA \| acute pancreatitis:HSPA1B,LTA \| tuberculosis:HLA-B \| autonomic nervous system disease:HLA-B \| dengue hemorrhagic fever:LTA \| prostate disease:HSPA1A \| aortic valve disease:HLA-B \| sclerosing cholangitis:HLA-C \| tooth disease:HLA-B \| dengue disease:LTA \| pancreas disease:HSPA1B,LTA \| influenza:HLA-B \| chronic leukemia:HLA-B \| Plasmodium falciparum malaria:HLA-B \| lower respiratory tract disease:DDR1,HSPA1A,HSPA1B,LTA,MICA \| Addison's disease:MICA \| ovarian disease:MSH5 \| essential hypertension:HSPA1A,HSPA1B,HSPA1L,LTA \| female reproductive system disease:LTA,MSH5 \| neuropathy:HLA-DRA \| Duchenne muscular dystrophy:HLA-B \| mouth disease:HLA-B \| adrenal cortical hypofunction:MICA \| migraine:LTA \| alopecia areata:MICA \| infertility:MICA,MSH5 \| peripheral nervous system disease:HLA-B \| age related macular degeneration:HLA-B \| degeneration of macula and posterior pole:HLA-B \| hemochromatosis:HLA-B \| cell type benign neoplasm:DDR1,MICA \| macular degeneration:HLA-B \| cholangitis:HLA-C \| pulmonary hypertension:HLA-B \| Crohn's disease:HSPA1B,LTA \| osteosarcoma:BAG6,MICA \| lung disease:DDR1,HSPA1A,HSPA1B,LTA,MICA \| spinal cord disease:HLA-C \| heart valve disease:HLA-B \| pulmonary edema:HSPA1A \| lipodystrophy:HLA-B \| inflammatory bowel disease:HSPA1B,LTA \| myopathy:HLA-B \| muscle tissue disease:HLA-B \| bone cancer:BAG6,MICA \| nasopharynx carcinoma:DDR1,HSPA1B \| pharynx cancer:DDR1,HSPA1B \| lymphoblastic leukemia:HSPA1A,HSPA1B,HSPA1L \| cardiomyopathy:HLA-B \| muscular disease:HLA-B \| endocrine organ benign neoplasm:DDR1,MICA \| metal metabolism disorder:HLA-B \| premature ovarian failure:MSH5 \| liver cirrhosis:DDR1 \| muscular dystrophy:HLA-B \| gallbladder disease:MICA \| esophageal carcinoma:HLA-B \| cholelithiasis:MICA \| skin disease:HCP5,HLA-B \| retinal disease:HLA-B,LTA \| female reproductive organ cancer:DDR1 \| connective tissue cancer:BAG6,MICA \| adenoma:DDR1,MICA \| extrinsic cardiomyopathy:HLA-B \| myocarditis:HLA-B \| pulmonary fibrosis:MICA \| coronary artery disease:LTA \| retinal degeneration:HLA-B \| integumentary system cancer:LTA \| skin cancer:LTA \| malignant ovarian surface epithelial-stromal neoplasm:DDR1 \| ovary epithelial cancer:DDR1 \| ovarian carcinoma:DDR1	antigen processing and presentation of exogenous peptide antigen:HLA-B,HLA-C,HLA-DRA \| antigen processing and presentation of exogenous antigen:HLA-B,HLA-C,HLA-DRA \| antigen processing and presentation of peptide antigen:HLA-B,HLA-C,HLA-DRA \| antigen processing and presentation:HLA-B,HLA-C,HLA-DRA \| interferon-gamma-mediated signaling pathway:HLA-B,HLA-C,HLA-DRA \| cellular response to interferon-gamma:HLA-B,HLA-C,HLA-DRA \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DRA \| response to interferon-gamma:HLA-B,HLA-C,HLA-DRA \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DRA \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DRA \| T cell receptor signaling pathway:HLA-DRA \| immune response-activating signal transduction:BAG6,FLOT1,HLA-DRA,HSPA1A,HSPA1B,NCR3 \| T cell costimulation:HLA-DRA \| immune response-activating cell surface receptor signaling pathway:BAG6,HLA-DRA,NCR3 \| lymphocyte costimulation:HLA-DRA \| antigen receptor-mediated signaling pathway:HLA-DRA \| immune response-regulating cell surface receptor signaling pathway:BAG6,HLA-DRA,NCR3 \| positive regulation of cell-cell adhesion:FLOT1,HLA-DRA \| positive regulation of leukocyte cell-cell adhesion:HLA-DRA \| positive regulation of T cell activation:HLA-DRA \| T cell activation:HLA-DRA,MICA \| regulation of cell-cell adhesion:FLOT1,HLA-DRA \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-B,HLA-C \| regulation of leukocyte cell-cell adhesion:HLA-DRA \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-B,HLA-C \| positive regulation of cell adhesion:FLOT1,HLA-DRA \| positive regulation of lymphocyte activation:HLA-DRA \| positive regulation of cell activation:HLA-DRA \| regulation of lymphocyte activation:HLA-DRA,MICA \| regulation of T cell activation:HLA-DRA \| regulation of leukocyte activation:HLA-DRA,MICA \| leukocyte cell-cell adhesion:HLA-DRA \| antigen processing and presentation of peptide antigen via MHC class I:HLA-B,HLA-C \| positive regulation of leukocyte activation:HLA-DRA \| lymphocyte mediated immunity:LTA,MICA,NCR3 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:LTA,MICA,NCR3 \| adaptive immune response:LTA,MICA,NCR3 \| humoral immune response mediated by circulating immunoglobulin:LTA \| natural killer cell mediated cytotoxicity:MICA,NCR3 \| natural killer cell mediated immunity:MICA,NCR3 \| T cell mediated cytotoxicity:MICA,NCR3 \| response to type I interferon:HLA-C,HLA-B \| type I interferon signaling pathway:HLA-B,HLA-C \| cellular response to type I interferon:HLA-B,HLA-C \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,LTA \| leukocyte mediated cytotoxicity:MICA,NCR3 \| regulation of humoral immune response:LTA \| positive regulation of defense response:FLOT1,HSPA1A,HSPA1B,LTA,NCR3 \| positive regulation of cytokine production:FLOT1,HSPA1A,HSPA1B,LTA \| T cell mediated immunity:MICA,NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:LTA,MICA,NCR3 \| positive regulation of innate immune response:FLOT1,HSPA1A,HSPA1B,NCR3 \| regulation of lymphocyte mediated immunity:LTA,MICA,NCR3 \| regulation of innate immune response:FLOT1,HSPA1A,HSPA1B,MICA,NCR3 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B,LTA \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B \| cell killing:MICA,NCR3 \| positive regulation of lymphocyte mediated immunity:LTA,NCR3 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:LTA,NCR3 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of natural killer cell mediated cytotoxicity:MICA,NCR3 \| chronic inflammatory response:LTA \| positive regulation of adaptive immune response:LTA,NCR3 \| regulation of natural killer cell mediated immunity:MICA,NCR3 \| interferon-gamma production:LTA \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| lymph node development:LTA \| immunoglobulin mediated immune response:LTA \| B cell mediated immunity:LTA \| mRNA catabolic process:HSPA1A,HSPA1B \| response to tumor necrosis factor:HSPA1A,HSPA1B,LTA \| regulation of chronic inflammatory response:LTA \| response to heat:HSPA1A,HSPA1B,HSPA1L,MICA \| regulation of humoral immune response mediated by circulating immunoglobulin:LTA \| positive regulation of nitric oxide biosynthetic process:DDAH2 \| positive regulation of nitric oxide metabolic process:DDAH2 \| regulation of leukocyte mediated immunity:LTA,MICA,NCR3 \| activation of innate immune response:FLOT1,HSPA1A,HSPA1B \| regulation of T cell mediated cytotoxicity:NCR3 \| positive regulation of leukocyte mediated immunity:LTA,NCR3 \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of inflammatory response to antigenic stimulus:LTA \| negative regulation of natural killer cell mediated cytotoxicity:MICA \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B \| microtubule nucleation:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of heterotypic cell-cell adhesion:FLOT1 \| negative regulation of natural killer cell mediated immunity:MICA \| regulation of leukocyte mediated cytotoxicity:MICA,NCR3 \| regulation of DNA-templated transcription in response to stress:HSPA1A \| negative regulation of immune effector process:MICA \| ER-associated misfolded protein catabolic process:BAG6 \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| gamma-delta T cell activation:MICA \| regulation of protein ubiquitination:HSPA1A,HSPA1B \| RNA catabolic process:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species biosynthetic process:DDAH2 \| negative regulation of growth of symbiont in host:LTA \| immune response to tumor cell:MICA,NCR3 \| response to topologically incorrect protein:BAG6,HSPA1A,HSPA1L \| positive regulation of humoral immune response:LTA \| regulation of growth of symbiont in host:LTA \| negative regulation of growth of symbiont involved in interaction with host:LTA \| negative regulation of leukocyte mediated cytotoxicity:MICA \| positive regulation of T cell mediated cytotoxicity:NCR3 \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| DNA-templated transcription, elongation:ZNRD1 \| humoral immune response:LTA \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| modulation of growth of symbiont involved in interaction with host:LTA \| innate immune response-activating signal transduction:FLOT1,HSPA1A,HSPA1B \| regulation of nitric oxide biosynthetic process:DDAH2 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:LTA,NCR3 \| regulation of translational fidelity:VARS2 \| regulation of cell killing:MICA,NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| growth of symbiont in host:LTA \| negative regulation of cell killing:MICA \| regulation of interleukin-8 production:HSPA1A,HSPA1B \| RNA phosphodiester bond hydrolysis:HSPA1A,RPP21,ZNRD1 \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| growth involved in symbiotic interaction:LTA \| growth of symbiont involved in interaction with host:LTA \| regulation of adaptive immune response:LTA,NCR3 \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L,MICA \| response to tumor cell:MICA,NCR3 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B \| regulation of protein stability:BAG6,FLOT1,HSPA1A,HSPA1B \| positive regulation of interferon-gamma production:LTA \| nitric oxide biosynthetic process:DDAH2 \| interleukin-8 production:HSPA1A,HSPA1B \| regulation of heterotypic cell-cell adhesion:FLOT1 \| positive regulation of protein complex assembly:HSPA1A,HSPA1B \| interaction with host:HSPA1A,HSPA1B \| signal transduction in absence of ligand:HSPA1A,HSPA1B \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of natural killer cell mediated immunity:NCR3 \| nitric oxide metabolic process:DDAH2 \| cellular response to misfolded protein:BAG6 \| regulation of inflammatory response to antigenic stimulus:LTA \| natural killer cell activation:BAG6,MICA,NCR3 \| reactive nitrogen species metabolic process:DDAH2 \| cellular response to topologically incorrect protein:BAG6,HSPA1A \| protein stabilization:BAG6,FLOT1,HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| response to misfolded protein:BAG6 \| mRNA cleavage:HSPA1A,ZNRD1 \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of organelle assembly:HSPA1A,HSPA1B \| regulation of transcription from RNA polymerase II promoter in response to stress:HSPA1A \| regulation of reactive oxygen species biosynthetic process:DDAH2 \| regulation of endocytosis:FLOT1 \| protein quality control for misfolded or incompletely synthesized proteins:BAG6 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| positive regulation of endocytosis:FLOT1 \| negative regulation of multi-organism process:LTA \| defense response to Gram-positive bacterium:LTA \| response to endoplasmic reticulum stress:BAG6,FLOT1,HSPA1A \| positive regulation of immune effector process:LTA,NCR3 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| transcription elongation from RNA polymerase I promoter:ZNRD1 \| termination of RNA polymerase I transcription:ZNRD1 \| pattern recognition receptor signaling pathway:FLOT1,HSPA1A,HSPA1B \| positive regulation of T cell mediated immunity:NCR3 \| spindle assembly:HSPA1A,HSPA1B \| nucleic acid phosphodiester bond hydrolysis:HSPA1A,RPP21,ZNRD1 \| transcription initiation from RNA polymerase I promoter:ZNRD1 \| positive regulation of B cell mediated immunity:LTA \| positive regulation of immunoglobulin mediated immune response:LTA \| positive regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| positive regulation of leukocyte mediated cytotoxicity:NCR3 \| reactive oxygen species biosynthetic process:DDAH2 \| negative regulation of immune system process:MICA \| positive regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| regulation of T cell mediated immunity:NCR3 \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| negative regulation of lymphocyte mediated immunity:MICA \| receptor-mediated endocytosis:FLOT1 \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| DNA-templated transcription, termination:ZNRD1 \| membrane assembly:FLOT1 \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:FLOT1,LY6G5B,LY6G5C \| regulation of interferon-gamma production:LTA \| viral life cycle:HSPA1A,HSPA1B \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| inflammatory response to antigenic stimulus:LTA \| cytolysis:MICA \| positive regulation of catabolic process:BAG6,HSPA1A \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:BAG6,HSPA1A \| negative regulation of proteolysis involved in cellular protein catabolic process:BAG6 \| positive regulation of cell killing:NCR3 \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| negative regulation of innate immune response:MICA \| mRNA cleavage involved in mRNA processing:HSPA1A \| microtubule polymerization:HSPA1A,HSPA1B \| regulation of inflammatory response:LTA \| synapsis:BAG6,MSH5 \| protein folding:HSPA1A,HSPA1B,HSPA1L \| negative regulation of leukocyte mediated immunity:MICA \| positive regulation of protein catabolic process:BAG6,HSPA1A \| positive regulation of cellular catabolic process:BAG6,HSPA1A \| regulation of B cell mediated immunity:LTA \| regulation of immunoglobulin mediated immune response:LTA \| tRNA aminoacylation for protein translation:VARS2 \| extracellular matrix organization:DDR1,FLOT1 \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| membrane biogenesis:FLOT1 \| extracellular structure organization:DDR1,FLOT1 \| heterotypic cell-cell adhesion:FLOT1 \| branching involved in mammary gland duct morphogenesis:DDR1 \| negative regulation of growth:HSPA1A,HSPA1B,LTA \| negative regulation of immune response:MICA \| tRNA aminoacylation:VARS2 \| regulation of binding:FLOT1 \| regulation of mRNA metabolic process:HSPA1A \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| syncytium formation by plasma membrane fusion:FLOT1 \| amino acid activation:VARS2 \| regulation of RNA stability:HSPA1A \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| syncytium formation:FLOT1 \| regulation of symbiosis, encompassing mutualism through parasitism:LTA \| regulation of monooxygenase activity:DDAH2 \| positive regulation of cellular component biogenesis:FLOT1,HSPA1A,HSPA1B \| regulation of cellular protein catabolic process:BAG6,HSPA1A \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| defense response to bacterium:LTA,MICA \| protein polymerization:HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| mitochondrial membrane organization:HSPA1A \| receptor metabolic process:FLOT1 \| reactive oxygen species metabolic process:DDAH2 \| regulation of receptor internalization:FLOT1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| homologous chromosome segregation:BAG6,MSH5 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:BAG6,HSPA1A \| positive regulation of cell junction assembly:FLOT1 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| negative regulation of cellular protein catabolic process:BAG6 \| negative regulation of catabolic process:BAG6 \| regulation of mRNA catabolic process:HSPA1A \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| negative regulation of cellular catabolic process:BAG6 \| cellular amino acid metabolic process:DDAH2,VARS2 \| transcription from RNA polymerase I promoter:ZNRD1 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| gland morphogenesis:DDR1 \| regulation of protein complex assembly:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| spindle organization:HSPA1A,HSPA1B \| regulation of protein catabolic process:BAG6,HSPA1A \| DNA-templated transcription, initiation:ZNRD1 \| chromosome organization involved in meiotic cell cycle:BAG6,MSH5 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| mammary gland duct morphogenesis:DDR1 \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| cellular response to oxidative stress:HSPA1A,HSPA1B \| regulation of striated muscle tissue development:FLOT1 \| positive regulation of striated muscle cell differentiation:FLOT1 \| receptor internalization:FLOT1 \| regulation of reactive oxygen species metabolic process:DDAH2 \| negative regulation of proteolysis:BAG6 \| ubiquitin-dependent ERAD pathway:BAG6 \| regulation of muscle tissue development:FLOT1 \| regulation of multi-organism process:LTA \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| negative regulation of fibroblast proliferation:LTA \| regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| mammary gland development:DDR1 \| response to unfolded protein:HSPA1A,HSPA1L \| response to oxidative stress:HSPA1A,HSPA1B \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| negative regulation of defense response:MICA \| smooth muscle cell migration:DDR1 \| negative regulation of leukocyte activation:MICA	0.112712	0.0637534	1.112271889951	0.1014	0.0641407	0.942588767099816	0.0664785	0.110138	0.262715099403079	0.467547	0.0694356	10.6697323690065	0.383654	0.0839755	5.27118132532429	0.551537	0.120082	5.28643134132665	0.0320331	0.0523654	0.266972953885215	-0.0231272	0.0666578	0.137463150344615	0.0864897	0.0854116	0.506420670210129	0.0183979	0.0353409	0.219929794642809				0.0576035	0.0609103	0.463066761463558	0.0327057	0.0352815	0.451082623905963	-0.0242379	0.0353811	0.306878320032697	0.0998682	0.0599033	1.02007257974672	0.0402362	0.033535	0.637883361275587	0.0714656	0.0388233	1.18275402370915	-0.043085	0.0574106	0.343929601393634	0.0332974	0.0203863	0.989691561128922	0.0465045	0.0255455	1.16310838038625	0.0177358	0.0335006	0.224377903010372	0.114693	0.104059	0.567811859235407	0.159428	0.144308	0.569507306278156	0.0731992	0.149323	0.204715200076335
rs28620926:40357171:A:G	known [10]	15	40357171	15q15.1	G	A	1	52	DHEAS ALL	7659	10.6525763042926	0.368063715889803	0.84151	SRP14-AS1 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); BMF (23 kb); SRP14 (26 kb); EIF2AK4 (29 kb)	1 Dehydroepiandrosterone sulphate levels // 0.719 Ewing sarcoma // 0.468 Endometrial cancer // 0.468 Endometrial endometrioid carcinoma	BMF \| C15orf57 \| CHST14 \| EIF2AK4 \| FSIP1 \| IVD \| RHOV \| RP11-521C20.2 \| RP11-521C20.4 \| RP11-532F12.5 \| SRP14 \| SRP14-AS1 \| THBS1 \| unnamed \| ZFYVE19		Herpes simplex infection:EIF2AK4 \| Phagosome:THBS1 \| Influenza A:EIF2AK4 \| Epstein-Barr virus infection:EIF2AK4 \| MicroRNAs in cancer:BMF,THBS1 \| Malaria:THBS1 \| Protein processing in endoplasmic reticulum:EIF2AK4 \| Measles:EIF2AK4	Activation of BH3-only proteins:BMF \| Intrinsic Pathway for Apoptosis:BMF	hepatitis:THBS1 \| hepatitis C:THBS1 \| urinary system disease:THBS1 \| myeloma:THBS1 \| bone marrow cancer:THBS1 \| proteinuria:THBS1 \| kidney disease:THBS1 \| collagen disease:THBS1 \| hemorrhagic disease:THBS1 \| blood coagulation disease:THBS1 \| rheumatic disease:THBS1 \| systemic scleroderma:THBS1 \| scleroderma:THBS1 \| hemorrhagic fever with renal syndrome:THBS1 \| hematopoietic system disease:THBS1 \| osteoporosis:THBS1 \| bone resorption disease:THBS1 \| cell type benign neoplasm:THBS1 \| thyroid cancer:THBS1 \| myositis:THBS1 \| myopathy:THBS1 \| muscle tissue disease:THBS1 \| muscular disease:THBS1 \| keratoacanthoma:THBS1 \| Down syndrome:THBS1 \| female reproductive organ cancer:THBS1 \| adenoma:THBS1 \| coronary artery disease:THBS1 \| integumentary system cancer:THBS1 \| skin cancer:THBS1	antigen processing and presentation:THBS1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:THBS1 \| modulation by virus of host morphology or physiology:EIF2AK4 \| modification by symbiont of host morphology or physiology:EIF2AK4 \| modulation by virus of host process:EIF2AK4 \| positive regulation of cell activation:THBS1 \| modulation by symbiont of host cellular process:EIF2AK4 \| positive regulation of leukocyte activation:THBS1 \| regulation of leukocyte activation:THBS1 \| modification of morphology or physiology of other organism involved in symbiotic interaction:EIF2AK4 \| cellular response to tumor necrosis factor:THBS1 \| chronic inflammatory response:THBS1 \| T cell activation:EIF2AK4 \| response to tumor necrosis factor:THBS1 \| modification of morphology or physiology of other organism:EIF2AK4 \| positive regulation of protein homooligomerization:BMF \| regulation of immune effector process:EIF2AK4 \| protein insertion into membrane:BMF \| adaptive immune response:EIF2AK4 \| regulation of antigen processing and presentation:THBS1 \| apoptotic cell clearance:THBS1 \| positive regulation of adaptive immune response:EIF2AK4 \| positive regulation of translation:EIF2AK4,THBS1 \| interaction with host:EIF2AK4 \| regulation of protein homooligomerization:BMF \| positive regulation of reactive oxygen species metabolic process:THBS1 \| positive regulation of cytokine production:THBS1 \| positive regulation of protein oligomerization:BMF \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:BMF \| cellular response to amino acid starvation:EIF2AK4 \| positive regulation of cellular amide metabolic process:EIF2AK4,THBS1 \| positive regulation of release of cytochrome c from mitochondria:BMF \| regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway:BMF \| positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway:BMF \| regulation of adaptive immune response:EIF2AK4 \| protein insertion into mitochondrial membrane involved in apoptotic signaling pathway:BMF \| cellular response to fibroblast growth factor stimulus:THBS1 \| response to drug:SRP14,THBS1 \| positive regulation of translational initiation:EIF2AK4 \| response to fibroblast growth factor:THBS1 \| mitochondrial outer membrane permeabilization:BMF \| phagocytosis:THBS1 \| regulation of autophagy:BMF,EIF2AK4 \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:BMF \| positive regulation of protein complex assembly:BMF \| negative regulation of autophagy:BMF \| regulation of defense response to virus:EIF2AK4 \| mitochondrial outer membrane permeabilization involved in programmed cell death:BMF \| cellular response to UV:BMF,EIF2AK4 \| positive regulation of mitochondrial membrane permeability:BMF \| mitochondrial membrane organization:BMF \| macrophage activation:THBS1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:BMF \| positive regulation of membrane permeability:BMF \| regulation of macrophage activation:THBS1 \| negative regulation of immune system process:THBS1 \| negative regulation of cellular catabolic process:BMF \| regulation of protein kinase B signaling:THBS1 \| negative regulation of hydrolase activity:THBS1 \| negative regulation of chemotaxis:THBS1 \| regulation of mononuclear cell migration:THBS1 \| negative regulation of ion transmembrane transport:THBS1 \| autophagy:BMF,EIF2AK4 \| process utilizing autophagic mechanism:BMF,EIF2AK4 \| regulation of protein processing:THBS1 \| negative regulation of catabolic process:BMF \| negative regulation of proteolysis:THBS1 \| blood vessel endothelial cell migration:THBS1 \| sprouting angiogenesis:THBS1 \| negative regulation of transmembrane transport:THBS1 \| regulation of protein complex assembly:BMF \| regulation of leukocyte chemotaxis:THBS1 \| regulation of protein maturation:THBS1 \| positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway:THBS1	-0.0161565	0.0177349	0.440809414233174	-0.0309763	0.0159558	1.2805112683689	0.013101	0.0349963	0.149880260071314	0.010103	0.0195144	0.218454285846062	0.00841677	0.0210589	0.161492814687638	0.0170733	0.0396678	0.175854633037778	0.0183892	0.0145546	0.684943262654492	0.00335202	0.0165902	0.0757677650556394	0.0492203	0.0277659	1.11514688495335	0.0694955	0.0103873	10.6525763042926	0.0579013	0.0129378	5.11753864709669	0.0847209	0.0167034	6.40507844101137	0.0226841	0.0102958	1.55943408317751	0.0146244	0.0108197	0.753277436168479	0.0440277	0.0175093	1.92376018022497	-0.00898752	0.00998466	0.434093177932342	0.0125718	0.0122073	0.518447020254251				0.00190699	0.00598495	0.124934683212051	0.00259306	0.00772765	0.132411727895387				-0.0326192	0.0294032	0.572835348810326	-0.0369117	0.0368906	0.498639439211245	-0.0281182	0.048677	0.24895735826168
rs6935999:32392757:G:A		6	32392757	6p21.32	A	G	0.983	6	OHP17 ALL	2070	10.5626791891708	0.0112314009661836		HLA-DRA (15 kb); BTNL2 (18 kb); HCG23 (31 kb); HLA-DRB9 (35 kb)	0.404 Marginal zone lymphoma // 0.347 Blood protein levels	- \| ABHD16A \| AGER \| AIF1 \| APOM \| ATF6B \| ATP6V1G2 \| B3GALT4 \| BAG6 \| BRD2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf25 \| C6orf48 \| CFB \| CLIC1 \| CSNK2B \| CUTA \| CYP21A2 \| DDAH2 \| DDR1 \| DXO \| FLOT1 \| GPANK1 \| GPSM3 \| HCG23 \| HCG27 \| HCP5 \| HLA-C \| HLA-DOA \| HLA-DOB \| HLA-DPA1 \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DQB1-AS1 \| HLA-DQB2 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB4 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB9 \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LY6G5B \| LY6G5C \| MCCD1 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| NOTCH4 \| PHF1 \| PPT2 \| PRRC2A \| PRRT1 \| PSMB9 \| RNF5 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP1 \| TAP2 \| TNF \| unnamed \| VARS \| VARS2 \| VPS52 \| XXbac-BPG154L12.4 \| XXbac-BPG181B23.7 \| XXbac-BPG254F23.6 \| ZBTB12	ABP1 \| FLOT1 \| HLA-C \| IER3 \| LIMS1 \| LINC00243 \| MDC1 \| NCR3 \| VARS2 \| ZNRD1	Type I diabetes mellitus:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Allograft rejection:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Graft-versus-host disease:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Antigen processing and presentation:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L,TAP2 \| Autoimmune thyroid disease:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Viral myocarditis:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Staphylococcus aureus infection:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Asthma:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Phagosome:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5,TAP2 \| Herpes simplex infection:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5,TAP2 \| Intestinal immune network for IgA production:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Rheumatoid arthritis:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Inflammatory bowel disease (IBD):HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Toxoplasmosis:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L \| Systemic lupus erythematosus:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Cell adhesion molecules (CAMs):HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Leishmaniasis:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Influenza A:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L \| Hematopoietic cell lineage:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Epstein-Barr virus infection:HLA-C,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Th1 and Th2 cell differentiation:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Th17 cell differentiation:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Tuberculosis:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Natural killer cell mediated cytotoxicity:HLA-C,NCR3 \| Endocytosis:HLA-C,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L \| Human cytomegalovirus infection:HLA-C,TAP2 \| Kaposi sarcoma-associated herpesvirus infection:HLA-C \| Viral carcinogenesis:HLA-C \| Spliceosome:HSPA1A,HSPA1B,HSPA1L \| Human immunodeficiency virus 1 infection:HLA-C,TAP2 \| Protein processing in endoplasmic reticulum:HSPA1A,HSPA1B,HSPA1L \| Cellular senescence:HLA-C \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:HLA-C \| Proteasome:PSMB9 \| Aminoacyl-tRNA biosynthesis:VARS2	Translocation of ZAP-70 to Immunological synapse:HLA-DRA,HLA-DRB1,HLA-DRB5 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DRA,HLA-DRB1,HLA-DRB5 \| Interferon gamma signaling:HLA-C,HLA-DRA,HLA-DRB1,HLA-DRB5 \| PD-1 signaling:HLA-DRA,HLA-DRB1,HLA-DRB5 \| Generation of second messenger molecules:HLA-DRA,HLA-DRB1,HLA-DRB5 \| Downstream TCR signaling:HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| Interferon Signaling:HLA-C,HLA-DRA,HLA-DRB1,HLA-DRB5 \| TCR signaling:HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| MHC class II antigen presentation:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Costimulation by the CD28 family:HLA-DRA,HLA-DRB1,HLA-DRB5 \| Endosomal/Vacuolar pathway:HLA-C \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,TAP2 \| ER-Phagosome pathway:HLA-C,PSMB9,TAP2 \| Antigen processing-Cross presentation:HLA-C,PSMB9,TAP2 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,NCR3 \| Interferon alpha/beta signaling:HLA-C \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:HSPA1A,HSPA1B,PSMB9 \| TNFR2 non-canonical NF-kB pathway:PSMB9 \| Butyrophilin (BTN) family interactions:BTNL2 \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| HIV Infection:PSMB9 \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B,PSMB9 \| Class I MHC mediated antigen processing & presentation:HLA-C,PSMB9,TAP2 \| Transcriptional regulation by RUNX3:PSMB9 \| Vpu mediated degradation of CD4:PSMB9 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B,PSMB9 \| SCF-beta-TrCP mediated degradation of Emi1:PSMB9 \| NIK-->noncanonical NF-kB signaling:PSMB9 \| Dectin-1 mediated noncanonical NF-kB signaling:PSMB9 \| Degradation of GLI1 by the proteasome:PSMB9 \| Degradation of GLI2 by the proteasome:PSMB9 \| GLI3 is processed to GLI3R by the proteasome:PSMB9 \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Regulation of PTEN stability and activity:PSMB9 \| Influenza Infection:HSPA1A,HSPA1B \| Defective CFTR causes cystic fibrosis:PSMB9 \| ABC-family proteins mediated transport:PSMB9 \| Activation of NF-kappaB in B cells:PSMB9 \| G2/M Transition:PSMB9 \| Mitotic G2-G2/M phases:PSMB9 \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| The role of GTSE1 in G2/M progression after G2 checkpoint:PSMB9 \| Neutrophil degranulation:HLA-C,HSPA1A,HSPA1B \| Regulation of APC/C activators between G1/S and early anaphase:PSMB9 \| ABC transporter disorders:PSMB9 \| Cyclin A:Cdk2-associated events at S phase entry:PSMB9 \| Interleukin-1 family signaling:PSMB9 \| Degradation of beta-catenin by the destruction complex:PSMB9 \| FCERI mediated NF-kB activation:PSMB9 \| Cyclin E associated events during G1/S transition :PSMB9 \| Downstream signaling events of B Cell Receptor (BCR):PSMB9 \| Influenza Life Cycle:HSPA1A,HSPA1B \| APC/C-mediated degradation of cell cycle proteins:PSMB9 \| Regulation of mitotic cell cycle:PSMB9 \| tRNA Aminoacylation:VARS2 \| Cross-presentation of soluble exogenous antigens (endosomes):PSMB9 \| Regulation of activated PAK-2p34 by proteasome mediated degradation:PSMB9 \| Regulation of ornithine decarboxylase (ODC):PSMB9 \| CDK-mediated phosphorylation and removal of Cdc6:PSMB9 \| Ubiquitin-dependent degradation of Cyclin D1:PSMB9 \| Ubiquitin-dependent degradation of Cyclin D:PSMB9 \| Autodegradation of the E3 ubiquitin ligase COP1:PSMB9 \| Regulation of Apoptosis:PSMB9 \| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A:PSMB9 \| p53-Independent DNA Damage Response:PSMB9 \| p53-Independent G1/S DNA damage checkpoint:PSMB9 \| Vif-mediated degradation of APOBEC3G:PSMB9 \| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis:PSMB9 \| C-type lectin receptors (CLRs):PSMB9 \| Degradation of AXIN:PSMB9 \| Regulation of RUNX3 expression and activity:PSMB9 \| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD:PSMB9 \| Degradation of DVL:PSMB9 \| Stabilization of p53:PSMB9 \| CLEC7A (Dectin-1) signaling:PSMB9 \| Hh mutants abrogate ligand secretion:PSMB9 \| CDT1 association with the CDC6:ORC:origin complex:PSMB9 \| SCF(Skp2)-mediated degradation of p27/p21:PSMB9 \| Regulation of expression of SLITs and ROBOs:PSMB9 \| Deadenylation-dependent mRNA decay:SKIV2L \| Chaperonin-mediated protein folding:SKIV2L \| Association of TriC/CCT with target proteins during biosynthesis:SKIV2L \| Autodegradation of Cdh1 by Cdh1:APC/C:PSMB9 \| Asymmetric localization of PCP proteins:PSMB9 \| Hedgehog ligand biogenesis:PSMB9 \| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha:PSMB9 \| p53-Dependent G1 DNA Damage Response:PSMB9 \| p53-Dependent G1/S DNA damage checkpoint:PSMB9 \| APC/C:Cdc20 mediated degradation of Securin:PSMB9 \| Hedgehog 'off' state:PSMB9	Kawasaki disease:HLA-C,HLA-DRB1,BTNL2 \| lymphadenitis:HLA-C,HLA-DRB1,BTNL2 \| lymph node disease:HLA-C,HLA-DRB1,BTNL2 \| lymphatic system disease:HLA-C,HLA-DRB1,BTNL2 \| leprosy:BTNL2,HLA-DRB1 \| sarcoidosis:BTNL2,HLA-DRB1,HSPA1L \| hypersensitivity reaction type IV disease:BTNL2,HLA-DRB1,HSPA1L \| autoimmune disease of endocrine system:HLA-C,HLA-DRB1,TAP2 \| multiple sclerosis:BTNL2,HLA-C,HLA-DRA,HLA-DRB1,HLA-DRB5 \| endocrine system disease:HLA-C,HLA-DRB1,HSPA1B,TAP2 \| autoimmune thyroiditis:HLA-DRB1 \| demyelinating disease:BTNL2,HLA-C,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Graves' disease:HLA-C,HLA-DRB1,TAP2 \| thyroid gland disease:HLA-C,HLA-DRB1,TAP2 \| intrahepatic cholestasis:HLA-DRB1 \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HLA-C,HLA-DRB1 \| primary bacterial infectious disease:BTNL2,HLA-DRB1,PSMB9,TAP2 \| hepatitis:HLA-C,HLA-DRB1,NCR3,PSMB9 \| hyperthyroidism:HLA-C,HLA-DRB1,TAP2 \| vitiligo:HLA-C \| spondylitis:HLA-C \| ankylosing spondylitis:HLA-C \| rheumatic fever:HLA-DRB1 \| bacterial infectious disease:BTNL2,HLA-DRB1,PSMB9,TAP2 \| aplastic anemia:HLA-DRB1 \| urticaria:HLA-DRB1 \| spondyloarthropathy:HLA-C \| vasculitis:HLA-DRB1 \| hypothyroidism:HLA-DRB1 \| Behcet's disease:HLA-DRB1 \| hepatitis C:HLA-C,HLA-DRB1,NCR3 \| autoimmune disease of the nervous system:HLA-DRA,HLA-DRB1 \| arthropathy:HLA-C \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,NCR3,TAP2 \| malaria:HLA-DRB1,NCR3 \| pulmonary sarcoidosis:HLA-DRB1 \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-DRB1 \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DRA \| neuromuscular junction disease:HLA-DRA \| brucellosis:TAP2,PSMB9 \| duodenal ulcer:HSPA1A \| cholestasis:HLA-DRB1 \| autoimmune hepatitis:HLA-DRB1 \| hepatitis B:HLA-C,HLA-DRB1,PSMB9 \| upper respiratory tract disease:HLA-C,HSPA1A,TAP2 \| uveitis:HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,NCR3 \| urinary system disease:HLA-DRB1,HSPA1A,LIMS1 \| multiple myeloma:NCR3 \| myeloma:NCR3 \| reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| bone marrow cancer:NCR3 \| uveal disease:HLA-DRB1,HSPA1L \| bile duct disease:HLA-C,HLA-DRB1 \| biliary tract disease:HLA-C,HLA-DRB1 \| azoospermia:HLA-DRB1,MSH5 \| proteinuria:HLA-DRB1 \| kidney disease:HLA-DRB1,HSPA1A,LIMS1 \| autoimmune disease of gastrointestinal tract:HLA-DRB1 \| blood coagulation disease:HLA-DRA,HLA-DRB1 \| allergic rhinitis:HLA-C,TAP2 \| hemorrhagic disease:HLA-DRA,HLA-DRB1 \| neuromuscular disease:HLA-DRA \| thyroiditis:HLA-DRB1 \| nasal cavity disease:HLA-C,TAP2 \| nose disease:HLA-C,TAP2 \| rhinitis:HLA-C,TAP2 \| collagen disease:HLA-DRB1,TAP2 \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:HLA-DRB1,HSPA1B \| nephritis:HLA-DRB1 \| celiac disease:HLA-DRB1 \| peptic ulcer disease:HSPA1A \| hematopoietic system disease:HLA-DRA,HLA-DRB1 \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DRB1 \| rheumatic disease:HLA-DRB1,TAP2 \| systemic scleroderma:HLA-DRB1,TAP2 \| scleroderma:HLA-DRB1,TAP2 \| male reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| male infertility:HLA-DRB1,MSH5 \| silicosis:HLA-DRB1 \| integumentary system disease:HLA-DRB1 \| sickle cell anemia:HLA-DRB1 \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2 \| Human immunodeficiency virus infectious disease:HLA-C,HLA-DRB1 \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B \| interstitial lung disease:HLA-DRB1 \| bronchial disease:HSPA1A,HSPA1B,TAP2 \| acute pancreatitis:HSPA1B \| tuberculosis:BTNL2,HLA-DRB1 \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| prostate disease:HLA-DRB1,HSPA1A \| pneumoconiosis:HLA-DRB1 \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1 \| autoimmune disease of peripheral nervous system:HLA-DRB1 \| Guillain-Barre syndrome:HLA-DRB1 \| pancreas disease:HLA-DRB1,HSPA1B \| open-angle glaucoma:HLA-DRB1,TAP2 \| influenza:HLA-DRB1 \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-DRB1 \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:HLA-DRB1,HSPA1A,HSPA1B,TAP2 \| ovarian disease:MSH5 \| gastritis:HLA-DRB1 \| dermatomyositis:HLA-DRB1 \| essential hypertension:HSPA1A,HSPA1B,HSPA1L,PSMB9 \| female reproductive system disease:MSH5 \| osteomyelitis:HLA-DRB1 \| neuropathy:HLA-DRA \| Sjogren's syndrome:PSMB9 \| migraine:HLA-DRB1 \| infertility:MSH5 \| peripheral nervous system disease:HLA-DRB1 \| autoimmune disease of urogenital tract:HLA-DRB1 \| primary biliary cirrhosis:HLA-DRB1 \| stomach disease:HLA-DRB1 \| cholangitis:HLA-C,HLA-DRB1 \| Crohn's disease:BTNL2,HSPA1B \| lung disease:HLA-DRB1,HSPA1A,HSPA1B \| spinal cord disease:HLA-C,HLA-DRB1 \| pulmonary edema:HSPA1A \| myositis:HLA-DRB1 \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B,BTNL2 \| myopathy:HLA-DRB1 \| muscle tissue disease:HLA-DRB1 \| nasopharynx carcinoma:HSPA1B \| pharynx cancer:HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| muscular disease:HLA-DRB1 \| bronchiectasis:TAP2 \| premature ovarian failure:MSH5 \| liver cirrhosis:HLA-DRB1 \| renal cell carcinoma:HLA-DRB1,TAP2 \| glaucoma:HLA-DRB1,TAP2 \| esophageal carcinoma:HLA-DRB1 \| skin disease:HLA-DRB1 \| retinal disease:HLA-DRB1,TAP2 \| female reproductive organ cancer:HLA-DRB1 \| primary open angle glaucoma:TAP2 \| severe combined immunodeficiency:HLA-DRB1 \| retinal degeneration:HLA-DRB1,TAP2 \| malignant ovarian surface epithelial-stromal neoplasm:HLA-DRB1 \| ovary epithelial cancer:HLA-DRB1 \| ovarian carcinoma:HLA-DRB1 \| combined T cell and B cell immunodeficiency:HLA-DRB1	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| antigen processing and presentation of peptide antigen:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| antigen processing and presentation:HLA-C,HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-DRA,HLA-DRB1,HLA-DRB5 \| cellular response to interferon-gamma:HLA-C,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| response to interferon-gamma:HLA-C,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DOB,HLA-DRA,HLA-DRB1,HLA-DRB5 \| T cell receptor signaling pathway:HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| immune response-activating signal transduction:HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,NCR3,PSMB9 \| T cell costimulation:HLA-DRA,HLA-DRB1,HLA-DRB5 \| immune response-activating cell surface receptor signaling pathway:HLA-DRA,HLA-DRB1,HLA-DRB5,NCR3,PSMB9 \| lymphocyte costimulation:HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen receptor-mediated signaling pathway:HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| immune response-regulating cell surface receptor signaling pathway:HLA-DRA,HLA-DRB1,HLA-DRB5,NCR3,PSMB9 \| positive regulation of cell-cell adhesion:HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of leukocyte cell-cell adhesion:HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of T cell activation:HLA-DRA,HLA-DRB1,HLA-DRB5 \| T cell activation:HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of cell-cell adhesion:HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,PSMB9,TAP2 \| regulation of leukocyte cell-cell adhesion:HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,PSMB9,TAP2 \| positive regulation of cell adhesion:HLA-DRA,HLA-DRB1,HLA-DRB5,LIMS1 \| positive regulation of lymphocyte activation:HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of cell activation:HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of lymphocyte activation:HLA-DRA,HLA-DRB1,HLA-DRB5,LST1 \| regulation of T cell activation:HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of leukocyte activation:HLA-DRA,HLA-DRB1,HLA-DRB5,LST1 \| leukocyte cell-cell adhesion:HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,PSMB9,TAP2 \| positive regulation of leukocyte activation:HLA-DRA,HLA-DRB1,HLA-DRB5 \| lymphocyte mediated immunity:NCR3 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| adaptive immune response:NCR3,TAP2 \| natural killer cell mediated cytotoxicity:NCR3 \| natural killer cell mediated immunity:NCR3 \| T cell mediated cytotoxicity:NCR3 \| response to type I interferon:HLA-C \| type I interferon signaling pathway:HLA-C \| cellular response to type I interferon:HLA-C \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,LIMS1,PSMB9 \| leukocyte mediated cytotoxicity:NCR3 \| positive regulation of defense response:HSPA1A,HSPA1B,NCR3,PSMB9 \| positive regulation of cytokine production:HSPA1A,HSPA1B \| T cell mediated immunity:NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:NCR3 \| positive regulation of innate immune response:HSPA1A,HSPA1B,NCR3,PSMB9 \| regulation of lymphocyte mediated immunity:NCR3 \| NIK/NF-kappaB signaling:LIMS1,PSMB9 \| regulation of innate immune response:HSPA1A,HSPA1B,NCR3,PSMB9 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B,LIMS1,PSMB9 \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B,PSMB9 \| cell killing:NCR3 \| positive regulation of lymphocyte mediated immunity:NCR3 \| regulation of lymphocyte proliferation:LST1 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| regulation of mononuclear cell proliferation:LST1 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of natural killer cell mediated cytotoxicity:NCR3 \| positive regulation of adaptive immune response:NCR3 \| regulation of natural killer cell mediated immunity:NCR3 \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B,PSMB9 \| regulation of leukocyte proliferation:LST1 \| mRNA catabolic process:HSPA1A,HSPA1B,PSMB9,SKIV2L \| response to tumor necrosis factor:HSPA1A,HSPA1B,LIMS1,PSMB9 \| response to heat:HSPA1A,HSPA1B,HSPA1L \| antigen processing and presentation via MHC class Ib:TAP2 \| regulation of leukocyte mediated immunity:NCR3 \| activation of innate immune response:HSPA1A,HSPA1B,PSMB9 \| regulation of T cell mediated cytotoxicity:NCR3 \| positive regulation of leukocyte mediated immunity:NCR3 \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| antigen processing and presentation of endogenous antigen:TAP2 \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B \| microtubule nucleation:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of leukocyte mediated cytotoxicity:NCR3 \| regulation of DNA-templated transcription in response to stress:HSPA1A,PSMB9 \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B,PSMB9 \| positive regulation of ubiquitin protein ligase activity:PSMB9 \| RNA catabolic process:HSPA1A,HSPA1B,PSMB9,SKIV2L \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:HSPA1A,HSPA1L \| positive regulation of T cell mediated cytotoxicity:NCR3 \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| innate immune response-activating signal transduction:HSPA1A,HSPA1B,PSMB9 \| regulation of ubiquitin protein ligase activity:PSMB9 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| lymphocyte proliferation:LST1 \| mononuclear cell proliferation:LST1 \| regulation of translational fidelity:VARS2 \| regulation of cell killing:NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B,PSMB9 \| regulation of interleukin-8 production:HSPA1A,HSPA1B \| regulation of antigen processing and presentation:HLA-DOB \| RNA phosphodiester bond hydrolysis:HSPA1A \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| regulation of adaptive immune response:NCR3 \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| leukocyte proliferation:LST1 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B \| regulation of protein stability:HSPA1A,HSPA1B \| interleukin-8 production:HSPA1A,HSPA1B \| positive regulation of protein complex assembly:HSPA1A,HSPA1B \| interaction with host:HSPA1A,HSPA1B \| positive regulation of ubiquitin-protein transferase activity:PSMB9 \| signal transduction in absence of ligand:HSPA1A,HSPA1B \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of natural killer cell mediated immunity:NCR3 \| regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB9 \| natural killer cell activation:NCR3 \| nuclear-transcribed mRNA catabolic process, exonucleolytic:SKIV2L \| cellular response to topologically incorrect protein:HSPA1A \| protein stabilization:HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| mRNA cleavage:HSPA1A \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| regulation of organelle assembly:HSPA1A,HSPA1B \| regulation of transcription from RNA polymerase II promoter in response to stress:HSPA1A,PSMB9 \| SCF-dependent proteasomal ubiquitin-dependent protein catabolic process:PSMB9 \| protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB9 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition:PSMB9 \| response to endoplasmic reticulum stress:HSPA1A \| positive regulation of immune effector process:NCR3 \| stimulatory C-type lectin receptor signaling pathway:PSMB9 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| regulation of ubiquitin-protein transferase activity:PSMB9 \| pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| innate immune response activating cell surface receptor signaling pathway:PSMB9 \| positive regulation of T cell mediated immunity:NCR3 \| positive regulation of NIK/NF-kappaB signaling:LIMS1 \| spindle assembly:HSPA1A,HSPA1B \| nucleic acid phosphodiester bond hydrolysis:HSPA1A \| exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay:SKIV2L \| nuclear-transcribed mRNA catabolic process:SKIV2L \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| positive regulation of response to endoplasmic reticulum stress:HSPA1A \| positive regulation of leukocyte mediated cytotoxicity:NCR3 \| negative regulation of immune system process:HLA-DOB,LST1 \| positive regulation of proteolysis involved in cellular protein catabolic process:HSPA1A,PSMB9 \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| post-translational protein modification:PSMB9 \| regulation of T cell mediated immunity:NCR3 \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB9 \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:LY6G5B,LY6G5C \| viral life cycle:HSPA1A,HSPA1B \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| regulation of proteolysis involved in cellular protein catabolic process:HSPA1A,PSMB9 \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| positive regulation of catabolic process:HSPA1A,PSMB9 \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:HSPA1A,PSMB9 \| positive regulation of cell killing:NCR3 \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| mRNA cleavage involved in mRNA processing:HSPA1A \| microtubule polymerization:HSPA1A,HSPA1B \| synapsis:MSH5 \| protein folding:HSPA1A,HSPA1B,HSPA1L \| positive regulation of protein catabolic process:HSPA1A,PSMB9 \| positive regulation of cellular catabolic process:HSPA1A,PSMB9 \| tRNA aminoacylation for protein translation:VARS2 \| nuclear-transcribed mRNA catabolic process, nonsense-mediated decay:SKIV2L \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| negative regulation of growth:HSPA1A,HSPA1B \| tRNA aminoacylation:VARS2 \| regulation of mRNA metabolic process:HSPA1A,PSMB9 \| regulation of NIK/NF-kappaB signaling:LIMS1 \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| amino acid activation:VARS2 \| regulation of RNA stability:HSPA1A,PSMB9 \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| regulation of cellular amino acid metabolic process:PSMB9 \| positive regulation of cellular component biogenesis:HSPA1A,HSPA1B \| regulation of cellular protein catabolic process:HSPA1A,PSMB9 \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| protein polymerization:HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| regulation of mitotic cell cycle phase transition:PSMB9 \| mitochondrial membrane organization:HSPA1A \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| protein polyubiquitination:PSMB9 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:HSPA1A \| homologous chromosome segregation:MSH5 \| positive regulation of cell junction assembly:LIMS1 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of mRNA catabolic process:HSPA1A,PSMB9 \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| cellular amino acid metabolic process:PSMB9,VARS2 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| regulation of protein complex assembly:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| spindle organization:HSPA1A,HSPA1B \| negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle:PSMB9 \| regulation of protein catabolic process:HSPA1A \| negative regulation of mitotic cell cycle:PSMB9 \| Fc-epsilon receptor signaling pathway:PSMB9 \| regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle:PSMB9 \| chromosome organization involved in meiotic cell cycle:MSH5 \| regulation of cell cycle phase transition:PSMB9 \| positive regulation of protein ubiquitination:PSMB9 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| cellular response to oxidative stress:HSPA1A,HSPA1B \| G2/M transition of mitotic cell cycle:PSMB9 \| negative regulation of ubiquitin protein ligase activity:PSMB9 \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| regulation of response to endoplasmic reticulum stress:HSPA1A \| response to unfolded protein:HSPA1A,HSPA1L \| regulation of transcription from RNA polymerase II promoter in response to hypoxia:PSMB9 \| response to oxidative stress:HSPA1A,HSPA1B \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of cellular amine metabolic process:PSMB9 \| negative regulation of leukocyte activation:LST1 \| cell cycle G2/M phase transition:PSMB9 \| anaphase-promoting complex-dependent catabolic process:PSMB9 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:SKIV2L \| regulation of G2/M transition of mitotic cell cycle:PSMB9	0.167481	0.0771903	1.5208192896142	0.23772	0.0733567	2.91301765229979	0.0653791	0.141067	0.19176673881738	0.563282	0.0841122	10.5626791891708	0.356929	0.096578	3.64211658565466	0.839311	0.154599	7.10812315592207	0.125792	0.0633717	1.32533355496927	0.0898952	0.0764243	0.620339213327307	0.167672	0.110494	0.887421807594228	-0.0233257	0.0466947	0.209432671429676	1.25542E-4	0.0562704	7.73733004635244E-4	-0.0564482	0.0786425	0.325238032961193	0.0189026	0.0458497	0.167401682927035	0.00519718	0.0470849	0.0399532589633753	0.0568096	0.0776962	0.332854430884545	0.110709	0.0450871	1.85168120990651							0.012711	0.0266883	0.197994321022477	0.00964121	0.0337582	0.110593519078557	0.0169696	0.0431381	0.158616124633181	0.267474	0.130341	1.39481243401146				0.341353	0.190293	1.13499676018113
rs139203625:95099865:C:T	novel2	11	95099865	11q21	T	C	0.92	5	PROG ALL	2070	10.4553863283378	0.0125289855072464		SESN3 (130 kb); ENDOD1 (230 kb)	NA	RP11-712B9.2		Longevity regulating pathway:SESN3	Transcriptional Regulation by TP53:SESN3 \| TP53 Regulates Metabolic Genes:SESN3		cellular response to amino acid stimulus:SESN3 \| nucleic acid phosphodiester bond hydrolysis:ENDOD1 \| cellular response to amino acid starvation:SESN3	0.524075	0.0786923	10.4553863283378	0.141194	0.0754369	1.21136787463112	0.742308	0.145465	6.475839	0.293057	0.0872632	3.09775390654048	0.16002	0.0994649	0.967014781576196	0.456934	0.162578	2.29393115767279	0.0952608	0.0652491	0.840267421387602	0.0522454	0.0784168	0.296396557991996	0.137706	0.114553	0.638797411330525	0.0936218	0.0460384	1.37679310708524	0.0748151	0.0574498	0.714836659965439	0.12056	0.0740063	0.98588706604546	0.0472864	0.0456273	0.522830975514617	0.00451133	0.0480935	0.033733865579596	0.0976601	0.0756527	0.706111747877248							0.02344	0.0697627	0.132606766934578	0.0292121	0.0264375	0.56995559781495	0.0146937	0.0344893	0.173872696214423	0.0486289	0.0409986	0.627865269592583	0.0915822	0.134144	0.305510628372599				0.372543	0.197151	1.22745020186025
rs151006058:51515455:G:GGAAT		15	51515455	15q21.2	GGAAT	G	0.939	0	E2 MEN	4191	10.391403372565	0.27145602481508	0.127017	RP11-108K3.1 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); CYP19A1 (0 kb, intron/Intron/MODIFIER \| near gene/Upstream gene/MODIFIER); MIR4713 (19 kb); TNFAIP8L3 (120 kb)	NA	CYP19A1 \| GLDN		Steroid hormone biosynthesis:CYP19A1	Cytochrome P450 - arranged by substrate type:CYP19A1 \| Metabolism of steroid hormones:CYP19A1 \| Phase I - Functionalization of compounds:CYP19A1 \| Endogenous sterols:CYP19A1 \| Metabolic disorders of biological oxidation enzymes:CYP19A1 \| Biological oxidations:CYP19A1	endocrine system disease:CYP19A1 \| male reproductive system disease:CYP19A1 \| male infertility:CYP19A1 \| hyperandrogenism:CYP19A1 \| gonadal disease:CYP19A1 \| polycystic ovary syndrome:CYP19A1 \| reproductive system disease:CYP19A1 \| prostate disease:CYP19A1 \| sex differentiation disease:CYP19A1 \| essential hypertension:CYP19A1 \| osteoporosis:CYP19A1 \| bone resorption disease:CYP19A1 \| cell type benign neoplasm:CYP19A1 \| infertility:CYP19A1 \| sporadic breast cancer:CYP19A1 \| ovarian disease:CYP19A1 \| female reproductive organ cancer:CYP19A1	chronic inflammatory response:CYP19A1 \| regulation of chronic inflammatory response:CYP19A1 \| cellular hormone metabolic process:CYP19A1 \| steroid catabolic process:CYP19A1 \| hormone biosynthetic process:CYP19A1 \| steroid metabolic process:CYP19A1 \| hormone metabolic process:CYP19A1 \| mammary gland development:CYP19A1 \| androgen metabolic process:CYP19A1 \| steroid biosynthetic process:CYP19A1 \| estrogen biosynthetic process:CYP19A1 \| ketone biosynthetic process:CYP19A1 \| negative regulation of immune system process:CYP19A1 \| negative regulation of chemotaxis:CYP19A1 \| lipid transport:CYP19A1,TNFAIP8L3 \| regulation of leukocyte chemotaxis:CYP19A1 \| lipid localization:CYP19A1,TNFAIP8L3	0.0279234	0.01926	0.83190930556334	0.0205814	0.0173535	0.627408315296699	0.031167	0.0385089	0.378495523947174	-0.0245472	0.0211935	0.607480669061026	-0.0165246	0.0228806	0.327633332305881	-0.033787	0.0430453	0.363748873713923	-0.00436202	0.0158169	0.106380807550034	0.00151957	0.0180279	0.0301937708460265	-0.0109585	0.0302031	0.144575951305462	0.0104323	0.0116902	0.429248135346616	0.00294132	0.0144243	0.0765383704056265	0.018678	0.0190244	0.486510717828923	-0.0043288	0.0114763	0.151177460022824	0.00722599	0.0120208	0.261411270854462	-0.0135709	0.0196143	0.310683147799962	0.066367	0.01119	8.52103978792981	0.0893163	0.013529	10.391403372565	0.0357922	0.0182166	1.30596282596725	0.00304695	0.00669176	0.187840296722692	0.0110662	0.00856772	0.706655126848768	-0.00743044	0.0105954	0.315942286596874	-0.00807422	0.0318327	0.097020772223342	-0.0085845	0.039722	0.0814810945836716	-0.0110446	0.0532258	0.0779610308881882
rs62059803:7451844:C:T		17	7451844	17p13.1	T	C	0.968	33	TESTO MEN	4291	10.3391165057865	0.22048862735959	0.113021	TNFSF12 (0.36 kb, near gene/Upstream gene/MODIFIER); TNFSF12-TNFSF13 (0.57 kb, near gene/Upstream gene/MODIFIER); TNFSF13 (9.8 kb); SENP3 (13 kb); SENP3-EIF4A1 (15 kb); EIF4A1 (24 kb); SNORA67 (24 kb); SNORA48 (26 kb); SNORD10 (28 kb); CD68 (31 kb); POLR2A (34 kb); MPDU1 (35 kb); SOX15 (40 kb); FXR2 (43 kb)	0.776 Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test) // 0.776 Systolic blood pressure x smoking status (current vs non-current) interaction (2df test) // 0.776 Systolic blood pressure x smoking status (ever vs never) interaction (2df test) // 0.776 Diastolic blood pressure x smoking status (ever vs never) interaction (2df test) // 0.768 Blood protein levels // 0.74 Chin dimples // 0.607 Testosterone levels // 0.607 Sex hormone-binding globulin levels // 0.492 IgA nephropathy	- \| AC113189.5 \| ACAP1 \| ASGR2 \| ATP1B2 \| C17orf61 \| C17orf61-PLSCR3 \| C17orf81 \| CD68 \| CHRNB1 \| CTDNEP1 \| CYB5D1 \| EIF4A1 \| EIF5A \| FGF11 \| FXR2 \| KCTD11 \| LOC100130387 \| LSMD1 \| MED31 \| MPDU1 \| PLSCR3 \| POLR2A \| RP11-186B7.4 \| SAT2 \| SENP3 \| SENP3-EIF4A1 \| SHBG \| SNORA48 \| SOX15 \| SPEM1 \| TMEM102 \| TMEM256-PLSCR3 \| TMEM88 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| TP53 \| ZBTB4	EIF4A1P2 \| EIF5AL1	Herpes simplex infection:POLR2A \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Epstein-Barr virus infection:POLR2A \| Endocytosis:ACAP1 \| Thyroid hormone synthesis:ASGR2,ATP1B2 \| Huntington disease:POLR2A \| Ferroptosis:SAT2 \| Lysosome:CD68 \| Aldosterone synthesis and secretion:ATP1B2 \| RNA transport:EIF4A1,FXR2	Interferon Signaling:EIF4A1 \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13 \| TP53 Regulates Transcription of DNA Repair Genes:POLR2A \| TNFR2 non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13,TNFSF13 \| MicroRNA (miRNA) biogenesis:POLR2A \| Transcriptional regulation of pluripotent stem cells:POLR2A \| Infectious disease:POLR2A \| Influenza Infection:POLR2A \| Transcriptional Regulation by TP53:POLR2A \| HIV Transcription Elongation:POLR2A \| Formation of HIV-1 elongation complex containing HIV-1 Tat:POLR2A \| Tat-mediated elongation of the HIV-1 transcript:POLR2A \| Transcription of the HIV genome:POLR2A \| Asparagine N-linked glycosylation:ASGR2,MPDU1 \| Formation of HIV elongation complex in the absence of HIV Tat:POLR2A \| ISG15 antiviral mechanism:EIF4A1 \| Antiviral mechanism by IFN-stimulated genes:EIF4A1 \| RNA Polymerase II Pre-transcription Events:POLR2A \| Formation of the Early Elongation Complex:POLR2A \| Formation of the HIV-1 Early Elongation Complex:POLR2A \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Pausing and recovery of Tat-mediated HIV elongation:POLR2A \| Tat-mediated HIV elongation arrest and recovery:POLR2A \| Formation of RNA Pol II elongation complex :POLR2A \| RNA Polymerase II Transcription Elongation:POLR2A \| HIV elongation arrest and recovery:POLR2A \| Pausing and recovery of HIV elongation:POLR2A \| Transcriptional regulation by small RNAs:POLR2A	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| lymphatic system disease:TNFSF13 \| hepatitis:EIF4A1 \| hepatitis C:EIF4A1 \| hypotrichosis:TNFSF13 \| urinary system disease:TNFSF12,TNFSF13 \| multiple myeloma:TNFSF13 \| myeloma:TNFSF13 \| bone marrow cancer:TNFSF13 \| hair disease:TNFSF13 \| proteinuria:TNFSF12 \| kidney disease:TNFSF12,TNFSF13 \| purpura:TNFSF13 \| alopecia:TNFSF13 \| collagen disease:TNFSF12,TNFSF13 \| nephritis:TNFSF12,TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| rheumatic disease:TNFSF12,TNFSF13 \| systemic scleroderma:TNFSF12,TNFSF13 \| scleroderma:TNFSF12,TNFSF13 \| integumentary system disease:TNFSF12,TNFSF13 \| hematopoietic system disease:TNFSF13 \| colon carcinoma:TNFSF13 \| intestinal cancer:SAT2,TNFSF13 \| malignant glioma:ATP1B2 \| interstitial lung disease:TNFSF12 \| myopathy:TNFSF12,TNFSF13 \| muscle tissue disease:TNFSF12,TNFSF13 \| Sjogren's syndrome:TNFSF13 \| muscular disease:TNFSF12,TNFSF13 \| alopecia areata:TNFSF13 \| non-small cell lung carcinoma:EIF5A,TNFSF13 \| colon cancer:TNFSF13 \| colorectal cancer:TNFSF13 \| large intestine cancer:TNFSF13 \| myositis:TNFSF13 \| lower respiratory tract disease:TNFSF12 \| lung adenocarcinoma:EIF5A \| cardiomyopathy:TNFSF12 \| liver cirrhosis:TNFSF13 \| lung disease:TNFSF12 \| chronic lymphocytic leukemia:TNFSF13 \| dilated cardiomyopathy:TNFSF12 \| acute myocardial infarction:TNFSF12 \| coronary artery disease:TNFSF12	positive regulation of cell activation:SOX15,TNFSF13 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF12,TNFSF13 \| positive regulation of lymphocyte activation:TNFSF13 \| positive regulation of leukocyte activation:TNFSF13 \| regulation of leukocyte activation:TNFSF13 \| regulation of lymphocyte activation:TNFSF13 \| postsynaptic membrane organization:CHRNB1 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| RNA secondary structure unwinding:EIF4A1 \| cellular response to tumor necrosis factor:TNFSF12,TNFSF13 \| response to tumor necrosis factor:TNFSF12,TNFSF13 \| ammonium ion metabolic process:SAT2 \| regulation of immune effector process:TNFSF13 \| positive regulation of cell cycle process:SOX15 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| B cell mediated immunity:TNFSF13 \| translational initiation:EIF4A1 \| positive regulation of adaptive immune response:TNFSF13 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:CHRNB1 \| nucleocytoplasmic transport:EIF5A \| nuclear transport:EIF5A \| positive regulation of DNA metabolic process:TNFSF13 \| chemical synaptic transmission, postsynaptic:CHRNB1 \| positive regulation of reactive oxygen species metabolic process:EIF5A \| stem cell proliferation:KCTD11 \| protein stabilization:ATP1B2 \| positive regulation of cell cycle:SOX15 \| regulation of lymphocyte mediated immunity:TNFSF13 \| nuclear-transcribed mRNA poly(A) tail shortening:EIF4A1 \| regulation of DNA metabolic process:TNFSF13 \| negative regulation of neurogenesis:KCTD11 \| negative regulation of translation:FXR2,POLR2A \| protein N-linked glycosylation via asparagine:ASGR2 \| DNA-templated transcription, elongation:POLR2A \| regulation of postsynaptic membrane potential:CHRNB1 \| synapse organization:CHRNB1 \| peptidyl-asparagine modification:ASGR2 \| positive regulation of cellular amide metabolic process:EIF5A \| negative regulation of cellular amide metabolic process:FXR2,POLR2A \| negative regulation of nervous system development:KCTD11 \| regulation of adaptive immune response:TNFSF13 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| receptor-mediated endocytosis:ASGR2 \| regulation of protein stability:ASGR2,ATP1B2 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| negative regulation of cell development:KCTD11 \| aging:EIF5A \| protein export from nucleus:EIF5A \| protein localization to nucleus:CTDNEP1 \| glycerolipid metabolic process:CTDNEP1 \| regulation of stem cell proliferation:KCTD11 \| mRNA catabolic process:EIF4A1,TNFSF13 \| triglyceride metabolic process:CTDNEP1 \| protein N-linked glycosylation:ASGR2 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| smoothened signaling pathway:KCTD11 \| somatic stem cell population maintenance:POLR2A \| regulation of viral process:POLR2A \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| nuclear export:EIF5A \| regulation of neural precursor cell proliferation:KCTD11 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:EIF4A1 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| acylglycerol metabolic process:CTDNEP1 \| potassium ion homeostasis:ATP1B2 \| neutral lipid metabolic process:CTDNEP1 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| regulation of symbiosis, encompassing mutualism through parasitism:POLR2A \| regulation of ion transmembrane transporter activity:ATP1B2 \| regulation of apoptotic signaling pathway:TNFSF12 \| regulation of transmembrane transporter activity:ATP1B2 \| RNA catabolic process:EIF4A1,TNFSF13 \| regulation of G0 to G1 transition:SOX15 \| regulation of membrane potential:ATP1B2,CHRNB1 \| transcription elongation from RNA polymerase II promoter:POLR2A \| regulation of striated muscle tissue development:SOX15 \| regulation of transporter activity:ATP1B2 \| G0 to G1 transition:SOX15 \| positive regulation of viral process:POLR2A \| regulation of muscle tissue development:SOX15 \| regulation of canonical Wnt signaling pathway:CTDNEP1 \| DNA-templated transcription, termination:POLR2A \| regulation of gene silencing by miRNA:POLR2A \| regulation of posttranscriptional gene silencing:POLR2A \| regulation of gene silencing by RNA:POLR2A	-0.007386	0.0208245	0.140941601017355	-0.0223279	0.0187838	0.629348150780896	0.0205864	0.0414154	0.208212540060985	0.0278097	0.0229035	0.648194033635624	0.0303443	0.0247576	0.656510660533906	0.0167001	0.0464464	0.143098392614433	0.0261282	0.0170842	0.898510693089732	0.0266547	0.0195005	0.764741808730474	0.0204599	0.0325723	0.275629087667846	-0.0133425	0.0123794	0.551102076403815				-0.01883	0.019823	0.465773301304853	0.058322	0.0122016	5.75597536304476	0.0845945	0.0128485	10.3391165057865	0.0284974	0.0206769	0.77434703783153	0.0416498	0.011853	3.35492274857356	0.0513908	0.0145557	3.3824063187831				0.0143824	0.00710271	1.36778573774994	0.0152632	0.00920028	1.01270563604268	0.0130954	0.0110797	0.6248230684519	-0.0168351	0.0344938	0.203731723275035	0.00160686	0.0432776	0.0130545826752902	-0.0452123	0.0571316	0.367539670801546
rs115448006:30669268:G:T		6	30669268	6p21.33	T	G	0.982	1	OHP17 ALL	2070	10.3049791301853	0.0100891304347826		MDC1 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Downstream gene/MODIFIER); MDC1-AS1 (1.6 kb, near gene/Upstream gene/MODIFIER); RPL7P4 (4 kb, near gene/Upstream gene/MODIFIER); NRM (10 kb); PPP1R18 (14 kb); TUBB (19 kb); FLOT1 (26 kb); DHX16 (28 kb); IER3 (42 kb); C6orf136 (48 kb); RN7SL353P (50 kb)	0.913 Plantar warts // 0.46 Response to angiotensin II receptor blocker therapy // 0.404 Blood protein levels // 0.375 Drug-induced liver injury	- \| ABCF1 \| ABHD16A \| AIF1 \| ATF6B \| ATP6V1G2 \| ATP6V1G2-DDX39B \| BAG6 \| C2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf48 \| CCHCR1 \| CLIC1 \| CSNK2B \| DDAH2 \| DDR1 \| DDX39B \| DDX39BP2 \| DXO \| FLOT1 \| GABBR1 \| GPANK1 \| HCG22 \| HCG27 \| HCG4 \| HCG4B \| HCG4P3 \| HCG4P7 \| HCG9 \| HCP5 \| HLA-A \| HLA-B \| HLA-C \| HLA-DQB1 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB6 \| HLA-E \| HLA-F \| HLA-F-AS1 \| HLA-G \| HLA-H \| HLA-J \| HLA-K \| HLA-T \| HLA-U \| HLA-V \| HLA-W \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LTB \| LY6G5B \| LY6G5C \| LY6G6E \| MICA \| MICB \| MICD \| MICE \| MICF \| MIR6891 \| MRPS18B \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| NRM \| POU5F1 \| PPP1R10 \| PPP1R11 \| PRRC2A \| RNF39 \| RPP21 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TCF19 \| TNF \| TRIM10 \| TRIM31 \| TRIM39 \| TUBB \| unnamed \| VARS2 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.12 \| XXbac-BPG299F13.17 \| Y RNA \| ZFP57 \| ZNRD1 \| ZNRD1-AS1	BTN3A2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| DXO \| HLA-DQA1 \| HLA-DRB1 \| HLA-DRB4 \| HLA-DRB5 \| HLA-V \| HSPA1L \| NHP2 \| STK19 \| TAP2 \| TMEM154	Type I diabetes mellitus:HLA-C,HLA-E \| Allograft rejection:HLA-C,HLA-E \| Graft-versus-host disease:HLA-C,HLA-E \| Antigen processing and presentation:HLA-C,HLA-E \| Autoimmune thyroid disease:HLA-C,HLA-E \| Viral myocarditis:HLA-C,HLA-E \| Phagosome:HLA-C,HLA-E,TUBB \| Herpes simplex infection:HLA-C,HLA-E \| Cell adhesion molecules (CAMs):HLA-C,HLA-E \| Epstein-Barr virus infection:HLA-C,HLA-E \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-E \| Natural killer cell mediated cytotoxicity:HLA-C,HLA-E,NCR3 \| Endocytosis:HLA-C,HLA-E \| Human cytomegalovirus infection:HLA-C,HLA-E \| Kaposi sarcoma-associated herpesvirus infection:HLA-C,HLA-E \| Viral carcinogenesis:HLA-C,HLA-E \| Human immunodeficiency virus 1 infection:HLA-C,HLA-E \| Spliceosome:DHX16 \| Cellular senescence:HLA-C,HLA-E \| Human papillomavirus infection:HLA-C,HLA-E \| Aminoacyl-tRNA biosynthesis:VARS2	Interferon gamma signaling:HLA-C,HLA-E \| Interferon Signaling:HLA-C,HLA-E \| Endosomal/Vacuolar pathway:HLA-C,HLA-E \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,HLA-E \| ER-Phagosome pathway:HLA-C,HLA-E \| Antigen processing-Cross presentation:HLA-C,HLA-E \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,HLA-E,NCR3 \| Interferon alpha/beta signaling:HLA-C,HLA-E \| TP53 Regulates Transcription of DNA Repair Genes:MDC1 \| Class I MHC mediated antigen processing & presentation:HLA-C,HLA-E \| G2/M Transition:TUBB \| Mitotic G2-G2/M phases:TUBB \| RNA Polymerase I Promoter Escape:ZNRD1 \| Transcriptional Regulation by TP53:MDC1 \| RNA Polymerase I Transcription Termination:ZNRD1 \| RNA Polymerase I Transcription Initiation:ZNRD1 \| Neutrophil degranulation:HLA-C,TUBB \| tRNA Aminoacylation:VARS2 \| RNA Polymerase I Promoter Clearance:ZNRD1 \| RNA Polymerase I Transcription:ZNRD1	Kawasaki disease:HLA-C,HLA-E,PRRC2A \| lymphadenitis:HLA-C,HLA-E,PRRC2A \| lymph node disease:HLA-C,HLA-E,PRRC2A \| lymphatic system disease:HLA-C,HLA-E,PRRC2A \| sarcoidosis:DDR1 \| hypersensitivity reaction type IV disease:DDR1 \| autoimmune disease of endocrine system:HLA-C \| multiple sclerosis:HLA-C \| endocrine system disease:HLA-C \| demyelinating disease:HLA-C \| Graves' disease:HLA-C \| thyroid gland disease:HLA-C \| intrahepatic cholestasis:HLA-E \| hypersensitivity reaction type I disease:HLA-C \| primary bacterial infectious disease:FLOT1 \| hepatitis:HLA-C,HLA-E,NCR3 \| hyperthyroidism:HLA-C \| vitiligo:DDR1,HLA-C \| spondylitis:HLA-C,HLA-E \| ankylosing spondylitis:HLA-C,HLA-E \| bacterial infectious disease:FLOT1 \| spondyloarthropathy:HLA-C,HLA-E \| vasculitis:DDR1,HLA-E \| Behcet's disease:HLA-E \| hepatitis C:HLA-C,HLA-E,NCR3 \| autoimmune disease of the nervous system:HLA-E \| arthropathy:HLA-C,HLA-E \| tropical spastic paraparesis:HLA-C \| parasitic infectious disease:NCR3,PRRC2A \| malaria:NCR3,PRRC2A \| pulmonary sarcoidosis:DDR1 \| myasthenia gravis:HLA-E \| neuromuscular junction disease:HLA-E \| cholestasis:HLA-E \| hepatitis B:HLA-C \| upper respiratory tract disease:HLA-C \| parasitic protozoa infectious disease:NCR3,PRRC2A \| urinary system disease:DDR1 \| multiple myeloma:IER3,NCR3 \| myeloma:IER3,NCR3 \| reproductive system disease:HLA-E,MSH5 \| bone marrow cancer:IER3,NCR3 \| bile duct disease:HLA-C,HLA-E \| biliary tract disease:HLA-C,HLA-E \| azoospermia:MSH5 \| proteinuria:DDR1 \| kidney disease:DDR1 \| allergic rhinitis:HLA-C \| neuromuscular disease:HLA-E \| nasal cavity disease:HLA-C \| nose disease:HLA-C \| rhinitis:HLA-C \| hematopoietic system disease:HLA-E \| anemia:HLA-E \| male reproductive system disease:MSH5 \| male infertility:MSH5 \| sickle cell anemia:HLA-E \| Human immunodeficiency virus infectious disease:HLA-C \| interstitial lung disease:DDR1 \| sclerosing cholangitis:HLA-C \| lower respiratory tract disease:DDR1 \| ovarian disease:MSH5 \| female reproductive system disease:MSH5 \| neuropathy:HLA-E \| infertility:HLA-E,MSH5 \| cell type benign neoplasm:DDR1 \| cholangitis:HLA-C \| lung disease:DDR1 \| spinal cord disease:HLA-C \| nasopharynx carcinoma:DDR1 \| pharynx cancer:DDR1 \| endocrine organ benign neoplasm:DDR1 \| premature ovarian failure:MSH5 \| liver cirrhosis:DDR1 \| esophageal carcinoma:MDC1 \| female reproductive organ cancer:DDR1 \| adenoma:DDR1 \| malignant ovarian surface epithelial-stromal neoplasm:DDR1 \| ovary epithelial cancer:DDR1 \| ovarian carcinoma:DDR1	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-E \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-E \| antigen processing and presentation of peptide antigen:HLA-C,HLA-E \| antigen processing and presentation:HLA-C,HLA-E \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-E \| cellular response to interferon-gamma:HLA-C,HLA-E \| response to interferon-gamma:HLA-C,HLA-E \| immune response-activating signal transduction:FLOT1,NCR3 \| immune response-activating cell surface receptor signaling pathway:NCR3 \| immune response-regulating cell surface receptor signaling pathway:NCR3 \| positive regulation of cell-cell adhesion:FLOT1,HLA-E \| positive regulation of leukocyte cell-cell adhesion:HLA-E \| positive regulation of T cell activation:HLA-E \| T cell activation:HLA-E \| regulation of cell-cell adhesion:FLOT1,HLA-E \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,HLA-E \| regulation of leukocyte cell-cell adhesion:HLA-E \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,HLA-E \| positive regulation of cell adhesion:FLOT1,HLA-E \| positive regulation of lymphocyte activation:HLA-E \| positive regulation of cell activation:HLA-E \| regulation of lymphocyte activation:HLA-E \| regulation of T cell activation:HLA-E \| regulation of leukocyte activation:HLA-E \| leukocyte cell-cell adhesion:HLA-E \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,HLA-E \| positive regulation of leukocyte activation:HLA-E \| lymphocyte mediated immunity:HLA-E,NCR3,TUBB \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,NCR3 \| adaptive immune response:HLA-E,NCR3 \| natural killer cell mediated cytotoxicity:HLA-E,NCR3,TUBB \| natural killer cell mediated immunity:HLA-E,NCR3,TUBB \| T cell mediated cytotoxicity:HLA-E,NCR3 \| response to type I interferon:HLA-C,HLA-E \| type I interferon signaling pathway:HLA-C,HLA-E \| cellular response to type I interferon:HLA-C,HLA-E \| leukocyte mediated cytotoxicity:HLA-E,NCR3,TUBB \| positive regulation of defense response:FLOT1,HLA-E,NCR3 \| positive regulation of cytokine production:FLOT1,HLA-E \| T cell mediated immunity:HLA-E,NCR3 \| regulation of immune effector process:HLA-E,NCR3 \| positive regulation of innate immune response:FLOT1,HLA-E,NCR3 \| positive regulation of T cell proliferation:HLA-E \| regulation of lymphocyte mediated immunity:HLA-E,NCR3 \| regulation of innate immune response:FLOT1,HLA-E,NCR3 \| regulation of T cell proliferation:HLA-E \| cell killing:HLA-E,NCR3,TUBB \| positive regulation of lymphocyte mediated immunity:HLA-E,NCR3 \| regulation of lymphocyte proliferation:HLA-E \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,NCR3 \| regulation of mononuclear cell proliferation:HLA-E \| regulation of natural killer cell mediated cytotoxicity:HLA-E,NCR3 \| positive regulation of adaptive immune response:HLA-E,NCR3 \| regulation of natural killer cell mediated immunity:HLA-E,NCR3 \| regulation of leukocyte proliferation:HLA-E \| antigen processing and presentation via MHC class Ib:HLA-E \| positive regulation of nitric oxide biosynthetic process:DDAH2 \| positive regulation of nitric oxide metabolic process:DDAH2 \| regulation of leukocyte mediated immunity:HLA-E,NCR3 \| activation of innate immune response:FLOT1 \| regulation of T cell mediated cytotoxicity:HLA-E,NCR3 \| positive regulation of leukocyte mediated immunity:HLA-E,NCR3 \| T cell proliferation:HLA-E \| antigen processing and presentation of endogenous antigen:HLA-E \| negative regulation of natural killer cell mediated cytotoxicity:HLA-E \| positive regulation of lymphocyte proliferation:HLA-E \| positive regulation of mononuclear cell proliferation:HLA-E \| positive regulation of heterotypic cell-cell adhesion:FLOT1 \| negative regulation of natural killer cell mediated immunity:HLA-E \| regulation of leukocyte mediated cytotoxicity:HLA-E,NCR3 \| negative regulation of immune effector process:HLA-E \| positive regulation of leukocyte proliferation:HLA-E \| positive regulation of reactive oxygen species biosynthetic process:DDAH2 \| immune response to tumor cell:NCR3 \| negative regulation of leukocyte mediated cytotoxicity:HLA-E \| positive regulation of T cell mediated cytotoxicity:HLA-E,NCR3 \| DNA-templated transcription, elongation:ZNRD1 \| humoral immune response:HLA-E \| innate immune response-activating signal transduction:FLOT1 \| regulation of nitric oxide biosynthetic process:DDAH2 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,NCR3 \| lymphocyte proliferation:HLA-E \| mononuclear cell proliferation:HLA-E \| regulation of immunoglobulin secretion:HLA-E \| regulation of translational fidelity:VARS2 \| regulation of cell killing:HLA-E,NCR3 \| negative regulation of cell killing:HLA-E \| RNA phosphodiester bond hydrolysis:ZNRD1 \| regulation of adaptive immune response:HLA-E,NCR3 \| response to tumor cell:NCR3 \| leukocyte proliferation:HLA-E \| regulation of protein stability:FLOT1 \| nitric oxide biosynthetic process:DDAH2 \| regulation of heterotypic cell-cell adhesion:FLOT1 \| immunoglobulin secretion:HLA-E \| positive regulation of natural killer cell mediated immunity:HLA-E,NCR3 \| nitric oxide metabolic process:DDAH2 \| natural killer cell activation:NCR3 \| reactive nitrogen species metabolic process:DDAH2 \| protein stabilization:FLOT1 \| mRNA cleavage:ZNRD1 \| positive regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of reactive oxygen species biosynthetic process:DDAH2 \| regulation of endocytosis:FLOT1 \| positive regulation of endocytosis:FLOT1 \| defense response to Gram-positive bacterium:HLA-E \| response to endoplasmic reticulum stress:FLOT1 \| positive regulation of immune effector process:HLA-E,NCR3 \| transcription elongation from RNA polymerase I promoter:ZNRD1 \| termination of RNA polymerase I transcription:ZNRD1 \| pattern recognition receptor signaling pathway:FLOT1 \| positive regulation of T cell mediated immunity:HLA-E,NCR3 \| spindle assembly:TUBB \| nucleic acid phosphodiester bond hydrolysis:ZNRD1 \| transcription initiation from RNA polymerase I promoter:ZNRD1 \| positive regulation of leukocyte mediated cytotoxicity:HLA-E,NCR3 \| reactive oxygen species biosynthetic process:DDAH2 \| CD8-positive, alpha-beta T cell activation:HLA-E \| negative regulation of immune system process:HLA-E \| regulation of T cell mediated immunity:HLA-E,NCR3 \| negative regulation of lymphocyte mediated immunity:HLA-E \| receptor-mediated endocytosis:FLOT1 \| DNA-templated transcription, termination:ZNRD1 \| membrane assembly:FLOT1 \| protein homooligomerization:FLOT1,LY6G5C \| positive regulation of cell killing:HLA-E,NCR3 \| negative regulation of innate immune response:HLA-E \| synapsis:MSH5 \| negative regulation of leukocyte mediated immunity:HLA-E \| tRNA aminoacylation for protein translation:VARS2 \| extracellular matrix organization:DDR1,FLOT1 \| membrane biogenesis:FLOT1 \| extracellular structure organization:DDR1,FLOT1 \| heterotypic cell-cell adhesion:FLOT1 \| branching involved in mammary gland duct morphogenesis:DDR1 \| negative regulation of immune response:HLA-E \| tRNA aminoacylation:VARS2 \| regulation of binding:FLOT1 \| syncytium formation by plasma membrane fusion:FLOT1 \| amino acid activation:VARS2 \| syncytium formation:FLOT1 \| regulation of monooxygenase activity:DDAH2 \| positive regulation of cellular component biogenesis:FLOT1 \| defense response to bacterium:HLA-E \| regulation of mitotic cell cycle phase transition:TUBB \| receptor metabolic process:FLOT1 \| immunoglobulin production:HLA-E \| reactive oxygen species metabolic process:DDAH2 \| regulation of immunoglobulin production:HLA-E \| regulation of receptor internalization:FLOT1 \| homologous chromosome segregation:MSH5 \| positive regulation of cell junction assembly:FLOT1 \| cellular amino acid metabolic process:DDAH2,VARS2 \| transcription from RNA polymerase I promoter:ZNRD1 \| gland morphogenesis:DDR1 \| spindle organization:TUBB \| negative regulation of mitotic cell cycle:MDC1 \| DNA-templated transcription, initiation:ZNRD1 \| chromosome organization involved in meiotic cell cycle:MSH5 \| regulation of cell cycle phase transition:TUBB \| mammary gland duct morphogenesis:DDR1 \| regulation of striated muscle tissue development:FLOT1 \| positive regulation of striated muscle cell differentiation:FLOT1 \| G2/M transition of mitotic cell cycle:TUBB \| receptor internalization:FLOT1 \| regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of muscle tissue development:FLOT1 \| mammary gland development:DDR1 \| negative regulation of defense response:HLA-E \| smooth muscle cell migration:DDR1 \| cell cycle G2/M phase transition:TUBB \| regulation of G2/M transition of mitotic cell cycle:TUBB	0.165708	0.0832895	1.3300029167111				0.0747742	0.130263	0.24722040100098	0.599756	0.0907674	10.3049791301853				0.604229	0.143358	4.54925527804747	-0.0162544	0.0684309	0.0903001211665465				-0.00705909	0.101807	0.0246876963601977	0.0239769	0.0501306	0.19897654984098							0.0434144	0.0492748	0.422185471560494																-0.00779444	0.028747	0.104420561650803							0.260045	0.135009	1.26576439977332				0.194779	0.17532	0.57355055273583
19:48370656:AAAAC:AAAACAAAC		19	48370656	19q13.33	AAAACAAAC	AAAAC	0.939	0	DHEAS ALL	7659	10.2454276933836	0.825448361404883	0.00499714	CTD-3098H1.2 (2.1 kb, near gene/Upstream gene/MODIFIER); SULT2A1 (3.1 kb, near gene/Downstream gene/MODIFIER); TPRX2P (5.9 kb); CRX (24 kb); TPRX1 (48 kb)	NA	CTD-3098H1.2		Chemical carcinogenesis:SULT2A1 \| Metabolism of xenobiotics by cytochrome P450:SULT2A1 \| Bile secretion:SULT2A1	Biological oxidations:SULT2A1 \| Phase II - Conjugation of compounds:SULT2A1	multiple myeloma:SELENOW \| myeloma:SELENOW \| bone marrow cancer:SELENOW \| polycystic ovary syndrome:SULT2A1	steroid catabolic process:SULT2A1 \| steroid metabolic process:SULT2A1 \| sulfur compound metabolic process:SULT2A1	0.0450255	0.022871	1.30870627730664	0.0292948	0.0208508	0.795177571540303	0.0651015	0.0454866	0.817111933650992	0.0964674	0.0250964	3.90389678649211	0.0444844	0.0274764	0.976011304936836	0.189642	0.0496046	3.84344782012591	8.75122E-4	0.0187907	0.0164373058197649	-0.0376135	0.0216417	1.08387992848536	0.0696285	0.0350534	1.32441135999956	0.0886646	0.0135328	10.2454276933836	0.0485256	0.0169233	2.38312660891089	0.136244	0.0216639	9.49545710089017	0.00465121	0.0133939	0.137634236512457	-0.0139592	0.0141366	0.490229098783659	0.0295759	0.0225851	0.720433429719988	-0.0415646	0.0130298	2.84683172502841	-0.0300707	0.0159595	1.22519627563361	-0.0472676	0.0208987	1.62501533016432	0.00692576	0.00778957	0.427191107947214	-0.0103434	0.0100901	0.51524901358327	0.0265236	0.0121559	1.53591602314002	-0.00106128	0.0379443	0.00979927104427717	-0.0497698	0.047781	0.526104474419033	0.0824946	0.0623168	0.730452033445715
rs140054334:31587042:C:T		6	31587042	6p21.33	T	C	0.994	12	OHP17 ALL	2070	10.146365659756	0.0173294685990338		PRRC2A (1.5 kb, near gene/Upstream gene/MODIFIER); AIF1 (2.2 kb, near gene/Downstream gene/MODIFIER); SNORA38 (3.8 kb, near gene/Upstream gene/MODIFIER); UQCRHP1 (7.9 kb); BAG6 (20 kb); NCR3 (26 kb); LST1 (30 kb); APOM (33 kb); LTB (37 kb); C6orf47 (39 kb); C6orf47-AS1 (39 kb); TNF (41 kb); GPANK1 (42 kb); LTA (45 kb); CSNK2B (46 kb)	0.489 Plantar warts // 0.489 Response to angiotensin II receptor blocker therapy // 0.438 Blood protein levels	- \| ABCF1 \| ABHD16A \| AGER \| AIF1 \| ATF6B \| ATP6V1G2 \| ATP6V1G2-DDX39B \| BAG6 \| BAT4 \| BRD2 \| C2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf25 \| C6orf48 \| CCHCR1 \| CFB \| CLIC1 \| CSNK2B \| DDAH2 \| DDR1 \| DDX39B \| DOM3Z \| DXO \| EHMT2 \| FLOT1 \| GPANK1 \| GPSM3 \| GTF2H4 \| HCG22 \| HCG23 \| HCG27 \| HCP5 \| HLA-A \| HLA-B \| HLA-C \| HLA-DOB \| HLA-DPA1 \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DQB2 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB2 \| HLA-DRB3 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB7 \| HLA-DRB8 \| HLA-E \| HLA-H \| HLA-J \| HLA-S \| HLA-T \| HLA-V \| HLA-W \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LY6G5B \| LY6G5C \| LY6G6C \| LY6G6E \| MICA \| MICB \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| PBX2 \| POU5F1 \| PPP1R10 \| PPP1R11 \| PRRC2A \| PSMB8 \| PSMB9 \| PSORS1C1 \| RDBP \| RNF5 \| RPP21 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| STK19P \| TAP2 \| TAPBP \| TCF19 \| TNF \| TNXA \| TRIM10 \| TRIM39 \| TUBB \| unnamed \| VARS \| VARS2 \| VWA7 \| XXbac-BPG154L12.4 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.12 \| XXbac-BPG299F13.17 \| ZBTB12 \| ZNRD1	BTN3A2 \| EXOC1 \| FLOT1 \| GABBR1 \| HLA-A \| HLA-DOB \| HLA-DQA1 \| HLA-DRB1 \| HLA-DRB4 \| HLA-DRB5 \| HLA-F \| HLA-H \| HLA-V \| IER3 \| NHP2 \| PARP2 \| PPP1R11 \| PSMB9 \| SSRP1 \| TAP2 \| TMEM154 \| TUBB \| ZAP70 \| ZNF672 \| ZNRD1	Type I diabetes mellitus:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA,TNF \| Allograft rejection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| Graft-versus-host disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| Antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,HSPA1A,HSPA1B,HSPA1L,TAP2,TNF \| Autoimmune thyroid disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Viral myocarditis:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Staphylococcus aureus infection:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Asthma:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Phagosome:ATP6V1G2,HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TAP2 \| Herpes simplex infection:CSNK2B,HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA,TAP2,TNF \| Intestinal immune network for IgA production:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Rheumatoid arthritis:ATP6V1G2,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,LTB,TNF \| Inflammatory bowel disease (IBD):HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Toxoplasmosis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TNF \| Systemic lupus erythematosus:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Cell adhesion molecules (CAMs):HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Leishmaniasis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Influenza A:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TNF \| Hematopoietic cell lineage:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Epstein-Barr virus infection:CSNK2B,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA,TNF \| Th1 and Th2 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Th17 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Tuberculosis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TNF \| Natural killer cell mediated cytotoxicity:HLA-C,HLA-E,NCR3,TNF \| Endocytosis:HLA-C,HLA-E,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L,TNF \| Human cytomegalovirus infection:ATF6B,HLA-C,HLA-E,TAP2,TNF \| Kaposi sarcoma-associated herpesvirus infection:HLA-C,HLA-E \| Viral carcinogenesis:ATF6B,HLA-C,HLA-E \| Spliceosome:HSPA1A,HSPA1B,HSPA1L \| Human immunodeficiency virus 1 infection:HLA-C,HLA-E,TAP2,TNF \| NF-kappa B signaling pathway:CSNK2B,LTA,LTB,TNF \| Protein processing in endoplasmic reticulum:ATF6B,HSPA1A,HSPA1B,HSPA1L,RNF5 \| Cellular senescence:HLA-C,HLA-E \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:CSNK2B,HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:ATF6B,HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:ATP6V1G2,HLA-C,HLA-E,TNF \| Pertussis:TNF \| TNF signaling pathway:ATF6B,LTA,TNF \| Aminoacyl-tRNA biosynthesis:VARS2 \| Type II diabetes mellitus:TNF \| Lysosome:NEU1 \| Cortisol synthesis and secretion:ATF6B	Translocation of ZAP-70 to Immunological synapse:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon gamma signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| PD-1 signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Generation of second messenger molecules:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Downstream TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon Signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| MHC class II antigen presentation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Costimulation by the CD28 family:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Endosomal/Vacuolar pathway:HLA-C,HLA-E \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,HLA-E,TAP2 \| ER-Phagosome pathway:HLA-C,HLA-E,TAP2 \| Antigen processing-Cross presentation:HLA-C,HLA-E,TAP2 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,HLA-E,NCR3 \| Interferon alpha/beta signaling:HLA-C,HLA-E \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:HSPA1A,HSPA1B \| TNFR2 non-canonical NF-kB pathway:LTA,LTB,TNF \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:LTA,LTB \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B \| Class I MHC mediated antigen processing & presentation:HLA-C,HLA-E,TAP2 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Regulation of PTEN stability and activity:CSNK2B \| Influenza Infection:HSPA1A,HSPA1B \| Defective CFTR causes cystic fibrosis:RNF5 \| ABC-family proteins mediated transport:ABCF1,RNF5 \| RNA Polymerase I Promoter Escape:ZNRD1 \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Transcriptional Regulation by TP53:CSNK2B \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| RNA Polymerase I Transcription Termination:ZNRD1 \| RNA Polymerase I Transcription Initiation:ZNRD1 \| Diseases associated with glycosylation precursor biosynthesis:NEU1 \| Neutrophil degranulation:CSNK2B,HLA-C,HSPA1A,HSPA1B,NEU1 \| ABC transporter disorders:RNF5 \| Influenza Life Cycle:HSPA1A,HSPA1B \| Transcriptional regulation of white adipocyte differentiation:TNF \| tRNA Aminoacylation:VARS2 \| Synthesis of PC:CSNK2B \| Mitophagy:CSNK2B \| Deadenylation-dependent mRNA decay:SKIV2L \| Chaperonin-mediated protein folding:CSNK2B,SKIV2L \| Association of TriC/CCT with target proteins during biosynthesis:SKIV2L \| RNA Polymerase I Promoter Clearance:ZNRD1 \| RNA Polymerase I Transcription:ZNRD1	Kawasaki disease:ABHD16A,BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A,TNF \| lymphadenitis:ABHD16A,BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A,TNF \| lymph node disease:ABHD16A,BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A,TNF \| lymphatic system disease:ABHD16A,BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A,TNF \| leprosy:HLA-DRB1,LTA,TNF \| sarcoidosis:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L,LTA,TNF \| hypersensitivity reaction type IV disease:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L,LTA,TNF \| autoimmune disease of endocrine system:HLA-C,HLA-DQA1,HLA-DRB1,TAP2,TNF \| multiple sclerosis:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| endocrine system disease:ABCF1,HLA-C,HLA-DQA1,HLA-DRB1,HSPA1B,LTA,TAP2,TNF \| autoimmune thyroiditis:HLA-DRB1 \| demyelinating disease:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Graves' disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2,TNF \| thyroid gland disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2,TNF \| intrahepatic cholestasis:HLA-DQA1,HLA-DRB1,HLA-E \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HLA-C,HLA-DQA1,HLA-DRB1,TNF \| primary bacterial infectious disease:FLOT1,HLA-DRB1,LTA,TAP2,TNF \| hepatitis:APOM,HLA-C,HLA-DQA1,HLA-DRB1,HLA-E,LTA,NCR3,TNF \| hyperthyroidism:HLA-C,HLA-DQA1,HLA-DRB1,TAP2,TNF \| vitiligo:DDR1,HLA-C,TNF \| spondylitis:HLA-C,HLA-E,TNF \| ankylosing spondylitis:HLA-C,HLA-E,TNF \| rheumatic fever:HLA-DQA1,HLA-DRB1,TNF \| bacterial infectious disease:FLOT1,HLA-DRB1,LTA,TAP2,TNF \| aplastic anemia:HLA-DQA1,HLA-DRB1,TNF \| urticaria:HLA-DRB1,TNF \| spondyloarthropathy:HLA-C,HLA-E,TNF \| vasculitis:DDR1,HLA-DRB1,HLA-E,TNF \| hypothyroidism:HLA-DRB1,TNF \| Behcet's disease:HLA-DRB1,HLA-E,TNF \| hepatitis C:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E,LTA,NCR3,TNF \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| arthropathy:HLA-C,HLA-E,TNF \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,LTA,NCR3,PRRC2A,TAP2,TNF \| malaria:HLA-DRB1,LTA,NCR3,PRRC2A,TNF \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:DDR1,HLA-DRB1,TNF \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-DRB1,LTA \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DQA1,HLA-DRA,HLA-E,TNF \| neuromuscular junction disease:HLA-DQA1,HLA-DRA,HLA-E,TNF \| brucellosis:TAP2,TNF \| duodenal ulcer:HSPA1A,LTA,TNF \| cholestasis:HLA-DQA1,HLA-DRB1,HLA-E \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-C,HLA-DQA1,HLA-DRB1,TNF \| upper respiratory tract disease:HLA-C,HSPA1A,TAP2,TNF \| uveitis:HLA-DQA1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,LTA,NCR3,PRRC2A,TNF \| urinary system disease:AIF1,DDR1,HLA-DQA1,HLA-DRB1,HSPA1A,TNF \| multiple myeloma:BAG6,IER3,LTA,NCR3,TNF \| myeloma:BAG6,IER3,LTA,NCR3,TNF \| reproductive system disease:HLA-DRB1,HLA-E,HSPA1A,LTA,MSH5,TNF \| bone marrow cancer:BAG6,IER3,LTA,NCR3,TNF \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L,TNF \| bile duct disease:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E \| complex regional pain syndrome:TNF \| biliary tract disease:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E \| azoospermia:HLA-DRB1,MSH5 \| proteinuria:DDR1,HLA-DRB1 \| kidney disease:AIF1,DDR1,HLA-DQA1,HLA-DRB1,HSPA1A,TNF \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DRB1,TNF \| type 1 diabetes mellitus:HLA-DQA1,LTA,TNF \| blood coagulation disease:HLA-DRA,HLA-DRB1,LTA \| allergic rhinitis:HLA-C,TAP2,TNF \| hemorrhagic disease:HLA-DRA,HLA-DRB1,LTA \| neuromuscular disease:HLA-DQA1,HLA-DRA,HLA-E,TNF \| thyroiditis:HLA-DRB1 \| nasal cavity disease:HLA-C,TAP2,TNF \| nose disease:HLA-C,TAP2,TNF \| rhinitis:HLA-C,TAP2,TNF \| collagen disease:AIF1,HLA-DRB1,TAP2,TNF \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:ABCF1,HLA-DRB1,HSPA1B,LTA,TNF \| nephritis:AIF1,HLA-DQA1,HLA-DRB1,TNF \| periodontitis:TNF \| celiac disease:HLA-DQA1,HLA-DRB1,TNF \| peptic ulcer disease:HSPA1A,LTA,TNF \| hematopoietic system disease:HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA,TNF \| gestational diabetes:TNF \| esophageal varix:TNF \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DQA1,HLA-DRB1,HLA-E,TNF \| rheumatic disease:AIF1,HLA-DRB1,TAP2,TNF \| systemic scleroderma:AIF1,HLA-DRB1,TAP2,TNF \| scleroderma:AIF1,HLA-DRB1,TAP2,TNF \| male reproductive system disease:HLA-DRB1,HSPA1A,MSH5,TNF \| male infertility:HLA-DRB1,MSH5,TNF \| silicosis:HLA-DRB1,TNF \| integumentary system disease:HLA-DQA1,HLA-DRB1,TNF \| polycystic ovary syndrome:TNF \| sickle cell anemia:HLA-DRB1,HLA-E,TNF \| periodontal disease:TNF \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2,TNF \| alpha 1-antitrypsin deficiency:TNF \| Human immunodeficiency virus infectious disease:HLA-C,HLA-DRB1,TNF \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B,TNF \| interstitial lung disease:DDR1,HLA-DRB1,TNF \| bronchial disease:HSPA1A,HSPA1B,LTA,TAP2,TNF \| acute pancreatitis:HSPA1B,LTA \| acne:TNF \| sebaceous gland disease:TNF \| tuberculosis:HLA-DRB1,TNF \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| dengue hemorrhagic fever:LTA,TNF \| autonomic nervous system disease:TNF \| prostate disease:HLA-DRB1,HSPA1A \| pneumoconiosis:HLA-DRB1,TNF \| aortic valve disease:TNF \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1,TNF \| tooth disease:TNF \| dengue disease:LTA,TNF \| autoimmune disease of peripheral nervous system:HLA-DRB1,TNF \| Guillain-Barre syndrome:HLA-DRB1,TNF \| pancreas disease:ABCF1,HLA-DRB1,HSPA1B,LTA,TNF \| open-angle glaucoma:HLA-DRB1,TAP2,TNF \| varicose veins:TNF \| influenza:HLA-DRB1,TNF \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-DQA1,HLA-DRB1,TNF \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B,LTA,TAP2,TNF \| ovarian disease:MSH5 \| neutropenia:TNF \| agranulocytosis:TNF \| gastritis:HLA-DRB1,TNF \| dermatomyositis:HLA-DRB1,TNF \| essential hypertension:HSPA1A,HSPA1B,HSPA1L,LTA \| female reproductive system disease:LTA,MSH5,TNF \| osteomyelitis:HLA-DRB1 \| neuropathy:HLA-DQA1,HLA-DRA,HLA-E,TNF \| plasma protein metabolism disease:TNF \| mouth disease:TNF \| osteoporosis:TNF \| Sjogren's syndrome:TNF \| bone resorption disease:TNF \| migraine:HLA-DRB1,LTA,TNF \| infertility:HLA-E,MSH5,TNF \| peripheral nervous system disease:HLA-DRB1,TNF \| age related macular degeneration:TNF \| degeneration of macula and posterior pole:TNF \| autoimmune disease of urogenital tract:HLA-DRB1,TNF \| primary biliary cirrhosis:HLA-DRB1,TNF \| cell type benign neoplasm:DDR1,TNF \| macular degeneration:TNF \| stomach disease:HLA-DRB1,TNF \| cholangitis:HLA-C,HLA-DRB1 \| pulmonary hypertension:TNF \| Crohn's disease:HSPA1B,LTA \| osteosarcoma:BAG6,TNF \| lung disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B,LTA,TNF \| spinal cord disease:HLA-C,HLA-DRB1 \| heart valve disease:TNF \| gallbladder carcinoma:TNF \| pulmonary edema:HSPA1A \| aortic valve stenosis:TNF \| gallbladder cancer:TNF \| myositis:HLA-DRB1,TNF \| lipodystrophy:TNF \| leukopenia:TNF \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B,LTA \| myopathy:HLA-DRB1,TNF \| muscle tissue disease:HLA-DRB1,TNF \| bone cancer:BAG6,TNF \| nasopharynx carcinoma:DDR1,HSPA1B \| axonal neuropathy:TNF \| pharynx cancer:DDR1,HSPA1B \| lymphoblastic leukemia:CSNK2B,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TNF \| cardiomyopathy:TNF \| muscular disease:HLA-DRB1,TNF \| endocrine organ benign neoplasm:DDR1 \| bronchiectasis:TAP2 \| premature ovarian failure:MSH5 \| liver cirrhosis:APOM,DDR1,HLA-DRB1,TNF \| renal cell carcinoma:HLA-DRB1,TAP2 \| muscular dystrophy:TNF \| glaucoma:HLA-DRB1,TAP2,TNF \| esophageal carcinoma:HLA-DRB1 \| skin disease:HLA-DRB1,TNF \| retinal disease:HLA-DRB1,LTA,TAP2,TNF \| female reproductive organ cancer:DDR1,HLA-DQA1,HLA-DRB1,TNF \| vein disease:TNF \| connective tissue cancer:BAG6,TNF \| adenoma:DDR1 \| primary open angle glaucoma:TAP2,TNF \| severe combined immunodeficiency:HLA-DRB1,TNF \| coronary artery disease:LTA,TNF \| retinal degeneration:HLA-DRB1,TAP2,TNF \| integumentary system cancer:LTA \| skin cancer:LTA \| malignant ovarian surface epithelial-stromal neoplasm:DDR1,HLA-DQA1,HLA-DRB1,TNF \| ovary epithelial cancer:DDR1,HLA-DQA1,HLA-DRB1,TNF \| ovarian carcinoma:DDR1,HLA-DQA1,HLA-DRB1,TNF \| combined T cell and B cell immunodeficiency:HLA-DRB1,TNF	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TAP2 \| antigen processing and presentation of peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TAP2 \| antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| cellular response to interferon-gamma:AIF1,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| response to interferon-gamma:AIF1,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell receptor signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating signal transduction:BAG6,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,NCR3 \| T cell costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| lymphocyte costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen receptor-mediated signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-regulating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| positive regulation of cell-cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| positive regulation of leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| positive regulation of T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| regulation of cell-cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,HLA-E,TAP2 \| regulation of leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,HLA-E,TAP2 \| positive regulation of cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| positive regulation of lymphocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| positive regulation of cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| regulation of lymphocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LST1 \| regulation of T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| regulation of leukocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LST1 \| leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,TNF \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,HLA-E,TAP2 \| positive regulation of leukocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| lymphocyte mediated immunity:HLA-E,LTA,NCR3,TNF \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,LTA,NCR3,TNF \| adaptive immune response:HLA-E,LTA,NCR3,TAP2,TNF \| humoral immune response mediated by circulating immunoglobulin:LTA,TNF \| natural killer cell mediated cytotoxicity:HLA-E,NCR3 \| natural killer cell mediated immunity:HLA-E,NCR3 \| T cell mediated cytotoxicity:HLA-E,NCR3 \| response to type I interferon:HLA-C,HLA-E \| type I interferon signaling pathway:HLA-C,HLA-E \| cellular response to type I interferon:HLA-C,HLA-E \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,LTA,LTB,TNF \| leukocyte mediated cytotoxicity:HLA-E,NCR3 \| regulation of humoral immune response:LTA,TNF \| positive regulation of defense response:FLOT1,HLA-E,HSPA1A,HSPA1B,LTA,NCR3,TNF \| positive regulation of cytokine production:FLOT1,HLA-E,HSPA1A,HSPA1B,LTA,LTB,TNF \| T cell mediated immunity:HLA-E,NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:HLA-E,LTA,NCR3,TNF \| positive regulation of innate immune response:FLOT1,HLA-E,HSPA1A,HSPA1B,NCR3 \| positive regulation of T cell proliferation:AIF1,HLA-E \| regulation of lymphocyte mediated immunity:HLA-E,LTA,NCR3,TNF \| NIK/NF-kappaB signaling:TNF \| regulation of innate immune response:FLOT1,HLA-E,HSPA1A,HSPA1B,NCR3 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B,LTA,LTB,TNF \| regulation of T cell proliferation:AIF1,HLA-E \| cell killing:HLA-E,NCR3 \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B \| positive regulation of lymphocyte mediated immunity:HLA-E,LTA,NCR3,TNF \| regulation of lymphocyte proliferation:AIF1,HLA-E,LST1 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,LTA,NCR3,TNF \| regulation of mononuclear cell proliferation:AIF1,HLA-E,LST1 \| regulation of natural killer cell mediated cytotoxicity:HLA-E,NCR3 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B,TNF \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B,TNF \| chronic inflammatory response:LTA,TNF \| positive regulation of adaptive immune response:HLA-E,LTA,NCR3,TNF \| regulation of natural killer cell mediated immunity:HLA-E,NCR3 \| interferon-gamma production:LTA,TNF \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| lymph node development:LTA,LTB \| immunoglobulin mediated immune response:LTA,TNF \| regulation of leukocyte proliferation:AIF1,HLA-E,LST1 \| B cell mediated immunity:LTA,TNF \| mRNA catabolic process:HSPA1A,HSPA1B,SKIV2L \| response to tumor necrosis factor:HSPA1A,HSPA1B,LTA,LTB,TNF \| regulation of chronic inflammatory response:LTA,TNF \| response to heat:HSPA1A,HSPA1B,HSPA1L \| antigen processing and presentation via MHC class Ib:HLA-E,TAP2 \| regulation of humoral immune response mediated by circulating immunoglobulin:LTA,TNF \| positive regulation of nitric oxide biosynthetic process:AIF1,DDAH2,TNF \| positive regulation of nitric oxide metabolic process:AIF1,DDAH2,TNF \| regulation of leukocyte mediated immunity:HLA-E,LTA,NCR3,TNF \| activation of innate immune response:FLOT1,HSPA1A,HSPA1B \| regulation of T cell mediated cytotoxicity:HLA-E,NCR3 \| positive regulation of leukocyte mediated immunity:HLA-E,LTA,NCR3,TNF \| T cell proliferation:AIF1,HLA-E \| antigen processing and presentation of endogenous antigen:HLA-E,TAP2 \| negative regulation of natural killer cell mediated cytotoxicity:HLA-E \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of inflammatory response to antigenic stimulus:LTA,TNF \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B,TNF \| microtubule nucleation:HSPA1A,HSPA1B \| positive regulation of phagocytosis:TNF \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B,TNF \| positive regulation of lymphocyte proliferation:AIF1,HLA-E \| positive regulation of mononuclear cell proliferation:AIF1,HLA-E \| positive regulation of heterotypic cell-cell adhesion:FLOT1,TNF \| negative regulation of natural killer cell mediated immunity:HLA-E \| regulation of leukocyte mediated cytotoxicity:HLA-E,NCR3 \| regulation of DNA-templated transcription in response to stress:ATF6B,HSPA1A \| negative regulation of immune effector process:HLA-E,TNF \| ER-associated misfolded protein catabolic process:BAG6,RNF5 \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B \| RNA catabolic process:HSPA1A,HSPA1B,SKIV2L \| positive regulation of leukocyte proliferation:AIF1,HLA-E \| positive regulation of reactive oxygen species biosynthetic process:AIF1,DDAH2,TNF \| negative regulation of growth of symbiont in host:LTA,TNF \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,HSPA1L,RNF5 \| negative regulation of leukocyte mediated cytotoxicity:HLA-E \| positive regulation of T cell mediated cytotoxicity:HLA-E,NCR3 \| positive regulation of humoral immune response:LTA,TNF \| regulation of growth of symbiont in host:LTA,TNF \| negative regulation of growth of symbiont involved in interaction with host:LTA,TNF \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,TNF \| DNA-templated transcription, elongation:ZNRD1 \| humoral immune response:HLA-E,LTA,TNF \| regulation of acute inflammatory response:TNF \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| modulation of growth of symbiont involved in interaction with host:LTA,TNF \| innate immune response-activating signal transduction:FLOT1,HSPA1A,HSPA1B \| regulation of nitric oxide biosynthetic process:AIF1,DDAH2,TNF \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,LTA,NCR3,TNF \| lymphocyte proliferation:AIF1,HLA-E,LST1 \| negative regulation of phosphoprotein phosphatase activity:TNF \| mononuclear cell proliferation:AIF1,HLA-E,LST1 \| regulation of immunoglobulin secretion:HLA-E,TNF \| regulation of translational fidelity:VARS2 \| positive regulation of interleukin-12 production:LTB \| positive regulation of translational initiation:TNF \| regulation of cell killing:HLA-E,NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| negative regulation of cell killing:HLA-E \| growth of symbiont in host:LTA,TNF \| regulation of interleukin-8 production:HSPA1A,HSPA1B,TNF \| regulation of antigen processing and presentation:HLA-DOB \| RNA phosphodiester bond hydrolysis:HSPA1A,RPP21,ZNRD1 \| steroid metabolic process:TNF \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| growth involved in symbiotic interaction:LTA,TNF \| growth of symbiont involved in interaction with host:LTA,TNF \| regulation of adaptive immune response:HLA-E,LTA,NCR3,TNF \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| leukocyte proliferation:AIF1,HLA-E,LST1 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B,TNF \| regulation of protein stability:BAG6,FLOT1,HSPA1A,HSPA1B,RNF5 \| positive regulation of interferon-gamma production:LTA,TNF \| positive regulation of translation:TNF \| nitric oxide biosynthetic process:AIF1,DDAH2,TNF \| interleukin-8 production:HSPA1A,HSPA1B,TNF \| regulation of heterotypic cell-cell adhesion:FLOT1,TNF \| immunoglobulin secretion:HLA-E,TNF \| positive regulation of protein complex assembly:HSPA1A,HSPA1B,TNF \| interaction with host:HSPA1A,HSPA1B \| signal transduction in absence of ligand:HSPA1A,HSPA1B,TNF \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B,TNF \| nucleocytoplasmic transport:TNF \| positive regulation of natural killer cell mediated immunity:HLA-E,NCR3 \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| podosome assembly:TNF \| nitric oxide metabolic process:AIF1,DDAH2,TNF \| nuclear transport:TNF \| cellular response to misfolded protein:BAG6,RNF5 \| regulation of inflammatory response to antigenic stimulus:LTA,TNF \| positive regulation of vascular smooth muscle cell proliferation:TNF \| regulation of phagocytosis:TNF \| natural killer cell activation:BAG6,NCR3 \| reactive nitrogen species metabolic process:AIF1,DDAH2,TNF \| nuclear-transcribed mRNA catabolic process, exonucleolytic:SKIV2L \| positive regulation of mononuclear cell migration:AIF1,TNF \| cellular response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,RNF5 \| protein stabilization:BAG6,FLOT1,HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| positive regulation of smooth muscle cell proliferation:AIF1,TNF \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| response to misfolded protein:BAG6,RNF5 \| mRNA cleavage:HSPA1A,ZNRD1 \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:AIF1,DDAH2,TNF \| regulation of organelle assembly:HSPA1A,HSPA1B,RNF5,TNF \| regulation of transcription from RNA polymerase II promoter in response to stress:ATF6B,HSPA1A \| regulation of reactive oxygen species biosynthetic process:AIF1,DDAH2,TNF \| protein ubiquitination involved in ubiquitin-dependent protein catabolic process:RNF5 \| regulation of endocytosis:FLOT1,TNF \| protein K63-linked ubiquitination:RNF5 \| protein quality control for misfolded or incompletely synthesized proteins:BAG6,RNF5 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| positive regulation of endocytosis:FLOT1,TNF \| negative regulation of multi-organism process:LTA,TNF \| regulation of activin receptor signaling pathway:CSNK2B \| negative regulation of protein dephosphorylation:TNF \| defense response to Gram-positive bacterium:HLA-E,LTA,TNF \| response to endoplasmic reticulum stress:ATF6B,BAG6,FLOT1,HSPA1A,RNF5 \| positive regulation of immune effector process:HLA-E,LTA,NCR3,TNF \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| transcription elongation from RNA polymerase I promoter:ZNRD1 \| termination of RNA polymerase I transcription:ZNRD1 \| pattern recognition receptor signaling pathway:FLOT1,HSPA1A,HSPA1B \| response to isoquinoline alkaloid:AIF1 \| response to morphine:AIF1 \| positive regulation of T cell mediated immunity:HLA-E,NCR3 \| positive regulation of NIK/NF-kappaB signaling:TNF \| spindle assembly:HSPA1A,HSPA1B \| ganglioside metabolic process:NEU1 \| positive regulation of cellular amide metabolic process:TNF \| regulation of interleukin-12 production:LTB \| nucleic acid phosphodiester bond hydrolysis:HSPA1A,RPP21,ZNRD1 \| exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay:SKIV2L \| transcription initiation from RNA polymerase I promoter:ZNRD1 \| nuclear-transcribed mRNA catabolic process:SKIV2L \| positive regulation of B cell mediated immunity:LTA,TNF \| positive regulation of immunoglobulin mediated immune response:LTA,TNF \| interleukin-12 production:LTB \| positive regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| positive regulation of leukocyte mediated cytotoxicity:HLA-E,NCR3 \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| reactive oxygen species biosynthetic process:AIF1,DDAH2,TNF \| CD8-positive, alpha-beta T cell activation:HLA-E \| negative regulation of immune system process:HLA-DOB,HLA-E,LST1,TNF \| positive regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| positive regulation of NF-kappaB import into nucleus:TNF \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B,TNF \| macroautophagy:ATP6V1G2,CSNK2B,RNF5 \| regulation of T cell mediated immunity:HLA-E,NCR3 \| negative regulation of lymphocyte mediated immunity:HLA-E \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| receptor-mediated endocytosis:FLOT1 \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| DNA-templated transcription, termination:ZNRD1 \| regulation of vascular smooth muscle cell proliferation:TNF \| vascular smooth muscle cell proliferation:TNF \| regulation of macroautophagy:ATP6V1G2,RNF5 \| membrane assembly:FLOT1 \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:FLOT1,LY6G5C \| regulation of interferon-gamma production:LTA,TNF \| viral life cycle:HSPA1A,HSPA1B,TNF \| regulation of osteoblast differentiation:TNF \| negative regulation of osteoblast differentiation:TNF \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress:ATF6B \| vitamin D biosynthetic process:TNF \| protein localization to nucleus:TNF \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| steroid biosynthetic process:TNF \| regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| regulation of mononuclear cell migration:AIF1,TNF \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| inflammatory response to antigenic stimulus:LTA,TNF \| positive regulation of catabolic process:BAG6,HSPA1A,TNF \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:BAG6,HSPA1A \| microglial cell activation:AIF1 \| negative regulation of proteolysis involved in cellular protein catabolic process:BAG6 \| response to salt stress:TNF \| positive regulation of cell killing:HLA-E,NCR3 \| endothelial cell development:TNF \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B,TNF \| negative regulation of innate immune response:HLA-E \| phagocytosis:AIF1,TNF \| mRNA cleavage involved in mRNA processing:HSPA1A \| regulation of heat generation:TNF \| regulation of autophagy:ATP6V1G2,RNF5 \| response to ammonium ion:AIF1 \| microtubule polymerization:HSPA1A,HSPA1B \| regulation of inflammatory response:LTA,TNF \| synapsis:BAG6,MSH5 \| macrophage activation:AIF1 \| protein folding:CSNK2B,HSPA1A,HSPA1B,HSPA1L \| negative regulation of leukocyte mediated immunity:HLA-E \| positive regulation of protein catabolic process:BAG6,HSPA1A,TNF \| positive regulation of cellular catabolic process:BAG6,HSPA1A,TNF \| acute inflammatory response:TNF \| regulation of B cell mediated immunity:LTA,TNF \| regulation of immunoglobulin mediated immune response:LTA,TNF \| tRNA aminoacylation for protein translation:VARS2 \| regulation of transcription factor import into nucleus:TNF \| nuclear-transcribed mRNA catabolic process, nonsense-mediated decay:SKIV2L \| extracellular matrix organization:DDR1,FLOT1,TNF \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| regulation of smooth muscle cell proliferation:AIF1,TNF \| membrane biogenesis:FLOT1 \| lipoprotein metabolic process:APOM \| extracellular structure organization:DDR1,FLOT1,TNF \| heterotypic cell-cell adhesion:FLOT1,TNF \| branching involved in mammary gland duct morphogenesis:DDR1 \| negative regulation of growth:HSPA1A,HSPA1B,LTA,TNF \| negative regulation of immune response:HLA-E,TNF \| transcription factor import into nucleus:TNF \| regulation of lipid catabolic process:TNF \| tRNA aminoacylation:VARS2 \| regulation of binding:CSNK2B,FLOT1 \| regulation of mRNA metabolic process:HSPA1A \| regulation of NIK/NF-kappaB signaling:TNF \| smooth muscle cell proliferation:AIF1,TNF \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| syncytium formation by plasma membrane fusion:FLOT1 \| amino acid activation:VARS2 \| regulation of RNA stability:HSPA1A \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| cellular response to amino acid stimulus:TNF \| syncytium formation:FLOT1 \| lipopolysaccharide-mediated signaling pathway:TNF \| fat-soluble vitamin biosynthetic process:TNF \| regulation of symbiosis, encompassing mutualism through parasitism:LTA,TNF \| regulation of monooxygenase activity:DDAH2,TNF \| positive regulation of cellular component biogenesis:FLOT1,HSPA1A,HSPA1B,TNF \| regulation of cellular protein catabolic process:BAG6,HSPA1A \| defense response to bacterium:HLA-E,LTA,TNF \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,TNF \| glial cell activation:AIF1 \| protein polymerization:AIF1,HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| regulation of mitotic cell cycle phase transition:AIF1 \| mitochondrial membrane organization:HSPA1A \| receptor metabolic process:FLOT1,TNF \| immunoglobulin production:HLA-E,TNF \| reactive oxygen species metabolic process:AIF1,DDAH2,TNF \| regulation of immunoglobulin production:HLA-E,TNF \| viral genome replication:TNF \| regulation of receptor internalization:FLOT1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| protein polyubiquitination:RNF5 \| cellular response to ammonium ion:AIF1 \| homologous chromosome segregation:BAG6,MSH5 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:BAG6,HSPA1A \| positive regulation of cell junction assembly:FLOT1 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| positive regulation of cytokine biosynthetic process:LTB,TNF \| negative regulation of cellular protein catabolic process:BAG6 \| negative regulation of catabolic process:BAG6,RNF5,TNF \| activin receptor signaling pathway:CSNK2B \| regulation of mRNA catabolic process:HSPA1A \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| negative regulation of cellular catabolic process:BAG6,RNF5 \| negative regulation of autophagy:RNF5 \| cellular amino acid metabolic process:DDAH2,VARS2 \| transcription from RNA polymerase I promoter:ZNRD1 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,TNF \| endothelium development:CSNK2B,TNF \| gland morphogenesis:DDR1,TNF \| regulation of phosphoprotein phosphatase activity:TNF \| regulation of protein complex assembly:HSPA1A,HSPA1B,TNF \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B,TNF \| spindle organization:HSPA1A,HSPA1B \| superoxide metabolic process:TNF \| negative regulation of phosphatase activity:TNF \| negative regulation of ossification:TNF \| ruffle assembly:AIF1 \| regulation of protein catabolic process:BAG6,HSPA1A,TNF \| negative regulation of mitotic cell cycle:TNF \| DNA-templated transcription, initiation:ZNRD1 \| negative regulation of hydrolase activity:TNF \| chromosome organization involved in meiotic cell cycle:BAG6,MSH5 \| negative regulation of chemotaxis:AIF1 \| regulation of cell cycle phase transition:AIF1 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B,TNF \| mammary gland duct morphogenesis:DDR1 \| phosphatidylcholine biosynthetic process:CSNK2B \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| autophagy:ATP6V1G2,CSNK2B,RNF5 \| process utilizing autophagic mechanism:ATP6V1G2,CSNK2B,RNF5 \| cellular response to oxidative stress:AIF1,HSPA1A,HSPA1B,TNF \| regulation of striated muscle tissue development:FLOT1 \| positive regulation of striated muscle cell differentiation:FLOT1 \| regulation of autophagosome assembly:RNF5 \| protein complex localization:TNF \| receptor internalization:FLOT1 \| regulation of translational initiation:TNF \| regulation of reactive oxygen species metabolic process:AIF1,DDAH2,TNF \| negative regulation of proteolysis:BAG6 \| ubiquitin-dependent ERAD pathway:BAG6,RNF5 \| regulation of muscle tissue development:FLOT1 \| regulation of multi-organism process:LTA,TNF \| heat generation:TNF \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B,TNF \| negative regulation of fibroblast proliferation:LTA \| regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| regulation of leukocyte chemotaxis:AIF1 \| mammary gland development:DDR1 \| response to unfolded protein:ATF6B,HSPA1A,HSPA1L \| response to oxidative stress:AIF1,HSPA1A,HSPA1B,TNF \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| negative regulation of defense response:HLA-E \| translational initiation:TNF \| regulation of viral process:TNF \| smooth muscle cell migration:AIF1,DDR1 \| negative regulation of viral life cycle:TNF \| negative regulation of leukocyte activation:LST1 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:SKIV2L	0.0598644	0.0644155	0.452449266223721	0.145387	0.0628917	1.67894244439683	-0.034508	0.114428	0.117486276852324	0.45969	0.0701585	10.146365659756	0.387194	0.0823902	5.5415691510601	0.554731	0.125445	4.94649899761358	0.0341325	0.0528797	0.285090450257135	-0.00233355	0.0654311	0.0125326088363142	0.0835055	0.0891414	0.45693447084231	0.0200528	0.0350857	0.245930834077431	-0.0266351	0.0427587	0.272996657709381	0.0819382	0.0581122	0.799861146142619	0.062222	0.0351845	1.11358824463988	-0.0302932	0.0359894	0.398002985937876	0.159076	0.059167	2.14415388372977	0.0364236	0.0332588	0.563125248709676	0.0778596	0.0396159	1.30651488151622	-0.034004	0.0547931	0.271752572265911	0.00845536	0.0203044	0.169350393233187	0.0206717	0.0259517	0.370880027104683	-0.00761927	0.0323486	0.0894860501357787	0.163462	0.105727	0.912772447794025	0.171745	0.141651	0.646735988682376	0.157198	0.158134	0.494123186977176
rs1802127:31729925:C:T		6	31729925	6p21.33	T	C	0.994	0	OHP17 ALL	2070	9.95368046193252	0.0167768115942029		MSH5 (0 kb, exon/Missense/MODERATE \| 3'utr/3 prime UTR/MODIFIER \| exon/Coding sequence/MODIFIER \| nc-exon/Non coding transcript exon/MODIFIER \| intron/NMD transcript/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Downstream gene/MODIFIER); MSH5-SAPCD1 (0 kb, exon/Missense/MODERATE \| 3'utr/3 prime UTR/MODIFIER \| exon/Coding sequence/MODIFIER \| nc-exon/Non coding transcript exon/MODIFIER \| intron/NMD transcript/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); SAPCD1 (0.65 kb, near gene/Upstream gene/MODIFIER); SAPCD1-AS1 (2.2 kb, near gene/Downstream gene/MODIFIER); VWA7 (3.4 kb, near gene/Downstream gene/MODIFIER); RNU6-850P (5.1 kb); VARS (15 kb); CLIC1 (22 kb); DDAH2 (32 kb); LSM2 (35 kb); C6orf25 (35 kb); LY6G6C (40 kb); LY6G6F (44 kb); LY6G6D (44 kb); HSPA1L (47 kb); LY6G6E (48 kb)	0.443 Plantar warts // 0.443 Response to angiotensin II receptor blocker therapy // 0.409 Blood protein levels	- \| ABCF1 \| ABHD16A \| AIF1 \| ATF6B \| ATP6V1G2 \| ATP6V1G2-DDX39B \| BAG6 \| C2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf48 \| CCHCR1 \| CFB \| CLIC1 \| CSNK2B \| DDAH2 \| DDR1 \| DDX39B \| DXO \| EHMT2 \| FLOT1 \| GPANK1 \| GPSM3 \| GTF2H4 \| HCG22 \| HCG23 \| HCG27 \| HCG4B \| HCG4P3 \| HCP5 \| HLA-A \| HLA-B \| HLA-C \| HLA-DOB \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB2 \| HLA-DRB3 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB7 \| HLA-DRB8 \| HLA-E \| HLA-H \| HLA-J \| HLA-T \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LY6G5B \| LY6G5C \| LY6G6E \| MICA \| MICB \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| PBX2 \| POU5F1 \| PPP1R10 \| PPP1R11 \| PRRC2A \| PSMB8 \| PSMB9 \| RDBP \| RNF5 \| RPP21 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP2 \| TCF19 \| TNF \| TRIM10 \| TRIM39 \| TUBB \| unnamed \| VARS \| VARS2 \| VWA7 \| XXbac-BPG154L12.4 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.12 \| XXbac-BPG299F13.17 \| ZBTB12 \| ZNRD1	BTN3A2 \| FLOT1 \| HLA-A \| HLA-DOB \| HLA-DQA1 \| HLA-DRB1 \| HLA-DRB4 \| HLA-DRB5 \| HLA-F \| HLA-H \| HLA-V \| IER3 \| NHP2 \| TAP2 \| ZNRD1	Type I diabetes mellitus:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Allograft rejection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Graft-versus-host disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TAP2 \| Autoimmune thyroid disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Viral myocarditis:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Staphylococcus aureus infection:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Asthma:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phagosome:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| Herpes simplex infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| Intestinal immune network for IgA production:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Rheumatoid arthritis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Inflammatory bowel disease (IBD):HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Toxoplasmosis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Systemic lupus erythematosus:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Cell adhesion molecules (CAMs):HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Leishmaniasis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Influenza A:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Hematopoietic cell lineage:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Epstein-Barr virus infection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Th1 and Th2 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Th17 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Tuberculosis:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Natural killer cell mediated cytotoxicity:HLA-C,NCR3 \| Endocytosis:HLA-C,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L \| Human cytomegalovirus infection:ATF6B,HLA-C,TAP2 \| Kaposi sarcoma-associated herpesvirus infection:HLA-C \| Viral carcinogenesis:ATF6B,GTF2H4,HLA-C \| Spliceosome:HSPA1A,HSPA1B,HSPA1L,LSM2 \| Human immunodeficiency virus 1 infection:HLA-C,TAP2 \| Protein processing in endoplasmic reticulum:ATF6B,HSPA1A,HSPA1B,HSPA1L,RNF5 \| Cellular senescence:HLA-C \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:ATF6B,HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:HLA-C \| TNF signaling pathway:ATF6B \| Aminoacyl-tRNA biosynthesis:VARS,VARS2 \| Lysosome:NEU1 \| Cortisol synthesis and secretion:ATF6B	Translocation of ZAP-70 to Immunological synapse:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon gamma signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| PD-1 signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Generation of second messenger molecules:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Downstream TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon Signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| MHC class II antigen presentation:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Costimulation by the CD28 family:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Endosomal/Vacuolar pathway:HLA-C \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,TAP2 \| ER-Phagosome pathway:HLA-C,TAP2 \| Antigen processing-Cross presentation:HLA-C,TAP2 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,NCR3 \| Interferon alpha/beta signaling:HLA-C \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:GTF2H4,HSPA1A,HSPA1B \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| TP53 Regulates Transcription of DNA Repair Genes:GTF2H4 \| HIV Infection:GTF2H4 \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B \| Class I MHC mediated antigen processing & presentation:HLA-C,TAP2 \| HIV Transcription Elongation:GTF2H4 \| Formation of HIV-1 elongation complex containing HIV-1 Tat:GTF2H4 \| Tat-mediated elongation of the HIV-1 transcript:GTF2H4 \| Formation of HIV elongation complex in the absence of HIV Tat:GTF2H4 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Influenza Infection:HSPA1A,HSPA1B \| Defective CFTR causes cystic fibrosis:RNF5 \| Formation of RNA Pol II elongation complex :GTF2H4 \| RNA Polymerase II Transcription Elongation:GTF2H4 \| Formation of the Early Elongation Complex:GTF2H4 \| Formation of the HIV-1 Early Elongation Complex:GTF2H4 \| ABC-family proteins mediated transport:RNF5 \| Post-translational modification: synthesis of GPI-anchored proteins:LY6G6C,LY6G6D \| HIV Life Cycle:GTF2H4 \| RNA Polymerase I Promoter Escape:GTF2H4,ZNRD1 \| Transcription of the HIV genome:GTF2H4 \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Transcriptional Regulation by TP53:GTF2H4 \| RNA Polymerase I Transcription Termination:GTF2H4,ZNRD1 \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| RNA Polymerase I Transcription Initiation:GTF2H4,ZNRD1 \| Diseases associated with glycosylation precursor biosynthesis:NEU1 \| Neutrophil degranulation:HLA-C,HSPA1A,HSPA1B,NEU1 \| ABC transporter disorders:RNF5 \| Influenza Life Cycle:HSPA1A,HSPA1B \| RNA Polymerase II Pre-transcription Events:GTF2H4 \| Dual Incision in GG-NER:GTF2H4 \| tRNA Aminoacylation:VARS,VARS2 \| Formation of Incision Complex in GG-NER:GTF2H4 \| Late Phase of HIV Life Cycle:GTF2H4 \| Deadenylation-dependent mRNA decay:LSM2 \| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection:GTF2H4 \| RNA Pol II CTD phosphorylation and interaction with CE:GTF2H4 \| RNA Polymerase I Promoter Clearance:GTF2H4,ZNRD1 \| RNA Polymerase I Transcription:GTF2H4,ZNRD1 \| mRNA Capping:GTF2H4	Kawasaki disease:ABHD16A,BAG6,HLA-C,HLA-DRB1,PRRC2A \| lymphadenitis:ABHD16A,BAG6,HLA-C,HLA-DRB1,PRRC2A \| lymph node disease:ABHD16A,BAG6,HLA-C,HLA-DRB1,PRRC2A \| lymphatic system disease:ABHD16A,BAG6,HLA-C,HLA-DRB1,PRRC2A \| leprosy:HLA-DRB1 \| sarcoidosis:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L \| hypersensitivity reaction type IV disease:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L \| autoimmune disease of endocrine system:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| multiple sclerosis:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| endocrine system disease:HLA-C,HLA-DQA1,HLA-DRB1,HSPA1B,TAP2 \| autoimmune thyroiditis:HLA-DRB1 \| demyelinating disease:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Graves' disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| thyroid gland disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| intrahepatic cholestasis:HLA-DQA1,HLA-DRB1 \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HLA-C,HLA-DQA1,HLA-DRB1 \| primary bacterial infectious disease:FLOT1,HLA-DRB1,TAP2 \| hepatitis:HLA-C,HLA-DQA1,HLA-DRB1,NCR3 \| hyperthyroidism:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| vitiligo:DDR1,HLA-C \| spondylitis:HLA-C \| ankylosing spondylitis:HLA-C \| rheumatic fever:HLA-DQA1,HLA-DRB1 \| bacterial infectious disease:FLOT1,HLA-DRB1,TAP2 \| aplastic anemia:HLA-DQA1,HLA-DRB1 \| urticaria:HLA-DRB1 \| spondyloarthropathy:HLA-C \| vasculitis:DDR1,HLA-DRB1 \| hypothyroidism:HLA-DRB1 \| Behcet's disease:HLA-DRB1 \| hepatitis C:HLA-C,HLA-DQA1,HLA-DRB1,NCR3 \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1 \| arthropathy:HLA-C \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,NCR3,PRRC2A,TAP2 \| malaria:HLA-DRB1,NCR3,PRRC2A \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:DDR1,HLA-DRB1 \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-DRB1 \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DQA1,HLA-DRA \| neuromuscular junction disease:HLA-DQA1,HLA-DRA \| brucellosis:TAP2 \| duodenal ulcer:HSPA1A \| cholestasis:HLA-DQA1,HLA-DRB1 \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-C,HLA-DQA1,HLA-DRB1 \| upper respiratory tract disease:HLA-C,HSPA1A,TAP2 \| uveitis:HLA-DQA1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,NCR3,PRRC2A \| urinary system disease:DDR1,HLA-DQA1,HLA-DRB1,HSPA1A \| multiple myeloma:BAG6,IER3,NCR3 \| myeloma:BAG6,IER3,NCR3 \| reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| bone marrow cancer:BAG6,IER3,NCR3 \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L \| bile duct disease:HLA-C,HLA-DQA1,HLA-DRB1 \| biliary tract disease:HLA-C,HLA-DQA1,HLA-DRB1 \| azoospermia:HLA-DRB1,MSH5 \| proteinuria:DDR1,HLA-DRB1 \| kidney disease:DDR1,HLA-DQA1,HLA-DRB1,HSPA1A \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DRB1 \| type 1 diabetes mellitus:HLA-DQA1 \| blood coagulation disease:HLA-DRA,HLA-DRB1 \| allergic rhinitis:HLA-C,TAP2 \| hemorrhagic disease:HLA-DRA,HLA-DRB1 \| neuromuscular disease:HLA-DQA1,HLA-DRA \| thyroiditis:HLA-DRB1 \| nasal cavity disease:HLA-C,TAP2 \| nose disease:HLA-C,TAP2 \| rhinitis:HLA-C,TAP2 \| collagen disease:HLA-DRB1,TAP2 \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:HLA-DRB1,HSPA1B \| nephritis:HLA-DQA1,HLA-DRB1 \| celiac disease:HLA-DQA1,HLA-DRB1 \| peptic ulcer disease:HSPA1A \| hematopoietic system disease:HLA-DQA1,HLA-DRA,HLA-DRB1 \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DQA1,HLA-DRB1 \| rheumatic disease:HLA-DRB1,TAP2 \| systemic scleroderma:HLA-DRB1,TAP2 \| scleroderma:HLA-DRB1,TAP2 \| male reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| male infertility:HLA-DRB1,MSH5 \| silicosis:HLA-DRB1 \| integumentary system disease:HLA-DQA1,HLA-DRB1 \| sickle cell anemia:HLA-DRB1 \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2 \| Human immunodeficiency virus infectious disease:HLA-C,HLA-DRB1 \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B \| interstitial lung disease:DDR1,HLA-DRB1 \| bronchial disease:HSPA1A,HSPA1B,TAP2 \| acute pancreatitis:HSPA1B \| tuberculosis:HLA-DRB1 \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| prostate disease:HLA-DRB1,HSPA1A \| pneumoconiosis:HLA-DRB1 \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1 \| autoimmune disease of peripheral nervous system:HLA-DRB1 \| Guillain-Barre syndrome:HLA-DRB1 \| pancreas disease:HLA-DRB1,HSPA1B \| open-angle glaucoma:HLA-DRB1,TAP2 \| influenza:HLA-DRB1 \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-DQA1,HLA-DRB1 \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B,TAP2 \| ovarian disease:MSH5 \| gastritis:HLA-DRB1 \| dermatomyositis:HLA-DRB1 \| essential hypertension:HSPA1A,HSPA1B,HSPA1L \| female reproductive system disease:MSH5 \| osteomyelitis:HLA-DRB1 \| neuropathy:HLA-DQA1,HLA-DRA \| migraine:HLA-DRB1 \| infertility:MSH5 \| peripheral nervous system disease:HLA-DRB1 \| autoimmune disease of urogenital tract:HLA-DRB1 \| primary biliary cirrhosis:HLA-DRB1 \| cell type benign neoplasm:DDR1 \| stomach disease:HLA-DRB1 \| cholangitis:HLA-C,HLA-DRB1 \| Crohn's disease:HSPA1B \| osteosarcoma:BAG6 \| lung disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B \| spinal cord disease:HLA-C,HLA-DRB1 \| gallbladder carcinoma:CLIC1 \| pulmonary edema:HSPA1A \| gallbladder cancer:CLIC1 \| myositis:HLA-DRB1 \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B \| myopathy:HLA-DRB1 \| muscle tissue disease:HLA-DRB1 \| bone cancer:BAG6 \| nasopharynx carcinoma:DDR1,HSPA1B \| pharynx cancer:DDR1,HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| muscular disease:HLA-DRB1 \| endocrine organ benign neoplasm:DDR1 \| bronchiectasis:TAP2 \| premature ovarian failure:MSH5 \| liver cirrhosis:DDR1,HLA-DRB1 \| renal cell carcinoma:HLA-DRB1,TAP2 \| glaucoma:HLA-DRB1,TAP2 \| esophageal carcinoma:HLA-DRB1 \| skin disease:HLA-DRB1 \| retinal disease:HLA-DRB1,TAP2 \| female reproductive organ cancer:DDR1,HLA-DQA1,HLA-DRB1 \| connective tissue cancer:BAG6 \| adenoma:DDR1 \| primary open angle glaucoma:TAP2 \| severe combined immunodeficiency:HLA-DRB1 \| retinal degeneration:HLA-DRB1,TAP2 \| malignant ovarian surface epithelial-stromal neoplasm:DDR1,HLA-DQA1,HLA-DRB1 \| ovary epithelial cancer:DDR1,HLA-DQA1,HLA-DRB1 \| ovarian carcinoma:DDR1,HLA-DQA1,HLA-DRB1 \| combined T cell and B cell immunodeficiency:HLA-DRB1	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation of peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| cellular response to interferon-gamma:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| response to interferon-gamma:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell receptor signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating signal transduction:BAG6,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,NCR3 \| T cell costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| lymphocyte costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen receptor-mediated signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-regulating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| positive regulation of cell-cell adhesion:FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of leukocyte cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of T cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of cell-cell adhesion:FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,TAP2 \| regulation of leukocyte cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,TAP2 \| positive regulation of cell adhesion:FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of lymphocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of lymphocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of T cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of leukocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| leukocyte cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,TAP2 \| positive regulation of leukocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| lymphocyte mediated immunity:NCR3 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| adaptive immune response:NCR3,TAP2 \| natural killer cell mediated cytotoxicity:NCR3 \| natural killer cell mediated immunity:NCR3 \| T cell mediated cytotoxicity:NCR3 \| response to type I interferon:HLA-C \| type I interferon signaling pathway:HLA-C \| cellular response to type I interferon:HLA-C \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| leukocyte mediated cytotoxicity:NCR3 \| positive regulation of defense response:FLOT1,HSPA1A,HSPA1B,NCR3 \| positive regulation of cytokine production:FLOT1,HSPA1A,HSPA1B \| T cell mediated immunity:NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:NCR3 \| positive regulation of innate immune response:FLOT1,HSPA1A,HSPA1B,NCR3 \| regulation of lymphocyte mediated immunity:NCR3 \| regulation of innate immune response:FLOT1,HSPA1A,HSPA1B,NCR3 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B \| cell killing:NCR3 \| positive regulation of lymphocyte mediated immunity:NCR3 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of natural killer cell mediated cytotoxicity:NCR3 \| positive regulation of adaptive immune response:NCR3 \| regulation of natural killer cell mediated immunity:NCR3 \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| mRNA catabolic process:HSPA1A,HSPA1B,LSM2 \| response to tumor necrosis factor:HSPA1A,HSPA1B \| response to heat:HSPA1A,HSPA1B,HSPA1L \| antigen processing and presentation via MHC class Ib:TAP2 \| positive regulation of nitric oxide biosynthetic process:DDAH2 \| positive regulation of nitric oxide metabolic process:DDAH2 \| regulation of leukocyte mediated immunity:NCR3 \| activation of innate immune response:FLOT1,HSPA1A,HSPA1B \| regulation of T cell mediated cytotoxicity:NCR3 \| positive regulation of leukocyte mediated immunity:NCR3 \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| antigen processing and presentation of endogenous antigen:TAP2 \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B \| microtubule nucleation:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of heterotypic cell-cell adhesion:FLOT1 \| regulation of leukocyte mediated cytotoxicity:NCR3 \| regulation of DNA-templated transcription in response to stress:ATF6B,HSPA1A \| ER-associated misfolded protein catabolic process:BAG6,RNF5 \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B \| RNA catabolic process:HSPA1A,HSPA1B,LSM2 \| positive regulation of reactive oxygen species biosynthetic process:DDAH2 \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,HSPA1L,RNF5 \| positive regulation of T cell mediated cytotoxicity:NCR3 \| C-terminal protein lipidation:LY6G6C,LY6G6D \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| DNA-templated transcription, elongation:GTF2H4,ZNRD1 \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| innate immune response-activating signal transduction:FLOT1,HSPA1A,HSPA1B \| regulation of nitric oxide biosynthetic process:DDAH2 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| regulation of translational fidelity:VARS,VARS2 \| regulation of cell killing:NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| regulation of interleukin-8 production:HSPA1A,HSPA1B \| regulation of antigen processing and presentation:HLA-DOB \| RNA phosphodiester bond hydrolysis:HSPA1A,ZNRD1 \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| regulation of adaptive immune response:NCR3 \| C-terminal protein amino acid modification:LY6G6C,LY6G6D \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B \| regulation of protein stability:BAG6,FLOT1,HSPA1A,HSPA1B,RNF5 \| nitric oxide biosynthetic process:DDAH2 \| interleukin-8 production:HSPA1A,HSPA1B \| regulation of heterotypic cell-cell adhesion:FLOT1 \| positive regulation of protein complex assembly:GTF2H4,HSPA1A,HSPA1B \| interaction with host:HSPA1A,HSPA1B \| signal transduction in absence of ligand:HSPA1A,HSPA1B \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of natural killer cell mediated immunity:NCR3 \| nitric oxide metabolic process:DDAH2 \| cellular response to misfolded protein:BAG6,RNF5 \| natural killer cell activation:BAG6,NCR3 \| reactive nitrogen species metabolic process:DDAH2 \| nuclear-transcribed mRNA catabolic process, exonucleolytic:LSM2 \| cellular response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,RNF5 \| protein stabilization:BAG6,FLOT1,HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| response to misfolded protein:BAG6,RNF5 \| mRNA cleavage:HSPA1A,ZNRD1 \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of organelle assembly:HSPA1A,HSPA1B,RNF5 \| regulation of transcription from RNA polymerase II promoter in response to stress:ATF6B,HSPA1A \| regulation of reactive oxygen species biosynthetic process:DDAH2 \| protein ubiquitination involved in ubiquitin-dependent protein catabolic process:RNF5 \| regulation of endocytosis:FLOT1 \| protein K63-linked ubiquitination:RNF5 \| protein quality control for misfolded or incompletely synthesized proteins:BAG6,RNF5 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| positive regulation of endocytosis:FLOT1 \| response to endoplasmic reticulum stress:ATF6B,BAG6,FLOT1,HSPA1A,RNF5 \| positive regulation of immune effector process:NCR3 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| transcription elongation from RNA polymerase I promoter:GTF2H4,ZNRD1 \| termination of RNA polymerase I transcription:GTF2H4,ZNRD1 \| pattern recognition receptor signaling pathway:FLOT1,HSPA1A,HSPA1B \| positive regulation of T cell mediated immunity:NCR3 \| spindle assembly:HSPA1A,HSPA1B \| ganglioside metabolic process:NEU1 \| nucleic acid phosphodiester bond hydrolysis:GTF2H4,HSPA1A,ZNRD1 \| transcription initiation from RNA polymerase I promoter:GTF2H4,ZNRD1 \| exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay:LSM2 \| nuclear-transcribed mRNA catabolic process:LSM2 \| positive regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| positive regulation of leukocyte mediated cytotoxicity:NCR3 \| reactive oxygen species biosynthetic process:DDAH2 \| negative regulation of immune system process:HLA-DOB \| positive regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| post-translational protein modification:LY6G6C,LY6G6D \| macroautophagy:RNF5 \| regulation of T cell mediated immunity:NCR3 \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| receptor-mediated endocytosis:FLOT1 \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| DNA-templated transcription, termination:GTF2H4,ZNRD1 \| regulation of macroautophagy:RNF5 \| membrane assembly:FLOT1 \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:FLOT1,LY6G5C,LY6G6C,LY6G6D \| viral life cycle:HSPA1A,HSPA1B \| regulation of osteoblast differentiation:CLIC1 \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress:ATF6B \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| positive regulation of catabolic process:BAG6,HSPA1A \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:BAG6,HSPA1A \| negative regulation of proteolysis involved in cellular protein catabolic process:BAG6 \| positive regulation of cell killing:NCR3 \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| mRNA cleavage involved in mRNA processing:HSPA1A \| regulation of autophagy:RNF5 \| response to ammonium ion:LY6G6D \| microtubule polymerization:HSPA1A,HSPA1B \| synapsis:BAG6,MSH5 \| protein lipidation:LY6G6C,LY6G6D \| protein folding:HSPA1A,HSPA1B,HSPA1L \| positive regulation of protein catabolic process:BAG6,HSPA1A \| positive regulation of cellular catabolic process:BAG6,HSPA1A \| tRNA aminoacylation for protein translation:VARS,VARS2 \| extracellular matrix organization:DDR1,FLOT1 \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| membrane biogenesis:FLOT1 \| lipoprotein metabolic process:LY6G6C,LY6G6D \| extracellular structure organization:DDR1,FLOT1 \| heterotypic cell-cell adhesion:FLOT1 \| branching involved in mammary gland duct morphogenesis:DDR1 \| negative regulation of growth:HSPA1A,HSPA1B \| lipoprotein biosynthetic process:LY6G6C,LY6G6D \| tRNA aminoacylation:VARS,VARS2 \| regulation of binding:FLOT1 \| transcription elongation from RNA polymerase II promoter:GTF2H4 \| regulation of mRNA metabolic process:HSPA1A \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| syncytium formation by plasma membrane fusion:FLOT1 \| amino acid activation:VARS,VARS2 \| regulation of RNA stability:HSPA1A \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| syncytium formation:FLOT1 \| regulation of monooxygenase activity:DDAH2 \| positive regulation of cellular component biogenesis:FLOT1,GTF2H4,HSPA1A,HSPA1B \| regulation of cellular protein catabolic process:BAG6,HSPA1A \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| protein polymerization:HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| mitochondrial membrane organization:HSPA1A \| receptor metabolic process:FLOT1 \| reactive oxygen species metabolic process:DDAH2 \| regulation of receptor internalization:FLOT1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| protein polyubiquitination:RNF5 \| homologous chromosome segregation:BAG6,MSH5 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:BAG6,HSPA1A \| cellular response to ammonium ion:LY6G6D \| positive regulation of cell junction assembly:FLOT1 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| negative regulation of cellular protein catabolic process:BAG6 \| negative regulation of catabolic process:BAG6,RNF5 \| regulation of mRNA catabolic process:HSPA1A \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| negative regulation of cellular catabolic process:BAG6,RNF5 \| negative regulation of autophagy:RNF5 \| cellular amino acid metabolic process:DDAH2,VARS,VARS2 \| transcription from RNA polymerase I promoter:GTF2H4,ZNRD1 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| gland morphogenesis:DDR1 \| regulation of protein complex assembly:GTF2H4,HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| spindle organization:HSPA1A,HSPA1B \| regulation of protein catabolic process:BAG6,HSPA1A \| platelet activation:CLIC1,MPIG6B \| DNA-templated transcription, initiation:GTF2H4,ZNRD1 \| chromosome organization involved in meiotic cell cycle:BAG6,MSH5 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| transcription initiation from RNA polymerase II promoter:GTF2H4 \| mammary gland duct morphogenesis:DDR1 \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| autophagy:RNF5 \| process utilizing autophagic mechanism:RNF5 \| cellular response to oxidative stress:HSPA1A,HSPA1B \| regulation of striated muscle tissue development:FLOT1 \| positive regulation of striated muscle cell differentiation:FLOT1 \| regulation of autophagosome assembly:RNF5 \| receptor internalization:FLOT1 \| regulation of reactive oxygen species metabolic process:DDAH2 \| negative regulation of proteolysis:BAG6 \| ubiquitin-dependent ERAD pathway:BAG6,RNF5 \| regulation of muscle tissue development:FLOT1 \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| 7-methylguanosine mRNA capping:GTF2H4 \| regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| mammary gland development:DDR1 \| response to unfolded protein:ATF6B,HSPA1A,HSPA1L \| response to oxidative stress:HSPA1A,HSPA1B \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| 7-methylguanosine RNA capping:GTF2H4 \| RNA capping:GTF2H4 \| smooth muscle cell migration:DDR1 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:LSM2	0.0395676	0.065401	0.26340830829372	0.0700677	0.0667374	0.531726535474899	-0.0468017	0.111983	0.170056516307536	0.461925	0.0712382	9.95368046193252	0.351527	0.0874806	4.20876984896075	0.571389	0.121161	5.5378326887033	0.0630267	0.0536698	0.619078182699392	0.0293486	0.0693191	0.172577735912056	0.0947348	0.0862356	0.564898135044162	0.0393082	0.0370251	0.540022814834054	-0.0247878	0.0458	0.230358336996971	0.115547	0.0602275	1.25926555565994	0.050558	0.0368526	0.769308452432844	-0.0487327	0.0385246	0.686385840421868	0.169001	0.059856	2.32322136841003	0.0331027	0.0353673	0.456815091186069				-0.0103695	0.0567022	0.0680872229570737	0.00159973	0.0213557	0.0267395682169983	0.0231262	0.0277718	0.392543904454601	-0.0225407	0.0333351	0.301966474928642	0.175797	0.106662	1.00228910829826	0.233452	0.150007	0.921231529809774	0.12215	0.150735	0.378808133774377
6:30932655:C:G		6	30932655	6p21.33	G	C	0.801	1	OHP17 ALL	2070	9.8156209193414	0.0102144927536232		HCG21 (10 kb); DPCR1 (11 kb); MUC21 (19 kb); SFTA2 (33 kb); VARS2 (38 kb); MUC22 (46 kb)	0.663 Plantar warts // 0.663 Response to angiotensin II receptor blocker therapy // 0.525 Blood protein levels	- \| ABCF1 \| ABHD16A \| AIF1 \| ATF6B \| ATP6V1G2 \| ATP6V1G2-DDX39B \| BAG6 \| C2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf48 \| CCHCR1 \| CLIC1 \| CSNK2B \| DDAH2 \| DDR1 \| DDX39B \| DXO \| FLOT1 \| GPANK1 \| GPSM3 \| GTF2H4 \| HCG22 \| HCG27 \| HCG4B \| HCG4P3 \| HCP5 \| HLA-A \| HLA-B \| HLA-C \| HLA-DOB \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB6 \| HLA-E \| HLA-H \| HLA-J \| HLA-T \| HLA-W \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LTB \| LY6G5B \| LY6G5C \| LY6G6E \| MICA \| MICB \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| PBX2 \| POU5F1 \| PPP1R10 \| PPP1R11 \| PRRC2A \| RDBP \| RNF5 \| RPP21 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP2 \| TCF19 \| TNF \| TRIM10 \| TRIM39 \| TUBB \| unnamed \| VARS \| VARS2 \| XXbac-BPG181B23.7 \| XXbac-BPG248L24.12 \| XXbac-BPG299F13.17 \| ZNRD1	BTN3A2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| DXO \| HLA-DQA1 \| HLA-DRB1 \| HLA-DRB4 \| HLA-DRB5 \| HLA-F \| HLA-V \| IER3 \| NHP2 \| STK19 \| TAP2 \| TMEM154 \| ZNRD1	Type I diabetes mellitus:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA \| Allograft rejection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Graft-versus-host disease:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Antigen processing and presentation:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,HSPA1A,HSPA1B,HSPA1L \| Autoimmune thyroid disease:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Viral myocarditis:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Staphylococcus aureus infection:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Asthma:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phagosome:ATP6V1G2,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Herpes simplex infection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA \| Intestinal immune network for IgA production:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Rheumatoid arthritis:ATP6V1G2,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Inflammatory bowel disease (IBD):HLA-DQA1,HLA-DRA,HLA-DRB1 \| Toxoplasmosis:HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Systemic lupus erythematosus:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Cell adhesion molecules (CAMs):HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| Leishmaniasis:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Influenza A:DDX39B,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Hematopoietic cell lineage:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Epstein-Barr virus infection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA \| Th1 and Th2 cell differentiation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Th17 cell differentiation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Tuberculosis:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Natural killer cell mediated cytotoxicity:HLA-C,HLA-E,NCR3 \| Endocytosis:HLA-C,HLA-E,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L \| Human cytomegalovirus infection:ATF6B,HLA-C,HLA-E \| Kaposi sarcoma-associated herpesvirus infection:HLA-C,HLA-E \| Viral carcinogenesis:ATF6B,HLA-C,HLA-E \| Spliceosome:DDX39B,HSPA1A,HSPA1B,HSPA1L \| Human immunodeficiency virus 1 infection:HLA-C,HLA-E \| NF-kappa B signaling pathway:LTA \| Protein processing in endoplasmic reticulum:ATF6B,HSPA1A,HSPA1B,HSPA1L \| Cellular senescence:HLA-C,HLA-E \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:ATF6B,HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:ATP6V1G2,HLA-C,HLA-E \| TNF signaling pathway:ATF6B,LTA \| Aminoacyl-tRNA biosynthesis:VARS2 \| Lysosome:NEU1 \| Cortisol synthesis and secretion:ATF6B	Translocation of ZAP-70 to Immunological synapse:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon gamma signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| PD-1 signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Generation of second messenger molecules:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Downstream TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon Signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| MHC class II antigen presentation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Costimulation by the CD28 family:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Endosomal/Vacuolar pathway:HLA-C,HLA-E \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,HLA-E \| ER-Phagosome pathway:HLA-C,HLA-E \| Antigen processing-Cross presentation:HLA-C,HLA-E \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,HLA-E,NCR3 \| Interferon alpha/beta signaling:HLA-C,HLA-E \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:HSPA1A,HSPA1B \| TNFR2 non-canonical NF-kB pathway:LTA \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:LTA \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B \| Class I MHC mediated antigen processing & presentation:HLA-C,HLA-E \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Influenza Infection:HSPA1A,HSPA1B \| ABC-family proteins mediated transport:ABCF1 \| RNA Polymerase I Promoter Escape:ZNRD1 \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| RNA Polymerase I Transcription Termination:ZNRD1 \| RNA Polymerase I Transcription Initiation:ZNRD1 \| Diseases associated with glycosylation precursor biosynthesis:NEU1 \| Neutrophil degranulation:HLA-C,HSPA1A,HSPA1B,NEU1 \| Influenza Life Cycle:HSPA1A,HSPA1B \| tRNA Aminoacylation:VARS2 \| C-type lectin receptors (CLRs):MUC21 \| Deadenylation-dependent mRNA decay:SKIV2L \| Chaperonin-mediated protein folding:SKIV2L \| Association of TriC/CCT with target proteins during biosynthesis:SKIV2L \| RNA Polymerase I Promoter Clearance:ZNRD1 \| RNA Polymerase I Transcription:ZNRD1	Kawasaki disease:BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A \| lymphadenitis:BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A \| lymph node disease:BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A \| lymphatic system disease:BAG6,HLA-C,HLA-DRB1,HLA-E,PRRC2A \| leprosy:HLA-DRB1,LTA \| sarcoidosis:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L,LTA \| hypersensitivity reaction type IV disease:DDR1,HLA-DQA1,HLA-DRB1,HSPA1L,LTA \| autoimmune disease of endocrine system:HLA-C,HLA-DQA1,HLA-DRB1 \| multiple sclerosis:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| endocrine system disease:ABCF1,HLA-C,HLA-DQA1,HLA-DRB1,HSPA1B,LTA \| autoimmune thyroiditis:HLA-DRB1 \| demyelinating disease:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Graves' disease:HLA-C,HLA-DQA1,HLA-DRB1 \| thyroid gland disease:HLA-C,HLA-DQA1,HLA-DRB1 \| intrahepatic cholestasis:HLA-DQA1,HLA-DRB1,HLA-E \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HLA-C,HLA-DQA1,HLA-DRB1 \| primary bacterial infectious disease:FLOT1,HLA-DRB1,LTA \| hepatitis:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E,LTA,NCR3 \| hyperthyroidism:HLA-C,HLA-DQA1,HLA-DRB1 \| vitiligo:DDR1,HLA-C \| spondylitis:HLA-C,HLA-E \| ankylosing spondylitis:HLA-C,HLA-E \| rheumatic fever:HLA-DQA1,HLA-DRB1 \| bacterial infectious disease:FLOT1,HLA-DRB1,LTA \| aplastic anemia:HLA-DQA1,HLA-DRB1 \| urticaria:HLA-DRB1 \| spondyloarthropathy:HLA-C,HLA-E \| vasculitis:DDR1,HLA-DRB1,HLA-E \| hypothyroidism:HLA-DRB1 \| Behcet's disease:HLA-DRB1,HLA-E \| hepatitis C:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E,LTA,NCR3 \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| arthropathy:HLA-C,HLA-E \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,LTA,NCR3,PRRC2A \| malaria:HLA-DRB1,LTA,NCR3,PRRC2A \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:DDR1,HLA-DRB1 \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-DRB1,LTA \| cystic echinococcosis:HLA-DRB1 \| myasthenia gravis:HLA-DQA1,HLA-DRA,HLA-E \| neuromuscular junction disease:HLA-DQA1,HLA-DRA,HLA-E \| duodenal ulcer:HSPA1A,LTA \| cholestasis:HLA-DQA1,HLA-DRB1,HLA-E \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-C,HLA-DQA1,HLA-DRB1 \| upper respiratory tract disease:HLA-C,HSPA1A \| uveitis:HLA-DQA1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,LTA,NCR3,PRRC2A \| urinary system disease:AIF1,DDR1,HLA-DQA1,HLA-DRB1,HSPA1A \| multiple myeloma:BAG6,IER3,LTA,NCR3 \| myeloma:BAG6,IER3,LTA,NCR3 \| reproductive system disease:HLA-DRB1,HLA-E,HSPA1A,LTA,MSH5 \| bone marrow cancer:BAG6,IER3,LTA,NCR3 \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L \| bile duct disease:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E \| biliary tract disease:HLA-C,HLA-DQA1,HLA-DRB1,HLA-E \| azoospermia:HLA-DRB1,MSH5 \| proteinuria:DDR1,HLA-DRB1 \| kidney disease:AIF1,DDR1,HLA-DQA1,HLA-DRB1,HSPA1A \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DRB1 \| type 1 diabetes mellitus:HLA-DQA1,LTA \| blood coagulation disease:HLA-DRA,HLA-DRB1,LTA \| allergic rhinitis:HLA-C \| hemorrhagic disease:HLA-DRA,HLA-DRB1,LTA \| neuromuscular disease:HLA-DQA1,HLA-DRA,HLA-E \| thyroiditis:HLA-DRB1 \| nasal cavity disease:HLA-C \| nose disease:HLA-C \| rhinitis:HLA-C \| collagen disease:AIF1,HLA-DRB1 \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:ABCF1,HLA-DRB1,HSPA1B,LTA \| nephritis:AIF1,HLA-DQA1,HLA-DRB1 \| celiac disease:HLA-DQA1,HLA-DRB1 \| peptic ulcer disease:HSPA1A,LTA \| hematopoietic system disease:HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LTA \| echinococcosis:HLA-DRB1 \| anemia:HLA-DQA1,HLA-DRB1,HLA-E \| rheumatic disease:AIF1,HLA-DRB1 \| systemic scleroderma:AIF1,HLA-DRB1 \| scleroderma:AIF1,HLA-DRB1 \| male reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| male infertility:HLA-DRB1,MSH5 \| silicosis:HLA-DRB1 \| integumentary system disease:HLA-DQA1,HLA-DRB1 \| sickle cell anemia:HLA-DRB1,HLA-E \| parasitic helminthiasis infectious disease:HLA-DRB1 \| Human immunodeficiency virus infectious disease:HLA-C,HLA-DRB1 \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B \| interstitial lung disease:DDR1,HLA-DRB1 \| bronchial disease:HSPA1A,HSPA1B,LTA \| acute pancreatitis:HSPA1B,LTA \| tuberculosis:HLA-DRB1 \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| dengue hemorrhagic fever:LTA \| prostate disease:HLA-DRB1,HSPA1A \| pneumoconiosis:HLA-DRB1 \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1 \| dengue disease:LTA \| autoimmune disease of peripheral nervous system:HLA-DRB1 \| Guillain-Barre syndrome:HLA-DRB1 \| pancreas disease:ABCF1,HLA-DRB1,HSPA1B,LTA \| open-angle glaucoma:HLA-DRB1 \| influenza:HLA-DRB1 \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-DQA1,HLA-DRB1 \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B,LTA \| ovarian disease:MSH5 \| gastritis:HLA-DRB1 \| dermatomyositis:HLA-DRB1 \| essential hypertension:HSPA1A,HSPA1B,HSPA1L,LTA \| female reproductive system disease:LTA,MSH5 \| osteomyelitis:HLA-DRB1 \| neuropathy:HLA-DQA1,HLA-DRA,HLA-E \| migraine:HLA-DRB1,LTA \| infertility:HLA-E,MSH5 \| peripheral nervous system disease:HLA-DRB1 \| autoimmune disease of urogenital tract:HLA-DRB1 \| primary biliary cirrhosis:HLA-DRB1 \| cell type benign neoplasm:DDR1 \| stomach disease:HLA-DRB1 \| cholangitis:HLA-C,HLA-DRB1 \| Crohn's disease:HSPA1B,LTA \| osteosarcoma:BAG6 \| lung disease:DDR1,HLA-DRB1,HSPA1A,HSPA1B,LTA \| spinal cord disease:HLA-C,HLA-DRB1 \| pulmonary edema:HSPA1A \| myositis:HLA-DRB1 \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B,LTA \| myopathy:HLA-DRB1 \| muscle tissue disease:HLA-DRB1 \| bone cancer:BAG6 \| nasopharynx carcinoma:DDR1,HSPA1B \| pharynx cancer:DDR1,HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| muscular disease:HLA-DRB1 \| endocrine organ benign neoplasm:DDR1 \| premature ovarian failure:MSH5 \| liver cirrhosis:DDR1,HLA-DRB1 \| renal cell carcinoma:HLA-DRB1 \| glaucoma:HLA-DRB1 \| esophageal carcinoma:HLA-DRB1 \| skin disease:HLA-DRB1 \| retinal disease:HLA-DRB1,LTA \| female reproductive organ cancer:DDR1,HLA-DQA1,HLA-DRB1 \| connective tissue cancer:BAG6 \| adenoma:DDR1 \| severe combined immunodeficiency:HLA-DRB1 \| coronary artery disease:DDX39B,LTA \| retinal degeneration:HLA-DRB1 \| integumentary system cancer:LTA \| skin cancer:LTA \| malignant ovarian surface epithelial-stromal neoplasm:DDR1,HLA-DQA1,HLA-DRB1 \| ovary epithelial cancer:DDR1,HLA-DQA1,HLA-DRB1 \| ovarian carcinoma:DDR1,HLA-DQA1,HLA-DRB1 \| combined T cell and B cell immunodeficiency:HLA-DRB1	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation of peptide antigen:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| cellular response to interferon-gamma:AIF1,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DQA1,HLA-DRA,HLA-DRB1 \| response to interferon-gamma:AIF1,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell receptor signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating signal transduction:BAG6,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,MUC21,NCR3 \| T cell costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,MUC21,NCR3 \| lymphocyte costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen receptor-mediated signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-regulating cell surface receptor signaling pathway:BAG6,HLA-DQA1,HLA-DRA,HLA-DRB1,MUC21,NCR3 \| positive regulation of cell-cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| positive regulation of leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| positive regulation of T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| regulation of cell-cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,MUC21 \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,HLA-E \| regulation of leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,HLA-E \| positive regulation of cell adhesion:AIF1,FLOT1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| positive regulation of lymphocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| positive regulation of cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| regulation of lymphocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LST1 \| regulation of T cell activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| regulation of leukocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E,LST1 \| leukocyte cell-cell adhesion:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,HLA-E \| positive regulation of leukocyte activation:AIF1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-E \| lymphocyte mediated immunity:HLA-E,LTA,NCR3 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,LTA,NCR3 \| adaptive immune response:HLA-E,LTA,NCR3 \| humoral immune response mediated by circulating immunoglobulin:LTA \| natural killer cell mediated cytotoxicity:HLA-E,NCR3 \| natural killer cell mediated immunity:HLA-E,NCR3 \| T cell mediated cytotoxicity:HLA-E,NCR3 \| response to type I interferon:HLA-C,HLA-E \| type I interferon signaling pathway:HLA-C,HLA-E \| cellular response to type I interferon:HLA-C,HLA-E \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,LTA \| leukocyte mediated cytotoxicity:HLA-E,NCR3 \| regulation of humoral immune response:LTA \| positive regulation of defense response:FLOT1,HLA-E,HSPA1A,HSPA1B,LTA,MUC21,NCR3 \| positive regulation of cytokine production:FLOT1,HLA-E,HSPA1A,HSPA1B,LTA \| T cell mediated immunity:HLA-E,NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:HLA-E,LTA,NCR3 \| positive regulation of innate immune response:FLOT1,HLA-E,HSPA1A,HSPA1B,MUC21,NCR3 \| positive regulation of T cell proliferation:AIF1,HLA-E \| regulation of lymphocyte mediated immunity:HLA-E,LTA,NCR3 \| regulation of innate immune response:FLOT1,HLA-E,HSPA1A,HSPA1B,MUC21,NCR3 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B,LTA \| regulation of T cell proliferation:AIF1,HLA-E \| cell killing:HLA-E,NCR3 \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B \| positive regulation of lymphocyte mediated immunity:HLA-E,LTA,NCR3 \| regulation of lymphocyte proliferation:AIF1,HLA-E,LST1 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,LTA,NCR3 \| regulation of mononuclear cell proliferation:AIF1,HLA-E,LST1 \| regulation of natural killer cell mediated cytotoxicity:HLA-E,NCR3 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| chronic inflammatory response:LTA \| positive regulation of adaptive immune response:HLA-E,LTA,NCR3 \| regulation of natural killer cell mediated immunity:HLA-E,NCR3 \| interferon-gamma production:LTA \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| lymph node development:LTA \| immunoglobulin mediated immune response:LTA \| regulation of leukocyte proliferation:AIF1,HLA-E,LST1 \| B cell mediated immunity:LTA \| mRNA catabolic process:HSPA1A,HSPA1B,SKIV2L \| response to tumor necrosis factor:HSPA1A,HSPA1B,LTA \| regulation of chronic inflammatory response:LTA \| response to heat:HSPA1A,HSPA1B,HSPA1L \| antigen processing and presentation via MHC class Ib:HLA-E \| regulation of humoral immune response mediated by circulating immunoglobulin:LTA \| positive regulation of nitric oxide biosynthetic process:AIF1,DDAH2 \| positive regulation of nitric oxide metabolic process:AIF1,DDAH2 \| regulation of leukocyte mediated immunity:HLA-E,LTA,NCR3 \| activation of innate immune response:FLOT1,HSPA1A,HSPA1B,MUC21 \| regulation of T cell mediated cytotoxicity:HLA-E,NCR3 \| positive regulation of leukocyte mediated immunity:HLA-E,LTA,NCR3 \| T cell proliferation:AIF1,HLA-E \| antigen processing and presentation of endogenous antigen:HLA-E \| negative regulation of natural killer cell mediated cytotoxicity:HLA-E \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of inflammatory response to antigenic stimulus:LTA \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B \| microtubule nucleation:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of lymphocyte proliferation:AIF1,HLA-E \| positive regulation of mononuclear cell proliferation:AIF1,HLA-E \| positive regulation of heterotypic cell-cell adhesion:FLOT1 \| negative regulation of natural killer cell mediated immunity:HLA-E \| regulation of leukocyte mediated cytotoxicity:HLA-E,NCR3 \| regulation of DNA-templated transcription in response to stress:ATF6B,HSPA1A \| negative regulation of immune effector process:HLA-E \| ER-associated misfolded protein catabolic process:BAG6 \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B \| RNA catabolic process:HSPA1A,HSPA1B,SKIV2L \| positive regulation of leukocyte proliferation:AIF1,HLA-E \| positive regulation of reactive oxygen species biosynthetic process:AIF1,DDAH2 \| negative regulation of growth of symbiont in host:LTA \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:ATF6B,BAG6,HSPA1A,HSPA1L \| negative regulation of leukocyte mediated cytotoxicity:HLA-E \| positive regulation of T cell mediated cytotoxicity:HLA-E,NCR3 \| positive regulation of humoral immune response:LTA \| regulation of growth of symbiont in host:LTA \| negative regulation of growth of symbiont involved in interaction with host:LTA \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| DNA-templated transcription, elongation:DDX39B,ZNRD1 \| humoral immune response:HLA-E,LTA \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| modulation of growth of symbiont involved in interaction with host:LTA \| innate immune response-activating signal transduction:FLOT1,HSPA1A,HSPA1B,MUC21 \| regulation of nitric oxide biosynthetic process:AIF1,DDAH2 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-E,LTA,NCR3 \| lymphocyte proliferation:AIF1,HLA-E,LST1 \| mononuclear cell proliferation:AIF1,HLA-E,LST1 \| regulation of immunoglobulin secretion:HLA-E \| regulation of translational fidelity:VARS2 \| regulation of cell killing:HLA-E,NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| negative regulation of cell killing:HLA-E \| growth of symbiont in host:LTA \| regulation of interleukin-8 production:HSPA1A,HSPA1B \| RNA phosphodiester bond hydrolysis:HSPA1A,RPP21,ZNRD1 \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| growth involved in symbiotic interaction:LTA \| growth of symbiont involved in interaction with host:LTA \| regulation of adaptive immune response:HLA-E,LTA,NCR3 \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| leukocyte proliferation:AIF1,HLA-E,LST1 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B \| regulation of protein stability:BAG6,FLOT1,HSPA1A,HSPA1B \| positive regulation of interferon-gamma production:LTA \| positive regulation of translation:DDX39B \| nitric oxide biosynthetic process:AIF1,DDAH2 \| interleukin-8 production:HSPA1A,HSPA1B \| regulation of heterotypic cell-cell adhesion:FLOT1 \| immunoglobulin secretion:HLA-E \| positive regulation of protein complex assembly:HSPA1A,HSPA1B \| interaction with host:DDX39B,HSPA1A,HSPA1B \| signal transduction in absence of ligand:HSPA1A,HSPA1B \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| nucleocytoplasmic transport:DDX39B \| positive regulation of natural killer cell mediated immunity:HLA-E,NCR3 \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| nitric oxide metabolic process:AIF1,DDAH2 \| nuclear transport:DDX39B \| cellular response to misfolded protein:BAG6 \| positive regulation of vascular smooth muscle cell proliferation:DDX39B \| regulation of inflammatory response to antigenic stimulus:LTA \| natural killer cell activation:BAG6,NCR3 \| reactive nitrogen species metabolic process:AIF1,DDAH2 \| nuclear-transcribed mRNA catabolic process, exonucleolytic:SKIV2L \| positive regulation of mononuclear cell migration:AIF1 \| cellular response to topologically incorrect protein:ATF6B,BAG6,HSPA1A \| protein stabilization:BAG6,FLOT1,HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| positive regulation of smooth muscle cell proliferation:AIF1,DDX39B \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| response to misfolded protein:BAG6 \| mRNA cleavage:HSPA1A,ZNRD1 \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:AIF1,DDAH2 \| regulation of organelle assembly:HSPA1A,HSPA1B \| regulation of transcription from RNA polymerase II promoter in response to stress:ATF6B,HSPA1A \| regulation of reactive oxygen species biosynthetic process:AIF1,DDAH2 \| regulation of endocytosis:FLOT1 \| protein quality control for misfolded or incompletely synthesized proteins:BAG6 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| positive regulation of endocytosis:FLOT1 \| negative regulation of multi-organism process:LTA \| defense response to Gram-positive bacterium:HLA-E,LTA \| response to endoplasmic reticulum stress:ATF6B,BAG6,FLOT1,HSPA1A \| positive regulation of immune effector process:HLA-E,LTA,NCR3 \| stimulatory C-type lectin receptor signaling pathway:MUC21 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| transcription elongation from RNA polymerase I promoter:ZNRD1 \| termination of RNA polymerase I transcription:ZNRD1 \| pattern recognition receptor signaling pathway:FLOT1,HSPA1A,HSPA1B \| innate immune response activating cell surface receptor signaling pathway:MUC21 \| response to isoquinoline alkaloid:AIF1 \| response to morphine:AIF1 \| positive regulation of T cell mediated immunity:HLA-E,NCR3 \| spindle assembly:HSPA1A,HSPA1B \| ganglioside metabolic process:NEU1 \| positive regulation of cellular amide metabolic process:DDX39B \| nucleic acid phosphodiester bond hydrolysis:HSPA1A,RPP21,ZNRD1 \| exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay:SKIV2L \| transcription initiation from RNA polymerase I promoter:ZNRD1 \| nuclear-transcribed mRNA catabolic process:SKIV2L \| positive regulation of B cell mediated immunity:LTA \| positive regulation of immunoglobulin mediated immune response:LTA \| positive regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| positive regulation of leukocyte mediated cytotoxicity:HLA-E,NCR3 \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| reactive oxygen species biosynthetic process:AIF1,DDAH2 \| CD8-positive, alpha-beta T cell activation:HLA-E \| negative regulation of immune system process:HLA-E,LST1 \| positive regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| macroautophagy:ATP6V1G2 \| regulation of T cell mediated immunity:HLA-E,NCR3 \| negative regulation of lymphocyte mediated immunity:HLA-E \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| receptor-mediated endocytosis:FLOT1 \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| DNA-templated transcription, termination:DDX39B,ZNRD1 \| regulation of vascular smooth muscle cell proliferation:DDX39B \| vascular smooth muscle cell proliferation:DDX39B \| regulation of macroautophagy:ATP6V1G2 \| membrane assembly:FLOT1 \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:FLOT1,LY6G5C \| regulation of interferon-gamma production:LTA \| protein export from nucleus:DDX39B \| viral life cycle:HSPA1A,HSPA1B \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress:ATF6B \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| regulation of proteolysis involved in cellular protein catabolic process:BAG6,HSPA1A \| regulation of mononuclear cell migration:AIF1 \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| inflammatory response to antigenic stimulus:LTA \| positive regulation of catabolic process:BAG6,HSPA1A \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:BAG6,HSPA1A \| microglial cell activation:AIF1 \| negative regulation of proteolysis involved in cellular protein catabolic process:BAG6 \| positive regulation of cell killing:HLA-E,NCR3 \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| negative regulation of innate immune response:HLA-E \| phagocytosis:AIF1 \| mRNA cleavage involved in mRNA processing:HSPA1A \| regulation of autophagy:ATP6V1G2 \| response to ammonium ion:AIF1 \| microtubule polymerization:HSPA1A,HSPA1B \| regulation of inflammatory response:LTA \| synapsis:BAG6,MSH5 \| macrophage activation:AIF1 \| protein folding:HSPA1A,HSPA1B,HSPA1L \| negative regulation of leukocyte mediated immunity:HLA-E \| positive regulation of protein catabolic process:BAG6,HSPA1A \| positive regulation of cellular catabolic process:BAG6,HSPA1A \| regulation of B cell mediated immunity:LTA \| regulation of immunoglobulin mediated immune response:LTA \| tRNA aminoacylation for protein translation:VARS2 \| nuclear-transcribed mRNA catabolic process, nonsense-mediated decay:SKIV2L \| extracellular matrix organization:DDR1,FLOT1 \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| regulation of smooth muscle cell proliferation:AIF1,DDX39B \| membrane biogenesis:FLOT1 \| extracellular structure organization:DDR1,FLOT1 \| heterotypic cell-cell adhesion:FLOT1 \| branching involved in mammary gland duct morphogenesis:DDR1 \| negative regulation of growth:HSPA1A,HSPA1B,LTA \| negative regulation of immune response:HLA-E \| tRNA aminoacylation:VARS2 \| regulation of binding:FLOT1 \| regulation of mRNA metabolic process:HSPA1A \| smooth muscle cell proliferation:AIF1,DDX39B \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| syncytium formation by plasma membrane fusion:FLOT1 \| amino acid activation:VARS2 \| regulation of RNA stability:HSPA1A \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| nuclear export:DDX39B \| syncytium formation:FLOT1 \| regulation of symbiosis, encompassing mutualism through parasitism:LTA \| regulation of monooxygenase activity:DDAH2 \| positive regulation of cellular component biogenesis:FLOT1,HSPA1A,HSPA1B \| regulation of cellular protein catabolic process:BAG6,HSPA1A \| defense response to bacterium:HLA-E,LTA \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| glial cell activation:AIF1 \| protein polymerization:AIF1,HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| regulation of mitotic cell cycle phase transition:AIF1 \| protein glycosylation:MUC21 \| macromolecule glycosylation:MUC21 \| mitochondrial membrane organization:HSPA1A \| receptor metabolic process:FLOT1 \| immunoglobulin production:HLA-E \| reactive oxygen species metabolic process:AIF1,DDAH2 \| regulation of immunoglobulin production:HLA-E \| regulation of receptor internalization:FLOT1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| cellular response to ammonium ion:AIF1 \| homologous chromosome segregation:BAG6,MSH5 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:BAG6,HSPA1A \| positive regulation of cell junction assembly:FLOT1 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| negative regulation of cellular protein catabolic process:BAG6 \| negative regulation of catabolic process:BAG6 \| regulation of mRNA catabolic process:HSPA1A \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| glycosylation:MUC21 \| negative regulation of cellular catabolic process:BAG6 \| cellular amino acid metabolic process:DDAH2,VARS2 \| transcription from RNA polymerase I promoter:ZNRD1 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| gland morphogenesis:DDR1 \| regulation of protein complex assembly:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| spindle organization:HSPA1A,HSPA1B \| ruffle assembly:AIF1 \| regulation of protein catabolic process:BAG6,HSPA1A \| DNA-templated transcription, initiation:ZNRD1 \| chromosome organization involved in meiotic cell cycle:BAG6,MSH5 \| negative regulation of chemotaxis:AIF1 \| regulation of cell cycle phase transition:AIF1 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| mammary gland duct morphogenesis:DDR1 \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| multi-organism transport:DDX39B \| multi-organism localization:DDX39B \| autophagy:ATP6V1G2 \| process utilizing autophagic mechanism:ATP6V1G2 \| cellular response to oxidative stress:AIF1,HSPA1A,HSPA1B \| regulation of striated muscle tissue development:DDX39B,FLOT1 \| positive regulation of striated muscle cell differentiation:DDX39B,FLOT1 \| receptor internalization:FLOT1 \| regulation of reactive oxygen species metabolic process:AIF1,DDAH2 \| negative regulation of proteolysis:BAG6 \| ubiquitin-dependent ERAD pathway:BAG6 \| regulation of muscle tissue development:DDX39B,FLOT1 \| regulation of multi-organism process:LTA \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| negative regulation of fibroblast proliferation:LTA \| regulation of response to endoplasmic reticulum stress:BAG6,HSPA1A \| regulation of leukocyte chemotaxis:AIF1 \| mammary gland development:DDR1 \| response to unfolded protein:ATF6B,HSPA1A,HSPA1L \| response to oxidative stress:AIF1,HSPA1A,HSPA1B \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| negative regulation of defense response:HLA-E \| smooth muscle cell migration:AIF1,DDR1 \| negative regulation of leukocyte activation:LST1 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:SKIV2L	0.052087	0.0921601	0.242594100990003				0.0206009	0.13863	0.0545974011286864	0.646087	0.1004	9.8156209193414				0.668226	0.148298	5.11195087017326	0.138027	0.0755924	1.16746490268056				0.170097	0.105306	0.971843721129461	0.00837322	0.0542513	0.0568315746677749							0.056441	0.0535671	0.534553198935695							0.0112659	0.052176	0.081419800208806							0.0192917	0.0311732	0.270825487405279							0.268284	0.149941	1.13239169863366				0.214534	0.182383	0.619980614055836
rs148331983:32482155:A:AGTTTATCCATTTT		6	32482155	6p21.32	AGTTTATCCATTTT	A	0.833	0	OHP17 ALL	2070	9.64398562210789	0.0191835700483092		HLA-DRB5 (3 kb, near gene/Downstream gene/MODIFIER); RNU1-61P (36 kb); HLA-DRB6 (38 kb); HLA-DRB9 (41 kb)	NA	APOM \| ATP6V1G2 \| B3GALT4 \| CLIC1 \| DDAH2 \| HLA-DMA \| HLA-DOB \| HLA-DPB1 \| HLA-DQA1 \| HLA-DRA \| HLA-DRB1 \| HSPA1L \| LSM2 \| LST1 \| LTB \| NEU1 \| PSMB8 \| PSMB9 \| RNF5 \| SKIV2L \| TAP2	ARHGAP24 \| BTN3A2 \| CLK3 \| DEF8 \| EEF1G \| EXOC1 \| GOLGA2 \| HLA-C \| HLA-G \| HLA-H \| KPNA2 \| ME2 \| RPL34 \| SSRP1 \| TINF2 \| TMEM154 \| VARS2 \| XRCC6 \| ZNF672	Type I diabetes mellitus:HLA-DRB5 \| Allograft rejection:HLA-DRB5 \| Graft-versus-host disease:HLA-DRB5 \| Antigen processing and presentation:HLA-DRB5 \| Autoimmune thyroid disease:HLA-DRB5 \| Viral myocarditis:HLA-DRB5 \| Staphylococcus aureus infection:HLA-DRB5 \| Asthma:HLA-DRB5 \| Phagosome:HLA-DRB5 \| Herpes simplex infection:HLA-DRB5 \| Intestinal immune network for IgA production:HLA-DRB5 \| Rheumatoid arthritis:HLA-DRB5 \| Inflammatory bowel disease (IBD):HLA-DRB5 \| Toxoplasmosis:HLA-DRB5 \| Systemic lupus erythematosus:HLA-DRB5 \| Cell adhesion molecules (CAMs):HLA-DRB5 \| Leishmaniasis:HLA-DRB5 \| Influenza A:HLA-DRB5 \| Hematopoietic cell lineage:HLA-DRB5 \| Epstein-Barr virus infection:HLA-DRB5 \| Human T-cell leukemia virus 1 infection:HLA-DRB5 \| Th1 and Th2 cell differentiation:HLA-DRB5 \| Th17 cell differentiation:HLA-DRB5 \| Tuberculosis:HLA-DRB5	Translocation of ZAP-70 to Immunological synapse:HLA-DRB5 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DRB5 \| Interferon gamma signaling:HLA-DRB5 \| PD-1 signaling:HLA-DRB5 \| Generation of second messenger molecules:HLA-DRB5 \| Downstream TCR signaling:HLA-DRB5 \| Interferon Signaling:HLA-DRB5 \| TCR signaling:HLA-DRB5 \| MHC class II antigen presentation:HLA-DRB5 \| Costimulation by the CD28 family:HLA-DRB5	multiple sclerosis:HLA-DRB5 \| demyelinating disease:HLA-DRB5	antigen processing and presentation of exogenous peptide antigen:HLA-DRB5 \| antigen processing and presentation of exogenous antigen:HLA-DRB5 \| antigen processing and presentation of peptide antigen:HLA-DRB5 \| antigen processing and presentation:HLA-DRB5 \| interferon-gamma-mediated signaling pathway:HLA-DRB5 \| cellular response to interferon-gamma:HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DRB5 \| response to interferon-gamma:HLA-DRB5 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DRB5 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DRB5 \| T cell receptor signaling pathway:HLA-DRB5 \| immune response-activating signal transduction:HLA-DRB5 \| T cell costimulation:HLA-DRB5 \| immune response-activating cell surface receptor signaling pathway:HLA-DRB5 \| lymphocyte costimulation:HLA-DRB5 \| antigen receptor-mediated signaling pathway:HLA-DRB5 \| immune response-regulating cell surface receptor signaling pathway:HLA-DRB5 \| positive regulation of cell-cell adhesion:HLA-DRB5 \| positive regulation of leukocyte cell-cell adhesion:HLA-DRB5 \| positive regulation of T cell activation:HLA-DRB5 \| T cell activation:HLA-DRB5 \| regulation of cell-cell adhesion:HLA-DRB5 \| regulation of leukocyte cell-cell adhesion:HLA-DRB5 \| positive regulation of cell adhesion:HLA-DRB5 \| positive regulation of lymphocyte activation:HLA-DRB5 \| positive regulation of cell activation:HLA-DRB5 \| regulation of lymphocyte activation:HLA-DRB5 \| regulation of T cell activation:HLA-DRB5 \| regulation of leukocyte activation:HLA-DRB5 \| leukocyte cell-cell adhesion:HLA-DRB5 \| positive regulation of leukocyte activation:HLA-DRB5	0.153623	0.0667305	1.66904876478774	0.232317	0.0634046	3.58862781141311	0.0481243	0.120836	0.160875314140824	0.463987	0.0727977	9.64398562210789	0.363318	0.0834028	4.84670355064469	0.614717	0.1344	5.24765494964562	0.197264	0.0546724	3.50061262899355	0.269687	0.0657533	4.3615666558191	0.104971	0.0955719	0.564749852082608	-0.0596622	0.0370759	0.968288645245407	-0.058499	0.0440748	0.734191982313643	-0.0552819	0.0636323	0.414570856693332	0.00277641	0.0370613	0.0267414157184767	0.00317891	0.0370822	0.0307313626750435	0.0422114	0.0643377	0.290929419165197	0.0641902	0.0349631	1.17804977656349	0.0776407	0.0409236	1.23807141020558	0.0310432	0.0592989	0.221397318058919	0.0339301	0.0213889	0.948226398204925	0.0427405	0.0267096	0.960367796808373	0.0230598	0.0352115	0.290276472149563	0.164128	0.109165	0.876559990924836	0.226518	0.145211	0.924380054071224	0.0704338	0.16491	0.174288990228294
rs9692804:144058625:G:A	novel1	8	144058625	8q24.3	A	G	0.916	192	ANDRO ALL	2070	9.58406725356153	0.426122946859903		RP11-273G15.2 (4.5 kb, near gene/Downstream gene/MODIFIER); CDC42P3 (19 kb); LY6E (41 kb); CYP11B2 (59 kb)	0.891 Diastolic blood pressure // 0.848 Estrone levels // 0.611 Plasma androstenedione levels in resected early stage-receptor positive breast cancer // 0.564 Mean arterial pressure // 0.53 Systolic blood pressure	C8orf31 \| C8orf55 \| C8ORF55 \| CTD-2292P10.4 \| GLI4 \| GML \| GRINA \| JRK \| LY6D \| LY6E \| LY6K \| LYNX1 \| LYPD2 \| NAPRT1 \| PSCA \| PUF60 \| RP11-273G15.2 \| RP11-706C16.7 \| RP13-582O9.5 \| SLURP1 \| THEM6 \| TIGD5 \| unnamed \| ZFP41 \| ZNF623		Steroid hormone biosynthesis:CYP11B2	Post-translational modification: synthesis of GPI-anchored proteins:LY6D,LY6E,LY6K,LYPD2 \| Cytochrome P450 - arranged by substrate type:CYP11B2 \| Endogenous sterols:CYP11B2 \| Metabolism of steroid hormones:CYP11B2 \| Metabolic disorders of biological oxidation enzymes:CYP11B2 \| Phase I - Functionalization of compounds:CYP11B2 \| Diseases of metabolism:CYP11B2 \| Metabolism of steroids:CYP11B2 \| Biological oxidations:CYP11B2	endocrine system disease:CYP11B2 \| glucocorticoid-remediable aldosteronism:CYP11B2 \| hyperaldosteronism:CYP11B2 \| adrenal gland hyperfunction:CYP11B2 \| adrenal cortex disease:CYP11B2 \| adrenal gland disease:CYP11B2 \| hemorrhagic disease:CYP11B2 \| blood coagulation disease:CYP11B2 \| hematopoietic system disease:CYP11B2 \| essential hypertension:CYP11B2 \| cell type benign neoplasm:CYP11B2 \| pulmonary edema:CYP11B2 \| lower respiratory tract disease:CYP11B2 \| myopathy:CYP11B2 \| muscle tissue disease:CYP11B2 \| adenoma:CYP11B2 \| cardiomyopathy:CYP11B2 \| muscular disease:CYP11B2 \| lung disease:CYP11B2	C-terminal protein lipidation:LY6D,LY6E,LY6K,LYPD2 \| C-terminal protein amino acid modification:LY6D,LY6E,LY6K,LYPD2 \| C21-steroid hormone biosynthetic process:CYP11B2 \| protein lipidation:LY6D,LY6E,LY6K,LYPD2 \| lipoprotein biosynthetic process:LY6D,LY6E,LY6K,LYPD2 \| C21-steroid hormone metabolic process:CYP11B2 \| lipoprotein metabolic process:LY6D,LY6E,LY6K,LYPD2 \| hormone biosynthetic process:CYP11B2 \| mineralocorticoid biosynthetic process:CYP11B2 \| mineralocorticoid metabolic process:CYP11B2 \| response to potassium ion:CYP11B2 \| aldehyde biosynthetic process:CYP11B2 \| glucocorticoid biosynthetic process:CYP11B2 \| glucocorticoid metabolic process:CYP11B2 \| post-translational protein modification:LY6D,LY6E,LY6K,LYPD2 \| cellular hormone metabolic process:CYP11B2 \| ketone biosynthetic process:CYP11B2 \| sterol metabolic process:CYP11B2 \| steroid biosynthetic process:CYP11B2 \| hormone metabolic process:CYP11B2 \| cellular aldehyde metabolic process:CYP11B2 \| steroid metabolic process:CYP11B2 \| cell recognition:LY6K \| regulation of neurotransmitter receptor activity:LYNX1 \| cellular response to metal ion:CYP11B2 \| regulation of blood pressure:CYP11B2 \| cellular response to inorganic substance:CYP11B2 \| regulation of hormone levels:CYP11B2 \| organic hydroxy compound metabolic process:CYP11B2 \| organic hydroxy compound biosynthetic process:CYP11B2 \| cellular ketone metabolic process:CYP11B2 \| flagellated sperm motility:LY6K \| sperm motility:LY6K \| response to metal ion:CYP11B2 \| potassium ion homeostasis:CYP11B2	0.00661663	0.0174315	0.152244161510012	-0.00622137	0.0157352	0.15950183683204	0.0107541	0.0345226	0.121814970704674	0.0353407	0.0191628	1.18513936288971	0.0379296	0.0207157	1.17181589712575	0.0295586	0.0388503	0.349682761216518	0.0900147	0.014171	9.58406725356153	0.0817186	0.0161876	6.29529538177953	0.104987	0.0269745	3.9634589304165	0.0184343	0.0105957	1.08673359763719	0.017156	0.0131857	0.713943426913014	0.0183241	0.0170592	0.548586634771233	0.04795	0.0103869	5.40836561619459	0.0295342	0.0109851	2.14413996309399	0.0713493	0.0175761	4.30814348442708	0.008142	0.010151	0.374173286714289	0.0128722	0.0124512	0.521110428711954	0.00633055	0.0162311	0.157067655694199	0.00569258	0.00606496	0.458501881852253	0.0136557	0.00782111	1.09253489323414	-0.005177	0.00951027	0.231957890233425	-0.0202852	0.0287719	0.317971413235485	0.0154077	0.0359764	0.174882996957764	-0.0851808	0.0478301	1.12278304618714
rs12591359:51539368:G:A		15	51539368	15q21.2	A	G	1	0	E2 ALL	6798	9.47540527740602	0.407252132980288	1.54431	RP11-108K3.1 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); CYP19A1 (0 kb, intron/Intron/MODIFIER \| near gene/Upstream gene/MODIFIER); MIR4713 (4.9 kb, near gene/Downstream gene/MODIFIER); GLDN (94 kb)	0.689 Hormone measurements // 0.689 Follicule stimulating hormone // 0.689 Total body bone mineral density // 0.683 Estradiol levels // 0.683 Estrone levels // 0.577 Endometrial cancer // 0.577 Endometrial endometrioid carcinoma // 0.558 Menarche (age at onset) // 0.421 Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer // 0.37 Thiazide-induced adverse metabolic effects in hypertensive patients	AP4E1 \| CYP19A1 \| DCAF13P3 \| DMXL2 \| GABPB1 \| GABPB1-AS1 \| GLDN \| GNB5 \| MAPK6 \| MYO5C \| RP11-108K3.1 \| RP11-707P17.2 \| SPPL2A \| TMOD2 \| TRPM7 \| USP8	BAZ1B	Steroid hormone biosynthesis:CYP19A1 \| Endocytosis:USP8 \| Kaposi sarcoma-associated herpesvirus infection:GNB5 \| Human cytomegalovirus infection:GNB5 \| Lysosome:AP4E1	Cytochrome P450 - arranged by substrate type:CYP19A1 \| Metabolism of steroid hormones:CYP19A1 \| Phase I - Functionalization of compounds:CYP19A1 \| Endogenous sterols:CYP19A1 \| Metabolic disorders of biological oxidation enzymes:CYP19A1 \| Biological oxidations:CYP19A1 \| Chaperonin-mediated protein folding:GNB5	endocrine system disease:CYP19A1 \| hepatitis:GNB5 \| hepatitis B:GNB5 \| male reproductive system disease:CYP19A1 \| male infertility:CYP19A1 \| hyperandrogenism:CYP19A1 \| gonadal disease:CYP19A1 \| polycystic ovary syndrome:CYP19A1 \| reproductive system disease:CYP19A1 \| prostate disease:CYP19A1 \| sex differentiation disease:CYP19A1 \| essential hypertension:CYP19A1 \| osteoporosis:CYP19A1 \| bone resorption disease:CYP19A1 \| cell type benign neoplasm:CYP19A1 \| infertility:CYP19A1 \| sporadic breast cancer:CYP19A1 \| ovarian disease:CYP19A1 \| female reproductive organ cancer:CYP19A1 \| cerebral palsy:AP4E1	tumor necrosis factor-mediated signaling pathway:SPPL2A \| cellular response to tumor necrosis factor:SPPL2A \| chronic inflammatory response:CYP19A1 \| response to tumor necrosis factor:SPPL2A \| regulation of chronic inflammatory response:CYP19A1 \| cellular hormone metabolic process:CYP19A1 \| steroid catabolic process:CYP19A1 \| hormone biosynthetic process:CYP19A1 \| steroid metabolic process:CYP19A1 \| hormone metabolic process:CYP19A1 \| mammary gland development:CYP19A1 \| androgen metabolic process:CYP19A1 \| actomyosin structure organization:TMOD2 \| steroid biosynthetic process:CYP19A1 \| regulation of tumor necrosis factor-mediated signaling pathway:SPPL2A \| protein folding:GNB5 \| estrogen biosynthetic process:CYP19A1 \| ketone biosynthetic process:CYP19A1 \| negative regulation of immune system process:CYP19A1 \| protein deubiquitination:USP8 \| negative regulation of chemotaxis:CYP19A1 \| calcium ion transmembrane transport:GNB5 \| protein modification by small protein removal:USP8 \| lipid transport:CYP19A1,TNFAIP8L3 \| regulation of leukocyte chemotaxis:CYP19A1 \| lipid localization:CYP19A1,TNFAIP8L3	-0.0355075	0.0170745	1.4237876901353	-0.0141343	0.0154642	0.442640796220868	-0.0582829	0.0337201	1.07618006809184	-0.0234055	0.0187978	0.671155766591769	-0.0150354	0.0203851	0.336388580526746	-0.0406878	0.0378373	0.54884167374216	-8.62552E-4	0.0140299	0.0218272465454274	0.0098695	0.0160596	0.268449106298683	-0.0218881	0.0265488	0.38725639682939	0.0137584	0.0102645	0.744440472855493	0.0237404	0.0128059	1.19545986536167	0.00394694	0.0164716	0.0911800065718447	0.0186511	0.0100983	1.18873138702638	0.0287024	0.0106647	2.14774270036739	0.00332104	0.0170777	0.0727271845010768	-0.0619644	0.0098641	9.47540527740602	-0.0652903	0.0120497	7.22088207338473	-0.0578597	0.0158551	3.58009709663937	-0.00621471	0.00588163	0.536584848478778	-0.00878137	0.00760965	0.604657878240273	-0.00286467	0.00918949	0.121913291311831	0.00337329	0.0282566	0.0433581392144384	-0.017996	0.0355324	0.212812373612576	0.0423025	0.0465158	0.439556521730679
rs955783:22299075:A:T		13	22299075	13q12.11	T	A	0.977	8	DHEAS ALL	7659	9.42280242516918	0.424924663794229	6.10673E-4	FGF9 (20 kb); RN7SL766P (66 kb); RPS7P10 (96 kb); MICU2 (120 kb)	0.384 Response to antipsychotic treatment	FGF9	CCPG1 \| CSNK1G2	Regulation of actin cytoskeleton:FGF9		endocrine system disease:FGF9 \| gonadal dysgenesis:FGF9 \| gonadal disease:FGF9	organ growth:FGF9 \| nucleocytoplasmic transport:FGF9 \| nuclear transport:FGF9 \| regulation of activin receptor signaling pathway:FGF9 \| cellular response to fibroblast growth factor stimulus:FGF9 \| lipid modification:FGF9 \| response to fibroblast growth factor:FGF9 \| protein localization to nucleus:FGF9 \| regulation of cardiac muscle tissue growth:FGF9 \| smoothened signaling pathway:FGF9 \| regulation of heart growth:FGF9 \| activin receptor signaling pathway:FGF9 \| regulation of protein kinase B signaling:FGF9 \| regulation of cardiac muscle tissue development:FGF9 \| cardiac muscle tissue growth:FGF9 \| regulation of striated muscle tissue development:FGF9 \| regulation of muscle tissue development:FGF9 \| heart growth:FGF9 \| positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway:FGF9 \| regulation of organ growth:FGF9	-0.0243096	0.0171869	0.803028383364843	-0.0135138	0.0152823	0.423998615374119	-0.0280994	0.03445	0.382269106396673	-0.0109186	0.0189165	0.248824091716943	-0.0130748	0.0201459	0.286975922873048	-0.00942614	0.0394679	0.0908153121926686	0.00206643	0.0141142	0.0537374117745959	-0.0053451	0.015872	0.132916888433155	0.0146686	0.0276792	0.22452717925859	0.0636697	0.0101661	9.42280242516918	0.0567802	0.0126579	5.13873688389351	0.0717924	0.0163482	4.94846932348714	0.0123787	0.0100554	0.660942285431562	-0.0137718	0.0105712	0.715224223747781	0.0424669	0.0172117	1.8660652976573	-0.0046352	0.00975701	0.19740276407023	0.00348958	0.0119807	0.113031813453063	-0.0146608	0.0156378	0.457808433350214	0.00721203	0.00584653	0.662804390545634	-0.00306414	0.00753712	0.164724266850492	0.0192638	0.00916418	1.44920071106116	-0.00395636	0.0284262	0.0509409639978167	0.0194544	0.0351498	0.23654579980214	-0.0500826	0.0483675	0.521691849377678
rs12674916:143957958:G:A		8	143957958	8q24.3	A	G	0.823	1	ANDRO ALL	2070	9.380426705214	0.639504106280193		GML (0 kb, intron/Intron/MODIFIER); CYP11B1 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); ZNHIT1P1 (18 kb); CYP11B2 (34 kb)	0.518 Systolic blood pressure // 0.48 Estrone levels // 0.419 Diastolic blood pressure // 0.403 Plasma androstenedione levels in resected early stage-receptor positive breast cancer // 0.326 Mean arterial pressure	C8orf55 \| C8ORF55 \| CTD-2292P10.4 \| EEF1D \| GML \| JRK \| LY6D \| LY6E \| LY6K \| LYNX1 \| LYPD2 \| NAPRT1 \| PSCA \| RP11-273G15.2 \| RP11-706C16.7 \| RP13-582O9.5 \| SLURP1 \| THEM6 \| TIGD5 \| unnamed \| ZFP41 \| ZNF623		Steroid hormone biosynthesis:CYP11B1,CYP11B2 \| Cortisol synthesis and secretion:CYP11B1	Post-translational modification: synthesis of GPI-anchored proteins:LY6D,LY6E,LYPD2 \| Cytochrome P450 - arranged by substrate type:CYP11B1,CYP11B2 \| Endogenous sterols:CYP11B1,CYP11B2 \| Metabolism of steroid hormones:CYP11B1,CYP11B2 \| Metabolic disorders of biological oxidation enzymes:CYP11B1,CYP11B2 \| Phase I - Functionalization of compounds:CYP11B1,CYP11B2 \| Diseases of metabolism:CYP11B1,CYP11B2 \| Metabolism of steroids:CYP11B1,CYP11B2 \| Biological oxidations:CYP11B1,CYP11B2	endocrine system disease:CYP11B1,CYP11B2 \| glucocorticoid-remediable aldosteronism:CYP11B1,CYP11B2 \| hyperaldosteronism:CYP11B1,CYP11B2 \| adrenal gland hyperfunction:CYP11B1,CYP11B2 \| adrenal cortex disease:CYP11B1,CYP11B2 \| adrenal gland disease:CYP11B1,CYP11B2 \| hemorrhagic disease:CYP11B2 \| blood coagulation disease:CYP11B2 \| hyperandrogenism:CYP11B1 \| polycystic ovary syndrome:CYP11B1 \| hematopoietic system disease:CYP11B2 \| sex differentiation disease:CYP11B1 \| essential hypertension:CYP11B2 \| gonadal disease:CYP11B1 \| cell type benign neoplasm:CYP11B1,CYP11B2 \| pulmonary edema:CYP11B2 \| lower respiratory tract disease:CYP11B2 \| myopathy:CYP11B2 \| muscle tissue disease:CYP11B2 \| adenoma:CYP11B1,CYP11B2 \| cardiomyopathy:CYP11B2 \| muscular disease:CYP11B2 \| lung disease:CYP11B2	C-terminal protein lipidation:LY6D,LY6E,LYPD2 \| C-terminal protein amino acid modification:LY6D,LY6E,LYPD2 \| C21-steroid hormone biosynthetic process:CYP11B1,CYP11B2 \| protein lipidation:LY6D,LY6E,LYPD2 \| lipoprotein biosynthetic process:LY6D,LY6E,LYPD2 \| C21-steroid hormone metabolic process:CYP11B1,CYP11B2 \| lipoprotein metabolic process:LY6D,LY6E,LYPD2 \| hormone biosynthetic process:CYP11B1,CYP11B2 \| mineralocorticoid biosynthetic process:CYP11B1,CYP11B2 \| mineralocorticoid metabolic process:CYP11B1,CYP11B2 \| response to potassium ion:CYP11B1,CYP11B2 \| aldehyde biosynthetic process:CYP11B1,CYP11B2 \| glucocorticoid biosynthetic process:CYP11B1,CYP11B2 \| glucocorticoid metabolic process:CYP11B1,CYP11B2 \| post-translational protein modification:LY6D,LY6E,LYPD2 \| cellular hormone metabolic process:CYP11B1,CYP11B2 \| ketone biosynthetic process:CYP11B1,CYP11B2 \| sterol metabolic process:CYP11B1,CYP11B2 \| steroid biosynthetic process:CYP11B1,CYP11B2 \| hormone metabolic process:CYP11B1,CYP11B2 \| cellular aldehyde metabolic process:CYP11B1,CYP11B2 \| steroid metabolic process:CYP11B1,CYP11B2 \| regulation of neurotransmitter receptor activity:LYNX1 \| cellular response to metal ion:CYP11B1,CYP11B2 \| regulation of blood pressure:CYP11B1,CYP11B2 \| cellular response to inorganic substance:CYP11B1,CYP11B2 \| regulation of hormone levels:CYP11B1,CYP11B2 \| organic hydroxy compound metabolic process:CYP11B1,CYP11B2 \| organic hydroxy compound biosynthetic process:CYP11B1,CYP11B2 \| regulation of G1/S transition of mitotic cell cycle:GML \| cellular ketone metabolic process:CYP11B1,CYP11B2 \| regulation of cell cycle G1/S phase transition:GML \| response to metal ion:CYP11B1,CYP11B2 \| G1/S transition of mitotic cell cycle:GML \| positive regulation of cell cycle process:GML \| cell cycle G1/S phase transition:GML \| potassium ion homeostasis:CYP11B2 \| positive regulation of cell cycle:GML	-0.0121514	0.0192014	0.278264383289129	0.017393	0.0174108	0.497594731859991	-0.0203699	0.0375728	0.230830269023947	-0.0312681	0.021116	0.857554216922716	-0.0116912	0.022955	0.214230397571827	-0.065045	0.0423961	0.901626278173662	-0.0980283	0.0156142	9.380426705214	-0.0809222	0.0179506	5.14829413044113	-0.12829	0.029394	4.83441146199329	-0.0248257	0.0114668	1.51731789103045	-0.0271014	0.0143397	1.23089308424801	-0.0205249	0.0183516	0.579408962110476	-0.0395923	0.0112948	3.34104468144179	-0.0195296	0.0119684	0.988302711885857	-0.0709728	0.0190092	3.72410383620463	-0.0133756	0.010979	0.651473177667824				-0.0240831	0.0174555	0.775510964707157	-0.00934606	0.006579	0.808448388426543	-0.0135709	0.0085303	0.952211294364931	-0.00322325	0.0102501	0.123105833731748	0.0378587	0.0316427	0.63513769989964	0.00420385	0.0398207	0.0381329745006743	0.0962826	0.0520295	1.18930788406243
rs35894069:7395176:G:A		17	7395176	17p13.1	A	G	0.972	1	TESTO MEN	4291	9.3444812436794	0.347078186902819	0.202956	POLR2A (0 kb, intron/Intron/MODIFIER); ZBTB4 (7.6 kb); SLC35G6 (8.8 kb); CHRNB1 (34 kb); FGF11 (47 kb)	0.506 Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test) // 0.506 Systolic blood pressure x smoking status (current vs non-current) interaction (2df test) // 0.506 Systolic blood pressure x smoking status (ever vs never) interaction (2df test) // 0.506 Diastolic blood pressure x smoking status (ever vs never) interaction (2df test) // 0.498 Blood protein levels // 0.469 Chin dimples // 0.402 Testosterone levels // 0.402 Sex hormone-binding globulin levels // 0.318 Protein quantitative trait loci // 0.316 Myopia // 0.309 IgA nephropathy	- \| AC113189.5 \| ACAP1 \| ASGR2 \| ATP1B2 \| C17orf61 \| C17orf61-PLSCR3 \| C17orf74 \| C17orf81 \| CD68 \| CHRNB1 \| CTC1 \| CTDNEP1 \| CYB5D1 \| EIF4A1 \| EIF5A \| FGF11 \| FXR2 \| KCTD11 \| LSMD1 \| MPDU1 \| PLSCR3 \| POLR2A \| RP11-186B7.4 \| SAT2 \| SENP3 \| SENP3-EIF4A1 \| SHBG \| SLC2A4 \| SLC35G6 \| SNORA48 \| SNORA67 \| SOX15 \| SPEM1 \| TMEM102 \| TMEM256-PLSCR3 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| TP53 \| YBX2 \| ZBTB4	EIF4A1P2 \| EIF5AL1	Herpes simplex infection:POLR2A \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Epstein-Barr virus infection:POLR2A \| Endocytosis:ACAP1 \| Huntington disease:POLR2A \| Ferroptosis:SAT2 \| Lysosome:CD68 \| RNA transport:EIF4A1	Interferon Signaling:EIF4A1 \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13 \| TP53 Regulates Transcription of DNA Repair Genes:POLR2A \| TNFR2 non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13,TNFSF13 \| MicroRNA (miRNA) biogenesis:POLR2A \| Transcriptional regulation of pluripotent stem cells:POLR2A \| Infectious disease:POLR2A \| Influenza Infection:POLR2A \| Transcriptional Regulation by TP53:POLR2A \| HIV Transcription Elongation:POLR2A \| Formation of HIV-1 elongation complex containing HIV-1 Tat:POLR2A \| Tat-mediated elongation of the HIV-1 transcript:POLR2A \| Transcription of the HIV genome:POLR2A \| Formation of HIV elongation complex in the absence of HIV Tat:POLR2A \| ISG15 antiviral mechanism:EIF4A1 \| Antiviral mechanism by IFN-stimulated genes:EIF4A1 \| RNA Polymerase II Pre-transcription Events:POLR2A \| Formation of the Early Elongation Complex:POLR2A \| Formation of the HIV-1 Early Elongation Complex:POLR2A \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Pausing and recovery of Tat-mediated HIV elongation:POLR2A \| Tat-mediated HIV elongation arrest and recovery:POLR2A \| Formation of RNA Pol II elongation complex :POLR2A \| RNA Polymerase II Transcription Elongation:POLR2A \| HIV elongation arrest and recovery:POLR2A \| Pausing and recovery of HIV elongation:POLR2A \| Transcriptional regulation by small RNAs:POLR2A	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| lymphatic system disease:TNFSF13 \| hepatitis:EIF4A1 \| hepatitis C:EIF4A1 \| hypotrichosis:TNFSF13 \| urinary system disease:TNFSF12,TNFSF13 \| multiple myeloma:TNFSF13 \| myeloma:TNFSF13 \| bone marrow cancer:TNFSF13 \| hair disease:TNFSF13 \| proteinuria:TNFSF12 \| kidney disease:TNFSF12,TNFSF13 \| purpura:TNFSF13 \| alopecia:TNFSF13 \| collagen disease:TNFSF12,TNFSF13 \| nephritis:TNFSF12,TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| rheumatic disease:TNFSF12,TNFSF13 \| systemic scleroderma:TNFSF12,TNFSF13 \| scleroderma:TNFSF12,TNFSF13 \| integumentary system disease:TNFSF12,TNFSF13 \| hematopoietic system disease:TNFSF13 \| colon carcinoma:TNFSF13 \| intestinal cancer:SAT2,TNFSF13 \| interstitial lung disease:TNFSF12 \| myopathy:TNFSF12,TNFSF13 \| muscle tissue disease:TNFSF12,TNFSF13 \| Sjogren's syndrome:TNFSF13 \| muscular disease:TNFSF12,TNFSF13 \| alopecia areata:TNFSF13 \| non-small cell lung carcinoma:EIF5A,TNFSF13 \| colon cancer:TNFSF13 \| colorectal cancer:TNFSF13 \| large intestine cancer:TNFSF13 \| myositis:TNFSF13 \| lower respiratory tract disease:TNFSF12 \| lung adenocarcinoma:EIF5A \| cardiomyopathy:TNFSF12 \| liver cirrhosis:TNFSF13 \| lung disease:TNFSF12 \| chronic lymphocytic leukemia:TNFSF13 \| dilated cardiomyopathy:TNFSF12 \| acute myocardial infarction:TNFSF12 \| coronary artery disease:TNFSF12	positive regulation of cell activation:SOX15,TNFSF13 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF12,TNFSF13 \| positive regulation of lymphocyte activation:TNFSF13 \| positive regulation of leukocyte activation:TNFSF13 \| regulation of leukocyte activation:TNFSF13 \| regulation of lymphocyte activation:TNFSF13 \| postsynaptic membrane organization:CHRNB1 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| RNA secondary structure unwinding:EIF4A1 \| cellular response to tumor necrosis factor:TNFSF12,TNFSF13 \| response to tumor necrosis factor:TNFSF12,TNFSF13 \| ammonium ion metabolic process:SAT2 \| regulation of immune effector process:TNFSF13 \| positive regulation of cell cycle process:SOX15 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| B cell mediated immunity:TNFSF13 \| translational initiation:EIF4A1 \| positive regulation of adaptive immune response:TNFSF13 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:CHRNB1 \| nucleocytoplasmic transport:EIF5A \| nuclear transport:EIF5A \| positive regulation of DNA metabolic process:TNFSF13 \| chemical synaptic transmission, postsynaptic:CHRNB1 \| positive regulation of reactive oxygen species metabolic process:EIF5A \| positive regulation of cell cycle:SOX15 \| regulation of lymphocyte mediated immunity:TNFSF13 \| nuclear-transcribed mRNA poly(A) tail shortening:EIF4A1 \| regulation of DNA metabolic process:TNFSF13 \| negative regulation of translation:POLR2A \| DNA-templated transcription, elongation:POLR2A \| regulation of postsynaptic membrane potential:CHRNB1 \| synapse organization:CHRNB1 \| positive regulation of cellular amide metabolic process:EIF5A \| negative regulation of cellular amide metabolic process:POLR2A \| regulation of adaptive immune response:TNFSF13 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| aging:EIF5A \| protein export from nucleus:EIF5A \| mRNA catabolic process:EIF4A1,TNFSF13 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| somatic stem cell population maintenance:POLR2A \| regulation of viral process:POLR2A \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| nuclear export:EIF5A \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:EIF4A1 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| regulation of symbiosis, encompassing mutualism through parasitism:POLR2A \| regulation of apoptotic signaling pathway:TNFSF12 \| RNA catabolic process:EIF4A1,TNFSF13 \| regulation of G0 to G1 transition:SOX15 \| regulation of membrane potential:CHRNB1 \| transcription elongation from RNA polymerase II promoter:POLR2A \| regulation of striated muscle tissue development:SOX15 \| G0 to G1 transition:SOX15 \| positive regulation of viral process:POLR2A \| regulation of muscle tissue development:SOX15 \| DNA-templated transcription, termination:POLR2A \| regulation of gene silencing by miRNA:POLR2A \| regulation of posttranscriptional gene silencing:POLR2A \| regulation of gene silencing by RNA:POLR2A	-0.0173667	0.0180326	0.47414699094558	-0.0106449	0.015998	0.295922443895141				0.0381522	0.0198259	1.26402365170572	0.0433232	0.0210572	1.39970247272742	0.0268297	0.0415469	0.285135666151872	0.00491867	0.0148046	0.130919722854916	0.0177949	0.0166069	0.546496665442621	-0.0218034	0.0291389	0.342414516162694	-0.0264547	0.0106104	1.89767951379817	-0.0207635	0.0133517	0.921112001709916	-0.0315964	0.0168472	1.2166110215823	0.0369003	0.0104814	3.36586748082077	0.0690591	0.0110764	9.3444812436794	-0.00648375	0.0178375	0.144942034868861	0.0347118	0.0101914	3.18095513173087	0.0465938	0.0125842	3.67076895430703	0.0154651	0.0162225	0.467970899480701	0.0073126	0.00609678	0.637585389063621	0.00604401	0.0079271	0.350867729456117	0.00919961	0.0094561	0.48067744638028	-0.0248121	0.0297379	0.393426254949971	-0.0491852	0.0365776	0.747239175401646	0.0268617	0.0510799	0.222467335760577
6:119191587:GTT:GT		6	119191587	6q22.31	GT	GTT	0.975	0	DHEAS ALL	7659	9.17387982561895	0.814625408016712	0.109935	MCM9 (0 kb); ASF1A (24 kb); FAM184A (89 kb); CEP85L (160 kb)	NA	ASF1A \| BRD7P3 \| CEP85L \| FAM184A \| MCM9 \| MCMDC1 \| PLN \| RP11-210H10 A.1 \| RP11-351A11.1	PENK		Formation of Senescence-Associated Heterochromatin Foci (SAHF):ASF1A		DNA replication initiation:MCM9	0.0223069	0.0222647	0.49961119194588	-0.00866958	0.0203701	0.173623888511275	0.0291975	0.0428486	0.304858186818391	0.00900082	0.0245005	0.146679679295893	-0.0302295	0.0268386	0.584660996422004	0.0636975	0.0485154	0.72209066473828	0.0148314	0.018277	0.379671315140859	-0.0091375	0.0211509	0.176656861469541	0.0465409	0.0340261	0.764954089934576	0.0805662	0.0130514	9.17387982561895	0.0850345	0.0165602	6.54922605142855	0.0755672	0.0205446	3.62915396176402				-0.0294311	0.0138517	1.47353407185527	0.0672077	0.0214433	2.76366683433243	-0.0148136	0.0125846	0.621336878820684	-0.0256191	0.0156136	0.996393004372191	0.00654547	0.0198135	0.130104434711387	0.00377463	0.00751083	0.21093073091006	0.0101568	0.00989422	0.516217350113703	-0.00392512	0.011487	0.13514731340598	0.0259084	0.0367357	0.318100581654691	0.07042	0.0465468	0.884219797201293	-0.043836	0.0597411	0.334097393739959
rs200943612:48412454:T:C		19	48412454	19q13.33	C	T	0.832	3	DHEAS WOMEN	3358	8.88165920461644	0.776021441334128	0.0570693	SULT2A1 (23 kb); TPRX2P (48 kb); BSPH1 (59 kb); CRX (66 kb)	0.385 Dehydroepiandrosterone sulphate levels // 0.385 Sex hormone levels	CABP5 \| CTD-3098H1.2 \| GLTSCR2 \| PRR24 \| SULT2A1		Chemical carcinogenesis:SULT2A1 \| Metabolism of xenobiotics by cytochrome P450:SULT2A1 \| Bile secretion:SULT2A1	Biological oxidations:SULT2A1 \| Phase II - Conjugation of compounds:SULT2A1	polycystic ovary syndrome:SULT2A1	steroid catabolic process:SULT2A1 \| steroid metabolic process:SULT2A1 \| sulfur compound metabolic process:SULT2A1 \| sperm capacitation:BSPH1,ELSPBP1	0.0148578	0.0222111	0.29790393012952	-5.37837E-4	0.0199054	0.00946225014205344	0.0159356	0.0449917	0.140743384089867	0.0583043	0.0244053	1.76997280443069	0.00191759	0.0262368	0.026065754597507	0.166112	0.0497377	3.05431579835235	-0.00175379	0.0182334	0.0346181253167756	-0.0506785	0.0206225	1.85023605106541	0.0917462	0.0349913	2.04914562312922	0.0755373	0.0132757	7.89581003135353	0.0284595	0.0167707	1.04720416782602	0.127251	0.0209785	8.88165920461644	3.93494E-4	0.0130989	0.0105346085276456	-0.0314161	0.0139618	1.61189702145079	0.0401502	0.0220662	1.1622234923818	-0.0221454	0.0128536	1.0710570151723	-0.0191388	0.0158981	0.640823096164347				0.0141446	0.00762793	1.19590215829562	8.86501E-4	0.00994793	0.0319884934006213	0.0284398	0.0117938	1.79885150531213	0.0118254	0.0368505	0.12591380815575	-0.00103106	0.0457372	0.00788055169469006	0.0364131	0.0622043	0.252987709207197
rs150507409:98983703:G:A		7	98983703	7q22.1	A	G	0.878	1	DHEAS ALL	7659	8.77823898673066	0.0558676432954693	0.651463	ARPC1A (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER); ARPC1B (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Downstream gene/MODIFIER \| near gene/Upstream gene/MODIFIER); PDAP1 (6 kb); BUD31 (23 kb); PTCD1 (31 kb); ATP5J2-PTCD1 (34 kb)	0.456 Blood protein levels // 0.44 Sex hormone levels // 0.44 Total body bone mineral density (age over 60) // 0.44 Total body bone mineral density // 0.44 Femoral neck bone mineral density // 0.44 Lumbar spine bone mineral density	- \| AP4M1 \| ARPC1B \| ATP5J2 \| BUD31 \| CNPY4 \| COPS6 \| CPSF4 \| CYP3A7 \| GAL3ST4 \| GS1-259H13.2 \| LAMTOR4 \| NYAP1 \| OR2AE1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| STAG3 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| TRIM4 \| ZCWPW1 \| ZKSCAN1 \| ZKSCAN5 \| ZNF394 \| ZNF789 \| ZSCAN21		Endocytosis:ARPC1A,ARPC1B \| Pathogenic Escherichia coli infection:ARPC1A,ARPC1B \| Spliceosome:BUD31 \| Shigellosis:ARPC1A,ARPC1B \| Bacterial invasion of epithelial cells:ARPC1A,ARPC1B \| Salmonella infection:ARPC1A,ARPC1B \| Regulation of actin cytoskeleton:ARPC1A,ARPC1B \| Fc gamma R-mediated phagocytosis:ARPC1A,ARPC1B	EPHB-mediated forward signaling:ARPC1A,ARPC1B \| EPH-Ephrin signaling:ARPC1A,ARPC1B \| RHO GTPases Activate WASPs and WAVEs:ARPC1A,ARPC1B \| Regulation of actin dynamics for phagocytic cup formation:ARPC1A,ARPC1B \| Fcgamma receptor (FCGR) dependent phagocytosis:ARPC1A,ARPC1B		immune response-activating signal transduction:ARPC1A,ARPC1B \| immune response-activating cell surface receptor signaling pathway:ARPC1A,ARPC1B \| immune response-regulating cell surface receptor signaling pathway:ARPC1A,ARPC1B \| ephrin receptor signaling pathway:ARPC1A,ARPC1B \| Arp2/3 complex-mediated actin nucleation:ARPC1A,ARPC1B \| actin nucleation:ARPC1A,ARPC1B \| phagocytosis:ARPC1A,ARPC1B \| positive regulation of protein complex assembly:ARPC1A,ARPC1B \| immune response-regulating cell surface receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| Fc-gamma receptor signaling pathway involved in phagocytosis:ARPC1A,ARPC1B \| Fc-gamma receptor signaling pathway:ARPC1A,ARPC1B \| Fc receptor mediated stimulatory signaling pathway:ARPC1A,ARPC1B \| positive regulation of actin filament polymerization:ARPC1A,ARPC1B \| regulation of protein complex assembly:ARPC1A,ARPC1B	0.0643812	0.0383358	1.03046714211066	0.0729535	0.0331928	1.55087041066592	-0.0284539	0.079853	0.141707086577152	0.0434183	0.0421946	0.517698232776557	0.0356563	0.0438179	0.380971400778549	0.0527627	0.0930517	0.243458214633287	0.0297257	0.0314818	0.461969473871097	0.0291522	0.0345175	0.399567314997583	0.0246641	0.0652766	0.151403268756392	-0.139681	0.0231744	8.77823898673066	-0.155804	0.0291085	7.06181312795515	-0.117519	0.0368504	2.84549690545591				0.0468621	0.0243037	1.26896029146513	-0.0539103	0.0393024	0.769134866358967	-0.0192408	0.0223843	0.408905327473163	-0.0195795	0.0277823	0.317884720319627	-0.0206764	0.0355914	0.250818885138284	-0.00173967	0.0133132	0.0476755107260075	-0.0277884	0.0172245	0.971925135062269	0.0306754	0.0207402	0.856576093379938	-0.0345044	0.0629497	0.233834860609741	-0.0051039	0.0757603	0.023972077788914	-0.0961505	0.113598	0.400529594560747
rs10786714:104598606:G:C	novel1	10	104598606	10q24.32	C	G	0.993	54	PROG MEN	1358	8.61973990290724	0.325648379970545		PFN1P11 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); CYP17A1 (1.3 kb, near gene/Upstream gene/MODIFIER); CYP17A1-AS1 (4.3 kb, near gene/Downstream gene/MODIFIER); PTGES3P4 (6.7 kb); C10orf32 (15 kb); C10orf32-ASMT (15 kb); WBP1L (23 kb); RNU6-372P (30 kb); AS3MT (31 kb); RNU6-1231P (35 kb)	0.991 Colorectal cancer // 0.773 Blood pressure // 0.763 Arsenic metabolism // 0.658 Waist circumference // 0.658 Hip circumference // 0.594 Sodium levels // 0.458 Schizophrenia // 0.458 Immature fraction of reticulocytes // 0.452 Autism spectrum disorder or schizophrenia // 0.377 Prostate cancer // 0.361 Chloride levels // 0.351 Mean corpuscular volume // 0.351 Mean corpuscular hemoglobin // 0.317 White blood cell count // 0.311 White matter lesion progression // 0.306 Creatine kinase levels // 0.304 Migraine // 0.302 Reticulocyte fraction of red cells // 0.302 High light scatter reticulocyte count // 0.302 High light scatter reticulocyte percentage of red cells // 0.301 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	- \| ACTR1A \| ARL3 \| AS3MT \| BORCS7 \| BORCS7-ASMT \| C10orf26 \| C10ORF26 \| C10orf32 \| C10ORF32 \| C10orf76 \| C10orf95 \| CALHM2 \| CNNM2 \| CYP17A1 \| CYP17A1-AS1 \| ELOVL3 \| FBXL15 \| GBF1 \| HPS6 \| HSA-MIR \| hsa-mir-1307 \| MARCKSL1P1 \| MFSD13A \| MIR1307 \| NT5C2 \| PCGF6 \| PDCD11 \| POLL \| PPRC1 \| PSD \| RP11-18I14.10 \| RP11-47A8.5 \| RP11-724N1.1 \| RP11-753C18.8 \| RP11-792D24.4 \| SFXN2 \| SH3PXD2A \| SUFU \| TAF5 \| TMEM180 \| TRIM8 \| USMG5 \| USMG5P1 \| WBP1L	D4S234E \| SCML1	Steroid hormone biosynthesis:CYP17A1 \| Cortisol synthesis and secretion:CYP17A1	Interferon gamma signaling:TRIM8 \| Interferon Signaling:TRIM8 \| Cytochrome P450 - arranged by substrate type:CYP17A1 \| MHC class II antigen presentation:ACTR1A \| Metabolism of steroid hormones:CYP17A1 \| Phase I - Functionalization of compounds:CYP17A1 \| Endogenous sterols:CYP17A1 \| Methylation:AS3MT \| HSP90 chaperone cycle for steroid hormone receptors (SHR):ACTR1A \| Metabolic disorders of biological oxidation enzymes:CYP17A1 \| Biological oxidations:AS3MT,CYP17A1 \| Degradation of GLI1 by the proteasome:SUFU \| Degradation of GLI2 by the proteasome:SUFU \| GLI3 is processed to GLI3R by the proteasome:SUFU \| Hedgehog 'on' state:SUFU \| Phase II - Conjugation of compounds:AS3MT \| Hedgehog 'off' state:SUFU \| Androgen biosynthesis:CYP17A1 \| M Phase:ACTR1A \| Signaling by Hedgehog:SUFU \| G2/M Transition:ACTR1A \| Mitotic G2-G2/M phases:ACTR1A \| Mitotic Prometaphase:ACTR1A \| Cilium Assembly:ACTR1A,ARL3	reproductive system disease:CYP17A1 \| polycystic ovary syndrome:CYP17A1 \| ovarian disease:CYP17A1 \| female reproductive system disease:CYP17A1 \| osteoporosis:CYP17A1 \| bone resorption disease:CYP17A1 \| infertility:CYP17A1 \| cell type benign neoplasm:ACTR1A,CYP17A1 \| myopathy:CYP17A1 \| muscle tissue disease:CYP17A1 \| muscular disease:CYP17A1 \| pleural cancer:ACTR1A \| malignant pleural mesothelioma:ACTR1A \| connective tissue cancer:ACTR1A	antigen processing and presentation of exogenous peptide antigen:ACTR1A \| antigen processing and presentation of exogenous antigen:ACTR1A \| antigen processing and presentation of peptide antigen:ACTR1A \| antigen processing and presentation:ACTR1A \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:ACTR1A \| interferon-gamma-mediated signaling pathway:TRIM8 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:ACTR1A \| antigen processing and presentation of peptide antigen via MHC class II:ACTR1A \| cellular response to interferon-gamma:TRIM8 \| response to interferon-gamma:TRIM8 \| glucocorticoid metabolic process:CYP17A1 \| toxin metabolic process:AS3MT \| glucocorticoid biosynthetic process:CYP17A1 \| negative regulation of protein ubiquitination:SUFU \| negative regulation of protein modification by small protein conjugation or removal:SUFU \| cellular hormone metabolic process:CYP17A1 \| hormone biosynthetic process:CYP17A1 \| secondary metabolic process:AS3MT \| cellular ketone metabolic process:CYP17A1 \| steroid metabolic process:CYP17A1 \| positive regulation of NF-kappaB transcription factor activity:TRIM8 \| interaction with host:TRIM8 \| nucleocytoplasmic transport:SUFU \| podosome assembly:SH3PXD2A \| nuclear transport:SUFU \| cytoplasmic sequestering of transcription factor:SUFU \| hormone metabolic process:CYP17A1 \| regulation of protein ubiquitination:SUFU \| negative regulation of multi-organism process:TRIM8 \| xenobiotic metabolic process:AS3MT \| regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:SUFU \| cellular response to xenobiotic stimulus:AS3MT \| response to xenobiotic stimulus:AS3MT \| regulation of protein modification by small protein conjugation or removal:SUFU \| smoothened signaling pathway:ARL3,SUFU \| androgen metabolic process:CYP17A1 \| cytoplasmic sequestering of protein:SUFU \| regulation of DNA binding transcription factor activity:SUFU,TRIM8 \| regulation of osteoblast differentiation:SUFU \| negative regulation of osteoblast differentiation:SUFU \| magnesium ion homeostasis:CNNM2 \| protein localization to nucleus:SUFU,TRIM8 \| steroid biosynthetic process:CYP17A1 \| positive regulation of catabolic process:TRIM8 \| viral entry into host cell:TRIM8 \| negative regulation of proteolysis involved in cellular protein catabolic process:SUFU \| regulation of autophagy:TRIM8 \| drug metabolic process:NT5C2 \| regulation of transcription factor import into nucleus:SUFU \| negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:SUFU \| transcription factor import into nucleus:SUFU \| C21-steroid hormone metabolic process:CYP17A1 \| entry into host cell:TRIM8 \| entry into host:TRIM8 \| entry into cell of other organism involved in symbiotic interaction:TRIM8 \| entry into other organism involved in symbiotic interaction:TRIM8 \| syncytium formation by plasma membrane fusion:SH3PXD2A \| syncytium formation:SH3PXD2A \| regulation of G2/M transition of mitotic cell cycle:ACTR1A \| positive regulation of DNA binding transcription factor activity:TRIM8 \| reactive oxygen species metabolic process:SH3PXD2A \| regulation of cell cycle G2/M phase transition:ACTR1A \| regulation of proteolysis involved in cellular protein catabolic process:SUFU \| protein ubiquitination involved in ubiquitin-dependent protein catabolic process:SUFU \| negative regulation of cellular protein catabolic process:SUFU \| negative regulation of catabolic process:SUFU \| negative regulation of cellular catabolic process:SUFU \| regulation of protein localization to nucleus:SUFU,TRIM8 \| superoxide metabolic process:SH3PXD2A \| positive regulation of cellular catabolic process:TRIM8 \| negative regulation of ossification:SUFU \| regulation of protein catabolic process:SUFU \| regulation of G0 to G1 transition:PCGF6 \| negative regulation of transcription factor import into nucleus:SUFU \| autophagy:TRIM8 \| process utilizing autophagic mechanism:TRIM8 \| G2/M transition of mitotic cell cycle:ACTR1A \| regulation of cellular protein catabolic process:SUFU \| G0 to G1 transition:PCGF6 \| negative regulation of proteolysis:SUFU \| cell cycle G2/M phase transition:ACTR1A \| negative regulation of viral life cycle:TRIM8	0.0509603	0.0177716	2.37891619746985	0.0951468	0.0158349	8.61973990290724	-0.0203393	0.0359371	0.243048363302726	0.0757422	0.01952	3.96808683553829	0.110168	0.020935	6.78212142197257	0.0125265	0.0397858	0.123222903488643	-0.0219626	0.0146085	0.876527307469805	-0.0187317	0.0166518	0.583645788734726	-0.0275905	0.0278892	0.490987102719941	-0.0264097	0.0109717	1.79368694806404	-0.0270527	0.0135317	1.34116660845198	-0.0258558	0.017867	0.830146360947826	-0.013451	0.0107362	0.677255733169037	0.00454079	0.0112694	0.16304326294045	-0.0374926	0.018323	1.39002055190814	-0.00236738	0.0105219	0.0851376926622202	3.43765E-4	0.0128204	0.00939123825761134	-0.0023436	0.0169608	0.0505611989634957	0.00215736	0.00626986	0.136211564072738	6.92826E-4	0.00802275	0.0309654276428863	0.0050451	0.00993464	0.213551696264703	0.0309261	0.0294	0.533176848934313	0.0390311	0.0368557	0.537925597137924	0.0152922	0.0487098	0.122825686501438
rs6937167:32417794:A:AT		6	32417794	6p21.32	AT	A	0.998	0	OHP17 WOMEN	712	8.59753398836169	0.0105372191011236		HLA-DRA (5 kb, near gene/Downstream gene/MODIFIER); HLA-DRB9 (9.8 kb); BTNL2 (43 kb); HCG23 (56 kb)	NA			Type I diabetes mellitus:HLA-DRA,HLA-DRB5 \| Allograft rejection:HLA-DRA,HLA-DRB5 \| Graft-versus-host disease:HLA-DRA,HLA-DRB5 \| Antigen processing and presentation:HLA-DRA,HLA-DRB5 \| Autoimmune thyroid disease:HLA-DRA,HLA-DRB5 \| Viral myocarditis:HLA-DRA,HLA-DRB5 \| Staphylococcus aureus infection:HLA-DRA,HLA-DRB5 \| Asthma:HLA-DRA,HLA-DRB5 \| Phagosome:HLA-DRA,HLA-DRB5 \| Herpes simplex infection:HLA-DRA,HLA-DRB5 \| Intestinal immune network for IgA production:HLA-DRA,HLA-DRB5 \| Rheumatoid arthritis:HLA-DRA,HLA-DRB5 \| Inflammatory bowel disease (IBD):HLA-DRA,HLA-DRB5 \| Toxoplasmosis:HLA-DRA,HLA-DRB5 \| Systemic lupus erythematosus:HLA-DRA,HLA-DRB5 \| Cell adhesion molecules (CAMs):HLA-DRA,HLA-DRB5 \| Leishmaniasis:HLA-DRA,HLA-DRB5 \| Influenza A:HLA-DRA,HLA-DRB5 \| Hematopoietic cell lineage:HLA-DRA,HLA-DRB5 \| Epstein-Barr virus infection:HLA-DRA,HLA-DRB5 \| Human T-cell leukemia virus 1 infection:HLA-DRA,HLA-DRB5 \| Th1 and Th2 cell differentiation:HLA-DRA,HLA-DRB5 \| Th17 cell differentiation:HLA-DRA,HLA-DRB5 \| Tuberculosis:HLA-DRA,HLA-DRB5	Translocation of ZAP-70 to Immunological synapse:HLA-DRA,HLA-DRB5 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DRA,HLA-DRB5 \| Interferon gamma signaling:HLA-DRA,HLA-DRB5 \| PD-1 signaling:HLA-DRA,HLA-DRB5 \| Generation of second messenger molecules:HLA-DRA,HLA-DRB5 \| Downstream TCR signaling:HLA-DRA,HLA-DRB5 \| Interferon Signaling:HLA-DRA,HLA-DRB5 \| TCR signaling:HLA-DRA,HLA-DRB5 \| MHC class II antigen presentation:HLA-DRA,HLA-DRB5 \| Costimulation by the CD28 family:HLA-DRA,HLA-DRB5 \| Butyrophilin (BTN) family interactions:BTNL2	Kawasaki disease:BTNL2 \| lymphadenitis:BTNL2 \| lymph node disease:BTNL2 \| leprosy:BTNL2 \| sarcoidosis:BTNL2 \| hypersensitivity reaction type IV disease:BTNL2 \| multiple sclerosis:BTNL2,HLA-DRA,HLA-DRB5 \| demyelinating disease:BTNL2,HLA-DRA,HLA-DRB5 \| lymphatic system disease:BTNL2 \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| primary bacterial infectious disease:BTNL2 \| bacterial infectious disease:BTNL2 \| autoimmune disease of the nervous system:HLA-DRA \| myasthenia gravis:HLA-DRA \| neuromuscular junction disease:HLA-DRA \| blood coagulation disease:HLA-DRA \| hemorrhagic disease:HLA-DRA \| neuromuscular disease:HLA-DRA \| hematopoietic system disease:HLA-DRA \| tuberculosis:BTNL2 \| neuropathy:HLA-DRA \| Crohn's disease:BTNL2 \| inflammatory bowel disease:BTNL2	antigen processing and presentation of exogenous peptide antigen:HLA-DRA,HLA-DRB5 \| antigen processing and presentation of exogenous antigen:HLA-DRA,HLA-DRB5 \| antigen processing and presentation of peptide antigen:HLA-DRA,HLA-DRB5 \| antigen processing and presentation:HLA-DRA,HLA-DRB5 \| interferon-gamma-mediated signaling pathway:HLA-DRA,HLA-DRB5 \| cellular response to interferon-gamma:HLA-DRA,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DRA,HLA-DRB5 \| response to interferon-gamma:HLA-DRA,HLA-DRB5 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DRA,HLA-DRB5 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DRA,HLA-DRB5 \| T cell receptor signaling pathway:HLA-DRA,HLA-DRB5 \| immune response-activating signal transduction:HLA-DRA,HLA-DRB5 \| T cell costimulation:HLA-DRA,HLA-DRB5 \| immune response-activating cell surface receptor signaling pathway:HLA-DRA,HLA-DRB5 \| lymphocyte costimulation:HLA-DRA,HLA-DRB5 \| antigen receptor-mediated signaling pathway:HLA-DRA,HLA-DRB5 \| immune response-regulating cell surface receptor signaling pathway:HLA-DRA,HLA-DRB5 \| positive regulation of cell-cell adhesion:HLA-DRA,HLA-DRB5 \| positive regulation of leukocyte cell-cell adhesion:HLA-DRA,HLA-DRB5 \| positive regulation of T cell activation:HLA-DRA,HLA-DRB5 \| T cell activation:HLA-DRA,HLA-DRB5 \| regulation of cell-cell adhesion:HLA-DRA,HLA-DRB5 \| regulation of leukocyte cell-cell adhesion:HLA-DRA,HLA-DRB5 \| positive regulation of cell adhesion:HLA-DRA,HLA-DRB5 \| positive regulation of lymphocyte activation:HLA-DRA,HLA-DRB5 \| positive regulation of cell activation:HLA-DRA,HLA-DRB5 \| regulation of lymphocyte activation:HLA-DRA,HLA-DRB5 \| regulation of T cell activation:HLA-DRA,HLA-DRB5 \| regulation of leukocyte activation:HLA-DRA,HLA-DRB5 \| leukocyte cell-cell adhesion:HLA-DRA,HLA-DRB5 \| positive regulation of leukocyte activation:HLA-DRA,HLA-DRB5							0.0924404	0.156511	0.255890163433033							1.02959	0.170533	8.59753398836169							0.181852	0.122465	0.860098884727221																																											0.270446	0.211117	0.697625773924417
rs6912701:32383573:C:T		6	32383573	6p21.32	T	C	1	5	OHP17 ALL	2070	8.57678854321604	0.0144927536231884		BTNL2 (8.7 kb); HCG23 (22 kb); HLA-DRA (24 kb); C6orf10 (44 kb); HLA-DRB9 (44 kb)	0.328 Marginal zone lymphoma	- \| ABHD16A \| AGER \| AGPAT1 \| AIF1 \| APOM \| ATF6B \| ATP6V1G2 \| BAG6 \| BRD2 \| C2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf48 \| CCHCR1 \| CFB \| CLIC1 \| CSNK2B \| CUTA \| CYP21A2 \| DDAH2 \| DOM3Z \| DXO \| EHMT2 \| FKBPL \| FLOT1 \| GPANK1 \| GPSM3 \| HCG23 \| HCG27 \| HCP5 \| HLA-B \| HLA-C \| HLA-DMA \| HLA-DOA \| HLA-DOB \| HLA-DPA1 \| HLA-DPB1 \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DQB1-AS1 \| HLA-DQB2 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB2 \| HLA-DRB3 \| HLA-DRB4 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB7 \| HLA-DRB8 \| HLA-DRB9 \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LSM2 \| LST1 \| LTA \| LY6G5B \| LY6G5C \| MCCD1 \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| NOTCH4 \| PBX2 \| PHF1 \| PPT2-EGFL8 \| PRRC2A \| PRRT1 \| PSMB9 \| RDBP \| RNF5 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP1 \| TAP2 \| TAPBP \| TCF19 \| TNF \| TNXA \| TNXB \| unnamed \| VARS \| VARS2 \| VPS52 \| XXbac-BPG154L12.4 \| XXbac-BPG254F23.6	BTN3A2 \| EXOC1 \| FLOT1 \| HCP5 \| HLA-C \| HLA-E \| LIMS1 \| LINC00243 \| NHP2 \| PPP1R11 \| TINF2 \| TMEM154 \| TUBB \| VARS2 \| XRCC6 \| ZNF672 \| ZNRD1	Type I diabetes mellitus:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Allograft rejection:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Graft-versus-host disease:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Antigen processing and presentation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TAP2 \| Autoimmune thyroid disease:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Viral myocarditis:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Staphylococcus aureus infection:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Asthma:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Phagosome:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,TAP2 \| Herpes simplex infection:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,TAP2 \| Intestinal immune network for IgA production:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Rheumatoid arthritis:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Inflammatory bowel disease (IBD):HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Toxoplasmosis:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Systemic lupus erythematosus:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Cell adhesion molecules (CAMs):HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Leishmaniasis:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Influenza A:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Hematopoietic cell lineage:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Epstein-Barr virus infection:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Th1 and Th2 cell differentiation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Th17 cell differentiation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Tuberculosis:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Natural killer cell mediated cytotoxicity:NCR3 \| Endocytosis:HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L \| Human cytomegalovirus infection:TAP2 \| Spliceosome:HSPA1A,HSPA1B,HSPA1L \| Human immunodeficiency virus 1 infection:TAP2 \| Protein processing in endoplasmic reticulum:HSPA1A,HSPA1B,HSPA1L \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:HSPA1A,HSPA1B,HSPA1L	Translocation of ZAP-70 to Immunological synapse:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Interferon gamma signaling:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| PD-1 signaling:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Generation of second messenger molecules:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Downstream TCR signaling:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Interferon Signaling:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| TCR signaling:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| MHC class II antigen presentation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Costimulation by the CD28 family:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:TAP2 \| ER-Phagosome pathway:TAP2 \| Antigen processing-Cross presentation:TAP2 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:NCR3 \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:HSPA1A,HSPA1B \| Butyrophilin (BTN) family interactions:BTNL2 \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B \| Class I MHC mediated antigen processing & presentation:TAP2 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Influenza Infection:HSPA1A,HSPA1B \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| Neutrophil degranulation:HSPA1A,HSPA1B \| Interleukin-1 family signaling:AGER \| Influenza Life Cycle:HSPA1A,HSPA1B \| Cytosolic sensors of pathogen-associated DNA :AGER	Kawasaki disease:HLA-DRB1,PRRC2A,BTNL2 \| lymphadenitis:HLA-DRB1,PRRC2A,BTNL2 \| lymph node disease:HLA-DRB1,PRRC2A,BTNL2 \| lymphatic system disease:HLA-DRB1,PRRC2A,BTNL2 \| leprosy:BTNL2,HLA-DQB1,HLA-DRB1 \| sarcoidosis:AGER,BTNL2,HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1L \| hypersensitivity reaction type IV disease:AGER,BTNL2,HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1L \| autoimmune disease of endocrine system:HLA-DQA1,HLA-DQB1,HLA-DRB1,TAP2 \| multiple sclerosis:BTNL2,HLA-DQA1,HLA-DQB1,HLA-DRA,HLA-DRB1 \| endocrine system disease:AGER,HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1B,TAP2 \| autoimmune thyroiditis:HLA-DQB1,HLA-DRB1 \| demyelinating disease:BTNL2,HLA-DQA1,HLA-DQB1,HLA-DRA,HLA-DRB1 \| Graves' disease:HLA-DQA1,HLA-DQB1,HLA-DRB1,TAP2 \| thyroid gland disease:HLA-DQA1,HLA-DQB1,HLA-DRB1,TAP2 \| intrahepatic cholestasis:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HLA-DQA1,HLA-DRB1,AGER,HLA-DQB1 \| primary bacterial infectious disease:BTNL2,HLA-DQB1,HLA-DRB1,TAP2 \| hepatitis:HLA-DQA1,HLA-DQB1,HLA-DRB1,NCR3 \| hyperthyroidism:HLA-DQA1,HLA-DQB1,HLA-DRB1,TAP2 \| rheumatic fever:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| bacterial infectious disease:BTNL2,HLA-DQB1,HLA-DRB1,TAP2 \| aplastic anemia:HLA-DQA1,HLA-DRB1,HLA-DQB1 \| urticaria:HLA-DRB1,HLA-DQB1 \| vasculitis:HLA-DRB1 \| hypothyroidism:HLA-DQB1,HLA-DRB1 \| Behcet's disease:HLA-DRB1 \| hepatitis C:HLA-DQA1,HLA-DRB1,NCR3,HLA-DQB1 \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DQB1 \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,NCR3,PRRC2A,TAP2 \| malaria:HLA-DRB1,NCR3,PRRC2A \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:HLA-DQB1,HLA-DRB1 \| pure red-cell aplasia:HLA-DQB1,HLA-DRB1 \| purpura:HLA-DRB1 \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DQA1,HLA-DQB1,HLA-DRA \| neuromuscular junction disease:HLA-DQA1,HLA-DRA,HLA-DQB1 \| brucellosis:TAP2 \| duodenal ulcer:HLA-DQB1,HSPA1A \| cholestasis:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| upper respiratory tract disease:HSPA1A,TAP2 \| uveitis:HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,NCR3,PRRC2A \| urinary system disease:AGER,AIF1,HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1A \| multiple myeloma:NCR3 \| myeloma:NCR3 \| reproductive system disease:HLA-DRB1,HSPA1A,MSH5,HLA-DQB1 \| bone marrow cancer:NCR3 \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L,HLA-DQB1 \| bile duct disease:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| biliary tract disease:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| azoospermia:HLA-DQB1,HLA-DRB1,MSH5 \| proteinuria:HLA-DRB1 \| kidney disease:AGER,AIF1,HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1A \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| type 1 diabetes mellitus:HLA-DQA1,HLA-DQB1 \| blood coagulation disease:HLA-DRA,HLA-DRB1 \| allergic rhinitis:TAP2 \| hemorrhagic disease:HLA-DRA,HLA-DRB1 \| neuromuscular disease:HLA-DQA1,HLA-DQB1,HLA-DRA \| thyroiditis:HLA-DQB1,HLA-DRB1 \| nasal cavity disease:TAP2 \| nose disease:TAP2 \| rhinitis:TAP2 \| collagen disease:AGER,AIF1,HLA-DRB1,TAP2 \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:AGER,HLA-DQB1,HLA-DRB1,HSPA1B \| nephritis:AIF1,HLA-DQA1,HLA-DQB1,HLA-DRB1 \| periodontitis:AGER,HLA-DQB1 \| celiac disease:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| peptic ulcer disease:HSPA1A,HLA-DQB1 \| hematopoietic system disease:HLA-DQA1,HLA-DQB1,HLA-DRA,HLA-DRB1 \| gestational diabetes:AGER,HLA-DQB1 \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DQA1,HLA-DRB1,HLA-DQB1 \| rheumatic disease:AGER,AIF1,HLA-DRB1,TAP2 \| systemic scleroderma:AGER,AIF1,HLA-DRB1,TAP2 \| scleroderma:AGER,AIF1,HLA-DRB1,TAP2 \| male reproductive system disease:HLA-DQB1,HLA-DRB1,HSPA1A,MSH5 \| male infertility:HLA-DQB1,HLA-DRB1,MSH5 \| silicosis:HLA-DQB1,HLA-DRB1 \| integumentary system disease:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| sickle cell anemia:HLA-DQB1,HLA-DRB1 \| periodontal disease:AGER,HLA-DQB1 \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2 \| Human immunodeficiency virus infectious disease:HLA-DQB1,HLA-DRB1 \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B \| interstitial lung disease:AGER,HLA-DQB1,HLA-DRB1 \| bronchial disease:HSPA1A,HSPA1B,TAP2 \| acute pancreatitis:HSPA1B \| tuberculosis:BTNL2,HLA-DQB1,HLA-DRB1 \| Vogt-Koyanagi-Harada disease:HLA-DQB1,HLA-DRB1 \| prostate disease:HLA-DRB1,HSPA1A \| aortic valve disease:AGER \| pneumoconiosis:HLA-DQB1,HLA-DRB1 \| schistosomiasis:HLA-DRB1 \| sclerosing cholangitis:HLA-DRB1 \| tooth disease:AGER,HLA-DQB1 \| autoimmune disease of peripheral nervous system:HLA-DRB1 \| Guillain-Barre syndrome:HLA-DRB1 \| pancreas disease:HLA-DRB1,HSPA1B,AGER,HLA-DQB1 \| open-angle glaucoma:HLA-DQB1,HLA-DRB1,TAP2 \| influenza:HLA-DRB1 \| low tension glaucoma:HLA-DQB1,HLA-DRB1 \| chronic leukemia:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:AGER,HLA-DQB1,HLA-DRB1,HSPA1A,HSPA1B,TAP2 \| ovarian disease:MSH5 \| neutropenia:HLA-DQB1 \| agranulocytosis:HLA-DQB1 \| gastritis:HLA-DQB1,HLA-DRB1 \| dermatomyositis:AGER,HLA-DRB1 \| essential hypertension:HSPA1A,HSPA1B,HSPA1L \| female reproductive system disease:MSH5 \| osteomyelitis:HLA-DQB1,HLA-DRB1 \| neuropathy:AGER,HLA-DQA1,HLA-DQB1,HLA-DRA \| mouth disease:AGER,HLA-DQB1 \| Sjogren's syndrome:AGER \| migraine:HLA-DRB1 \| infertility:MSH5 \| peripheral nervous system disease:HLA-DRB1 \| autoimmune disease of urogenital tract:HLA-DQB1,HLA-DRB1 \| primary biliary cirrhosis:HLA-DQB1,HLA-DRB1 \| stomach disease:HLA-DRB1,HLA-DQB1 \| cholangitis:HLA-DRB1 \| Crohn's disease:BTNL2,HSPA1B \| lung disease:AGER,HLA-DQB1,HLA-DRB1,HSPA1A,HSPA1B \| spinal cord disease:HLA-DRB1 \| heart valve disease:AGER \| pulmonary edema:HSPA1A \| aortic valve stenosis:AGER \| myositis:AGER,HLA-DRB1 \| leukopenia:HLA-DQB1 \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B,BTNL2 \| myopathy:AGER,HLA-DQB1,HLA-DRB1 \| muscle tissue disease:AGER,HLA-DQB1,HLA-DRB1 \| nasopharynx carcinoma:HSPA1B \| pharynx cancer:HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| cardiomyopathy:HLA-DQB1 \| muscular disease:AGER,HLA-DQB1,HLA-DRB1 \| bronchiectasis:TAP2 \| premature ovarian failure:MSH5 \| liver cirrhosis:HLA-DQB1,HLA-DRB1 \| renal cell carcinoma:HLA-DQB1,HLA-DRB1,TAP2 \| glaucoma:HLA-DRB1,TAP2,HLA-DQB1 \| esophageal carcinoma:HLA-DRB1 \| retinal disease:AGER,HLA-DQB1,HLA-DRB1,TAP2 \| skin disease:HLA-DQB1,HLA-DRB1 \| female reproductive organ cancer:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| extrinsic cardiomyopathy:HLA-DQB1 \| myocarditis:HLA-DQB1 \| pulmonary fibrosis:AGER \| primary open angle glaucoma:TAP2 \| severe combined immunodeficiency:HLA-DRB1 \| coronary artery disease:AGER \| retinal degeneration:HLA-DQB1,HLA-DRB1,TAP2 \| malignant ovarian surface epithelial-stromal neoplasm:HLA-DQA1,HLA-DRB1 \| ovary epithelial cancer:HLA-DQA1,HLA-DRB1 \| ovarian carcinoma:HLA-DQA1,HLA-DRB1 \| combined T cell and B cell immunodeficiency:HLA-DRB1	antigen processing and presentation of exogenous peptide antigen:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation of peptide antigen:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| cellular response to interferon-gamma:AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| response to interferon-gamma:AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| T cell receptor signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| immune response-activating signal transduction:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,NCR3 \| T cell costimulation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| immune response-activating cell surface receptor signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,NCR3 \| lymphocyte costimulation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| antigen receptor-mediated signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| immune response-regulating cell surface receptor signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,NCR3 \| positive regulation of cell-cell adhesion:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| positive regulation of leukocyte cell-cell adhesion:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| positive regulation of T cell activation:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| T cell activation:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| regulation of cell-cell adhesion:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:TAP2 \| regulation of leukocyte cell-cell adhesion:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class I:TAP2 \| positive regulation of cell adhesion:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| positive regulation of lymphocyte activation:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| positive regulation of cell activation:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| regulation of lymphocyte activation:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,LST1 \| regulation of T cell activation:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| regulation of leukocyte activation:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1,LST1 \| leukocyte cell-cell adhesion:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class I:TAP2 \| positive regulation of leukocyte activation:AGER,AIF1,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRA,HLA-DRB1 \| lymphocyte mediated immunity:AGER,HLA-DQB1,NCR3 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:AGER,HLA-DQB1,NCR3 \| adaptive immune response:AGER,HLA-DQB1,NCR3,TAP2 \| humoral immune response mediated by circulating immunoglobulin:HLA-DQB1 \| natural killer cell mediated cytotoxicity:NCR3 \| natural killer cell mediated immunity:NCR3 \| T cell mediated cytotoxicity:NCR3,AGER \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| leukocyte mediated cytotoxicity:NCR3,AGER \| positive regulation of defense response:HSPA1A,HSPA1B,NCR3 \| positive regulation of cytokine production:AGER,HSPA1A,HSPA1B \| T cell mediated immunity:AGER,NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:AGER,NCR3 \| positive regulation of innate immune response:HSPA1A,HSPA1B,NCR3 \| positive regulation of T cell proliferation:AGER,AIF1 \| regulation of lymphocyte mediated immunity:NCR3,AGER \| NIK/NF-kappaB signaling:AGER \| regulation of innate immune response:HSPA1A,HSPA1B,NCR3 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B \| regulation of T cell proliferation:AGER,AIF1 \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B \| cell killing:NCR3,AGER \| positive regulation of lymphocyte mediated immunity:NCR3 \| regulation of lymphocyte proliferation:AGER,AIF1,LST1 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| regulation of mononuclear cell proliferation:AGER,AIF1,LST1 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of natural killer cell mediated cytotoxicity:NCR3 \| positive regulation of adaptive immune response:NCR3 \| regulation of natural killer cell mediated immunity:NCR3 \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| immunoglobulin mediated immune response:HLA-DQB1 \| regulation of leukocyte proliferation:AGER,AIF1,LST1 \| B cell mediated immunity:HLA-DQB1 \| mRNA catabolic process:HSPA1A,HSPA1B \| response to tumor necrosis factor:HSPA1A,HSPA1B \| response to heat:HSPA1A,HSPA1B,HSPA1L \| antigen processing and presentation via MHC class Ib:TAP2 \| positive regulation of nitric oxide biosynthetic process:AIF1 \| positive regulation of nitric oxide metabolic process:AIF1 \| regulation of leukocyte mediated immunity:NCR3,AGER \| activation of innate immune response:HSPA1A,HSPA1B \| regulation of T cell mediated cytotoxicity:AGER,NCR3 \| positive regulation of leukocyte mediated immunity:NCR3 \| T cell proliferation:AGER,AIF1 \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| antigen processing and presentation of endogenous antigen:TAP2 \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B \| microtubule nucleation:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of lymphocyte proliferation:AGER,AIF1 \| positive regulation of mononuclear cell proliferation:AGER,AIF1 \| regulation of leukocyte mediated cytotoxicity:AGER,NCR3 \| regulation of DNA-templated transcription in response to stress:HSPA1A \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B \| RNA catabolic process:HSPA1A,HSPA1B \| positive regulation of leukocyte proliferation:AGER,AIF1 \| positive regulation of reactive oxygen species biosynthetic process:AIF1 \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:HSPA1A,HSPA1L \| positive regulation of T cell mediated cytotoxicity:NCR3 \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| humoral immune response:HLA-DQB1 \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| innate immune response-activating signal transduction:HSPA1A,HSPA1B \| regulation of nitric oxide biosynthetic process:AIF1 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3,AGER \| lymphocyte proliferation:AGER,AIF1,LST1 \| mononuclear cell proliferation:AGER,AIF1,LST1 \| positive regulation of interleukin-12 production:AGER \| regulation of cell killing:AGER,NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| regulation of interleukin-8 production:HSPA1A,HSPA1B \| RNA phosphodiester bond hydrolysis:HSPA1A \| regulation of dendritic cell differentiation:AGER \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| regulation of adaptive immune response:NCR3,AGER \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| leukocyte proliferation:AGER,AIF1,LST1 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B,AGER \| regulation of protein stability:HSPA1A,HSPA1B \| nitric oxide biosynthetic process:AIF1 \| interleukin-8 production:HSPA1A,HSPA1B \| positive regulation of protein complex assembly:HSPA1A,HSPA1B \| interaction with host:HSPA1A,HSPA1B \| signal transduction in absence of ligand:HSPA1A,HSPA1B \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| nucleocytoplasmic transport:AGER \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of natural killer cell mediated immunity:NCR3 \| nitric oxide metabolic process:AIF1 \| nuclear transport:AGER \| natural killer cell activation:NCR3 \| reactive nitrogen species metabolic process:AIF1 \| positive regulation of mononuclear cell migration:AIF1 \| cellular response to topologically incorrect protein:HSPA1A \| protein stabilization:HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| positive regulation of smooth muscle cell proliferation:AIF1 \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| mRNA cleavage:HSPA1A \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:AIF1 \| regulation of organelle assembly:HSPA1A,HSPA1B \| regulation of transcription from RNA polymerase II promoter in response to stress:HSPA1A \| regulation of reactive oxygen species biosynthetic process:AIF1 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| response to endoplasmic reticulum stress:HSPA1A \| positive regulation of immune effector process:NCR3 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| response to isoquinoline alkaloid:AIF1 \| response to morphine:AIF1 \| positive regulation of T cell mediated immunity:NCR3 \| positive regulation of NIK/NF-kappaB signaling:AGER \| spindle assembly:HSPA1A,HSPA1B \| regulation of interleukin-12 production:AGER \| nucleic acid phosphodiester bond hydrolysis:HSPA1A \| interleukin-12 production:AGER \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| positive regulation of response to endoplasmic reticulum stress:HSPA1A \| positive regulation of leukocyte mediated cytotoxicity:NCR3 \| reactive oxygen species biosynthetic process:AIF1 \| negative regulation of immune system process:LST1 \| positive regulation of proteolysis involved in cellular protein catabolic process:HSPA1A \| positive regulation of NF-kappaB import into nucleus:AGER \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| regulation of T cell mediated immunity:AGER,NCR3 \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| receptor-mediated endocytosis:AGER \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:LY6G5B,LY6G5C \| viral life cycle:HSPA1A,HSPA1B \| mitochondrial outer membrane permeabilization:HSPA1A \| protein localization to nucleus:AGER \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| regulation of proteolysis involved in cellular protein catabolic process:HSPA1A \| regulation of mononuclear cell migration:AIF1 \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| positive regulation of catabolic process:HSPA1A \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:HSPA1A \| microglial cell activation:AGER,AIF1 \| positive regulation of cell killing:NCR3 \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| phagocytosis:AIF1 \| mRNA cleavage involved in mRNA processing:HSPA1A \| response to ammonium ion:AIF1 \| microtubule polymerization:HSPA1A,HSPA1B \| regulation of inflammatory response:AGER \| synapsis:MSH5 \| macrophage activation:AGER,AIF1 \| protein folding:HSPA1A,HSPA1B,HSPA1L \| positive regulation of protein catabolic process:HSPA1A \| positive regulation of cellular catabolic process:HSPA1A \| regulation of transcription factor import into nucleus:AGER \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| regulation of smooth muscle cell proliferation:AIF1 \| negative regulation of growth:HSPA1A,HSPA1B \| transcription factor import into nucleus:AGER \| regulation of binding:AGER \| regulation of mRNA metabolic process:HSPA1A \| regulation of NIK/NF-kappaB signaling:AGER \| smooth muscle cell proliferation:AIF1 \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| regulation of RNA stability:HSPA1A \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| positive regulation of cellular component biogenesis:HSPA1A,HSPA1B \| regulation of cellular protein catabolic process:HSPA1A \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,AGER \| glial cell activation:AGER,AIF1 \| protein polymerization:AIF1,HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| regulation of mitotic cell cycle phase transition:AIF1 \| mitochondrial membrane organization:HSPA1A \| immunoglobulin production:HLA-DQB1 \| reactive oxygen species metabolic process:AIF1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| cellular response to ammonium ion:AIF1 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:HSPA1A \| homologous chromosome segregation:MSH5 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of macrophage activation:AGER \| regulation of mRNA catabolic process:HSPA1A \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,AGER \| regulation of protein complex assembly:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| spindle organization:HSPA1A,HSPA1B \| ruffle assembly:AIF1 \| regulation of protein catabolic process:HSPA1A \| chromosome organization involved in meiotic cell cycle:MSH5 \| negative regulation of chemotaxis:AIF1 \| regulation of cell cycle phase transition:AIF1 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| cellular response to oxidative stress:AIF1,HSPA1A,HSPA1B \| protein complex localization:AGER \| regulation of reactive oxygen species metabolic process:AIF1 \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| regulation of response to endoplasmic reticulum stress:HSPA1A \| regulation of leukocyte chemotaxis:AIF1 \| response to unfolded protein:HSPA1A,HSPA1L \| response to oxidative stress:AIF1,HSPA1A,HSPA1B \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| smooth muscle cell migration:AIF1 \| negative regulation of leukocyte activation:LST1	0.126341	0.0696795	1.15520545172006	0.131343	0.0662893	1.32099752050376	0.0423456	0.122401	0.137049126610555	0.454746	0.0760662	8.57678854321604	0.282169	0.0871641	2.90789369539476	0.704901	0.140108	6.20847004861699	0.0669123	0.0572214	0.615476342817655	0.019453	0.0689278	0.109123685829323	0.140075	0.0998769	0.792605328062484	-0.0197996	0.0376733	0.222432544073506	-0.0056029	0.0468252	0.0434685281332738	-0.0378784	0.0607829	0.273134295119016	0.00858497	0.0378406	0.0859092407740991	0.00321165	0.039344	0.0292157946706954	0.022403	0.0633216	0.140566866997809	0.0387396	0.0357535	0.555053183877104	0.0786974	0.043487	1.15276120966157				0.015602	0.0218134	0.323804972232374				0.0115509	0.0340115	0.134218154687963	0.314261	0.114591	2.21091237908696	0.271576	0.151106	1.13950088508708	0.369694	0.174991	1.45601634106106
rs200025476:32683564:A:T		6	32683564	6p21.32	T	A	0.978	20	OHP17 ALL	2070	8.53585039045158	0.0116227053140097		XXbac-BPG254F23.7 (2.2 kb, near gene/Upstream gene/MODIFIER); MTCO3P1 (8.8 kb); HLA-DQB3 (15 kb); HLA-DQA2 (26 kb); MIR3135B (34 kb); HLA-DQB2 (40 kb); HLA-DQB1 (47 kb)	NA	- \| ATF6B \| C4A \| C4B \| C4B 2 \| C6orf10 \| CLIC1 \| CSNK2B \| DDAH2 \| DDR1 \| DDX39B \| DXO \| FLOT1 \| GPANK1 \| GPSM3 \| HCG23 \| HCG27 \| HCP5 \| HLA-C \| HLA-DMB \| HLA-DOA \| HLA-DOB \| HLA-DQA1 \| HLA-DQB1 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB5 \| HLA-DRB6 \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LY6G5B \| LY6G5C \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| PSMB9 \| RDBP \| RNF5 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP2 \| unnamed \| VARS2 \| XXbac-BPG154L12.4 \| XXbac-BPG181B23.7 \| ZBTB12	FLOT1 \| HCP5 \| HLA-C \| LIMS1 \| LINC00243 \| LST1 \| NCR3 \| TAP2 \| VARS2 \| ZNRD1	Type I diabetes mellitus:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Allograft rejection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Graft-versus-host disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TAP2 \| Autoimmune thyroid disease:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Viral myocarditis:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Staphylococcus aureus infection:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Asthma:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Phagosome:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1,TAP2 \| Herpes simplex infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1,TAP2 \| Intestinal immune network for IgA production:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Rheumatoid arthritis:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Inflammatory bowel disease (IBD):HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Toxoplasmosis:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Systemic lupus erythematosus:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Cell adhesion molecules (CAMs):HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Leishmaniasis:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Influenza A:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Hematopoietic cell lineage:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Epstein-Barr virus infection:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Th1 and Th2 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Th17 cell differentiation:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Tuberculosis:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DRB1 \| Natural killer cell mediated cytotoxicity:HLA-C,NCR3 \| Endocytosis:HLA-C,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L \| Human cytomegalovirus infection:HLA-C,TAP2 \| Kaposi sarcoma-associated herpesvirus infection:HLA-C \| Viral carcinogenesis:HLA-C \| Spliceosome:HSPA1A,HSPA1B,HSPA1L \| Human immunodeficiency virus 1 infection:HLA-C,TAP2 \| Protein processing in endoplasmic reticulum:HSPA1A,HSPA1B,HSPA1L \| Cellular senescence:HLA-C \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:HLA-C	Translocation of ZAP-70 to Immunological synapse:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| Interferon gamma signaling:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| PD-1 signaling:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| Generation of second messenger molecules:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| Downstream TCR signaling:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| Interferon Signaling:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| TCR signaling:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| MHC class II antigen presentation:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| Costimulation by the CD28 family:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| Endosomal/Vacuolar pathway:HLA-C \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,TAP2 \| ER-Phagosome pathway:HLA-C,TAP2 \| Antigen processing-Cross presentation:HLA-C,TAP2 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,NCR3 \| Interferon alpha/beta signaling:HLA-C \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:HSPA1A,HSPA1B \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B \| Class I MHC mediated antigen processing & presentation:HLA-C,TAP2 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Influenza Infection:HSPA1A,HSPA1B \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| Neutrophil degranulation:HLA-C,HSPA1A,HSPA1B \| Influenza Life Cycle:HSPA1A,HSPA1B	Kawasaki disease:HLA-C,HLA-DRB1 \| lymphadenitis:HLA-C,HLA-DRB1 \| lymph node disease:HLA-C,HLA-DRB1 \| lymphatic system disease:HLA-C,HLA-DRB1 \| leprosy:HLA-DQB1,HLA-DRB1 \| sarcoidosis:HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1L \| hypersensitivity reaction type IV disease:HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1L \| autoimmune disease of endocrine system:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1,TAP2 \| multiple sclerosis:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1 \| endocrine system disease:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1B,TAP2 \| autoimmune thyroiditis:HLA-DQB1,HLA-DRB1 \| demyelinating disease:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1 \| Graves' disease:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1,TAP2 \| thyroid gland disease:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1,TAP2 \| intrahepatic cholestasis:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| hypersensitivity reaction type I disease:HLA-C,HLA-DQA1,HLA-DRB1,HLA-DQB1 \| primary bacterial infectious disease:HLA-DQB1,HLA-DRB1,TAP2 \| hepatitis:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1,NCR3 \| hyperthyroidism:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1,TAP2 \| vitiligo:HLA-C \| spondylitis:HLA-C \| ankylosing spondylitis:HLA-C \| rheumatic fever:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| bacterial infectious disease:HLA-DQB1,HLA-DRB1,TAP2 \| aplastic anemia:HLA-DQA1,HLA-DRB1,HLA-DQB1 \| urticaria:HLA-DRB1,HLA-DQB1 \| spondyloarthropathy:HLA-C \| vasculitis:HLA-DRB1 \| hypothyroidism:HLA-DQB1,HLA-DRB1 \| Behcet's disease:HLA-DRB1 \| hepatitis C:HLA-C,HLA-DQA1,HLA-DRB1,NCR3,HLA-DQB1 \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRB1,HLA-DQB1 \| arthropathy:HLA-C \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,NCR3,TAP2 \| malaria:HLA-DRB1,NCR3 \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:HLA-DQB1,HLA-DRB1 \| pure red-cell aplasia:HLA-DQB1,HLA-DRB1 \| purpura:HLA-DRB1 \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DQA1,HLA-DQB1 \| neuromuscular junction disease:HLA-DQA1,HLA-DQB1 \| brucellosis:TAP2 \| duodenal ulcer:HLA-DQB1,HSPA1A \| cholestasis:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1 \| upper respiratory tract disease:HLA-C,HSPA1A,TAP2 \| uveitis:HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,NCR3 \| urinary system disease:HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1A \| multiple myeloma:NCR3 \| myeloma:NCR3 \| reproductive system disease:HLA-DRB1,HSPA1A,MSH5,HLA-DQB1 \| bone marrow cancer:NCR3 \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L,HLA-DQB1 \| bile duct disease:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1 \| biliary tract disease:HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1 \| azoospermia:HLA-DQB1,HLA-DRB1,MSH5 \| proteinuria:HLA-DRB1 \| kidney disease:HLA-DQA1,HLA-DQB1,HLA-DRB1,HSPA1A \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| type 1 diabetes mellitus:HLA-DQA1,HLA-DQB1 \| blood coagulation disease:HLA-DRB1 \| allergic rhinitis:HLA-C,TAP2 \| hemorrhagic disease:HLA-DRB1 \| neuromuscular disease:HLA-DQA1,HLA-DQB1 \| thyroiditis:HLA-DQB1,HLA-DRB1 \| nasal cavity disease:HLA-C,TAP2 \| nose disease:HLA-C,TAP2 \| rhinitis:HLA-C,TAP2 \| collagen disease:HLA-DRB1,TAP2 \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:HLA-DQB1,HLA-DRB1,HSPA1B \| nephritis:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| periodontitis:HLA-DQB1 \| celiac disease:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| peptic ulcer disease:HSPA1A,HLA-DQB1 \| hematopoietic system disease:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| gestational diabetes:HLA-DQB1 \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DQA1,HLA-DRB1,HLA-DQB1 \| rheumatic disease:HLA-DRB1,TAP2 \| systemic scleroderma:HLA-DRB1,TAP2 \| scleroderma:HLA-DRB1,TAP2 \| male reproductive system disease:HLA-DQB1,HLA-DRB1,HSPA1A,MSH5 \| male infertility:HLA-DQB1,HLA-DRB1,MSH5 \| silicosis:HLA-DQB1,HLA-DRB1 \| integumentary system disease:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| sickle cell anemia:HLA-DQB1,HLA-DRB1 \| periodontal disease:HLA-DQB1 \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2 \| Human immunodeficiency virus infectious disease:HLA-C,HLA-DQB1,HLA-DRB1 \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B \| interstitial lung disease:HLA-DQB1,HLA-DRB1 \| bronchial disease:HSPA1A,HSPA1B,TAP2 \| acute pancreatitis:HSPA1B \| tuberculosis:HLA-DQB1,HLA-DRB1 \| Vogt-Koyanagi-Harada disease:HLA-DQB1,HLA-DRB1 \| prostate disease:HLA-DRB1,HSPA1A \| pneumoconiosis:HLA-DQB1,HLA-DRB1 \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1 \| tooth disease:HLA-DQB1 \| autoimmune disease of peripheral nervous system:HLA-DRB1 \| Guillain-Barre syndrome:HLA-DRB1 \| pancreas disease:HLA-DRB1,HSPA1B,HLA-DQB1 \| open-angle glaucoma:HLA-DQB1,HLA-DRB1,TAP2 \| influenza:HLA-DRB1 \| low tension glaucoma:HLA-DQB1,HLA-DRB1 \| chronic leukemia:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:HLA-DQB1,HLA-DRB1,HSPA1A,HSPA1B,TAP2 \| ovarian disease:MSH5 \| neutropenia:HLA-DQB1 \| agranulocytosis:HLA-DQB1 \| gastritis:HLA-DQB1,HLA-DRB1 \| dermatomyositis:HLA-DRB1 \| essential hypertension:HSPA1A,HSPA1B,HSPA1L \| female reproductive system disease:MSH5 \| osteomyelitis:HLA-DQB1,HLA-DRB1 \| neuropathy:HLA-DQA1,HLA-DQB1 \| mouth disease:HLA-DQB1 \| migraine:HLA-DRB1 \| infertility:MSH5 \| peripheral nervous system disease:HLA-DRB1 \| autoimmune disease of urogenital tract:HLA-DQB1,HLA-DRB1 \| primary biliary cirrhosis:HLA-DQB1,HLA-DRB1 \| stomach disease:HLA-DRB1,HLA-DQB1 \| cholangitis:HLA-C,HLA-DRB1 \| Crohn's disease:HSPA1B \| lung disease:HLA-DQB1,HLA-DRB1,HSPA1A,HSPA1B \| spinal cord disease:HLA-C,HLA-DRB1 \| pulmonary edema:HSPA1A \| myositis:HLA-DRB1 \| leukopenia:HLA-DQB1 \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B \| myopathy:HLA-DQB1,HLA-DRB1 \| muscle tissue disease:HLA-DQB1,HLA-DRB1 \| nasopharynx carcinoma:HSPA1B \| pharynx cancer:HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| cardiomyopathy:HLA-DQB1 \| muscular disease:HLA-DQB1,HLA-DRB1 \| bronchiectasis:TAP2 \| premature ovarian failure:MSH5 \| liver cirrhosis:HLA-DQB1,HLA-DRB1 \| renal cell carcinoma:HLA-DQB1,HLA-DRB1,TAP2 \| glaucoma:HLA-DRB1,TAP2,HLA-DQB1 \| esophageal carcinoma:HLA-DRB1 \| skin disease:HLA-DQB1,HLA-DRB1 \| retinal disease:HLA-DQB1,HLA-DRB1,TAP2 \| female reproductive organ cancer:HLA-DQA1,HLA-DQB1,HLA-DRB1 \| extrinsic cardiomyopathy:HLA-DQB1 \| myocarditis:HLA-DQB1 \| primary open angle glaucoma:TAP2 \| severe combined immunodeficiency:HLA-DRB1 \| retinal degeneration:HLA-DQB1,HLA-DRB1,TAP2 \| malignant ovarian surface epithelial-stromal neoplasm:HLA-DQA1,HLA-DRB1 \| ovary epithelial cancer:HLA-DQA1,HLA-DRB1 \| ovarian carcinoma:HLA-DQA1,HLA-DRB1 \| combined T cell and B cell immunodeficiency:HLA-DRB1	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1,TAP2 \| antigen processing and presentation of peptide antigen:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1,TAP2 \| antigen processing and presentation:HLA-C,HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| cellular response to interferon-gamma:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| response to interferon-gamma:HLA-C,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DOB,HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| T cell receptor signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| immune response-activating signal transduction:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1,HSPA1A,HSPA1B,NCR3 \| T cell costimulation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| immune response-activating cell surface receptor signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1,NCR3 \| lymphocyte costimulation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| antigen receptor-mediated signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| immune response-regulating cell surface receptor signaling pathway:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1,NCR3 \| positive regulation of cell-cell adhesion:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| positive regulation of leukocyte cell-cell adhesion:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| positive regulation of T cell activation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| T cell activation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| regulation of cell-cell adhesion:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,TAP2 \| regulation of leukocyte cell-cell adhesion:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,TAP2 \| positive regulation of cell adhesion:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| positive regulation of lymphocyte activation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| positive regulation of cell activation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| regulation of lymphocyte activation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| regulation of T cell activation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| regulation of leukocyte activation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| leukocyte cell-cell adhesion:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,TAP2 \| positive regulation of leukocyte activation:HLA-DQA1,HLA-DQA2,HLA-DQB1,HLA-DQB2,HLA-DRB1 \| lymphocyte mediated immunity:HLA-DQB1,NCR3 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:HLA-DQB1,NCR3 \| adaptive immune response:HLA-DQB1,NCR3,TAP2 \| humoral immune response mediated by circulating immunoglobulin:HLA-DQB1 \| natural killer cell mediated cytotoxicity:NCR3 \| natural killer cell mediated immunity:NCR3 \| T cell mediated cytotoxicity:NCR3 \| response to type I interferon:HLA-C \| type I interferon signaling pathway:HLA-C \| cellular response to type I interferon:HLA-C \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| leukocyte mediated cytotoxicity:NCR3 \| positive regulation of defense response:GPSM3,HSPA1A,HSPA1B,NCR3 \| positive regulation of cytokine production:GPSM3,HSPA1A,HSPA1B \| T cell mediated immunity:NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:NCR3 \| positive regulation of innate immune response:HSPA1A,HSPA1B,NCR3 \| regulation of lymphocyte mediated immunity:NCR3 \| regulation of innate immune response:HSPA1A,HSPA1B,NCR3 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B \| cell killing:NCR3 \| positive regulation of lymphocyte mediated immunity:NCR3 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of natural killer cell mediated cytotoxicity:NCR3 \| positive regulation of adaptive immune response:NCR3 \| regulation of natural killer cell mediated immunity:NCR3 \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| immunoglobulin mediated immune response:HLA-DQB1 \| B cell mediated immunity:HLA-DQB1 \| mRNA catabolic process:HSPA1A,HSPA1B \| response to tumor necrosis factor:HSPA1A,HSPA1B \| response to heat:HSPA1A,HSPA1B,HSPA1L \| antigen processing and presentation via MHC class Ib:TAP2 \| positive regulation of nitric oxide biosynthetic process:DDAH2 \| positive regulation of nitric oxide metabolic process:DDAH2 \| regulation of leukocyte mediated immunity:NCR3 \| activation of innate immune response:HSPA1A,HSPA1B \| regulation of T cell mediated cytotoxicity:NCR3 \| positive regulation of leukocyte mediated immunity:NCR3 \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| antigen processing and presentation of endogenous antigen:TAP2 \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B \| microtubule nucleation:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of leukocyte mediated cytotoxicity:NCR3 \| regulation of DNA-templated transcription in response to stress:HSPA1A \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B \| RNA catabolic process:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species biosynthetic process:DDAH2 \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:HSPA1A,HSPA1L \| positive regulation of T cell mediated cytotoxicity:NCR3 \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| humoral immune response:HLA-DQB1 \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| innate immune response-activating signal transduction:HSPA1A,HSPA1B \| regulation of nitric oxide biosynthetic process:DDAH2 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| regulation of cell killing:NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| regulation of interleukin-8 production:HSPA1A,HSPA1B \| regulation of antigen processing and presentation:HLA-DOB \| RNA phosphodiester bond hydrolysis:HSPA1A \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| regulation of adaptive immune response:NCR3 \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B \| regulation of protein stability:HSPA1A,HSPA1B \| nitric oxide biosynthetic process:DDAH2 \| interleukin-8 production:HSPA1A,HSPA1B \| positive regulation of protein complex assembly:HSPA1A,HSPA1B \| interaction with host:HSPA1A,HSPA1B \| signal transduction in absence of ligand:HSPA1A,HSPA1B \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of natural killer cell mediated immunity:NCR3 \| nitric oxide metabolic process:DDAH2 \| natural killer cell activation:NCR3 \| reactive nitrogen species metabolic process:DDAH2 \| cellular response to topologically incorrect protein:HSPA1A \| protein stabilization:HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| mRNA cleavage:HSPA1A \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of organelle assembly:HSPA1A,HSPA1B \| regulation of transcription from RNA polymerase II promoter in response to stress:HSPA1A \| regulation of reactive oxygen species biosynthetic process:DDAH2 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| response to endoplasmic reticulum stress:HSPA1A \| positive regulation of immune effector process:NCR3 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| positive regulation of T cell mediated immunity:NCR3 \| spindle assembly:HSPA1A,HSPA1B \| nucleic acid phosphodiester bond hydrolysis:HSPA1A \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| positive regulation of response to endoplasmic reticulum stress:HSPA1A \| positive regulation of leukocyte mediated cytotoxicity:NCR3 \| reactive oxygen species biosynthetic process:DDAH2 \| negative regulation of immune system process:HLA-DOB \| positive regulation of proteolysis involved in cellular protein catabolic process:HSPA1A \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| regulation of T cell mediated immunity:NCR3 \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| mitotic spindle assembly:HSPA1A,HSPA1B \| viral life cycle:HSPA1A,HSPA1B \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| regulation of proteolysis involved in cellular protein catabolic process:HSPA1A \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| positive regulation of catabolic process:HSPA1A \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:HSPA1A \| positive regulation of cell killing:NCR3 \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| mRNA cleavage involved in mRNA processing:HSPA1A \| microtubule polymerization:HSPA1A,HSPA1B \| regulation of inflammatory response:GPSM3 \| synapsis:MSH5 \| protein folding:HSPA1A,HSPA1B,HSPA1L \| positive regulation of protein catabolic process:HSPA1A \| positive regulation of cellular catabolic process:HSPA1A \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| negative regulation of growth:HSPA1A,HSPA1B \| regulation of mRNA metabolic process:HSPA1A \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| regulation of RNA stability:HSPA1A \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| regulation of monooxygenase activity:DDAH2 \| positive regulation of cellular component biogenesis:HSPA1A,HSPA1B \| regulation of cellular protein catabolic process:HSPA1A \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| protein polymerization:HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| mitochondrial membrane organization:HSPA1A \| immunoglobulin production:HLA-DQB1 \| reactive oxygen species metabolic process:DDAH2 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:HSPA1A \| homologous chromosome segregation:MSH5 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of mRNA catabolic process:HSPA1A \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| cellular amino acid metabolic process:DDAH2 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| regulation of protein complex assembly:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| spindle organization:HSPA1A,HSPA1B \| regulation of protein catabolic process:HSPA1A \| chromosome organization involved in meiotic cell cycle:MSH5 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| cellular response to oxidative stress:HSPA1A,HSPA1B \| regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| regulation of response to endoplasmic reticulum stress:HSPA1A \| regulation of leukocyte chemotaxis:GPSM3 \| response to unfolded protein:HSPA1A,HSPA1L \| response to oxidative stress:HSPA1A,HSPA1B \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B	0.182141	0.0779633	1.70832707226234				0.172146	0.130574	0.727283718603553	0.507765	0.0851576	8.53585039045158				0.688868	0.14393	5.68392057011321	0.0960709	0.064044	0.873715950600623				0.0927286	0.102516	0.436490437212582	-0.0578012	0.04481	0.705359650048355				-0.015902	0.0755551	0.0791975758271462	-0.058618	0.0444799	0.726875984709603				0.0108217	0.0736303	0.0539640514624564	0.017445	0.0427668	0.165363792212406				-0.0451811	0.0712266	0.279124907699044	-0.0148641	0.0258121	0.248174521619654				0.00126205	0.0415849	0.0106440819669659	0.322597	0.127155	1.94863520768987				0.259393	0.176518	0.847228695184985
rs34289079:7593319:T:C		17	7593319	17p13.1	C	T	0.887	33	TESTO MEN	4291	8.44362994756719	0.0961251456536938	0.00386682	WRAP53 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); TP53 (2.5 kb, near gene/Upstream gene/MODIFIER); RP11-199F11.2 (3.6 kb, near gene/Upstream gene/MODIFIER); EFNB3 (15 kb); DNAH2 (27 kb); ATP1B2 (32 kb)	0.363 Cognitive function	- \| ASGR1 \| AURKB \| C17orf61 \| C17orf81 \| CD68 \| CHD3 \| CTDNEP1 \| CYB5D1 \| DLG4 \| DNAH2 \| EFNB3 \| EIF4A1 \| EIF5A \| GABARAP \| LSMD1 \| MPDU1 \| NDEL1 \| PER1 \| RP11-186B7.4 \| RPL26 \| SAT2 \| SNORA48 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| WRAP53 \| ZBTB4		Herpes simplex infection:TP53 \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Epstein-Barr virus infection:TP53 \| Human T-cell leukemia virus 1 infection:TP53 \| Thyroid hormone synthesis:ASGR1,ATP1B2 \| Huntington disease:DLG4,DNAH2,TP53 \| Kaposi sarcoma-associated herpesvirus infection:TP53 \| Ferroptosis:TP53 \| Cellular senescence:TP53 \| Transcriptional misregulation in cancer:TP53 \| Viral carcinogenesis:TP53 \| Small cell lung cancer:TP53 \| Human cytomegalovirus infection:TP53 \| Endocrine resistance:TP53 \| Aldosterone synthesis and secretion:ATP1B2 \| Measles:TP53	TP53 Regulates Transcription of DNA Repair Genes:TP53 \| TNFR2 non-canonical NF-kB pathway:TNFSF13 \| Pre-NOTCH Transcription and Translation:TP53 \| Association of TriC/CCT with target proteins during biosynthesis:TP53,WRAP53 \| EPHB-mediated forward signaling:EFNB3 \| Pre-NOTCH Expression and Processing:TP53 \| Transcriptional Regulation by TP53:TP53 \| Neurexins and neuroligins:DLG4 \| Asparagine N-linked glycosylation:ASGR1,MPDU1 \| TP53 Regulates Metabolic Genes:TP53 \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Protein-protein interactions at synapses:DLG4 \| Regulation of TP53 Activity through Phosphorylation:TP53 \| EPH-Ephrin signaling:EFNB3 \| Chaperonin-mediated protein folding:TP53,WRAP53 \| Formation of Senescence-Associated Heterochromatin Foci (SAHF):TP53 \| Protein folding:TP53,WRAP53 \| Signaling by NOTCH:TP53	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| endocrine system disease:TP53 \| lymphatic system disease:TNFSF13,TP53 \| intrahepatic cholestasis:TP53 \| Graves' disease:TP53 \| autoimmune disease of endocrine system:TP53 \| hyperthyroidism:TP53 \| hypersensitivity reaction type I disease:TP53 \| hepatitis:TP53 \| hepatitis C:TP53 \| aplastic anemia:TP53 \| hypotrichosis:TNFSF13 \| duodenal ulcer:TP53 \| cholestasis:TP53 \| urinary system disease:TNFSF13,TP53 \| multiple myeloma:TNFSF13,TP53 \| myeloma:TNFSF13,TP53 \| bone marrow cancer:TNFSF13,TP53 \| primary bacterial infectious disease:TP53 \| bile duct disease:TP53 \| hair disease:TNFSF13 \| vitiligo:TP53 \| biliary tract disease:TP53 \| thyroid gland disease:TP53 \| kidney disease:TNFSF13 \| purpura:TNFSF13 \| hepatitis B:TP53 \| alopecia:TNFSF13 \| collagen disease:TNFSF13 \| nephritis:TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| keratoconjunctivitis sicca:TP53 \| keratoconjunctivitis:TP53 \| bacterial infectious disease:TP53 \| dry eye syndrome:TP53 \| lacrimal apparatus disease:TP53 \| rheumatic disease:TNFSF13 \| systemic scleroderma:TNFSF13 \| scleroderma:TNFSF13 \| male reproductive system disease:TP53 \| male infertility:TP53 \| peptic ulcer disease:TP53 \| integumentary system disease:TNFSF13,TP53 \| Human immunodeficiency virus infectious disease:TP53 \| hematopoietic system disease:TNFSF13,TP53 \| colon carcinoma:EFNB3,TNFSF13,TP53 \| intestinal cancer:EFNB3,TNFSF13,TP53 \| reproductive system disease:TP53 \| germ cell and embryonal cancer:TP53 \| sporadic breast cancer:TP53 \| malignant glioma:ATP1B2,TP53 \| mammary Paget's disease:TP53 \| open-angle glaucoma:TP53 \| varicose veins:TP53 \| influenza:TP53 \| astrocytoma:TP53 \| gastritis:TP53 \| breast adenocarcinoma:TP53 \| myopathy:TNFSF13,TP53 \| muscle tissue disease:TNFSF13,TP53 \| neuropathy:TP53 \| tuberculosis:TP53 \| Sjogren's syndrome:TNFSF13 \| muscular disease:TNFSF13,TP53 \| alopecia areata:TNFSF13 \| chronic leukemia:TP53 \| cell type benign neoplasm:TP53 \| teratoma:TP53 \| Alzheimer's disease:DLG4,TP53 \| non-small cell lung carcinoma:EIF5A,TNFSF13,TP53 \| colon cancer:EFNB3,TNFSF13,TP53 \| tauopathy:DLG4,TP53 \| cholangitis:TP53 \| colorectal cancer:EFNB3,TNFSF13,TP53 \| stomach disease:TP53 \| large intestine cancer:EFNB3,TNFSF13,TP53 \| gallbladder carcinoma:TP53 \| esophagus squamous cell carcinoma:TP53 \| gallbladder cancer:TP53 \| infertility:TP53 \| neurofibroma:TP53 \| anemia:TP53 \| myositis:TNFSF13 \| lower respiratory tract disease:TP53 \| lung adenocarcinoma:EIF5A,TP53 \| cardiomyopathy:TP53 \| keratoacanthoma:TP53 \| primary immunodeficiency disease:TP53 \| liver cirrhosis:TNFSF13,TP53 \| gallbladder disease:TP53 \| pleural cancer:TP53 \| malignant pleural mesothelioma:TP53 \| esophageal carcinoma:TP53 \| mouth disease:TP53 \| lung disease:TP53 \| chronic lymphocytic leukemia:TNFSF13,TP53 \| female reproductive organ cancer:TP53 \| ataxia telangiectasia:TP53 \| vein disease:TP53 \| dilated cardiomyopathy:TP53 \| adenoma:TP53 \| acute myocardial infarction:TP53 \| gastric adenocarcinoma:TP53 \| coronary artery disease:TP53 \| integumentary system cancer:TP53 \| skin cancer:TP53	T cell costimulation:EFNB3 \| lymphocyte costimulation:EFNB3 \| positive regulation of leukocyte cell-cell adhesion:EFNB3 \| positive regulation of cell-cell adhesion:EFNB3 \| positive regulation of cell activation:EFNB3,TNFSF13 \| positive regulation of T cell activation:EFNB3 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF13 \| positive regulation of cell adhesion:EFNB3 \| positive regulation of lymphocyte activation:EFNB3,TNFSF13 \| positive regulation of leukocyte activation:EFNB3,TNFSF13 \| regulation of leukocyte activation:EFNB3,TNFSF13 \| regulation of lymphocyte activation:EFNB3,TNFSF13 \| postsynaptic membrane organization:DLG4 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| regulation of cell-cell adhesion:EFNB3 \| regulation of DNA biosynthetic process:TP53,WRAP53 \| regulation of leukocyte cell-cell adhesion:EFNB3 \| regulation of telomerase activity:TP53,WRAP53 \| cellular response to tumor necrosis factor:TNFSF13 \| DNA biosynthetic process:TP53,WRAP53 \| regulation of T cell activation:EFNB3 \| T cell activation:EFNB3 \| locomotory exploration behavior:DLG4 \| replicative senescence:TP53 \| response to tumor necrosis factor:TNFSF13 \| leukocyte cell-cell adhesion:EFNB3 \| regulation of immune effector process:TNFSF13 \| telomere maintenance via telomerase:WRAP53 \| RNA-dependent DNA biosynthetic process:WRAP53 \| positive regulation of cell cycle process:TP53 \| telomere maintenance via telomere lengthening:WRAP53 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| positive regulation of excitatory postsynaptic potential:DLG4 \| B cell mediated immunity:TNFSF13 \| exploration behavior:DLG4 \| positive regulation of adaptive immune response:TNFSF13 \| regulation of cell cycle G2/M phase transition:TP53 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:DLG4 \| interaction with host:EFNB3 \| nucleocytoplasmic transport:EIF5A,TP53 \| protein localization to synapse:DLG4 \| nuclear transport:EIF5A,TP53 \| positive regulation of DNA metabolic process:TNFSF13,WRAP53 \| chemical synaptic transmission, postsynaptic:DLG4 \| modulation of excitatory postsynaptic potential:DLG4 \| regulation of glutamate receptor signaling pathway:DLG4 \| negative regulation of DNA biosynthetic process:TP53 \| positive regulation of telomerase activity:WRAP53 \| positive regulation of reactive oxygen species metabolic process:EIF5A,TP53 \| protein stabilization:ATP1B2 \| positive regulation of cell cycle:TP53 \| negative regulation of growth:TP53 \| peptidyl-tyrosine phosphorylation:TP53 \| regulation of lymphocyte mediated immunity:TNFSF13 \| peptidyl-tyrosine modification:TP53 \| regulation of neurotransmitter receptor activity:DLG4 \| regulation of DNA metabolic process:TNFSF13,TP53,WRAP53 \| negative regulation of neurogenesis:EFNB3 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:TP53 \| cell cycle G2/M phase transition:TP53 \| protein N-linked glycosylation via asparagine:ASGR1 \| regulation of postsynaptic membrane potential:DLG4 \| synapse organization:DLG4 \| peptidyl-asparagine modification:ASGR1 \| positive regulation of cellular amide metabolic process:EIF5A \| neuromuscular process controlling balance:DLG4 \| regulation of mitotic cell cycle phase transition:TP53 \| negative regulation of nervous system development:EFNB3 \| regulation of adaptive immune response:TNFSF13 \| negative regulation of axonogenesis:EFNB3 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| receptor-mediated endocytosis:ASGR1,DLG4 \| regulation of lymphocyte apoptotic process:TP53 \| mitochondrial outer membrane permeabilization:TP53 \| protein localization to nucleoplasm:WRAP53 \| regulation of protein stability:ATP1B2 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| telomere maintenance:WRAP53 \| negative regulation of cell development:EFNB3 \| regulation of cell cycle phase transition:TP53 \| aging:EIF5A,TP53 \| negative regulation of cell growth:TP53 \| protein export from nucleus:EIF5A,TP53 \| positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress:TP53 \| protein localization to nucleus:CTDNEP1,WRAP53 \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:TP53 \| telomere organization:WRAP53 \| mitochondrial outer membrane permeabilization involved in programmed cell death:TP53 \| glycerolipid metabolic process:CTDNEP1 \| positive regulation of mitochondrial membrane permeability:TP53 \| positive regulation of DNA biosynthetic process:WRAP53 \| regulation of mitochondrial membrane permeability involved in apoptotic process:TP53 \| positive regulation of membrane permeability:TP53 \| regulation of DNA-templated transcription in response to stress:TP53 \| mRNA catabolic process:TNFSF13 \| lymphocyte apoptotic process:TP53 \| triglyceride metabolic process:CTDNEP1 \| protein N-linked glycosylation:ASGR1 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| positive regulation of protein complex assembly:TP53 \| locomotory behavior:DLG4,EFNB3 \| cellular response to UV:TP53 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| negative regulation of neuron differentiation:EFNB3 \| protein localization to chromosome:WRAP53 \| nuclear export:EIF5A,TP53 \| glutamate receptor signaling pathway:DLG4 \| regulation of mitochondrial membrane permeability:TP53 \| negative regulation of cell morphogenesis involved in differentiation:EFNB3 \| execution phase of apoptosis:TP53 \| regulation of leukocyte apoptotic process:TP53 \| mitochondrial membrane organization:TP53 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| acylglycerol metabolic process:CTDNEP1 \| potassium ion homeostasis:ATP1B2 \| neutral lipid metabolic process:CTDNEP1 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| DNA geometric change:TP53 \| regulation of receptor internalization:DLG4 \| cellular response to extracellular stimulus:ASGR1,TP53 \| regulation of membrane permeability:TP53 \| ephrin receptor signaling pathway:EFNB3 \| regulation of fibroblast proliferation:TP53 \| regulation of ion transmembrane transporter activity:ATP1B2,DLG4 \| fibroblast proliferation:TP53 \| regulation of apoptotic signaling pathway:TP53 \| regulation of transmembrane transporter activity:ATP1B2,DLG4 \| RNA catabolic process:TNFSF13 \| negative regulation of hydrolase activity:TP53 \| regulation of endocytosis:DLG4 \| neuromuscular process:DLG4 \| regulation of membrane potential:ATP1B2,DLG4 \| negative regulation of receptor-mediated endocytosis:DLG4 \| autophagy:TP53 \| process utilizing autophagic mechanism:TP53 \| cell aging:TP53 \| leukocyte apoptotic process:TP53 \| regulation of transporter activity:ATP1B2,DLG4 \| vocalization behavior:DLG4 \| RNA localization to Cajal body:WRAP53 \| telomerase RNA localization to Cajal body:WRAP53 \| telomerase RNA localization:WRAP53 \| RNA localization to nucleus:WRAP53 \| regulation of canonical Wnt signaling pathway:CTDNEP1 \| cellular response to light stimulus:TP53 \| axonogenesis:EFNB3	0.00545357	0.0293276	0.0693056123354646	0.0234353	0.0263274	0.427657072364042	-0.0362169	0.0582967	0.272105920400255	-0.00862776	0.0322656	0.10281897673028	-0.0118423	0.0347101	0.134882398324256	-7.3506E-4	0.0659255	0.00387945651265892	0.0380424	0.0240585	0.943190399126	0.0155448	0.0273413	0.244308805911578	0.0821324	0.0461383	1.12215314896543	0.00476767	0.0173129	0.106226035714243	0.00392993	0.0216548	0.0675313088861492	0.00413992	0.0276919	0.0549452257445605	-0.0684107	0.017079	4.20847004861699	-0.106121	0.0179819	8.44362994756719	-0.0092353	0.0289933	0.124891256340486	-0.0226057	0.0165817	0.762481395366893	-0.0457212	0.0204122	1.60036780667	0.0165528	0.0265319	0.273512411620996	-0.00193618	0.00994001	0.0728555699179477	-0.0106633	0.0128797	0.389637984460036	0.00848036	0.0154885	0.233573767305058	-0.032811	0.0484805	0.302231176618568	0.0444739	0.0602573	0.336669466201851	-0.180792	0.0813008	1.57687869630666
19:48461878:TA:AA		19	48461878	19q13.33	AA	TA	0.987	0	DHEAS WOMEN	3358	8.42945939504095	0.184642108397856	0.0134996	BSPH1 (9.4 kb); ELSPBP1 (36 kb); CABP5 (71 kb); SULT2A1 (72 kb)	NA			Chemical carcinogenesis:SULT2A1 \| Metabolism of xenobiotics by cytochrome P450:SULT2A1 \| Bile secretion:SULT2A1	Biological oxidations:SULT2A1 \| Phase II - Conjugation of compounds:SULT2A1	polycystic ovary syndrome:SULT2A1	steroid catabolic process:SULT2A1 \| steroid metabolic process:SULT2A1 \| sulfur compound metabolic process:SULT2A1 \| sperm capacitation:BSPH1,ELSPBP1	-0.0254465	0.0217346	0.616504191300001	-0.0238657	0.0196694	0.647410401020374	-0.027133	0.0435974	0.272695473573814	-0.0628073	0.0238802	2.06553992996473	-0.0361346	0.0259213	0.786370695445032	-0.118155	0.0480442	1.84896741824356	-0.00279777	0.0178462	0.0577731176991547	0.0253162	0.0204229	0.666879324871848	-0.0586966	0.0337708	1.08286119606612	-0.0726302	0.012952	7.68806822058123	-0.0311999	0.016267	1.25875461627826	-0.12152	0.02061	8.42945939504095	0.00424598	0.0127855	0.130875106373457	0.0245221	0.0135583	1.15176160416117	-0.0221085	0.0215495	0.515814088902006	0.0439357	0.0124631	3.37359187565124	0.0430288	0.0153519	2.29537853766733	0.0324202	0.0198929	0.986501296452583	-0.0138206	0.00743937	1.19926093268027	5.53465E-4	0.00967151	0.0202854961876602	-0.0301708	0.0115536	2.04490710648057	-0.0195538	0.0359637	0.231581691091467	-0.0173855	0.0449926	0.155362556295755	-0.0174731	0.059973	0.11301716532431
rs11078696:7459299:G:T		17	7459299	17p13.1	T	G	0.869	9	TESTO MEN	4291	8.41833473328238	0.805436028897693	0.0892386	TNFSF12 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); TNFSF12-TNFSF13 (0 kb, intron/Intron/MODIFIER); TNFSF13 (2.3 kb, near gene/Upstream gene/MODIFIER); SENP3 (5.9 kb); SENP3-EIF4A1 (7.3 kb); EIF4A1 (17 kb); SNORA67 (17 kb); SNORA48 (19 kb); SNORD10 (21 kb); CD68 (23 kb); MPDU1 (28 kb); SOX15 (32 kb); FXR2 (35 kb); POLR2A (41 kb)	0.565 IgA nephropathy // 0.565 Non-albumin protein levels // 0.565 IgA levels // 0.565 Albumin-globulin ratio // 0.319 Hormone measurements	- \| AC113189.5 \| ACAP1 \| ASGR1 \| ATP1B2 \| C17orf81 \| CD68 \| CHRNB1 \| CTC1 \| CTDNEP1 \| EIF4A1 \| EIF5A \| FGF11 \| KCNAB3 \| KDM6B \| MPDU1 \| PLSCR3 \| POLR2A \| RP11-186B7.4 \| SAT2 \| SENP3 \| SENP3-EIF4A1 \| SLC35G6 \| SNORA48 \| SOX15 \| TMEM102 \| TMEM88 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| TRAPPC1 \| TXNDC17 \| ZBTB4	EIF4A1P2	Herpes simplex infection:POLR2A \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Epstein-Barr virus infection:POLR2A \| Thyroid hormone synthesis:ATP1B2 \| Huntington disease:POLR2A \| Ferroptosis:SAT2 \| Lysosome:CD68 \| Aldosterone synthesis and secretion:ATP1B2 \| RNA transport:EIF4A1,FXR2	Interferon Signaling:EIF4A1 \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13 \| TP53 Regulates Transcription of DNA Repair Genes:POLR2A \| TNFR2 non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13,TNFSF13 \| MicroRNA (miRNA) biogenesis:POLR2A \| Transcriptional regulation of pluripotent stem cells:POLR2A \| Infectious disease:POLR2A \| Influenza Infection:POLR2A \| Transcriptional Regulation by TP53:POLR2A \| HIV Transcription Elongation:POLR2A \| Formation of HIV-1 elongation complex containing HIV-1 Tat:POLR2A \| Tat-mediated elongation of the HIV-1 transcript:POLR2A \| Transcription of the HIV genome:POLR2A \| Asparagine N-linked glycosylation:MPDU1 \| Formation of HIV elongation complex in the absence of HIV Tat:POLR2A \| ISG15 antiviral mechanism:EIF4A1 \| Antiviral mechanism by IFN-stimulated genes:EIF4A1 \| RNA Polymerase II Pre-transcription Events:POLR2A \| Formation of the Early Elongation Complex:POLR2A \| Formation of the HIV-1 Early Elongation Complex:POLR2A \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Pausing and recovery of Tat-mediated HIV elongation:POLR2A \| Tat-mediated HIV elongation arrest and recovery:POLR2A \| Formation of RNA Pol II elongation complex :POLR2A \| RNA Polymerase II Transcription Elongation:POLR2A \| HIV elongation arrest and recovery:POLR2A \| Pausing and recovery of HIV elongation:POLR2A \| Transcriptional regulation by small RNAs:POLR2A	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| lymphatic system disease:TNFSF13 \| hepatitis:EIF4A1 \| hepatitis C:EIF4A1 \| hypotrichosis:TNFSF13 \| urinary system disease:TNFSF12,TNFSF13 \| multiple myeloma:TNFSF13 \| myeloma:TNFSF13 \| bone marrow cancer:TNFSF13 \| hair disease:TNFSF13 \| proteinuria:TNFSF12 \| kidney disease:TNFSF12,TNFSF13 \| purpura:TNFSF13 \| alopecia:TNFSF13 \| collagen disease:TNFSF12,TNFSF13 \| nephritis:TNFSF12,TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| rheumatic disease:TNFSF12,TNFSF13 \| systemic scleroderma:TNFSF12,TNFSF13 \| scleroderma:TNFSF12,TNFSF13 \| integumentary system disease:TNFSF12,TNFSF13 \| hematopoietic system disease:TNFSF13 \| colon carcinoma:TNFSF13 \| intestinal cancer:SAT2,TNFSF13 \| malignant glioma:ATP1B2 \| interstitial lung disease:TNFSF12 \| myopathy:TNFSF12,TNFSF13 \| muscle tissue disease:TNFSF12,TNFSF13 \| Sjogren's syndrome:TNFSF13 \| muscular disease:TNFSF12,TNFSF13 \| alopecia areata:TNFSF13 \| non-small cell lung carcinoma:EIF5A,TNFSF13 \| colon cancer:TNFSF13 \| colorectal cancer:TNFSF13 \| large intestine cancer:TNFSF13 \| myositis:TNFSF13 \| lower respiratory tract disease:TNFSF12 \| lung adenocarcinoma:EIF5A \| cardiomyopathy:TNFSF12 \| liver cirrhosis:TNFSF13 \| lung disease:TNFSF12 \| chronic lymphocytic leukemia:TNFSF13 \| dilated cardiomyopathy:TNFSF12 \| acute myocardial infarction:TNFSF12 \| coronary artery disease:TNFSF12	positive regulation of cell activation:SOX15,TNFSF13 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF12,TNFSF13,TXNDC17 \| positive regulation of lymphocyte activation:TNFSF13 \| positive regulation of leukocyte activation:TNFSF13 \| regulation of leukocyte activation:TNFSF13 \| regulation of lymphocyte activation:TNFSF13 \| postsynaptic membrane organization:CHRNB1 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| RNA secondary structure unwinding:EIF4A1 \| cellular response to tumor necrosis factor:TNFSF12,TNFSF13,TXNDC17 \| response to tumor necrosis factor:TNFSF12,TNFSF13,TXNDC17 \| ammonium ion metabolic process:SAT2 \| regulation of immune effector process:TNFSF13 \| positive regulation of cell cycle process:SOX15 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| B cell mediated immunity:TNFSF13 \| translational initiation:EIF4A1 \| positive regulation of adaptive immune response:TNFSF13 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:CHRNB1 \| nucleocytoplasmic transport:EIF5A \| nuclear transport:EIF5A \| positive regulation of DNA metabolic process:TNFSF13 \| chemical synaptic transmission, postsynaptic:CHRNB1 \| positive regulation of reactive oxygen species metabolic process:EIF5A \| protein stabilization:ATP1B2 \| positive regulation of cell cycle:SOX15 \| regulation of lymphocyte mediated immunity:TNFSF13 \| nuclear-transcribed mRNA poly(A) tail shortening:EIF4A1 \| regulation of DNA metabolic process:TNFSF13 \| negative regulation of translation:FXR2,POLR2A \| DNA-templated transcription, elongation:POLR2A \| regulation of postsynaptic membrane potential:CHRNB1 \| synapse organization:CHRNB1 \| positive regulation of cellular amide metabolic process:EIF5A \| negative regulation of cellular amide metabolic process:FXR2,POLR2A \| regulation of adaptive immune response:TNFSF13 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| regulation of protein stability:ATP1B2 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| aging:EIF5A \| protein export from nucleus:EIF5A \| mRNA catabolic process:EIF4A1,TNFSF13 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| somatic stem cell population maintenance:POLR2A \| regulation of viral process:POLR2A \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| nuclear export:EIF5A \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:EIF4A1 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| potassium ion homeostasis:ATP1B2 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| regulation of symbiosis, encompassing mutualism through parasitism:POLR2A \| regulation of ion transmembrane transporter activity:ATP1B2 \| regulation of apoptotic signaling pathway:TNFSF12 \| regulation of transmembrane transporter activity:ATP1B2 \| RNA catabolic process:EIF4A1,TNFSF13 \| regulation of G0 to G1 transition:SOX15 \| regulation of membrane potential:ATP1B2,CHRNB1 \| transcription elongation from RNA polymerase II promoter:POLR2A \| regulation of striated muscle tissue development:SOX15 \| regulation of transporter activity:ATP1B2 \| G0 to G1 transition:SOX15 \| positive regulation of viral process:POLR2A \| regulation of muscle tissue development:SOX15 \| DNA-templated transcription, termination:POLR2A \| regulation of gene silencing by miRNA:POLR2A \| regulation of posttranscriptional gene silencing:POLR2A \| regulation of gene silencing by RNA:POLR2A	0.0189696	0.023098	0.385536240574177	-0.0176514	0.0207833	0.40245837967472	0.094997	0.0448677	1.46550176018275	0.0318466	0.0254066	0.677421010262721	0.0058851	0.0274008	0.0809365587692399	0.0836881	0.0516595	0.976011304936836	0.00930271	0.0189614	0.204987352582481	0.00665178	0.021585	0.120329648473728	0.0168655	0.0362965	0.1922492312272	0.00185801	0.0134423	0.0505777884415405	0.00621618	0.0168885	0.147020123550609	-0.00175201	0.021389	0.0293198585844291	0.0514469	0.0133005	3.95973399255392	0.0827127	0.0140382	8.41833473328238	0.0139392	0.0224993	0.27119024528172	0.0275416	0.0129099	1.48287671054028	0.053024	0.0158715	3.07818351568983	-0.0057029	0.0206153	0.106759371070337	0.00507575	0.00773027	0.291210403565152	0.00935136	0.0100604	0.452693058901958	-4.64115E-4	0.0119808	0.0136318545720302	-0.0422176	0.0381736	0.570430194298615	-0.0308744	0.0474675	0.28774858422345	-0.0643895	0.0642486	0.499480859081369
rs73729220:32342119:A:G		6	32342119	6p21.32	G	A	0.999	2	OHP17 ALL	2070	8.40417983156669	0.0159408212560386		C6orf10 (2.4 kb, near gene/Upstream gene/MODIFIER); HCG23 (16 kb); BTNL2 (20 kb); RNU6-603P (21 kb); HNRNPA1P2 (48 kb)	0.945 Marginal zone lymphoma // 0.767 Blood protein levels	- \| ABHD16A \| AGER \| AIF1 \| APOM \| ATF6B \| ATP6V1G2 \| BAG6 \| BRD2 \| BTNL2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf25 \| C6orf48 \| CFB \| CLIC1 \| CSNK2B \| CUTA \| CYP21A2 \| DDAH2 \| DDR1 \| DDX39B \| DOM3Z \| DXO \| FLOT1 \| GPANK1 \| GPSM3 \| HCG23 \| HCG27 \| HCP5 \| HLA-B \| HLA-C \| HLA-DOA \| HLA-DOB \| HLA-DPA1 \| HLA-DPB1 \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DQB1-AS1 \| HLA-DQB2 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB2 \| HLA-DRB3 \| HLA-DRB4 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB7 \| HLA-DRB8 \| HLA-DRB9 \| HSPA1A \| HSPA1B \| HSPA1L \| IER3 \| LINC00243 \| LSM2 \| LST1 \| LTA \| LY6G5B \| LY6G5C \| MCCD1 \| MIR6891 \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| NOTCH4 \| PHF1 \| PPT2 \| PRRC2A \| PRRT1 \| PSMB9 \| RDBP \| RNF5 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP1 \| TAP2 \| TAPBP \| TNF \| unnamed \| VARS \| VARS2 \| VPS52 \| XXbac-BPG154L12.4 \| XXbac-BPG181B23.7 \| XXbac-BPG254F23.6 \| ZBTB12	ABP1 \| EXOC1 \| FLOT1 \| HLA-A \| HLA-C \| IER3 \| LIMS1 \| LINC00243 \| TRIM26 \| TUBB \| unnamed \| VARS2 \| XRCC6 \| ZNF672 \| ZNRD1	Type I diabetes mellitus:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Allograft rejection:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Graft-versus-host disease:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Antigen processing and presentation:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L,TAP2 \| Autoimmune thyroid disease:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Viral myocarditis:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Staphylococcus aureus infection:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Asthma:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Phagosome:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,TAP2 \| Herpes simplex infection:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,TAP2 \| Intestinal immune network for IgA production:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Rheumatoid arthritis:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Inflammatory bowel disease (IBD):HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Toxoplasmosis:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L \| Systemic lupus erythematosus:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Cell adhesion molecules (CAMs):HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Leishmaniasis:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Influenza A:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L \| Hematopoietic cell lineage:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Epstein-Barr virus infection:HLA-C,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Th1 and Th2 cell differentiation:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Th17 cell differentiation:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Tuberculosis:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Natural killer cell mediated cytotoxicity:HLA-C,NCR3 \| Endocytosis:HLA-C,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L \| Human cytomegalovirus infection:HLA-C,TAP2 \| Kaposi sarcoma-associated herpesvirus infection:HLA-C \| Viral carcinogenesis:HLA-C \| Spliceosome:HSPA1A,HSPA1B,HSPA1L \| Human immunodeficiency virus 1 infection:HLA-C,TAP2 \| Protein processing in endoplasmic reticulum:HSPA1A,HSPA1B,HSPA1L \| Cellular senescence:HLA-C \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:HLA-C \| Proteasome:PSMB9	Translocation of ZAP-70 to Immunological synapse:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Interferon gamma signaling:HLA-C,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| PD-1 signaling:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Generation of second messenger molecules:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Downstream TCR signaling:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| Interferon Signaling:HLA-C,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| TCR signaling:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| MHC class II antigen presentation:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Costimulation by the CD28 family:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Endosomal/Vacuolar pathway:HLA-C \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,TAP2 \| ER-Phagosome pathway:HLA-C,PSMB9,TAP2 \| Antigen processing-Cross presentation:HLA-C,PSMB9,TAP2 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,NCR3 \| Interferon alpha/beta signaling:HLA-C \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:HSPA1A,HSPA1B,PSMB9 \| TNFR2 non-canonical NF-kB pathway:PSMB9 \| Butyrophilin (BTN) family interactions:BTNL2 \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| HIV Infection:PSMB9 \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B,PSMB9 \| Class I MHC mediated antigen processing & presentation:HLA-C,PSMB9,TAP2 \| Transcriptional regulation by RUNX3:PSMB9 \| Vpu mediated degradation of CD4:PSMB9 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B,PSMB9 \| SCF-beta-TrCP mediated degradation of Emi1:PSMB9 \| NIK-->noncanonical NF-kB signaling:PSMB9 \| Dectin-1 mediated noncanonical NF-kB signaling:PSMB9 \| Degradation of GLI1 by the proteasome:PSMB9 \| Degradation of GLI2 by the proteasome:PSMB9 \| GLI3 is processed to GLI3R by the proteasome:PSMB9 \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Regulation of PTEN stability and activity:PSMB9 \| Influenza Infection:HSPA1A,HSPA1B \| Defective CFTR causes cystic fibrosis:PSMB9 \| ABC-family proteins mediated transport:PSMB9 \| Activation of NF-kappaB in B cells:PSMB9 \| G2/M Transition:PSMB9 \| Mitotic G2-G2/M phases:PSMB9 \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| The role of GTSE1 in G2/M progression after G2 checkpoint:PSMB9 \| Neutrophil degranulation:HLA-C,HSPA1A,HSPA1B \| Regulation of APC/C activators between G1/S and early anaphase:PSMB9 \| ABC transporter disorders:PSMB9 \| Cyclin A:Cdk2-associated events at S phase entry:PSMB9 \| Interleukin-1 family signaling:AGER,PSMB9 \| Degradation of beta-catenin by the destruction complex:PSMB9 \| FCERI mediated NF-kB activation:PSMB9 \| Cyclin E associated events during G1/S transition :PSMB9 \| Downstream signaling events of B Cell Receptor (BCR):PSMB9 \| Influenza Life Cycle:HSPA1A,HSPA1B \| APC/C-mediated degradation of cell cycle proteins:PSMB9 \| Regulation of mitotic cell cycle:PSMB9 \| Cross-presentation of soluble exogenous antigens (endosomes):PSMB9 \| Regulation of activated PAK-2p34 by proteasome mediated degradation:PSMB9 \| Regulation of ornithine decarboxylase (ODC):PSMB9 \| CDK-mediated phosphorylation and removal of Cdc6:PSMB9 \| Ubiquitin-dependent degradation of Cyclin D1:PSMB9 \| Ubiquitin-dependent degradation of Cyclin D:PSMB9 \| Autodegradation of the E3 ubiquitin ligase COP1:PSMB9 \| Regulation of Apoptosis:PSMB9 \| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A:PSMB9 \| p53-Independent DNA Damage Response:PSMB9 \| p53-Independent G1/S DNA damage checkpoint:PSMB9 \| Vif-mediated degradation of APOBEC3G:PSMB9 \| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis:PSMB9 \| C-type lectin receptors (CLRs):PSMB9 \| Degradation of AXIN:PSMB9 \| Regulation of RUNX3 expression and activity:PSMB9 \| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD:PSMB9 \| Degradation of DVL:PSMB9 \| Stabilization of p53:PSMB9 \| CLEC7A (Dectin-1) signaling:PSMB9 \| Hh mutants abrogate ligand secretion:PSMB9 \| CDT1 association with the CDC6:ORC:origin complex:PSMB9 \| SCF(Skp2)-mediated degradation of p27/p21:PSMB9 \| Regulation of expression of SLITs and ROBOs:PSMB9 \| Cytosolic sensors of pathogen-associated DNA :AGER \| Autodegradation of Cdh1 by Cdh1:APC/C:PSMB9 \| Asymmetric localization of PCP proteins:PSMB9 \| Hedgehog ligand biogenesis:PSMB9 \| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha:PSMB9 \| p53-Dependent G1 DNA Damage Response:PSMB9 \| p53-Dependent G1/S DNA damage checkpoint:PSMB9 \| APC/C:Cdc20 mediated degradation of Securin:PSMB9 \| Hedgehog 'off' state:PSMB9	Kawasaki disease:HLA-C,HLA-DRB1,PRRC2A,BTNL2 \| lymphadenitis:HLA-C,HLA-DRB1,PRRC2A,BTNL2 \| lymph node disease:HLA-C,HLA-DRB1,PRRC2A,BTNL2 \| lymphatic system disease:HLA-C,HLA-DRB1,PRRC2A,BTNL2 \| leprosy:BTNL2,HLA-DRB1 \| sarcoidosis:AGER,BTNL2,HLA-DQA1,HLA-DRB1,HSPA1L \| hypersensitivity reaction type IV disease:AGER,BTNL2,HLA-DQA1,HLA-DRB1,HSPA1L \| autoimmune disease of endocrine system:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| multiple sclerosis:BTNL2,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| endocrine system disease:AGER,HLA-C,HLA-DQA1,HLA-DRB1,HSPA1B,TAP2 \| autoimmune thyroiditis:HLA-DRB1 \| demyelinating disease:BTNL2,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| Graves' disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| thyroid gland disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| intrahepatic cholestasis:HLA-DQA1,HLA-DRB1 \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HLA-C,HLA-DQA1,HLA-DRB1,AGER \| primary bacterial infectious disease:BTNL2,HLA-DRB1,PSMB9,TAP2 \| hepatitis:HLA-C,HLA-DPA1,HLA-DQA1,HLA-DRB1,NCR3,PSMB9 \| hyperthyroidism:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| vitiligo:HLA-C \| spondylitis:HLA-C \| ankylosing spondylitis:HLA-C \| rheumatic fever:HLA-DQA1,HLA-DRB1 \| bacterial infectious disease:BTNL2,HLA-DRB1,PSMB9,TAP2 \| aplastic anemia:HLA-DQA1,HLA-DRB1 \| urticaria:HLA-DRB1 \| spondyloarthropathy:HLA-C \| vasculitis:HLA-DRB1 \| hypothyroidism:HLA-DRB1 \| Behcet's disease:HLA-DRB1 \| hepatitis C:HLA-C,HLA-DQA1,HLA-DRB1,NCR3 \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1 \| arthropathy:HLA-C \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,NCR3,PRRC2A,TAP2 \| malaria:HLA-DRB1,NCR3,PRRC2A \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:HLA-DRB1 \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-DRB1 \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DQA1,HLA-DRA \| neuromuscular junction disease:HLA-DQA1,HLA-DRA \| brucellosis:TAP2,PSMB9 \| duodenal ulcer:HSPA1A \| cholestasis:HLA-DQA1,HLA-DRB1 \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-C,HLA-DPA1,HLA-DQA1,HLA-DRB1,PSMB9 \| upper respiratory tract disease:HLA-C,HSPA1A,TAP2 \| uveitis:HLA-DQA1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,NCR3,PRRC2A \| urinary system disease:AGER,AIF1,HLA-DQA1,HLA-DRB1,HSPA1A,LIMS1 \| multiple myeloma:NCR3 \| myeloma:NCR3 \| reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| bone marrow cancer:NCR3 \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L \| bile duct disease:HLA-C,HLA-DQA1,HLA-DRB1 \| biliary tract disease:HLA-C,HLA-DQA1,HLA-DRB1 \| azoospermia:HLA-DRB1,MSH5 \| proteinuria:HLA-DRB1 \| kidney disease:AGER,AIF1,HLA-DQA1,HLA-DRB1,HSPA1A,LIMS1 \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DRB1 \| type 1 diabetes mellitus:HLA-DQA1 \| blood coagulation disease:HLA-DRA,HLA-DRB1 \| allergic rhinitis:HLA-C,TAP2 \| hemorrhagic disease:HLA-DRA,HLA-DRB1 \| neuromuscular disease:HLA-DQA1,HLA-DRA \| thyroiditis:HLA-DRB1 \| nasal cavity disease:HLA-C,TAP2 \| nose disease:HLA-C,TAP2 \| rhinitis:HLA-C,TAP2 \| collagen disease:AGER,AIF1,HLA-DRB1,TAP2 \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:AGER,HLA-DRB1,HSPA1B \| nephritis:AIF1,HLA-DQA1,HLA-DRB1 \| periodontitis:AGER \| celiac disease:HLA-DQA1,HLA-DRB1 \| peptic ulcer disease:HSPA1A \| hematopoietic system disease:HLA-DQA1,HLA-DRA,HLA-DRB1 \| gestational diabetes:AGER \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DQA1,HLA-DRB1 \| rheumatic disease:AGER,AIF1,HLA-DRB1,TAP2 \| systemic scleroderma:AGER,AIF1,HLA-DRB1,TAP2 \| scleroderma:AGER,AIF1,HLA-DRB1,TAP2 \| male reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| male infertility:HLA-DRB1,MSH5 \| silicosis:HLA-DRB1 \| integumentary system disease:HLA-DQA1,HLA-DRB1 \| sickle cell anemia:HLA-DRB1 \| periodontal disease:AGER \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2 \| Human immunodeficiency virus infectious disease:HLA-C,HLA-DRB1 \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B \| interstitial lung disease:AGER,HLA-DRB1 \| bronchial disease:HSPA1A,HSPA1B,TAP2 \| acute pancreatitis:HSPA1B \| tuberculosis:BTNL2,HLA-DRB1 \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| prostate disease:HLA-DRB1,HSPA1A \| aortic valve disease:AGER \| pneumoconiosis:HLA-DRB1 \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1 \| tooth disease:AGER \| autoimmune disease of peripheral nervous system:HLA-DRB1 \| Guillain-Barre syndrome:HLA-DRB1 \| pancreas disease:HLA-DRB1,HSPA1B,AGER \| open-angle glaucoma:HLA-DRB1,TAP2 \| influenza:HLA-DRB1 \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-DQA1,HLA-DRB1 \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:AGER,HLA-DRB1,HSPA1A,HSPA1B,TAP2 \| ovarian disease:MSH5 \| gastritis:HLA-DRB1 \| dermatomyositis:AGER,HLA-DRB1 \| essential hypertension:HSPA1A,HSPA1B,HSPA1L,PSMB9 \| female reproductive system disease:MSH5 \| osteomyelitis:HLA-DRB1 \| neuropathy:AGER,HLA-DQA1,HLA-DRA \| mouth disease:AGER \| Sjogren's syndrome:AGER,PSMB9 \| migraine:HLA-DRB1 \| infertility:MSH5 \| peripheral nervous system disease:HLA-DRB1 \| autoimmune disease of urogenital tract:HLA-DRB1 \| primary biliary cirrhosis:HLA-DRB1 \| stomach disease:HLA-DRB1 \| cholangitis:HLA-C,HLA-DRB1 \| Crohn's disease:BTNL2,HSPA1B \| lung disease:AGER,HLA-DRB1,HSPA1A,HSPA1B \| spinal cord disease:HLA-C,HLA-DRB1 \| heart valve disease:AGER \| pulmonary edema:HSPA1A \| aortic valve stenosis:AGER \| myositis:AGER,HLA-DRB1 \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B,BTNL2 \| myopathy:AGER,HLA-DRB1 \| muscle tissue disease:AGER,HLA-DRB1 \| nasopharynx carcinoma:HSPA1B \| pharynx cancer:HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| muscular disease:AGER,HLA-DRB1 \| bronchiectasis:TAP2 \| premature ovarian failure:MSH5 \| liver cirrhosis:HLA-DRB1 \| renal cell carcinoma:HLA-DRB1,TAP2 \| glaucoma:HLA-DRB1,TAP2 \| esophageal carcinoma:HLA-DRB1 \| retinal disease:AGER,HLA-DRB1,TAP2 \| skin disease:HLA-DRB1 \| female reproductive organ cancer:HLA-DQA1,HLA-DRB1 \| pulmonary fibrosis:AGER \| primary open angle glaucoma:TAP2 \| severe combined immunodeficiency:HLA-DRB1 \| coronary artery disease:AGER \| retinal degeneration:HLA-DRB1,TAP2 \| malignant ovarian surface epithelial-stromal neoplasm:HLA-DQA1,HLA-DRB1 \| ovary epithelial cancer:HLA-DQA1,HLA-DRB1 \| ovarian carcinoma:HLA-DQA1,HLA-DRB1 \| combined T cell and B cell immunodeficiency:HLA-DRB1	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| antigen processing and presentation of peptide antigen:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| antigen processing and presentation:HLA-C,HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| cellular response to interferon-gamma:AIF1,HLA-C,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| response to interferon-gamma:AIF1,HLA-C,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DOB,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| T cell receptor signaling pathway:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| immune response-activating signal transduction:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HSPA1A,HSPA1B,NCR3,PSMB9 \| T cell costimulation:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| immune response-activating cell surface receptor signaling pathway:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,NCR3,PSMB9 \| lymphocyte costimulation:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen receptor-mediated signaling pathway:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,PSMB9 \| immune response-regulating cell surface receptor signaling pathway:HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,NCR3,PSMB9 \| positive regulation of cell-cell adhesion:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of leukocyte cell-cell adhesion:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of T cell activation:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| T cell activation:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of cell-cell adhesion:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,PSMB9,TAP2 \| regulation of leukocyte cell-cell adhesion:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,PSMB9,TAP2 \| positive regulation of cell adhesion:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,LIMS1 \| positive regulation of lymphocyte activation:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| positive regulation of cell activation:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of lymphocyte activation:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,LST1 \| regulation of T cell activation:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| regulation of leukocyte activation:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5,LST1 \| leukocyte cell-cell adhesion:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,PSMB9,TAP2 \| positive regulation of leukocyte activation:AGER,AIF1,HLA-DPA1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB5 \| lymphocyte mediated immunity:AGER,NCR3 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:AGER,NCR3 \| adaptive immune response:AGER,NCR3,TAP2 \| natural killer cell mediated cytotoxicity:NCR3 \| natural killer cell mediated immunity:NCR3 \| T cell mediated cytotoxicity:NCR3,AGER \| response to type I interferon:HLA-C \| type I interferon signaling pathway:HLA-C \| cellular response to type I interferon:HLA-C \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B,LIMS1,PSMB9 \| leukocyte mediated cytotoxicity:NCR3,AGER \| positive regulation of defense response:GPSM3,HSPA1A,HSPA1B,NCR3,PSMB9 \| positive regulation of cytokine production:AGER,GPSM3,HLA-DPA1,HSPA1A,HSPA1B \| T cell mediated immunity:AGER,NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:AGER,NCR3 \| positive regulation of innate immune response:HSPA1A,HSPA1B,NCR3,PSMB9 \| positive regulation of T cell proliferation:AGER,AIF1,HLA-DPA1 \| regulation of lymphocyte mediated immunity:NCR3,AGER \| NIK/NF-kappaB signaling:AGER,LIMS1,PSMB9 \| regulation of innate immune response:HSPA1A,HSPA1B,NCR3,PSMB9 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B,LIMS1,PSMB9 \| regulation of T cell proliferation:AGER,AIF1,HLA-DPA1 \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B,PSMB9 \| cell killing:NCR3,AGER \| positive regulation of lymphocyte mediated immunity:NCR3 \| regulation of lymphocyte proliferation:AGER,AIF1,HLA-DPA1,LST1 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| regulation of mononuclear cell proliferation:AGER,AIF1,HLA-DPA1,LST1 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of natural killer cell mediated cytotoxicity:NCR3 \| positive regulation of adaptive immune response:NCR3 \| regulation of natural killer cell mediated immunity:NCR3 \| interferon-gamma production:HLA-DPA1 \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B,PSMB9 \| regulation of leukocyte proliferation:AGER,AIF1,HLA-DPA1,LST1 \| mRNA catabolic process:HSPA1A,HSPA1B,PSMB9 \| response to tumor necrosis factor:HSPA1A,HSPA1B,LIMS1,PSMB9 \| response to heat:HSPA1A,HSPA1B,HSPA1L \| antigen processing and presentation via MHC class Ib:TAP2 \| positive regulation of nitric oxide biosynthetic process:AIF1 \| positive regulation of nitric oxide metabolic process:AIF1 \| regulation of leukocyte mediated immunity:NCR3,AGER \| activation of innate immune response:HSPA1A,HSPA1B,PSMB9 \| regulation of T cell mediated cytotoxicity:AGER,NCR3 \| positive regulation of leukocyte mediated immunity:NCR3 \| T cell proliferation:AGER,AIF1,HLA-DPA1 \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| antigen processing and presentation of endogenous antigen:TAP2 \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B \| microtubule nucleation:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of lymphocyte proliferation:AGER,AIF1,HLA-DPA1 \| positive regulation of mononuclear cell proliferation:AGER,AIF1,HLA-DPA1 \| regulation of leukocyte mediated cytotoxicity:AGER,NCR3 \| regulation of DNA-templated transcription in response to stress:HSPA1A,PSMB9 \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B,PSMB9 \| positive regulation of ubiquitin protein ligase activity:PSMB9 \| RNA catabolic process:HSPA1A,HSPA1B,PSMB9 \| positive regulation of leukocyte proliferation:AGER,AIF1,HLA-DPA1 \| positive regulation of reactive oxygen species biosynthetic process:AIF1 \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:HSPA1A,HSPA1L \| positive regulation of T cell mediated cytotoxicity:NCR3 \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| innate immune response-activating signal transduction:HSPA1A,HSPA1B,PSMB9 \| regulation of ubiquitin protein ligase activity:PSMB9 \| regulation of nitric oxide biosynthetic process:AIF1 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3,AGER \| lymphocyte proliferation:AGER,AIF1,HLA-DPA1,LST1 \| mononuclear cell proliferation:AGER,AIF1,HLA-DPA1,LST1 \| positive regulation of interleukin-12 production:AGER \| regulation of cell killing:AGER,NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B,PSMB9 \| regulation of interleukin-8 production:HSPA1A,HSPA1B \| regulation of antigen processing and presentation:HLA-DOB \| RNA phosphodiester bond hydrolysis:HSPA1A \| regulation of dendritic cell differentiation:AGER \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| regulation of adaptive immune response:NCR3,AGER \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| leukocyte proliferation:AGER,AIF1,HLA-DPA1,LST1 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B,AGER \| regulation of protein stability:HSPA1A,HSPA1B \| positive regulation of interferon-gamma production:HLA-DPA1 \| nitric oxide biosynthetic process:AIF1 \| interleukin-8 production:HSPA1A,HSPA1B \| positive regulation of protein complex assembly:HSPA1A,HSPA1B \| interaction with host:HSPA1A,HSPA1B \| positive regulation of ubiquitin-protein transferase activity:PSMB9 \| signal transduction in absence of ligand:HSPA1A,HSPA1B \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| nucleocytoplasmic transport:AGER \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of natural killer cell mediated immunity:NCR3 \| regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB9 \| nitric oxide metabolic process:AIF1 \| nuclear transport:AGER \| natural killer cell activation:NCR3 \| reactive nitrogen species metabolic process:AIF1 \| positive regulation of mononuclear cell migration:AIF1 \| cellular response to topologically incorrect protein:HSPA1A \| protein stabilization:HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| positive regulation of smooth muscle cell proliferation:AIF1 \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| mRNA cleavage:HSPA1A \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:AIF1 \| regulation of organelle assembly:HSPA1A,HSPA1B \| regulation of transcription from RNA polymerase II promoter in response to stress:HSPA1A,PSMB9 \| regulation of reactive oxygen species biosynthetic process:AIF1 \| SCF-dependent proteasomal ubiquitin-dependent protein catabolic process:PSMB9 \| protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB9 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition:PSMB9 \| response to endoplasmic reticulum stress:HSPA1A \| positive regulation of immune effector process:NCR3 \| stimulatory C-type lectin receptor signaling pathway:PSMB9 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| regulation of ubiquitin-protein transferase activity:PSMB9 \| pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| innate immune response activating cell surface receptor signaling pathway:PSMB9 \| response to isoquinoline alkaloid:AIF1 \| response to morphine:AIF1 \| positive regulation of T cell mediated immunity:NCR3 \| positive regulation of NIK/NF-kappaB signaling:AGER,LIMS1 \| spindle assembly:HSPA1A,HSPA1B \| regulation of interleukin-12 production:AGER \| nucleic acid phosphodiester bond hydrolysis:HSPA1A \| interleukin-12 production:AGER \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| positive regulation of response to endoplasmic reticulum stress:HSPA1A \| positive regulation of leukocyte mediated cytotoxicity:NCR3 \| reactive oxygen species biosynthetic process:AIF1 \| negative regulation of immune system process:HLA-DOB,LST1 \| positive regulation of proteolysis involved in cellular protein catabolic process:HSPA1A,PSMB9 \| positive regulation of NF-kappaB import into nucleus:AGER \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| post-translational protein modification:PSMB9 \| regulation of T cell mediated immunity:AGER,NCR3 \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| receptor-mediated endocytosis:AGER \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process:PSMB9 \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:LY6G5B,LY6G5C \| regulation of interferon-gamma production:HLA-DPA1 \| viral life cycle:HSPA1A,HSPA1B \| mitochondrial outer membrane permeabilization:HSPA1A \| protein localization to nucleus:AGER \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| regulation of proteolysis involved in cellular protein catabolic process:HSPA1A,PSMB9 \| regulation of mononuclear cell migration:AIF1 \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| positive regulation of catabolic process:HSPA1A,PSMB9 \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:HSPA1A,PSMB9 \| microglial cell activation:AGER,AIF1 \| positive regulation of cell killing:NCR3 \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| phagocytosis:AIF1 \| mRNA cleavage involved in mRNA processing:HSPA1A \| response to ammonium ion:AIF1 \| microtubule polymerization:HSPA1A,HSPA1B \| regulation of inflammatory response:AGER,GPSM3 \| synapsis:MSH5 \| macrophage activation:AGER,AIF1 \| protein folding:HSPA1A,HSPA1B,HSPA1L \| positive regulation of protein catabolic process:HSPA1A,PSMB9 \| positive regulation of cellular catabolic process:HSPA1A,PSMB9 \| regulation of transcription factor import into nucleus:AGER \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| regulation of smooth muscle cell proliferation:AIF1 \| negative regulation of growth:HSPA1A,HSPA1B \| transcription factor import into nucleus:AGER \| regulation of binding:AGER \| regulation of mRNA metabolic process:HSPA1A,PSMB9 \| regulation of NIK/NF-kappaB signaling:AGER,LIMS1 \| smooth muscle cell proliferation:AIF1 \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| regulation of RNA stability:HSPA1A,PSMB9 \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| regulation of cellular amino acid metabolic process:PSMB9 \| positive regulation of cellular component biogenesis:HSPA1A,HSPA1B \| regulation of cellular protein catabolic process:HSPA1A,PSMB9 \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,AGER \| glial cell activation:AGER,AIF1 \| protein polymerization:AIF1,HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| regulation of mitotic cell cycle phase transition:AIF1,PSMB9 \| mitochondrial membrane organization:HSPA1A \| reactive oxygen species metabolic process:AIF1 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| protein polyubiquitination:PSMB9 \| cellular response to ammonium ion:AIF1 \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:HSPA1A \| homologous chromosome segregation:MSH5 \| positive regulation of cell junction assembly:LIMS1 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of macrophage activation:AGER \| regulation of mRNA catabolic process:HSPA1A,PSMB9 \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| cellular amino acid metabolic process:PSMB9 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B,AGER \| regulation of protein complex assembly:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| spindle organization:HSPA1A,HSPA1B \| ruffle assembly:AIF1 \| negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle:PSMB9 \| regulation of protein catabolic process:HSPA1A \| platelet activation:MPIG6B \| negative regulation of mitotic cell cycle:PSMB9 \| Fc-epsilon receptor signaling pathway:PSMB9 \| regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle:PSMB9 \| chromosome organization involved in meiotic cell cycle:MSH5 \| negative regulation of chemotaxis:AIF1 \| regulation of cell cycle phase transition:AIF1,PSMB9 \| positive regulation of protein ubiquitination:PSMB9 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| cellular response to oxidative stress:AIF1,HSPA1A,HSPA1B \| G2/M transition of mitotic cell cycle:PSMB9 \| protein complex localization:AGER \| regulation of reactive oxygen species metabolic process:AIF1 \| negative regulation of ubiquitin protein ligase activity:PSMB9 \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| regulation of response to endoplasmic reticulum stress:HSPA1A \| regulation of leukocyte chemotaxis:AIF1,GPSM3 \| response to unfolded protein:HSPA1A,HSPA1L \| regulation of transcription from RNA polymerase II promoter in response to hypoxia:PSMB9 \| response to oxidative stress:AIF1,HSPA1A,HSPA1B \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of cellular amine metabolic process:PSMB9 \| smooth muscle cell migration:AIF1 \| negative regulation of leukocyte activation:LST1 \| cell cycle G2/M phase transition:PSMB9 \| anaphase-promoting complex-dependent catabolic process:PSMB9 \| regulation of G2/M transition of mitotic cell cycle:PSMB9	0.0802508	0.0665854	0.641585408382236	0.123122	0.0637639	1.2700022614142	0.0524157	0.121885	0.175766745202407	0.429629	0.0726698	8.40417983156669	0.231409	0.0839259	2.22868229167923	0.670827	0.132785	6.25410816033881	0.111271	0.0546195	1.37926655025497	0.0712337	0.0662708	0.548801717985916	0.143544	0.0946484	0.88667846782167	-0.00825524	0.0392273	0.0791887159769551	-0.027027	0.0477944	0.242798384273578	0.00762161	0.0650494	0.0425229729347477				0.0354343	0.0400428	0.424575436701697				0.0844757	0.0372193	1.63400314051579	0.148155	0.044657	3.04197155101843	-0.0201412	0.0601273	0.132153185789468	0.00309556	0.022496	0.0503402290108475				0.0278724	0.0358724	0.359354615513114	0.214443	0.108658	1.31363547318968	0.225918	0.145235	0.920598043683183	0.212413	0.163224	0.71314624499494
rs67836407:22292089:GAGGTT:G		13	22292089	13q12.11	G	GAGGTT	0.942	0	DHEAS ALL	7659	8.30250998438206	0.60716359838099	2.61951	FGF9 (13 kb); RN7SL766P (73 kb); RPS7P10 (89 kb); MICU2 (110 kb)	NA	EFHA1		Regulation of actin cytoskeleton:FGF9		endocrine system disease:FGF9 \| gonadal dysgenesis:FGF9 \| gonadal disease:FGF9	organ growth:FGF9 \| nucleocytoplasmic transport:FGF9 \| nuclear transport:FGF9 \| regulation of activin receptor signaling pathway:FGF9 \| cellular response to fibroblast growth factor stimulus:FGF9 \| lipid modification:FGF9 \| response to fibroblast growth factor:FGF9 \| protein localization to nucleus:FGF9 \| regulation of cardiac muscle tissue growth:FGF9 \| smoothened signaling pathway:FGF9 \| regulation of heart growth:FGF9 \| activin receptor signaling pathway:FGF9 \| regulation of protein kinase B signaling:FGF9 \| regulation of cardiac muscle tissue development:FGF9 \| cardiac muscle tissue growth:FGF9 \| regulation of striated muscle tissue development:FGF9 \| regulation of muscle tissue development:FGF9 \| heart growth:FGF9 \| positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway:FGF9 \| regulation of organ growth:FGF9	-0.01979	0.017939	0.568514007188591	-0.0210363	0.0162	0.711475793420152	-0.0300158	0.0351734	0.405103827537793	-0.0157918	0.019739	0.372854419339517	-0.017216	0.0213609	0.376327995287708	-0.0146902	0.0399046	0.146981132502172	0.023269	0.0147203	0.942760033126509	0.00762123	0.0168301	0.186591162254011	0.0509562	0.027927	1.16444132189421	0.0612256	0.01047	8.30250998438206	0.068419	0.0131628	6.69560211436242	0.0552716	0.016649	3.04539187204145	0.00699565	0.0103845	0.300572490343027	-0.0163238	0.0110193	0.858537683979731	0.0459087	0.0174635	2.06712256969952	-0.00603131	0.0100248	0.261683306436353	-0.013184	0.012416	0.540150838441945	0.00806523	0.0158605	0.213891980360821	0.0107472	0.00602802	1.12722391561763	0.0026019	0.00785942	0.130415119470223	0.0199859	0.00932442	1.49374127292725	0.0270407	0.029602	0.442367700805225	0.031714	0.037182	0.404668047506	0.0207834	0.0488852	0.173365512671506
rs9989237:94795202:C:T	known [2]	14	94795202	14q32.13	T	C	0.999	10	CORT ALL	7667	8.24307876570261	0.224232750749967	0.734416	SERPINA6 (5.5 kb); SERPINA2P (35 kb); SERPINA10 (36 kb); SERPINA1 (48 kb); PPP4R4 (49 kb)	NA	DDX24 \| DICER1 \| IFI27L1 \| IFI27L2 \| PPP4R4 \| SERPINA1 \| SERPINA11 \| SERPINA6 \| SERPINA9 \| unnamed		Complement and coagulation cascades:SERPINA1	Asparagine N-linked glycosylation:SERPINA1 \| Post-translational protein phosphorylation:SERPINA1,SERPINA10 \| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs):SERPINA1,SERPINA10 \| Platelet activation, signaling and aggregation:SERPINA1	endocrine system disease:SERPINA1 \| hepatitis:SERPINA1 \| hepatitis C:SERPINA1 \| cholestasis:SERPINA1 \| uveitis:SERPINA1 \| bile duct disease:SERPINA1 \| uveal disease:SERPINA1 \| biliary tract disease:SERPINA1 \| vasculitis:SERPINA1 \| hepatic vascular disease:SERPINA1 \| gestational diabetes:SERPINA1 \| esophageal varix:SERPINA1 \| vein disease:SERPINA1 \| pancreatitis:SERPINA1 \| alpha 1-antitrypsin deficiency:SERPINA1 \| Human immunodeficiency virus infectious disease:SERPINA1 \| severe combined immunodeficiency:SERPINA1 \| combined T cell and B cell immunodeficiency:SERPINA1 \| thyroid carcinoma:SERPINA1 \| pneumoconiosis:SERPINA1 \| thyroid cancer:SERPINA1 \| pancreas disease:SERPINA1 \| varicose veins:SERPINA1 \| interstitial lung disease:SERPINA1 \| plasma protein metabolism disease:SERPINA1 \| chromosomal disease:SERPINA1 \| lower respiratory tract disease:SERPINA1 \| bronchial disease:SERPINA1 \| bronchiectasis:SERPINA1 \| liver cirrhosis:SERPINA1 \| lung disease:SERPINA1 \| primary immunodeficiency disease:SERPINA1	negative regulation of hydrolase activity:PPP4R4,SERPINA1,SERPINA10,SERPINA6 \| glucocorticoid metabolic process:SERPINA6 \| regulation of endopeptidase activity:SERPINA1,SERPINA10,SERPINA6 \| regulation of peptidase activity:SERPINA1,SERPINA10,SERPINA6 \| negative regulation of endopeptidase activity:SERPINA1,SERPINA10,SERPINA6 \| negative regulation of peptidase activity:SERPINA1,SERPINA10,SERPINA6 \| negative regulation of proteolysis:SERPINA1,SERPINA10,SERPINA6 \| regulation of phosphoprotein phosphatase activity:PPP4R4 \| negative regulation of phosphoprotein phosphatase activity:PPP4R4 \| regulation of protein dephosphorylation:PPP4R4 \| steroid metabolic process:SERPINA6 \| negative regulation of protein dephosphorylation:PPP4R4 \| regulation of phosphatase activity:PPP4R4 \| blood coagulation:SERPINA1,SERPINA10 \| hemostasis:SERPINA1,SERPINA10 \| coagulation:SERPINA1,SERPINA10 \| post-translational protein modification:SERPINA1,SERPINA10 \| regulation of dephosphorylation:PPP4R4 \| acute inflammatory response:SERPINA1 \| negative regulation of phosphatase activity:PPP4R4 \| protein dephosphorylation:PPP4R4	-0.0176633	0.0198196	0.428378501599504	-0.00789343	0.0179812	0.179967429145895	-0.0499181	0.0392606	0.691292623582277	-0.0164624	0.0218065	0.346424760575176	-0.0223549	0.0236944	0.461413699983688	-0.0127984	0.0438425	0.113263995922989	0.00678311	0.016271	0.169535799857713	0.00507667	0.0186712	0.104720584758645	0.00491567	0.0307533	0.0589603858801831	0.0155342	0.012127	0.698518572778581	0.0290189	0.0151793	1.25251128451627	0.00102003	0.0193935	0.0186104648558439	-0.00340549	0.0118867	0.110979699389714	0.00297858	0.0126522	0.0894380227600465	-0.00403402	0.019984	0.0757083057016094	-0.00149151	0.0116762	0.0465520106882209	-0.00452093	0.0143748	0.123125439274282	0.00804267	0.0185728	0.177185538574809	0.0403298	0.00692366	8.24307876570261	0.0370085	0.00898525	4.41924489974262	0.0452752	0.0107792	4.57411216260854	0.0184933	0.0328167	0.241743069394748	0.00223045	0.0411204	0.0192010751768836	0.0545857	0.0545546	0.498408129005507
14:94792771:GTT:GT		14	94792771	14q32.13	GT	GTT	0.98	0	CORT ALL	7667	8.22297575719425	0.227028107473588	0.697878	SERPINA6 (3 kb, near gene/Upstream gene/MODIFIER); SERPINA10 (33 kb); SERPINA2P (37 kb); PPP4R4 (47 kb)	NA			Complement and coagulation cascades:SERPINA1	Asparagine N-linked glycosylation:SERPINA1 \| Post-translational protein phosphorylation:SERPINA1,SERPINA10 \| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs):SERPINA1,SERPINA10 \| Platelet activation, signaling and aggregation:SERPINA1	endocrine system disease:SERPINA1 \| hepatitis:SERPINA1 \| hepatitis C:SERPINA1 \| cholestasis:SERPINA1 \| uveitis:SERPINA1 \| bile duct disease:SERPINA1 \| uveal disease:SERPINA1 \| biliary tract disease:SERPINA1 \| vasculitis:SERPINA1 \| hepatic vascular disease:SERPINA1 \| gestational diabetes:SERPINA1 \| esophageal varix:SERPINA1 \| vein disease:SERPINA1 \| pancreatitis:SERPINA1 \| alpha 1-antitrypsin deficiency:SERPINA1 \| Human immunodeficiency virus infectious disease:SERPINA1 \| severe combined immunodeficiency:SERPINA1 \| combined T cell and B cell immunodeficiency:SERPINA1 \| thyroid carcinoma:SERPINA1 \| pneumoconiosis:SERPINA1 \| thyroid cancer:SERPINA1 \| pancreas disease:SERPINA1 \| varicose veins:SERPINA1 \| interstitial lung disease:SERPINA1 \| plasma protein metabolism disease:SERPINA1 \| chromosomal disease:SERPINA1 \| lower respiratory tract disease:SERPINA1 \| bronchial disease:SERPINA1 \| bronchiectasis:SERPINA1 \| liver cirrhosis:SERPINA1 \| lung disease:SERPINA1 \| primary immunodeficiency disease:SERPINA1	negative regulation of hydrolase activity:PPP4R4,SERPINA1,SERPINA10,SERPINA6 \| glucocorticoid metabolic process:SERPINA6 \| regulation of endopeptidase activity:SERPINA1,SERPINA10,SERPINA6 \| regulation of peptidase activity:SERPINA1,SERPINA10,SERPINA6 \| negative regulation of endopeptidase activity:SERPINA1,SERPINA10,SERPINA6 \| negative regulation of peptidase activity:SERPINA1,SERPINA10,SERPINA6 \| negative regulation of proteolysis:SERPINA1,SERPINA10,SERPINA6 \| regulation of phosphoprotein phosphatase activity:PPP4R4 \| negative regulation of phosphoprotein phosphatase activity:PPP4R4 \| regulation of protein dephosphorylation:PPP4R4 \| steroid metabolic process:SERPINA6 \| negative regulation of protein dephosphorylation:PPP4R4 \| regulation of phosphatase activity:PPP4R4 \| blood coagulation:SERPINA1,SERPINA10 \| hemostasis:SERPINA1,SERPINA10 \| coagulation:SERPINA1,SERPINA10 \| post-translational protein modification:SERPINA1,SERPINA10 \| regulation of dephosphorylation:PPP4R4 \| acute inflammatory response:SERPINA1 \| negative regulation of phosphatase activity:PPP4R4 \| protein dephosphorylation:PPP4R4	-0.0172741	0.0199123	0.413677177926967	-0.00736992	0.018081	0.165180157776256	-0.0546209	0.039426	0.780077704154573	-0.0135224	0.0219092	0.269887441423905	-0.0186524	0.0238282	0.362622360946726	-0.011706	0.0439849	0.102256929088829	0.00833031	0.0163465	0.214398993604262	0.00543073	0.0187746	0.112141991721889	0.00825434	0.0308518	0.10285419766459	0.0179482	0.0121855	0.851483719162436	0.0311354	0.0152382	1.386920711689	0.00361358	0.0195094	0.0690234762653829	-0.00141201	0.0119441	0.0429221373819524	0.00457019	0.0127034	0.143255405232731	-0.00188598	0.0200861	0.0337676617562321	-7.24653E-4	0.0117302	0.0219377770589908	-0.0011399	0.0144282	0.0282469679755305	0.00497154	0.0186765	0.102322885264204	0.0404721	0.00695732	8.22297575719425	0.0366712	0.00902291	4.31703946886227	0.0459696	0.0108421	4.65055345119883	0.024362	0.0329572	0.337363032295245	0.00941744	0.0413374	0.0862799017880389	0.058191	0.0546973	0.540965047539232
rs114341625:112578458:G:A	novel2	3	112578458	3q13.2	A	G	0.955	3	CORT ALL	7667	8.1945072976831	0.018120907786618	0.524741	CD200R1L (13 kb); CD200R1 (62 kb); GTPBP8 (130 kb); C3orf17 (140 kb)	NA	ATP6V1A \| C3orf17 \| CD200R1 \| GTPBP8 \| SLC35A5 \| WDR52		Kaposi sarcoma-associated herpesvirus infection:CD200R1,CD200R1L	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:CD200R1			-0.0258943	0.0679564	0.152914962004336	0.0166459	0.05975	0.10757145305477	-0.0712974	0.139298	0.215548184405478	-0.0981653	0.0747363	0.723161511110615	-0.0790859	0.0787278	0.501284293735714	-0.155757	0.15938	0.483109139318258	-0.0288922	0.0557788	0.218582860662791	0.00828982	0.0620416	0.0487960934581655	-0.121831	0.111774	0.558943031228195	-0.00977759	0.0384388	0.0973380038928629	0.00184771	0.0478065	0.0136000376175941				-0.0142019	0.038394	0.147851343263538	-0.0113557	0.0398976	0.110174658024887	-0.0439174	0.0666561	0.292445152213103							0.00925469	0.0591443	0.057665480263401	-0.128447	0.0221222	8.1945072976831	-0.115467	0.0284758	4.29970568151621	-0.142245	0.0347362	4.374542	0.0486626	0.112721	0.176525118736372	-0.00662319	0.139033	0.0168195106011904	0.166618	0.192716	0.411643123753044
rs35679777:68034459:CG:C	novel4	6	6834459	6q12	C	CG	0.999	0	E2 ALL	6798	8.1691759651567	0.380714842600765	0.782556	RNA5SP208 (140 kb); RNU6-280P (220 kb)	NA							-0.010403	0.0172507	0.262374074433194	-0.0102035	0.0154482	0.293241264515361	0.00564842	0.0347251	0.0600890606522299	-0.011446	0.0189791	0.262394734992011	-0.0098296	0.0203634	0.201086371876733	-0.00748442	0.0390342	0.0716036356038689	0.0104805	0.0141592	0.337931922228444	0.00989792	0.0160407	0.269779117997645	0.0169697	0.0273726	0.271248634982209	-5.57682E-5	0.0103937	0.00186320572055506	0.00418929	0.012934	0.12725244015235	-0.00423261	0.0167335	0.0967401285234974	0.010691	0.010219	0.529480728499528	0.0147503	0.0107755	0.766904851282581				0.0577234	0.00995841	8.1691759651567	0.0393347	0.0122194	2.890671	0.0741314	0.0159642	5.4655119081985	-7.95462E-5	0.00595638	0.00465223674567739	0.00490737	0.00767744	0.28174999251213	-0.00707457	0.00934627	0.347670483609113	0.00537768	0.0285157	0.0703583638770128	0.00390933	0.0354359	0.0399232629787975	0.00368455	0.0480855	0.0273603089226293
rs72906582:45222771:G:A	novel3	18	45222771	18q21.1	A	G	0.964	17	PROG WOMEN	1261	8.12492252325029	0.101244203013481	6.59622E-4	TPMTP1 (66 kb); SMAD2 (140 kb)	NA	PIAS2 \| SMAD2 \| ST8SIA5		Inflammatory bowel disease (IBD):SMAD2 \| Human T-cell leukemia virus 1 infection:SMAD2 \| Th17 cell differentiation:SMAD2 \| Endocytosis:SMAD2 \| Cellular senescence:SMAD2 \| Relaxin signaling pathway:SMAD2 \| Apelin signaling pathway:SMAD2 \| Ubiquitin mediated proteolysis:PIAS2 \| Signaling pathways regulating pluripotency of stem cells:SMAD2	Transcriptional regulation of pluripotent stem cells:SMAD2	urinary system disease:PIAS2,SMAD2 \| multiple myeloma:SMAD2 \| myeloma:SMAD2 \| bone marrow cancer:SMAD2 \| kidney disease:PIAS2,SMAD2 \| collagen disease:SMAD2 \| nephritis:SMAD2 \| rheumatic disease:SMAD2 \| systemic scleroderma:SMAD2 \| scleroderma:SMAD2 \| integumentary system disease:SMAD2 \| cell type benign neoplasm:SMAD2 \| glomerulonephritis:SMAD2 \| amyotrophic lateral sclerosis:SMAD2 \| lower respiratory tract disease:SMAD2 \| bronchial disease:SMAD2 \| motor neuron disease:SMAD2 \| lung disease:SMAD2 \| female reproductive organ cancer:SMAD2 \| asthma:SMAD2 \| adenoma:SMAD2 \| integumentary system cancer:SMAD2 \| skin cancer:SMAD2	foregut morphogenesis:SMAD2 \| signal transduction involved in regulation of gene expression:SMAD2 \| regulation of mesoderm development:SMAD2 \| negative regulation of intracellular steroid hormone receptor signaling pathway:PIAS2 \| digestive tract development:SMAD2 \| digestive system development:SMAD2 \| regulation of gene expression, epigenetic:SMAD2 \| gene silencing by miRNA:SMAD2 \| posttranscriptional gene silencing by RNA:SMAD2 \| posttranscriptional gene silencing:SMAD2 \| digestive tract morphogenesis:SMAD2 \| gene silencing by RNA:SMAD2 \| endoderm formation:SMAD2 \| regulation of activin receptor signaling pathway:SMAD2 \| regulation of ossification:PIAS2 \| ossification:PIAS2 \| cellular response to dsRNA:SMAD2 \| negative regulation of transforming growth factor beta receptor signaling pathway:SMAD2 \| osteoblast differentiation:PIAS2 \| negative regulation of cellular response to transforming growth factor beta stimulus:SMAD2 \| negative regulation of translation:SMAD2 \| regulation of intracellular steroid hormone receptor signaling pathway:PIAS2 \| mesoderm formation:SMAD2 \| pancreas development:SMAD2 \| mesoderm morphogenesis:SMAD2 \| endoderm development:SMAD2 \| negative regulation of cellular amide metabolic process:SMAD2 \| hormone-mediated signaling pathway:PIAS2 \| regulation of epithelial to mesenchymal transition:SMAD2 \| gene silencing:SMAD2 \| regulation of BMP signaling pathway:SMAD2 \| post-embryonic development:SMAD2 \| response to dsRNA:SMAD2 \| regulation of transforming growth factor beta receptor signaling pathway:SMAD2 \| regulation of cellular response to transforming growth factor beta stimulus:SMAD2 \| renal system development:SMAD2 \| negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway:SMAD2 \| regulation of osteoblast differentiation:PIAS2 \| determination of left/right symmetry:SMAD2 \| intracellular receptor signaling pathway:PIAS2 \| activin receptor signaling pathway:SMAD2 \| determination of bilateral symmetry:SMAD2 \| specification of symmetry:SMAD2 \| formation of primary germ layer:SMAD2 \| urogenital system development:SMAD2 \| mesoderm development:SMAD2 \| epithelial to mesenchymal transition:SMAD2 \| intracellular steroid hormone receptor signaling pathway:PIAS2 \| negative regulation of cellular response to growth factor stimulus:SMAD2 \| somatic stem cell population maintenance:SMAD2 \| transmembrane receptor protein serine/threonine kinase signaling pathway:SMAD2 \| regulation of binding:SMAD2	0.140791	0.0281928	6.19281823350953	0.0347859	0.0256685	0.755522481833114	0.318619	0.0551308	8.12492252325029	0.0840146	0.0311493	2.15179240278554	0.003563	0.0338559	0.0380092385430776	0.219603	0.0622721	3.34849132832137	0.0304565	0.0232711	0.719517239569672	3.77452E-4	0.0266705	0.00493107328508809	0.0773128	0.0439649	1.10186304953128	-0.0116609	0.0166644	0.315078374327002	-0.0247623	0.0207501	0.633147630487736	0.00381715	0.0268293	0.0521434635271791	0.0271158	0.0164623	1.00205515927867				0.0800302	0.0278825	2.38708481553918	0.00711207	0.0159999	0.182648194536236	0.00188761	0.0194791	0.0348914728982105	0.00880213	0.0259367	0.134107546120645	0.00669581	0.00957418	0.314862216162133	0.00262816	0.01237	0.0800087568983288	0.0144233	0.0149949	0.473517274019285	0.0267949	0.0467538	0.246695070530037	0.0294645	0.0586913	0.210606159264056	0.0290616	0.077354	0.150421517359175
rs5935876:6922078:G:A	novel1	23	6922078	Xp22.31	A	G	0.982	278	DHEAS ALL	7650	8.08300996296987	0.374331568627451	0.347581	HDHD1 (45 kb); MIR4767 (140 kb); STS (220 kb)	NA	HDHD1 \| HDHD1A \| NLGN4X \| PUDP \| STS		Cell adhesion molecules (CAMs):NLGN4X \| Steroid hormone biosynthesis:STS	Gamma carboxylation, hypusine formation and arylsulfatase activation:STS	polycystic ovary syndrome:STS \| reproductive system disease:STS \| neuropathy:STS \| cell type benign neoplasm:STS \| astrocytoma:STS \| brain cancer:STS \| specific developmental disorder:NLGN4X,STS \| endocrine organ benign neoplasm:STS \| female reproductive organ cancer:STS \| adenoma:STS \| glioblastoma multiforme:STS	steroid catabolic process:STS \| organ growth:NLGN4X \| postsynaptic membrane organization:NLGN4X \| steroid metabolic process:STS \| post-translational protein modification:STS \| postsynaptic membrane assembly:NLGN4X \| receptor-mediated endocytosis:NLGN4X \| membrane assembly:NLGN4X \| presynaptic membrane organization:NLGN4X \| membrane biogenesis:NLGN4X \| postsynapse assembly:NLGN4X \| modulation of excitatory postsynaptic potential:NLGN4X \| neuron cell-cell adhesion:NLGN4X \| presynapse assembly:NLGN4X \| synaptic vesicle recycling:NLGN4X \| vocalization behavior:NLGN4X	0.0360876	0.0271842	0.73404600176525	0.0199852	0.0221934	0.434133299368178	0.128295	0.0698463	1.17890721388401	0.0239878	0.0299082	0.3740499543161	0.01129276	0.02926	0.15515144074597	0.0826592	0.0786944	0.531797458547978	0.0777768	0.0222524	3.31540326234153	0.0876642	0.022923	3.86291503200198	0.0481106	0.055223	0.415738901757069	-0.0971084	0.0168501	8.08300996296987	-0.0563848	0.0185186	2.63289578174924	-0.188607	0.0333804	7.79523719461589	-0.00455113	0.0164808	0.10655173085991	0.00385598	0.0154184	0.0955452178476948				-0.0291987	0.0159165	1.17665099089311	-0.037635	0.0175125	1.49987609395766	-0.0140109	0.0321312	0.178617500252701							0.0124042	0.0187462	0.293989268015477	0.0580214	0.0448892	0.70703987899252	0.0470532	0.050826	0.450094735384862	0.0944346	0.0970988	0.480019833008663
rs142754737:43865714:C:T	novel1	11	43865714	11p11.2	T	C	0.937	7	PROG WOMEN	1261	8.06021426219854	0.0142552712133228	0.426706	HSD17B12 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Downstream gene/MODIFIER); RP11-613D13.5 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); ALKBH3 (37 kb); SEC14L1P1 (53 kb)	NA	- \| ALKBH3 \| HSD17B12 \| TTC17		Steroid hormone biosynthesis:HSD17B12	Metabolism of steroid hormones:HSD17B12 \| Androgen biosynthesis:HSD17B12		positive regulation of cell adhesion:HSD17B12 \| DNA methylation or demethylation:ALKBH3 \| cellular hormone metabolic process:HSD17B12 \| oxidative demethylation:ALKBH3 \| hormone biosynthetic process:HSD17B12 \| DNA modification:ALKBH3 \| steroid metabolic process:HSD17B12 \| hormone metabolic process:HSD17B12 \| steroid biosynthetic process:HSD17B12 \| estrogen biosynthetic process:HSD17B12 \| coenzyme biosynthetic process:HSD17B12 \| fatty acid derivative metabolic process:HSD17B12	0.345894	0.0696468	6.13188244109844	0.13656	0.0627846	1.52580705437428	0.798375	0.138746	8.06021426219854	0.240311	0.0768993	2.74408135956067	0.249053	0.0826224	2.58117687436974	0.233298	0.157332	0.858355856687185	0.0775923	0.0574831	0.751489718381217	0.0732322	0.0652746	0.5815329790534	0.0931593	0.110471	0.398645223729474	-0.0372806	0.0442842	0.398077919064475	-0.112249	0.0586902	1.25334478732169	0.0285004	0.0666126	0.174731009703314							0.0350166	0.0695572	0.211359395932614	0.0491843	0.0434212	0.58951126769455	0.0947835	0.0561939	1.03783530928414	0.0143104	0.0660032	0.081784550555641	0.0299485	0.0252566	0.627616464685803	0.00278897	0.0343084	0.029090393622087	0.0568735	0.0372762	0.895933046432431	0.06289	0.113571	0.236713549598502	-0.0361411	0.14144	0.0978017744899347	0.245713	0.190255	0.705602119972071
rs67462449:7377539:C:CTTT		17	7377539	17p13.1	CTTT	C	0.849	0	TESTO MEN	4291	8.01345353045888	0.635030529014216	0.108354	ZBTB4 (0 kb, intron/Intron/MODIFIER); SLC35G6 (7.2 kb); POLR2A (10 kb); CHRNB1 (17 kb); FGF11 (29 kb); TMEM102 (37 kb); C17orf74 (47 kb)	0.361 Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test) // 0.361 Systolic blood pressure x smoking status (current vs non-current) interaction (2df test) // 0.361 Systolic blood pressure x smoking status (ever vs never) interaction (2df test) // 0.361 Diastolic blood pressure x smoking status (ever vs never) interaction (2df test) // 0.353 Blood protein levels // 0.339 Chin dimples	- \| AC113189.5 \| ACAP1 \| ASGR2 \| ATP1B2 \| C17orf61 \| C17orf61-PLSCR3 \| CD68 \| CHRNB1 \| CTDNEP1 \| EIF4A1 \| EIF5A \| FGF11 \| FXR2 \| KCTD11 \| MPDU1 \| PLSCR3 \| POLR2A \| RP11-186B7.4 \| SAT2 \| SENP3 \| SHBG \| SNORA48 \| SOX15 \| SPEM1 \| TMEM102 \| TMEM256-PLSCR3 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| TP53		Herpes simplex infection:POLR2A \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Epstein-Barr virus infection:POLR2A \| Endocytosis:ACAP1 \| Huntington disease:POLR2A \| Ferroptosis:SAT2 \| Lysosome:CD68 \| RNA transport:EIF4A1	Interferon Signaling:EIF4A1 \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13 \| TP53 Regulates Transcription of DNA Repair Genes:POLR2A \| TNFR2 non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13,TNFSF13 \| MicroRNA (miRNA) biogenesis:POLR2A \| Transcriptional regulation of pluripotent stem cells:POLR2A \| Infectious disease:POLR2A \| Influenza Infection:POLR2A \| Transcriptional Regulation by TP53:POLR2A \| HIV Transcription Elongation:POLR2A \| Formation of HIV-1 elongation complex containing HIV-1 Tat:POLR2A \| Tat-mediated elongation of the HIV-1 transcript:POLR2A \| Transcription of the HIV genome:POLR2A \| Formation of HIV elongation complex in the absence of HIV Tat:POLR2A \| ISG15 antiviral mechanism:EIF4A1 \| Antiviral mechanism by IFN-stimulated genes:EIF4A1 \| RNA Polymerase II Pre-transcription Events:POLR2A \| Formation of the Early Elongation Complex:POLR2A \| Formation of the HIV-1 Early Elongation Complex:POLR2A \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Pausing and recovery of Tat-mediated HIV elongation:POLR2A \| Tat-mediated HIV elongation arrest and recovery:POLR2A \| Formation of RNA Pol II elongation complex :POLR2A \| RNA Polymerase II Transcription Elongation:POLR2A \| HIV elongation arrest and recovery:POLR2A \| Pausing and recovery of HIV elongation:POLR2A \| Transcriptional regulation by small RNAs:POLR2A	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| lymphatic system disease:TNFSF13 \| hepatitis:EIF4A1 \| hepatitis C:EIF4A1 \| hypotrichosis:TNFSF13 \| urinary system disease:TNFSF12,TNFSF13 \| multiple myeloma:TNFSF13 \| myeloma:TNFSF13 \| bone marrow cancer:TNFSF13 \| hair disease:TNFSF13 \| proteinuria:TNFSF12 \| kidney disease:TNFSF12,TNFSF13 \| purpura:TNFSF13 \| alopecia:TNFSF13 \| collagen disease:TNFSF12,TNFSF13 \| nephritis:TNFSF12,TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| rheumatic disease:TNFSF12,TNFSF13 \| systemic scleroderma:TNFSF12,TNFSF13 \| scleroderma:TNFSF12,TNFSF13 \| integumentary system disease:TNFSF12,TNFSF13 \| hematopoietic system disease:TNFSF13 \| colon carcinoma:TNFSF13 \| intestinal cancer:SAT2,TNFSF13 \| interstitial lung disease:TNFSF12 \| myopathy:TNFSF12,TNFSF13 \| muscle tissue disease:TNFSF12,TNFSF13 \| Sjogren's syndrome:TNFSF13 \| muscular disease:TNFSF12,TNFSF13 \| alopecia areata:TNFSF13 \| non-small cell lung carcinoma:EIF5A,TNFSF13 \| colon cancer:TNFSF13 \| colorectal cancer:TNFSF13 \| large intestine cancer:TNFSF13 \| myositis:TNFSF13 \| lower respiratory tract disease:TNFSF12 \| lung adenocarcinoma:EIF5A \| cardiomyopathy:TNFSF12 \| liver cirrhosis:TNFSF13 \| lung disease:TNFSF12 \| chronic lymphocytic leukemia:TNFSF13 \| dilated cardiomyopathy:TNFSF12 \| acute myocardial infarction:TNFSF12 \| coronary artery disease:TNFSF12	positive regulation of cell activation:SOX15,TNFSF13 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF12,TNFSF13 \| positive regulation of cell adhesion:TMEM102 \| positive regulation of lymphocyte activation:TNFSF13 \| positive regulation of leukocyte activation:TNFSF13 \| regulation of leukocyte activation:TNFSF13 \| regulation of lymphocyte activation:TNFSF13 \| postsynaptic membrane organization:CHRNB1 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| RNA secondary structure unwinding:EIF4A1 \| cellular response to tumor necrosis factor:TNFSF12,TNFSF13 \| response to tumor necrosis factor:TNFSF12,TNFSF13 \| ammonium ion metabolic process:SAT2 \| regulation of immune effector process:TNFSF13 \| positive regulation of cell cycle process:SOX15 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| B cell mediated immunity:TNFSF13 \| translational initiation:EIF4A1 \| positive regulation of adaptive immune response:TNFSF13 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:CHRNB1 \| nucleocytoplasmic transport:EIF5A \| nuclear transport:EIF5A \| positive regulation of DNA metabolic process:TNFSF13 \| chemical synaptic transmission, postsynaptic:CHRNB1 \| positive regulation of reactive oxygen species metabolic process:EIF5A \| positive regulation of cell cycle:SOX15 \| peptidyl-tyrosine phosphorylation:TMEM102 \| regulation of lymphocyte mediated immunity:TNFSF13 \| peptidyl-tyrosine modification:TMEM102 \| nuclear-transcribed mRNA poly(A) tail shortening:EIF4A1 \| regulation of DNA metabolic process:TNFSF13 \| negative regulation of translation:POLR2A \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:TMEM102 \| DNA-templated transcription, elongation:POLR2A \| regulation of postsynaptic membrane potential:CHRNB1 \| synapse organization:CHRNB1 \| positive regulation of cellular amide metabolic process:EIF5A \| negative regulation of cellular amide metabolic process:POLR2A \| regulation of adaptive immune response:TNFSF13 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| mitochondrial outer membrane permeabilization:TMEM102 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| aging:EIF5A \| protein export from nucleus:EIF5A \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:TMEM102 \| mitochondrial outer membrane permeabilization involved in programmed cell death:TMEM102 \| positive regulation of mitochondrial membrane permeability:TMEM102 \| regulation of mitochondrial membrane permeability involved in apoptotic process:TMEM102 \| positive regulation of membrane permeability:TMEM102 \| mRNA catabolic process:EIF4A1,TNFSF13 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| somatic stem cell population maintenance:POLR2A \| regulation of viral process:POLR2A \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| nuclear export:EIF5A \| regulation of mitochondrial membrane permeability:TMEM102 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:EIF4A1 \| mitochondrial membrane organization:TMEM102 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| regulation of membrane permeability:TMEM102 \| regulation of symbiosis, encompassing mutualism through parasitism:POLR2A \| regulation of apoptotic signaling pathway:TMEM102,TNFSF12 \| RNA catabolic process:EIF4A1,TNFSF13 \| regulation of G0 to G1 transition:SOX15 \| regulation of membrane potential:CHRNB1 \| transcription elongation from RNA polymerase II promoter:POLR2A \| regulation of striated muscle tissue development:SOX15 \| G0 to G1 transition:SOX15 \| positive regulation of viral process:POLR2A \| regulation of muscle tissue development:SOX15 \| DNA-templated transcription, termination:POLR2A \| regulation of leukocyte chemotaxis:TMEM102 \| regulation of gene silencing by miRNA:POLR2A \| regulation of posttranscriptional gene silencing:POLR2A \| regulation of gene silencing by RNA:POLR2A	0.0060841	0.0187121	0.127781939412239	0.00733798	0.0167491	0.179552225459887	0.00123882	0.0377946	0.0115070394942561	-0.0507393	0.0205571	1.86456837696577	-0.05542	0.0220267	1.92143444068288	-0.0378856	0.0423968	0.429642725666719	-0.029017	0.0153466	1.23067216267929	-0.0215842	0.0173824	0.668465408540599	-0.040759	0.0297153	0.768005699305248	0.00814764	0.0112572	0.328637368549604	0.00365289	0.0140948	0.0993559944611484	0.0130499	0.0179889	0.329585287459016	-0.0451103	0.0110629	4.34195901505646	-0.067072	0.0116932	8.01345353045888	-0.0202812	0.0187888	0.552228186105944	-0.0318551	0.0107705	2.50860048216445	-0.0495663	0.013303	3.71088171378157	-0.0113884	0.0171039	0.296266812301363	-0.00874399	0.0064495	0.756527873834387	-0.00367283	0.00835579	0.180285670206313	-0.0153498	0.0100537	0.896822524756187	-2.37031E-4	0.0308522	0.00266998142143869	0.0152494	0.0383135	0.160720604500867	-0.0345718	0.0521175	0.29470517556445
rs13222543:100015457:C:T		7	100015457	7q22.1	T	C	0.812	1	DHEAS MEN	4301	7.98730615830483	0.0174094236224134	0.449065	ZCWPW1 (0 kb, intron/Intron/MODIFIER \| near gene/Downstream gene/MODIFIER \| near gene/Upstream gene/MODIFIER); MEPCE (11 kb); PPP1R35 (17 kb); PILRA (18 kb); C7orf61 (39 kb); RN7SL161P (45 kb); TSC22D4 (46 kb)	1 Blood metabolite levels // 1 Blood metabolite ratios // 0.426 Metabolic traits // 0.426 Dehydroepiandrosterone sulphate levels // 0.426 Estrone levels	- \| AP4M1 \| C7orf59 \| CNPY4 \| COPS6 \| EPHB4 \| LAMTOR4 \| MCM7 \| MEPCE \| OR2AE1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| STAG3 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| STAG3OS \| TAF6 \| TRIM4 \| TRIP6 \| TSC22D4 \| ZCWPW1 \| ZKSCAN1 \| ZKSCAN5 \| ZNF3 \| ZNHIT1 \| ZSCAN21	NNAT	Herpes simplex infection:PILRA \| Lysosome:AP4M1	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:PILRA,PILRB \| EPHB-mediated forward signaling:EPHB4 \| EPH-Ephrin signaling:EPHB4	multiple myeloma:EPHB4 \| myeloma:EPHB4 \| bone marrow cancer:EPHB4 \| specific developmental disorder:AP4M1 \| cerebral palsy:AP4M1	immune response-activating signal transduction:PVRIG \| immune response-activating cell surface receptor signaling pathway:PVRIG \| T cell receptor signaling pathway:PVRIG \| immune response-regulating cell surface receptor signaling pathway:PVRIG \| antigen receptor-mediated signaling pathway:PVRIG \| protein localization to vacuole:AP4M1 \| ephrin receptor signaling pathway:EPHB4 \| nucleocytoplasmic transport:TRIP6 \| protein localization to lysosome:AP4M1 \| nuclear transport:TRIP6 \| cytoplasmic sequestering of transcription factor:TRIP6 \| leukocyte homeostasis:TSC22D4 \| protein targeting to vacuole:AP4M1 \| positive regulation of NF-kappaB import into nucleus:TRIP6 \| cytoplasmic sequestering of protein:TRIP6 \| protein localization to nucleus:TRIP6 \| regulation of transcription factor import into nucleus:TRIP6 \| transcription factor import into nucleus:TRIP6 \| negative regulation of immune system process:PVRIG,TSC22D4 \| snRNA metabolic process:MEPCE \| negative regulation of phosphatase activity:PPP1R35 \| negative regulation of hydrolase activity:PPP1R35 \| negative regulation of transcription factor import into nucleus:TRIP6 \| blood vessel endothelial cell migration:EPHB4 \| sprouting angiogenesis:EPHB4	-0.0626549	0.0618865	0.506601903906198	-0.0323617	0.0574274	0.241715033457017	-0.197553	0.123184	0.963462922919376	-0.0836606	0.0680788	0.65904653245294	-0.110607	0.0756428	0.841912044644965	-0.0608289	0.131672	0.190949617447644	-0.0328287	0.0508056	0.285464041254616	-0.0424486	0.0596245	0.321819536985751	-0.0321605	0.0923636	0.13798973892034	-0.220414	0.0422364	6.74397536944864	-0.30917	0.0539962	7.98730615830483	-0.137302	0.0660338	1.42489648107015	-0.00665327	0.0403157	0.0610197066625842	0.0456767	0.0447312	0.512594339828133	-0.0955178	0.0650957	0.846850038743081	0.0111383	0.0407576	0.105331769820202	0.0863085	0.0516015	1.0249971829289	-0.10768900000000001	0.0620248	1.08342762364898	-0.0167663	0.0239631	0.315037107613412	-0.0528616	0.0316168	1.02440829026471	0.027549	0.0366363	0.344789509029079	-0.0341407	0.102561	0.131203379515346	-0.064922	0.131151	0.207139245671999	0.0310479	0.164448	0.0704252671588668
rs3867595:7379776:G:C		17	7379776	17p13.1	C	G	0.884	1	TESTO ALL	7643	7.98159911809756	0.0169014130576998	0.110172	ZBTB4 (0 kb, intron/Intron/MODIFIER); SLC35G6 (4.9 kb, near gene/Upstream gene/MODIFIER); POLR2A (7.9 kb); CHRNB1 (19 kb); FGF11 (32 kb); TMEM102 (39 kb); C17orf74 (49 kb)	0.341 Testosterone levels // 0.341 Sex hormone-binding globulin levels	- \| ALOX12 \| C17orf81 \| CD68 \| CHRNB1 \| CTDNEP1 \| EIF5A \| FGF11 \| KCNAB3 \| LSMD1 \| MPDU1 \| NLGN2 \| PLSCR3 \| POLR2A \| RP11-186B7.4 \| SENP3 \| SNORA48 \| SOX15 \| SPEM1 \| TMEM102 \| TMEM88 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| TRAPPC1 \| ZBTB4		Herpes simplex infection:POLR2A \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Epstein-Barr virus infection:POLR2A \| Huntington disease:POLR2A	TP53 Regulates Transcription of DNA Repair Genes:POLR2A \| TNFR2 non-canonical NF-kB pathway:TNFSF13 \| MicroRNA (miRNA) biogenesis:POLR2A \| Transcriptional regulation of pluripotent stem cells:POLR2A \| Infectious disease:POLR2A \| Influenza Infection:POLR2A \| Transcriptional Regulation by TP53:POLR2A \| HIV Transcription Elongation:POLR2A \| Formation of HIV-1 elongation complex containing HIV-1 Tat:POLR2A \| Tat-mediated elongation of the HIV-1 transcript:POLR2A \| Transcription of the HIV genome:POLR2A \| Asparagine N-linked glycosylation:MPDU1 \| Formation of HIV elongation complex in the absence of HIV Tat:POLR2A \| RNA Polymerase II Pre-transcription Events:POLR2A \| Formation of the Early Elongation Complex:POLR2A \| Formation of the HIV-1 Early Elongation Complex:POLR2A \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Pausing and recovery of Tat-mediated HIV elongation:POLR2A \| Tat-mediated HIV elongation arrest and recovery:POLR2A \| Formation of RNA Pol II elongation complex :POLR2A \| RNA Polymerase II Transcription Elongation:POLR2A \| HIV elongation arrest and recovery:POLR2A \| Pausing and recovery of HIV elongation:POLR2A \| Transcriptional regulation by small RNAs:POLR2A	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| lymphatic system disease:TNFSF13 \| hypotrichosis:TNFSF13 \| urinary system disease:TNFSF13 \| multiple myeloma:TNFSF13 \| myeloma:TNFSF13 \| bone marrow cancer:TNFSF13 \| hair disease:TNFSF13 \| kidney disease:TNFSF13 \| purpura:TNFSF13 \| alopecia:TNFSF13 \| collagen disease:TNFSF13 \| nephritis:TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| rheumatic disease:TNFSF13 \| systemic scleroderma:TNFSF13 \| scleroderma:TNFSF13 \| integumentary system disease:TNFSF13 \| hematopoietic system disease:TNFSF13 \| colon carcinoma:TNFSF13 \| intestinal cancer:TNFSF13 \| myopathy:TNFSF13 \| muscle tissue disease:TNFSF13 \| Sjogren's syndrome:TNFSF13 \| muscular disease:TNFSF13 \| alopecia areata:TNFSF13 \| non-small cell lung carcinoma:EIF5A,TNFSF13 \| colon cancer:TNFSF13 \| colorectal cancer:TNFSF13 \| large intestine cancer:TNFSF13 \| myositis:TNFSF13 \| lung adenocarcinoma:EIF5A \| liver cirrhosis:TNFSF13 \| chronic lymphocytic leukemia:TNFSF13	positive regulation of cell activation:TNFSF13 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF13 \| positive regulation of cell adhesion:TMEM102 \| positive regulation of lymphocyte activation:TNFSF13 \| positive regulation of leukocyte activation:TNFSF13 \| regulation of leukocyte activation:TNFSF13 \| regulation of lymphocyte activation:TNFSF13 \| postsynaptic membrane organization:CHRNB1 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| cellular response to tumor necrosis factor:TNFSF13 \| response to tumor necrosis factor:TNFSF13 \| regulation of immune effector process:TNFSF13 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| B cell mediated immunity:TNFSF13 \| positive regulation of adaptive immune response:TNFSF13 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:CHRNB1 \| nucleocytoplasmic transport:EIF5A \| nuclear transport:EIF5A \| positive regulation of DNA metabolic process:TNFSF13 \| chemical synaptic transmission, postsynaptic:CHRNB1 \| positive regulation of reactive oxygen species metabolic process:EIF5A \| peptidyl-tyrosine phosphorylation:TMEM102 \| regulation of lymphocyte mediated immunity:TNFSF13 \| peptidyl-tyrosine modification:TMEM102 \| regulation of DNA metabolic process:TNFSF13 \| negative regulation of translation:POLR2A \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:TMEM102 \| DNA-templated transcription, elongation:POLR2A \| regulation of postsynaptic membrane potential:CHRNB1 \| synapse organization:CHRNB1 \| positive regulation of cellular amide metabolic process:EIF5A \| negative regulation of cellular amide metabolic process:POLR2A \| regulation of adaptive immune response:TNFSF13 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| mitochondrial outer membrane permeabilization:TMEM102 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| aging:EIF5A \| protein export from nucleus:EIF5A \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:TMEM102 \| mitochondrial outer membrane permeabilization involved in programmed cell death:TMEM102 \| positive regulation of mitochondrial membrane permeability:TMEM102 \| regulation of mitochondrial membrane permeability involved in apoptotic process:TMEM102 \| positive regulation of membrane permeability:TMEM102 \| mRNA catabolic process:TNFSF13 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| somatic stem cell population maintenance:POLR2A \| regulation of viral process:POLR2A \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| nuclear export:EIF5A \| regulation of mitochondrial membrane permeability:TMEM102 \| mitochondrial membrane organization:TMEM102 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| regulation of membrane permeability:TMEM102 \| regulation of symbiosis, encompassing mutualism through parasitism:POLR2A \| regulation of apoptotic signaling pathway:TMEM102 \| RNA catabolic process:TNFSF13 \| regulation of membrane potential:CHRNB1 \| transcription elongation from RNA polymerase II promoter:POLR2A \| positive regulation of viral process:POLR2A \| DNA-templated transcription, termination:POLR2A \| regulation of leukocyte chemotaxis:TMEM102 \| regulation of gene silencing by miRNA:POLR2A \| regulation of posttranscriptional gene silencing:POLR2A \| regulation of gene silencing by RNA:POLR2A	-0.00464921	0.0701262	0.0235826119846827	0.00254798	0.0653312	0.0137232852726779	-0.040161	0.12964	0.121063639707981	-0.128414	0.0771003	1.01793284282923	-0.0741188	0.0860878	0.409594015309134	-0.209568	0.14778	0.805213788858602	0.00322948	0.0575615	0.0198765887317363	0.0240295	0.0678322	0.140736778416766	-0.0267901	0.103798	0.0988654767246436	0.0297631	0.0408601	0.331278706371361				-0.0185932	0.0659715	0.108981887598371	-0.231364	0.0404232	7.98159911809756	-0.241832	0.0422914	7.96805455468595	-0.196297	0.0679342	2.41360175583393	-0.0705202	0.0386254	1.16820378697916	-0.119158	0.0476114	1.90923773856357	-0.00531515	0.0613412	0.0310736437310292	-0.0296703	0.0235007	0.684537677477285	-0.00837033	0.0304064	0.106182776032537	-0.0563735	0.0367724	0.902166790267756	0.119888	0.116357	0.518597506175541	0.133277	0.150881	0.423401835371188	0.0958456	0.182176	0.222587678503256
rs139441768:90679263:T:C	novel4	5	90679263	5q14.3	C	T	0.904	2	PROG ALL	2070	7.89146880114213	0.0117106280193237		ARRDC3 (0.087 kb, near gene/Upstream gene/MODIFIER); LUCAT1 (69 kb); RAB5CP2 (93 kb); RNU4-90P (110 kb)	NA						negative regulation of homeostatic process:ARRDC3 \| regulation of heat generation:ARRDC3 \| regulation of homeostatic process:ARRDC3 \| regulation of protein modification by small protein conjugation or removal:ARRDC3 \| heat generation:ARRDC3 \| multicellular organismal homeostasis:ADGRV1,ARRDC3	0.45207	0.0791544	7.89146880114213	0.155067	0.0794433	1.29112719286341	0.6113884	0.1479081	4.447124	0.228273	0.087626	2.03379864389534	0.227599	0.104677	1.5249800151335	0.207666	0.154583	0.745758961836335	0.0216393	0.0654815	0.130133735101348	0.0445043	0.0825955	0.229075857298699	-0.0211874	0.108563	0.0729778281090877																																					0.0196247	0.130793	0.0551498136347395	-0.0624597	0.182494	0.135361971624086	0.132415	0.187192	0.319144370115748
X:6960700:TG:TGG		23	6960700	Xp22.31	TGG	TG	0.977	0	DHEAS ALL	7650	7.86903936987784	0.529926470588235	0.962423	HDHD1 (6.3 kb); MIR4767 (110 kb); STS (180 kb)	NA	HDHD1 \| HDHD1A \| NLGN4X \| PUDP \| STS		Cell adhesion molecules (CAMs):NLGN4X \| Steroid hormone biosynthesis:STS	Gamma carboxylation, hypusine formation and arylsulfatase activation:STS	polycystic ovary syndrome:STS \| reproductive system disease:STS \| neuropathy:STS \| cell type benign neoplasm:STS \| astrocytoma:STS \| brain cancer:STS \| specific developmental disorder:NLGN4X,STS \| endocrine organ benign neoplasm:STS \| female reproductive organ cancer:STS \| adenoma:STS \| glioblastoma multiforme:STS	steroid catabolic process:STS \| organ growth:NLGN4X \| postsynaptic membrane organization:NLGN4X \| steroid metabolic process:STS \| post-translational protein modification:STS \| postsynaptic membrane assembly:NLGN4X \| receptor-mediated endocytosis:NLGN4X \| membrane assembly:NLGN4X \| presynaptic membrane organization:NLGN4X \| membrane biogenesis:NLGN4X \| postsynapse assembly:NLGN4X \| modulation of excitatory postsynaptic potential:NLGN4X \| neuron cell-cell adhesion:NLGN4X \| presynapse assembly:NLGN4X \| synaptic vesicle recycling:NLGN4X \| vocalization behavior:NLGN4X	-0.01561574	0.0264266	0.255983331700476	-0.0093668	0.0216216	0.177226031745652	-0.0949248	0.0679628	0.789149307274757	-0.00781976	0.029069	0.103500788971458	0.00279402	0.028501	0.0353062923238324	-0.0658968	0.0759674	0.413416070687076	-0.078564	0.0216198	3.54361422666133	-0.0876904	0.0223206	4.04710734671467	-0.058852	0.0532788	0.569107781682363	0.0929846	0.0163723	7.86903936987784	0.0708701	0.017923	4.11457658078602	0.143003	0.0327413	4.90106223007539	0.00575572	0.0160187	0.143052507337902	-0.00550818	0.0149444	0.14725048585313				0.0111664	0.0154317	0.328540191795284	0.0138383	0.0169606	0.382420985266633				0.00155502	0.00937032	0.0613827196245503	0.0122387	0.0106588	0.600542614504458	-0.0251035	0.0183257	0.767682528488278	-0.0231102	0.0436568	0.224307287737694	0.01236552	0.0495138	0.0953769482018654	-0.1472402	0.0938086	0.931899520775334
rs111730697:22317658:T:TATCC		13	22317658	13q12.11	TATCC	T	0.805	0	DHEAS ALL	7659	7.79134101336498	0.259692779736258	1.41888	FGF9 (39 kb); RN7SL766P (47 kb); RPS7P10 (110 kb); LINC00424 (130 kb)	NA			Regulation of actin cytoskeleton:FGF9		endocrine system disease:FGF9 \| gonadal dysgenesis:FGF9 \| gonadal disease:FGF9	organ growth:FGF9 \| nucleocytoplasmic transport:FGF9 \| nuclear transport:FGF9 \| regulation of activin receptor signaling pathway:FGF9 \| cellular response to fibroblast growth factor stimulus:FGF9 \| lipid modification:FGF9 \| response to fibroblast growth factor:FGF9 \| protein localization to nucleus:FGF9 \| regulation of cardiac muscle tissue growth:FGF9 \| smoothened signaling pathway:FGF9 \| regulation of heart growth:FGF9 \| activin receptor signaling pathway:FGF9 \| regulation of protein kinase B signaling:FGF9 \| regulation of cardiac muscle tissue development:FGF9 \| cardiac muscle tissue growth:FGF9 \| regulation of striated muscle tissue development:FGF9 \| regulation of muscle tissue development:FGF9 \| heart growth:FGF9 \| positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway:FGF9 \| regulation of organ growth:FGF9	-0.00715224	0.0215587	0.130705488174068	0.0145105	0.0191682	0.347582489785504	-0.018214	0.042607	0.174558302440534	-0.013419	0.0237174	0.242908539669139	0.00188661	0.0252704	0.0266416618836319	-0.0333144	0.0494608	0.300321804796207	-0.0325129	0.017682	1.1798412493334	-0.00800288	0.0199059	0.162587082498492	-0.0735943	0.0345935	1.47196048332282	-0.0719463	0.0127368	7.79134101336498	-0.070903	0.0161087	4.96864405825692	-0.071587	0.0201082	3.43094109736391	-0.00854298	0.0126021	0.302916318569356	0.0186615	0.0134458	0.782076719421994	-0.0381678	0.0212896	1.13664263566127	0.00452618	0.0122922	0.147085928883825	-0.0043954	0.0152667	0.111586286200048	0.0112712	0.0194335	0.2503231914882	-0.0123646	0.00732469	1.03906995994126	-5.77864E-4	0.0095743	0.0214214480768081	-0.0251723	0.0112847	1.59001111480936	-0.0551231	0.0355115	0.918080492007669	-0.0707079	0.0438841	0.969121091749273	-0.031314	0.0605919	0.217913108851545
rs77032081:13363279:C:T	novel3	11	13363279	11p15.2	T	C	0.932	3	PROG WOMEN	1261	7.78098687603881	0.017956161776368	0.0346787	ARNTL (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); RN7SKP151 (11 kb); BTBD10 (46 kb); PTH (150 kb)	NA	ARNTL		Herpes simplex infection:ARNTL \| Parathyroid hormone synthesis, secretion and action:PTH \| Dopaminergic synapse:ARNTL		endocrine system disease:PTH \| urinary system disease:PTH \| myeloma:PTH \| bone marrow cancer:PTH \| kidney disease:PTH \| polycystic ovary syndrome:PTH \| aortic valve disease:PTH \| heart valve disease:PTH \| aortic valve stenosis:PTH \| amyotrophic lateral sclerosis:BTBD10 \| motor neuron disease:BTBD10 \| coronary artery disease:PTH	positive regulation of skeletal muscle tissue development:ARNTL \| negative regulation of intracellular steroid hormone receptor signaling pathway:ARNTL \| nucleocytoplasmic transport:ARNTL \| nuclear transport:ARNTL \| regulation of skeletal muscle tissue development:ARNTL \| columnar/cuboidal epithelial cell development:ARNTL \| regulation of ossification:PTH \| ossification:PTH \| regulation of intracellular steroid hormone receptor signaling pathway:ARNTL \| pancreas development:ARNTL \| positive regulation of leukocyte proliferation:PTH \| positive regulation of striated muscle tissue development:ARNTL \| positive regulation of muscle organ development:ARNTL \| positive regulation of muscle tissue development:ARNTL \| regulation of protein secretion:ARNTL \| hormone-mediated signaling pathway:ARNTL,PTH \| protein localization to nucleus:ARNTL \| positive regulation of ossification:PTH \| regulation of peptide secretion:ARNTL \| regulation of canonical Wnt signaling pathway:ARNTL \| ribonucleotide biosynthetic process:PTH \| ribose phosphate biosynthetic process:PTH \| columnar/cuboidal epithelial cell differentiation:ARNTL \| protein import into nucleus:ARNTL \| positive regulation of nucleotide biosynthetic process:PTH \| positive regulation of purine nucleotide biosynthetic process:PTH \| cellular response to oxidative stress:ARNTL \| molting cycle:ARNTL \| hair cycle:ARNTL \| regulation of fat cell differentiation:ARNTL \| nuclear import:ARNTL \| canonical Wnt signaling pathway:ARNTL \| positive regulation of canonical Wnt signaling pathway:ARNTL \| negative regulation of ossification:PTH \| regulation of Wnt signaling pathway:ARNTL \| protein import:ARNTL \| nucleotide biosynthetic process:PTH \| regulation of leukocyte proliferation:PTH \| nucleoside phosphate biosynthetic process:PTH \| intracellular steroid hormone receptor signaling pathway:ARNTL \| regulation of striated muscle tissue development:ARNTL \| regulation of epithelial cell differentiation:ARNTL \| positive regulation of nucleotide metabolic process:PTH \| positive regulation of purine nucleotide metabolic process:PTH \| regulation of muscle tissue development:ARNTL \| regulation of muscle organ development:ARNTL \| epithelial cell proliferation:BTBD10 \| regulation of purine nucleotide biosynthetic process:PTH	0.260374	0.064853	4.21033328348379	-0.0275468	0.0600816	0.189313928247121	0.704529	0.124815	7.78098687603881	6.11614E-4	0.0716284	0.00296853636401619	-0.125103	0.0791252	0.94274100023236	0.186814	0.139411	0.743116359248172	-0.0191596	0.0534388	0.142678964268778	-0.0442369	0.0623778	0.32026602457579	0.00762143	0.0979092	0.027808273775426	-0.0171224	0.0390652	0.179690144678914	-0.0597471	0.0477898	0.675256737296413	0.0417754	0.0643033	0.287425212215136							0.0506302	0.0653458	0.358073982494028	-0.0565597	0.0377418	0.872963268044416	-0.0593791	0.0449345	0.729675263997477				0.0131278	0.0224046	0.253432740495958	0.0275991	0.0285439	0.476781769156376	-0.00403423	0.035769	0.0408626916880709	0.0246786	0.109218	0.0855203868824726	0.167219	0.141431	0.624724224132252	-0.180296	0.171254	0.53342151144606
rs2431830:48380206:C:T		19	48380206	19q13.33	T	C	0.996	20	DHEAS ALL	7659	7.75954810449467	0.730061496278888	0.0642353	SULT2A1 (0 kb, intron/Intron/MODIFIER); TPRX2P (15 kb); CRX (34 kb); TPRX1 (58 kb)	0.655 Blood metabolite levels // 0.456 Blood metabolite ratios // 0.456 Gallstone disease // 0.31 Dehydroepiandrosterone sulphate levels // 0.31 Sex hormone levels	CA11 \| CABP5 \| CTD-3098H1.2 \| EMP3 \| GLTSCR1 \| GLTSCR2 \| LIG1 \| PLA2G4C \| PRR24 \| SEPW1 \| SULT2A1 \| TMEM160	VRK3	Chemical carcinogenesis:SULT2A1 \| Metabolism of xenobiotics by cytochrome P450:SULT2A1 \| Bile secretion:SULT2A1	Biological oxidations:SULT2A1 \| Phase II - Conjugation of compounds:SULT2A1	polycystic ovary syndrome:SULT2A1	steroid catabolic process:SULT2A1 \| steroid metabolic process:SULT2A1 \| sulfur compound metabolic process:SULT2A1 \| sperm capacitation:BSPH1	0.00405093	0.019054	0.0800552304978746	-0.00966123	0.0174233	0.237075480733422	0.0255334	0.0373709	0.305874105432653	0.0460973	0.0209387	1.5558286834733	-8.9429E-4	0.0229678	0.0136999775798274	0.126185	0.0411709	2.64585312941309	-0.00738022	0.0156394	0.195827843410711	-0.0299919	0.0180748	1.01196215230361	0.0310457	0.0290456	0.544398450956806	0.0633974	0.0112485	7.75954810449467	0.0358072	0.0140671	1.96204390614082	0.0948782	0.0180251	6.85016530328422	-0.00666904	0.011129	0.260421327078977	-0.0160573	0.0117502	0.7650602694601	0.0139359	0.0187323	0.340172188326248	-0.034153	0.0108474	2.78484907663748	-0.0295199	0.0132718	1.58283399823679	-0.0319155	0.0174154	1.1748186881663				-0.00383689	0.008386	0.188903786135938				0.0286233	0.0315633	0.438191673833969	-0.00553659	0.039987	0.0506592812559392	0.0876113	0.0512427	1.05665241721682
rs117430166:99827531:C:T		7	99827531	7q22.1	T	C	0.883	1	DHEAS MEN	4301	7.73037966289911	0.0432336665891653	0.164078	GATS (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); GATS (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); PVRIG (8.4 kb); STAG3 (8.4 kb)	0.619 Metabolic traits // 0.619 Dehydroepiandrosterone sulphate levels // 0.619 Estrone levels // 0.491 Blood metabolite levels // 0.491 Blood metabolite ratios // 0.48 Obesity-related traits	- \| AC073842.5 \| ACHE \| AP4M1 \| C7orf43 \| C7orf59 \| CNPY4 \| COPS6 \| CYP3A7 \| EPHB4 \| FIS1 \| GAL3ST4 \| GATS \| GIGYF1 \| GS1-259H13.2 \| LAMTOR4 \| MCM7 \| MEPCE \| OR2AE1 \| PILRA \| PILRB \| PMS2P1 \| PTCD1 \| PVRIG \| PVRIG2P \| SAP25 \| STAG3 \| STAG3L5P \| STAG3L5P-PVRIG2P-PILRB \| STAG3OS \| TAF6 \| TRIM4 \| TRIP6 \| TSC22D4 \| UFSP1 \| ZCWPW1 \| ZKSCAN1 \| ZKSCAN5 \| ZNF3 \| ZNF394 \| ZNHIT1 \| ZSCAN21	NNAT \| PMS2 \| PMS2P5 \| TIMP1	Herpes simplex infection:PILRA,TAF6 \| Lysosome:AP4M1	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:PILRA,PILRB \| EPHB-mediated forward signaling:EPHB4 \| mTORC1-mediated signalling:LAMTOR4 \| EPH-Ephrin signaling:EPHB4 \| Energy dependent regulation of mTOR by LKB1-AMPK:LAMTOR4 \| Infectious disease:TAF6 \| mTOR signalling:LAMTOR4 \| Transcriptional Regulation by TP53:LAMTOR4,TAF6 \| Transcription of the HIV genome:TAF6 \| Regulation of PTEN gene transcription:LAMTOR4 \| RNA Polymerase II Pre-transcription Events:TAF6 \| Macroautophagy:LAMTOR4 \| TP53 Regulates Metabolic Genes:LAMTOR4	multiple myeloma:EPHB4 \| myeloma:EPHB4 \| bone marrow cancer:EPHB4 \| specific developmental disorder:AP4M1 \| female reproductive organ cancer:STAG3 \| cerebral palsy:AP4M1	immune response-activating signal transduction:PVRIG \| immune response-activating cell surface receptor signaling pathway:PVRIG \| T cell receptor signaling pathway:PVRIG \| immune response-regulating cell surface receptor signaling pathway:PVRIG \| antigen receptor-mediated signaling pathway:PVRIG \| protein localization to vacuole:AP4M1,LAMTOR4 \| ephrin receptor signaling pathway:EPHB4 \| nucleocytoplasmic transport:TRIP6 \| protein localization to lysosome:AP4M1,LAMTOR4 \| nuclear transport:TRIP6 \| positive regulation of TOR signaling:LAMTOR4 \| cytoplasmic sequestering of transcription factor:TRIP6 \| leukocyte homeostasis:TSC22D4 \| protein targeting to vacuole:AP4M1 \| DNA-templated transcription, elongation:TAF6 \| positive regulation of NF-kappaB import into nucleus:TRIP6 \| post-translational protein modification:COPS6 \| cytoplasmic sequestering of protein:TRIP6 \| protein localization to nucleus:TRIP6 \| cellular response to amino acid stimulus:LAMTOR4 \| regulation of autophagy:LAMTOR4 \| regulation of transcription factor import into nucleus:TRIP6 \| smoothened signaling pathway:GPC2 \| transcription factor import into nucleus:TRIP6 \| regulation of macroautophagy:LAMTOR4 \| negative regulation of immune system process:PVRIG,TSC22D4 \| snRNA metabolic process:MEPCE,TAF6 \| negative regulation of transcription factor import into nucleus:TRIP6 \| regulation of TOR signaling:LAMTOR4 \| autophagy:LAMTOR4 \| process utilizing autophagic mechanism:LAMTOR4 \| transcription elongation from RNA polymerase II promoter:TAF6 \| blood vessel endothelial cell migration:EPHB4 \| sprouting angiogenesis:EPHB4 \| ncRNA transcription:TAF6	-0.012439	0.0410566	0.118078086453888	-0.0196515	0.0369026	0.225883938028723	-0.0663436	0.0817107	0.380041031633696	-0.0359093	0.0451641	0.369923160473893	-0.0660083	0.0486124	0.757612639403327	-6.38191E-6	0.0923744	2.38868533991808E-5	-0.0327089	0.0336934	0.479161578198342	-0.0622147	0.0382838	0.981399350623058	0.00744765	0.0647926	0.0416650297442628	-0.124655	0.0258156	5.86184577696109	-0.18205	0.0323673	7.73037966289911	-0.0621062	0.0411549	0.881811356530928	0.0191784	0.0251763	0.35047140737125	0.039699	0.0270161	0.848605631348993	-0.0109153	0.0423036	0.0988742018993811	0.00437533	0.0248042	0.0655096287289328	0.0483612	0.0307737	0.93530246609966	-0.0503061	0.0391336	0.701977022445313	-0.0132754	0.0147515	0.433971656200081	-0.0442793	0.0191431	1.68363749798755	0.0235854	0.0229509	0.516959302316127	-0.0401426	0.0674344	0.258280485299921	-0.0290506	0.0836937	0.137529907659868	-0.0482536	0.114133	0.172250885430948
rs57159061:81590962:T:C	known [8]	16	81590962	16q23.2	C	T	0.847	11	DHEAS ALL	7659	7.72049047060693	0.0750952121686904	0.357375	CMIP (0 kb, intron/Intron/MODIFIER); GAN (170 kb); MIR4720 (170 kb); PLCG2 (180 kb)	0.964 Dehydroepiandrosterone sulphate levels	PLCG2				urinary system disease:CMIP \| kidney disease:CMIP \| neuropathy:GAN \| axonal neuropathy:GAN	post-translational protein modification:GAN	0.0591226	0.034094	1.08066559255752	0.036291	0.0295495	0.658355798414595	0.104542	0.07214	0.831817892217862	-0.029029	0.0375317	0.357196288770155	-0.0182532	0.0389669	0.194123459545334	-0.0485137	0.0827131	0.25359468318842	0.00389076	0.0280056	0.0508442827773688	-0.00871009	0.0306983	0.109769620741877	0.0385702	0.0580126	0.295543181852527	0.117829	0.020964	7.72049047060693	0.0912883	0.0257788	3.39981477283119	0.149075	0.0342206	4.87848283234815				-0.0114247	0.0214667	0.225787512069757										0.0178242	0.0332091	0.228076823887355				-0.0210143	0.0152354	0.775208043507319	0.00695904	0.0192153	0.144340947723931	-0.0263515	0.0562439	0.194185258348194	0.00267489	0.0674535	0.0139568795030368	-0.0978435	0.102189	0.470228401683001
rs9268559:32389391:A:G		6	32389391	6p21.32	G	A	0.974	0	OHP17 ALL	2070	7.68586933134742	0.0137550724637681		BTNL2 (14 kb); HLA-DRA (18 kb); HCG23 (28 kb); HLA-DRB9 (38 kb); C6orf10 (50 kb)	0.519 Blood protein levels // 0.42 Migraine // 0.376 Economic and political preferences (environmentalism) // 0.376 Hepatitis B vaccine response // 0.323 Ulcerative colitis // 0.321 Marginal zone lymphoma	- \| ABHD16A \| AGER \| AIF1 \| APOM \| BAG6 \| BRD2 \| C4A \| C4B \| C4B 2 \| C6orf10 \| C6orf136 \| C6orf48 \| CCHCR1 \| CLIC1 \| CSNK2B \| CUTA \| CYP21A1P \| DDAH2 \| DDR1 \| DHX16 \| DOM3Z \| DXO \| EHMT2 \| GPANK1 \| GPSM3 \| HCG23 \| HCG27 \| HCP5 \| HLA-C \| HLA-DOA \| HLA-DOB \| HLA-DPA1 \| HLA-DQA1 \| HLA-DQA2 \| HLA-DQB1 \| HLA-DQB2 \| HLA-DRA \| HLA-DRB1 \| HLA-DRB2 \| HLA-DRB3 \| HLA-DRB4 \| HLA-DRB5 \| HLA-DRB6 \| HLA-DRB7 \| HLA-DRB8 \| HSPA1A \| HSPA1B \| HSPA1L \| LSM2 \| LST1 \| LTA \| LTB \| LY6G5B \| LY6G5C \| LY6G6C \| MCCD1 \| MDC1 \| MICA \| MICB \| MSH5 \| MSH5-SAPCD1 \| NCR3 \| NEU1 \| PHF1 \| PRRC2A \| PSMB8 \| PSMB9 \| PSORS1C1 \| PSORS1C2 \| RNF5 \| SAPCD1 \| SKIV2L \| SLC44A4 \| STK19 \| TAP1 \| TAP2 \| TNF \| unnamed \| VARS \| VARS2 \| VPS52 \| XXbac-BPG299F13.17 \| Y RNA \| ZBTB12	BTN3A3 \| FLOT1 \| HCP5 \| HLA-C \| IAH1 \| KIAA2013 \| LIMS1 \| LINC00243 \| LST1 \| MDC1 \| NHP2 \| TINF2 \| unnamed \| VARS2 \| XPO5 \| ZNF672	Type I diabetes mellitus:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Allograft rejection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Graft-versus-host disease:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Antigen processing and presentation:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L,TAP2 \| Autoimmune thyroid disease:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Viral myocarditis:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Staphylococcus aureus infection:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Asthma:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phagosome:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| Herpes simplex infection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| Intestinal immune network for IgA production:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Rheumatoid arthritis:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Inflammatory bowel disease (IBD):HLA-DQA1,HLA-DRA,HLA-DRB1 \| Toxoplasmosis:HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Systemic lupus erythematosus:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Cell adhesion molecules (CAMs):HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Leishmaniasis:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Influenza A:HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Hematopoietic cell lineage:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Epstein-Barr virus infection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| Human T-cell leukemia virus 1 infection:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Th1 and Th2 cell differentiation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Th17 cell differentiation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Tuberculosis:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Natural killer cell mediated cytotoxicity:HLA-C,NCR3 \| Endocytosis:HLA-C,HSPA1A,HSPA1B,HSPA1L \| Legionellosis:HSPA1A,HSPA1B,HSPA1L \| Human cytomegalovirus infection:HLA-C,TAP2 \| Kaposi sarcoma-associated herpesvirus infection:HLA-C \| Viral carcinogenesis:HLA-C \| Spliceosome:HSPA1A,HSPA1B,HSPA1L \| Human immunodeficiency virus 1 infection:HLA-C,TAP2 \| Protein processing in endoplasmic reticulum:HSPA1A,HSPA1B,HSPA1L \| Cellular senescence:HLA-C \| Longevity regulating pathway - multiple species:HSPA1A,HSPA1B,HSPA1L \| Measles:HSPA1A,HSPA1B,HSPA1L \| Estrogen signaling pathway:HSPA1A,HSPA1B,HSPA1L \| Human papillomavirus infection:HLA-C	Translocation of ZAP-70 to Immunological synapse:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Phosphorylation of CD3 and TCR zeta chains:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon gamma signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| PD-1 signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Generation of second messenger molecules:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Downstream TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Interferon Signaling:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| TCR signaling:HLA-DQA1,HLA-DRA,HLA-DRB1 \| MHC class II antigen presentation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Costimulation by the CD28 family:HLA-DQA1,HLA-DRA,HLA-DRB1 \| Endosomal/Vacuolar pathway:HLA-C \| Antigen Presentation: Folding, assembly and peptide loading of class I MHC:HLA-C,TAP2 \| ER-Phagosome pathway:HLA-C,TAP2 \| Antigen processing-Cross presentation:HLA-C,TAP2 \| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell:HLA-C,NCR3 \| Interferon alpha/beta signaling:HLA-C \| Attenuation phase:HSPA1A,HSPA1B,HSPA1L \| Infectious disease:HSPA1A,HSPA1B \| Butyrophilin (BTN) family interactions:BTNL2 \| HSP90 chaperone cycle for steroid hormone receptors (SHR):HSPA1A,HSPA1B,HSPA1L \| HSF1-dependent transactivation:HSPA1A,HSPA1B,HSPA1L \| TP53 Regulates Transcription of DNA Repair Genes:MDC1 \| AUF1 (hnRNP D0) binds and destabilizes mRNA:HSPA1A,HSPA1B \| Class I MHC mediated antigen processing & presentation:HLA-C,TAP2 \| Regulation of mRNA stability by proteins that bind AU-rich elements:HSPA1A,HSPA1B \| Regulation of HSF1-mediated heat shock response:HSPA1A,HSPA1B,HSPA1L \| Influenza Infection:HSPA1A,HSPA1B \| Cellular response to heat stress:HSPA1A,HSPA1B,HSPA1L \| Transcriptional Regulation by TP53:MDC1 \| Export of Viral Ribonucleoproteins from Nucleus:HSPA1A,HSPA1B \| Neutrophil degranulation:HLA-C,HSPA1A,HSPA1B \| Influenza Life Cycle:HSPA1A,HSPA1B	Kawasaki disease:HLA-C,HLA-DRB1,BTNL2 \| lymphadenitis:HLA-C,HLA-DRB1,BTNL2 \| lymph node disease:HLA-C,HLA-DRB1,BTNL2 \| lymphatic system disease:HLA-C,HLA-DRB1,BTNL2 \| leprosy:BTNL2,HLA-DRB1 \| sarcoidosis:BTNL2,HLA-DQA1,HLA-DRB1,HSPA1L \| hypersensitivity reaction type IV disease:BTNL2,HLA-DQA1,HLA-DRB1,HSPA1L \| autoimmune disease of endocrine system:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| multiple sclerosis:BTNL2,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| endocrine system disease:HLA-C,HLA-DQA1,HLA-DRB1,HSPA1B,TAP2 \| autoimmune thyroiditis:HLA-DRB1 \| demyelinating disease:BTNL2,HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| Graves' disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| thyroid gland disease:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| intrahepatic cholestasis:HLA-DQA1,HLA-DRB1 \| cavernous hemangioma:HLA-DRA \| vascular hemostatic disease:HLA-DRA \| hypersensitivity reaction type I disease:HCP5,HLA-C,HLA-DQA1,HLA-DRB1 \| primary bacterial infectious disease:BTNL2,HLA-DRB1,TAP2 \| hepatitis:HLA-C,HLA-DQA1,HLA-DRB1,NCR3 \| hyperthyroidism:HLA-C,HLA-DQA1,HLA-DRB1,TAP2 \| vitiligo:HLA-C \| spondylitis:HLA-C \| ankylosing spondylitis:HLA-C \| rheumatic fever:HLA-DQA1,HLA-DRB1 \| bacterial infectious disease:BTNL2,HLA-DRB1,TAP2 \| aplastic anemia:HLA-DQA1,HLA-DRB1 \| urticaria:HCP5,HLA-DRB1 \| spondyloarthropathy:HLA-C \| vasculitis:HLA-DRB1 \| hypothyroidism:HLA-DRB1 \| Behcet's disease:HLA-DRB1 \| hepatitis C:HLA-C,HLA-DQA1,HLA-DRB1,NCR3 \| autoimmune disease of the nervous system:HLA-DQA1,HLA-DRA,HLA-DRB1 \| arthropathy:HLA-C \| hypotrichosis:HLA-DQA1 \| tropical spastic paraparesis:HLA-C,HLA-DRB1 \| parasitic infectious disease:HLA-DRB1,NCR3,TAP2 \| malaria:HLA-DRB1,NCR3 \| hair disease:HLA-DQA1 \| pulmonary sarcoidosis:HLA-DRB1 \| pure red-cell aplasia:HLA-DRB1 \| purpura:HLA-DRB1 \| cystic echinococcosis:HLA-DRB1,TAP2 \| myasthenia gravis:HLA-DQA1,HLA-DRA \| neuromuscular junction disease:HLA-DQA1,HLA-DRA \| brucellosis:TAP2 \| duodenal ulcer:HSPA1A \| cholestasis:HLA-DQA1,HLA-DRB1 \| autoimmune hepatitis:HLA-DQA1,HLA-DRB1 \| hepatitis B:HLA-C,HLA-DQA1,HLA-DRB1 \| upper respiratory tract disease:HLA-C,HSPA1A,TAP2 \| uveitis:HLA-DQA1,HLA-DRB1,HSPA1L \| parasitic protozoa infectious disease:HLA-DRB1,NCR3 \| urinary system disease:HLA-DQA1,HLA-DRB1,HSPA1A \| multiple myeloma:NCR3 \| myeloma:NCR3 \| reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| bone marrow cancer:NCR3 \| uveal disease:HLA-DQA1,HLA-DRB1,HSPA1L \| bile duct disease:HLA-C,HLA-DQA1,HLA-DRB1 \| biliary tract disease:HLA-C,HLA-DQA1,HLA-DRB1 \| azoospermia:HLA-DRB1,MSH5 \| proteinuria:HLA-DRB1 \| kidney disease:HLA-DQA1,HLA-DRB1,HSPA1A \| alopecia:HLA-DQA1 \| autoimmune disease of gastrointestinal tract:HLA-DQA1,HLA-DRB1 \| type 1 diabetes mellitus:HLA-DQA1 \| blood coagulation disease:HLA-DRA,HLA-DRB1 \| allergic rhinitis:HLA-C,TAP2 \| hemorrhagic disease:HLA-DRA,HLA-DRB1 \| neuromuscular disease:HLA-DQA1,HLA-DRA \| thyroiditis:HLA-DRB1 \| nasal cavity disease:HLA-C,TAP2 \| nose disease:HLA-C,TAP2 \| rhinitis:HLA-C,TAP2 \| collagen disease:HLA-DRB1,TAP2 \| prostatitis:HLA-DRB1,HSPA1A \| pancreatitis:HLA-DRB1,HSPA1B \| nephritis:HLA-DQA1,HLA-DRB1 \| celiac disease:HLA-DQA1,HLA-DRB1 \| peptic ulcer disease:HSPA1A \| hematopoietic system disease:HLA-DQA1,HLA-DRA,HLA-DRB1 \| echinococcosis:HLA-DRB1,TAP2 \| anemia:HLA-DQA1,HLA-DRB1 \| rheumatic disease:HLA-DRB1,TAP2 \| systemic scleroderma:HLA-DRB1,TAP2 \| scleroderma:HLA-DRB1,TAP2 \| male reproductive system disease:HLA-DRB1,HSPA1A,MSH5 \| male infertility:HLA-DRB1,MSH5 \| silicosis:HLA-DRB1 \| integumentary system disease:HCP5,HLA-DQA1,HLA-DRB1 \| sickle cell anemia:HLA-DRB1 \| parasitic helminthiasis infectious disease:HLA-DRB1,TAP2 \| Human immunodeficiency virus infectious disease:HLA-C,HLA-DRB1 \| reactive arthritis:HLA-DRB1 \| alcoholic pancreatitis:HSPA1B \| interstitial lung disease:HLA-DRB1 \| bronchial disease:HSPA1A,HSPA1B,TAP2 \| acute pancreatitis:HSPA1B \| tuberculosis:BTNL2,HLA-DRB1 \| Vogt-Koyanagi-Harada disease:HLA-DRB1 \| prostate disease:HLA-DRB1,HSPA1A \| pneumoconiosis:HLA-DRB1 \| sclerosing cholangitis:HLA-C,HLA-DRB1 \| schistosomiasis:HLA-DRB1 \| autoimmune disease of peripheral nervous system:HLA-DRB1 \| Guillain-Barre syndrome:HLA-DRB1 \| pancreas disease:HLA-DRB1,HSPA1B \| open-angle glaucoma:HLA-DRB1,TAP2 \| influenza:HLA-DRB1 \| low tension glaucoma:HLA-DRB1 \| chronic leukemia:HLA-DQA1,HLA-DRB1 \| Plasmodium falciparum malaria:HLA-DRB1 \| lower respiratory tract disease:HLA-DRB1,HSPA1A,HSPA1B,TAP2 \| ovarian disease:MSH5 \| gastritis:HLA-DRB1 \| dermatomyositis:HLA-DRB1 \| essential hypertension:HSPA1A,HSPA1B,HSPA1L \| female reproductive system disease:MSH5 \| osteomyelitis:HLA-DRB1 \| neuropathy:HLA-DQA1,HLA-DRA \| migraine:HLA-DRB1 \| infertility:MSH5 \| peripheral nervous system disease:HLA-DRB1 \| autoimmune disease of urogenital tract:HLA-DRB1 \| primary biliary cirrhosis:HLA-DRB1 \| stomach disease:HLA-DRB1 \| cholangitis:HLA-C,HLA-DRB1 \| Crohn's disease:BTNL2,HSPA1B \| lung disease:HLA-DRB1,HSPA1A,HSPA1B \| spinal cord disease:HLA-C,HLA-DRB1 \| pulmonary edema:HSPA1A \| myositis:HLA-DRB1 \| Henoch-Schoenlein purpura:HLA-DRB1 \| hypersensitivity reaction type III disease:HLA-DRB1 \| hypersensitivity vasculitis:HLA-DRB1 \| inflammatory bowel disease:HSPA1B,BTNL2 \| myopathy:HLA-DRB1 \| muscle tissue disease:HLA-DRB1 \| nasopharynx carcinoma:HSPA1B \| pharynx cancer:HSPA1B \| lymphoblastic leukemia:HLA-DRB1,HSPA1A,HSPA1B,HSPA1L \| muscular disease:HLA-DRB1 \| bronchiectasis:TAP2 \| premature ovarian failure:MSH5 \| liver cirrhosis:HLA-DRB1 \| renal cell carcinoma:HLA-DRB1,TAP2 \| glaucoma:HLA-DRB1,TAP2 \| esophageal carcinoma:HLA-DRB1,MDC1 \| skin disease:HCP5,HLA-DRB1 \| retinal disease:HLA-DRB1,TAP2 \| female reproductive organ cancer:HLA-DQA1,HLA-DRB1 \| primary open angle glaucoma:TAP2 \| severe combined immunodeficiency:HLA-DRB1 \| retinal degeneration:HLA-DRB1,TAP2 \| malignant ovarian surface epithelial-stromal neoplasm:HLA-DQA1,HLA-DRB1 \| ovary epithelial cancer:HLA-DQA1,HLA-DRB1 \| ovarian carcinoma:HLA-DQA1,HLA-DRB1 \| combined T cell and B cell immunodeficiency:HLA-DRB1	antigen processing and presentation of exogenous peptide antigen:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation of exogenous antigen:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation of peptide antigen:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| antigen processing and presentation:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1,TAP2 \| interferon-gamma-mediated signaling pathway:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| cellular response to interferon-gamma:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class II:HLA-DQA1,HLA-DRA,HLA-DRB1 \| response to interferon-gamma:HLA-C,HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class II:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell receptor signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating signal transduction:HLA-DQA1,HLA-DRA,HLA-DRB1,HSPA1A,HSPA1B,NCR3 \| T cell costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-activating cell surface receptor signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| lymphocyte costimulation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen receptor-mediated signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1 \| immune response-regulating cell surface receptor signaling pathway:HLA-DQA1,HLA-DRA,HLA-DRB1,NCR3 \| positive regulation of cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of leukocyte cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of T cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| T cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent:HLA-C,TAP2 \| regulation of leukocyte cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of exogenous peptide antigen via MHC class I:HLA-C,TAP2 \| positive regulation of cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of lymphocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| positive regulation of cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of lymphocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1,LST1 \| regulation of T cell activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| regulation of leukocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1,LST1 \| leukocyte cell-cell adhesion:HLA-DQA1,HLA-DRA,HLA-DRB1 \| antigen processing and presentation of peptide antigen via MHC class I:HLA-C,TAP2 \| positive regulation of leukocyte activation:HLA-DQA1,HLA-DRA,HLA-DRB1 \| lymphocyte mediated immunity:NCR3 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| adaptive immune response:NCR3,TAP2 \| natural killer cell mediated cytotoxicity:NCR3 \| natural killer cell mediated immunity:NCR3 \| T cell mediated cytotoxicity:NCR3 \| response to type I interferon:HLA-C \| type I interferon signaling pathway:HLA-C \| cellular response to type I interferon:HLA-C \| tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| leukocyte mediated cytotoxicity:NCR3 \| positive regulation of defense response:HSPA1A,HSPA1B,NCR3 \| positive regulation of cytokine production:HSPA1A,HSPA1B \| T cell mediated immunity:NCR3 \| protein refolding:HSPA1A,HSPA1B,HSPA1L \| regulation of immune effector process:NCR3 \| positive regulation of innate immune response:HSPA1A,HSPA1B,NCR3 \| regulation of lymphocyte mediated immunity:NCR3 \| regulation of innate immune response:HSPA1A,HSPA1B,NCR3 \| cellular response to tumor necrosis factor:HSPA1A,HSPA1B \| negative regulation of protein ubiquitination:HSPA1A,HSPA1B \| cell killing:NCR3 \| positive regulation of lymphocyte mediated immunity:NCR3 \| regulation of lymphocyte proliferation:LST1 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| regulation of mononuclear cell proliferation:LST1 \| negative regulation of signal transduction in absence of ligand:HSPA1A,HSPA1B \| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of natural killer cell mediated cytotoxicity:NCR3 \| positive regulation of adaptive immune response:NCR3 \| regulation of natural killer cell mediated immunity:NCR3 \| negative regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| regulation of leukocyte proliferation:LST1 \| mRNA catabolic process:HSPA1A,HSPA1B \| response to tumor necrosis factor:HSPA1A,HSPA1B \| response to heat:HSPA1A,HSPA1B,HSPA1L \| antigen processing and presentation via MHC class Ib:TAP2 \| positive regulation of nitric oxide biosynthetic process:DDAH2 \| positive regulation of nitric oxide metabolic process:DDAH2 \| regulation of leukocyte mediated immunity:NCR3 \| activation of innate immune response:HSPA1A,HSPA1B \| regulation of T cell mediated cytotoxicity:NCR3 \| positive regulation of leukocyte mediated immunity:NCR3 \| negative regulation of inclusion body assembly:HSPA1A,HSPA1B \| antigen processing and presentation of endogenous antigen:TAP2 \| positive regulation of interleukin-8 production:HSPA1A,HSPA1B \| microtubule nucleation:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| regulation of leukocyte mediated cytotoxicity:NCR3 \| regulation of DNA-templated transcription in response to stress:HSPA1A \| nucleotide-binding oligomerization domain containing 2 signaling pathway:HSPA1A,HSPA1B \| regulation of protein ubiquitination:HSPA1A,HSPA1B \| RNA catabolic process:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species biosynthetic process:DDAH2 \| immune response to tumor cell:NCR3 \| response to topologically incorrect protein:HSPA1A,HSPA1L \| positive regulation of T cell mediated cytotoxicity:NCR3 \| regulation of tumor necrosis factor-mediated signaling pathway:HSPA1A,HSPA1B \| regulation of inclusion body assembly:HSPA1A,HSPA1B \| innate immune response-activating signal transduction:HSPA1A,HSPA1B \| regulation of nitric oxide biosynthetic process:DDAH2 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:NCR3 \| lymphocyte proliferation:LST1 \| mononuclear cell proliferation:LST1 \| regulation of cell killing:NCR3 \| regulation of protein modification by small protein conjugation or removal:HSPA1A,HSPA1B \| regulation of interleukin-8 production:HSPA1A,HSPA1B \| RNA phosphodiester bond hydrolysis:HSPA1A \| regulation of mitotic spindle assembly:HSPA1A,HSPA1B \| regulation of adaptive immune response:NCR3 \| response to temperature stimulus:HSPA1A,HSPA1B,HSPA1L \| response to tumor cell:NCR3 \| leukocyte proliferation:LST1 \| positive regulation of NF-kappaB transcription factor activity:HSPA1A,HSPA1B \| regulation of protein stability:HSPA1A,HSPA1B \| nitric oxide biosynthetic process:DDAH2 \| interleukin-8 production:HSPA1A,HSPA1B \| positive regulation of protein complex assembly:HSPA1A,HSPA1B \| interaction with host:HSPA1A,HSPA1B \| signal transduction in absence of ligand:HSPA1A,HSPA1B \| extrinsic apoptotic signaling pathway in absence of ligand:HSPA1A,HSPA1B \| positive regulation of microtubule polymerization:HSPA1A,HSPA1B \| inclusion body assembly:HSPA1A,HSPA1B \| positive regulation of natural killer cell mediated immunity:NCR3 \| nitric oxide metabolic process:DDAH2 \| natural killer cell activation:NCR3 \| reactive nitrogen species metabolic process:DDAH2 \| cellular response to topologically incorrect protein:HSPA1A \| protein stabilization:HSPA1A,HSPA1B \| positive regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| regulation of cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| mRNA cleavage:HSPA1A \| positive regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of spindle assembly:HSPA1A,HSPA1B \| positive regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of organelle assembly:HSPA1A,HSPA1B \| regulation of transcription from RNA polymerase II promoter in response to stress:HSPA1A \| regulation of reactive oxygen species biosynthetic process:DDAH2 \| positive regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| response to endoplasmic reticulum stress:HSPA1A \| positive regulation of immune effector process:NCR3 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:HSPA1A \| pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| positive regulation of T cell mediated immunity:NCR3 \| spindle assembly:HSPA1A,HSPA1B \| nucleic acid phosphodiester bond hydrolysis:HSPA1A \| regulation of mitotic spindle organization:HSPA1A,HSPA1B \| positive regulation of response to endoplasmic reticulum stress:HSPA1A \| positive regulation of leukocyte mediated cytotoxicity:NCR3 \| reactive oxygen species biosynthetic process:DDAH2 \| negative regulation of immune system process:LST1 \| positive regulation of proteolysis involved in cellular protein catabolic process:HSPA1A \| negative regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| regulation of T cell mediated immunity:NCR3 \| nucleotide-binding oligomerization domain containing signaling pathway:HSPA1A,HSPA1B \| regulation of microtubule polymerization:HSPA1A,HSPA1B \| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway:HSPA1A,HSPA1B \| regulation of spindle organization:HSPA1A,HSPA1B \| mitotic spindle assembly:HSPA1A,HSPA1B \| protein homooligomerization:LY6G5C \| viral life cycle:HSPA1A,HSPA1B \| mitochondrial outer membrane permeabilization:HSPA1A \| positive regulation of protein polymerization:HSPA1A,HSPA1B \| regulation of proteolysis involved in cellular protein catabolic process:HSPA1A \| cellular response to heat:HSPA1A,HSPA1B,HSPA1L \| positive regulation of catabolic process:HSPA1A \| viral entry into host cell:HSPA1A,HSPA1B \| positive regulation of cellular protein catabolic process:HSPA1A \| positive regulation of cell killing:NCR3 \| extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| mRNA cleavage involved in mRNA processing:HSPA1A \| microtubule polymerization:HSPA1A,HSPA1B \| synapsis:MSH5 \| protein folding:HSPA1A,HSPA1B,HSPA1L \| positive regulation of protein catabolic process:HSPA1A \| positive regulation of cellular catabolic process:HSPA1A \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| negative regulation of growth:HSPA1A,HSPA1B \| regulation of mRNA metabolic process:HSPA1A \| entry into host cell:HSPA1A,HSPA1B \| entry into host:HSPA1A,HSPA1B \| entry into cell of other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| entry into other organism involved in symbiotic interaction:HSPA1A,HSPA1B \| regulation of RNA stability:HSPA1A \| mitochondrial outer membrane permeabilization involved in programmed cell death:HSPA1A \| regulation of monooxygenase activity:DDAH2 \| positive regulation of cellular component biogenesis:HSPA1A,HSPA1B \| regulation of cellular protein catabolic process:HSPA1A \| positive regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| protein polymerization:HSPA1A,HSPA1B \| positive regulation of mitochondrial membrane permeability:HSPA1A \| mitochondrial membrane organization:HSPA1A \| reactive oxygen species metabolic process:DDAH2 \| regulation of mitochondrial membrane permeability involved in apoptotic process:HSPA1A \| positive regulation of membrane permeability:HSPA1A \| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress:HSPA1A \| homologous chromosome segregation:MSH5 \| regulation of microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| regulation of mRNA catabolic process:HSPA1A \| cytoplasmic pattern recognition receptor signaling pathway:HSPA1A,HSPA1B \| cellular amino acid metabolic process:DDAH2 \| regulation of DNA binding transcription factor activity:HSPA1A,HSPA1B \| regulation of protein complex assembly:HSPA1A,HSPA1B \| regulation of extrinsic apoptotic signaling pathway:HSPA1A,HSPA1B \| spindle organization:HSPA1A,HSPA1B \| regulation of protein catabolic process:HSPA1A \| negative regulation of mitotic cell cycle:MDC1 \| chromosome organization involved in meiotic cell cycle:MSH5 \| regulation of cytokine-mediated signaling pathway:HSPA1A,HSPA1B \| RNA splicing, via endonucleolytic cleavage and ligation:HSPA1A \| cellular response to oxidative stress:HSPA1A,HSPA1B \| regulation of reactive oxygen species metabolic process:DDAH2 \| regulation of response to cytokine stimulus:HSPA1A,HSPA1B \| regulation of response to endoplasmic reticulum stress:HSPA1A \| response to unfolded protein:HSPA1A,HSPA1L \| response to oxidative stress:HSPA1A,HSPA1B \| microtubule polymerization or depolymerization:HSPA1A,HSPA1B \| negative regulation of leukocyte activation:LST1	0.138717	0.0719203	1.26842976725521	0.182096	0.0671535	2.16877543058183	0.0473308	0.129231	0.146192924121122	0.442409	0.0785964	7.68586933134742	0.226148	0.0885403	1.96849054877387	0.762177	0.148411	6.4389618561406	0.0880902	0.0590555	0.866643150265828	0.0552861	0.0699004	0.367416183566193	0.12949	0.105908	0.653917076332865	0.00242737	0.0391789	0.0220031037693031				0.00568065	0.0654895	0.0311077000608549							0.0632021	0.0676403	0.455801686844497	0.0654682	0.0373135	1.1005231308849	0.118796	0.0440301	2.15650373432113				0.00718208	0.0226286	0.124390135026379	0.0080732	0.0286727	0.10886524581185	0.00406787	0.0364274	0.0404411034782556	0.308234	0.117677	2.0517132327087	0.35261	0.153655	1.65952019118987	0.243159	0.182511	0.737055566257698
rs79589801:211054061:C:T	novel3	1	211054061	1q32.2	T	C	0.807	0	PROG WOMEN	1261	7.67160204647787	0.0143406026962728	1.68352	KCNH1 (0 kb, intron/Intron/MODIFIER); IPO8P1 (18 kb); HHAT (200 kb)	NA					cell type benign neoplasm:KCNH1 \| esophageal carcinoma:KCNH1 \| adenoma:KCNH1	positive regulation of mitochondrion organization:HHAT \| protein acylation:HHAT \| regulation of mitochondrion organization:HHAT \| positive regulation of protein targeting to mitochondrion:HHAT \| protein lipidation:HHAT \| lipoprotein metabolic process:HHAT \| smoothened signaling pathway:HHAT \| regulation of protein targeting to mitochondrion:HHAT \| lipoprotein biosynthetic process:HHAT \| positive regulation of protein transport:HHAT \| positive regulation of establishment of protein localization to mitochondrion:HHAT \| mitochondrial transport:HHAT \| response to calcium ion:KCNH1 \| regulation of establishment of protein localization to mitochondrion:HHAT \| regulation of protein targeting:HHAT	0.371084	0.0735692	6.30477494827276	0.0592719	0.0675164	0.420033581034919	0.808409	0.144331	7.67160204647787	0.198628	0.0813197	1.83366463011977	0.0418087	0.0890097	0.194745243799519	0.487796	0.160745	2.60261624434272	0.0944862	0.0607229	0.921340220273065	0.0743217	0.0700951	0.538804714807546	0.142922	0.113353	0.682402528607138	-0.00908651	0.0462169	0.0735875779106778	0.0140427	0.0544118	0.0988992877532313	-0.0509134	0.0805193	0.278039426627493	0.0389127	0.04512	0.410662638183606	0.0606509	0.0455418	0.737698447226097	0.0339862	0.0795966	0.174318184685994	-0.0184466	0.0441428	0.170034031062263	-0.00361402	0.0512728	0.0251168059185839	-0.0623922	0.0774739	0.376101820948918	0.0169397	0.0263222	0.284109420532446	-0.0100584	0.0324451	0.121161216303143	0.0573502	0.0441447	0.712431150157221	0.195352	0.120996	0.972365034222456	0.163873	0.153948	0.541644723118617	0.243531	0.195369	0.671616318697948
rs858516:7537098:C:T		17	7537098	17p13.1	T	C	0.861	5	TESTO MEN	4291	7.6414408274504	0.583872407364251	0.0289115	SHBG (0.4 kb, near gene/Downstream gene/MODIFIER); SAT2 (5.9 kb); ATP1B2 (13 kb); FXR2 (19 kb); TP53 (28 kb); MPDU1 (41 kb); SOX15 (44 kb)	0.981 Sex hormone-binding globulin levels // 0.981 Androgen levels // 0.911 Red cell distribution width // 0.791 Blood protein levels // 0.629 Esophageal squamous cell carcinoma	- \| AC113189.5 \| ACAP1 \| ASGR1 \| ASGR2 \| ATP1B2 \| C17orf49 \| C17orf81 \| CD68 \| CHRNB1 \| CNTROB \| CTC1 \| CTDNEP1 \| EIF4A1 \| EIF5A \| FGF11 \| FXR2 \| KDM6B \| LOC100130387 \| LSMD1 \| MPDU1 \| NLGN2 \| NM 172089 \| PLSCR3 \| POLR2A \| RNASEK \| RP11-186B7.4 \| SAT2 \| SENP3 \| SENP3-EIF4A1 \| SHBG \| SNORA48 \| SOX15 \| SPEM1 \| TMEM102 \| TMEM88 \| TMEM95 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| TP53 \| TRAPPC1 \| TXNDC17 \| ZBTB4	ANKRD34B \| EIF4A1P2	Herpes simplex infection:TP53 \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Epstein-Barr virus infection:TP53 \| Human T-cell leukemia virus 1 infection:TP53 \| Thyroid hormone synthesis:ASGR1,ATP1B2 \| Huntington disease:TP53 \| Kaposi sarcoma-associated herpesvirus infection:TP53 \| Ferroptosis:SAT2,TP53 \| Cellular senescence:TP53 \| Transcriptional misregulation in cancer:TP53 \| Viral carcinogenesis:TP53 \| Small cell lung cancer:TP53 \| Human cytomegalovirus infection:TP53 \| Lysosome:CD68 \| Endocrine resistance:TP53 \| Aldosterone synthesis and secretion:ATP1B2 \| RNA transport:EIF4A1,FXR2 \| Measles:TP53	Interferon Signaling:EIF4A1 \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13 \| TP53 Regulates Transcription of DNA Repair Genes:TP53 \| TNFR2 non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13,TNFSF13 \| Pre-NOTCH Transcription and Translation:TP53 \| Association of TriC/CCT with target proteins during biosynthesis:TP53 \| Pre-NOTCH Expression and Processing:TP53 \| Transcriptional Regulation by TP53:TP53 \| Asparagine N-linked glycosylation:ASGR1,MPDU1 \| ISG15 antiviral mechanism:EIF4A1 \| Antiviral mechanism by IFN-stimulated genes:EIF4A1 \| TP53 Regulates Metabolic Genes:TP53 \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Regulation of TP53 Activity through Phosphorylation:TP53 \| Chaperonin-mediated protein folding:TP53 \| Formation of Senescence-Associated Heterochromatin Foci (SAHF):TP53 \| Protein folding:TP53 \| Signaling by NOTCH:TP53	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| endocrine system disease:SHBG,TP53 \| lymphatic system disease:TNFSF13,TP53 \| intrahepatic cholestasis:SHBG,TP53 \| Graves' disease:TP53 \| autoimmune disease of endocrine system:TP53 \| hyperthyroidism:TP53 \| hypersensitivity reaction type I disease:TP53 \| hepatitis:EIF4A1,TP53 \| hepatitis C:EIF4A1,TP53 \| aplastic anemia:TP53 \| hypotrichosis:TNFSF13 \| duodenal ulcer:TP53 \| cholestasis:SHBG,TP53 \| urinary system disease:TNFSF12,TNFSF13,TP53 \| multiple myeloma:TNFSF13,TP53 \| myeloma:TNFSF13,TP53 \| bone marrow cancer:TNFSF13,TP53 \| primary bacterial infectious disease:TP53 \| bile duct disease:SHBG,TP53 \| hair disease:TNFSF13 \| vitiligo:TP53 \| biliary tract disease:SHBG,TP53 \| thyroid gland disease:TP53 \| proteinuria:TNFSF12 \| kidney disease:TNFSF12,TNFSF13 \| purpura:TNFSF13 \| hepatitis B:TP53 \| alopecia:TNFSF13 \| collagen disease:TNFSF12,TNFSF13 \| nephritis:TNFSF12,TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| keratoconjunctivitis sicca:TP53 \| keratoconjunctivitis:TP53 \| bacterial infectious disease:TP53 \| dry eye syndrome:TP53 \| lacrimal apparatus disease:TP53 \| gestational diabetes:SHBG \| rheumatic disease:TNFSF12,TNFSF13 \| systemic scleroderma:TNFSF12,TNFSF13 \| scleroderma:TNFSF12,TNFSF13 \| male reproductive system disease:SHBG,TP53 \| male infertility:SHBG,TP53 \| hyperandrogenism:SHBG \| polycystic ovary syndrome:SHBG \| peptic ulcer disease:TP53 \| integumentary system disease:TNFSF12,TNFSF13,TP53 \| Human immunodeficiency virus infectious disease:TP53 \| hematopoietic system disease:TNFSF13,TP53 \| colon carcinoma:TNFSF13,TP53 \| intestinal cancer:SAT2,TNFSF13,TP53 \| reproductive system disease:SHBG,TP53 \| sex differentiation disease:SHBG \| germ cell and embryonal cancer:TP53 \| sporadic breast cancer:SHBG,TP53 \| malignant glioma:ATP1B2,TP53 \| mammary Paget's disease:TP53 \| open-angle glaucoma:TP53 \| pancreas disease:SHBG \| varicose veins:TP53 \| influenza:TP53 \| astrocytoma:TP53 \| interstitial lung disease:TNFSF12 \| gastritis:TP53 \| gonadal dysgenesis:SHBG \| gonadal disease:SHBG \| breast adenocarcinoma:TP53 \| myopathy:SHBG,TNFSF12,TNFSF13,TP53 \| muscle tissue disease:SHBG,TNFSF12,TNFSF13,TP53 \| neuropathy:TP53 \| tuberculosis:TP53 \| osteoporosis:SHBG \| Sjogren's syndrome:TNFSF13 \| bone resorption disease:SHBG \| muscular disease:SHBG,TNFSF12,TNFSF13,TP53 \| alopecia areata:TNFSF13 \| chronic leukemia:TP53 \| cell type benign neoplasm:TP53 \| teratoma:TP53 \| Alzheimer's disease:SHBG,TP53 \| non-small cell lung carcinoma:EIF5A,TNFSF13,TP53 \| colon cancer:TNFSF13,TP53 \| tauopathy:SHBG,TP53 \| cholangitis:TP53 \| colorectal cancer:TNFSF13,TP53 \| stomach disease:TP53 \| large intestine cancer:TNFSF13,TP53 \| gallbladder carcinoma:TP53 \| esophagus squamous cell carcinoma:TP53 \| gallbladder cancer:TP53 \| female reproductive organ cancer:SHBG,TP53 \| infertility:SHBG,TP53 \| neurofibroma:TP53 \| anemia:TP53 \| myositis:TNFSF13 \| lower respiratory tract disease:TNFSF12,TP53 \| lung adenocarcinoma:EIF5A,TP53 \| cardiomyopathy:TNFSF12,TP53 \| keratoacanthoma:TP53 \| primary immunodeficiency disease:TP53 \| liver cirrhosis:TNFSF13,TP53 \| gallbladder disease:TP53 \| pleural cancer:TP53 \| malignant pleural mesothelioma:TP53 \| esophageal carcinoma:TP53 \| mouth disease:TP53 \| lung disease:TNFSF12,TP53 \| chronic lymphocytic leukemia:TNFSF13,TP53 \| ataxia telangiectasia:TP53 \| vein disease:TP53 \| dilated cardiomyopathy:TNFSF12,TP53 \| adenoma:TP53 \| acute myocardial infarction:TNFSF12,TP53 \| gastric adenocarcinoma:TP53 \| coronary artery disease:TNFSF12,TP53 \| integumentary system cancer:TP53 \| skin cancer:TP53	positive regulation of cell activation:SOX15,TNFSF13 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF12,TNFSF13 \| positive regulation of lymphocyte activation:TNFSF13 \| positive regulation of leukocyte activation:TNFSF13 \| regulation of leukocyte activation:TNFSF13 \| regulation of lymphocyte activation:TNFSF13 \| postsynaptic membrane organization:CHRNB1 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| regulation of DNA biosynthetic process:TP53 \| RNA secondary structure unwinding:EIF4A1 \| regulation of telomerase activity:TP53 \| cellular response to tumor necrosis factor:TNFSF12,TNFSF13 \| DNA biosynthetic process:TP53 \| replicative senescence:TP53 \| response to tumor necrosis factor:TNFSF12,TNFSF13 \| ammonium ion metabolic process:SAT2 \| regulation of immune effector process:TNFSF13 \| positive regulation of cell cycle process:SOX15,TP53 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| B cell mediated immunity:TNFSF13 \| translational initiation:EIF4A1 \| positive regulation of adaptive immune response:TNFSF13 \| regulation of cell cycle G2/M phase transition:TP53 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:CHRNB1 \| nucleocytoplasmic transport:EIF5A,TP53 \| nuclear transport:EIF5A,TP53 \| positive regulation of DNA metabolic process:TNFSF13 \| chemical synaptic transmission, postsynaptic:CHRNB1 \| negative regulation of DNA biosynthetic process:TP53 \| positive regulation of reactive oxygen species metabolic process:EIF5A,TP53 \| protein stabilization:ATP1B2,TMEM88 \| positive regulation of cell cycle:SOX15,TP53 \| negative regulation of growth:TP53 \| peptidyl-tyrosine phosphorylation:TP53 \| regulation of lymphocyte mediated immunity:TNFSF13 \| peptidyl-tyrosine modification:TP53 \| nuclear-transcribed mRNA poly(A) tail shortening:EIF4A1 \| regulation of DNA metabolic process:TNFSF13,TP53 \| negative regulation of translation:FXR2 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:TP53 \| cell cycle G2/M phase transition:TP53 \| protein N-linked glycosylation via asparagine:ASGR1 \| regulation of postsynaptic membrane potential:CHRNB1 \| synapse organization:CHRNB1 \| peptidyl-asparagine modification:ASGR1 \| positive regulation of cellular amide metabolic process:EIF5A \| negative regulation of cellular amide metabolic process:FXR2 \| regulation of mitotic cell cycle phase transition:TP53 \| regulation of adaptive immune response:TNFSF13 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| receptor-mediated endocytosis:ASGR1 \| regulation of lymphocyte apoptotic process:TP53 \| mitochondrial outer membrane permeabilization:TP53 \| regulation of protein stability:ATP1B2,TMEM88 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| regulation of cell cycle phase transition:TP53 \| aging:EIF5A,TP53 \| negative regulation of cell growth:TP53 \| protein export from nucleus:EIF5A,TP53 \| positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress:TP53 \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:TP53 \| mitochondrial outer membrane permeabilization involved in programmed cell death:TP53 \| positive regulation of mitochondrial membrane permeability:TP53 \| regulation of mitochondrial membrane permeability involved in apoptotic process:TP53 \| positive regulation of membrane permeability:TP53 \| regulation of DNA-templated transcription in response to stress:TP53 \| mRNA catabolic process:EIF4A1,TNFSF13 \| lymphocyte apoptotic process:TP53 \| protein N-linked glycosylation:ASGR1 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| positive regulation of protein complex assembly:TP53 \| cellular response to UV:TP53 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| nuclear export:EIF5A,TP53 \| regulation of mitochondrial membrane permeability:TP53 \| execution phase of apoptosis:TP53 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:EIF4A1 \| regulation of leukocyte apoptotic process:TP53 \| mitochondrial membrane organization:TP53 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| potassium ion homeostasis:ATP1B2 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| DNA geometric change:TP53 \| cellular response to extracellular stimulus:ASGR1,TP53 \| regulation of membrane permeability:TP53 \| regulation of fibroblast proliferation:TP53 \| regulation of ion transmembrane transporter activity:ATP1B2 \| fibroblast proliferation:TP53 \| regulation of apoptotic signaling pathway:TNFSF12,TP53 \| regulation of transmembrane transporter activity:ATP1B2 \| RNA catabolic process:EIF4A1,TNFSF13 \| negative regulation of hydrolase activity:TP53 \| regulation of G0 to G1 transition:SOX15 \| regulation of membrane potential:ATP1B2,CHRNB1 \| autophagy:TP53 \| process utilizing autophagic mechanism:TP53 \| cell aging:TP53 \| leukocyte apoptotic process:TP53 \| regulation of striated muscle tissue development:SOX15 \| regulation of transporter activity:ATP1B2 \| G0 to G1 transition:SOX15 \| regulation of muscle tissue development:SOX15 \| regulation of canonical Wnt signaling pathway:TMEM88 \| cellular response to light stimulus:TP53	-0.00899421	0.0182025	0.206716121971134	-0.0316458	0.0161621	1.29729294737877	0.0544418	0.0362811	0.874616339532293	0.0119888	0.0200256	0.260067079805183	-0.00929842	0.0213315	0.178500882812612	0.0534385	0.0416692	0.698737718919011	-0.00688839	0.0149412	0.190558806696773	-0.00757001	0.0168041	0.185464746156286	-0.00645146	0.0292606	0.0832524097481363	-0.0159226	0.0103467	0.90718464875274	-0.00963308	0.0129463	0.340247285075646	-0.0238031	0.0165307	0.824241827746707	0.0377103	0.0102964	3.60240582739658	0.0602525	0.0107805	7.6414408274504	0.01255	0.0176137	0.32226168394398	0.03035	0.00988548	2.66970394858558	0.0364934	0.0121572	2.57124176048244	0.0197124	0.0158529	0.670195477835931	0.00433439	0.00596275	0.330422806768362	0.00134781	0.00772715	0.0647290909533666	0.00781189	0.00928445	0.3978021420592	-0.0148383	0.03008	0.206308774243237	-0.046218	0.037117	0.671041722948794	0.0492919	0.0512791	0.472669182266429
rs12913657:51000968:T:C		15	51000968	15q21.2	C	T	0.985	3	E2 MEN	4191	7.60720283649909	0.144226795514197	1.91236	SPPL2A (0 kb, intron/Intron/MODIFIER); RN7SL354P (20 kb); TRPM7 (22 kb); USP50 (160 kb)	0.494 Chloride levels // 0.365 Creatinine levels // 0.365 Glomerular filtration rate // 0.303 Fibrinogen levels	AC012100.1 \| AP4E1 \| CYP19A1 \| DCAF13P3 \| GABPB1 \| GABPB1-AS1 \| GLDN \| HDC \| RP11-108K3.2 \| RP11-507J18.1 \| RP11-562A8.4 \| RP11-562A8.5 \| SPPL2A \| TMOD2 \| TNFAIP8L3 \| TRPM7 \| USP50 \| USP8		NOD-like receptor signaling pathway:TRPM7 \| Endocytosis:USP8 \| Cellular senescence:TRPM7 \| Lysosome:AP4E1		cell type benign neoplasm:TRPM7 \| adenoma:TRPM7 \| cerebral palsy:AP4E1	tumor necrosis factor-mediated signaling pathway:SPPL2A \| cellular response to tumor necrosis factor:SPPL2A \| response to tumor necrosis factor:SPPL2A \| protein tetramerization:TRPM7 \| actomyosin structure organization:TRPM7 \| magnesium ion homeostasis:TRPM7 \| regulation of tumor necrosis factor-mediated signaling pathway:SPPL2A \| protein deubiquitination:USP50,USP8 \| calcium ion transmembrane transport:TRPM7 \| protein modification by small protein removal:USP50,USP8	-0.0250542	0.0250237	0.499161366090353	-0.0305952	0.0227782	0.746080739425089	-0.0216453	0.0486004	0.183063060172214	-0.0198186	0.027534	0.326298217914485	-0.0484316	0.0300146	0.97123766724569	0.0231506	0.0548808	0.171808156473022	-0.0222705	0.0205393	0.555388491632315	-0.0297731	0.0236533	0.681216917565549	-0.0144854	0.0384955	0.150694242487142	0.00873582	0.0144406	0.263433000884533	0.00113984	0.0180165	0.0224803324170433	0.0186554	0.0231761	0.375866476856108	0.00982807	0.01433	0.307316963107464	0.017249	0.0150555	0.598735628436851	0.00787792	0.0242371	0.127753962904598	-0.0702482	0.0138291	6.42254496738951	-0.0939528	0.0168515	7.60720283649909	-0.0371082	0.0223343	1.01495454276852	-0.00771838	0.00831276	0.452040789412814	-0.0139537	0.0107671	0.709992115274119	-2.89743E-6	0.0129717	7.73112986885129E-5	-0.0128825	0.0415222	0.12124905398719	-0.0113735	0.0522356	0.0821427860970056	-0.01118	0.0684392	0.0603375037469278
rs140935700:90611965:G:A		5	90611965	5q14.3	A	G	0.843	0	PROG ALL	2070	7.59606486827327	0.0135640096618357		LUCAT1 (1.7 kb, near gene/Upstream gene/MODIFIER); RP11-213H15.4 (1.7 kb, near gene/Upstream gene/MODIFIER); RNU4-90P (45 kb); ARRDC3 (53 kb)	NA						negative regulation of homeostatic process:ARRDC3 \| regulation of heat generation:ARRDC3 \| regulation of homeostatic process:ARRDC3 \| regulation of protein modification by small protein conjugation or removal:ARRDC3 \| heat generation:ARRDC3 \| multicellular organismal homeostasis:ADGRV1,ARRDC3	0.424947	0.0759846	7.59606486827327	0.173325	0.0756013	1.65712549321755				0.160694	0.0841539	1.24923557802314	0.192876	0.0997037	1.27358986833274	0.104131	0.149591	0.312835928053133	0.0505984	0.062831	0.375993422958432	0.0757351	0.0786244	0.474187106523548	0.00734434	0.104962	0.0249194456508963	-0.0547025	0.0502371	0.55877003623766	0.0204303	0.065222	0.122573362861873	-0.143233	0.0774722	1.19056352128226				-0.0461553	0.0541611	0.404381443407344	-0.112138	0.0753823	0.863723464339708	-0.0898569	0.0485192	1.19363142031037	-0.127409	0.0617754	1.40710408689536				-0.00835296	0.0285195	0.113729862192329	0.0427791	0.0385616	0.573049786345024	-0.056993	0.0425903	0.742703100104448	0.155525	0.125532	0.666516451840995	0.0734962	0.174024	0.172080452346316	0.268086	0.180637	0.85936313327873
rs8042456:40290476:G:T		15	40290476	15q15.1	T	G	0.975	8	DHEAS ALL	7659	7.5749583896058	0.590634547591069	0.039112	EIF2AK4 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); SRP14 (37 kb); SRP14-AS1 (41 kb); H3F3AP1 (47 kb)	0.74 Endometrial cancer // 0.74 Endometrial endometrioid carcinoma // 0.438 Dehydroepiandrosterone sulphate levels // 0.324 Ewing sarcoma	BMF \| C15orf57 \| CHST14 \| EIF2AK4 \| FSIP1 \| LOC100131089 \| PLCB2 \| RHOV \| RP11-521C20.2 \| RP11-521C20.4 \| SRP14 \| SRP14-AS1 \| THBS1		Herpes simplex infection:EIF2AK4 \| Phagosome:THBS1 \| Influenza A:EIF2AK4 \| Epstein-Barr virus infection:EIF2AK4 \| MicroRNAs in cancer:THBS1 \| Malaria:THBS1 \| Protein processing in endoplasmic reticulum:EIF2AK4 \| Measles:EIF2AK4		hepatitis:THBS1 \| hepatitis C:THBS1 \| urinary system disease:THBS1 \| myeloma:THBS1 \| bone marrow cancer:THBS1 \| proteinuria:THBS1 \| kidney disease:THBS1 \| collagen disease:THBS1 \| hemorrhagic disease:THBS1 \| blood coagulation disease:THBS1 \| rheumatic disease:THBS1 \| systemic scleroderma:THBS1 \| scleroderma:THBS1 \| hemorrhagic fever with renal syndrome:THBS1 \| hematopoietic system disease:THBS1 \| osteoporosis:THBS1 \| bone resorption disease:THBS1 \| cell type benign neoplasm:THBS1 \| thyroid cancer:THBS1 \| myositis:THBS1 \| myopathy:THBS1 \| muscle tissue disease:THBS1 \| muscular disease:THBS1 \| keratoacanthoma:THBS1 \| Down syndrome:THBS1 \| female reproductive organ cancer:THBS1 \| adenoma:THBS1 \| coronary artery disease:THBS1 \| integumentary system cancer:THBS1 \| skin cancer:THBS1	antigen processing and presentation:THBS1 \| antigen processing and presentation of peptide or polysaccharide antigen via MHC class II:THBS1 \| modulation by virus of host morphology or physiology:EIF2AK4 \| modification by symbiont of host morphology or physiology:EIF2AK4 \| modulation by virus of host process:EIF2AK4 \| positive regulation of cell activation:THBS1 \| modulation by symbiont of host cellular process:EIF2AK4 \| positive regulation of leukocyte activation:THBS1 \| regulation of leukocyte activation:THBS1 \| modification of morphology or physiology of other organism involved in symbiotic interaction:EIF2AK4 \| cellular response to tumor necrosis factor:THBS1 \| chronic inflammatory response:THBS1 \| T cell activation:EIF2AK4 \| response to tumor necrosis factor:THBS1 \| modification of morphology or physiology of other organism:EIF2AK4 \| regulation of immune effector process:EIF2AK4 \| adaptive immune response:EIF2AK4 \| regulation of antigen processing and presentation:THBS1 \| apoptotic cell clearance:THBS1 \| positive regulation of adaptive immune response:EIF2AK4 \| positive regulation of translation:EIF2AK4,THBS1 \| interaction with host:EIF2AK4 \| positive regulation of reactive oxygen species metabolic process:THBS1 \| positive regulation of cytokine production:THBS1 \| cellular response to amino acid starvation:EIF2AK4 \| positive regulation of cellular amide metabolic process:EIF2AK4,THBS1 \| regulation of adaptive immune response:EIF2AK4 \| cellular response to fibroblast growth factor stimulus:THBS1 \| response to drug:SRP14,THBS1 \| positive regulation of translational initiation:EIF2AK4 \| response to fibroblast growth factor:THBS1 \| phagocytosis:THBS1 \| regulation of autophagy:EIF2AK4 \| regulation of defense response to virus:EIF2AK4 \| cellular response to UV:EIF2AK4 \| macrophage activation:THBS1 \| regulation of macrophage activation:THBS1 \| negative regulation of immune system process:THBS1 \| regulation of protein kinase B signaling:THBS1 \| negative regulation of hydrolase activity:THBS1 \| negative regulation of chemotaxis:THBS1 \| regulation of mononuclear cell migration:THBS1 \| negative regulation of ion transmembrane transport:THBS1 \| autophagy:EIF2AK4 \| process utilizing autophagic mechanism:EIF2AK4 \| regulation of protein processing:THBS1 \| negative regulation of proteolysis:THBS1 \| blood vessel endothelial cell migration:THBS1 \| sprouting angiogenesis:THBS1 \| negative regulation of transmembrane transport:THBS1 \| regulation of leukocyte chemotaxis:THBS1 \| regulation of protein maturation:THBS1 \| positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway:THBS1	-0.0182924	0.0172011	0.54105108096779	8.1969E-4	0.015491	0.018721539875009	-0.0627281	0.0340454	1.18439170604328	-0.032772	0.0189159	1.0791835043848	-0.0334472	0.020398	0.994411991224136	-0.0363114	0.0384818	0.461305645589146	-0.0308192	0.0141067	1.53727565510212	-0.0291568	0.0160652	1.15639103786198	-0.0376373	0.0269718	0.786952651333662	-0.0579139	0.0104117	7.5749583896058	-0.0457575	0.0129856	3.37106267248369	-0.0744006	0.0167153	5.06830775491086	-0.0322406	0.0102395	2.78507936276593	-0.0257609	0.0108239	1.76163017946666	-0.0432231	0.0173593	1.89355071148576	-0.0173301	0.0100157	1.07790127051484	-0.0314629	0.0122803	1.98273287276361	-0.00277934	0.0160156	0.0643783816591027	-0.00109653	0.00597187	0.068381968259491	0.00217156	0.00771272	0.108861897706357	-0.00439304	0.00934906	0.194884672804727	0.0480302	0.028426	1.03976522311903	0.0354169	0.0355951	0.494954536364729	0.0730345	0.0471877	0.913113639587595
rs4227:7491177:G:T		17	7491177	17p13.1	T	G	0.905	6	TESTO MEN	4291	7.46210789923732	0.71889419715684	0.043823	MPDU1 (0 kb, 3'utr/3 prime UTR/MODIFIER \| nc-exon/Non coding transcript exon/MODIFIER \| intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Downstream gene/MODIFIER); SOX15 (0.32 kb, near gene/Downstream gene/MODIFIER); FXR2 (3.4 kb, near gene/Downstream gene/MODIFIER); AC113189.5 (3.8 kb, near gene/Upstream gene/MODIFIER); CD68 (5.7 kb); SNORA67 (5.8 kb); EIF4A1 (8.9 kb); SENP3-EIF4A1 (9.1 kb); SNORD10 (11 kb); SNORA48 (13 kb); SENP3 (16 kb); SHBG (26 kb); TNFSF12 (26 kb); TNFSF13 (26 kb); TNFSF12-TNFSF13 (26 kb); SAT2 (38 kb)	1 IgA nephropathy // 0.799 Testosterone levels // 0.799 Sex hormone-binding globulin levels // 0.595 Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test) // 0.595 Systolic blood pressure x smoking status (current vs non-current) interaction (2df test) // 0.595 Systolic blood pressure x smoking status (ever vs never) interaction (2df test) // 0.595 Diastolic blood pressure x smoking status (ever vs never) interaction (2df test) // 0.579 Blood protein levels // 0.541 Chin dimples	- \| AC113189.5 \| ACAP1 \| ASGR2 \| ATP1B2 \| C17orf61 \| C17orf61-PLSCR3 \| C17orf81 \| CD68 \| CHRNB1 \| CTDNEP1 \| CYB5D1 \| EFNB3 \| EIF4A1 \| EIF5A \| FGF11 \| FXR2 \| KCTD11 \| LOC100130387 \| MPDU1 \| NLGN2 \| PLSCR3 \| POLR2A \| RP11-186B7.4 \| SAT2 \| SENP3 \| SENP3-EIF4A1 \| SHBG \| SLC35G6 \| SNORA48 \| SOX15 \| SPEM1 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| TP53 \| TRAPPC1 \| unnamed	EIF4A1P2 \| EIF5AL1	Herpes simplex infection:POLR2A \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Epstein-Barr virus infection:POLR2A \| Endocytosis:ACAP1 \| Huntington disease:POLR2A \| Ferroptosis:SAT2 \| Lysosome:CD68 \| RNA transport:EIF4A1,FXR2	Interferon Signaling:EIF4A1 \| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13 \| TP53 Regulates Transcription of DNA Repair Genes:POLR2A \| TNFR2 non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13,TNFSF13 \| MicroRNA (miRNA) biogenesis:POLR2A \| Transcriptional regulation of pluripotent stem cells:POLR2A \| Infectious disease:POLR2A \| Influenza Infection:POLR2A \| Transcriptional Regulation by TP53:POLR2A \| HIV Transcription Elongation:POLR2A \| Formation of HIV-1 elongation complex containing HIV-1 Tat:POLR2A \| Tat-mediated elongation of the HIV-1 transcript:POLR2A \| Transcription of the HIV genome:POLR2A \| Asparagine N-linked glycosylation:MPDU1 \| Formation of HIV elongation complex in the absence of HIV Tat:POLR2A \| ISG15 antiviral mechanism:EIF4A1 \| Antiviral mechanism by IFN-stimulated genes:EIF4A1 \| RNA Polymerase II Pre-transcription Events:POLR2A \| Formation of the Early Elongation Complex:POLR2A \| Formation of the HIV-1 Early Elongation Complex:POLR2A \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Pausing and recovery of Tat-mediated HIV elongation:POLR2A \| Tat-mediated HIV elongation arrest and recovery:POLR2A \| Formation of RNA Pol II elongation complex :POLR2A \| RNA Polymerase II Transcription Elongation:POLR2A \| HIV elongation arrest and recovery:POLR2A \| Pausing and recovery of HIV elongation:POLR2A \| Transcriptional regulation by small RNAs:POLR2A	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| endocrine system disease:SHBG \| lymphatic system disease:TNFSF13 \| intrahepatic cholestasis:SHBG \| hepatitis:EIF4A1 \| hepatitis C:EIF4A1 \| hypotrichosis:TNFSF13 \| cholestasis:SHBG \| urinary system disease:TNFSF12,TNFSF13 \| multiple myeloma:TNFSF13 \| myeloma:TNFSF13 \| bone marrow cancer:TNFSF13 \| bile duct disease:SHBG \| hair disease:TNFSF13 \| biliary tract disease:SHBG \| proteinuria:TNFSF12 \| kidney disease:TNFSF12,TNFSF13 \| purpura:TNFSF13 \| alopecia:TNFSF13 \| collagen disease:TNFSF12,TNFSF13 \| nephritis:TNFSF12,TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| gestational diabetes:SHBG \| rheumatic disease:TNFSF12,TNFSF13 \| systemic scleroderma:TNFSF12,TNFSF13 \| scleroderma:TNFSF12,TNFSF13 \| male reproductive system disease:SHBG \| male infertility:SHBG \| hyperandrogenism:SHBG \| polycystic ovary syndrome:SHBG \| integumentary system disease:TNFSF12,TNFSF13 \| hematopoietic system disease:TNFSF13 \| colon carcinoma:TNFSF13 \| intestinal cancer:SAT2,TNFSF13 \| reproductive system disease:SHBG \| sex differentiation disease:SHBG \| sporadic breast cancer:SHBG \| pancreas disease:SHBG \| interstitial lung disease:TNFSF12 \| gonadal dysgenesis:SHBG \| gonadal disease:SHBG \| myopathy:SHBG,TNFSF12,TNFSF13 \| muscle tissue disease:SHBG,TNFSF12,TNFSF13 \| osteoporosis:SHBG \| Sjogren's syndrome:TNFSF13 \| bone resorption disease:SHBG \| muscular disease:SHBG,TNFSF12,TNFSF13 \| alopecia areata:TNFSF13 \| Alzheimer's disease:SHBG \| non-small cell lung carcinoma:EIF5A,TNFSF13 \| colon cancer:TNFSF13 \| tauopathy:SHBG \| colorectal cancer:TNFSF13 \| large intestine cancer:TNFSF13 \| female reproductive organ cancer:SHBG \| infertility:SHBG \| myositis:TNFSF13 \| lower respiratory tract disease:TNFSF12 \| lung adenocarcinoma:EIF5A \| cardiomyopathy:TNFSF12 \| liver cirrhosis:TNFSF13 \| lung disease:TNFSF12 \| chronic lymphocytic leukemia:TNFSF13 \| dilated cardiomyopathy:TNFSF12 \| acute myocardial infarction:TNFSF12 \| coronary artery disease:TNFSF12	positive regulation of cell activation:SOX15,TNFSF13 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF12,TNFSF13 \| positive regulation of lymphocyte activation:TNFSF13 \| positive regulation of leukocyte activation:TNFSF13 \| regulation of leukocyte activation:TNFSF13 \| regulation of lymphocyte activation:TNFSF13 \| postsynaptic membrane organization:CHRNB1 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| RNA secondary structure unwinding:EIF4A1 \| cellular response to tumor necrosis factor:TNFSF12,TNFSF13 \| response to tumor necrosis factor:TNFSF12,TNFSF13 \| ammonium ion metabolic process:SAT2 \| regulation of immune effector process:TNFSF13 \| positive regulation of cell cycle process:SOX15 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| B cell mediated immunity:TNFSF13 \| translational initiation:EIF4A1 \| positive regulation of adaptive immune response:TNFSF13 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:CHRNB1 \| nucleocytoplasmic transport:EIF5A \| nuclear transport:EIF5A \| positive regulation of DNA metabolic process:TNFSF13 \| chemical synaptic transmission, postsynaptic:CHRNB1 \| positive regulation of reactive oxygen species metabolic process:EIF5A \| stem cell proliferation:KCTD11 \| positive regulation of cell cycle:SOX15 \| regulation of lymphocyte mediated immunity:TNFSF13 \| nuclear-transcribed mRNA poly(A) tail shortening:EIF4A1 \| regulation of DNA metabolic process:TNFSF13 \| negative regulation of neurogenesis:KCTD11 \| negative regulation of translation:FXR2,POLR2A \| DNA-templated transcription, elongation:POLR2A \| regulation of postsynaptic membrane potential:CHRNB1 \| synapse organization:CHRNB1 \| positive regulation of cellular amide metabolic process:EIF5A \| negative regulation of cellular amide metabolic process:FXR2,POLR2A \| negative regulation of nervous system development:KCTD11 \| regulation of adaptive immune response:TNFSF13 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| negative regulation of cell development:KCTD11 \| aging:EIF5A \| protein export from nucleus:EIF5A \| regulation of stem cell proliferation:KCTD11 \| mRNA catabolic process:EIF4A1,TNFSF13 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| smoothened signaling pathway:KCTD11 \| somatic stem cell population maintenance:POLR2A \| regulation of viral process:POLR2A \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| nuclear export:EIF5A \| regulation of neural precursor cell proliferation:KCTD11 \| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay:EIF4A1 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| regulation of symbiosis, encompassing mutualism through parasitism:POLR2A \| regulation of apoptotic signaling pathway:TNFSF12 \| RNA catabolic process:EIF4A1,TNFSF13 \| regulation of G0 to G1 transition:SOX15 \| regulation of membrane potential:CHRNB1 \| transcription elongation from RNA polymerase II promoter:POLR2A \| regulation of striated muscle tissue development:SOX15 \| G0 to G1 transition:SOX15 \| positive regulation of viral process:POLR2A \| regulation of muscle tissue development:SOX15 \| DNA-templated transcription, termination:POLR2A \| regulation of gene silencing by miRNA:POLR2A \| regulation of posttranscriptional gene silencing:POLR2A \| regulation of gene silencing by RNA:POLR2A	0.0118506	0.0199301	0.257927979273824	0.0261016	0.0176658	0.854592249292861	-0.0399573	0.0403441	0.492180545827942	-0.0233245	0.0219227	0.541393874512511	-0.0259342	0.0232929	0.575547972209599	-0.0157952	0.0459185	0.136105793954084	-0.0119727	0.0163584	0.33318822128519	-0.015038	0.0183532	0.384344485134748	-0.00418643	0.0322104	0.0473886717909804	0.022816	0.0114776	1.32952499641427	0.0106975	0.0141849	0.346055593254887	0.0382361	0.0186187	1.3978238504336	-0.042067	0.0113915	3.65411482867407	-0.06512	0.0118038	7.46210789923732	-0.0157139	0.0197226	0.371000421575331	-0.0298354	0.0109775	2.18239695355789	-0.0394663	0.013323	2.51516652001851	-0.0127462	0.0179222	0.321515309679131	-0.0118881	0.00660567	1.14321191913178	-0.00855133	0.00846444	0.505333463063769	-0.0161991	0.0104382	0.918346705230338	0.0231452	0.0329039	0.317063802089458	0.022638	0.0405282	0.239163776790284	0.0213097	0.0564268	0.15131465405792
17:7591511:C:CGGGG		17	7591511	17p13.1	CGGGG	C	0.914	0	TESTO MEN	4291	7.45432926776887	0.0751241668608716	0.367241	WRAP53 (0 kb, 5'utr/5 prime UTR/MODIFIER \| intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| near gene/Upstream gene/MODIFIER); TP53 (0.66 kb, near gene/Upstream gene/MODIFIER); RP11-199F11.2 (1.8 kb, near gene/Upstream gene/MODIFIER); EFNB3 (17 kb); DNAH2 (29 kb); ATP1B2 (30 kb)	0.325 Cognitive function	- \| ASGR1 \| AURKB \| C17orf81 \| CD68 \| CHD3 \| CTDNEP1 \| CYB5D1 \| DLG4 \| DNAH2 \| EFNB3 \| EIF4A1 \| EIF5A \| GABARAP \| LSMD1 \| MPDU1 \| NDEL1 \| PER1 \| RP11-186B7.4 \| RPL26 \| SAT2 \| SNORA48 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| WRAP53 \| ZBTB4		Herpes simplex infection:TP53 \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Epstein-Barr virus infection:TP53 \| Human T-cell leukemia virus 1 infection:TP53 \| Thyroid hormone synthesis:ASGR1,ATP1B2 \| Huntington disease:DLG4,DNAH2,TP53 \| Kaposi sarcoma-associated herpesvirus infection:TP53 \| Ferroptosis:TP53 \| Cellular senescence:TP53 \| Transcriptional misregulation in cancer:TP53 \| Viral carcinogenesis:TP53 \| Small cell lung cancer:TP53 \| Human cytomegalovirus infection:TP53 \| Lysosome:CD68 \| Endocrine resistance:TP53 \| Aldosterone synthesis and secretion:ATP1B2 \| Measles:TP53	TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13 \| TP53 Regulates Transcription of DNA Repair Genes:TP53 \| TNFR2 non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13,TNFSF13 \| Pre-NOTCH Transcription and Translation:TP53 \| Association of TriC/CCT with target proteins during biosynthesis:TP53,WRAP53 \| EPHB-mediated forward signaling:EFNB3 \| Pre-NOTCH Expression and Processing:TP53 \| Transcriptional Regulation by TP53:TP53 \| Neurexins and neuroligins:DLG4 \| Asparagine N-linked glycosylation:ASGR1,MPDU1 \| TP53 Regulates Metabolic Genes:TP53 \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Protein-protein interactions at synapses:DLG4 \| Regulation of TP53 Activity through Phosphorylation:TP53 \| EPH-Ephrin signaling:EFNB3 \| Chaperonin-mediated protein folding:TP53,WRAP53 \| Formation of Senescence-Associated Heterochromatin Foci (SAHF):TP53 \| Protein folding:TP53,WRAP53 \| Signaling by NOTCH:TP53	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| endocrine system disease:TP53 \| lymphatic system disease:TNFSF13,TP53 \| intrahepatic cholestasis:TP53 \| Graves' disease:TP53 \| autoimmune disease of endocrine system:TP53 \| hyperthyroidism:TP53 \| hypersensitivity reaction type I disease:TP53 \| hepatitis:TP53 \| hepatitis C:TP53 \| aplastic anemia:TP53 \| hypotrichosis:TNFSF13 \| duodenal ulcer:TP53 \| cholestasis:TP53 \| urinary system disease:TNFSF12,TNFSF13,TP53 \| multiple myeloma:TNFSF13,TP53 \| myeloma:TNFSF13,TP53 \| bone marrow cancer:TNFSF13,TP53 \| primary bacterial infectious disease:TP53 \| bile duct disease:TP53 \| hair disease:TNFSF13 \| vitiligo:TP53 \| biliary tract disease:TP53 \| thyroid gland disease:TP53 \| proteinuria:TNFSF12 \| kidney disease:TNFSF12,TNFSF13 \| purpura:TNFSF13 \| hepatitis B:TP53 \| alopecia:TNFSF13 \| collagen disease:TNFSF12,TNFSF13 \| nephritis:TNFSF12,TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| keratoconjunctivitis sicca:TP53 \| keratoconjunctivitis:TP53 \| bacterial infectious disease:TP53 \| dry eye syndrome:TP53 \| lacrimal apparatus disease:TP53 \| rheumatic disease:TNFSF12,TNFSF13 \| systemic scleroderma:TNFSF12,TNFSF13 \| scleroderma:TNFSF12,TNFSF13 \| male reproductive system disease:TP53 \| male infertility:TP53 \| peptic ulcer disease:TP53 \| integumentary system disease:TNFSF12,TNFSF13,TP53 \| Human immunodeficiency virus infectious disease:TP53 \| hematopoietic system disease:TNFSF13,TP53 \| colon carcinoma:EFNB3,TNFSF13,TP53 \| intestinal cancer:EFNB3,TNFSF13,TP53 \| reproductive system disease:TP53 \| germ cell and embryonal cancer:TP53 \| sporadic breast cancer:TP53 \| malignant glioma:ATP1B2,TP53 \| mammary Paget's disease:TP53 \| open-angle glaucoma:TP53 \| varicose veins:TP53 \| influenza:TP53 \| astrocytoma:TP53 \| interstitial lung disease:TNFSF12 \| gastritis:TP53 \| breast adenocarcinoma:TP53 \| myopathy:TNFSF12,TNFSF13,TP53 \| muscle tissue disease:TNFSF12,TNFSF13,TP53 \| neuropathy:TP53 \| tuberculosis:TP53 \| Sjogren's syndrome:TNFSF13 \| muscular disease:TNFSF12,TNFSF13,TP53 \| alopecia areata:TNFSF13 \| chronic leukemia:TP53 \| cell type benign neoplasm:TP53 \| teratoma:TP53 \| Alzheimer's disease:DLG4,TP53 \| non-small cell lung carcinoma:EIF5A,TNFSF13,TP53 \| colon cancer:EFNB3,TNFSF13,TP53 \| tauopathy:DLG4,TP53 \| cholangitis:TP53 \| colorectal cancer:EFNB3,TNFSF13,TP53 \| stomach disease:TP53 \| large intestine cancer:EFNB3,TNFSF13,TP53 \| gallbladder carcinoma:TP53 \| esophagus squamous cell carcinoma:TP53 \| gallbladder cancer:TP53 \| infertility:TP53 \| neurofibroma:TP53 \| anemia:TP53 \| myositis:TNFSF13 \| lower respiratory tract disease:TNFSF12,TP53 \| lung adenocarcinoma:EIF5A,TP53 \| cardiomyopathy:TNFSF12,TP53 \| keratoacanthoma:TP53 \| primary immunodeficiency disease:TP53 \| liver cirrhosis:TNFSF13,TP53 \| gallbladder disease:TP53 \| pleural cancer:TP53 \| malignant pleural mesothelioma:TP53 \| esophageal carcinoma:TP53 \| mouth disease:TP53 \| lung disease:TNFSF12,TP53 \| chronic lymphocytic leukemia:TNFSF13,TP53 \| female reproductive organ cancer:TP53 \| ataxia telangiectasia:TP53 \| vein disease:TP53 \| dilated cardiomyopathy:TNFSF12,TP53 \| adenoma:TP53 \| acute myocardial infarction:TNFSF12,TP53 \| gastric adenocarcinoma:TP53 \| coronary artery disease:TNFSF12,TP53 \| integumentary system cancer:TP53 \| skin cancer:TP53	T cell costimulation:EFNB3 \| lymphocyte costimulation:EFNB3 \| positive regulation of leukocyte cell-cell adhesion:EFNB3 \| positive regulation of cell-cell adhesion:EFNB3 \| positive regulation of cell activation:EFNB3,TNFSF13 \| positive regulation of T cell activation:EFNB3 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF12,TNFSF13 \| positive regulation of cell adhesion:EFNB3 \| positive regulation of lymphocyte activation:EFNB3,TNFSF13 \| positive regulation of leukocyte activation:EFNB3,TNFSF13 \| regulation of leukocyte activation:EFNB3,TNFSF13 \| regulation of lymphocyte activation:EFNB3,TNFSF13 \| postsynaptic membrane organization:DLG4 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| regulation of cell-cell adhesion:EFNB3 \| regulation of DNA biosynthetic process:TP53,WRAP53 \| regulation of leukocyte cell-cell adhesion:EFNB3 \| regulation of telomerase activity:TP53,WRAP53 \| cellular response to tumor necrosis factor:TNFSF12,TNFSF13 \| DNA biosynthetic process:TP53,WRAP53 \| regulation of T cell activation:EFNB3 \| T cell activation:EFNB3 \| locomotory exploration behavior:DLG4 \| replicative senescence:TP53 \| response to tumor necrosis factor:TNFSF12,TNFSF13 \| leukocyte cell-cell adhesion:EFNB3 \| regulation of immune effector process:TNFSF13 \| telomere maintenance via telomerase:WRAP53 \| RNA-dependent DNA biosynthetic process:WRAP53 \| positive regulation of cell cycle process:TP53 \| telomere maintenance via telomere lengthening:WRAP53 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| positive regulation of excitatory postsynaptic potential:DLG4 \| B cell mediated immunity:TNFSF13 \| exploration behavior:DLG4 \| positive regulation of adaptive immune response:TNFSF13 \| regulation of cell cycle G2/M phase transition:TP53 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:DLG4 \| interaction with host:EFNB3 \| nucleocytoplasmic transport:EIF5A,TP53 \| protein localization to synapse:DLG4 \| nuclear transport:EIF5A,TP53 \| positive regulation of DNA metabolic process:TNFSF13,WRAP53 \| chemical synaptic transmission, postsynaptic:DLG4 \| modulation of excitatory postsynaptic potential:DLG4 \| regulation of glutamate receptor signaling pathway:DLG4 \| negative regulation of DNA biosynthetic process:TP53 \| positive regulation of telomerase activity:WRAP53 \| positive regulation of reactive oxygen species metabolic process:EIF5A,TP53 \| protein stabilization:ATP1B2 \| positive regulation of cell cycle:TP53 \| negative regulation of growth:TP53 \| peptidyl-tyrosine phosphorylation:TP53 \| regulation of lymphocyte mediated immunity:TNFSF13 \| peptidyl-tyrosine modification:TP53 \| regulation of neurotransmitter receptor activity:DLG4 \| regulation of DNA metabolic process:TNFSF13,TP53,WRAP53 \| negative regulation of neurogenesis:EFNB3 \| regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway:TP53 \| cell cycle G2/M phase transition:TP53 \| protein N-linked glycosylation via asparagine:ASGR1 \| regulation of postsynaptic membrane potential:DLG4 \| synapse organization:DLG4 \| peptidyl-asparagine modification:ASGR1 \| positive regulation of cellular amide metabolic process:EIF5A \| neuromuscular process controlling balance:DLG4 \| regulation of mitotic cell cycle phase transition:TP53 \| negative regulation of nervous system development:EFNB3 \| regulation of adaptive immune response:TNFSF13 \| negative regulation of axonogenesis:EFNB3 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| receptor-mediated endocytosis:ASGR1,DLG4 \| regulation of lymphocyte apoptotic process:TP53 \| mitochondrial outer membrane permeabilization:TP53 \| protein localization to nucleoplasm:WRAP53 \| regulation of protein stability:ATP1B2 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| telomere maintenance:WRAP53 \| negative regulation of cell development:EFNB3 \| regulation of cell cycle phase transition:TP53 \| aging:EIF5A,TP53 \| negative regulation of cell growth:TP53 \| protein export from nucleus:EIF5A,TP53 \| positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress:TP53 \| protein localization to nucleus:CTDNEP1,WRAP53 \| positive regulation of mitochondrial membrane permeability involved in apoptotic process:TP53 \| telomere organization:WRAP53 \| mitochondrial outer membrane permeabilization involved in programmed cell death:TP53 \| glycerolipid metabolic process:CTDNEP1 \| positive regulation of mitochondrial membrane permeability:TP53 \| positive regulation of DNA biosynthetic process:WRAP53 \| regulation of mitochondrial membrane permeability involved in apoptotic process:TP53 \| positive regulation of membrane permeability:TP53 \| regulation of DNA-templated transcription in response to stress:TP53 \| mRNA catabolic process:TNFSF13 \| lymphocyte apoptotic process:TP53 \| triglyceride metabolic process:CTDNEP1 \| protein N-linked glycosylation:ASGR1 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| positive regulation of protein complex assembly:TP53 \| locomotory behavior:DLG4,EFNB3 \| cellular response to UV:TP53 \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| negative regulation of neuron differentiation:EFNB3 \| protein localization to chromosome:WRAP53 \| nuclear export:EIF5A,TP53 \| glutamate receptor signaling pathway:DLG4 \| regulation of mitochondrial membrane permeability:TP53 \| negative regulation of cell morphogenesis involved in differentiation:EFNB3 \| execution phase of apoptosis:TP53 \| regulation of leukocyte apoptotic process:TP53 \| mitochondrial membrane organization:TP53 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| acylglycerol metabolic process:CTDNEP1 \| potassium ion homeostasis:ATP1B2 \| neutral lipid metabolic process:CTDNEP1 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| DNA geometric change:TP53 \| regulation of receptor internalization:DLG4 \| cellular response to extracellular stimulus:ASGR1,TP53 \| regulation of membrane permeability:TP53 \| ephrin receptor signaling pathway:EFNB3 \| regulation of fibroblast proliferation:TP53 \| regulation of ion transmembrane transporter activity:ATP1B2,DLG4 \| fibroblast proliferation:TP53 \| regulation of apoptotic signaling pathway:TNFSF12,TP53 \| regulation of transmembrane transporter activity:ATP1B2,DLG4 \| RNA catabolic process:TNFSF13 \| negative regulation of hydrolase activity:TP53 \| regulation of endocytosis:DLG4 \| neuromuscular process:DLG4 \| regulation of membrane potential:ATP1B2,DLG4 \| negative regulation of receptor-mediated endocytosis:DLG4 \| autophagy:TP53 \| process utilizing autophagic mechanism:TP53 \| cell aging:TP53 \| leukocyte apoptotic process:TP53 \| regulation of transporter activity:ATP1B2,DLG4 \| vocalization behavior:DLG4 \| RNA localization to Cajal body:WRAP53 \| telomerase RNA localization to Cajal body:WRAP53 \| telomerase RNA localization:WRAP53 \| RNA localization to nucleus:WRAP53 \| regulation of canonical Wnt signaling pathway:CTDNEP1 \| cellular response to light stimulus:TP53 \| axonogenesis:EFNB3	0.00381504	0.0325702	0.0425047724992186	0.0211499	0.0296459	0.322656806149853	-0.0246548	0.0634005	0.156536739372855	-0.0301257	0.0358273	0.397370370907602	-0.0196194	0.0390792	0.21061673929699	-0.0472365	0.0714017	0.293736373834104	0.0388526	0.0267209	0.835367619934282	0.0266889	0.0307795	0.413366568053205	0.0614261	0.0500448	0.657435209691273	0.0117172	0.0193249	0.264162463579088	0.00482788	0.0241543	0.0749061421418301	0.0180455	0.0309547	0.251875570770743	-0.0781964	0.0190379	4.39779562975847	-0.110668	0.0200713	7.45432926776887	-0.023399	0.0321097	0.331453815351436	-0.0167603	0.0184607	0.438973789209112	-0.0392005	0.0227488	1.07132307401198	0.0202153	0.0293672	0.308719538679266	0.00402102	0.011095	0.144456010908661	-0.00107115	0.0143835	0.0265784039631467	0.0101127	0.0172944	0.252803450409147	-0.0364524	0.0537913	0.302714847880884	0.0634079	0.06795	0.454801780132632	-0.209589	0.0875145	1.77227265158883
rs9989479:7418109:A:G		17	7418109	17p13.1	G	A	0.965	36	TESTO ALL	7643	7.44408612534746	0.963836320816433	0.0427826	POLR2A (0.18 kb, near gene/Downstream gene/MODIFIER); ZBTB4 (31 kb); SLC35G6 (32 kb); TNFSF12 (34 kb); TNFSF12-TNFSF13 (34 kb); TNFSF13 (43 kb); SENP3 (47 kb); SENP3-EIF4A1 (48 kb)	NA	- \| ALOX12 \| ATP1B2 \| AURKB \| C17orf81 \| CD68 \| CHRNB1 \| CTDNEP1 \| EFNB3 \| EIF4A1 \| EIF5A \| FGF11 \| KCNAB3 \| LSMD1 \| MPDU1 \| NLGN2 \| PLSCR3 \| POLR2A \| RP11-186B7.4 \| SENP3 \| SENP3-EIF4A1 \| SNORA48 \| SOX15 \| SPEM1 \| TMEM102 \| TMEM88 \| TNFSF12 \| TNFSF12-TNFSF13 \| TNFSF13 \| TRAPPC1 \| ZBTB4		Herpes simplex infection:POLR2A \| Intestinal immune network for IgA production:TNFSF13 \| Rheumatoid arthritis:TNFSF13 \| Cell adhesion molecules (CAMs):NLGN2 \| Epstein-Barr virus infection:POLR2A \| Huntington disease:POLR2A	TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13 \| TP53 Regulates Transcription of DNA Repair Genes:POLR2A \| TNFR2 non-canonical NF-kB pathway:TNFSF12,TNFSF12-TNFSF13,TNFSF13 \| MicroRNA (miRNA) biogenesis:POLR2A \| Transcriptional regulation of pluripotent stem cells:POLR2A \| Infectious disease:POLR2A \| Influenza Infection:POLR2A \| Transcriptional Regulation by TP53:POLR2A \| HIV Transcription Elongation:POLR2A \| Formation of HIV-1 elongation complex containing HIV-1 Tat:POLR2A \| Tat-mediated elongation of the HIV-1 transcript:POLR2A \| Neurexins and neuroligins:NLGN2 \| Transcription of the HIV genome:POLR2A \| Asparagine N-linked glycosylation:MPDU1,TRAPPC1 \| Formation of HIV elongation complex in the absence of HIV Tat:POLR2A \| RNA Polymerase II Pre-transcription Events:POLR2A \| Formation of the Early Elongation Complex:POLR2A \| Formation of the HIV-1 Early Elongation Complex:POLR2A \| Regulation of mRNA stability by proteins that bind AU-rich elements:TNFSF13 \| Pausing and recovery of Tat-mediated HIV elongation:POLR2A \| Tat-mediated HIV elongation arrest and recovery:POLR2A \| Protein-protein interactions at synapses:NLGN2 \| Neutrophil degranulation:TRAPPC1 \| RAB GEFs exchange GTP for GDP on RABs:TRAPPC1 \| Formation of RNA Pol II elongation complex :POLR2A \| RNA Polymerase II Transcription Elongation:POLR2A \| HIV elongation arrest and recovery:POLR2A \| Pausing and recovery of HIV elongation:POLR2A \| Transcriptional regulation by small RNAs:POLR2A	Kawasaki disease:TNFSF13 \| lymphadenitis:TNFSF13 \| lymph node disease:TNFSF13 \| lymphatic system disease:TNFSF13 \| hypotrichosis:TNFSF13 \| urinary system disease:TNFSF12,TNFSF13 \| multiple myeloma:TNFSF13 \| myeloma:TNFSF13 \| bone marrow cancer:TNFSF13 \| hair disease:TNFSF13 \| proteinuria:TNFSF12 \| kidney disease:TNFSF12,TNFSF13 \| purpura:TNFSF13 \| alopecia:TNFSF13 \| collagen disease:TNFSF12,TNFSF13 \| nephritis:TNFSF12,TNFSF13 \| hemorrhagic disease:TNFSF13 \| blood coagulation disease:TNFSF13 \| rheumatic disease:TNFSF12,TNFSF13 \| systemic scleroderma:TNFSF12,TNFSF13 \| scleroderma:TNFSF12,TNFSF13 \| integumentary system disease:TNFSF12,TNFSF13 \| hematopoietic system disease:TNFSF13 \| colon carcinoma:TNFSF13 \| intestinal cancer:TNFSF13 \| interstitial lung disease:TNFSF12 \| myopathy:TNFSF12,TNFSF13 \| muscle tissue disease:TNFSF12,TNFSF13 \| Sjogren's syndrome:TNFSF13 \| muscular disease:TNFSF12,TNFSF13 \| alopecia areata:TNFSF13 \| non-small cell lung carcinoma:EIF5A,TNFSF13 \| colon cancer:TNFSF13 \| colorectal cancer:TNFSF13 \| large intestine cancer:TNFSF13 \| myositis:TNFSF13 \| lower respiratory tract disease:TNFSF12 \| lung adenocarcinoma:EIF5A \| cardiomyopathy:TNFSF12 \| liver cirrhosis:TNFSF13 \| lung disease:TNFSF12 \| chronic lymphocytic leukemia:TNFSF13 \| dilated cardiomyopathy:TNFSF12 \| acute myocardial infarction:TNFSF12 \| coronary artery disease:TNFSF12	positive regulation of cell activation:SOX15,TNFSF13 \| lymphocyte mediated immunity:TNFSF13 \| tumor necrosis factor-mediated signaling pathway:TNFSF12,TNFSF13 \| positive regulation of lymphocyte activation:TNFSF13 \| positive regulation of leukocyte activation:TNFSF13 \| regulation of leukocyte activation:TNFSF13 \| regulation of lymphocyte activation:TNFSF13 \| postsynaptic membrane organization:CHRNB1,NLGN2 \| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| cellular response to tumor necrosis factor:TNFSF12,TNFSF13 \| locomotory exploration behavior:NLGN2 \| response to tumor necrosis factor:TNFSF12,TNFSF13 \| regulation of immune effector process:TNFSF13 \| positive regulation of cell cycle process:SOX15 \| adaptive immune response:TNFSF13 \| immunoglobulin mediated immune response:TNFSF13 \| positive regulation of excitatory postsynaptic potential:NLGN2 \| B cell mediated immunity:TNFSF13 \| exploration behavior:NLGN2 \| positive regulation of adaptive immune response:TNFSF13 \| regulation of neurotransmitter receptor activity:NLGN2 \| positive regulation of translation:EIF5A \| excitatory postsynaptic potential:CHRNB1,NLGN2 \| nucleocytoplasmic transport:EIF5A \| protein localization to synapse:NLGN2 \| nuclear transport:EIF5A \| positive regulation of DNA metabolic process:TNFSF13 \| chemical synaptic transmission, postsynaptic:CHRNB1,NLGN2 \| modulation of excitatory postsynaptic potential:NLGN2 \| regulation of glutamate receptor signaling pathway:NLGN2 \| positive regulation of reactive oxygen species metabolic process:EIF5A \| positive regulation of cell cycle:SOX15 \| regulation of lymphocyte mediated immunity:TNFSF13 \| regulation of DNA metabolic process:TNFSF13 \| negative regulation of translation:POLR2A \| DNA-templated transcription, elongation:POLR2A \| regulation of postsynaptic membrane potential:CHRNB1,NLGN2 \| synapse organization:CHRNB1,NLGN2 \| positive regulation of cellular amide metabolic process:EIF5A \| negative regulation of cellular amide metabolic process:POLR2A \| neuromuscular process controlling balance:NLGN2 \| regulation of adaptive immune response:TNFSF13 \| positive regulation of lymphocyte mediated immunity:TNFSF13 \| receptor-mediated endocytosis:NLGN2 \| postsynaptic membrane assembly:NLGN2 \| positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| aging:EIF5A \| membrane assembly:NLGN2 \| protein export from nucleus:EIF5A \| presynaptic membrane organization:NLGN2 \| protein localization to nucleus:CTDNEP1 \| glycerolipid metabolic process:CTDNEP1 \| mRNA catabolic process:TNFSF13 \| triglyceride metabolic process:CTDNEP1 \| membrane biogenesis:NLGN2 \| positive regulation of B cell mediated immunity:TNFSF13 \| positive regulation of immunoglobulin mediated immune response:TNFSF13 \| somatic stem cell population maintenance:POLR2A \| locomotory behavior:NLGN2 \| regulation of viral process:POLR2A \| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains:TNFSF13 \| nuclear export:EIF5A \| postsynapse assembly:NLGN2 \| glutamate receptor signaling pathway:NLGN2 \| regulation of leukocyte mediated immunity:TNFSF13 \| immunoglobulin production:TNFSF13 \| acylglycerol metabolic process:CTDNEP1 \| neuron cell-cell adhesion:NLGN2 \| neutral lipid metabolic process:CTDNEP1 \| positive regulation of leukocyte mediated immunity:TNFSF13 \| regulation of synapse assembly:NLGN2 \| regulation of symbiosis, encompassing mutualism through parasitism:POLR2A \| regulation of ion transmembrane transporter activity:NLGN2 \| regulation of apoptotic signaling pathway:TNFSF12 \| regulation of transmembrane transporter activity:NLGN2 \| RNA catabolic process:TNFSF13 \| neuromuscular process:NLGN2 \| regulation of G0 to G1 transition:SOX15 \| regulation of membrane potential:CHRNB1,NLGN2 \| presynapse assembly:NLGN2 \| transcription elongation from RNA polymerase II promoter:POLR2A \| synaptic vesicle recycling:NLGN2 \| regulation of striated muscle tissue development:SOX15 \| regulation of transporter activity:NLGN2 \| G0 to G1 transition:SOX15 \| positive regulation of viral process:POLR2A \| regulation of muscle tissue development:SOX15 \| regulation of canonical Wnt signaling pathway:CTDNEP1 \| DNA-templated transcription, termination:POLR2A \| regulation of gene silencing by miRNA:POLR2A \| regulation of posttranscriptional gene silencing:POLR2A \| regulation of gene silencing by RNA:POLR2A	0.029008	0.047984	0.263162255632327	0.0214551	0.0442844	0.201956686564625				0.103229	0.0527472	1.29691764952094	0.0750574	0.0583396	0.702309506753444	0.139506	0.102857	0.75588870988744	0.0365163	0.0393818	0.451105938732763	0.0222205	0.0459819	0.201349354554731	0.0528119	0.0722122	0.332722668340382				-0.0261426	0.0341182	0.353073082830201	0.125669	0.0429711	2.46218719909526	0.148523	0.0269573	7.44408612534746	0.149382	0.0284521	6.81855088482657	0.137723	0.0451144	2.64442780606973	0.0524125	0.0262194	1.34095230642323	0.0854887	0.0320403	2.11765650324144	0.00848387	0.0421322	0.0755062047678788	0.00714222	0.0156187	0.188783032497795	0.00511144	0.0204536	0.0954678381771703	0.00869969	0.0240614	0.144069761469442	0.0528745	0.0789569	0.298302522974151	0.0221044	0.101421	0.0822298982486436	0.112505	0.125654	0.430729115850472
rs5895733:143959477:CAT:C		8	143959477	8q24.3	C	CAT	0.846	0	ANDRO ALL	2070	7.38110611479282	0.655915700483092		GML (0 kb, intron/Intron/MODIFIER); CYP11B1 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); ZNHIT1P1 (19 kb); CYP11B2 (32 kb)	0.522 Estrone levels // 0.498 Systolic blood pressure // 0.444 Diastolic blood pressure // 0.331 Mean arterial pressure // 0.319 Plasma androstenedione levels in resected early stage-receptor positive breast cancer	C8orf31 \| C8orf55 \| C8ORF55 \| CTD-2292P10.4 \| GML \| JRK \| LY6D \| LY6E \| LY6K \| LYNX1 \| LYPD2 \| NAPRT1 \| PSCA \| RP11-273G15.2 \| RP11-706C16.7 \| RP13-582O9.5 \| SLURP1 \| THEM6 \| unnamed \| ZNF623		Steroid hormone biosynthesis:CYP11B1,CYP11B2 \| Cortisol synthesis and secretion:CYP11B1	Post-translational modification: synthesis of GPI-anchored proteins:LY6D,LY6E,LYPD2 \| Cytochrome P450 - arranged by substrate type:CYP11B1,CYP11B2 \| Endogenous sterols:CYP11B1,CYP11B2 \| Metabolism of steroid hormones:CYP11B1,CYP11B2 \| Metabolic disorders of biological oxidation enzymes:CYP11B1,CYP11B2 \| Phase I - Functionalization of compounds:CYP11B1,CYP11B2 \| Diseases of metabolism:CYP11B1,CYP11B2 \| Metabolism of steroids:CYP11B1,CYP11B2 \| Biological oxidations:CYP11B1,CYP11B2	endocrine system disease:CYP11B1,CYP11B2 \| glucocorticoid-remediable aldosteronism:CYP11B1,CYP11B2 \| hyperaldosteronism:CYP11B1,CYP11B2 \| adrenal gland hyperfunction:CYP11B1,CYP11B2 \| adrenal cortex disease:CYP11B1,CYP11B2 \| adrenal gland disease:CYP11B1,CYP11B2 \| hemorrhagic disease:CYP11B2 \| blood coagulation disease:CYP11B2 \| hyperandrogenism:CYP11B1 \| polycystic ovary syndrome:CYP11B1 \| hematopoietic system disease:CYP11B2 \| sex differentiation disease:CYP11B1 \| essential hypertension:CYP11B2 \| gonadal disease:CYP11B1 \| cell type benign neoplasm:CYP11B1,CYP11B2 \| pulmonary edema:CYP11B2 \| lower respiratory tract disease:CYP11B2 \| myopathy:CYP11B2 \| muscle tissue disease:CYP11B2 \| adenoma:CYP11B1,CYP11B2 \| cardiomyopathy:CYP11B2 \| muscular disease:CYP11B2 \| lung disease:CYP11B2	C-terminal protein lipidation:LY6D,LY6E,LYPD2 \| C-terminal protein amino acid modification:LY6D,LY6E,LYPD2 \| C21-steroid hormone biosynthetic process:CYP11B1,CYP11B2 \| protein lipidation:LY6D,LY6E,LYPD2 \| lipoprotein biosynthetic process:LY6D,LY6E,LYPD2 \| C21-steroid hormone metabolic process:CYP11B1,CYP11B2 \| lipoprotein metabolic process:LY6D,LY6E,LYPD2 \| hormone biosynthetic process:CYP11B1,CYP11B2 \| mineralocorticoid biosynthetic process:CYP11B1,CYP11B2 \| mineralocorticoid metabolic process:CYP11B1,CYP11B2 \| response to potassium ion:CYP11B1,CYP11B2 \| aldehyde biosynthetic process:CYP11B1,CYP11B2 \| glucocorticoid biosynthetic process:CYP11B1,CYP11B2 \| glucocorticoid metabolic process:CYP11B1,CYP11B2 \| post-translational protein modification:LY6D,LY6E,LYPD2 \| cellular hormone metabolic process:CYP11B1,CYP11B2 \| ketone biosynthetic process:CYP11B1,CYP11B2 \| sterol metabolic process:CYP11B1,CYP11B2 \| steroid biosynthetic process:CYP11B1,CYP11B2 \| hormone metabolic process:CYP11B1,CYP11B2 \| cellular aldehyde metabolic process:CYP11B1,CYP11B2 \| steroid metabolic process:CYP11B1,CYP11B2 \| regulation of neurotransmitter receptor activity:LYNX1 \| cellular response to metal ion:CYP11B1,CYP11B2 \| regulation of blood pressure:CYP11B1,CYP11B2 \| cellular response to inorganic substance:CYP11B1,CYP11B2 \| regulation of hormone levels:CYP11B1,CYP11B2 \| organic hydroxy compound metabolic process:CYP11B1,CYP11B2 \| organic hydroxy compound biosynthetic process:CYP11B1,CYP11B2 \| regulation of G1/S transition of mitotic cell cycle:GML \| cellular ketone metabolic process:CYP11B1,CYP11B2 \| regulation of cell cycle G1/S phase transition:GML \| response to metal ion:CYP11B1,CYP11B2 \| G1/S transition of mitotic cell cycle:GML \| positive regulation of cell cycle process:GML \| cell cycle G1/S phase transition:GML \| potassium ion homeostasis:CYP11B2 \| positive regulation of cell cycle:GML	-0.0165915	0.0188653	0.421077845975903	0.0150825	0.0170332	0.424745168004851	-0.0399719	0.0372668	0.547515877874784	-0.032301	0.0207471	0.922090926773041	-0.0245132	0.0224477	0.560632564000853	-0.0447192	0.041961	0.542257341933799	-0.0846384	0.0153757	7.38110611479282	-0.0660831	0.0175999	3.74263826372474	-0.117467	0.0291232	4.21515527934065	-0.0123327	0.0113625	0.556345932387095				-0.00135158	0.0181798	0.0265322361151812	-0.0397388	0.0111689	3.42745365982439	-0.0159198	0.0118478	0.747030525776429	-0.0736223	0.0188187	4.03875740679219	-0.0190427	0.0108892	1.09511898922089	-0.0114265	0.0134152	0.404120357427449				0.00143361	0.00651144	0.0831561511171874	-0.00563804	0.00843626	0.297625477367593	0.0105215	0.0101508	0.522933759399013	0.0474997	0.0310694	0.89802278348091	0.00420185	0.0390025	0.0389473818973198	0.124764	0.0512047	1.82152954548062
X:7061182:C:CT		23	7061182	Xp22.31	CT	C	0.985	0	DHEAS WOMEN	3353	7.30810993426542	0.616185058156875	1.00809	HDHD1 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); MIR4767 (4.7 kb, near gene/Upstream gene/MODIFIER); STS (76 kb)	NA			Steroid hormone biosynthesis:STS	Gamma carboxylation, hypusine formation and arylsulfatase activation:STS	polycystic ovary syndrome:STS \| reproductive system disease:STS \| neuropathy:STS \| cell type benign neoplasm:STS \| astrocytoma:STS \| brain cancer:STS \| specific developmental disorder:STS \| endocrine organ benign neoplasm:STS \| female reproductive organ cancer:STS \| adenoma:STS \| glioblastoma multiforme:STS	steroid catabolic process:STS \| steroid metabolic process:STS \| post-translational protein modification:STS	-0.0313718	0.0270134	0.609706215358433	-0.01635994	0.0220716	0.338481674728673	-0.11673	0.0693649	1.03429324901276	-0.0261462	0.0297164	0.42131495662131	-0.0131117	0.029096	0.18553664282379	-0.0883462	0.0779756	0.589055827241282	-0.0769634	0.022111	3.29213102992007	-0.0895806	0.022788	4.05129760103381	-0.039247	0.054735	0.324599310507705	0.0903748	0.0167863	7.13721707139292	0.0501323	0.01843	2.1853935269343	0.181824	0.0333364	7.30810993426542	0.00121752	0.0164045	0.0264860731745856	-0.00672253	0.0153385	0.179677007627999				0.0287434	0.0158456	1.15687503003852	0.0372387	0.0174141	1.48835322690797	0.0128585	0.0320793	0.162069563305516							-0.0150871	0.018705	0.376847919721969	-0.0598866	0.0446122	0.745630801080276	-0.0465828	0.0505604	0.447272178931714	-0.1031146	0.0961946	0.546485965691725

References of known loci
[2] Bolton et al. (2014)
[3] Chen et al. (2013)
[4] Eriksson et al. (2018)
[5] Jin et al. (2012)
[7] Ohlsson et al. (2011)
[8] Prins et al. (2017)
[9] Ruth et al. (2016)
[10] Zhai et al. (2011)
[11] Dudenkov et al. (2017)

100

Supplemental Table 3: Look-up of cis and trans eQTLs. The table is restricted to the 22 lead SNPs, for which cis or trans eQTLs were found. Chromosomal positions are as reported in the original eQTL study. NA: Information not available

SNP	chromosome of SNP	position of SNP	r2 SNP & eQTL-SNP	distance SNP & GWAS-SNP	reference LD calculation	eQTL-SNP	eQTL-gene	eQTL-gene probe ID	cis/trans	eQTL tissue	eQTL p-value or q-value	eQTL statistic type	chromosome of eQTL-SNP	position of eQTL-SNP	choromosome of eQTL-gene	transcription start position eQTL-gene	transcription end position eQTL-gene	distance eQTL-SNP eQTL-gene	PMID / doi / Reference
7:99025328:C:T	7	99025328	0.306705	314721	ref1: TG phase3 v5	rs12538820	-	40317	cis	blood	3.11547E-28	pval	7	99340049	7	99806651	99806652	466602	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.741559	265816	ref1: TG phase3 v5	rs118168183	-	40317	cis	blood	3.34844E-6	pval	7	99291144	7	99806651	99806652	515507	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	AP4M1	ILMN_1779512	cis	PBMC and Whole Blood	6.31856797397087E-10	pval	7	98965615	7	99699130	99704802	733515	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.888	307620	ref1: TG phase3 v5	rs45446698	AP4M1	ILMN_1779512	cis	PBMC and Whole Blood	0.00129865318547675	pval	7	99332948	7	99699130	99704802	366182	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	AP4M1	ILMN_1779512	cis	PBMC	1.11568354646807E-6	pval	7	98965615	7	99699130	99704802	733515	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.888	307620	ref1: TG phase3 v5	rs45446698	AP4M1	ILMN_1779512	cis	PBMC	0.00338422506014749	pval	7	99332948	7	99699130	99704802	366182	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	AP4M1	ILMN_1779512	cis	Whole Blood	3.75818543271121E-5	pval	7	98965615	7	99699130	99704802	733515	LIFE Adult (in preparation**)
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	AP4M1	37052	cis	blood	1.17717E-8	pval	7	98965615	7	99704574	99704575	738959	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.336434	494667	ref1: TG phase3 v5	rs11761383	AP4M1	37052	cis	blood	3.02312E-7	pval	7	99519995	7	99704574	99704575	184579	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.329462	7071	ref1: TG phase3 v5	rs11973173	ARPC1A	NA	cis	Thyroid	2.06981E-9	pval	7	99032399	7	98923521	98963880	68519	29022597
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	rs10226310	ARPC1A	NA	cis	Thyroid	1.07886E-6	pval	7	99118320	7	98923521	98963880	154440	29022597
7:99025328:C:T	7	99025328	0.33252	182	ref1: TG phase3 v5	7:99025510	ARPC1A	3014714	cis	Whole_Blood	5.65457540687621E-6	pval	7	99025510	7	98971875	98992402	33108	28122634
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	7:99118320	ARPC1A	3014714	cis	Whole_Blood	1.59477713364217E-5	pval	7	99118320	7	98971875	98992402	125918	28122634
7:99025328:C:T	7	99025328	0.312176	137359	ref1: TG phase3 v5	rs10265385	ARPC1A	27782	cis	blood	5.93196E-6	pval	7	99162687	7	98963576	98963577	199110	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.312176	171850	ref1: TG phase3 v5	rs10240199	ARPC1A	27782	cis	blood	6.31974E-6	pval	7	99197178	7	98963576	98963577	233601	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.33252	182	ref1: TG phase3 v5	rs28419687	ARPC1B	ILMN_1804530	cis	PBMC and Whole Blood	1.01643886576673E-32	pval	7	99025510	7	98972329	98992402	33108	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.8546	105506	ref1: TG phase3 v5	rs34670419	ARPC1B	ILMN_1804530	cis	PBMC and Whole Blood	4.71923772735927E-4	pval	7	99130834	7	98972329	98992402	138432	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.33252	182	ref1: TG phase3 v5	rs28419687	ARPC1B	ILMN_1804530	cis	PBMC	1.9000492211475E-22	pval	7	99025510	7	98972329	98992402	33108	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.8546	105506	ref1: TG phase3 v5	rs34670419	ARPC1B	ILMN_1804530	cis	PBMC	4.40656422610024E-4	pval	7	99130834	7	98972329	98992402	138432	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.329462	7071	ref1: TG phase3 v5	rs11973173	ARPC1B	NA	cis	Thyroid	3.1069E-21	pval	7	99032399	7	98971872	98992424	39975	29022597
7:99025328:C:T	7	99025328	0.471891	116045	ref1: TG phase3 v5	rs10278040	ARPC1B	NA	cis	Thyroid	1.69048E-11	pval	7	99141373	7	98971872	98992424	148949	29022597
7:99025328:C:T	7	99025328	0.384652	138623	ref1: TG phase3 v5	rs75293196	ARPC1B	ILMN_1804530	cis	Whole Blood	2.18139325332341E-12	pval	7	99163951	7	98972329	98992402	171549	LIFE Adult (in preparation**)
7:99025328:C:T	7	99025328	0.471891	116045	ref1: TG phase3 v5	rs10278040	ARPC1B	ILMN_1804530	cis	Whole Blood	0.00208459177764884	pval	7	99141373	7	98972329	98992402	148971	LIFE Adult (in preparation**)
7:99025328:C:T	7	99025328	0.33252	182	ref1: TG phase3 v5	7:99025510	ARPC1B	3014714	cis	Whole_Blood	5.65457540687621E-6	pval	7	99025510	7	98971875	98992402	33108	28122634
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	7:99118320	ARPC1B	3014714	cis	Whole_Blood	1.59477713364217E-5	pval	7	99118320	7	98971875	98992402	125918	28122634
7:99025328:C:T	7	99025328	0.33252	182	ref1: TG phase3 v5	rs28419687	ARPC1B	2219	cis	blood	4.75917E-23	pval	7	99025510	7	98988833	98988834	36676	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.471891	116045	ref1: TG phase3 v5	rs10278040	ARPC1B	2219	cis	blood	6.79265E-7	pval	7	99141373	7	98988833	98988834	152539	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	ATP5J2	NA	cis	Artery_Tibial	8.17151E-5	pval	7	98965615	7	99046098	99063954	80483	29022597
7:99025328:C:T	7	99025328	0.329462	34622	ref1: TG phase3 v5	rs28627543	ATP5J2	NA	cis	Cells_Transformed_fibroblasts	1.50177E-5	pval	7	99059950	7	99046098	99063954	0	29022597
7:99025328:C:T	7	99025328	0.341977	76175	ref1: TG phase3 v5	rs66509940	ATP5J2	NA	cis	Cells_Transformed_fibroblasts	8.26313E-5	pval	7	99101503	7	99046098	99063954	37549	29022597
7:99025328:C:T	7	99025328	0.33252	182	ref1: TG phase3 v5	rs28419687	ATP5J2	ILMN_2310621	cis	PBMC and Whole Blood	1.52673995881937E-4	pval	7	99025510	7	99055785	99063808	30275	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.471891	116045	ref1: TG phase3 v5	rs10278040	ATP5J2	ILMN_2310621	cis	PBMC and Whole Blood	0.00113548698323265	pval	7	99141373	7	99055785	99063808	77565	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.341977	81346	ref1: TG phase3 v5	rs9656060	ATP5J2	ILMN_2310621	cis	PBMC	1.25456064387445E-4	pval	7	99106674	7	99055785	99063808	42866	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.471891	116045	ref1: TG phase3 v5	rs10278040	ATP5J2	ILMN_2310621	cis	PBMC	2.36136879696212E-4	pval	7	99141373	7	99055785	99063808	77565	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	ATP5J2	37356	cis	blood	7.18275E-6	pval	7	98965615	7	99055890	99055891	90275	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.341977	76175	ref1: TG phase3 v5	rs66509940	BUD31	ILMN_1710697	cis	PBMC and Whole Blood	2.11368292588021E-4	pval	7	99101503	7	99006601	99017238	84265	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	rs10226310	BUD31	ILMN_1710697	cis	PBMC and Whole Blood	7.50645032117299E-4	pval	7	99118320	7	99006601	99017238	101082	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.388583	692	ref1: TG phase3 v5	rs190256229	BUD31	ILMN_1710697	cis	Whole Blood	0.00153379699276312	pval	7	99024636	7	99006601	99017238	7398	LIFE Adult (in preparation**)
7:99025328:C:T	7	99025328	0.388583	28488	ref1: TG phase3 v5	rs12535424	BUD31	ILMN_1710697	cis	Whole Blood	0.0026721136968945	pval	7	99053816	7	99006601	99017238	36578	LIFE Adult (in preparation**)
7:99025328:C:T	7	99025328	0.384652	170745	ref1: TG phase3 v5	7:99196073	BUD31	3014742	cis	Whole_Blood	1.44410908441612E-14	pval	7	99196073	7	99006285	99017235	178838	28122634
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	7:99118320	BUD31	3014742	cis	Whole_Blood	8.39653301579873E-14	pval	7	99118320	7	99006285	99017235	101085	28122634
7:99025328:C:T	7	99025328	0.341977	90349	ref1: TG phase3 v5	rs12533251	BUD31	4490706	cis	blood	0.00347345139792154	pval	7	99115677	7	99006591	99017239	98438	24013639
7:99025328:C:T	7	99025328	0.384652	170745	ref1: TG phase3 v5	rs10273424	BUD31	4490706	cis	blood	0.00347568274925589	pval	7	99196073	7	99006591	99017239	178834	24013639
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	BUD31	17940	cis	blood	1.37358E-6	pval	7	98965615	7	99015162	99015163	49547	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.341977	81346	ref1: TG phase3 v5	rs9656060	CNPY4	NA	cis	Adipose_Subcutaneous	1.35708E-5	pval	7	99106674	7	99717236	99723134	610562	29022597
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	rs10226310	CNPY4	NA	cis	Adipose_Subcutaneous	3.51273E-5	pval	7	99118320	7	99717236	99723134	598916	29022597
7:99025328:C:T	7	99025328	0.306705	314721	ref1: TG phase3 v5	rs12538820	CNPY4	NA	cis	Adipose_Visceral_Omentum	6.49838E-6	pval	7	99340049	7	99717236	99723134	377187	29022597
7:99025328:C:T	7	99025328	0.388583	28488	ref1: TG phase3 v5	rs12535424	CNPY4	NA	cis	Adipose_Visceral_Omentum	5.59958E-5	pval	7	99053816	7	99717236	99723134	663420	29022597
7:99025328:C:T	7	99025328	0.388583	28488	ref1: TG phase3 v5	rs12535424	CNPY4	NA	cis	Breast_Mammary_Tissue	3.40267E-5	pval	7	99053816	7	99717236	99723134	663420	29022597
7:99025328:C:T	7	99025328	0.341977	81346	ref1: TG phase3 v5	rs9656060	CNPY4	NA	cis	Esophagus_Muscularis	1.16456E-5	pval	7	99106674	7	99717236	99723134	610562	29022597
7:99025328:C:T	7	99025328	0.341977	90349	ref1: TG phase3 v5	rs12533251	CNPY4	NA	cis	Esophagus_Muscularis	1.88564E-5	pval	7	99115677	7	99717236	99723134	601559	29022597
7:99025328:C:T	7	99025328	0.33252	304	ref1: TG phase3 v5	rs11982726	CNPY4	ILMN_2252408	cis	PBMC and Whole Blood	1.33300139421609E-45	pval	7	99025632	7	99717265	99723126	691633	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.888	307620	ref1: TG phase3 v5	rs45446698	CNPY4	ILMN_2252408	cis	PBMC and Whole Blood	3.12129773639807E-6	pval	7	99332948	7	99717265	99723126	384317	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.33252	304	ref1: TG phase3 v5	rs11982726	CNPY4	ILMN_2252408	cis	PBMC	6.38510158074329E-31	pval	7	99025632	7	99717265	99723126	691633	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.888	307620	ref1: TG phase3 v5	rs45446698	CNPY4	ILMN_2252408	cis	PBMC	3.72634370477251E-4	pval	7	99332948	7	99717265	99723126	384317	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.33252	304	ref1: TG phase3 v5	rs11982726	CNPY4	ILMN_2252408	cis	Whole Blood	3.2306131300217E-15	pval	7	99025632	7	99717265	99723126	691633	LIFE Adult (in preparation**)
7:99025328:C:T	7	99025328	0.888	307620	ref1: TG phase3 v5	rs45446698	CNPY4	ILMN_2252408	cis	Whole Blood	0.00270158452599696	pval	7	99332948	7	99717265	99723126	384317	LIFE Adult (in preparation**)
7:99025328:C:T	7	99025328	0.33252	304	ref1: TG phase3 v5	7:99025632	CNPY4	3015276	cis	Whole_Blood	4.21987901687157E-6	pval	7	99025632	7	99717265	99723126	691633	28122634
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	7:99118320	CNPY4	3015276	cis	Whole_Blood	2.66747280212458E-5	pval	7	99118320	7	99717265	99723126	598945	28122634
7:99025328:C:T	7	99025328	0.306705	314721	ref1: TG phase3 v5	rs12538820	CNPY4	41565	cis	blood	1.93923E-28	pval	7	99340049	7	99722964	99722965	382915	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	rs10226310	CNPY4	41565	cis	blood	5.09195E-25	pval	7	99118320	7	99722964	99722965	604644	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.384652	9883	ref1: TG phase3 v5	rs6955891	COPS6	ILMN_1764431	cis	PBMC and Whole Blood	8.3942919532418E-5	pval	7	99035211	7	99686583	99689820	651372	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.888	307620	ref1: TG phase3 v5	rs45446698	COPS6	ILMN_1764431	cis	PBMC and Whole Blood	6.54334817793161E-4	pval	7	99332948	7	99686583	99689820	353635	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.384652	21289	ref1: TG phase3 v5	rs45618033	COPS6	ILMN_1764431	cis	PBMC	7.70545787814584E-4	pval	7	99046617	7	99686583	99689820	639966	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.8546	105506	ref1: TG phase3 v5	rs34670419	COPS6	ILMN_1764431	cis	PBMC	0.00150806949934639	pval	7	99130834	7	99686583	99689820	555749	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	COPS6	ILMN_1764431	cis	Whole Blood	0.00142942044889265	pval	7	98965615	7	99686583	99689820	720968	LIFE Adult (in preparation**)
7:99025328:C:T	7	99025328	0.384652	141216	ref1: TG phase3 v5	rs36104094	CPSF4	NA	cis	Cells_Transformed_fibroblasts	3.97839E-8	pval	7	99166544	7	99036545	99054994	111550	29022597
7:99025328:C:T	7	99025328	0.471891	116045	ref1: TG phase3 v5	rs10278040	CPSF4	NA	cis	Cells_Transformed_fibroblasts	4.86728E-6	pval	7	99141373	7	99036545	99054994	86379	29022597
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	CPSF4	ILMN_1660426	cis	PBMC and Whole Blood	3.02698786958133E-10	pval	7	98965615	7	99036563	99054994	70948	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	CPSF4	ILMN_1660426	cis	PBMC	6.44939151689062E-10	pval	7	98965615	7	99036563	99054994	70948	LIFE Heart (in preparation**)
7:99025328:C:T	7	99025328	0.329462	7071	ref1: TG phase3 v5	rs11973173	CPSF4	ILMN_1660426	cis	Whole Blood	7.33312024213454E-4	pval	7	99032399	7	99036563	99054994	4164	LIFE Adult (in preparation**)
7:99025328:C:T	7	99025328	0.471891	116045	ref1: TG phase3 v5	rs10278040	CPSF4	ILMN_1660426	cis	Whole Blood	0.00124779601846369	pval	7	99141373	7	99036563	99054994	86379	LIFE Adult (in preparation**)
7:99025328:C:T	7	99025328	0.384652	159450	ref1: TG phase3 v5	rs7809615	CPSF4	5560010	cis	blood	3.69587599909881E-8	pval	7	99184778	7	99036562	99054996	129782	24013639
7:99025328:C:T	7	99025328	0.471891	116045	ref1: TG phase3 v5	rs10278040	CPSF4	5560010	cis	blood	6.88294059679755E-4	pval	7	99141373	7	99036562	99054996	86377	24013639
7:99025328:C:T	7	99025328	0.312176	137359	ref1: TG phase3 v5	rs10265385	CPSF4	45501	cis	blood	1.25729E-13	pval	7	99162687	7	99054924	99054925	107762	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	rs10226310	CPSF4	45501	cis	blood	5.18871E-7	pval	7	99118320	7	99054924	99054925	63395	https://doi.org/10.1101/447367
7:99025328:C:T	7	99025328	0.306705	314721	ref1: TG phase3 v5	rs12538820	CYP3A5	NA	cis	Adipose_Subcutaneous	3.64234E-5	pval	7	99340049	7	99245817	99277621	62428	29022597
7:99025328:C:T	7	99025328	0.388583	28488	ref1: TG phase3 v5	rs12535424	CYP3A5	NA	cis	Adipose_Subcutaneous	3.92538E-5	pval	7	99053816	7	99245817	99277621	192001	29022597
7:99025328:C:T	7	99025328	0.384652	9883	ref1: TG phase3 v5	rs6955891	CYP3A5	NA	cis	Colon_Sigmoid	3.36861E-5	pval	7	99035211	7	99245817	99277621	210606	29022597
7:99025328:C:T	7	99025328	0.388583	692	ref1: TG phase3 v5	rs190256229	CYP3A5	NA	cis	Colon_Sigmoid	3.92181E-5	pval	7	99024636	7	99245817	99277621	221181	29022597
7:99025328:C:T	7	99025328	0.388583	28488	ref1: TG phase3 v5	rs12535424	CYP3A5	NA	cis	Lung	3.46338E-8	pval	7	99053816	7	99245817	99277621	192001	29022597
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	rs10226310	CYP3A5	NA	cis	Lung	2.62348E-6	pval	7	99118320	7	99245817	99277621	127497	29022597
7:99025328:C:T	7	99025328	0.888	307620	ref1: TG phase3 v5	rs45446698	CYP3A7	NA	cis	Adrenal_Gland	8.58197E-11	pval	7	99332948	7	99302667	99332719	229	29022597
7:99025328:C:T	7	99025328	0.306705	314721	ref1: TG phase3 v5	rs12538820	CYP3A7	NA	cis	Esophagus_Muscularis	5.98021E-5	pval	7	99340049	7	99302667	99332719	7330	29022597
7:99025328:C:T	7	99025328	0.318532	59713	ref1: TG phase3 v5	rs143524414	GAL3ST4	ILMN_1693452	cis	PBMC and Whole Blood	2.26359981548317E-4	pval	7	98965615	7	99756866	99766373	791251	LIFE Adult&Heart (in preparation**)
7:99025328:C:T	7	99025328	0.384652	9883	ref1: TG phase3 v5	rs6955891	GS1-259H13.2	NA	cis	Adipose_Subcutaneous	1.10089E-10	pval	7	99035211	7	99195689	99208439	160478	29022597
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	rs10226310	GS1-259H13.2	NA	cis	Adipose_Subcutaneous	6.61445E-10	pval	7	99118320	7	99195689	99208439	77369	29022597
7:99025328:C:T	7	99025328	0.384652	141216	ref1: TG phase3 v5	rs36104094	GS1-259H13.2	NA	cis	Adipose_Visceral_Omentum	2.42264E-13	pval	7	99166544	7	99195689	99208439	29145	29022597
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	rs10226310	GS1-259H13.2	NA	cis	Adipose_Visceral_Omentum	8.17253E-13	pval	7	99118320	7	99195689	99208439	77369	29022597
7:99025328:C:T	7	99025328	0.312176	171850	ref1: TG phase3 v5	rs10240199	GS1-259H13.2	NA	cis	Adrenal_Gland	3.69378E-8	pval	7	99197178	7	99195689	99208439	0	29022597
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	rs10226310	GS1-259H13.2	NA	cis	Adrenal_Gland	3.13397E-7	pval	7	99118320	7	99195689	99208439	77369	29022597
7:99025328:C:T	7	99025328	0.384652	45556	ref1: TG phase3 v5	rs10808111	GS1-259H13.2	NA	cis	Artery_Aorta	1.36923E-8	pval	7	99070884	7	99195689	99208439	124805	29022597
7:99025328:C:T	7	99025328	0.471891	116045	ref1: TG phase3 v5	rs10278040	GS1-259H13.2	NA	cis	Artery_Aorta	5.05705E-5	pval	7	99141373	7	99195689	99208439	54316	29022597
7:99025328:C:T	7	99025328	0.384652	9883	ref1: TG phase3 v5	rs6955891	GS1-259H13.2	NA	cis	Artery_Tibial	3.57951E-9	pval	7	99035211	7	99195689	99208439	160478	29022597
7:99025328:C:T	7	99025328	0.400943	92992	ref1: TG phase3 v5	rs10226310	GS1-259H13.2	NA	cis	Artery_Tibial	7.24238E-8	pval	7	99118320	7	99195689	99208439	77369	29022597
7:99025328:C:T	7	99025328	0.400788	75952	ref1: TG phase3 v5	rs10215765	GS1-259H13.2	NA	cis	Brain_Cerebellum	2.83916E-5	pval	7	99101280	7	99195689	99208439	94409	29022597
7:99025328:C:T	7	99025328	0.349954	166693	ref1: TG phase3 v5	rs35384085	GS1-259H13.2	NA	cis	Brain_Frontal_Cortex_BA9	5.5654E-6	pval	7	99192021	7	99195689	99208439	3668	29022597

↑ Previous 1 2 3 4 5 6 7 8 9 … 24 25 Next ↓

100

Supplemental Table 4: GWAS lookup for genome-wide significant SNPs. The table is restricted to the 22 lead SNPs, for which GWAS hits in at least LD r²>0.3 were found.

SNP

chromosome of SNP

position of SNP

r2 SNP & GWAS-SNP

distance SNP & GWAS-SNP

reference LD calculation

GWAS-SNP

GWAS-phenotype

GWAs-p-value

GWAS-p-value-details

GWAS reported genes

GWAS first author

GWAS date

GWAS PMID

rs145827824:32103749:C:G

32103749

0.489013

236035

ref1: TG phase3 v5

rs9501618

Blood protein levels

9.0E-26

(Complement C4, C4A.C4B.4481.34.2)

Sun BB

2018-06-06T0:0:0+0000

29875488

rs145827824:32103749:C:G

32103749

0.422257

774720

ref1: TG phase3 v5

rs114029601

Blood protein levels

1.0E-175

(alpha-2-macroglobulin receptor-associated protein, LRPAP1.3640.14.3)

Sun BB

2018-06-06T0:0:0+0000

29875488

rs145827824:32103749:C:G

32103749

0.422257

774720

ref1: TG phase3 v5

rs114029601

Blood protein levels

1.0E-132

(alpha-2-macroglobulin receptor-associated protein, LRPAP1.8829.4.3)

Sun BB

2018-06-06T0:0:0+0000

29875488

rs145827824:32103749:C:G

32103749

0.422257

729764

ref1: TG phase3 v5

rs116795853

Blood protein levels

1.0E-18

(DnaJ homolog subfamily B member 11, DNAJB11.7110.2.3)

MICA

Sun BB

2018-06-06T0:0:0+0000

29875488

rs145827824:32103749:C:G

32103749

0.329078

173398

ref1: TG phase3 v5

rs2734331

Blood metabolite levels

7.0E-13

(X-11470)

SKIV2L

Shin SY

2014-05-11T0:0:0+0000

24816252

rs145827824:32103749:C:G

32103749

0.309826

266838

ref1: TG phase3 v5

rs9461741

Marginal zone lymphoma

4.0E-15

BTNL2

Vijai J

2015-01-08T0:0:0+0000

25569183

rs145827824:32103749:C:G

32103749

0.302391

236496

ref2: TG phase1 v3

rs9267663

Economic and political preferences (environmentalism)

6.0E-6

EHMT2

Benjamin DJ

2012-05-07T0:0:0+0000

22566634

rs145827824:32103749:C:G

32103749

0.302391

232893

ref2: TG phase1 v3

rs9267665

Hepatitis B vaccine response

1.0E-17

HLA

Png E

2011-07-15T0:0:0+0000

21764829

7:99025328:C:T

99025328

0.888

307620

ref1: TG phase3 v5

rs45446698

Blood protein levels

5.0E-74

(DNA repair protein RAD51 homolog 4, RAD51L3.12554.10.3)

CYP3A7

Sun BB

2018-06-06T0:0:0+0000

29875488

7:99025328:C:T

99025328

0.8546

105506

ref1: TG phase3 v5

rs34670419

Sex hormone levels

6.0E-14

(Progesterone)

ZKSCAN5, CYP3A4, CYP3A7

Ruth KS

2015-05-27T0:0:0+0000

26014426

7:99025328:C:T

99025328

0.8546

105506

ref1: TG phase3 v5

rs34670419

Sex hormone levels

2.0E-14

(DHEAS)

ZKSCAN5, CYP3A4, CYP3A7

Ruth KS

2015-05-27T0:0:0+0000

26014426

7:99025328:C:T

99025328

0.8546

105506

ref1: TG phase3 v5

rs34670419

Sex hormone levels

2.0E-7

(Testosterone)

ZKSCAN5, CYP3A4, CYP3A7

Ruth KS

2015-05-27T0:0:0+0000

26014426

7:99025328:C:T

99025328

0.8546

105506

ref1: TG phase3 v5

rs34670419

Total body bone mineral density (age over 60)

1.0E-9

Medina-Gomez C

2018-01-04T0:0:0+0000

29304378

7:99025328:C:T

99025328

0.8546

105506

ref1: TG phase3 v5

rs34670419

Total body bone mineral density

1.0E-8

ZKSCAN5

Medina-Gomez C

2018-01-04T0:0:0+0000

29304378

7:99025328:C:T

99025328

0.8546

105506

ref1: TG phase3 v5

rs34670419

Femoral neck bone mineral density

8.0E-6

ZKSCAN5

Pei YF

2018-02-27T0:0:0+0000

29499414

7:99025328:C:T

99025328

0.8546

105506

ref1: TG phase3 v5

rs34670419

Lumbar spine bone mineral density

1.0E-8

ZKSCAN5

Pei YF

2018-02-27T0:0:0+0000

29499414

7:99025328:C:T

99025328

0.836967

49710

ref1: TG phase3 v5

rs148982377

Sex hormone levels

2.0E-14

(DHEAS)

ZNF789

Ruth KS

2015-05-27T0:0:0+0000

26014426

7:99025328:C:T

99025328

0.836967

49710

ref1: TG phase3 v5

rs148982377

Sex hormone levels

3.0E-13

(Progesterone)

ZNF789

Ruth KS

2015-05-27T0:0:0+0000

26014426

7:99025328:C:T

99025328

0.836967

49710

ref1: TG phase3 v5

rs148982377

Sex hormone levels

5.0E-7

(Testosterone)

ZNF789

Ruth KS

2015-05-27T0:0:0+0000

26014426

7:99025328:C:T

99025328

0.471891

116045

ref1: TG phase3 v5

rs10278040

Blood metabolite levels

9.0E-113

(androsterone sulfate)

CYP3A5

Shin SY

2014-05-11T0:0:0+0000

24816252

7:99025328:C:T

99025328

0.471891

116045

ref1: TG phase3 v5

rs10278040

Blood metabolite levels

1.0E-29

(5alpha-androstan-3beta,17beta-diol disulfate)

CYP3A5

Shin SY

2014-05-11T0:0:0+0000

24816252

7:99025328:C:T

99025328

0.400943

93473

ref1: TG phase3 v5

rs11761528

Dehydroepiandrosterone sulphate levels

3.0E-36

ZKSCAN5

Zhai G

2011-04-14T0:0:0+0000

21533175

7:99025328:C:T

99025328

0.384652

50503

ref1: TG phase3 v5

rs10235235

Diffuse cutaneous systemic sclerosis

2.0E-6

(EA)

ATP5J2, CPSF4

Gorlova OY

2018-01-02T0:0:0+0000

29293537

7:99025328:C:T

99025328

0.384652

138623

ref1: TG phase3 v5

rs11974702

Blood metabolite levels

3.0E-75

(epiandrosterone sulfate)

CYP3A5

Shin SY

2014-05-11T0:0:0+0000

24816252

7:99025328:C:T

99025328

0.384652

159450

ref1: TG phase3 v5

rs7809615

Blood metabolite ratios

8.0E-139

(androsterone sulfate/4-androsten-3beta,17beta-diol disulfate 2)

CYP3A5

Shin SY

2014-05-11T0:0:0+0000

24816252

7:99025328:C:T

99025328

0.341977

90349

ref1: TG phase3 v5

rs12533251

Blood metabolite levels

2.0E-11

(X-18601)

CYP3A5

Shin SY

2014-05-11T0:0:0+0000

24816252

7:99025328:C:T

99025328

0.302172

464243

ref1: TG phase3 v5

rs17277546

Metabolic traits

9.0E-40

(androsterone sulfate + 2 other traits)

CYP3A4

Suhre K

2011-08-31T0:0:0+0000

21886157

7:99025328:C:T

99025328

0.302172

464243

ref1: TG phase3 v5

rs17277546

Dehydroepiandrosterone sulphate levels

2.0E-11

TRIM4, CYP3A43

Zhai G

2011-04-14T0:0:0+0000

21533175

7:99025328:C:T

99025328

0.302172

464243

ref1: TG phase3 v5

rs17277546

Estrone levels

6.0E-14

TRIM4

Eriksson AL

2018-01-09T0:0:0+0000

29325096

rs9692804:144058625:G:A

144058625

0.890801

2330

ref1: TG phase3 v5

rs62524579

Diastolic blood pressure

4.0E-9

RP11-273G15.2

Warren HR

2017-01-30T0:0:0+0000

28135244

rs9692804:144058625:G:A

144058625

0.847672

80201

ref1: TG phase3 v5

rs10093796

Estrone levels

1.0E-8

CYP11B1/B2

Eriksson AL

2018-01-09T0:0:0+0000

29325096

rs9692804:144058625:G:A

144058625

0.610653

51521

ref1: TG phase3 v5

rs6988985

Plasma androstenedione levels in resected early stage-receptor positive breast cancer

7.0E-7

LOC100288248, CYP11B2

Dudenkov TM

2017-04-20T0:0:0+0000

28429243

rs9692804:144058625:G:A

144058625

0.564025

62262

ref1: TG phase3 v5

rs6418

Mean arterial pressure

9.0E-11

CYP11B2

Kanai M

2018-02-05T0:0:0+0000

29403010

rs9692804:144058625:G:A

144058625

0.52952

75664

ref1: TG phase3 v5

rs62525059

Systolic blood pressure

4.0E-12

CYP11B1, CYP11B2

Kanai M

2018-02-05T0:0:0+0000

29403010

rs10786714:104598606:G:C

104598606

0.991147

3358

ref1: TG phase3 v5

rs4919687

Colorectal cancer

8.0E-12

CYP17A1

Zeng C

2016-03-08T0:0:0+0000

26965516

rs10786714:104598606:G:C

104598606

0.773488

30405

ref1: TG phase3 v5

rs12416687

Blood pressure

4.0E-9

(EA, MAP, Age 50-59)

AS3MT

Simino J

2014-06-19T0:0:0+0000

24954895

rs10786714:104598606:G:C

104598606

0.762841

24972

ref1: TG phase3 v5

rs9527

Arsenic metabolism

3.0E-9

(DMA%)

AS3MT, C10orf32

Pierce BL

2012-02-23T0:0:0+0000

22383894

rs10786714:104598606:G:C

104598606

0.658351

1682

ref1: TG phase3 v5

rs6163

Waist circumference

4.0E-8

(EA)

CYP17A1

Shungin D

2015-02-12T0:0:0+0000

25673412

rs10786714:104598606:G:C

104598606

0.658351

1682

ref1: TG phase3 v5

rs6163

Hip circumference

2.0E-8

(EA)

CYP17A1

Shungin D

2015-02-12T0:0:0+0000

25673412

rs10786714:104598606:G:C

104598606

0.658351

1682

ref1: TG phase3 v5

rs6163

Hip circumference

4.0E-6

(EA, men)

CYP17A1

Shungin D

2015-02-12T0:0:0+0000

25673412

rs10786714:104598606:G:C

104598606

0.593722

13481

ref1: TG phase3 v5

rs4919683

Sodium levels

6.0E-15

WBP1L, CYP17A1

Kanai M

2018-02-05T0:0:0+0000

29403010

rs10786714:104598606:G:C

104598606

0.457779

27280

ref1: TG phase3 v5

rs11191424

Schizophrenia

4.0E-20

ARL3, AS3MT, C10orf32, C10orf32-AS3MT, CNNM2, WBP1L

Li Z

2017-10-09T0:0:0+0000

28991256

rs10786714:104598606:G:C

104598606

0.457779

30267

ref1: TG phase3 v5

rs7085104

Schizophrenia

4.0E-13

MIR1307, SFXN2, ST13P13, PCGF6, PDCD11, NT5C2, TAF5, AS3MT, C10orf32, INA, USMG5, WBP1L, CNNM2, CALHM1, CALHM2, CYP17A1, CALHM3

Ripke S

2013-08-25T0:0:0+0000

23974872

rs10786714:104598606:G:C

104598606

0.457779

30267

ref1: TG phase3 v5

rs7085104

Immature fraction of reticulocytes

4.0E-11

C10orf32-ASMT

Astle WJ

2016-11-17T0:0:0+0000

27863252

rs10786714:104598606:G:C

104598606

0.452344

13729

ref1: TG phase3 v5

rs11191419

Schizophrenia

3.0E-18

Goes FS

2015-07-21T0:0:0+0000

26198764

rs10786714:104598606:G:C

104598606

0.452344

13729

ref1: TG phase3 v5

rs11191419

Schizophrenia

6.0E-19

ARL3, AS3MT, C10orf32, CNNM2, CYP17A1, INA, NT5C2, PCGF6, PDCD11, SFXN2, TAF5, TRIM8, USMG5, WBP1L

Ripke S

2014-07-22T0:0:0+0000

25056061

rs10786714:104598606:G:C

104598606

0.452344

13729

ref1: TG phase3 v5

rs11191419

Autism spectrum disorder or schizophrenia

1.0E-16

AS3MT, BORCS7, BORCS7-ASMT, CNNM2, CYP17A1, NT5C2, SFXN2, WBP1L

Anney RJL

2017-05-22T0:0:0+0000

28540026

rs10786714:104598606:G:C

104598606

0.376846

184385

ref1: TG phase3 v5

rs3850699

Prostate cancer

5.0E-10

CNNM2, CUEDC2, CYP17A1, FBXL15, LOC100505761, MIR146B, PSD, SFXN2, SUFU, TMEM180, ARL3, ACTR1A, AS3MT, TRIM8, C10orf32, C10orf32-AS3MT, WBP1L, C10orf95

Eeles RA

2013-04-01T0:0:0+0000

23535732

rs10786714:104598606:G:C

104598606

0.376846

184385

ref1: TG phase3 v5

rs3850699

Prostate cancer

6.0E-16

Intergenic

Schumacher FR

2018-06-11T0:0:0+0000

29892016

rs10786714:104598606:G:C

104598606

0.360796

28322

ref2: TG phase1 v3

rs73351820

Chloride levels

3.0E-10

WBP1L

Kanai M

2018-02-05T0:0:0+0000

29403010

rs10786714:104598606:G:C

104598606

0.350791

192989

ref1: TG phase3 v5

rs200510190

Mean corpuscular volume

5.0E-17

CNNM2

Astle WJ

2016-11-17T0:0:0+0000

27863252

rs10786714:104598606:G:C

104598606

0.350791

192989

ref1: TG phase3 v5

rs200510190

Mean corpuscular hemoglobin

2.0E-21

CNNM2

Astle WJ

2016-11-17T0:0:0+0000

27863252

rs10786714:104598606:G:C

104598606

0.321395

100372

ref1: TG phase3 v5

rs4919694

Arsenic metabolism

3.0E-8

(MMA%)

CNNM2

Pierce BL

2012-02-23T0:0:0+0000

22383894

rs10786714:104598606:G:C

104598606

0.317269

249912

ref1: TG phase3 v5

rs35879747

White blood cell count

4.0E-9

SUFU

Kanai M

2018-02-05T0:0:0+0000

29403010

rs10786714:104598606:G:C

104598606

0.311479

156825

ref2: TG phase1 v3

rs10883817

White matter lesion progression

1.0E-6

CNNM2, AS3MT, NT5C2

Hofer E

2015-10-08T0:0:0+0000

26451028

rs10786714:104598606:G:C

104598606

0.305625

71015

ref1: TG phase3 v5

rs9663140

Creatine kinase levels

3.0E-9

BORCS7-ASMT, CNNM2

Kanai M

2018-02-05T0:0:0+0000

29403010

rs10786714:104598606:G:C

104598606

0.303627

150112

ref1: TG phase3 v5

rs1890185

Migraine

4.0E-7

intergenic

Anttila V

2013-06-23T0:0:0+0000

23793025

rs10786714:104598606:G:C

104598606

0.302494

268352

ref1: TG phase3 v5

rs7896547

Reticulocyte fraction of red cells

3.0E-55

NT5C2

Astle WJ

2016-11-17T0:0:0+0000

27863252

rs10786714:104598606:G:C

104598606

0.302494

268352

ref1: TG phase3 v5

rs7896547

High light scatter reticulocyte count

1.0E-40

NT5C2

Astle WJ

2016-11-17T0:0:0+0000

27863252

rs10786714:104598606:G:C

104598606

0.302494

268352

ref1: TG phase3 v5

rs7896547

High light scatter reticulocyte percentage of red cells

4.0E-42

NT5C2

Astle WJ

2016-11-17T0:0:0+0000

27863252

rs10786714:104598606:G:C

104598606

0.30092

177302

ref1: TG phase3 v5

rs7914558

Schizophrenia

2.0E-8

CNNM2

Ripke S

2011-09-18T0:0:0+0000

21926974

rs10786714:104598606:G:C

104598606

0.30092

177302

ref1: TG phase3 v5

rs7914558

Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)

2.0E-9

(Modelling analysis)

CNNM2

Smoller JW

2013-02-27T0:0:0+0000

23453885

rs28620926:40357171:A:G

40357171

3570

ref1: TG phase3 v5

rs7181230

Dehydroepiandrosterone sulphate levels

5.0E-11

BMF

Zhai G

2011-04-14T0:0:0+0000

21533175

rs28620926:40357171:A:G

40357171

0.718617

17677

ref1: TG phase3 v5

rs4924410

Ewing sarcoma

7.0E-9

BMF, SRP14, EIF2AK4

Postel-Vinay S

2012-02-12T0:0:0+0000

22327514

rs28620926:40357171:A:G

40357171

0.467712

35047

ref1: TG phase3 v5

rs937213

Endometrial cancer

2.0E-8

EIF2AK, BMF

Cheng TH

2016-05-02T0:0:0+0000

27135401

rs28620926:40357171:A:G

40357171

0.467712

35047

ref1: TG phase3 v5

rs937213

Endometrial endometrioid carcinoma

2.0E-7

EIF2AK, BMF

Cheng TH

2016-05-02T0:0:0+0000

27135401

rs17601876:51553909:A:G

51553909

ref1: TG phase3 v5

rs17601876

Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer

4.0E-6

CYP19A1

Dudenkov TM

2017-04-20T0:0:0+0000

28429243

rs17601876:51553909:A:G

51553909

0.682076

8455

ref1: TG phase3 v5

rs12907866

Menarche (age at onset)

4.0E-7

(AA)

CYP19A1

Demerath EW

2013-04-17T0:0:0+0000

23599027

rs17601876:51553909:A:G

51553909

0.525037

16103

ref1: TG phase3 v5

rs2414098

Endometrial cancer

5.0E-13

CYP19A1

Cheng TH

2016-05-02T0:0:0+0000

27135401

rs17601876:51553909:A:G

51553909

0.525037

16103

ref1: TG phase3 v5

rs2414098

Endometrial endometrioid carcinoma

2.0E-13

CYP19A1

Cheng TH

2016-05-02T0:0:0+0000

27135401

rs17601876:51553909:A:G

51553909

0.525037

16103

ref1: TG phase3 v5

rs2414098

Total body bone mineral density

2.0E-8

CYP19A1

Medina-Gomez C

2018-01-04T0:0:0+0000

29304378

rs17601876:51553909:A:G

51553909

0.457981

29617

ref1: TG phase3 v5

rs2414095

Hormone measurements

7.0E-31

(Oestradiol)

CYP19A1

Chen Z

2013-09-18T0:0:0+0000

24049095

rs17601876:51553909:A:G

51553909

0.457981

29617

ref1: TG phase3 v5

rs2414095

Follicule stimulating hormone

2.0E-16

(FSH)

CYP19A1

Chen Z

2013-09-18T0:0:0+0000

24049095

rs17601876:51553909:A:G

51553909

0.457981

29617

ref1: TG phase3 v5

rs2414095

Total body bone mineral density

6.0E-10

(European)

Medina-Gomez C

2018-01-04T0:0:0+0000

29304378

rs17601876:51553909:A:G

51553909

0.45403

19362

ref1: TG phase3 v5

rs727479

Estradiol levels

5.0E-7

MIR4713, CYP19A1

Prescott J

2012-06-04T0:0:0+0000

22675492

rs17601876:51553909:A:G

51553909

0.45403

19362

ref1: TG phase3 v5

rs727479

Estradiol levels

8.0E-30

CYP19A1

Eriksson AL

2018-01-09T0:0:0+0000

29325096

rs17601876:51553909:A:G

51553909

0.45403

19362

ref1: TG phase3 v5

rs727479

Estrone levels

2.0E-22

CYP19A1

Eriksson AL

2018-01-09T0:0:0+0000

29325096

rs17601876:51553909:A:G

51553909

0.341881

37854

ref1: TG phase3 v5

rs2899472

Cerebrospinal fluid AB1-42 levels

2.0E-9

(Controls)

CYP19A1

Han MR

2010-10-08T0:0:0+0000

20932310

rs17601876:51553909:A:G

51553909

0.341881

37854

ref1: TG phase3 v5

rs2899472

Estrone levels

6.0E-23

CYP19A1

Eriksson AL

2018-01-09T0:0:0+0000

29325096

rs57159061:81590962:T:C

81590962

0.964168

351

ref2: TG phase1 v3

rs2911280

Dehydroepiandrosterone sulphate levels

6.0E-10

CMIP

Prins BP

2017-09-08T0:0:0+0000

28887542

rs296360:48388658:T:C

48388658

0.984441

3601

ref1: TG phase3 v5

rs2547231

Blood metabolite levels

3.0E-22

(5alpha-androstan-3beta,17beta-diol disulfate)

SULT2A1

Shin SY

2014-05-11T0:0:0+0000

24816252

rs296360:48388658:T:C

48388658

0.984441

3601

ref1: TG phase3 v5

rs2547231

Blood metabolite levels

4.0E-16

(X-12850)

SULT2A1

Shin SY

2014-05-11T0:0:0+0000

24816252

rs296360:48388658:T:C

48388658

0.984441

3601

ref1: TG phase3 v5

rs2547231

Blood metabolite levels

3.0E-11

(X-12456)

SULT2A1

Shin SY

2014-05-11T0:0:0+0000

24816252

rs296360:48388658:T:C

48388658

0.984441

3601

ref1: TG phase3 v5

rs2547231

Blood metabolite ratios

3.0E-191

(X-11440/4-androsten-3beta,17beta-diol disulfate 2)

SULT2A1

Shin SY

2014-05-11T0:0:0+0000

24816252

rs296360:48388658:T:C

48388658

0.984441

3601

ref1: TG phase3 v5

rs2547231

Gallstone disease

1.0E-7

(EA)

SULT2A1

Joshi AD

2016-04-16T0:0:0+0000

27094239

rs296360:48388658:T:C

48388658

0.901025

17556

ref1: TG phase3 v5

rs296381

Blood metabolite levels

5.0E-143

(X-11440)

SULT2A1

Shin SY

2014-05-11T0:0:0+0000

24816252

rs296360:48388658:T:C

48388658

0.901025

17556

ref1: TG phase3 v5

rs296381

Blood metabolite levels

1.0E-10

(X-13429)

SULT2A1

Shin SY

2014-05-11T0:0:0+0000

24816252

rs296360:48388658:T:C

48388658

0.851638

23135

ref1: TG phase3 v5

rs296396

Blood metabolite levels

1.0E-92

(4-androsten-3beta,17beta-diol disulfate 1)

SULT2A1

Shin SY

2014-05-11T0:0:0+0000

24816252

rs296360:48388658:T:C

48388658

0.851638

23135

ref1: TG phase3 v5

rs296396

Blood metabolite levels

1.0E-12

(dehydroisoandrosterone sulfate (DHEA-S))

SULT2A1

Shin SY

2014-05-11T0:0:0+0000

24816252

rs296360:48388658:T:C

48388658

0.719171

13235

ref1: TG phase3 v5

rs2637125

Dehydroepiandrosterone sulphate levels

3.0E-19

SULT2A1

Zhai G

2011-04-14T0:0:0+0000

21533175

rs296360:48388658:T:C

48388658

0.719171

13235

ref1: TG phase3 v5

rs2637125

Sex hormone levels

2.0E-6

(DHEAS)

SULT2A1

Ruth KS

2015-05-27T0:0:0+0000

26014426

rs296360:48388658:T:C

48388658

0.502652

16463

ref1: TG phase3 v5

rs182420

Blood metabolite levels

6.0E-12

(androsterone sulfate)

SULT2A1

Shin SY

2014-05-11T0:0:0+0000

24816252

↑ Previous 1 2 3 4 5 Next ↓

Supplement Table 5: Sex-interaction test for the 14 novel , two candidate and eight known SNPs. Betas, se, p-values and r² correspond to the top phenotype. Differences of Betas between men and women is calculated. Typ "novel1" denotes novel SNPs with candidate genes in metabolism, "novel2": WNT4 pathway, "novel3": other biological plausibility and "novel4" other hits. "Candidate" refers to the two tested candidate genes of the steroid pathway and "known" to previously published loci replicated in our data.

				ALL				MEN				WOMEN				MEN vs. WOMEN
NR	SNP	typ	toppheno	beta A	se A	p A	r²	beta M	se M	p M	r²	beta F	se F	p F	r²	meandiff	meandiff se	meandiff p
1	rs145827824:32103749:C:G	novel1	OHP17	0.699809	0.0846222	2.37316E-16	0.0319818497126429	0.57225	0.107828	1.300361E-7	0.0203185915121582	0.797658	0.139096	1.44797E-8	0.0441483686470693	0.225408	0.175995951089791	0.200279124359685
2	rs9692804:144058625:G:A	novel1	ANDRO	0.0900147	0.014171	2.60575E-10	0.0191192886390141	0.0817186	0.0161876	5.06646E-7	0.0184205500505195	0.104987	0.0269745	1.08778E-4	0.0208324930138488	0.0232684	0.0314588945134758	0.459515699740819
3	rs10786714:104598606:G:C	novel1	PROG	0.0509603	0.0177716	0.00417911	0.00395656971585695	0.0951468	0.0158349	2.40027E-9	0.0258977770327949	-0.0203393	0.0359371	0.571415	2.53957214651262E-4	-0.1154861	0.039271098971381	0.00327429013698352
4	rs5935876:6922078:G:A	novel1	DHEAS	-0.0971084	0.0168501	8.26019E-9	0.00431774836225664	-0.0563848	0.0185186	0.00232865	0.00215081595988309	-0.188607	0.0333804	1.60237E-8	0.00941764761225234	-0.1322222	0.0381731535260057	5.32704478173989E-4
5	rs142754737:43865714:C:T	novel1	PROG	0.345894	0.0696468	7.38104E-7	0.011775222344794	0.13656	0.0627846	0.0297984	0.00347160783283134	0.798375	0.138746	8.70534E-9	0.0255859396364667	0.661815	0.15229037564193	1.38804321544915E-5
6	rs615567:22319209:A:T	novel2	DHEAS	-0.0778523	0.0102432	2.95296E-14	0.00748576629389003	-0.0716892	0.0128678	2.52996E-8	0.00716484120112273	-0.0851216	0.016306	1.78662E-7	0.00804996120846394	-0.0134324	0.0207717575770564	0.517847801706131
7	rs139203625:95099865:C:T	novel2	PROG	0.524075	0.0786923	3.5044E-11	0.0209770746758675	0.141194	0.0754369	0.0614656	0.00257303770999889	0.742308	0.145465	3.34319E-7	0.0202329406203473	0.601114	0.163862113090885	2.44060166246191E-4
8	rs114341625:112578458:G:A	novel2	CORT	-0.128447	0.0221222	6.38988E-9	0.00437784509928099	-0.115467	0.0284758	5.01527E-5	0.00380835433897128	-0.142245	0.0347362	4.221415E-5	0.00495720698306317	-0.026778	0.0449163085758391	0.55105803140794
9	rs36139342:119204625:A:AC	novel3	DHEAS	-0.0871928	0.0127335	7.5155E-12	0.00608475290442499	-0.0882746	0.0160836	4.05368E-8	0.00695511675419705	-0.0861025	0.0201414	1.91231E-5	0.00541270588370993	0.0021721	0.0257751466129681	0.932840888203353
10	rs72906582:45222771:G:A	novel3	PROG	0.140791	0.0281928	6.41478E-7	0.0119042503598791	0.0347859	0.0256685	0.175581	0.001350575271681	0.318619	0.0551308	7.50028E-9	0.0258039405911259	0.2838331	0.0608134606883213	3.05221788841475E-6
11	rs77032081:13363279:C:T	novel3	PROG	0.260374	0.064853	6.16122E-5	0.00772673527705935	-0.0275468	0.0600816	0.646675	1.54771980797443E-4	0.704529	0.124815	1.65582E-8	0.0246440586562044	0.7320758	0.138522860508871	1.25791624324875E-7
12	rs79589801:211054061:C:T	novel3	PROG	0.371084	0.0735692	4.95707E-7	0.0121416227060612	0.0592719	0.0675164	0.38016	5.67195756931239E-4	0.808409	0.144331	2.13009E-8	0.0242747898035652	0.7491371	0.159342090578604	2.58334591922377E-6
13	rs77533229:43479638:G:A	novel4	DHEAS	-0.149331	0.0371098	5.72072E-5	0.00210976179656694	0.0646403	0.0455445	0.155819	4.68125237191188E-4	-0.425435	0.0604601	1.96952E-12	0.0145308510329337	-0.4900753	0.0756949481290528	9.52233455048058E-11
14	rs35679777:68034459:CG:C	novel4	E2	0.0577234	0.00995841	6.77367E-9	0.00491814635476158	0.0393347	0.0122194	0.001286261	0.0024663902655351	0.0741314	0.0159642	3.42364E-6	0.00820335840342423	0.0347967	0.0201039652307698	0.0834807241156056
15	rs139441768:90679263:T:C	novel4	PROG	0.45207	0.0791544	1.2839E-8	0.0155131793641832	0.155067	0.0794433	0.0511532	0.00279774224677392	0.6113884	0.1479081	3.571708E-5	0.0133687333261586	0.4563214	0.16789295387389	0.00656916115924446
16	rs10802103:120046363:T:G	candidate	OHP17	0.0742372	0.0212962	5.00673E-4	0.00583615145860054	0.109994	0.0229919	1.90638E-6	0.0165741069350453	0.00183185	0.0429944	0.966027	2.54961691370304E-6	-0.10816215	0.0487559831915017	0.0265249488118186
17	rs111447088:74677767:C:T	candidate	E2	0.0769748	0.0292781	0.00856136	0.00101575469326974	0.0421165	0.0360749	0.24302	3.25113793167891E-4	0.138465	0.046583	0.00295457	0.00337765044874059	0.0963485	0.0589183697925358	0.101988698980714
18	7:99025328:C:T	known	DHEAS	-0.303133	0.0273303	1.38041E-28	0.0158083034729316	-0.325069	0.0342714	2.42041E-21	0.0204893018178627	-0.274535	0.0435938	3.02335E-10	0.0116725608306703	0.050534	0.0554522159737553	0.362133568718998
19	rs17601876:51553909:A:G	known	E2	0.0694361	0.00959628	4.63034E-13	0.00764278580420531	0.07022449	0.01173398	2.167724E-9	0.00847369987445793	0.063851	0.0154557	3.60851E-5	0.00650403879015907	-0.00637349	0.0194052814751655	0.742578249285235
20	rs296360:48388658:T:C	known	DHEAS	-0.0922151	0.0132595	3.53466E-12	0.00627543368568438	-0.0489511	0.0166344	0.00325303	0.0020094057258959	-0.142747	0.0211364	1.44222E-11	0.0134008390478737	-0.0937959	0.0268970382815655	4.88069000787754E-4
21	rs35695070:7343539:GC:G	known	TESTO	0.0408821	0.0102775	6.95496E-5	0.0020659955574228	0.0734806	0.0108972	1.55046E-11	0.0104852622366578	-0.00266917	0.0173836	0.877968	7.03341049213454E-6	-0.07614977	0.0205167862200687	2.05966509652501E-4
22	rs28620926:40357171:A:G	known	DHEAS	0.0694955	0.0103873	2.22548E-11	0.00581038847036012	0.0579013	0.0129378	7.62889E-6	0.00463520128100538	0.0847209	0.0167034	3.93479E-7	0.00760284570879682	0.0268196	0.0211279492710485	0.204302127976962
23	rs9989237:94795202:C:T	known	CORT	0.0403298	0.00692366	5.71375E-9	0.00440592915061133	0.0370085	0.00898525	3.80851E-5	0.0039288329366859	0.0452752	0.0107792	2.66617E-5	0.00521390709645587	0.0082667	0.0140330278344518	0.555801683604618
24	rs57159061:81590962:T:C	known	DHEAS	0.117829	0.020964	1.90331E-8	0.00410767804061758	0.0912883	0.0257788	3.98277E-4	0.00290717378630682	0.149075	0.0342206	1.32287E-5	0.00561961101498629	0.0577867	0.0428438559632534	0.177409410704373

Supplemental Table 6: Genetic association and annotation for steroid hormone loci HSD3B and CYP11A1. The two strongest associations of the respective loci are colored blue

SNP INFO								top phenotype					Annotation with nearby genes, eQTLs in LD, known traits of other GWAS, and pathway enrichment								PROG ALL			PROG MEN			PROG WOMEN			17-OHP ALL			17-OHP MEN			17-OHP WOMEN			ANDRO ALL			ANDRO MEN			ANDRO WOMEN			DHEAS ALL			DHEAS MEN			DHEAS WOMEN			TESTO ALL			TESTO MEN			TESTO WOMEN			E2 ALL			E2 MEN			E2 WOMEN			CORT ALL			CORT MEN			CORT WOMEN			ALDO ALL			ALDO MEN			ALDO WOMEN
SNP	status	chr	position	Cytoband	EA	OA	info-score	phenotype	N	log-p	EAF	Cochran's Q	nearest genes (functional relevance)	correlating GWAS	cis-eQTL genes	trans-eQTL genes	KEGG pathway	Reactome pathway	DOSE pathway	GO pathway	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p	beta	se	log p
rs10802103:120046363:T:G	candidate	1	120046363	1p12	G	T	0.975	OHP17 MEN	1358	5.71979052685925	0.736599779086892		HSD3B1 (3.5 kb, near gene/Upstream gene/MODIFIER); GAPDHP58 (6.9 kb); HSD3BP1 (30 kb); GAPDHP32 (30 kb); HSD3BP3 (35 kb); GAPDHP23 (41 kb)	NA	FCGR1B \| GAPDHP58 \| HAO2 \| PHGDH \| RP11-418J17.1 \| WARS2	KIAA2026	Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	0.0191035	0.0194092	0.487971007753227	0.0341763	0.0175658	1.28476486737654	0.0209635	0.038419	0.232619249881878	0.0742372	0.0212962	3.30044582834781	0.109994	0.0229919	5.71979052685925	0.00183185	0.0429944	0.0150107350885	0.00643892	0.0159347	0.163552450780459	-0.00618339	0.0182638	0.133716206191352	0.0229447	0.0301448	0.349865451842501	-0.0239322	0.0115021	1.42639165142206	-0.0174316	0.0142861	0.652873028212057	-0.0354766	0.0185494	1.25332299636817	0.00135796	0.0113517	0.04345700797831	0.0215334	0.011918	1.14999925427226	-0.0137358	0.019266	0.32250802280156	0.0158579	0.0110218	0.823286697878035	0.00977458	0.0134593	0.330034487245272	0.0215172	0.017753	0.646857305638862	0.00158508	0.00660255	0.0913670245038793	2.02522E-4	0.008509	0.008326122882521	0.00296363	0.0103708	0.110666357009592	0.00897889	0.0319685	0.108550636663544	0.0424052	0.0400917	0.537022829964501	-0.0491613	0.0529096	0.452056776761485
rs182134740:119947330:G:A		1	119947330	1p12	A	G	0.924	OHP17 ALL	2070	4.56986848338261	0.0154926072463768		HSD3B2 (10 kb); HAO2 (11 kb); HSD3BP2 (34 kb); HAO2-IT1 (34 kb)	NA	HIST2H3DP1 \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.107455	0.0713061	0.879505038606515	0.0309117	0.0633554	0.203638703706159	0.10332	0.139731	0.337573680385638	0.328856	0.0781589	4.56986848338261	0.209112	0.0833209	1.91369356947064	0.552844	0.162764	3.142418458849	0.0585147	0.058548	0.497978684205606	0.0115491	0.0657888	0.0651608117894603	0.139535	0.114973	0.647256157270435	-0.0156709	0.0441439	0.141106850926159	-0.0338651	0.0545905	0.271622677420566	-0.0188325	0.0717587	0.100737218349496	0.0430916	0.0431081	0.498261741833015	0.0306529	0.045339	0.301909898457667	0.050365	0.0741764	0.303517797690704	0.0524807	0.0423234	0.667605981793553	0.0956524	0.0519296	1.18388734979316	0.0137399	0.0680494	0.075727435214253	0.0628538	0.0251682	1.90265243864152	0.0305167	0.0322771	0.462905332921058	0.0974084	0.0398001	1.84201768192682	0.25384	0.118355	1.49355991368197	0.196586	0.145727	0.750630405308484	0.379198	0.202902	1.20712245274492
rs5777396:120021365:CA:C		1	120021365	1p12	C	CA	0.971	OHP17 MEN	1358	4.50961446355099	0.70309646539028		HSD3BP1 (4.9 kb); GAPDHP23 (16 kb); GAPDHP58 (17 kb); HSD3B1 (28 kb); HSD3BP2 (33 kb)	NA	FCGR1B \| GAPDHP58 \| PHGDH \| WARS2 \| ZNF697		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2,PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	0.0500451	0.0185882	2.14549781072728	0.0432074	0.0167141	2.00704374264939	0.051171	0.0367992	0.78419594047201	0.0794565	0.0204116	3.99023900459377	0.0917388	0.0219435	4.50961446355099	0.0459779	0.0417624	0.566556609447892	0.0101112	0.0152828	0.293880744703964	-0.010099	0.0173954	0.250545835648141	0.0399291	0.0292796	0.761730531148853	-0.0115188	0.0110293	0.528255157190295	-0.0103957	0.0137047	0.348603734408614	-0.0171133	0.0177898	0.473579300027928	0.00151602	0.0108837	0.0509917546757541	0.00605245	0.0114327	0.224369166477967	-0.00327018	0.0185506	0.0654656956919568	0.00912996	0.0105534	0.412318213368305	-0.00203801	0.0129197	0.058161727260122	0.0238698	0.0169469	0.798652043875752	0.00189477	0.0063305	0.116506070180744	-3.02017E-4	0.0081557	0.0130223604685936	0.00348004	0.00994526	0.138824762359742	0.0418376	0.0306361	0.763944155157635	0.071392	0.0382367	1.20682868158326	-0.00887003	0.0511874	0.0642514705099348
rs4659181:120015567:C:G		1	120015567	1p12	G	C	0.958	OHP17 MEN	1358	4.33636596676425	0.680507731958763		HSD3BP1 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); GAPDHP23 (9.9 kb); GAPDHP58 (23 kb); HSD3BP2 (27 kb); HSD3B1 (34 kb); HSD3B2 (50 kb)	NA	FCGR1B \| GAPDHP58 \| HAO2 \| PHGDH \| RP11-418J17.1 \| WARS2	KIAA2026	Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2,PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	0.0340485	0.0182719	1.20381920761531	0.0268753	0.0166766	0.969440754708844	0.038862	0.035894	0.554478304948904	0.0653648	0.020068	2.94176003313346	0.0893918	0.0218675	4.33636596676425	0.0132836	0.0400129	0.130767693384985	0.00716376	0.0150099	0.198445376575843	-0.00662925	0.0173314	0.153568862776747	0.0229509	0.0280547	0.383429970391197	-0.0100992	0.0108862	0.451533189746628	-0.0136377	0.0135597	0.502332402001608	-0.00982957	0.0175232	0.240456796828511	0.00383547	0.0107336	0.142158712076176	0.00492063	0.0113163	0.178035380307166	-0.00346515	0.0181273	0.0713972925672716	0.00403395	0.0104047	0.155999007351017	2.78691E-4	0.0127673	0.00762987002712044	0.0058628	0.0166507	0.139806382904916	-0.00186868	0.00624696	0.11643111065462	-0.00534883	0.0080791	0.294192715467974	0.00226896	0.00977837	0.0880395557664623	-0.00345178	0.0301186	0.041546496068096	0.0227665	0.0381325	0.259174047019907	-0.0440529	0.0490974	0.431915668684606
rs33952871:119956030:C:CA		1	119956030	1p12	CA	C	0.977	OHP17 MEN	1358	4.29657276485957	0.678617083946981		HSD3B2 (1.5 kb, near gene/Upstream gene/MODIFIER); HAO2 (19 kb); HSD3BP2 (26 kb); HAO2-IT1 (43 kb); GAPDHP23 (49 kb)	0.543 Blood metabolite levels	FCGR1B \| GAPDHP58 \| HAO2 \| HAO2-IT1 \| PHGDH \| RP11-418J17.1 \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2,PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	0.032742	0.0177442	1.18609824566971	0.0204462	0.0160156	0.694758293004303	0.0722446	0.0352878	1.39116386681527	0.0663336	0.0194834	3.17055341602258	0.0853709	0.0209947	4.29657276485957	0.0268024	0.0395564	0.302541361459161	0.00170029	0.0145769	0.0423189801141647	-0.00389875	0.0166392	0.0889601729728677	0.00857756	0.0277527	0.120698209323087	-0.0287356	0.0107544	2.12259582409067	-0.0291613	0.0133902	1.53135585542309	-0.0310225	0.0173045	1.13659564294577	5.4119E-4	0.0105687	0.0181084881964608	0.0169932	0.011157	0.893700287682139	-0.0233938	0.0179147	0.717593162042043	0.0105021	0.0103148	0.510602670969636	0.0167361	0.0126715	0.729134911260221	-0.00849634	0.0164604	0.217716614653121	0.00240092	0.00616231	0.156878146278559	-0.00177073	0.00795403	0.0841618699716949	0.00759929	0.00965852	0.365118852525132	-0.0427783	0.0292487	0.842413295406294	-0.0217404	0.0366831	0.256869820835341	-0.0796844	0.0483834	0.999861047996926
rs11802093:119990519:A:G		1	119990519	1p12	G	A	0.986	ALDO ALL	1993	4.13606301785141	0.0869237832413447		HSD3BP2 (1.8 kb, near gene/Downstream gene/MODIFIER); GAPDHP23 (14 kb); HSD3BP1 (19 kb); HSD3B2 (25 kb); GAPDHP58 (48 kb)	NA	LOC644242 \| PHGDH \| RP11-114O18.1 \| RP11-439A17.9 \| RP5-871G17.5 \| WARS2 \| ZNF697	PLA2G4C	Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.055063	0.0304563	1.15019867331732	0.00916945	0.0278317	0.129679215634994	0.115074	0.058687	1.30189336211198	0.0566793	0.033511	1.04135108173963	0.076062	0.0366274	1.41995362045201	0.0321928	0.0664993	0.201723049966202	-0.0465924	0.0249981	1.20421241035633	-0.0629316	0.028849	1.53277382713484	-0.0117183	0.0466495	0.0959696984167303	0.03043	0.0180953	1.03321833067313	-8.79859E-4	0.0226209	0.0136883242024639	0.0674686	0.0289713	1.70181743291496	0.0140033	0.0178534	0.3636776284646	0.0215196	0.0188937	0.5939540041547	-0.00548216	0.0299943	0.0680460761652275	0.00195246	0.0174039	0.0406356317992757	0.00166514	0.0213326	0.0278971812484681	3.88662E-4	0.0277722	0.00487660924704233	0.00166468	0.0103866	0.0591514466170725	-0.0144613	0.0134731	0.548038654222276	0.0214094	0.0161761	0.731274636361865	-0.198897	0.0500456	4.13606301785141	-0.167831	0.0638693	2.06065050483482	-0.255457	0.0803132	2.81376432124478
rs75260979:119938047:CA:CAA		1	119938047	1p12	CAA	CA	0.936	ALDO ALL	1993	4.0562612003335	0.0712983642749624		HAO2 (1.3 kb, near gene/Downstream gene/MODIFIER); HSD3B2 (20 kb); HAO2-IT1 (25 kb); HSD3BP2 (44 kb)	NA	FAM72B \| HSD3B2 \| HSD3BP2 \| REG4 \| RP11-418J17.1 \| WARS2	FGF9 \| SYT5	Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.0628988	0.0344793	1.16584135095277	0.0272912	0.0314263	0.414179575488139	0.145214	0.0656472	1.56921568153325	0.0779666	0.0379255	1.39871374167667	0.112589	0.0413206	2.18589963640086	0.0318507	0.0756545	0.171416788340394	-0.0351093	0.0283138	0.667331324038898	-0.0408056	0.0326211	0.675328706231561	-0.0142764	0.0530695	0.103474884782102	0.0257946	0.0193882	0.73665276818458	0.00972196	0.0241052	0.163222201310023	0.0458498	0.0312414	0.847060701987348	0.0195722	0.0193461	0.506279917755575	0.0223774	0.0202001	0.571939755452012	0.0139848	0.0328723	0.173585672874235	0.0046854	0.0185264	0.0967243917907516	-0.00518214	0.0225797	0.086993520178038	0.0145169	0.0299157	0.202392498816434	-0.00711073	0.0111852	0.279877923430808	-0.0231193	0.014452	0.959959679270381	0.0120376	0.0175022	0.308391659522351	-0.221135	0.0562684	4.0562612003335	-0.172592	0.0715297	1.79683923807466	-0.312632	0.0909256	3.20697064616628
rs71074423:120055204:GA:G		1	120055204	1p12	G	GA	0.86	OHP17 ALL	2070	3.8918410487436	0.389916666666667		HSD3B1 (0 kb, intron/Intron/MODIFIER \| near gene/Downstream gene/MODIFIER); GAPDHP58 (16 kb); GAPDHP32 (21 kb); HSD3BP3 (26 kb); HSD3BP1 (39 kb); GAPDHP27 (46 kb); GAPDHP23 (50 kb)	NA	ADAM30 \| FCGR1B \| GAPDHP32 \| GAPDHP58 \| HMGCS2 \| HSD3BP4 \| PHGDH \| RP11-418J17.1 \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	0.0377296	0.0184308	1.38959963973534	0.0238113	0.0165319	0.82388847434138	0.0674899	0.0367884	1.17670187185877	0.07760739999999999	0.020226	3.8918410487436	0.0673868	0.0217299	2.70601904376557	0.0835973	0.0416491	1.3457290983975	0.014279	0.0151406	0.461245347847723	0.00373289	0.0171784	0.0819665161650591	0.0237554	0.0292829	0.379342479955321	-0.010985	0.0111733	0.487403645371523	4.30678E-4	0.0139345	0.0108421833242777	-0.0299169	0.0179406	1.02042977455092	-0.0103159	0.0109807	0.459053939540034	0.00490399	0.0116131	0.172101752824524	-0.026597	0.0186726	0.811538387703679	-0.00404291	0.010709	0.15132880658119	0.00986374	0.0131838	0.342602776650849	-0.01975	0.0170563	0.607491223168389	-0.00787076	0.00639595	0.660592288485951	-0.0161566	0.00825983	1.2970518931485	0.00142294	0.0100174	0.0520548373461027	0.020576	0.0304191	0.302025670510856	0.0893053	0.037755	1.74096069022026	-0.103763	0.0512187	1.36485618140325
rs10733104:120113504:G:T		1	120113504	1p12	T	G	0.99	OHP17 MEN	1358	3.63213180189985	0.608949189985272		HSD3BP4 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); GAPDHP27 (11 kb); HSD3BP3 (25 kb); GAPDHP33 (25 kb); LINC00622 (27 kb); HSD3BP5 (30 kb); GAPDHP32 (36 kb); ZNF697 (49 kb)	NA	ADAM30 \| FCGR1B \| GAPDHP32 \| GAPDHP58 \| HMGCS2 \| HSD3BP4 \| PHGDH \| RP11-418J17.1 \| WARS2 \| ZNF697		Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1 \| Carbon metabolism:PHGDH	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1 \| electron transport chain:PHGDH	0.00566102	0.0174149	0.127748717510045	0.0157396	0.015568	0.505587967941538	0.0014696	0.0347266	0.0149131898653204	0.0489328	0.0191299	1.97466135903	0.0753656	0.0204251	3.63213180189985	-0.00906428	0.0395028	0.0869399315781096	0.00422886	0.0142947	0.114985562286629	-0.00765224	0.0161695	0.196468459756456	0.0221544	0.0276965	0.372594198346236	-0.0100805	0.0103271	0.482796181858138	-0.0102898	0.0129228	0.37070459661844	-0.0139438	0.0165223	0.39934940725405	-0.00684682	0.0101891	0.299641606359858	-0.00766719	0.0107734	0.321787646880876	-0.00945812	0.0173169	0.232886451852092	-0.00133073	0.00992872	0.0489637742582505	-0.00151531	0.0122087	0.0451677332313608	-0.00552491	0.0159178	0.137556136555791	0.00388749	0.00592828	0.290744459197537	9.32809E-4	0.0076788	0.044162220367416	0.00737971	0.00925029	0.371614135568616	0.0360791	0.0287455	0.678646019571708	0.0600887	0.0356001	1.03775571367625	-0.00847563	0.048715	0.0645280031406744
rs140961900:119949228:G:T		1	119949228	1p12	T	G	0.909	CORT WOMEN	3366	3.48472769981481	0.0138706179441473	0.0169692	HSD3B2 (8.3 kb); HAO2 (12 kb); HSD3BP2 (32 kb); HAO2-IT1 (36 kb)	NA	FAM72B \| HSD3B2 \| HSD3BP2 \| REG4 \| RP11-418J17.1 \| RP5-871G17.5 \| WARS2	FGF9 \| SYT5	Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	-0.0683419	0.072246	0.4630894671654	-0.156693	0.0613476	1.96849862686773	0.197978	0.159664	0.667587800544671	0.0189769	0.0795003	0.0907858715292253	0.0114956	0.0810547	0.0519593763353033	0.0363992	0.183542	0.0742466172463856	-0.0346737	0.0593094	0.252693865164735	-0.0772356	0.0638179	0.645135087207356	0.0786405	0.12871	0.266480144229791	0.0211643	0.0426692	0.207686770785426	0.00496759	0.0513645	0.0348194731107159	0.0388637	0.0716153	0.231099329860063	0.0597487	0.0421009	0.807301553322885	-0.0019958	0.0427522	0.0164792551991595	0.124791	0.0765073	0.987715481965654	0.0349918	0.0407548	0.408306678067941	0.0340586	0.0487691	0.314303036332763	0.0113555	0.0684008	0.0614072314337156	0.0513253	0.0244974	1.4417847897895	-0.0125367	0.0304832	0.166931336025493	0.144489	0.0402198	3.48472769981481	0.24887600000000001	0.117759	1.45981823548078	0.277928	0.139299	1.3350751671416	0.179759	0.221788	0.378890218164903
rs112987949:119971287:C:CTT		1	119971287	1p12	CTT	C	0.901	CORT WOMEN	3366	3.39715356242539	0.0221000297088532	0.0435262	HSD3B2 (5.6 kb); HSD3BP2 (10 kb); GAPDHP23 (33 kb); HAO2 (35 kb); HSD3BP1 (39 kb)	NA			Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	-0.0337822	0.0604323	0.239414686674773	-0.0723219	0.0516849	0.790602958005007	0.0443975	0.131772	0.133020704787675	-0.0102661	0.0664916	0.0568464252871096	0.00370169	0.0681737	0.0192215023426775	-0.0799875	0.151502	0.223524010321831	-0.00848167	0.0496079	0.0633550842080036	-0.0214276	0.0537016	0.161184269395492	3.35104E-4	0.106287	0.00109362643440678	0.00295581	0.0348535	0.0303907484881955	0.00814041	0.0427519	0.0710984482373357	-0.00351976	0.0570414	0.021911740479698	0.0147074	0.0345643	0.173622593010886	0.010515	0.0356098	0.114764902016344	0.0201105	0.0615357	0.128537403277428	-0.00849638	0.0333529	0.097495075863176	-0.00656672	0.0403542	0.0601149958571094	-0.0156426	0.0551459	0.109761792250934	0.05911	0.0200513	2.49498575991589	0.0186737	0.0254091	0.334994384595378	0.113616	0.0320984	3.39715356242539	0.230332	0.0987994	1.7025327640254	0.266389	0.117637	1.62511057701126	0.161891	0.183132	0.423658649794207
rs58627883:119937237:C:T		1	119937237	1p12	T	C	0.824	CORT WOMEN	3366	3.36521450023854	0.019124477124183	0.146273	HAO2 (0.48 kb, near gene/Downstream gene/MODIFIER); HSD3B2 (20 kb); HAO2-IT1 (24 kb); HSD3BP2 (44 kb)	NA	HSD3BP2 \| REG4 \| RP11-418J17.1 \| WARS2	FGF9	Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	-0.0671118	0.0696038	0.474877415841751	-0.124563	0.0623613	1.33745559151779	0.0582718	0.138819	0.170918900378598	-0.0751054	0.0765767	0.48570067638695	-0.0118266	0.0823172	0.0526736395667871	-0.225347	0.157086	0.818562324164961	-0.0432565	0.0571376	0.347655010875763	-0.0465365	0.0648346	0.325118659988591	-0.0579106	0.110322	0.221994262642587	0.0218435	0.0388538	0.241100970172627	0.0136135	0.0478868	0.110030837728135	0.0345448	0.0632966	0.232673419217079	0.0425929	0.0387837	0.565253901650083	0.038782	0.0400607	0.477549245604469	0.0571157	0.0670668	0.404037767965511	-0.0168163	0.0367735	0.188787057078183	-0.0040226	0.0449438	0.0321329719995414	-0.0478651	0.05939	0.376466443173163	0.065756	0.0224198	2.47396328306387	0.0200088	0.0287119	0.313474552521655	0.124895	0.0354801	3.36521450023854	0.294372	0.113044	2.03237995933997	0.383283	0.140737	2.1839211764245	0.149641	0.190144	0.364955796576345
rs74114308:119935543:T:C		1	119935543	1p12	C	T	0.992	ALDO WOMEN	686	3.29859609355244	0.0711820699708455		HAO2 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); HSD3B2 (22 kb); HAO2-IT1 (23 kb); HSD3BP2 (46 kb)	NA	LOC644242 \| PHGDH \| RP11-114O18.1 \| RP11-439A17.9 \| RP5-871G17.5 \| WARS2 \| ZNF697	PLA2G4C	Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.0588527	0.0347342	1.04409443565599	0.032135	0.0319769	0.501546083760619	0.130849	0.0656185	1.33589982031234	0.0860569	0.0381938	1.61343861467708	0.122246	0.0420326	2.43266420629663	0.0432294	0.0749273	0.248600788620857	-0.0401119	0.028517	0.796703242256529	-0.039192	0.0331979	0.623448590429122	-0.0289223	0.0525566	0.234867380817238	0.0306746	0.0201851	0.890772540003904	0.0125849	0.0250113	0.211234354353016	0.0539196	0.0326856	1.00429242902	0.0202545	0.0199998	0.506979949791328	0.0240171	0.0209186	0.600468182765603	0.00390038	0.0338248	0.0418189806278742	0.0106205	0.0192786	0.235297203241211	-0.00679225	0.0234823	0.112163357591934	0.0215951	0.031035	0.312886804940474	-7.79563E-4	0.0116056	0.0239046187741738	-0.0197588	0.0149539	0.729558751819074	0.0221021	0.0182388	0.646693632013066	-0.186884	0.0568426	2.98821394276218	-0.114057	0.0729425	0.927595681339998	-0.315933	0.0903687	3.29859609355244
rs141141351:120067943:G:A		1	120067943	1p12	A	G	0.871	E2 ALL	6798	2.85528260778033	0.0148187628714328	0.00114835	GAPDHP32 (8.4 kb); HSD3B1 (10 kb); HSD3BP3 (13 kb); GAPDHP58 (28 kb); GAPDHP27 (33 kb); HSD3BP4 (39 kb)	NA	NOTCH2 \| WARS2	SEC22B	Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1	0.0593597	0.0702443	0.399917285654151	0.0814827	0.0624232	0.716691985498185	-0.04584	0.145636	0.123236169540293	-0.00966334	0.077295	0.0455061550512457	0.0782344	0.0823028	0.465982783103179	-0.211043	0.161208	0.719164497818815	0.0461947	0.0576595	0.373527208399811	0.0951399	0.0648051	0.846758477891445	-0.0714577	0.113179	0.277362787368939	-0.0764332	0.044894	1.05228892800569	-0.0744665	0.0539937	0.775099354080279	-0.0716192	0.0756648	0.463596870723851	-0.0503445	0.0435195	0.606698620163338	-0.00463935	0.0448731	0.0373205647224423	-0.117047	0.0764164	0.901024191853522	-0.138826	0.043443	2.85528260778033	-0.107528	0.0512754	1.44384711532295	-0.169933	0.0732769	1.69054443701909	0.0335251	0.0255834	0.721129840907816	0.0463087	0.0319256	0.832936816646515	0.0164168	0.0420264	0.157346459619949	0.00650389	0.11566	0.0199229637676668	0.130883	0.14373	0.440494355200699	-0.227981	0.194975	0.614932013101014
rs2885796:120111662:T:C		1	120111662	1p12	C	T	1	OHP17 MEN	1358	2.84927118398878	0.729381443298969		HSD3BP4 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); GAPDHP27 (9.3 kb); HSD3BP3 (23 kb); GAPDHP33 (27 kb); LINC00622 (29 kb); HSD3BP5 (32 kb); GAPDHP32 (34 kb)	NA	FCGR1B \| GAPDHP58 \| HAO2 \| PHGDH \| RP11-418J17.1 \| WARS2 \| ZNF697	KIAA2026	Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1 \| Carbon metabolism:PHGDH	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1 \| electron transport chain:PHGDH	0.0123226	0.0190083	0.286612792644305	0.0149927	0.0171062	0.419140002375271	0.0218389	0.0377916	0.249224785014405	0.0625917	0.0208694	2.56238576998275	0.0718603	0.022469	2.84927118398878	0.0396228	0.0425611	0.453221746325239	0.0129374	0.0156015	0.390337304136631	-0.00620641	0.0177662	0.138531903264784	0.0442878	0.0298251	0.860089444124317	-0.0207228	0.0113015	1.17581882473562	-0.00942523	0.014114	0.297340313042871	-0.0372615	0.0181042	1.40259005056463	-0.00507971	0.0111455	0.18804983999078	0.00590317	0.0117651	0.210530695838414	-0.00475394	0.018883	0.0962433400673698	0.0109638	0.0108308	0.506674418566304	0.0051299	0.0133216	0.154792159405236	0.0212528	0.0173165	0.658162036105827	0.00590148	0.0064869	0.440149609570475	0.00514919	0.00839338	0.267962668723708	0.00606146	0.0101313	0.259915347955652	0.0464385	0.0313164	0.859290883061867	0.105412	0.0389753	2.15939901659872	-0.0624729	0.0523864	0.631780077867502
rs10923862:120108452:G:A		1	120108452	1p12	A	G	0.889	ALDO MEN	1307	2.77133278106764	0.178332134659526		HSD3BP4 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); GAPDHP27 (6.1 kb); HSD3BP3 (20 kb); GAPDHP33 (30 kb); GAPDHP32 (31 kb); LINC00622 (32 kb); HSD3BP5 (36 kb)	NA	GAPDHP32 \| HMGCS2 \| HSD3BP4 \| PHGDH \| WARS2		Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1 \| Carbon metabolism:PHGDH	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1 \| electron transport chain:PHGDH	0.00614606	0.0234242	0.100697240042332	0.00471141	0.0209038	0.0852793136458831	-0.0049064	0.0467385	0.0379172890574256	0.0350778	0.0257599	0.760865759426558	0.0577445	0.0275086	1.4438326340936	-0.0211438	0.0533994	0.159732644038866	7.29168E-4	0.0192276	0.0133388682049047	-0.00557752	0.0217049	0.0984103747785113	0.00442983	0.0374592	0.0429211785644239	-0.00637468	0.0142269	0.184355850868035	-0.00166445	0.0175447	0.0341311368511323	-0.0166556	0.0231668	0.325897011008821	-0.0107576	0.0139792	0.354998472939692	-0.00260645	0.0146479	0.0661231354770873	-0.0254319	0.0240253	0.537891128786659	-0.00805992	0.0136304	0.256249636936715	0.0135016	0.0166055	0.38072818596672	-0.0341312	0.0220457	0.915159294009573	0.00193324	0.00814174	0.0902787349612924	-0.00460679	0.010408	0.181747046326724	0.00963629	0.0129173	0.341351469357849	0.119064	0.0385865	2.68629936140012	0.149839	0.0476294	2.77133278106764	0.0652629	0.0658801	0.491851550163147
rs4659197:120091616:G:A		1	120091616	1p12	A	G	0.922	OHP17 MEN	1358	2.61931852726217	0.682353092783505		HSD3BP3 (3.1 kb, near gene/Downstream gene/MODIFIER); GAPDHP27 (9.8 kb); GAPDHP32 (14 kb); HSD3BP4 (15 kb); HSD3B1 (34 kb); GAPDHP33 (47 kb); LINC00622 (49 kb)	NA	FCGR1B \| GAPDHP58 \| PHGDH \| RP11-418J17.1 \| WARS2 \| ZNF697	KIAA2026	Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1 \| Carbon metabolism:PHGDH	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1 \| electron transport chain:PHGDH	0.0203853	0.0187091	0.559061021879902	0.024728	0.0167642	0.852530826437812	0.00923123	0.0375972	0.0936401728647476	0.0608385	0.0205458	2.50860048216445	0.0670227	0.0220391	2.61931852726217	0.0443917	0.04218	0.533194637924713	0.00368572	0.0153611	0.0912994958463298	-0.0149331	0.0174161	0.407425784061182	0.035782	0.0295784	0.644385673909034	-0.0108757	0.01112	0.48404936710195	-0.0197913	0.0137941	0.820006096973862	-0.00557484	0.0179828	0.121160642259066	-0.00349099	0.0109666	0.124802678985218	-0.00272667	0.0115042	0.0900991324026979	-0.00200956	0.0187422	0.0387621551571604	0.0127108	0.0106561	0.632757793273696	0.00515862	0.0130134	0.160016931230438	0.0212356	0.0172322	0.661882308523142	0.00208624	0.00638202	0.12857360518914	-0.00398327	0.00820783	0.202411878404045	0.00899343	0.0100504	0.430770098682188	0.0653441	0.0307878	1.46944814083251	0.0991016	0.0381824	2.01990250358255	0.00260725	0.0519695	0.0177274097922962
rs74503651:120075457:C:T		1	120075457	1p12	T	C	0.878	ALDO MEN	1307	2.60751760955897	0.0176025248661056		GAPDHP32 (0.92 kb, near gene/Downstream gene/MODIFIER); HSD3BP3 (5.7 kb); HSD3B1 (18 kb); GAPDHP27 (26 kb); HSD3BP4 (31 kb); GAPDHP58 (36 kb)	NA	FAM72B \| HSD3B2 \| HSD3BP2 \| REG4 \| RP11-418J17.1 \| RP5-871G17.5 \| WARS2	FGF9 \| SYT5	Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1	-0.0954643	0.0692479	0.774248893352829	-0.148741	0.061044	1.82526004925553	0.0517171	0.144931	0.141937657985591	-0.0654963	0.0762071	0.408722752100431	-0.0660195	0.0806167	0.384080444668483	-0.0645916	0.161035	0.162118133392874	-0.0409292	0.0568596	0.326323996165578	-0.0905049	0.063475	0.812067740483154	0.0632114	0.112941	0.239674791338284	0.0415237	0.0410653	0.505931716666166	0.0172248	0.0499849	0.136442803077255	0.0762439	0.0679697	0.581738493203107	0.0319589	0.0404887	0.366612350910907	-0.00919453	0.0416645	0.0833660539526628	0.0829702	0.0710199	0.614932013101014	0.0276354	0.0392263	0.317752908007045	0.013086	0.047218	0.106974888878911	0.0228822	0.0645142	0.140966234288407	0.0293371	0.0235747	0.670923637880816	-0.0135942	0.0297385	0.188705231273384	0.0860514	0.0380299	1.62612845731841	0.339321	0.112917	2.57045442231611	0.420523	0.138647	2.60751760955897	0.174726	0.194634	0.432206939712334
rs10802107:120068932:C:A		1	120068932	1p12	A	C	0.988	E2 WOMEN	2607	2.53299455378155	0.243560606060606	2.1432	GAPDHP32 (7.4 kb); HSD3B1 (11 kb); HSD3BP3 (12 kb); GAPDHP58 (29 kb); GAPDHP27 (32 kb); HSD3BP4 (38 kb)	NA	GAPDHP58 \| PHGDH \| WARS2 \| ZNF697		Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1 \| Carbon metabolism:PHGDH	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1 \| electron transport chain:PHGDH	0.00287374	0.0196207	0.053759529746181	0.0101349	0.0180266	0.241042713338769	-0.0256435	0.0376242	0.304947576494557	0.0130434	0.0215847	0.26303092536014	0.0308955	0.0237483	0.713330252869696	-0.00960894	0.0423883	0.0857986332850637	0.00849887	0.0161042	0.223490587013023	-0.00575285	0.0187191	0.119962545058656	0.0378571	0.029699	0.692852821379344	-0.0062468	0.0117484	0.225539970725499	-0.0158024	0.0146387	0.552273105403353	0.00552312	0.0188987	0.113455132397025	0.00847204	0.0115651	0.333641165113506	-0.00515568	0.0122174	0.171965576869521	0.0218998	0.0194187	0.586001567325658	0.0161966	0.011307	0.81811355616171	-0.0132078	0.0137847	0.471100003677497	0.0538838	0.0181128	2.53299455378155	0.0109053	0.00673603	0.976920469276128	0.0145881	0.00871941	1.02541232388932	0.00668112	0.0105293	0.279231457392125	0.0238174	0.0324169	0.334798126830073	0.0120146	0.0413407	0.112728247474023	0.0393275	0.0521923	0.345436521051257
rs111447088:74677767:C:T	candidate	15	74677767	15q24.1	T	C	0.921	E2 WOMEN	2607	2.52950571620941	0.0310048139624089	0.0630236	CYP11A1 (18 kb); SEMA7A (24 kb); CCDC33 (49 kb); UBL7 (61 kb)	NA	ARID3B \| C15orf59 \| COMMD4 \| CSK \| CTD-2311M21.2 \| CYP11A1 \| CYP1A1 \| EDC3 \| IMP3 \| LOXL1 \| MAN2C1 \| MPI \| NEO1 \| PPCDC \| RP11-10O17.1 \| SEMA7A \| SNUPN \| UBL7 \| ULK3	BCAT1 \| PSTPIP1	Ovarian steroidogenesis:CYP11A1 \| Steroid hormone biosynthesis:CYP11A1 \| Cortisol synthesis and secretion:CYP11A1 \| Aldosterone synthesis and secretion:CYP11A1 \| Cushing syndrome:CYP11A1	Metabolism of steroid hormones:CYP11A1 \| Metabolism of steroids:CYP11A1 \| Cytochrome P450 - arranged by substrate type:CYP11A1 \| Phase I - Functionalization of compounds:CYP11A1	hypospadias:CYP11A1 \| essential hypertension:CYP11A1 \| physical disorder:CYP11A1 \| polycystic ovary syndrome:CYP11A1	cellular hormone metabolic process:CYP11A1 \| hormone biosynthetic process:CYP11A1 \| hormone metabolic process:CYP11A1 \| vitamin D metabolic process:CYP11A1 \| steroid metabolic process:CYP11A1 \| positive regulation of axon extension:SEMA7A \| fat-soluble vitamin metabolic process:CYP11A1 \| negative regulation of endocytosis:CSK \| steroid biosynthetic process:CYP11A1 \| cellular senescence:ULK3 \| positive regulation of axonogenesis:SEMA7A \| regulation of axon extension:SEMA7A \| protein autophosphorylation:CSK,ULK3 \| Fc receptor mediated stimulatory signaling pathway:CSK \| bone remodeling:CSK \| regulation of hormone levels:CYP11A1 \| post-Golgi vesicle-mediated transport:CSK \| regulation of extent of cell growth:SEMA7A \| regulation of ERK1 and ERK2 cascade:CSK,SEMA7A \| cell aging:ULK3 \| axon extension:SEMA7A \| ERK1 and ERK2 cascade:CSK,SEMA7A \| aging:ULK3 \| vitamin metabolic process:CYP11A1 \| positive regulation of cell morphogenesis involved in differentiation:SEMA7A \| immune response-regulating cell surface receptor signaling pathway:CSK \| neuron projection extension:SEMA7A \| regulation of cell size:SEMA7A \| regulation of axonogenesis:SEMA7A \| regulation of cell growth:SEMA7A \| positive regulation of cell growth:SEMA7A \| tissue remodeling:CSK \| positive regulation of developmental growth:SEMA7A \| axonogenesis:NEO1,SEMA7A \| regulation of vesicle-mediated transport:CSK \| positive regulation of ERK1 and ERK2 cascade:SEMA7A \| developmental cell growth:SEMA7A \| axon development:NEO1,SEMA7A	0.0145363	0.0506702	0.111128882699035	-0.0407813	0.0448362	0.439835028656846	0.0404623	0.100559	0.162784786099361	0.0193437	0.0557462	0.137492951449532	0.0129809	0.0591144	0.0829021938714388	0.0596282	0.117441	0.213389817488432	-0.00699397	0.041592	0.0622429608273347	-0.0242854	0.0465643	0.220350848318401	0.0496916	0.0823691	0.262397118965892	0.0617356	0.0306882	1.35407691051249	0.0573797	0.0380206	0.88188414368544	0.0676228	0.0496619	0.761191413293702	0.0358953	0.0301196	0.63198102814762	0.0238703	0.0316236	0.346445011202992	0.0732296	0.0518718	0.801271452744495	0.0769748	0.0292781	2.06745724074571	0.0421165	0.0360749	0.614357983470767	0.138465	0.046583	2.52950571620941	-0.0150782	0.0175854	0.4075911625619	-0.0321686	0.0225152	0.815092894766224	0.00300536	0.0278037	0.0390903929792887	0.0463235	0.0847106	0.233180564023049	-0.0355043	0.105588	0.132688697668122	0.189442	0.141928	0.73898469011383
rs112616375:119951508:C:CAGAA		1	119951508	1p12	CAGAA	C	0.977	OHP17 MEN	1358	2.52010236344829	0.633732695139912		HSD3B2 (6 kb); HAO2 (15 kb); HSD3BP2 (30 kb); HAO2-IT1 (39 kb)	NA	HAO2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.0179032	0.0172871	0.522165640455858	0.0187959	0.0156391	0.638971374186328	0.0405021	0.0341561	0.627633047245777	0.0370451	0.0190065	1.28885019140788	0.0610794	0.0205575	2.52010236344829	-0.00764838	0.0383128	0.0747771491950699	-0.00466611	0.014193	0.129379586759168	-0.00541976	0.0162465	0.131510148585058	-0.00418952	0.0268736	0.0574170735618272	-0.0288729	0.010434	2.24764957271277	-0.022588	0.0130211	1.08201634713585	-0.0374895	0.0167423	1.59959845058313	-0.00159047	0.0102635	0.0570746936852402	0.0157046	0.0108563	0.829703072966422	-0.0248261	0.0173353	0.817836523434112	0.00592521	0.0100362	0.255759448385033	0.00296274	0.0123188	0.0915482246873276	-0.00539436	0.0160082	0.133041943008688	-0.00185564	0.00598119	0.121263982418613	-0.00501851	0.0077366	0.286886793359975	0.00213892	0.00934883	0.0866991298001095	-0.0523091	0.0285782	1.17171076504845	-0.038188	0.0359262	0.540610528185143	-0.0780075	0.0470767	1.00888960385508
rs7172632:74675658:T:G		15	74675658	15q24.1	G	T	0.883	ALDO WOMEN	686	2.38188911826283	0.0694734548104956		CYP11A1 (16 kb); SEMA7A (26 kb); CCDC33 (47 kb); UBL7 (63 kb)	NA	ARID3B \| CSK \| CYP11A1 \| CYP1A1 \| LOXL1 \| MAN2C1 \| SCAMP5 \| SEMA7A \| UBL7 \| ULK3	BCAT1	Ovarian steroidogenesis:CYP11A1 \| Steroid hormone biosynthesis:CYP11A1 \| Cortisol synthesis and secretion:CYP11A1 \| Aldosterone synthesis and secretion:CYP11A1 \| Cushing syndrome:CYP11A1	Metabolism of steroid hormones:CYP11A1 \| Metabolism of steroids:CYP11A1 \| Cytochrome P450 - arranged by substrate type:CYP11A1 \| Phase I - Functionalization of compounds:CYP11A1	hypospadias:CYP11A1 \| essential hypertension:CYP11A1 \| physical disorder:CYP11A1 \| polycystic ovary syndrome:CYP11A1	cellular hormone metabolic process:CYP11A1 \| hormone biosynthetic process:CYP11A1 \| hormone metabolic process:CYP11A1 \| vitamin D metabolic process:CYP11A1 \| steroid metabolic process:CYP11A1 \| positive regulation of axon extension:SEMA7A \| fat-soluble vitamin metabolic process:CYP11A1 \| steroid biosynthetic process:CYP11A1 \| positive regulation of axonogenesis:SEMA7A \| regulation of axon extension:SEMA7A \| regulation of hormone levels:CYP11A1 \| regulation of extent of cell growth:SEMA7A \| regulation of ERK1 and ERK2 cascade:SEMA7A \| axon extension:SEMA7A \| ERK1 and ERK2 cascade:SEMA7A \| vitamin metabolic process:CYP11A1 \| positive regulation of cell morphogenesis involved in differentiation:SEMA7A \| neuron projection extension:SEMA7A \| regulation of cell size:SEMA7A \| regulation of axonogenesis:SEMA7A \| regulation of cell growth:SEMA7A \| positive regulation of cell growth:SEMA7A \| positive regulation of developmental growth:SEMA7A \| axonogenesis:SEMA7A \| positive regulation of ERK1 and ERK2 cascade:SEMA7A \| developmental cell growth:SEMA7A \| axon development:SEMA7A	0.0138992	0.0362452	0.154031142553932	-0.0202646	0.0327402	0.270793079304113	0.0796343	0.0713207	0.578100064156831	0.0304543	0.0398724	0.351564847935342	0.0196107	0.0431569	0.187347298250576	0.0738373	0.0807693	0.442569798955678	-0.0203737	0.0297488	0.306704042790052	-0.0210134	0.0339952	0.270354187760725	-0.00165016	0.0566866	0.0102010182556879	0.0353702	0.0216259	0.991680933270165	0.0387971	0.0266562	0.837011661412672	0.0337482	0.0352419	0.470753207206564	0.0401974	0.0212931	1.22877494979754	0.0256725	0.0222278	0.605367984314778	0.0529269	0.0364609	0.833833444019025	0.0455665	0.0206805	1.55956638439156	0.0318944	0.0251275	0.68965936325582	0.0801263	0.0334767	1.7775800945836	0.00192513	0.012421	0.0570845995855623	-0.00347614	0.015888	0.0825927035688425	0.00848025	0.0197062	0.175904769621444	0.0625629	0.0606041	0.51992547342538	-0.0672657	0.0762169	0.422923161063138	0.286034	0.0994485	2.38188911826283
rs41427946:120109260:C:T		1	120109260	1p12	T	C	1	ALDO MEN	1307	2.37172144586639	0.0416985462892119		HSD3BP4 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); GAPDHP27 (6.9 kb); HSD3BP3 (21 kb); GAPDHP33 (30 kb); LINC00622 (31 kb); GAPDHP32 (32 kb); HSD3BP5 (35 kb)	NA	PHGDH		Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1 \| Carbon metabolism:PHGDH	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1 \| electron transport chain:PHGDH	0.0158546	0.0445309	0.141553039189747	-0.0677031	0.0376896	1.13867950347154	0.122858	0.0957693	0.699965679182894	-0.057446	0.0489776	0.618037022344002	-0.057701	0.0497121	0.609123155820452	-0.0829841	0.114521	0.328897539065737	-0.0577117	0.0365313	0.941923373854293	-0.0500392	0.0391572	0.695720638929059	-0.0988233	0.080271	0.660179019053645	0.0124353	0.0247	0.211374940339662	0.00261894	0.0304191	0.0308679629560271	0.0280942	0.0401704	0.314871183241445	0.00742526	0.0246897	0.117127824116909	0.0146057	0.0253767	0.24801689343372	-0.0209935	0.0441	0.197881287813123	-0.0187616	0.0236908	0.36815155160066	0.00213031	0.028545	0.0266370442054305	-0.056114	0.0395205	0.80786482620079	-0.0118235	0.0142695	0.390042940941965	-0.00838382	0.0181351	0.191203833154757	-0.01617	0.0227425	0.321406058472998	-0.194152	0.0729664	2.10473716666437	-0.245419	0.0856877	2.37172144586639	-0.0323391	0.140222	0.0874203426473169
rs4659174:119956344:G:A		1	119956344	1p12	A	G	0.971	ALDO WOMEN	686	2.35813837033221	0.116784985422741		HSD3B2 (1.2 kb, near gene/Upstream gene/MODIFIER); HAO2 (20 kb); HSD3BP2 (25 kb); HAO2-IT1 (43 kb); GAPDHP23 (48 kb)	NA	LOC644242 \| PHGDH \| RP11-114O18.1 \| RP11-439A17.9 \| RP5-871G17.5 \| WARS2 \| ZNF697	PLA2G4C	Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.0385052	0.0273195	0.798999111096605	0.00436698	0.0246162	0.0658961279388384	0.102982	0.0538857	1.25189961625892	0.0554905	0.0300462	1.18766430495329	0.0783522	0.0323764	1.80549120824222	0.0134027	0.0611214	0.0827592439462921	-0.0411609	0.0224171	1.17730768268415	-0.0424569	0.025534	1.01505974072642	-0.0382584	0.0428491	0.429183960764635	0.0249603	0.0161192	0.915405850232498	0.00516434	0.019951	0.0992233527069593	0.0493014	0.0261177	1.22862273618353	0.0267225	0.015921	1.03030272615989	0.0326507	0.0166541	1.30159407606892	0.0109508	0.0271948	0.162927592915921	0.0064803	0.0154715	0.170488458923407	0.0150544	0.0187956	0.373494365229201	-0.0095345	0.0250869	0.152487800832084	0.0137587	0.00925744	0.862592079964339	-0.00307753	0.011889	0.0992249900125222	0.0350608	0.014592	1.78853237556086	-0.0967303	0.0449359	1.50213085850291	-0.0335882	0.0564224	0.258260019538283	-0.211773	0.0740807	2.35813837033221
rs75633256:119935133:C:A		1	119935133	1p12	A	C	0.891	ALDO ALL	1993	2.2476956628689	0.0227167586552935		HAO2 (0 kb, nc-exon/Non coding transcript exon/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); HAO2-IT1 (22 kb); HSD3B2 (22 kb); HSD3BP2 (46 kb)	NA	LOC644242 \| RP11-114O18.1 \| ZNF697		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.031965	0.0590395	0.230417392743363	-0.00648725	0.0523351	0.0450978641373603	0.178036	0.11653	0.897706965390312	0.00360374	0.0649591	0.0196493317308901	0.0649714	0.0689593	0.460580116248507	-0.104067	0.136251	0.35139997346097	-0.0742503	0.0484371	0.901536258190643	-0.053761	0.0543217	0.491459507965882	-0.102199	0.0955311	0.545040867005196	0.0352501	0.0354227	0.495289967603248	-0.0211266	0.0436434	0.201808748204626	0.109202	0.0576782	1.23419142088247	0.0400132	0.0348287	0.600992938839587	0.0361331	0.0363254	0.495015628022035	0.0572331	0.0602516	0.465768224212476	0.00575586	0.0337084	0.0632767006809837	0.0426992	0.0412757	0.521566265866866	-0.0480016	0.0540509	0.42655281664864	0.016621	0.020315	0.383770323292642	-0.00716304	0.0259142	0.106664976849547	0.046286	0.0322994	0.818588063778063	-0.268495	0.0969207	2.2476956628689	-0.239677	0.120065	1.33612953502429	-0.332346	0.164363	1.36087225062948
rs150280453:120103235:C:G		1	120103235	1p12	G	C	0.93	E2 ALL	6798	2.23628082725527	0.0107458075904678	0.559616	GAPDHP27 (0.84 kb, near gene/Upstream gene/MODIFIER); HSD3BP4 (3.5 kb, near gene/Upstream gene/MODIFIER); HSD3BP3 (15 kb); GAPDHP32 (26 kb); GAPDHP33 (36 kb); LINC00622 (37 kb); HSD3BP5 (41 kb); HSD3B1 (46 kb)	NA			Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1	0.054415	0.0805615	0.301492330998765	0.103723	0.0805938	0.702635676113051				-0.0177669	0.0886418	0.0751208713607011	0.0959298	0.106262	0.435560017052219	-0.160036	0.154957	0.519903906399463	0.0744962	0.0661141	0.585085118683244	0.0470277	0.0837244	0.240773471594911	0.0931298	0.108716	0.406784843989889	0.126687	0.0509349	1.89028312179711				0.119655	0.0803282	0.865392637521278	0.056948	0.0496578	0.599529361694234				0.0285171	0.0786134	0.144607456296371	0.135697	0.0491895	2.23628082725527							-6.47162E-4	0.0290705	0.0077828261110158				0.0255406	0.0442193	0.249074481701267	-0.0799381	0.13076	0.266764204005438	0.0530922	0.18172	0.113392538624793	-0.227864	0.187331	0.649242372521891
rs200594574:119961237:TCTTTTATTATTATTA:T		1	119961237	1p12	T	TCTTTTATTATTATTA	0.857	PROG WOMEN	1261	2.23290724111967	0.0501806106264869	0.0633567	HSD3B2 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); HSD3BP2 (20 kb); HAO2 (24 kb); GAPDHP23 (43 kb); HAO2-IT1 (48 kb); HSD3BP1 (49 kb)	NA	RP5-871G17.5 \| WARS2 \| ZNF697	PLA2G4C	Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.0640085	0.0407511	0.934043288649907	-0.0416321	0.036947	0.584984894951903	0.219362	0.0795908	2.23290724111967	0.0904342	0.0448165	1.35918973680615	0.0711674	0.0486834	0.841586240054582	0.119804	0.0900028	0.736172268789173	0.0030642	0.0334695	0.0328907516994355	-0.00983103	0.0383803	0.0980645982485432	0.0224243	0.0632031	0.14095361707259	0.00636971	0.0245197	0.0996142981402058	-0.0106162	0.0309517	0.135724522330702	0.0256843	0.0388194	0.293962775571364	0.0300958	0.0241348	0.672841398207921	0.0183378	0.0258281	0.320837485685951	0.035384	0.0403347	0.419822288589145	-0.0235785	0.0236546	0.496386338227498	2.67999E-4	0.0293428	0.00317629081183408	-0.039031	0.0372092	0.531363236400254	0.0378849	0.0140609	2.15163412108989	0.0203655	0.0183887	0.571738825221292	0.0589908	0.0216738	2.18752449921489	-0.091062	0.0671742	0.756024886898425	-0.0313186	0.0849132	0.147328519837663	-0.191489	0.109622	1.09087259338395
rs58712424:74635105:A:G		15	74635105	15q24.1	G	A	0.849	PROG ALL	2070	2.15187002500739	0.0391417826086957		CYP11A1 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| near gene/Downstream gene/MODIFIER \| near gene/Upstream gene/MODIFIER); CCDC33 (6.3 kb); SEMA7A (67 kb); UBL7 (100 kb)	NA	COMMD4 \| CSK \| CTD-2311M21.2 \| CYP11A1 \| GOLGA6A		Ovarian steroidogenesis:CYP11A1 \| Steroid hormone biosynthesis:CYP11A1 \| Cortisol synthesis and secretion:CYP11A1 \| Aldosterone synthesis and secretion:CYP11A1 \| Cushing syndrome:CYP11A1	Metabolism of steroid hormones:CYP11A1 \| Metabolism of steroids:CYP11A1 \| Cytochrome P450 - arranged by substrate type:CYP11A1 \| Phase I - Functionalization of compounds:CYP11A1	hypospadias:CYP11A1 \| essential hypertension:CYP11A1 \| physical disorder:CYP11A1 \| polycystic ovary syndrome:CYP11A1	cellular hormone metabolic process:CYP11A1 \| hormone biosynthetic process:CYP11A1 \| hormone metabolic process:CYP11A1 \| vitamin D metabolic process:CYP11A1 \| steroid metabolic process:CYP11A1 \| fat-soluble vitamin metabolic process:CYP11A1 \| steroid biosynthetic process:CYP11A1 \| regulation of hormone levels:CYP11A1 \| vitamin metabolic process:CYP11A1	0.127955	0.0474396	2.15187002500739	-5.0926E-4	0.0431184	0.00411132160361324	0.213114	0.0937415	1.6382532820241	0.0563761	0.0522696	0.551435892317178	0.0477857	0.0568184	0.397416998871502	0.0709981	0.105011	0.301729773252083	-0.00104835	0.0390082	0.0094116529851733	-0.035873	0.0447605	0.373643205721184	0.0612855	0.0736443	0.391917044374134	-0.0125597	0.0258607	0.202592565458218	0.02424	0.0327229	0.338343461461461	-0.0593227	0.040799	0.835825658083351	-0.0267115	0.0259565	0.517930032788216	-0.0213458	0.0274282	0.360088389182951	-0.0521886	0.0436622	0.634553200159293	0.0133029	0.0248358	0.227523530085974	0.00557436	0.0306606	0.0676617198027377	0.0229138	0.0395228	0.250204958187028	-0.0105155	0.0149657	0.31670074776034	-0.0124436	0.0196467	0.278607398612555	-0.00866834	0.0229694	0.151264816234721	-0.0836122	0.0782706	0.544333044817599	-0.0799749	0.0988335	0.3782485032881	-0.084889	0.128248	0.293922612689924
rs187677131:119942426:G:A		1	119942426	1p12	A	G	0.853	OHP17 MEN	1358	2.14778969423982	0.0414388217967599		HAO2 (5.7 kb); HSD3B2 (15 kb); HAO2-IT1 (29 kb); HSD3BP2 (39 kb)	NA	HSD3BP5 \| PHGDH \| RP11-418J17.1 \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2,PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	0.00340111	0.0469595	0.0258246357330065	8.79868E-4	0.0411428	0.00747254945517361	-0.0345036	0.0998039	0.13694017590397	-0.0785177	0.0516354	0.89106645588549	-0.145784	0.0540843	2.14778969423982	0.0697603	0.110974	0.275888046038788	-0.0352916	0.0385378	0.44382177348845	-0.0543751	0.0426942	0.692448341724816	0.00669229	0.0778603	0.0308036202696935	0.0321899	0.0297897	0.55301416953375	-8.11801E-4	0.0365654	0.0077616035513393	0.0825071	0.0488458	1.04003421084856	0.0209736	0.0289477	0.329069837345274	0.0191217	0.0303066	0.277301102660071	0.0503026	0.0504884	0.496081361871641	0.00150642	0.0283894	0.0187786752344196	0.0241801	0.0348798	0.31143958901735	-0.0151077	0.0457729	0.129973193224526	-0.00742313	0.016971	0.179260112730118	-0.00288834	0.021527	0.0490191960608954	-0.0184195	0.0272128	0.302343549465424	0.0623509	0.0772822	0.376873777140697	0.0585311	0.0941139	0.272373356383521	0.0676861	0.135649	0.209042446654696
rs113687116:119941899:T:A		1	119941899	1p12	A	T	0.813	ALDO ALL	1993	2.10173842288645	0.0157345208228801		HAO2 (5.1 kb); HSD3B2 (16 kb); HAO2-IT1 (29 kb); HSD3BP2 (40 kb)	NA	FAM46C \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	-0.0205421	0.0768272	0.102811272531644	-0.0357192	0.0754165	0.196650105500745	-0.0437451	0.13636	0.125891174671797	0.059104	0.0845158	0.314770762527221	0.0394185	0.099407	0.160037020366739	0.0752936	0.1509	0.209039635496126	0.0535086	0.0630519	0.402109644758804	0.104477	0.0782622	0.73965428183309	-0.0139327	0.105862	0.0480178334057323	0.0772407	0.042458	1.16192703830564	0.0993794	0.0564059	1.10739011761347	0.0617914	0.0638248	0.477589676695986	0.00428055	0.0425617	0.0362641022731353	-0.0305993	0.0475046	0.284424480049007	0.0302163	0.0666671	0.186836828856531	-0.0298256	0.0400535	0.34057253733227	-0.0483535	0.0527531	0.444479933702609	-0.0184317	0.058823	0.122616558563758	0.00773167	0.024544	0.123348081929039	0.03918	0.0339258	0.6052997217234	-0.0229038	0.0357296	0.282744021681749	0.333262	0.125357	2.10173842288645	0.308946	0.171934	1.13915132386324	0.367436	0.181998	1.35765420973955
rs61808475:120023111:A:G		1	120023111	1p12	G	A	0.825	OHP17 ALL	2070	2.07680573633219	0.929009903381642		HSD3BP1 (6.7 kb); GAPDHP58 (15 kb); GAPDHP23 (17 kb); HSD3B1 (27 kb); HSD3BP2 (34 kb)	NA	PHGDH \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2,PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	0.0251467	0.0360565	0.313707012630417	-0.0044902	0.0331237	0.0495426488024918	0.0714541	0.0712451	0.500459997694269	0.10452	0.0396069	2.07680573633219	0.0943835	0.0435843	1.51540550994877	0.106239	0.0779442	0.761168860156735	0.0241352	0.0295949	0.382089015476944	0.0102563	0.0343924	0.116006016947956	0.0358064	0.0547267	0.28975905209434	-0.0324266	0.0221059	0.846456463966042	-0.0112765	0.0275066	0.166318161510783	-0.053355	0.0356402	0.871658899617022	7.41063E-4	0.0216462	0.0120255489822781	0.00779744	0.0229183	0.134490359872781	0.0169827	0.036334	0.193677546513504	0.0215441	0.0213409	0.504836010067834	-0.00595421	0.0258987	0.0871585721600495	0.0621497	0.0344022	1.14977601359875	0.00121015	0.012628	0.0344902144671541	-0.0125301	0.0162994	0.354534499867781	0.0194329	0.0198175	0.485727254752635	-0.0198812	0.0593942	0.132024855307933	0.0492777	0.0756909	0.288078098624511	-0.12395	0.0957331	0.708087511683787
rs75938737:120031042:C:T		1	120031042	1p12	T	C	0.963	TESTO MEN	4291	2.02088203587031	0.0562879282218597	0.605825	GAPDHP58 (7.4 kb); HSD3BP1 (15 kb); HSD3B1 (19 kb); GAPDHP23 (25 kb); HSD3BP2 (42 kb); GAPDHP32 (45 kb)	NA	PHGDH \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2,PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	-0.0875436	0.039681	1.56097220893907	-0.0105793	0.0357158	0.115138392792544	-0.0991651	0.0758025	0.71941252502124	-0.0507246	0.0436937	0.609398686411286	-0.00633555	0.0470773	0.0491650767144678	-0.116541	0.089245	0.716637702928702	-0.00450041	0.0326095	0.0504899689952761	0.0241667	0.0370802	0.288464395345717	-0.0451223	0.0626506	0.326402260944891	-0.027122	0.022165	0.6554348289962	-0.0148517	0.0275627	0.229146516175667	-0.0346626	0.0357595	0.478359890059266	0.0111355	0.0221379	0.211152425723541	0.0597472	0.0230469	2.02088203587031	-0.0110457	0.0379616	0.112903940691612	0.00325836	0.0211448	0.0567365427271819	0.0213026	0.025836	0.387600823101303	-0.0150871	0.0342125	0.180966331110438	-0.00438162	0.0128004	0.135415949359954	0.00847494	0.0165305	0.215972864381456	-0.020059	0.0200638	0.49835476721836	-0.0669914	0.0666166	0.502078417312015	-0.0533379	0.0828994	0.283934022254778	-0.105779	0.1121	0.461298107913621
rs116103231:119948936:G:A		1	119948936	1p12	A	G	0.84	DHEAS WOMEN	3358	1.94283998039171	0.0220043031566409	0.202037	HSD3B2 (8.6 kb); HAO2 (12 kb); HSD3BP2 (33 kb); HAO2-IT1 (36 kb)	NA	PHGDH		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.0463199	0.0647009	0.324103480338508	0.119292	0.0553347	1.50482767771973	-0.0488504	0.138793	0.139743468725603	0.0784558	0.0711711	0.567935496307783	0.159134	0.0729322	1.53335032267999	-0.146789	0.161314	0.439910363789343	0.0865075	0.0530808	0.985857638454994	0.120483	0.057461	1.44131182499047	-0.0145818	0.113213	0.0469398971474827	-0.0899899	0.0362675	1.88302054218172	-0.0403743	0.0443953	0.439945046258929	-0.150568	0.0595134	1.94283998039171	-0.0294979	0.0362385	0.38127326001955	-0.0304646	0.0371647	0.384705565143217	-0.0309246	0.0645867	0.199230699571693	-0.0147472	0.0345589	0.174198824183798	-0.0574815	0.0417819	0.772372921747923	0.0424833	0.0571041	0.34017979246948	0.0275015	0.0209391	0.723432507385317	0.0297038	0.0264903	0.58144019807968	0.0260755	0.0336217	0.358514982693814	0.0839426	0.109625	0.352685505134096	0.0740195	0.131404	0.241596090282812	0.1136	0.199515	0.244668733442496
rs79346361:120001155:G:A		1	120001155	1p12	A	G	0.86	TESTO MEN	4291	1.94079264503285	0.024831740852948	0.205404	GAPDHP23 (3.5 kb, near gene/Downstream gene/MODIFIER); HSD3BP1 (8.7 kb); HSD3BP2 (12 kb); HSD3B2 (35 kb); GAPDHP58 (37 kb); HSD3B1 (49 kb)	NA	NOTCH2 \| PHGDH \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2,PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	-0.107059	0.0610933	1.09769135978526	-0.0227802	0.0538581	0.172381337746018	-0.0751385	0.118362	0.27938843866923	-0.0163882	0.0672632	0.0928407967113855	0.0422114	0.0709844	0.257925619706542	-0.136733	0.142812	0.470214295862755	0.0392274	0.0501769	0.362078192370475	0.0886795	0.0558742	0.948006725688885	-0.0631489	0.100208	0.276724158180891	-0.0732127	0.0352932	1.41975035840307	-0.0319785	0.0439379	0.330934283075159	-0.117449	0.0568077	1.41241810807538	0.0063109	0.0349963	0.0670734049271642	0.0925461	0.0366036	1.94079264503285	-0.0735138	0.0604184	0.650332074492949	0.0331425	0.0333789	0.493831980958319	0.057748	0.041268	0.79126043725614	-0.00404977	0.0533431	0.0271110740764837	-0.017012	0.0203218	0.395212535982208	0.0130765	0.0261618	0.209578304545955	-0.0571446	0.0319329	1.1335318902281	-0.0504073	0.102153	0.206383507555199	-0.0794414	0.123687	0.283324854966005	0.00830169	0.181756	0.0161108706406092
rs415630:120112792:G:A		1	120112792	1p12	A	G	0.951	CORT MEN	4301	1.93834776123993	0.167906440362706	0.0300297	HSD3BP4 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); GAPDHP27 (10 kb); HSD3BP3 (24 kb); GAPDHP33 (26 kb); LINC00622 (28 kb); HSD3BP5 (31 kb); GAPDHP32 (35 kb); ZNF697 (49 kb)	NA	GAPDHP58 \| PHGDH \| WARS2 \| ZNF697		Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1	-0.00409509	0.0231967	0.065557606661981	0.0028759	0.020763	0.0506797788615024	-0.0107239	0.0453361	0.0899030442025841	0.0333252	0.0255104	0.717640763534409	0.0497264	0.0273339	1.16052886619646	0.00954627	0.0525099	0.0676317776465408	0.00967663	0.0190394	0.213718608173261	-0.0013632	0.0215589	0.0224629528260961	0.0369378	0.0368061	0.500416005837649	-0.00331508	0.0138024	0.0914131215222417	-0.00129655	0.0173163	0.0267266359267059	-0.00720083	0.0220014	0.128748818370355	0.0058241	0.0136053	0.174836225983241	-0.00764757	0.0144315	0.224632067408641	0.024009	0.0230318	0.526932198596558	0.00959885	0.0132858	0.327908610328139	-0.00955264	0.0163245	0.25303048086619	0.0343245	0.0212731	0.972112445047523	0.0129254	0.00791757	0.988950006600912	0.0259613	0.0102762	1.93834776123993	-0.00265684	0.0123086	0.0813915134147955	-0.00715831	0.0383815	0.0695252349212202	-0.0277178	0.0476669	0.251028623249247	0.0270668	0.0647535	0.170001911302621
rs149160089:119952402:G:C		1	119952402	1p12	C	G	0.942	PROG WOMEN	1261	1.87903472211448	0.0149171292624901	1.44182	HSD3B2 (5.2 kb); HAO2 (16 kb); HSD3BP2 (29 kb); HAO2-IT1 (39 kb)	NA	WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.162239	0.0726142	1.59223020930699	-0.0133016	0.0674173	0.0738531328364423	0.346473	0.139819	1.87903472211448	0.164445	0.0799039	1.40108152102435	0.0881639	0.08883	0.493319120699892	0.270687	0.154259	1.09835426948253	-0.0337228	0.0596711	0.242575879640294	-0.0288302	0.069998	0.167172508660207	-0.0530685	0.108417	0.204362560428639	0.0304829	0.0446051	0.305958433435132	0.0220799	0.057774	0.153458780314754	0.0377583	0.0687223	0.234549019438586	0.0246246	0.0437612	0.241363601219713	-0.00476338	0.0483217	0.0355164428749981	0.0282533	0.0706451	0.161650320246158	-0.0136521	0.0440274	0.121192215810143	0.0579204	0.0551265	0.532533969681264	-0.0580679	0.0677513	0.407374740330928	-0.0132077	0.0255873	0.217723067430197	-0.00192435	0.0343461	0.0198515846397798	-0.0223123	0.0383276	0.251449953345219	-0.140567	0.122003	0.603113999126267	-0.179074	0.158173	0.588745726430367	-0.0723516	0.191142	0.151712330904723
rs60540990:74623833:C:A		15	74623833	15q24.1	A	C	0.973	DHEAS ALL	7659	1.87009108273732	0.0659683379031205	0.154804	CCDC33 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); CYP11A1 (6.3 kb); SEMA7A (78 kb); UBL7 (110 kb)	NA	ARID3B \| CSK \| CTD-2311M21.2 \| CYP11A1 \| CYP1A1 \| GOLGA6A \| LOXL1 \| MAN2C1 \| NEO1 \| SEMA7A \| UBL7	BCAT1 \| MAN2C1	Ovarian steroidogenesis:CYP11A1 \| Steroid hormone biosynthesis:CYP11A1 \| Cortisol synthesis and secretion:CYP11A1 \| Aldosterone synthesis and secretion:CYP11A1 \| Cushing syndrome:CYP11A1	Metabolism of steroid hormones:CYP11A1 \| Metabolism of steroids:CYP11A1 \| Cytochrome P450 - arranged by substrate type:CYP11A1 \| Phase I - Functionalization of compounds:CYP11A1	hypospadias:CYP11A1 \| essential hypertension:CYP11A1 \| physical disorder:CYP11A1 \| polycystic ovary syndrome:CYP11A1	cellular hormone metabolic process:CYP11A1 \| hormone biosynthetic process:CYP11A1 \| hormone metabolic process:CYP11A1 \| vitamin D metabolic process:CYP11A1 \| steroid metabolic process:CYP11A1 \| fat-soluble vitamin metabolic process:CYP11A1 \| steroid biosynthetic process:CYP11A1 \| regulation of hormone levels:CYP11A1 \| vitamin metabolic process:CYP11A1	0.0175052	0.0338576	0.21810610391216	0.00215853	0.0313448	0.0245185606716552	-0.018317	0.0640145	0.110826082926112	0.0213616	0.0372491	0.246889790482468	0.0453313	0.0412964	0.564588870925726	0.00117875	0.0723664	0.00567888721636463	0.0349365	0.0277824	0.68045258023996	0.0252004	0.0325391	0.357742288778324	0.0648979	0.0507006	0.696899022425465	0.0506651	0.0205068	1.87009108273732	0.0611338	0.0253279	1.80156836489268	0.0355771	0.0333849	0.542760183457188	0.013678	0.0201395	0.303613028225079	0.019413	0.0211574	0.44508341872803	0.0202749	0.033911	0.259703644183148	0.0321745	0.019632	0.99465644310232	0.0246981	0.0238808	0.521387336018317	0.0523448	0.0316244	1.00929095375023	-0.00208443	0.011743	0.0659502147354145	-0.015838	0.0150982	0.531392761563386	0.011927	0.0185267	0.28422722770879	0.0257236	0.0564306	0.188055866692176	-0.0759467	0.0726518	0.528629066768463	0.179838	0.0891758	1.35534480971151
1:120104419:C:T		1	120104419	1p12	T	C	0.869	DHEAS WOMEN	3358	1.86465105066535	0.0620683621203097	0.251627	GAPDHP27 (2 kb, near gene/Upstream gene/MODIFIER); HSD3BP4 (2.3 kb, near gene/Upstream gene/MODIFIER); HSD3BP3 (16 kb); GAPDHP32 (27 kb); GAPDHP33 (34 kb); LINC00622 (36 kb); HSD3BP5 (40 kb); HSD3B1 (47 kb)	NA	GAPDHP32 \| GAPDHP33 \| HSD3BP4 \| LINC00622 \| LOC644242 \| WARS2 \| ZNF697		Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1	-0.0503339	0.0381564	0.727541065939026	-0.0016575	0.0345783	0.0169265159949599	-0.09975	0.073525	0.75725488865148	0.0208265	0.0419944	0.207613213854222	0.0262145	0.0455712	0.247780942554802	-5.78985E-4	0.0846511	0.00237556165010975	0.0379206	0.0313219	0.645588045130512	0.0241337	0.0358977	0.299717804906594	0.0536444	0.0593417	0.43615359643806	-0.0395573	0.0229652	1.07067867377646	0.00349137	0.0294706	0.0430180298264166	-0.0880298	0.035695	1.86465105066535	-0.0231312	0.0225835	0.514678990222105	-0.0167521	0.0245277	0.305733595138698	-0.0285668	0.0373158	0.352666917927602	-0.00451224	0.0222479	0.0760936434402357	-0.0200155	0.0279027	0.324982798379434	0.00120471	0.0346944	0.0121997142481276	0.0151454	0.0131674	0.601962720257969	0.0286823	0.0174422	0.99960931075009	0.00160373	0.0200023	0.0286796105222113	0.0487236	0.0633629	0.354569870188434	0.0435272	0.0798455	0.232288444164807	0.0589673	0.104269	0.242681422233678
rs6692504:120098815:A:G		1	120098815	1p12	G	A	0.975	ALDO MEN	1307	1.85796424615718	0.385555087987758		GAPDHP27 (2.6 kb, near gene/Downstream gene/MODIFIER); HSD3BP4 (7.9 kb); HSD3BP3 (10 kb); GAPDHP32 (21 kb); GAPDHP33 (40 kb); HSD3B1 (41 kb); LINC00622 (42 kb); HSD3BP5 (45 kb)	NA	ADAM30 \| GAPDHP32 \| HMGCS2 \| HSD3BP4 \| PHGDH \| RP11-418J17.1 \| WARS2 \| ZNF697		Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1 \| Carbon metabolism:PHGDH	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1 \| electron transport chain:PHGDH	0.0063396600000000004	0.0174658	0.144687440769877	0.0129845	0.0155563	0.393569188332667	0.00627527	0.0351454	0.0663659474425908	0.0323715	0.019203	1.0362348320881	0.0466876	0.0204704	1.64361270005147	-0.004074	0.0399274	0.0367988663123976	-0.00761529	0.0143358	0.225240043333206	-0.00869227	0.0161551	0.228685232902988	-0.0116168	0.0280026	0.168526324240007	-0.00523463	0.0105755	0.20717703213223	-0.00148138	0.0132247	0.0405717329861294	-0.0140281	0.0169297	0.390058933815672	-0.0131749	0.0103949	0.688241901945578	-0.0018717	0.0110139	0.0629547731877884	-0.0264223	0.0176926	0.868605918182627	-0.00739993	0.0101657	0.331004076539191	0.0106893	0.0125338	0.404782742125287	-0.0333941	0.0161946	1.40668180523942	-0.00339047	0.0060542	0.239980330502622	-0.0111488	0.00783266	0.810714670008925	0.00560497	0.00945495	0.257032265591833	0.0460759	0.028776	0.960613644828871	0.0874768	0.0355022	1.85796424615718	-0.0317331	0.0490637	0.285674432306677
rs3207643:119928193:T:G		1	119928193	1p12	G	T	0.858	DHEAS WOMEN	3358	1.82534137781043	0.230450268016677	0.0546128	HAO2 (0 kb, intron/Intron/MODIFIER); HAO2-IT1 (15 kb); HSD3B2 (29 kb); HSD3BP2 (53 kb)	NA	PHGDH \| WARS2		Ovarian steroidogenesis:HSD3B2 \| Steroid hormone biosynthesis:HSD3B2 \| Cortisol synthesis and secretion:HSD3B2 \| Aldosterone synthesis and secretion:HSD3B2 \| Cushing syndrome:HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B2 \| Androgen biosynthesis:HSD3B2 \| Metabolism of steroids:HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B2 \| physical disorder:HSD3B2	cellular hormone metabolic process:HSD3B2 \| androgen biosynthetic process:HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B2 \| mineralocorticoid metabolic process:HSD3B2 \| hormone biosynthetic process:HSD3B2 \| hormone metabolic process:HSD3B2 \| glucocorticoid biosynthetic process:HSD3B2 \| glucocorticoid metabolic process:HSD3B2 \| androgen metabolic process:HSD3B2 \| steroid metabolic process:HSD3B2 \| steroid biosynthetic process:HSD3B2 \| regulation of hormone levels:HSD3B2	-7.58954E-4	0.0208456	0.0127986610673794	0.00671391	0.0185915	0.143839265256008	-0.0130517	0.041598	0.122798603654564	0.00172567	0.0229341	0.0268596721634822	0.00925105	0.0245049	0.151289426790648	-0.0112779	0.0475874	0.0900537090007194	0.0157017	0.0171072	0.445136672090274	0.0157713	0.0193003	0.383017492593545	0.0167689	0.0333741	0.210768414765826	-0.0197814	0.0120773	0.993773634623244	0.00256812	0.0150357	0.0632952903659876	-0.0472445	0.0194136	1.82534137781043	-0.0159518	0.0119737	0.738066574934669	-0.00349912	0.0125519	0.107671609371908	-0.0275458	0.020509199999999998	0.746560218831088	-0.00139615	0.0115677	0.0438632780226442	0.00437788	0.0141392	0.120993053838453	-0.0127799	0.0186895	0.306186025072173	-0.00162157	0.00694872	0.0885866857532576	0.00590628	0.00896201	0.292537985211338	-0.0112174	0.0108914	0.518492877106283	-0.00159834	0.0343697	0.01641294997491	-0.0114953	0.0425924	0.103866919744158	0.0138706	0.0583544	0.0903434314580018
1:119937264:T:TTA		1	119937264	1p12	TTA	T	0.819	ALDO ALL	1993	1.80997101248984	0.0270419121926744		HAO2 (0.51 kb, near gene/Downstream gene/MODIFIER); HSD3B2 (20 kb); HAO2-IT1 (24 kb); HSD3BP2 (44 kb)	NA			Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	-0.0181753	0.0585256	0.121379982331166	-0.0667263	0.0542586	0.659571750088262	-0.0232526	0.111334	0.0785413938467224	-0.00276786	0.0643906	0.0151501234241653	-0.0644564	0.0715354	0.434475662333115	0.0731617	0.124481	0.254223561953789	0.0130403	0.0480397	0.104537120595409	0.0152076	0.0563683	0.103825549145164	-0.00710488	0.0873344	0.0291024677032229	0.0490871	0.0321638	0.896298880410486	0.0514816	0.0404975	0.691124115875004	0.0511079	0.0510912	0.498732545542806	-0.0383449	0.0322412	0.630198055088643	-0.0796669	0.033993	1.71903030362613	0.0116426	0.0538496	0.0815355857358012	-0.0161712	0.0305248	0.224557040666352	-0.0457938	0.037791	0.646657054577376	0.0230278	0.0483141	0.198165639535973	0.00283401	0.0185766	0.0561361446300653	-0.00728255	0.0243074	0.116633303839229	0.0150475	0.0286588	0.222178938910434	0.23568	0.0972749	1.80997101248984	0.199166	0.126211	0.940065678109909	0.306259	0.152271	1.34979450433395
rs377497874:119932883:AT:ATT		1	119932883	1p12	ATT	AT	0.985	CORT WOMEN	3366	1.79255414601575	0.0303153594771242	0.22877	HAO2 (0 kb, intron/Intron/MODIFIER \| near gene/Downstream gene/MODIFIER \| near gene/Upstream gene/MODIFIER); HAO2-IT1 (20 kb); HSD3B2 (25 kb); HSD3BP2 (49 kb)	NA			Ovarian steroidogenesis:HSD3B2 \| Steroid hormone biosynthesis:HSD3B2 \| Cortisol synthesis and secretion:HSD3B2 \| Aldosterone synthesis and secretion:HSD3B2 \| Cushing syndrome:HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B2 \| Androgen biosynthesis:HSD3B2 \| Metabolism of steroids:HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B2 \| physical disorder:HSD3B2	cellular hormone metabolic process:HSD3B2 \| androgen biosynthetic process:HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B2 \| mineralocorticoid metabolic process:HSD3B2 \| hormone biosynthetic process:HSD3B2 \| hormone metabolic process:HSD3B2 \| glucocorticoid biosynthetic process:HSD3B2 \| glucocorticoid metabolic process:HSD3B2 \| androgen metabolic process:HSD3B2 \| steroid metabolic process:HSD3B2 \| steroid biosynthetic process:HSD3B2 \| regulation of hormone levels:HSD3B2	-0.0456964	0.0482763	0.463475645833153	-0.0403343	0.0422357	0.4688315867513	-0.0174633	0.101925	0.063506364212557	-0.00653614	0.0531243	0.0447496500363049	0.0430609	0.0556762	0.357129075363836	-0.142811	0.114904	0.668927167601228	-0.0276043	0.0396304	0.313213630191945	-0.010872	0.0438684	0.0945808513672281	-0.0836278	0.0806226	0.522933759399013	0.00283681	0.0284868	0.0358936495165465	-0.00133599	0.0344391	0.0136511251285387	0.00633216	0.0476256	0.0485522213232936	0.029731	0.0281146	0.537173908947387	0.0247861	0.0287089	0.411234319052181	0.0348549	0.0500561	0.313158249045718	-0.0087034	0.0270534	0.126289464056042	0.0129158	0.0324516	0.160755189271325	-0.0528059	0.0451136	0.616549091777679	0.0339868	0.0163589	1.42309224772399	0.0122748	0.0205063	0.260073403116146	0.0641768	0.0266723	1.79255414601575	0.146182	0.0790951	1.18892659892689	0.2171	0.0958499	1.62568249717847	0.00566057	0.140722	0.01415829284454
rs34468200:120058254:C:T		1	120058254	1p12	T	C	0.863	TESTO WOMEN	3352	1.79204265702706	0.0159540572792363	1.19311	HSD3B1 (0.57 kb, near gene/Downstream gene/MODIFIER); GAPDHP32 (18 kb); GAPDHP58 (19 kb); HSD3BP3 (23 kb); HSD3BP1 (42 kb); GAPDHP27 (43 kb); HSD3BP4 (48 kb)	NA	NOTCH2 \| RP11-418J17.1 \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.11824	0.0757863	0.924920430305938	0.0262301	0.068179	0.154590620424282	0.235753	0.149167	0.943087529528925	-0.10946	0.0833935	0.722452668474002	-0.174455	0.0897448	1.28304559136485	0.00399185	0.170049	0.00820793781662726	0.0166906	0.062243	0.103138270848855	-0.029677	0.0707916	0.17061580971075	0.0974974	0.119219	0.383265142190652	-0.0492718	0.0447994	0.566380555577946	0.0595434	0.0580696	0.515438239045659	-0.159393	0.068807	1.68761105062941	-0.0790076	0.0441978	1.13169537274017	0.0282028	0.0482781	0.252508177424836	-0.17514	0.0728022	1.79204265702706	-0.0696464	0.0436302	0.956936525023598	-0.00572739	0.0551168	0.0375179613031383	-0.128568	0.0672844	1.25158402822107	0.00475293	0.0257359	0.0688071603094361	0.00131541	0.0343897	0.0134575621046528	0.00893589	0.0386731	0.0876360368786369	0.182705	0.124054	0.850882542630297	0.0895934	0.153327	0.252509730967774	0.373694	0.210917	1.11418154127674
rs2362811:120014923:G:A		1	120014923	1p12	A	G	0.971	OHP17 ALL	2070	1.74315241793933	0.430573913043478		HSD3BP1 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); GAPDHP23 (9.3 kb); GAPDHP58 (24 kb); HSD3BP2 (26 kb); HSD3B1 (35 kb); HSD3B2 (49 kb)	NA	FCGR1B \| PHGDH \| RP11-418J17.1 \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2,PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	0.0292569	0.0167994	1.08757811830119	0.0229165	0.0151612	0.883096850317361	0.0326974	0.0335749	0.481324216884133	0.0437055	0.018471	1.74315241793933	0.0407752	0.0199697	1.38342156998922	0.0348169	0.0376358	0.449491586739529	0.00604431	0.0137989	0.179528586562359	-9.43633E-4	0.0157556	0.0212485625953398	0.00772656	0.0264129	0.113527887847024	-0.00748226	0.0102851	0.330750082203521	-0.0124282	0.0128199	0.478435679742028	-0.00511846	0.0165409	0.120912726156164	-0.00493801	0.0100829	0.204595534806547	0.00595899	0.0106751	0.239050801658044	-0.0229638	0.0170941	0.746783187497871	-0.00172954	0.00990461	0.064805720332058	0.0133806	0.0121268	0.568863093310614	-0.0192753	0.0158753	0.648431718919547	-0.00461531	0.00588419	0.363681641970796	-0.00980527	0.00759789	0.705822664709368	0.00192809	0.00922575	0.0785965582789138	-0.00994056	0.0276717	0.142993346636589	0.0302589	0.0345858	0.418172038460011	-0.0774982	0.0462726	1.02489736896107
rs34291690:120099137:G:A		1	120099137	1p12	A	G	0.88	ALDO WOMEN	686	1.63636545994152	0.17271749271137		GAPDHP27 (2.2 kb, near gene/Downstream gene/MODIFIER); HSD3BP4 (7.6 kb); HSD3BP3 (11 kb); GAPDHP32 (22 kb); GAPDHP33 (40 kb); LINC00622 (41 kb); HSD3B1 (41 kb); HSD3BP5 (45 kb)	NA	ADAM30 \| GAPDHP32 \| HMGCS2 \| HSD3BP4 \| PHGDH		Ovarian steroidogenesis:HSD3B1 \| Steroid hormone biosynthesis:HSD3B1 \| Cortisol synthesis and secretion:HSD3B1 \| Aldosterone synthesis and secretion:HSD3B1 \| Cushing syndrome:HSD3B1 \| Carbon metabolism:PHGDH	Metabolism of steroid hormones:HSD3B1 \| Androgen biosynthesis:HSD3B1 \| Metabolism of steroids:HSD3B1	essential hypertension:HSD3B1 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1 \| androgen biosynthetic process:HSD3B1 \| mineralocorticoid biosynthetic process:HSD3B1 \| mineralocorticoid metabolic process:HSD3B1 \| hormone biosynthetic process:HSD3B1 \| hormone metabolic process:HSD3B1 \| glucocorticoid biosynthetic process:HSD3B1 \| glucocorticoid metabolic process:HSD3B1 \| androgen metabolic process:HSD3B1 \| steroid metabolic process:HSD3B1 \| steroid biosynthetic process:HSD3B1 \| regulation of hormone levels:HSD3B1 \| electron transport chain:PHGDH	3.66343E-4	0.0234624	0.00544354528985878	0.0033421	0.0211023	0.0583971465712581	0.0248689	0.0472099	0.223043978814944	0.0232165	0.025808	0.433626153993564	0.0237711	0.0278071	0.405849528509147	0.0177611	0.0525822	0.133339977577976	-0.00916236	0.0192575	0.197718297776025	-0.00923344	0.0219099	0.171656596490035	-0.0124002	0.0368822	0.132643899092911	-0.00268287	0.0143101	0.0699255291555097	-0.008358	0.0179229	0.193156198770602	0.00159623	0.0228616	0.0248734538134329	-0.00575847	0.0140338	0.16649335693597	0.00205755	0.0149164	0.050468992532892	-0.00906576	0.0236934	0.153665981146751	-0.00407774	0.0138103	0.114757548604523	0.00464668	0.0170264	0.105172944930286	-0.0236902	0.0219408	0.55243423351507	-0.0102195	0.00818917	0.673543290912867	-0.0201735	0.0106131	1.24163699699871	0.00209069	0.0127597	0.0605566307475344	-0.0464817	0.0388227	0.635749268754024	0.00887002	0.0484592	0.0681385349123161	-0.147232	0.0646635	1.63636545994152
rs4505257:74654146:T:C		15	74654146	15q24.1	C	T	0.964	DHEAS ALL	7659	1.59870632259456	0.124677451364408	0.756763	CTD-2311M21.2 (0 kb, nc-exon/Non coding transcript exon/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); CYP11A1 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); CTD-2311M21.3 (3.6 kb, near gene/Upstream gene/MODIFIER); CCDC33 (25 kb); SEMA7A (47 kb)	NA	AC100835.2 \| ARID3B \| C15ORF39 \| CCDC33 \| CLK3 \| CSK \| CTD-2311M21.2 \| CYP11A1 \| EDC3 \| GOLGA6A \| ISLR \| ISLR2 \| MAN2C1 \| MPI \| PML \| RP11-247C2.2 \| RP11-60L3.2 \| RP11-69H7.2 \| SCAMP2 \| SCAMP5 \| SNUPN \| STOML1 \| STRA6 \| TBC1D21 \| UBL7 \| ULK3 \| unnamed	SLC2A3	Ovarian steroidogenesis:CYP11A1 \| Steroid hormone biosynthesis:CYP11A1 \| Cortisol synthesis and secretion:CYP11A1 \| Aldosterone synthesis and secretion:CYP11A1 \| Cushing syndrome:CYP11A1 \| Acute myeloid leukemia:PML \| Ubiquitin mediated proteolysis:PML	Metabolism of steroid hormones:CYP11A1 \| Interferon gamma signaling:PML \| Metabolism of steroids:CYP11A1 \| Interferon Signaling:PML \| Cytochrome P450 - arranged by substrate type:CYP11A1 \| Phase I - Functionalization of compounds:CYP11A1	hypospadias:CYP11A1 \| essential hypertension:CYP11A1 \| physical disorder:CYP11A1 \| polycystic ovary syndrome:CYP11A1 \| head and neck carcinoma:PML \| head and neck cancer:PML \| acute leukemia:PML	cellular hormone metabolic process:CYP11A1 \| hormone biosynthetic process:CYP11A1 \| hormone metabolic process:CYP11A1 \| interferon-gamma-mediated signaling pathway:PML \| vitamin D metabolic process:CYP11A1 \| steroid metabolic process:CYP11A1 \| cellular response to interferon-gamma:PML \| positive regulation of axon extension:SEMA7A \| fat-soluble vitamin metabolic process:CYP11A1 \| response to interferon-gamma:PML \| negative regulation of endocytosis:CSK \| steroid biosynthetic process:CYP11A1 \| cellular senescence:PML,ULK3 \| positive regulation of axonogenesis:SEMA7A \| regulation of axon extension:SEMA7A \| protein autophosphorylation:CSK,ULK3 \| Fc receptor mediated stimulatory signaling pathway:CSK \| bone remodeling:CSK \| regulation of hormone levels:CYP11A1 \| post-Golgi vesicle-mediated transport:CSK,SCAMP2 \| regulation of extent of cell growth:SEMA7A \| regulation of ERK1 and ERK2 cascade:CSK,SEMA7A \| cell aging:PML,ULK3 \| axon extension:SEMA7A \| ERK1 and ERK2 cascade:CSK,SEMA7A \| aging:PML,ULK3 \| vitamin metabolic process:CYP11A1 \| positive regulation of cell morphogenesis involved in differentiation:SEMA7A \| immune response-regulating cell surface receptor signaling pathway:CSK \| neuron projection extension:SEMA7A \| regulation of cell size:SEMA7A \| regulation of axonogenesis:SEMA7A \| regulation of cell growth:PML,SEMA7A \| positive regulation of cell growth:SEMA7A \| regulation of G1/S transition of mitotic cell cycle:PML \| tissue remodeling:CSK \| regulation of cytokine secretion:PML \| positive regulation of developmental growth:SEMA7A \| axonogenesis:SEMA7A \| regulation of cell cycle G1/S phase transition:PML \| cytokine secretion:PML \| regulation of vesicle-mediated transport:CSK,TBC1D21 \| positive regulation of ERK1 and ERK2 cascade:SEMA7A \| developmental cell growth:SEMA7A \| axon development:SEMA7A	-0.0173011	0.0261596	0.293751748329737	-0.00846506	0.0234388	0.143851966586656	-0.00614343	0.0529926	0.042053836923721	0.0186396	0.0287807	0.286267596197975	0.0112007	0.030894	0.144482661467725	0.0386722	0.0591349	0.289589817658066	-0.0293651	0.0214651	0.765867576714275	-0.0138396	0.0243355	0.244388848741928	-0.0553227	0.0414388	0.739237155063832	-0.0349326	0.0156059	1.59870632259456	-0.0408266	0.0191153	1.48551600166776	-0.0251147	0.0256412	0.484986328046342	0.00441532	0.0153731	0.111287095422411	0.00753757	0.0159609	0.196033774567542	-0.00430266	0.0265649	0.0598168344688033	2.59354E-4	0.01497	0.00604513047002393	0.00391797	0.0180558	0.0818574325255537	-0.0136026	0.0245644	0.236759991797101	-0.00145165	0.00894023	0.0599753630335169	-0.00363321	0.0113849	0.125152462074173	0.00318181	0.0142616	0.0843596016766462	0.0370388	0.0433802	0.405267219823357	0.092271	0.053782	1.06316317014593	-0.0753665	0.0733018	0.516789397527277
rs150562828:74656895:C:T		15	74656895	15q24.1	T	C	0.842	CORT WOMEN	3366	1.59798980698276	0.0170154625668449	0.264626	CTD-2311M21.2 (0 kb, nc-exon/Non coding transcript exon/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Downstream gene/MODIFIER); CYP11A1 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); CTD-2311M21.3 (0.88 kb, near gene/Upstream gene/MODIFIER); CCDC33 (28 kb); SEMA7A (45 kb)	0.467 Facial morphology (factor 9, facial height related to vertical position of nasion)	- \| COMMD4 \| COX5A \| CTD-2323K18.1 \| FBXO22 \| IMP3 \| MAN2C1 \| NRG4 \| PML \| SCAMP2 \| SNUPN \| UBL7 \| ULK3		Ovarian steroidogenesis:CYP11A1 \| Steroid hormone biosynthesis:CYP11A1 \| Cortisol synthesis and secretion:CYP11A1 \| Aldosterone synthesis and secretion:CYP11A1 \| Cushing syndrome:CYP11A1	Metabolism of steroid hormones:CYP11A1 \| Metabolism of steroids:CYP11A1 \| Cytochrome P450 - arranged by substrate type:CYP11A1 \| Phase I - Functionalization of compounds:CYP11A1	hypospadias:CYP11A1 \| essential hypertension:CYP11A1 \| physical disorder:CYP11A1 \| polycystic ovary syndrome:CYP11A1	cellular hormone metabolic process:CYP11A1 \| hormone biosynthetic process:CYP11A1 \| hormone metabolic process:CYP11A1 \| vitamin D metabolic process:CYP11A1 \| steroid metabolic process:CYP11A1 \| positive regulation of axon extension:SEMA7A \| fat-soluble vitamin metabolic process:CYP11A1 \| steroid biosynthetic process:CYP11A1 \| cellular senescence:ULK3 \| positive regulation of axonogenesis:SEMA7A \| regulation of axon extension:SEMA7A \| protein autophosphorylation:ULK3 \| regulation of hormone levels:CYP11A1 \| post-Golgi vesicle-mediated transport:SCAMP2 \| regulation of extent of cell growth:SEMA7A \| regulation of ERK1 and ERK2 cascade:SEMA7A \| cell aging:ULK3 \| axon extension:SEMA7A \| ERK1 and ERK2 cascade:SEMA7A \| aging:ULK3 \| vitamin metabolic process:CYP11A1 \| positive regulation of cell morphogenesis involved in differentiation:SEMA7A \| neuron projection extension:SEMA7A \| regulation of cell size:SEMA7A \| regulation of axonogenesis:SEMA7A \| regulation of cell growth:SEMA7A \| positive regulation of cell growth:SEMA7A \| electron transport chain:COX5A \| positive regulation of developmental growth:SEMA7A \| axonogenesis:SEMA7A \| positive regulation of ERK1 and ERK2 cascade:SEMA7A \| developmental cell growth:SEMA7A \| axon development:SEMA7A	0.106492	0.064298	1.0095394887483	-0.0147387	0.0565357	0.0999798992580518	0.219788	0.131641	1.02228782366369	0.0272953	0.0707843	0.155011788333622	-0.0496798	0.0745079	0.296681963038307	0.188705	0.150925	0.674494598915043	-0.0124225	0.0528119	0.0893430509206136	0.00385134	0.0587041	0.0233286611138688	-0.0510518	0.105961	0.200591898880893	-0.00965321	0.0427046	0.0855690406921794	-0.0602324	0.0531877	0.589315538458988	0.0504585	0.0686324	0.335153145943757	0.02773	0.0410762	0.301360184958059	0.0338552	0.0438937	0.356024510882316	0.0104157	0.070357	0.0543787985016965	0.0194134	0.0407426	0.198098474624967	0.0265392	0.0509457	0.220103501914541	0.0240421	0.0638881	0.15077597052231	-0.0485639	0.0242123	1.347923928069	-0.0204162	0.0310459	0.291759314217941	-0.0854733	0.0381956	1.59798980698276	-0.00284497	0.105567	0.00943783849709045	-0.0281534	0.129052	0.0823149281623553	0.0531225	0.183706	0.112080149075397
rs17023709:119992077:A:T		1	119992077	1p12	T	A	0.822	ANDRO MEN	1358	1.51859607273032	0.0288832083946981		HSD3BP2 (3.4 kb, near gene/Downstream gene/MODIFIER); GAPDHP23 (13 kb); HSD3BP1 (18 kb); HSD3B2 (26 kb); GAPDHP58 (46 kb)	NA	LOC644242 \| PHGDH \| RP11-114O18.1 \| RP11-439A17.9 \| RP5-871G17.5 \| WARS2 \| ZNF697		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2	0.0335556	0.0531817	0.27725422814022	0.00117459	0.0500956	0.0081995288690391	0.0890155	0.0980343	0.439045394506546	0.067259	0.0584968	0.601428118454217	0.0851868	0.0659891	0.70564180976025	0.0504076	0.110493	0.188169720097515	-0.0420566	0.0436474	0.474458954828637	-0.112599	0.0519257	1.51859607273032	0.068365	0.0774707	0.422708159521638	0.0281751	0.0316584	0.427731487034776	-0.0221429	0.0403757	0.234032086377339	0.079365	0.0495773	0.960927104568028	0.00467496	0.031202	0.0550733900137844	0.0324924	0.0336993	0.475017424690702	-0.0545771	0.0508694	0.547719701132091	0.00164739	0.0306115	0.0190508515419653	-0.028498	0.0380357	0.343222605764687	0.0266695	0.0478883	0.238381838270689	-0.00684662	0.0181346	0.151338036736145	-0.0273563	0.0240183	0.593950594058694	0.0154529	0.027591	0.240007499945132	-0.12896	0.0867691	0.862101778809924	-0.0607989	0.113849	0.226644407471447	-0.236436	0.133482	1.11374509870425
rs67607949:119997166:A:G		1	119997166	1p12	G	A	0.889	ALDO MEN	1307	1.49779827997349	0.188426702371844		GAPDHP23 (7.5 kb); HSD3BP2 (8.5 kb); HSD3BP1 (13 kb); HSD3B2 (32 kb); GAPDHP58 (41 kb)	NA	PHGDH \| WARS2		Ovarian steroidogenesis:HSD3B1,HSD3B2 \| Steroid hormone biosynthesis:HSD3B1,HSD3B2 \| Cortisol synthesis and secretion:HSD3B1,HSD3B2 \| Aldosterone synthesis and secretion:HSD3B1,HSD3B2 \| Cushing syndrome:HSD3B1,HSD3B2 \| Carbon metabolism:HAO2,PHGDH	Metabolism of steroid hormones:HSD3B1,HSD3B2 \| Androgen biosynthesis:HSD3B1,HSD3B2 \| Metabolism of steroids:HSD3B1,HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B1,HSD3B2 \| physical disorder:HSD3B2 \| polycystic ovary syndrome:HSD3B1 \| tuberculosis:PHGDH	cellular hormone metabolic process:HSD3B1,HSD3B2 \| androgen biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B1,HSD3B2 \| mineralocorticoid metabolic process:HSD3B1,HSD3B2 \| hormone biosynthetic process:HSD3B1,HSD3B2 \| hormone metabolic process:HSD3B1,HSD3B2 \| glucocorticoid biosynthetic process:HSD3B1,HSD3B2 \| glucocorticoid metabolic process:HSD3B1,HSD3B2 \| androgen metabolic process:HSD3B1,HSD3B2 \| steroid metabolic process:HSD3B1,HSD3B2 \| steroid biosynthetic process:HSD3B1,HSD3B2 \| regulation of hormone levels:HSD3B1,HSD3B2 \| electron transport chain:PHGDH	-0.0063767	0.0229661	0.107179952250669	0.00664111	0.020741	0.125592407192672	-0.0320835	0.0450639	0.321944386494744	0.0296555	0.0252591	0.618866861682949	0.032411	0.027325	0.627493036637101	0.0134697	0.0511918	0.100982645300088	0.00127424	0.0188516	0.0240556129941598	-0.00357291	0.0215366	0.0613497059048599	0.00146937	0.0359086	0.01440693610071	-0.0110938	0.0140456	0.366916520109504	-0.0129228	0.0174227	0.33889184005951	-0.012105	0.022719	0.226095858154468	-0.0117435	0.0137781	0.404468506958464	-0.00344891	0.014545	0.0901424226540604	-0.0360122	0.0233772	0.908533532281802	-0.0141842	0.0135214	0.531400143167812	0.015679	0.0164887	0.466407134581699	-0.0456179	0.0217448	1.44471566471238	6.03674E-4	0.00803312	0.0268273332180219	-0.00815849	0.010335	0.366658821451959	0.0116242	0.0126469	0.446087859618124	0.0619589	0.0378572	0.991987800961366	0.101839	0.0473792	1.49779827997349	-0.00576866	0.0630046	0.0328851301828246
rs72691186:119932836:C:T		1	119932836	1p12	T	C	0.854	ALDO WOMEN	686	1.47742667110688	0.0294708454810496		HAO2 (0 kb, intron/Intron/MODIFIER \| near gene/Downstream gene/MODIFIER \| near gene/Upstream gene/MODIFIER); HAO2-IT1 (20 kb); HSD3B2 (25 kb); HSD3BP2 (49 kb)	NA	WARS2		Ovarian steroidogenesis:HSD3B2 \| Steroid hormone biosynthesis:HSD3B2 \| Cortisol synthesis and secretion:HSD3B2 \| Aldosterone synthesis and secretion:HSD3B2 \| Cushing syndrome:HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B2 \| Androgen biosynthesis:HSD3B2 \| Metabolism of steroids:HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B2 \| physical disorder:HSD3B2	cellular hormone metabolic process:HSD3B2 \| androgen biosynthetic process:HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B2 \| mineralocorticoid metabolic process:HSD3B2 \| hormone biosynthetic process:HSD3B2 \| hormone metabolic process:HSD3B2 \| glucocorticoid biosynthetic process:HSD3B2 \| glucocorticoid metabolic process:HSD3B2 \| androgen metabolic process:HSD3B2 \| steroid metabolic process:HSD3B2 \| steroid biosynthetic process:HSD3B2 \| regulation of hormone levels:HSD3B2	-0.00260038	0.0492091	0.0186970555932391	0.017419	0.0432502	0.162918745111461	-0.0229067	0.102072	0.0848994719986415	0.0230004	0.0541369	0.173287188459985	-0.0120922	0.0570095	0.0798484872417323	0.113691	0.115527	0.487579782111224	0.0296601	0.0403869	0.334616033885673	-0.0158028	0.0449087	0.139675172220136	0.138893	0.0809204	1.06286341135763	-0.0347611	0.0296362	0.618298431041797	-0.0532292	0.0365285	0.838446339124541	-0.0153192	0.048228	0.124500609782061	0.00876059	0.0291696	0.116950414147327	-0.00293049	0.0303935	0.0347098493006202	0.0667419	0.0506503	0.726757906045399	0.00581507	0.0283257	0.0770966059334544	0.0269749	0.034459	0.362773528714897	-0.0226505	0.0464096	0.203765742868877	-0.00611329	0.0169903	0.143278357986065	-0.0170798	0.0216605	0.36613580980483	0.0075675	0.0270181	0.108234583624455	-0.111487	0.0833278	0.742151099926033	-0.0255427	0.0999227	0.0978442073108779	-0.322432	0.151188	1.47742667110688
rs139794652:74643319:T:A		15	74643319	15q24.1	A	T	0.959	PROG ALL	2070	1.44977898719536	0.0140345410628019		CYP11A1 (0 kb, intron/NMD transcript/MODIFIER \| intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER); CTD-2311M21.2 (0 kb, intron/Intron/MODIFIER \| nc-RNA/Non coding transcript/MODIFIER \| near gene/Upstream gene/MODIFIER); CCDC33 (15 kb); SEMA7A (58 kb)	NA	ARID3B \| CLK3 \| COMMD4 \| CSK \| CTD-2311M21.2 \| CYP11A1 \| GOLGA6A \| MAN2C1		Ovarian steroidogenesis:CYP11A1 \| Steroid hormone biosynthesis:CYP11A1 \| Cortisol synthesis and secretion:CYP11A1 \| Aldosterone synthesis and secretion:CYP11A1 \| Cushing syndrome:CYP11A1	Metabolism of steroid hormones:CYP11A1 \| Metabolism of steroids:CYP11A1 \| Cytochrome P450 - arranged by substrate type:CYP11A1 \| Phase I - Functionalization of compounds:CYP11A1	hypospadias:CYP11A1 \| essential hypertension:CYP11A1 \| physical disorder:CYP11A1 \| polycystic ovary syndrome:CYP11A1	cellular hormone metabolic process:CYP11A1 \| hormone biosynthetic process:CYP11A1 \| hormone metabolic process:CYP11A1 \| vitamin D metabolic process:CYP11A1 \| steroid metabolic process:CYP11A1 \| fat-soluble vitamin metabolic process:CYP11A1 \| steroid biosynthetic process:CYP11A1 \| protein autophosphorylation:CLK3 \| regulation of hormone levels:CYP11A1 \| vitamin metabolic process:CYP11A1	0.153153	0.0727915	1.44977898719536	0.0761157	0.0669293	0.592384782150784	0.08315	0.143322	0.250414399946213	0.144115	0.0801074	1.14170106807544	0.140934	0.0881767	0.957790819596541	0.156301	0.157311	0.493811671544134	0.0108496	0.0598128	0.067486663563135	-0.0210202	0.0695255	0.117794327317816	0.0698006	0.110387	0.277878814608751	-0.0337886	0.0396717	0.404088420973093	0.0188097	0.0506276	0.148593037895564	-0.0904088	0.0620036	0.839213442883996	-0.0281913	0.039787	0.320026398296697	-0.0118899	0.0423826	0.10842574871815	-0.0610038	0.0661009	0.448470713924488	0.0739977	0.037893	1.29377224850393	0.0953791	0.0473166	1.35828104816721	0.0536668	0.0591463	0.438637402363382	0.00486268	0.0229593	0.0797373251219845	-0.00792127	0.030409	0.0999142979263622	0.0196285	0.0348785	0.241396157340123	-0.10981	0.118104	0.452717692036697	-0.188277	0.150491	0.67545622334231	0.0232259	0.190314	0.0443589039805345
rs140793456:74667907:TAA:T		15	74667907	15q24.1	T	TAA	0.956	ALDO ALL	1993	1.38601555007481	0.80871801304566		CYP11A1 (7.8 kb); SEMA7A (34 kb); CCDC33 (39 kb); UBL7 (70 kb)	0.352 Blood protein levels	ARID3B \| C15orf17 \| COX5A \| CSK \| CTD-2311M21.2 \| CYP11A1 \| FAM219B \| GOLGA6A \| ISLR \| ISLR2 \| MAN2C1 \| MPI \| PML \| RP11-247C2.2 \| RP11-60L3.2 \| RP11-69H7.2 \| SCAMP2 \| SCAMP5 \| STOML1 \| STRA6 \| UBL7 \| ULK3	MAN2C1 \| SLC2A3	Ovarian steroidogenesis:CYP11A1 \| Steroid hormone biosynthesis:CYP11A1 \| Cortisol synthesis and secretion:CYP11A1 \| Aldosterone synthesis and secretion:CYP11A1 \| Cushing syndrome:CYP11A1 \| Acute myeloid leukemia:PML \| Ubiquitin mediated proteolysis:PML	Metabolism of steroid hormones:CYP11A1 \| Interferon gamma signaling:PML \| Metabolism of steroids:CYP11A1 \| Interferon Signaling:PML \| Cytochrome P450 - arranged by substrate type:CYP11A1 \| Phase I - Functionalization of compounds:CYP11A1	hypospadias:CYP11A1 \| essential hypertension:CYP11A1 \| physical disorder:CYP11A1 \| polycystic ovary syndrome:CYP11A1 \| head and neck carcinoma:PML \| head and neck cancer:PML \| acute leukemia:PML	cellular hormone metabolic process:CYP11A1 \| hormone biosynthetic process:CYP11A1 \| hormone metabolic process:CYP11A1 \| interferon-gamma-mediated signaling pathway:PML \| vitamin D metabolic process:CYP11A1 \| steroid metabolic process:CYP11A1 \| cellular response to interferon-gamma:PML \| positive regulation of axon extension:SEMA7A \| fat-soluble vitamin metabolic process:CYP11A1 \| response to interferon-gamma:PML \| negative regulation of endocytosis:CSK \| steroid biosynthetic process:CYP11A1 \| cellular senescence:PML,ULK3 \| positive regulation of axonogenesis:SEMA7A \| regulation of axon extension:SEMA7A \| protein autophosphorylation:CSK,ULK3 \| Fc receptor mediated stimulatory signaling pathway:CSK \| bone remodeling:CSK \| regulation of hormone levels:CYP11A1 \| post-Golgi vesicle-mediated transport:CSK,SCAMP2 \| regulation of extent of cell growth:SEMA7A \| regulation of ERK1 and ERK2 cascade:CSK,SEMA7A \| cell aging:PML,ULK3 \| axon extension:SEMA7A \| ERK1 and ERK2 cascade:CSK,SEMA7A \| aging:PML,ULK3 \| vitamin metabolic process:CYP11A1 \| positive regulation of cell morphogenesis involved in differentiation:SEMA7A \| immune response-regulating cell surface receptor signaling pathway:CSK \| neuron projection extension:SEMA7A \| regulation of cell size:SEMA7A \| regulation of axonogenesis:SEMA7A \| regulation of cell growth:PML,SEMA7A \| positive regulation of cell growth:SEMA7A \| regulation of G1/S transition of mitotic cell cycle:PML \| tissue remodeling:CSK \| regulation of cytokine secretion:PML \| positive regulation of developmental growth:SEMA7A \| axonogenesis:SEMA7A \| regulation of cell cycle G1/S phase transition:PML \| cytokine secretion:PML \| regulation of vesicle-mediated transport:CSK \| positive regulation of ERK1 and ERK2 cascade:SEMA7A \| developmental cell growth:SEMA7A \| axon development:SEMA7A	-0.0219574	0.0220413	0.495839167206567	0.0107395	0.0194873	0.235336774254334	-0.0453616	0.0450959	0.502423541412645	0.00258377	0.0242553	0.0384949029944518	0.00235869	0.0256885	0.0329882028840239	0.00932744	0.0511432	0.0678622331927713	-0.0133336	0.0180941	0.336049497664742	-0.00506358	0.020236	0.0955820186123045	-0.0258101	0.0358606	0.326126095245574	-0.0042667	0.0131573	0.127422461952875	-0.0228637	0.0164858	0.781249238902251	0.020649	0.0209975	0.487567770518531	0.00275295	0.0129594	0.0799951812797244	0.0233589	0.0137174	1.05259814061506	-0.0152608	0.02213	0.309408803152632	0.0113133	0.0125831	0.433434065203164	0.0175415	0.0155866	0.584339006994379	0.00479785	0.0200003	0.0912914574197951	-0.00309622	0.00754889	0.166411802636782	-0.00956246	0.00977338	0.48430229311754	0.0059258	0.0117734	0.211310646628222	0.074449	0.0364283	1.38601555007481	0.0786909	0.0445654	1.10972600666071	0.0626397	0.0633215	0.490931954982838
rs143778811:119931963:T:C		1	119931963	1p12	C	T	0.932	ANDRO MEN	1358	1.35862902189137	0.0122927098674521		HAO2 (0 kb, intron/Intron/MODIFIER \| near gene/Downstream gene/MODIFIER \| near gene/Upstream gene/MODIFIER); HAO2-IT1 (19 kb); HSD3B2 (26 kb); HSD3BP2 (50 kb)	NA	NOTCH2 \| PHGDH \| WARS2 \| ZNF697		Ovarian steroidogenesis:HSD3B2 \| Steroid hormone biosynthesis:HSD3B2 \| Cortisol synthesis and secretion:HSD3B2 \| Aldosterone synthesis and secretion:HSD3B2 \| Cushing syndrome:HSD3B2 \| Carbon metabolism:HAO2	Metabolism of steroid hormones:HSD3B2 \| Androgen biosynthesis:HSD3B2 \| Metabolism of steroids:HSD3B2	hypospadias:HSD3B2 \| essential hypertension:HSD3B2 \| physical disorder:HSD3B2	cellular hormone metabolic process:HSD3B2 \| androgen biosynthetic process:HSD3B2 \| mineralocorticoid biosynthetic process:HSD3B2 \| mineralocorticoid metabolic process:HSD3B2 \| hormone biosynthetic process:HSD3B2 \| hormone metabolic process:HSD3B2 \| glucocorticoid biosynthetic process:HSD3B2 \| glucocorticoid metabolic process:HSD3B2 \| androgen metabolic process:HSD3B2 \| steroid metabolic process:HSD3B2 \| steroid biosynthetic process:HSD3B2 \| regulation of hormone levels:HSD3B2	0.0991826	0.0804484	0.662013914725362	0.0280474	0.0708467	0.159737035582388				-0.0542056	0.0885329	0.267260550706953	-0.107111	0.0933413	0.59968655485967	0.0611766	0.188589	0.127414308703378	0.044033	0.0660514	0.296646707081701	0.148234	0.0734562	1.35862902189137	-0.178324	0.13212	0.750703784455723	0.0891844	0.0469769	1.23932349844741	0.0739042	0.0572	0.706977941837528	0.11202	0.0777081	0.825562203547954	-0.00641688	0.0464833	0.050510946470874	-0.0206988	0.0477213	0.177522007764801	-0.0487951	0.0817738	0.259083346276323	0.0157639	0.0448343	0.139580533414619	0.0560347	0.0539179	0.524788041198424	-0.054186	0.0740821	0.333000257317172	0.0270572	0.0270262	0.499275149949771	0.0127094	0.0340943	0.149158406872686	0.0512752	0.043606	0.620433440027134	0.0423623	0.131757	0.126184340561976	-0.0600766	0.161663	0.148594872318709	0.24363	0.227808	0.544783482034364

Supplemental Table 7: Summary of all analyzed literature SNPs reported to be associated with steroid hormones. For each study, first author and year is provided. P-values are colored red, if they reach nominal significance (p<0.05). SNPs were successfully replicated when direction of effects were concordant and the association reached at least nominal significance in our data.

SNP Info	literature info							replication info					ALL		MEN		WOMEN		Replication		locus lead SNP in our data (r2 lit-lead)
lit SNP	Study	Pheno	Gene	EA	EAF	beta	p-value	SNP	Cytoband	info	EA	EAF	beta	-logp	beta	-logp	beta	-logp	replicated	comment	lead SNP	r2	beta	-logp	beta	-logp	beta	-logp
rs12150660	Ohlsson 2011	TESTO MEN	SHBG	T	0.23	31.8	1.2E-41	rs12150660:7521915:G:T	17p13.1	0.899	T	0.250012374737823	0.0513828	4.92122428474597	0.0800614	10.2575851898817	0.0184666	0.441952972452723	1		rs35695070:7343539:GC:G	0.212286	0.0408821	4.15770536341877	0.0734806	10.8095394335565	-0.00266917	0.0565213128828303
rs11761528	Zhai 2011	DHEAS ALL	ZKSCAN5	T	0.08	-0.16	3.15E-36	rs11761528:99118801:C:T	7q22.1	0.995	T	0.0871368977673325	-0.141551	14.8501191696353	-0.12675	7.94843846829934	-0.156331	7.465360980929	1
rs2414095	Chen 2013	E2 MEN	CYP19A1	A	0.31	-0.08	6.54E-31	rs2899470:51503677:T:G	15q21.2	1	G	0.578993821712268	0.0628489	9.88445272354337	0.0649689	7.40842678685961	0.0593533	3.68949998640284	1	as proxy SNP (r²=0.61)	rs17601876:51553909:A:G	0.435257	0.0694361	12.3343871181176	0.07022449	8.663996	0.063851	4.44267208683599
rs727479	Eriksson 2018	E2 MEN	CYP19A1	A	0.65	1.39	8.2E-30	rs2899470:51503677:T:G	15q21.2	1	G	0.578993821712268	0.0628489	9.88445272354337	0.0649689	7.40842678685961	0.0593533	3.68949998640284	1	as proxy SNP (r²=0.61)
rs2445762	Chen 2013	E2 MEN	CYP19A1	C	0.28	-0.08	7.75E-28	rs2445762:51617708:T:C	15q21.2	1	C	0.244704324801412	0.0343936	2.68754124757932	0.0328406	1.80151061607512	0.035201	1.29524909570933	0
rs6258	Ohlsson 2011	TESTO MEN	SHBG	T	0.02	-82.3	2.3E-22	rs6258:7534678:C:T	17p13.1											no proxy SNP in LD
rs2637125	Zhai 2011	DHEAS ALL	SULT2A1	A	0.15	-0.09	2.61E-19	rs2637125:48401893:G:A	19q13.33	0.999	A	0.169870805588197	-0.0912927	11.2379744938728	-0.0508759	2.66882788848135	-0.139331	10.282014290323	1		rs296360:48388658:T:C	0.727494	-0.0922151	11.4516523547738	-0.0489511	2.48771193156156	-0.142747	10.8409684861503
rs740160	Zhai 2011	DHEAS ALL	ARPC1A	T	0.05	0.15	1.56E-16	rs740160:98957880:C:T	7q22.1	0.989	T	0.0439417808219179	-0.019228	0.366767945746529	0.0244256	0.377266999569573	-0.0723932	1.18758202148573	0
rs148982377	Ruth 2016	DHEAS ALL	ZNF789	C	0.038	-0.255	1.82E-14	rs148982377:99075038:T:C	7q22.1	0.994	C	0.0418983548766158	-0.268007	26.2603817762248	-0.287705	19.4473524650698	-0.241836	8.96150700601194	1
rs34670419	Ruth 2016	DHEAS ALL	ZKSCAN5 / CYP3A4 / CYP3A7	T	0.037	-0.259	1.97E-14	rs34670419:99130834:G:T	7q22.1	1	T	0.0404099751925839	-0.268772	25.656398429307	-0.282397	18.2677494201057	-0.249009	9.1847809915738	1		7:99025328:C:T	0.847971	-0.303133	27.8599919032424	-0.325069	20.6161110614346	-0.274535	9.51951157354003
rs34670419	Ruth 2016	PROG ALL	ZKSCAN5 / CYP3A4 / CYP3A7	T	0.037	-0.346	6.09E-14	rs34670419:99130834:G:T	7q22.1	1	T	0.0404099751925839	0.0524288	0.684048537322359	0.0342685	0.452411109050585	0.031009	0.150144667734949	0
rs148982377	Ruth 2016	PROG ALL	ZNF789	C	0.038	-0.331	2.99E-13	rs148982377:99075038:T:C	7q22.1	0.994	C	0.0418983548766158	0.050609	0.659357622439295	0.0338358	0.448063523196025	0.0374357	0.190348049665354	0
rs727428	Jin 2012	TESTO MEN	SHBG	T	0.414	-0.073	1.26E-12	rs727428:7537792:T:C	17p13.1	0.858	C	0.584333488697273	0.0374426	3.57752999337336	0.059878	7.5966598122779	0.0126635	0.32756684834311	1
rs12589136	Bolton 2014	CORT ALL	SERPINA6 / SERPINA1	T	0.22	0.1	3.32E-12	rs12589136:94793686:G:T	14q32.13	1	T	0.223490283031172	0.0401634	8.17675797829542	0.0367613	4.3685592751177	0.0452295	4.5596624855406	1		rs9989237:94795202:C:T	0.993903	0.0403298	8.24307876570261	0.0370085	4.41924489974262	0.0452752	4.57411216260854
rs78900934	Prins 2017	DHEAS ALL	PPIAP7	A	0.31	0.05	5.88E-12	rs78900934:101738121:C:A	1p21.2	0.997	A	0.319840514427471	0.0543526	6.3096913725169	0.0494349	3.6408629845671	0.0584259	3.09125126751874	1
rs112295236	Ruth 2016	PROG ALL	SLC22A9	G	0.062	0.255	7.68E-12	rs112295236:62915346:C:G	11q12.3	0.978	G	0.0587622931717549	0.0196242	0.219256524991344	-0.0155719	0.188235366802147	0.0575567	0.35338652980779	0
rs17277546	Zhai 2011	DHEAS ALL	TRIM4 / CYP3A43	A	0.05	-0.11	4.5E-11	rs17277546:99489571:G:A	7q22.1	0.908	A	0.0457946859903381	-0.160048	9.56877780674422	-0.176919	7.40776882036297	-0.141888	3.430425963035	1
rs2749527	Bolton 2014	CORT ALL	SERPINA6 / SERPINA1	T	0.49	-0.08	5.21E-11	rs2749527:94827068:C:T	14q32.13	0.988	T	0.509692317725316	-0.0281537	5.85272879402581	-0.0206109	2.20384281752038	-0.0379568	4.49573443944074	1
rs7181230	Zhai 2011	DHEAS ALL	BMF	G	0.33	0.05	5.44E-11	rs7181230:40360741:A:G	15q15.1	0.997	G	0.368401096748923	0.069586	10.6430262350209	0.0577653	5.08508644570144	0.0851567	6.43587862448435	1		rs28620926:40357171:A:G	1	0.0694955	10.6525763042926	0.0579013	5.11753864709669	0.0847209	6.40507844101137
rs2911280	Prins 2017	DHEAS ALL	CMIP	A	0.08	0.09	5.97E-10	rs2911280:81591313:A:G	16q23.2	0.841	G	0.923867541454498	-0.117171	7.68713956933953	-0.0907728	3.38028907425677	-0.148371	4.87414478398958	1		rs57159061:81590962:T:C	0.656314	0.117829	7.72049047060693	0.0912883	3.39981477283119	0.149075	4.87848283234815
rs2497306	Zhai 2011	DHEAS ALL	HHEX	C	0.49	-0.04	4.64E-9	rs2497306:94485211:A:C	10q23.33	1	C	0.492268041237113	-0.0156726	0.922941117025195	-0.0180147	0.823324284487769	-0.0145296	0.432015477478869	0
rs10822184	Jin 2012	TESTO MEN	JMJD1C	T	0.49	-0.058	1.12E-8	rs10822184:65337153:T:C	10q21.3	1	C	0.518115942028985	0.0271116	2.18024817928685	0.0368129	3.34209551975946	0.0122873	0.327715527939458	1
rs2075230	Chen 2013	TESTO MEN	SHBG	G	0.29	-0.28	1.13E-8	rs2075230:7487108:A:G	17p13.1	0.957	G	0.155119738988581	-0.0218561	0.954669196158038	-0.0523393	3.43269713866882	0.0102022	0.184140118330222	1
rs5934505	Jin 2012	TESTO MEN	FAM9B	G	0.278	0.091	1.61E-8	rs5934505:8913826:T:C	Xp22.31	0.995	C	0.256028421304036	0.0403477	1.57084548791855	0.0643222	3.83124625817449			1	different strand
rs117585797	Ruth 2016	E2 ALL	ANO2	A	0.013	0.624	1.63E-8	rs117585797:6011490:C:A	12p13.31											no proxy SNP in LD
rs6738028	Zhai 2011	DHEAS ALL	BCL2L11	G	0.4	-0.04	1.72E-8	rs6738028:111949327:G:C	2q13	0.966	C	0.591859119989555	0.0434589	4.55569439327992	0.0363247	2.32427571944251	0.0537376	2.87039710428069	1
rs2185570	Zhai 2011	DHEAS ALL	CYP2C9	C	0.13	-0.06	2.29E-8	rs2185570:96751270:T:C	10q23.33	0.983	C	0.122102774463007	-0.0111061	0.318879115061704	-0.024188	0.651366132601686	0.00589166	0.09011302756869	0
rs1864729	Liu 2013	E2 WOMEN	TSPYL5	A	0.098	1.589	3.49E-8	rs1864729:98282189:G:A	8q22.1	0.999	A	0.0584581033617662	-0.014937	0.345029742734676	-0.00407329	0.0623687849480527	-0.0190214	0.255866678788713	0
rs11621961	Bolton 2014	CORT ALL	SERPINA6 / SERPINA1	T	0.36	-0.08	3.97E-8	rs11621961:94769476:C:T	14q32.13	0.837	T	0.365248337028825	-0.0191913	2.78522500897483	-0.0144552	1.16440517404892	-0.0245908	2.03437080231245	1

100

Supplemental Table 8: Summary of all 169 CAD SNPs. Duplicated proxy SNPs are marked red. Only the best association per SNP is shown (hormone, analysis group). Log10-transformed pvaules are colored with respect to nominal significance (green) and adjusted nominal significance (red)

literature info									SNP info						top phenotype
SNP	Chr	Cytoband	Study	Gene	EA	EAF	OR	p-value	used SNP	r2 (lit-used)	EA	OA	EAF	info	phenotype	N	beta	-logp
rs61848342:12303813:T:C	10	10p13	vdHarst 2018	CDC123, NUDT5, OPTN	T	0.64	0.96	6.3E-10	rs61848342:12303813:T:C	1	C	T	0.332298415287812	0.97	TESTO MEN	4291	0.042029	3.78283465524024
rs12202017:134173151:A:G	6	6q23.2	Nelson 2017	TCF21	A	0.702	1.07	6.0E-14	rs2327426:134202690:T:C	0.913053	C	T	0.26244699046873	0.992	DHEAS ALL	7659	0.0421151	3.62189293749026
rs3827066:44586023:C:T	20	20q13.12	vdHarst 2018	PCIF1, ZNF335, NEURL2, PLTP	T	0.14	1.04	4.4E-9	rs3827066:44586023:C:T	1	T	C	0.165883544303798	0.953	E2 WOMEN	2607	-0.0764452	3.51402885503576
rs667920:136069472:G:T	3	3q22.3	vdHarst 2018	STAG1, MSL2, NCK1, PPP2R3A	T	0.78	1.05	6.0E-15	rs667920:136069472:G:T	1	T	G	0.787642488954345	0.997	OHP17 MEN	1358	0.0880699	3.4335990442914
rs17517928:216291359:C:T	2	2q35	Klarin 2017	FN1	C	0.75	1.06	1.06E-8	rs17517928:216291359:C:T	1	T	C	0.26998826137994	1	CORT ALL	7667	0.0213627	3.06306774707918
rs7947761:100624599:A:G	11	11q22.1	vdHarst 2018	ARHGAP42	A	0.72	0.96	3.0E-9	rs7947761:100624599:A:G	1	G	A	0.264116715758468	0.994	PROG MEN	1358	0.0550771	2.92422317883927
rs11099493:82587050:A:G	4	4q21.22	vdHarst 2018	HNRNPD, RASGEF1B	A	0.69	1.04	5.1E-10	rs11099493:82587050:A:G	1	G	A	0.320947272013607	1	TESTO ALL	7643	0.0338407	2.87829574326296
rs4299376:44072576:G:T	2	2p21	Nelson 2017	ABCG5, ABCG8	G	0.319	1.06	5.7E-10	rs4299376:44072576:G:T	1	T	G	0.68127912113462	0.994	CORT MEN	4301	-0.0252385	2.76860942572969
rs13003675:233584109:C:T	2	2q37.1	Nelson 2017	KCNJ13, GIGYF2	T	0.361	1.04	1.7E-6	rs13003675:233584109:C:T	1	T	C	0.309843294460641	0.998	ALDO WOMEN	686	0.0504272	2.64183663708693
rs2244608:121416988:A:G	12	12q24.31	Verweij 2017	HNF1A, OASL	G	0.317	1.056	1.856867E-10	rs2244608:121416988:A:G	1	G	A	0.34606800744013	0.968	CORT MEN	4301	-0.0239442	2.61086936969336
rs2258287:121454313:C:A	12	12q24.31	Howson 2017	C12orf43	A	0.34	1.05	6.0E-9	rs2244608:121416988:A:G	0.657349	G	A	0.34606800744013	0.968	CORT MEN	4301	-0.0239442	2.61086936969336
rs1508798:9556694:T:C	5	5p15.31	vdHarst 2018	SEMA5A, TAS2R1	T	0.81	1.05	4.8E-13	rs1508798:9556694:T:C	1	C	T	0.210674157303371	1	OHP17 WOMEN	712	-0.141587	2.5070720698606
rs11191416:104604916:T:G	10	10q24.32	Nelson 2017	CYP17A1, CNNM2, NT5C2	T	0.89	1.08	5.6E-9	rs11191416:104604916:T:G	1	G	T	0.113095729013255	0.997	ANDRO MEN	1358	0.0248666	2.46092264602267
rs2107732:45077978:G:A	7	7p13	vdHarst 2018	CCM2, MYO1G	A	0.09	0.94	3.6E-8	rs2107732:45077978:G:A	1	A	G	0.0927646980854197	0.932	ANDRO MEN	1358	0.0282487	2.43117193522877
rs1317507:113631780:A:C	13	13q34	vdHarst 2018	MCF2L, PCID2, CUL4A	A	0.26	1.04	8.4E-12	rs1317507:113631780:A:C	1	C	A	0.755308910162003	0.846	ANDRO MEN	1358	0.0200911	2.41502685634717
rs1050362:72130815:C:A	16	16q22.2	Howson 2017	DHX38	A	0.38	1.04	2.32E-7	rs1050362:72130815:C:A	1	A	C	0.342541304347826	0.998	PROG ALL	2070	-0.0502533	2.40629092351425
rs17678683:145286559:T:G	2	2q22.3	Nelson 2017	ZEB2, AC074093.1	G	0.089	1.08	1.2E-7	rs17678683:145286559:T:G	1	G	T	0.110947331460674	0.972	ANDRO WOMEN	712	0.0441534	2.38034015944617
rs72743461:67441750:C:A	15	15q22.33	Nelson 2017	SMAD3	C	0.783	1.07	4.8E-12	rs72743461:67441750:C:A	1	A	C	0.245018960674157	0.996	OHP17 WOMEN	712	0.125062	2.36816979969393
rs6984210:22033615:C:G	8	8p21.3	vdHarst 2018	BMP1, SFTPC, DMTN, PHYHIP, DOK2, XPO7	C	0.94	0.92	2.1E-11	rs4515546:22033325:C:T	0.967732	T	C	0.0356413328502415	0.808	ANDRO ALL	2070	0.118314	2.28332652275075
rs11057830:125307053:G:A	12	12q24.31	Nelson 2017	SCARB1	A	0.147	1.07	4.2E-9	rs11057830:125307053:G:A	1	A	G	0.148445008912656	0.954	CORT WOMEN	3366	-0.036839	2.27518937618174
rs112635299:94838142:G:T	14	14q32.13	vdHarst 2018	SERPINA2, SERPINA1	T	0.02	0.87	8.4E-10	rs112635299:94838142:G:T	1	T	G	0.0158346539268235	0.903	TESTO MEN	4291	0.119203	2.2347793793936
rs12999907:164957251:A:G	2	2q24.3	vdHarst 2018	FIGN	A	0.82	1.06	2.4E-11	rs12999907:164957251:A:G	1	G	A	0.137356039325843	0.978	OHP17 WOMEN	712	-0.154311	2.20718123083076
rs7797644	7		vdHarst 2018	DAGLB, RAC1, FAM220A, KDELR2	T	0.23	0.96	2.1E-8	rs71531392:6466636:C:T	0.992836	T	C	0.20166999608304	0.997	DHEAS ALL	7659	0.0340262	2.19370468186282
rs12897:172115902:G:A	3	3q26.31	vdHarst 2018	FNDC3B	A	0.59	0.96	1.9E-10	rs12897:172115902:G:A	1	A	G	0.617182846932698	1	DHEAS WOMEN	3358	-0.0447501	2.10868336946776
rs742115:11327021:C:T	6	6p24.2	Nelson 2017	ADTRP, C6orf105	C	0.484	1.04	2.9E-5	rs742115:11327021:C:T	1	T	C	0.506372893258427	0.948	OHP17 WOMEN	712	0.105239	2.09607209064848
rs12500824:77416627:A:G	4	4q21.1	vdHarst 2018	SHROOM3, SEPT11, FAM47E, STBD1	A	0.36	1.04	4.1E-10	rs12500824:77416627:A:G	1	G	A	0.667168584579977	0.997	E2 WOMEN	2607	-0.043175	2.07869649660397
rs4266144:156852592:C:G	3	3q25.31	vdHarst 2018	CCNL1, TIPARP	C	0.68	0.97	1.4E-8	rs4266144:156852592:C:G	1	G	C	0.326100421348315	0.921	ANDRO WOMEN	712	0.0300591	2.06016387795357
rs11810571:151762308:C:G	1	1q21.3	Verweij 2017	TDRKH	G	0.171	1.069	1.723432E-10	rs11810571:151762308:C:G	1	G	C	0.850897357058747	0.978	TESTO ALL	7643	0.0363515	2.03500443779429
rs17680741:82251514:T:C	10	10q23.1	vdHarst 2018	TSPAN14, MAT1A, FAM213A	T	0.72	1.05	2.3E-11	rs17680741:82251514:T:C	1	C	T	0.296053935860058	0.998	ALDO WOMEN	686	0.0510049	2.03407100627678
rs2832227:30533076:A:G	21	21q21.3	vdHarst 2018	MAP3K7CL, BACH1	A	0.82	0.96	1.7E-9	rs2832227:30533076:A:G	1	G	A	0.137827850038256	0.995	ALDO MEN	1307	-0.12856	2.02306753082065
9:136149399:G:A	9	9q34.2	Nelson 2017	ABO	A	0.192	1.08	1.3E-12	9:136149399:G:A	1	A	G	0.217910788188794	0.991	CORT MEN	4301	-0.0234959	2.02197158126269
rs585967:21270554:A:C	2	2p24.1	Nelson 2017	APOB	C	0.844	1.07	2.8E-8	rs585967:21270554:A:C	1	C	A	0.861422109443954	0.99	E2 ALL	6798	-0.0361478	2.01974976466074
rs7623687:49448566:A:C	3	3p21.31	Verweij 2017	RHOA, AMT, TCTA, CDHR4, KLHDC8B	A	0.859	1.069	3.2844E-8	rs7623687:49448566:A:C	1	C	A	0.153476462363085	0.97	TESTO MEN	4291	0.0374134	1.94501944427297
rs6841581:148401190:G:A	4	4q31.22	Nelson 2017	EDNRA	A	0.153	1.07	4.6E-10	rs6841581:148401190:G:A	1	A	G	0.142553475935829	0.996	CORT WOMEN	3366	0.0315105	1.86343796341002
rs6700559:200646073:C:T	1	1q32.1	Howson 2017	DDX59	T	0.47	0.96	2.5E-8	rs6700559:200646073:C:T	1	T	C	0.459323073252207	0.99	E2 MEN	4191	0.0297655	1.86170361889031
rs9897596:17593453:T:C	17	17p11.2	Nelson 2017	RAI1, PEMT, RASD1	T	0.523	1.04	3.1E-6	rs9897596:17593453:T:C	1	C	T	0.493609858172518	0.948	DHEAS MEN	4301	0.031117	1.85583381609552
rs16986953:19942473:G:A	2	2p24.1	Nelson 2017	AK097927	A	0.073	1.11	4.8E-10	rs16986953:19942473:G:A	1	A	G	0.0743609550561798	0.979	ANDRO WOMEN	712	0.049726	1.84860563134899
rs33928862:75308440:TCAGCCTCCTGAG:T	16	16q23.1	Verweij 2017	BCAR1	T	0.527	1.049	2.470137E-8	rs3851738:75387533:G:C	0.717879	C	G	0.609426141567447	0.999	TESTO ALL	7643	0.024635	1.84567647100094
rs3851738:75387533:G:C	16	16q23.1	Klarin 2017	CFDP1	C	0.6	1.05	2.43E-8	rs3851738:75387533:G:C	1	C	G	0.609426141567447	0.999	TESTO ALL	7643	0.024635	1.84567647100094
rs11170820:54513915:C:G	12	12q13.13	Verweij 2017	HOXC4	G	0.065	1.098	4.085375E-8	rs11170820:54513915:C:G	1	G	C	0.0625462840746055	0.886	CORT ALL	7667	-0.03069	1.83105489946069
rs1321309:36638636:G:A	6	6p21.2	vdHarst 2018	CDKN1A, PI16	A	0.49	1.03	3.4E-8	rs1321309:36638636:G:A	1	A	G	0.491035265700483	0.999	PROG ALL	2070	-0.0403864	1.81891995540769
rs11057401:124427306:T:A	12	12q24.31	Klarin 2017	CCDC92	T	0.69	1.06	3.88E-9	rs11057401:124427306:T:A	1	A	T	0.304143960674157	0.994	OHP17 WOMEN	712	-0.100331	1.80821654495817
rs3775058:96117371:A:T	4	4q22.3	vdHarst 2018	UNC5C	A	0.23	1.04	7.6E-9	rs3775058:96117371:A:T	1	T	A	0.784641554321967	0.966	PROG WOMEN	1261	0.104798	1.7970759723622
rs3936511:55860781:A:G	5	5q11.2	vdHarst 2018	MAP3K1, MIER3	A	0.82	0.96	3.7E-8	rs3936511:55860781:A:G	1	G	A	0.179684536082474	0.996	OHP17 MEN	1358	-0.0610779	1.79181940601805
rs17608766:45013271:T:C	17	17q21.32	Howson 2017	GOSR2	C	0.14	1.07	4.14E-8	rs17608766:45013271:T:C	1	C	T	0.123705408515535	1	E2 WOMEN	2607	0.0570812	1.78548994546697
rs139016349:138099161:T:TTTC	3	3q22.3	Nelson 2017	MRAS	I	0.163	1.08	9.2E-12	rs139016349:138099161:T:TTTC	1	TTTC	T	0.172194010720112	0.993	TESTO MEN	4291	-0.0331493	1.78383937792218
rs35541991:22583856:CA:C	6	6p22.3	Verweij 2017	HDGFL1	C	0.348	1.049	2.567297E-8	rs35541991:22583856:CA:C	1	C	CA	0.33210235640648	1	ANDRO MEN	1358	0.0167142	1.76621221466875
rs10237377:139757136:G:T	7	7q34	Howson 2017	PARP12	T	0.35	0.95	1.7E-7	rs10237377:139757136:G:T	1	T	G	0.375352708672402	0.988	DHEAS MEN	4301	0.0311339	1.76459276846708
rs1892094:169094459:C:T	1	1q24.2	Howson 2017	ATP1B1	T	0.5	0.96	3.99E-8	rs1892094:169094459:C:T	1	T	C	0.497224170842281	0.991	E2 MEN	4191	0.0283334	1.75575010078802
rs2246942:91004886:A:G	10	10q23.31	Nelson 2017	LIPA	G	0.349	1.08	3.5E-16	rs2246942:91004886:A:G	1	G	A	0.325513254786451	0.974	PROG MEN	1358	-0.037385	1.66921297501325
rs2839812:103673294:T:A	11	11q22.3	Nelson 2017	PDGFD	T	0.307	1.06	2.0E-11	rs2839812:103673294:T:A	1	A	T	0.724890258079516	0.997	CORT MEN	4301	-0.0188378	1.64807620542985
rs582384:45896437:C:A	2	2p21	vdHarst 2018	PRKCE, TMEM247	A	0.53	1.03	7.6E-9	rs582384:45896437:C:A	1	A	C	0.580750893388922	0.966	DHEAS WOMEN	3358	0.0375572	1.64411956971065
rs4472337:34769765:C:T	6	6p21.31	Nelson 2017	ANKS1A	T	0.155	1.06	2.4E-6	rs4472337:34769765:C:T	1	T	C	0.163025362318841	0.996	OHP17 ALL	2070	-0.0570179	1.6427914889784
rs114452520:107176780:C:T	7	7q22.3	Nelson 2017	7q22	T	0.28	1.05	9.6E-7	rs114452520:107176780:C:T	1	T	C	0.309659620991254	0.998	ALDO WOMEN	686	0.0526529	1.63163128573164
rs2954029:126490972:A:T	8	8q24.13	Nelson 2017	TRIB1	A	0.541	1.06	5.2E-13	rs2954029:126490972:A:T	1	T	A	0.482414948453608	0.997	OHP17 MEN	1358	-0.0453331	1.6199679417213
rs201267813:10284499:G:GA	11	11p15.4	Nelson 2017	MRVI1, CTR9	I	0.071	1.05	0.0012	rs201267813:10284499:G:GA	1	GA	G	0.0654161835748792	0.995	OHP17 ALL	2070	-0.0857286	1.61458857709586
rs247616:56989590:C:T	16	16q13	Nelson 2017	CETP	C	0.678	1.04	1.0E-6	rs56228609:56987765:C:T	0.971568	T	C	0.309545389330899	0.942	CORT ALL	7667	0.014342	1.59679022588915
rs2071382:91428197:T:C	15	15q26.1	Nelson 2017	FURIN, FES	T	0.464	1.06	7.1E-13	rs2071382:91428197:T:C	1	C	T	0.499214887640449	0.907	OHP17 WOMEN	712	0.0906856	1.57737405250897
rs7164479:79123054:C:T	15	15q25.1	Nelson 2017	ADAMTS7	T	0.578	1.07	6.4E-18	rs7164479:79123054:C:T	1	T	C	0.59035592113853	0.917	DHEAS ALL	7659	0.0233243	1.55026248994297
rs7306455:95355541:G:A	12	12q22	vdHarst 2018	NDUFA12, FGD6	A	0.1	0.95	1.0E-8	rs7306455:95355541:G:A	1	A	G	0.0760006763285024	0.977	OHP17 ALL	2070	0.0773782	1.54886318990283
rs590121:75274150:G:T	11	11q13.5	Howson 2017	SERPINH1	T	0.3	1.05	1.54E-8	rs590121:75274150:G:T	1	T	G	0.320844803370787	0.96	ANDRO WOMEN	712	0.0294017	1.54267684115126
rs10139550:100145710:C:G	14	14q32.2	Nelson 2017	HHIPL1	G	0.421	1.05	1.8E-9	rs10139550:100145710:C:G	1	G	C	0.4484941089838	0.868	ANDRO MEN	1358	0.0168115	1.54199252406492
rs73015714:17855763:C:G	19	19p13.11	vdHarst 2018	MAP1S, FCHO1, COLGALT1	C	0.8	0.94	8.3E-14	rs73015714:17855763:C:G	1	G	C	0.192273469994058	0.954	CORT WOMEN	3366	-0.0251643	1.53879270121201
rs1887318:30321598:C:T	10	10p11.23	Nelson 2017	KIAA1462	T	0.428	1.06	4.1E-12	rs2487928:30323892:G:A	0.992036	A	G	0.479489279888138	0.976	TESTO MEN	4291	0.0226341	1.53525567365409
rs35879803:146782837:C:A	4	4q31.21	Verweij 2017	ZNF827	C	0.655	1.051	3.826364E-8	rs35879803:146782837:C:A	1	A	C	0.310091206179441	0.978	CORT WOMEN	3366	-0.0214504	1.52712512288169
rs138120077:41790086:GTTATGGTA:G	19	19q13.2	Verweij 2017	HNRNPUL1, TGFB1ed, CCDC97	G	0.172	1.072	9.440455E-9	rs138120077:41790086:GTTATGGTA:G	1	G	GTTATGGTA	0.154088775510204	0.859	ALDO WOMEN	686	0.06766	1.52286426903888
rs7116641:43696917:T:G	11	11p11.2	vdHarst 2018	HSD17B12	T	0.69	0.97	1.0E-8	rs58817325:43875316:G:A	0.709298	A	G	0.286696545562835	0.999	DHEAS WOMEN	3358	-0.03941	1.51508546402033
rs11617955:110818102:T:A	13	13q34	Nelson 2017	COL4A1, COL4A2	T	0.891	1.09	4.1E-10	rs11617955:110818102:T:A	1	A	T	0.113380167402929	0.92	CORT MEN	4301	-0.0262573	1.51289133297904
rs1351525:13301548:A:T	11	11p15.2	Verweij 2017	ARNTL	T	0.3	1.049	4.085375E-8	rs1351525:13301548:A:T	1	T	A	0.69457009997675	0.983	DHEAS MEN	4301	0.0297746	1.50597348605947
rs3130683:31888367:C:T	6	6p21.33	Nelson 2017	C2	T	0.86	1.08	2.8E-8	rs3130683:31888367:C:T	1	T	C	0.866107063585325	0.981	DHEAS ALL	7659	0.0317404	1.5035200933351
rs7500448:83045790:A:G	16	16q23.3	Verweij 2017	CDH13	A	0.752	1.069	4.83E-11	rs7500448:83045790:A:G	1	G	A	0.266077777777778	0.981	PROG ALL	2070	-0.0412648	1.49650212193869
rs9964304:47229717:A:C	18	18q21.1	vdHarst 2018	ACAA2, RPL17	A	0.72	0.96	1.1E-9	rs9964304:47229717:A:C	1	C	A	0.310354565537555	0.992	PROG MEN	1358	-0.0348162	1.47952563797858
rs7568458:85788175:T:A	2	2p11.2	Nelson 2017	VAMP5, VAMP8, GGCX	A	0.452	1.06	2.4E-13	rs7568458:85788175:T:A	1	A	T	0.450695187165775	0.985	CORT MEN	4301	-0.0159268	1.47910660288771
rs35614134:57832856:A:AC	18	18q21.32	Nelson 2017	PMAIP1, MC4R	I	0.248	1.04	1.7E-5	rs35614134:57832856:A:AC	1	AC	A	0.23571297372704	0.998	DHEAS MEN	4301	-0.0313621	1.46017770673483
rs6689306:154395946:A:G	1	1q21.3	Nelson 2017	IL6R	A	0.435	1.05	1.5E-9	rs6689306:154395946:A:G	1	G	A	0.556317058960616	0.962	TESTO MEN	4291	0.0225526	1.45534295558399
rs6494488:65024204:G:A	15	15q22.31	Howson 2017	OAZ2	G	0.18	0.95	1.43E-6	rs6494488:65024204:G:A	1	A	G	0.845468742543546	0.991	E2 MEN	4191	0.034013	1.44206713350634
rs1867624:62387091:C:T	17	17q23.3	Howson 2017	PECAM1	C	0.39	0.96	1.14E-7	rs1867624:62387091:C:T	1	T	C	0.582225218658892	0.994	ALDO WOMEN	686	0.0486456	1.43792136099179
rs2229357:57843711:G:A	12	12q13.3	Nelson 2017	LRP1	G	0.764	1.05	3.4E-6	rs2229357:57843711:G:A	1	A	G	0.238845144356955	1	E2 MEN	4191	0.0288706	1.42587725053716
rs2107595:19049388:G:A	7	7p21.1	Nelson 2017	HDAC9	A	0.182	1.08	3.4E-13	rs2107595:19049388:G:A	1	A	G	0.166460355881198	0.99	TESTO ALL	7643	0.0278174	1.41612140150137
rs8068952:59286644:G:C	17	17q23.2	Nelson 2017	BCAS3	G	0.228	1.07	1.4E-9	rs8068952:59286644:G:C	1	C	G	0.744647105471848	1	PROG WOMEN	1261	-0.0784109	1.41561223055304
rs17581137:96146414:A:C	15	15q26.2	vdHarst 2018		A	0.75	1.04	1.2E-8	rs17581137:96146414:A:C	1	C	A	0.25695404334654	0.978	TESTO MEN	4291	0.025063	1.4075922726975
rs77335401:131759825:T:C	5	5q31.1	Nelson 2017	SLC22A4, SLC22A5	C	0.116	1.05	7.6E-5	rs77335401:131759825:T:C	1	C	T	0.113219613457409	0.974	E2 MEN	4191	-0.0384673	1.40521090878296
rs2083636:19865263:T:G	8	8p21.3	Nelson 2017	LPL	T	0.742	1.05	6.4E-8	rs2083636:19865263:T:G	1	G	T	0.265217201166181	0.999	ALDO WOMEN	686	0.0526528	1.40212060700212
rs10841443:20220033:C:G	12	12p12.2	Klarin 2017	RP11-664H17.1	G	0.67	1.05	2.23E-8	rs10841443:20220033:C:G	1	G	C	0.713287187039764	0.974	ANDRO MEN	1358	0.0172705	1.37452394757595
rs964184:116648917:G:C	11	11q23.3	Nelson 2017	ZNF259, APOA5, APOA1	G	0.163	1.05	4.7E-6	rs964184:116648917:G:C	1	C	G	0.853498542274053	1	ALDO WOMEN	686	0.0685906	1.370228639542
rs2681472:90008959:A:G	12	12q21.33	Nelson 2017	ATP2B1	G	0.189	1.07	7.6E-11	rs2681472:90008959:A:G	1	G	A	0.145792270531401	0.995	PROG ALL	2070	-0.0474908	1.33891079470317
rs56015508:39152041:C:A	6	6p21.2	Nelson 2017	KCNK5	C	0.794	1.06	1.1E-7	rs56015508:39152041:C:A	1	A	C	0.225267640537368	0.988	CORT ALL	7667	-0.0137751	1.31791722813513
rs11838267:7175872:T:C	12	12p13.31	vdHarst 2018	C1S	T	0.87	1.05	6.1E-10	rs11838267:7175872:T:C	1	C	T	0.144342783505155	0.997	ANDRO MEN	1358	0.0224157	1.29641030815121
rs1591805:126717064:A:G	6	6q22.32	vdHarst 2018	CENPW	A	0.49	1.04	2.1E-10	rs1591805:126717064:A:G	1	G	A	0.474968599033816	0.992	PROG ALL	2070	-0.0327723	1.29212422219632
rs60154123:210468999:C:T	1	1q32.2	vdHarst 2018	HHAT, SERTAD4, DIEXF	T	0.15	1.05	2.5E-8	rs60154123:210468999:C:T	1	T	C	0.123252505243533	0.986	TESTO MEN	4291	0.0306941	1.2749144756959
rs10267593:1937261:G:A	7	7p22.3	vdHarst 2018	MAD1L1	A	0.2	0.96	1.8E-8	rs10267593:1937261:G:A	1	A	G	0.205184142394822	0.866	E2 ALL	6798	0.0244422	1.2712007872858
rs7528419:109817192:A:G	1	1p13.3	Nelson 2017	SORT1	A	0.782	1.11	3.8E-27	rs56246620:109816863:T:TC	0.780232	TC	T	0.183647864506627	0.81	ANDRO MEN	1358	0.0229777	1.26246228598649
rs1870634:44480811:T:G	10	10q11.21	Nelson 2017	CXCL12	G	0.648	1.06	5.5E-13	rs1870634:44480811:T:G	1	G	T	0.682485252808989	0.998	OHP17 WOMEN	712	0.0805756	1.2612432174118
rs8108632:41854534:T:A	19	19q13.2	Verweij 2017	TGFB1, B9D2	T	0.588	1.052	9.53985E-9	rs8108632:41854534:T:A	1	A	T	0.552002915451895	0.914	ALDO WOMEN	686	0.0508089	1.26089225891289
rs11830157:118265441:T:G	12	12q24.23	Nelson 2017	KSR2	G	0.382	1.03	0.0017	rs11830157:118265441:T:G	1	G	T	0.404618605259715	1	TESTO ALL	7643	0.0192582	1.25234819225965
rs7617773:48193515:C:T	3	3p21.31	vdHarst 2018	CDC25A, SPINK8, MAP4, ZNF589	T	0.67	1.04	2.3E-11	rs7617773:48193515:C:T	1	T	C	0.692906082498253	0.95	TESTO MEN	4291	-0.0215653	1.24769335824492

↑ Previous 1 2 Next ↓

Supplemental Table 9: Results of Mendelian Randomization analysis. All 22 hits of our (meta-)GWAS were considered as instruments. CAD association was caluclated using LIFE-Heart data only (logistic regression). a)-c) Causal estimates based on single IVs defined as ratio of gentic effect on CAD by genetic effect on steroid. If possible, causal estimates of multiple IVs is calculated using the inverse-variance weighted method. Significant results (p<0.05) are colored red. For more details see Supplemental data.

a) ALL		Y ~ G			X ~ G			causal estimate per SNP			causal estimate of multiple SNPs
SNP	top phenotype	beta	se	pval	beta	se	pval	beta	se	pval	beta	se	pval	df	Q
rs9692804:144058625:G:A	ANDRO	0.0883407778446708	0.0424883745772436	0.0376012434437852	0.0900147	0.014171	2.60575E-10	0.98140390230341	0.496658847140035	0.0481534043281156
rs114341625:112578458:G:A	CORT	-0.315502078115604	0.148064455890921	0.03310209593747	-0.128447	0.0221222	6.38988E-9	2.4562821873271	1.22790296676817	0.0454583983224301	1.702	0.828	0.04	1	0.8839
rs9989237:94795202:C:T	CORT	0.0362377370835763	0.0480015799742535	0.450292180374728	0.0403298	0.00692366	5.71375E-9	0.898535005965223	1.20018054166127	0.454058219468214
rs77533229:43479638:G:A	DHEAS	-0.0777099218882482	0.149480450785787	0.603156424754866	-0.149331	0.0371098	5.72072E-5	0.520387072263952	1.00931968446307	0.606146377307443	0.312	0.176	0.076	7	4.4474
rs36139342:119204625:A:AC	DHEAS	0.023586845831697	0.0515413137778201	0.647218364481756	-0.0871928	0.0127335	7.5155E-12	-0.270513687273456	0.592437552811283	0.647950448233676	Sensitivity (p<1E-5)
7:99025328:C:T	DHEAS	-0.0146280562186808	0.109595027436632	0.893818745153106	-0.303133	0.0273303	1.38041E-28	0.0482562314847963	0.361567241632592	0.893826387105474	0.306	0.179	0.087	6	4.4029
rs615567:22319209:A:T	DHEAS	-0.0612334922993408	0.0411959729665531	0.137174645516785	-0.0778523	0.0102432	2.95296E-14	0.786534146060435	0.539179847286738	0.144631097898864
rs28620926:40357171:A:G	DHEAS	-0.00792000228582301	0.0417202871208692	0.849437835352289	0.0694955	0.0103873	2.22548E-11	-0.113964246401897	0.600572384882549	0.849497683627921
rs57159061:81590962:T:C	DHEAS	0.0150852294503039	0.0796478199468265	0.84977999009247	0.117829	0.020964	1.90331E-8	0.128026457411197	0.676344775077599	0.849864194203416
rs296360:48388658:T:C	DHEAS	-0.0189748349302286	0.0527239491463233	0.718929212946464	-0.0922151	0.0132595	3.53466E-12	0.205767113306049	0.572514653579251	0.719288889203322
rs5935876:6922078:G:A	DHEAS	-0.0691958091390917	0.0319245117260955	0.0301981097272573	-0.0971084	0.0168501	8.26019E-9	0.712562550089299	0.351233457317088	0.0424844353421479
rs35679777:68034459:CG:C	E2	0.0733008038719058	0.0414192878941234	0.076772743409413	0.0577234	0.00995841	6.77367E-9	1.26986289566979	0.750245892784104	0.0905324695226965	0.278	0.449	0.535	1	3.1357
rs17601876:51553909:A:G	E2	-0.0248665291294881	0.0399078290586394	0.533219454470521	0.0694361	0.00959628	4.63034E-13	-0.358121051290151	0.576868905704242	0.534730271184715
rs145827824:32103749:C:G	OHP17	-0.525959782278057	0.180981565702844	0.00365904669461987	0.699809	0.0846222	2.37316E-16	-0.751576190472052	0.274119671285657	0.00611070112885681
rs79589801:211054061:C:T	PROG	-0.368842280805738	0.184683105575848	0.045807469786361	0.371084	0.0735692	4.95707E-7	-0.993958997978189	0.535277811919971	0.0633249495269811	-0.243	0.194	0.209	6	6.5057
rs139441768:90679263:T:C	PROG	-0.0679378666540618	0.21894457029922	0.756335031298721	0.45207	0.0791544	1.2839E-8	-0.150281741000424	0.485029924308823	0.75668252322366	Sensitivity (p<1E-5)
rs10786714:104598606:G:C	PROG	-0.0128096316891892	0.0426670758888529	0.764007166662009	0.0509603	0.0177716	0.00417911	-0.251364919146654	0.841837463309321	0.7652522881901	-0.243	0.217	0.264	5	6.5056
rs77032081:13363279:C:T	PROG	-0.220704793370054	0.15248837448401	0.147797555105488	0.260374	0.064853	6.16122E-5	-0.847645284744461	0.62254529890091	0.173330441826506
rs142754737:43865714:C:T	PROG	-0.167964455508535	0.166155518720894	0.312070511981299	0.345894	0.0696468	7.38104E-7	-0.485595169354008	0.490215359772667	0.321893061076972
rs139203625:95099865:C:T	PROG	0.183156402181188	0.190406053516161	0.336087123400758	0.524075	0.0786923	3.5044E-11	0.349485096944498	0.367088578540257	0.341073813488214
rs72906582:45222771:G:A	PROG	-0.00327649424787102	0.0672165586161187	0.961122239806219	0.140791	0.0281928	6.41478E-7	-0.0232720432973061	0.477443591362422	0.961124090306414
rs35695070:7343539:GC:G	TESTO	0.0307929158998252	0.0425205329817433	0.468949513903534	0.0408821	0.0102775	6.95496E-5	0.753212674980619	1.05717299058699	0.476168726331327


b) MEN		Y ~ G			X ~ G			causal estimate per SNP			causal estimate of multiple SNPs
SNP	top phenotype	beta	se	pval	beta	se	pval	beta	se	pval	beta	se	pval		Q
rs9692804:144058625:G:A	ANDRO	0.126178129029773	0.0544434617075765	0.0204711080032694	0.0817186	0.0161876	5.06646E-7	1.54405642081206	0.733085882824914	0.0351833194210336
rs114341625:112578458:G:A	CORT	-0.547486284277608	0.180619005122299	0.00243610842091064	-0.115467	0.0284758	5.01527E-5	4.74149570247437	1.95299277568144	0.0151902921525551	3.373	1.139	0.003	1	1.6278
rs9989237:94795202:C:T	CORT	0.0677455949428968	0.0614673707766704	0.270401187269059	0.0370085	0.00898525	3.80851E-5	1.83054149568064	1.71933332388578	0.287020318054961
rs77533229:43479638:G:A	DHEAS	0.0227527241137642	0.190517493246793	0.90493793866971	0.0646403	0.0455445	0.155819	0.351989766658945	2.95776443609716	0.905271123988931	-0.235	0.313	0.454	7	9.4639
rs36139342:119204625:A:AC	DHEAS	0.0733791803447363	0.0669873627488642	0.273333437958402	-0.0882746	0.0160836	4.05368E-8	-0.831260411768915	0.773818571940106	0.282718864309989	Sensitivity (p<1E-5)
7:99025328:C:T	DHEAS	0.0322011544095774	0.140385483566662	0.818576169264848	-0.325069	0.0342714	2.42041E-21	-0.0990594440244298	0.431989905625226	0.818628271740706	-0.453	0.314	0.149	3	2.9412
rs615567:22319209:A:T	DHEAS	0.0216520926359921	0.0527528353190738	0.681480165299533	-0.0716892	0.0128678	2.52996E-8	-0.302027259838192	0.73784897457876	0.68229398296723
rs28620926:40357171:A:G	DHEAS	-0.101520261093515	0.0535208057907811	0.0578494138995171	0.0579013	0.0129378	7.62889E-6	-1.75333301831764	1.0039432804727	0.0807334321702783
rs57159061:81590962:T:C	DHEAS	-0.0712876549327431	0.100801100856673	0.4794353169045	0.0912883	0.0257788	3.98277E-4	-0.780906807693243	1.12601065245699	0.487985563299124
rs296360:48388658:T:C	DHEAS	0.0792258823013609	0.0691358559737637	0.251817946972069	-0.0489511	0.0166344	0.00325303	-1.61846990775204	1.51565187685471	0.285593820167756
rs5935876:6922078:G:A	DHEAS	-0.0690195155556132	0.0375609903929775	0.0661314214421093	-0.0563848	0.0185186	0.00232865	1.2240801697552	0.778066921249105	0.115664991871925
rs35679777:68034459:CG:C	E2	0.065222889879077	0.0525471845745981	0.21452256663616	0.0393347	0.0122194	0.001286261	1.65815145098544	1.43176890337266	0.246817563313875	-0.048	0.638	0.94	1	2.1129
rs17601876:51553909:A:G	E2	-0.0387866164324631	0.0510220047404833	0.447138694644282	0.07022449	0.01173398	2.167724E-9	-0.552323219897548	0.732393661206968	0.450768551379231
rs145827824:32103749:C:G	OHP17	-0.475930366377712	0.236879417591746	0.0445194003636303	0.57225	0.107828	1.300361E-7	-0.831682597427194	0.442615362244717	0.0602419229790763
rs79589801:211054061:C:T	PROG	-0.421620886586319	0.230278442272322	0.0671128210866539	0.0592719	0.0675164	0.38016	-7.11333509785107	8.98605001065703	0.42859538079417	-0.2	0.581	0.73	6	8.6816
rs139441768:90679263:T:C	PROG	0.189380604165696	0.303410176756795	0.532513621833179	0.155067	0.0794433	0.0511532	1.22128244027225	2.05424333803354	0.552166423061775
rs10786714:104598606:G:C	PROG	-0.0449125440891413	0.0543019730766722	0.408186832672847	0.0951468	0.0158349	2.40027E-9	-0.472034204924825	0.576099205111178	0.412579504725985
rs77032081:13363279:C:T	PROG	-0.267389082778421	0.196983715652019	0.174648687675104	-0.0275468	0.0600816	0.646675	9.70672030066727	22.346124926391	0.664012175772767
rs142754737:43865714:C:T	PROG	-0.0819986161121218	0.211789955100937	0.698630710424281	0.13656	0.0627846	0.0297984	-0.600458524546879	1.57527191097057	0.703071394788774
rs139203625:95099865:C:T	PROG	0.413271076541616	0.265077523776824	0.118982793781298	0.141194	0.0754369	0.0614656	2.92697335964429	2.44339042761809	0.230950218620072
rs72906582:45222771:G:A	PROG	-0.00579780986821912	0.0859574434693369	0.946223647930365	0.0347859	0.0256685	0.175581	-0.166671262443091	2.47410137811829	0.946290030393007
rs35695070:7343539:GC:G	TESTO	0.0604032821161237	0.0544104013237991	0.266937759077357	0.0734806	0.0108972	1.55046E-11	0.822030333395803	0.750441002499632	0.273343033444352


c) WOMEN		Y ~ G			X ~ G			causal estimate per SNP			causal estimate of multiple SNPs
SNP	top phenotype	beta	se	pval	beta	se	pval	beta	se	pval	beta	se	pval		Q
rs9692804:144058625:G:A	ANDRO	0.0127566862591387	0.072697702678018	0.860705798341721	0.104987	0.0269745	1.08778E-4	0.121507293847226	0.693148208278034	0.860845710788262
rs114341625:112578458:G:A	CORT	0.156669494314293	0.261557115757123	0.549181089063222	-0.142245	0.0347362	4.221415E-5	-1.10140598484511	1.8583458475294	0.553394763903251	-1.12	1.297	0.388	1	2.0E-4
rs9989237:94795202:C:T	CORT	-0.0515776397769716	0.0827878030307926	0.533277866221066	0.0452752	0.0107792	2.66617E-5	-1.13920291411129	1.84855187167548	0.537717815991723
rs77533229:43479638:G:A	DHEAS	-0.375412319408082	0.273732985449094	0.170233335435158	-0.425435	0.0604601	1.96952E-12	0.882419921746169	0.655525904180207	0.178262151294491	0.904	0.252	3.29502E-4	7	8.4845
rs36139342:119204625:A:AC	DHEAS	-0.0318193495758977	0.086583461255834	0.713246715759606	-0.0861025	0.0201414	1.91231E-5	0.369551982531259	1.00929485254664	0.714254131076025	Sensitivity (p<1E-5)
7:99025328:C:T	DHEAS	-0.165938487894232	0.192009264325556	0.38746635669668	-0.274535	0.0435938	3.02335E-10	0.604434727427219	0.705953053952541	0.391888946667579	0.929	0.311	0.003	5	8.1835
rs615567:22319209:A:T	DHEAS	-0.253953147391822	0.071517083274306	3.83852292271446E-4	-0.0851216	0.016306	1.78662E-7	2.98341604706469	1.01612746270413	0.00332404907093074
rs28620926:40357171:A:G	DHEAS	0.128518165065287	0.0704225592520256	0.0680074700821933	0.0847209	0.0167034	3.93479E-7	1.51695939331719	0.883398347633749	0.0859451682339626
rs57159061:81590962:T:C	DHEAS	0.146670677689889	0.135589152130052	0.279373095131808	0.149075	0.0342206	1.32287E-5	0.983871726915239	0.937158005186893	0.2937888516159
rs296360:48388658:T:C	DHEAS	-0.144932388459594	0.0885372407227415	0.101637725797464	-0.142747	0.0211364	1.44222E-11	1.01530952285928	0.638198355061262	0.111632167295798
rs5935876:6922078:G:A	DHEAS	-0.0890213052677835	0.0712362960456287	0.21142297710377	-0.188607	0.0333804	1.60237E-8	0.47199364428565	0.386824452402858	0.222398426183714
rs35679777:68034459:CG:C	E2	0.0837526513342501	0.0722195006569956	0.246172682230483	0.0741314	0.0159642	3.42364E-6	1.12978645127773	1.00413070405135	0.260530206770217	0.486	0.721	0.5	1	0.9642
rs17601876:51553909:A:G	E2	-0.0186602469237363	0.068417414460773	0.785052170848498	0.063851	0.0154557	3.60851E-5	-0.292246745136901	1.07384932390948	0.78550765085982
rs145827824:32103749:C:G	OHP17	-0.477344821783009	0.300904810938968	0.112656564282082	0.797658	0.139096	1.44797E-8	-0.598432939659614	0.391403241922864	0.126278769713995
rs79589801:211054061:C:T	PROG	-0.320167290981217	0.32966906745283	0.331459729733987	0.808409	0.144331	2.13009E-8	-0.396046173386513	0.413884609272533	0.338617742471503	-0.218	0.164	0.184	6	2.2212
rs139441768:90679263:T:C	PROG	-0.407076282952549	0.366064387328069	0.266123252383162	0.6113884	0.1479081	3.571708E-5	-0.665822712620241	0.620031201868008	0.282888320815405
rs10786714:104598606:G:C	PROG	0.0102342655452454	0.0735315065470205	0.889306295424472	-0.0203393	0.0359371	0.571415	-0.50317688146816	3.72295520515716	0.892489140439319	-0.217	0.164	0.186	5	2.2149
rs77032081:13363279:C:T	PROG	-0.0601125361418983	0.25177063624279	0.811292369205915	0.704529	0.124815	1.65582E-8	-0.0853230117452912	0.357679766164052	0.811457784583391
rs142754737:43865714:C:T	PROG	-0.389737673780823	0.302897479825286	0.198199464223418	0.798375	0.138746	8.70534E-9	-0.488163674690244	0.388761841992297	0.209229023157777
rs139203625:95099865:C:T	PROG	-0.0478647113963147	0.306973730169735	0.87609256922628	0.742308	0.145465	3.34319E-7	-0.0644809316298824	0.413732571216016	0.876149904331697
rs72906582:45222771:G:A	PROG	0.0255585912197558	0.115042621806972	0.824184443567902	0.318619	0.0551308	7.50028E-9	0.0802167831163735	0.361333105227659	0.824312087071362
rs35695070:7343539:GC:G	TESTO	-0.0343655398784383	0.0727484701477667	0.636649519249272	-0.00266917	0.0173836	0.877968	12.87499105656	88.1697260235245	0.88390159180809

Rows per page to display:

Navigate

Health Atlas - Local Data Hub/Leipzig

Registered Repository